HIV and the Brain New Challenges in the Modern Era

Edited by Robert H. Paul, PhD Ned Charlton Sacktor, MD Victor Valcour, MD Karen Tokie Tashima, MD



CURRENT CLINICAL NEUROLOGY

Series Editor: Daniel Tarsy, MD Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA

For other titles published in this series, go to www.springer.com/series/7630

Robert H. Paul • Ned Charlton Sacktor Victor Valcour • Karen Tokie Tashima Editors

HIV and the Brain

New Challenges in the Modern Era

💥 Humana Press

Editors Robert H. Paul, PhD Department of Psychology Behavioral Neuroscience University of Missouri – St. Louis St. Louis, MO, USA

Ned Charlton Sacktor, MD Johns Hopkins University School of Medicine Johns Hopkins Bayview Medical Center Baltimore, MD, USA

Victor Valcour, MD Department of Geriatric Medicine John A. Burns School of Medicine University of Hawaii Honolulu, HI, USA *and* Memory and Aging Center Department of Neurology UCSF San Francisco, CA, USA Karen Tokie Tashima, MD Alpert Medical School of Brown University The Miriam Hospital Providence, RI, USA

ISBN: 978-1-93411-508-4 DOI: 10.1007/978-1-59745-434-6 ISBN: 978-1-59745-434-6 (eBook)

Library of Congress Control Number: 2008943241

© Humana Press, a part of Springer Science+Business Media, LLC 2009

All rights reserved. This work may not be translated or copied in whole or in part without the written pernission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, Nev York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrie val, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden.

The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights.

While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept an y legal responsibility for an y errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

springer.com

Series Editor's Introduction

It is now more than a quarter century since the appearance of the frst reported cases of the acquired immunodef iciency syndrome (AIDS). Although successful treatments with highly acti ve antiretroviral therapies have made a major impact on survival, there still remains no vaccine for prevention and the available therapies do not cure the disease. As a result, AIDS has been transformed into a chronic, lifelong disease which requires continuous antiretro viral drug treatment together with ongoing treatment of the associated systemic medical complications. It appears that as survival improves, the prevalence of chronic central nervous system involvement may be increasing. As pointed out by the editors of this volume, this shift in emphasis requires further examination of how AIDS affects the brain in terms of cogniti ve function, neuropsychiatric manifestations, activities of daily living, and quality of life. They also go on to ask the interesting question of how AIDS involvement of the brain interacts with normal aging.

In *HIV and the Brain*, Drs. Paul, Sacktor, Valcour, and Tashima have assembled an impressive international team of experts to summarize the current state of k nowledge concerning brain function in AIDS. Early chapters review epidemiology, pathophysiology, neuropathology, neuroimaging, and HIV genetics follo wed by a series of chapters concerning the neuropsychological, behavioral, and neuropsychiatric aspects of the disease. Finally, several chapters are devoted to examining the interaction of the aging brain on the e xpression of AIDS-related cognitive impairment. This v olume is lar gely directed to a clinical audience with the hope of advancing multidisciplinary translational research that may serve to increase the understanding of how HIV affects the brain. The sobering statement by the editors that AIDS may be the most common cause of dementia among people under age 40 should lend impetus to the importance of more effectively dealing with this most dreaded complication of the disease.

Daniel Tarsy, MD Professor of Neurology Harvard Medical School Vice Chair, Department of Neurology Beth Israel Deaconess Medical Center Boston, MA

Preface

The history of human immunodeficiency virus (HIV) is very familiar to clinicians and researchers invested in this field, and a number of e xcellent texts have been published that provide contemporary summaries of the disease. This remains true in terms of the impact of the virus on the brain, which is an area of focus that has been appreciated since the early period of the HIV epidemic. Based on this, one may ask why yet another book is needed that specifically focuses on HIV and the brain. Below we answer this question and in the process establish the rationale, purpose, and scope of this important and timely contribution to the field.

Although treatment of HIV with highly acti ve antiretroviral therapy (HAART) has become standard in the developed world, and more common in the developing countries, no current therapies "cure" HIV. This has resulted in HIV transitioning from a time-limited, f atal disease to a chronic condition that requires constant medical intervention. As such, whereas in the past clinical care providers and the scientific community may have largely focused on efforts to prevent mortality prior to the availability of HAART, there is now a greater focus on addressing factors that negatively impact overall quality of life among individuals infected with HIV who are surviving the disease in the context of chronic treatment. This paradigm shift has brought brain function associated with HIV into the clinical forefront because the impact of the virus on the brain is directly related to cognitively the expression of neuropsychiatric symptoms, independence in activities of daily living (including medication adherence), and ultimately patients' perceived ratings of quality of life.

In addition to the general recognition noted above that brain function is now an important aspect of both HIV -related clinical care and research, ne w areas of emphasis have emerged in the modern era of the HIV pandemic that w arrant an update on HIV and the brain. In part, these changes reflect outcomes associated with a population of patients who are li ving longer, such as the impact of HIV on the brain in the context of chronic, long-term treatment with HAART, as well as the potential synergistic effects of HIV and advanced age on cognitive outcomes. The HIV population is aging, in part due to the longer survi val times associated with treatment and there is concern that HIV , like many other medical f actors, may interact with the aging process to increase cognitive burden among patients. Finally, a focus on international studies of brain dysfunction in the context of HIV has

emerged within the last decade, and this work may offer important insights into the neuropathogenesis of brain impairment associated with the virus. HIV includes multiple genetic strains (clades), and reports suggest potential dif ferences in biological properties and neurovirulence across these clades. Answering these issues is complicated by the global geographic distribution of the clade subtypes, and the inherent need to conduct cross-cultural studies of neuropsychological function. Several chapters in this book review this literature and provide guidance and insight for future studies.

The purpose of this edited v olume is to summarize the e xtant knowledge of brain function in the context of chronic treatment, interactions between age and HIV on the brain, and international studies of brain in volvement with an emphasis on clade diversity. Scientif c authorities in each of the three areas ha ve provided comprehensive and insightful reviews of the literature. Each chapter is written with a clinical audience in mind, and while the science is of suff cient rigor to serve as an important resource for basic scientists, a major goal of this book is to present the science in a manner that is ultimately useful to both bench scientists as well as clinical researchers and clinical-care providers. Ideally, a book that is attractive to these audiences will f acilitate the development of future transdisciplinary and translational studies to further de velop our understanding of HIV and the brain. Given current estimates that HIV may be the most common cause of dementia worldwide among individuals under the age of 40, the research re viewed and guidelines proposed within this book are both timely and important in a global and international context.

University of Missouri St. Louis, St. Louis, MO, USA Johns Hopkins University, Baltimore, MD, USA UCSF, San Francisco, CA, USA Brown University, Pawtucket RI, USA Robert H. Paul Ned C. Sacktor Victor Valcour Karen T. Tashima

Contents

1	Neurocognitive Changes in AIDS: Evolution of Treatment of HIV Infection Erna Milunka Kojic and Charles C.J. Carpenter	1
2	Global Incidence and Epidemiology of the AIDS Pandemic, Distribution of HIV Subtypes, and Epidemiology of Hepatitis C Infection Among HIV-Positive Individuals Karen T. Tashima and Aadia I. Rana	9
3	New Insights into HIV Neuropathogenesis Tory P. Johnson and Avindra Nath	17
4	Neuropathological Findings Associated with Long-Term HAART Iain C. Anthony and Jeanne E. Bell	29
5	Biomarkers of HIV-Related Central Nervous System Disease Bruce James Brew and Scott Letendre	49
6	Neuroimaging Among HIV-Infected Patients: Current Knowledge and Future Directions David F. Tate, Jared J. Conley, Dominik S. Meier, Bradford A. Navia, Ronald Cohen, and Charles R.G. Guttmann	75
7	The Assessment of HIV-Associated Neurocognitive Disorders: New Challenges in the HAART Era Lucette A. Cysique and Bruce J. Brew	109
8	The Changing Face of HIV-Associated Cognitive and Neuropsychiatric Disturbance Ron Cohen	133

9	Youth with HIV/AIDS: Neurobehavioral Consequences	187
	Susannah Allison, Pamela L. Wolters, and Pim Brouwers	
10	Co-Occurrence of HIV, Hepatitis C, and Substance Use Disorders: Effects on Brain Functioning Raul Gonzalez, Phillip J. Quartana, and Eileen M. Martin	213
11	The Functional Impact of HIV-Associated Neuropsychological Decline Matthew J. Wright, Ellen Woo, Terry R. Barclay, and Charles H. Hinkin	233
12	Adjunctive Therapy for Long-Term Support of Cognitive Impairment Joshua T. Dearborn, Susan E. Maloney, Nicole Hicklin, Elizabeth M. Lane, and Robert Paul	249
13	HIV-1 Genetic Diversity and Its Biological Significance Michael M. Thomson	267
14	Opportunistic Infections in the Brain in Developing Countries Marcus Tulius T. Silva and Beatriz Grinsztejn	293
15	Impact of Clade Diversity on Neuropsychological Outcomes Robert Paul, Ned Sacktor, Lucette Cysique, Bruce Brew, and Victor Valcour	319
16	The Effects of Aging on HIV Disease Robert C. Kalayjian and Lena Al-Harthi	331
17	Neuropsychology of Healthy Aging Molly E. Zimmerman and Adam M. Brickman	347
18	Interactions Between Advanced Age and HIV Cognitive Impairment Victor Valcour and Aaron M. McMurtray	369
Ind	ex	393

Contributors

Lena Al-Harthi

Graduate Program in Immunology and Microbiology, Rush Medical College, Chicago, IL, USA

Susannah Allison

Infant, Child, & Adolescent Research Programs, Center for Mental Health Research on AIDS, Division of AIDS & Health and Behavior Research, National Institute of Mental Health, NIH, Bethesda, MD, USA

Iain C. Anthony

Centre for Infectious Diseases, University of Edinburgh, Edinburgh, Scotland

Terry R. Barclay

HealthEast Hospitals and Clinics, Department of Psychology, St. Paul, MN, USA

Jeanne E. Bell

Pathology (Neuropathology), University of Edinburgh, Western General Hospital, Edinburgh, Scotland

Bruce J. Brew

University of New South Wales, Sydney, NSW, Australia; Department of Neurology, St. Vincent's Hospital, Victoria St. Darlinghurst, NSW, Australia

Adam Brinkman

Department of Neurology, College of Physicians and Surgeons, Columbia University, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, New York, NY, USA

Pim Brouwers

Infant, Child, & Adolescent Research Programs, Center for Mental Health Research on AIDS, Bethesda, MD, USA

Charles C.J. Carpenter

Brown University, Providence, RI, USA

Ron Cohen

Department of Psychiatry, Brown University, Providence, RI, USA

Jared J. Conley

Center for Neurological Imaging, Brigham and Women's Hospital, Boston, MA, USA

Lucette A. Cysique

University of New South Wales, Sydney, NSW, Australia Department of Neurology, St. Vincent's Hospital, Victoria St. Darlinghurst, NSW, Australia

Joshua T. Dearborn University of Missouri – St. Louis, St. Louis, MO, USA

Raul Gonzalez

Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA

Beatriz Grinsztejn

STD/AIDS Clinical Research Laboratory, Evandro Chagas Clinical Research Institute (IPEC), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil

Charles R.G. Guttmann

Center for Neurological Imaging, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Nicole Hicklin

Department of Psychology, Behavioral Neuroscience, University of Missouri – St. Louis, St. Louis, MO, USA

Charles H. Hinkin

Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at the University of California Los Angeles, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA, USA

Tory P. Johnson

Department of Neurology, Johns Hopkins University, Baltimore, MD, USA

Robert C. Kalayjian

MetroHealth Medical Center, Cleveland, OH, USA Case Western Reserve University School of Medicine, Cleveland, OH, USA

Erna Milunka Kojic

Brown University, Providence, RI, USA

Elizabeth M. Lane

Department of Psychology, Behavioral Neuroscience, University of Missouri – St. Louis, St. Louis, MO, USA

Scott Letendre

HIV Neurobehavioral Research Center, University of California, San Diego, CA, USA

xii

Susan E. Maloney

Department of Psychology, Behavioral Neuroscience, University of Missouri – St. Louis, St. Louis, MO, USA

Eileen Martin

Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA

Aaron M. McMurtray

Neurology Division, Department of Medicine, John A. Burns School of Medicine University of Hawaii, HACRP, Leahi Hospital, Honolulu, HI, USA

Dominik S. Meier

Center for Neurological Imaging, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Avindra Nath

Department of Neurology, Johns Hopkins University, Baltimore, MD, USA

Bradford A. Navia

Tufts New England Medical Center, Tufts University, Boston, MA, USA

Robert Paul

Department of Psychology, Behavioral Neuroscience, University of Missouri – St. Louis, St. Louis, MO, USA

Phillip J. Quartana

Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA

Aadia I. Rana

Alpert Medical School of Brown University, The Miriam Hospital, Providence, RI, USA

Ned Sacktor

Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA

Marcus Tulius T. Silva

Clinical Research Laboratory on Neuroinfection, Evandro Chagas Clinical Research Institute (IPEC), Oswaldo Cruz Foundation (FIOCRUZ), Avenida Brasil, Rio de Janeiro, Brazil

Karen T. Tashima

Alpert Medical School of Brown University, The Miriam Hospital, Providence, RI, USA

David F. Tate

Center for Neurological Imaging, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Boston University School of Medicine, Boston, MA, USA

Michael M. Thomson

Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain

Victor Valcour

Department of Geriatric Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA; Memory and Aging Center, Department of Neurology, UCSF, San Francisco, CA, USA

Pamela L. Wolters

Neuropsychology Contract, Medical Illness Counseling Center and National Cancer Institute, Bethesda, MD, USA

Ellen Woo

Department of Neurology and Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA

Matthew J. Wright

Department of Psychiatry, Psychology Division, Harbor-UCCA Medical Center, David Geffen School of Medicine at UCCA, Torrance, CA, USA

Molly E. Zimmerman

Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA

Neurocognitive Changes in AIDS: Evolution of Treatment of HIV Infection

Erna Milunka Kojic and Charles C.J. Carpenter

The acquired immunodeficiency syndrome (AIDS) was first identified as a distinct clinical entity in June 1981 when the CDC reported the occurrence of five cases of Pneumocystis pneumonia (PCP), accompanied by se vere wasting, in young men who had sex with men (MSMs) in Los Angeles (1). This was quickly followed by reports of several cases of Kaposi's sarcoma, also associated with severe wasting, in 25 young MSMs in New York City and California (2). Of these cases, six developed pneumonia (confirmed in four cases as PCP), one had central nervous system (CNS) toxoplasmosis, and another had cryptococcal meningitis and e xtensive mucosal candidiasis. Since past experience with both Pneumocystis pneumonia and Kaposi's sarcoma in young individuals was almost entirely limited to persons with severe immunodeficiency, these observations suggested that immunodeficiency, of uncertain origin, provided the background for de velopment of these usually f atal illnesses in previously healthy young men. Following the initial reports from Los Angeles and New York City, similar observations were reported in the MSM community in San Francisco, and e xtensive investigations were carried out to attempt to determine the basis for the immunodeficiency in these individuals.

Over the next 12 months, man y additional cases of PCP pneumonia, Kaposi' s sarcoma, and cryptococcal meningitis were identified in young MSMs, especially in major US cities on the East and W est coasts. In most cases, the individuals had no prior indication of immunodeficiency, which provided the basis for nomenclature of AIDS that was applied to this syndrome by the CDC in 1982.

In September 1982, three men with hemophilia were observed to develop severe PCP, and immunological studies were similar to those in the MSM population with AIDS (3). Each of these men had recei ved infusions of e xogenous Factor VIII derived from plasma pools collected from up to 1,000 donors. These collective ve

E.M. Kojic (🖂)

Assistant Professor of Medicine, Brown University, 164Summit Ave, Providence, RI 02906, USA ekojic@lifespan.org

observations in MSM populations and in hemophiliacs suggested that the se vere underlying insufficiency was caused by an infectious agent, which was transmitted both sexually and parenterally in a manner similar to that of the hepatitis B virus. The subsequent recognition of AIDS occurrence in both male and female intra venous drug users (13% of reported cases of AIDS by September 1982) added further credence to the concept that an infectious agent, most lik ely a virus, was responsible for the rapidly e xpanding epidemic of AIDS. The death in late 1982, from an AIDS-like illness, of a 20-month-old child who had recei ved multiple blood transfusions, appeared to conf irm transmission of an infectious agent by blood. Experience in Western Europe and Australia demonstrated that AIDS w as also spreading, largely in the same population groups in which it had been recognized in the United States.

In late 1983, a viral agent, initially called human T lymphocyte virus III, was identified by Dr. Luc Montagner (4). This virus, now called HIV-1, was confirmed as the etiologic agent of AIDS by Dr . Robert Gallo in 1984 (5). These two investigators and their colleagues were independently successful in de veloping an enzyme-linked immunosorbent assay (ELISA), which could detect antibodies in persons infected by HIV-1. Application of this assay made it possible to identify individuals at an earlier, preclinical, state of HIV infection. Further studies of the commercial test (ELISA), in lar ge numbers of "at-risk" indi viduals (intravenous drug users and MSMs) in 1985, indicated that the majority of persons who had been infected by the HIV virus were not yet symptomatic. Subsequent cohort observ ations, notably the Multicenter AIDS Cohort Study (MACS) initiated in 1984, have indicated that the average individual who acquires HIV infection remains asymptomatic, but at risk of transmitting the virus by either se xual or intravenous infection route, for an average of 9–10 years before developing distinctive infections or neoplasms associated with immunodeficiency.

With the development of the diagnostic test, it became clear that the HIV -1 infection was even more prevalent in sub-Saharan Africa, and that HIV -1 was the etiologic agent of "slim disease," a wasting illness that has been identified in Central and West Africa in the late 1970s. Epidemiologic observations in Africa, as well as increasing identification of HIV-1 infection in sexual partners of intravenous drug users in Europe and the United States, confirmed that the HIV virus could be transmitted heterose xually, and this has been the predominant route of HIV transmission worldwide.

Thus, by 1985, the etiologic agent for AIDS had been identified and persons living asymptomatically with the virus could be detected. This led to increasing major efforts by the pharmaceutical industry to develop effective antiretroviral agents.

The first potential antiretroviral agent to which the HIV virus sho wed in vitro susceptibility was the reverse transcriptase inhibitor (RTI) azidothymidine (AZT), subsequently known as zidovudine. Zidovudine, which has originally been de veloped as a potential chemotherapeutic agent for the treatment of cancer, was found to be effective in inhibiting the gro wth of HIV-1 in vitro. Extensive field trials of this agent were initiated in 1986 by the ne wly established NIH-supported AIDS

Clinical Trials Group (ACTG). Initial randomized controlled trials of this agent indicated a signif icant decrease in mortality in HIV -infected individuals who received this agent for 24 weeks(6). On this basis, and with additional support from subsequent studies by the A CTG, the FDA approved in 1989 the use of AZT for persons living with HIV infection who had a CD4 cell count of <500.

During the first 2 years this agent was employed (most often in doses of 600 mg but sometimes in doses as great as 1,500 mg/day), side ef fects, especially nausea, headache, and anemia, were common. Follow-up studies over several years demonstrated that the clinical benefit of monotherapy with zidovudine was transient. In 1990, a state-of-the-art panel con vened by the NIH suggested that azidothymidine, because of the demonstrated short-term survival benefit, should be given in divided doses of 600 mg daily to all persons living with HIV infection who had CD4 counts <500/mm³. The recommendation of a CD4 count of 500 as the threshold for initiation of treatment was made on an arbitrary basis (7).

In 1992, second (didanosine, or ddI) and third (dideoxycitidine, or ddC) antiretroviral drugs were approved by the FDA for administration to persons with CD4 counts <500. Each of these agents w as approved for use as a single agent against HIV infection, on the basis of short-term benefit in clinical trials. Both didanosine and dideoxycitidine proved to have serious toxicities, of which the most frequent was severe, sometimes crippling, peripheral neuropathy.

In 1992, an NIH Advisory P anel recommended that the three a vailable agents, AZT, ddI, and ddC be used in sequence, with discontinuation of an initial agent when either major toxicity occurred, or when CD4 count be gan to fall after an initial rise (8). The panel recommended that all HIV -infected individuals with CD4 T-cell counts below 500 be treated with such sequential monotherap y.

In 1992, trials of combination therap y with two of the above agents were initiated both in the United States and W estern Europe. By 1995, two major clinical trials, the Delta trial in Europe (9) and an A CTG trial in the United States (10), indicated that combined use of AZT and ddI w as more effective than AZT monotherapy in preventing the progression of immunodef iciency and death in persons living with HIV infection. The toxicities of any two-drug combination of the three available drugs, however, proved to be major limiting f actors. It became clear that the use of ddI and ddC together w as prohibitive because of frequent neurotoxicity and occasional lactic acidosis.

Each of the initial three antiretro viral agents acted by the same mechanism, inhibition of reverse transcriptase, an enzyme essential to the replication of retroviruses.

While the early e valuations of HIV therap y were based on clinical endpoints (i.e., progression to clinical AIDS or death), extensive immunological and virological studies defined two precise laboratory determinations, the CD4 T -cell count (CD4) and the plasma HIV-RNA level (the plasma viral load, PVL), which, in concert, proved to be effective gauges of the rate of progression of HIV disease, and of the response to antiretro viral therapy. Most helpful were longitudinal studies obtained from the Multicenter AIDS Cohort Study, which was initiated in 1985, and included men either infected by, or at high risk for, HIV infection (11). The studies,




Fig. 1 The relationship of CD4 T-cell count and plasma HIV-1 RNA level to the 3-year probability of progression of persons living with HIV to clinical AIDS or death, in the preHAART era (10) (*See Color Plates*)

partially summarized in Fig. 1, provided the basis for more effective evaluation of the effectiveness of antiretroviral therapy and for earlier predication of f ailure of ART months or years before detectable change in clinical status (12).

Intensive further investigations by the NIH, several pharmaceutical companies, and many academic medical centers, especially in Europe and North America, have been initiated in late 1980s to de velop an inhibitor of HIV protease, as protease activity is also essential for the replication of the HIV virus in human cells. In 1995, controlled clinical trials demonstrated that a protease inhibitor (saquina vir) was markedly effective in rapidly decreasing the le vel of HIV-RNA in persons li ving with HIV. The decrease in plasma viral load (PVL) was followed by a more gradual increase in the CD4 cell count. In rapidsuccession, two additional protease inhibitors, indinavir and ritonavir, were also shown to delay disease progression and death in persons living with HIV infection. All three protease inhibitors were approved by the FDA by early 1996. Studies indicated that resistance to each of the protease inhibitors also developed, although at a slower pace, than resistance to the reverse transcriptase inhibitors, over a period of months after initiation of monotherap y with each of the three protease inhibitors. These observations led to trials of three-drug combination therapy, including a protease inhibitor and two reverse transcriptase inhibitors. These highly active antiretroviral therapy (HAART) regimens caused significant and prolonged decreases in PVL, associated with progressi ve increases in CD4 count (13). These responses were accompanied by mark ed reductions in progression of HIV infection and death in persons living with HIV/AIDS.

By early 1998, both the International AIDS Society, USA, and the Department of Health and Human Services (DHHS) recommended that all persons li ving with HIV infection with CD4 counts <500, receive three-drug therapy, including a protease inhibitor and two reverse transcriptase inhibitors (14).

In 1998, a third cate gory of antiretro viral agent, the nonnucleoside re verse transcriptase inhibitor (NNRTI), was also shown to be effective, when given with two nucleoside reverse transcriptase inhibitors, in rapidly decreasing viral load with a subsequent progressive increase in CD4 count in persons li ving with HIV infection. It became clear that a three-drug regimen containing either efavirenz or nevirapine combined with two nucleosides was likewise markedly effective in decreasing disease progression and death related to HIV infection. Antiretro viral therapy, widely known as HAART, was universally recommended throughout the industrialized world by the end of the decade (15). HAART was rapidly adopted for treatment of HIV infection throughout the industrialized w orld, with marked clinical results in clinical progression and death. Figure 2, presenting data from the CDC, demonstrates a fourfold decrease in age-adjusted death rates in USA due to HIV infections within 3 years after widespread application of HAAR T to treat HIV infection (16). Subsequent results have been most marked in Western Europe, where antiretroviral medications are generally provided, when indicated, to all persons who require therap y. Figure 3, based on reports from a multicenter European collaboration, demonstrates that in a 12,574 patient longitudinal cohort study, there was little AIDS-related mortality in persons with CD4 counts >200 who initiated triple-drug treatment o ver a 3-year period. Indi viduals who began therapy at CD4 counts <200 also e xperienced a highly significant decrease in likelihood of progression to AIDS or death(17). Results from the British Columbia




Fig. 2 This figure demonstrates the rapid reduction in age-related mortality rate due to HIV infection within 3 years follo wing widespread adoption of HAAR T therapy. Data from Centers for Disease Control and Prevention (http://www.cdc.gov/HIV/graphics) *Sec (Color Plates)*




Fig. 3 Three-year probability of progression to AIDS in the HAART era, 1998–2002, in the ART Cohort Collaboration (17) (See Color Plates)

cohort were equally striking during that time period, as were smaller controlled clinical trials in the United States. Thus the widespread utilization of HAAR T ensured that the great majority of persons living with HIV in Western Europe and North America could be restored to good functional health by effective antiretroviral therapy.

In 2005, enfurvitide, the first of an additional class of antiretroviral agents, entry inhibitors, was approved for use by the FD A. Although more difficult to use than the earlier commonly utilized antiretro viral agent, as it required subcutaneous injection twice daily, enfurvitide in combination with tw o other antiretro viral agents to which the patient's virus was partially susceptible has proved to be life-saving in the small subset of patients with e xtensive resistance to other classes of retroviral agents.

In 2007, raltegravir, the first inhibitor of integrase, another enzyme essential to the replication of HIV, was shown to be highly effective when used with two other antiretroviral agents, and received FDA approval. This agent acts by preventing the integration of the single-stranded HIV -RNA into the DN A of the host cell, and provides a powerful additional approach to the treatment of persons with anteced-ent resistance to other classes of antiretroviral agents.

Also approved by the FDA in 2007 was a second class of entry inhibitor, maraviroc, which prevents binding of the HIV virus to the CCR5 receptor molecule of the CD4 T-cell, the primary tar get of HIV. This agent provides another effective agent for use in persons who have developed extensive resistance to previous antiretroviral agents, but its use is limited to the 75–85% of individuals infected by HIV strains which must utilize the CCR5 receptor. Thus, it is no w possible to provide effective therapy to all individuals newly infected with the HIV virus. In majority of the cases, the initial therapy can remain effective for periods of at least a decade. If adherence to the antiretro viral therapy regimen is excellent, there is little opportunity for the infecting virus to de velop resistance to an effective HAART regimen.

Alterations in Neurocognition in HIV Infection

Neurocognitive deterioration has been recognized in HIV-infected individuals since the year in which AIDS was first recognized as a clinical entity. Prior to the development of effective antiretroviral therapy, the AIDS dementia complex (ADC), in which impaired intellectual function, often associated with progressi ve vacuolar myelopathy, was a common finding. The ADC, characterized by poor concentration, diminished memory, motor dysfunction, and often social withdra wal and apathy, seldom if ever occurs in persons who be gin antiretroviral therapy prior to developing moderately severe immunodeficiency (e.g., before the CD4 count f alls below 350 cells/mm³). It has rarely been recognized in patients in whom the CD4 count has never fallen below 200 cells/mm³.

There are at least tw o major issues that ha ve not been adequately resolv ed in regard to neurocognitive changes related to HIV infection. The first is whether HIV infection may impair intellectual function in the early stages of immunodeficiency, i.e., when the CD4 count remains at a level above 350 cells/mm³, the time at which initiation of antiretroviral therapy is currently recommended throughout the industrialized world. If indeed, intellectual deterioration related to the HIV infection can be demonstrated to occur, even in a small subset of patients with CD4 counts above this threshold, this finding would provide a sound basis for recommending initiation of antiretroviral therapy in all patients at an earlier stage in the progression of HIV disease.

A second unresolved issue is whether or not HIV-related cognitive dysfunction, once established in persons with more adv anced HIV infection, will predictably improve following months or years of effective antiretroviral therapy.

Both these questions are of major importance in this phase of the HIV/AIDS pandemic, as the answers may prove critical to the timing of initiation of antiretroviral therapy. If HIV-related neurocognitive changes developed in some individuals at higher CD4 cell counts andheurocognitive dysfunction, once established, failed predictably to improve with effective antiretroviral therapy, a major worldwide effort would have to be initiated to identify and treat HIV infection at earlier stages of immunodef iciency. Although this would initially impose a large worldwide financial burden (especially in developing countries where the current WHO guidelines recommend initiation of therapy at a CD4 count threshold of 200 cells/mm³), earlier initiation of HAART should become the international standard. This text explores the current understanding of the neurocognitive changes that occur in the course of HIV infection, describes the structural neuroimaging correlates of these changes, and discusses current approaches to the prevention, evaluation, and approaches to treatment of altered cognition in persons living with HIV infection.

References

- 1 Pneumocystis pneumonia Los Angeles. MMWR 1981;30:250-2.
- Kaposi's sarcoma and pneumoc ystis pneumonia among homose xual men Ne w York City and California. MMWR 1981;30:305–8.
- 3 Pneumocystis carinii pneumonia among patients with Hemophilia A. MMWR 1982;31:465-7.
- 4 .Barre-SinoussiF, ChermannJC RayF, etal .Isolationof a T lymphocytic retrovirus from a patient at risk for acquired immunodeficiency syndrome (AIDS). *Science* 1983 ; 220 : 868 71 .
- 5 .GalloRC SalahuddinSZ Popoic M et al .Frequent detection and isolation of cytopathic retrovirus (HTLV-III) from AIDS and at risk for AIDS. *Science* 1984 ; 224 : 500 3 .
- 6 .FischlMA RichmanDD GriecoMH Theefficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. *NEJM* 1987 ; 317 : 185 91 .
- 7. State-of-the-Art conference on Azidothymidine therap y for early HIV infection. Am *J Med* 1990;89:335–44.
- 8 .Sande M ,Carpenter CCJ ,Cobbs GC et al . Antiretroviral therapy for adult HIV-infected patients: recommendations from a state-of-the-art conference. *JAMA* 1993 ; 270 : 2583 9 .
- 9. Delta Coordinating Committee. Delta: a randomized, double-blind, controlled trial comparing combination of zido vudine plus didanosine or zalcitibine with zido vudine alone in HIV infected individuals. *Lancet* 1996;335:1081–90.
- 10 HammerSM KatzensteinDA, HughesMD et al. Trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4+ cell counts from 200 to 500 per cubic millimeter *.NEJM* 1996; 333 : 1081 90.
- 11 MellorsJW, RinaldoCR GuptaP, etal .Prognosisin HIV infection predicted by the quantity of virus in plasma. *Science* 1996 ; 272 : 1169 70 .
- 12 MellorsJW, RinaldoCR GuptaP etal .Plasmaviral load and CD4 T lymphocytes as prognostic markers in HIV infection. *Annals Int Med* 1997; 126 : 946 – 54.
- HammerSM SquiresE HughesMD etal .Controlledtrial of two nucleoside analogues plus indinavir in persons with HIV virus infection and CD4 counts of 20/mL or less
 NEJM 1997 ; 337 : 725 33 .
- 14 .CarpenterCCJ FischlMA HammerSM et al .Antiretroviral therapy for HIV infection in 1998 .JAMA 1998 ; 280 : 78 86 .
- CarpenterCCJ CooperDA , FischlMA etal .Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA panel. JAMA 2000 ; 283 : 381 90 .
 Contrast for Disease control and Deputation 2002 (http://www.do.gov/IUV/combine).
- 16 Centers for Disease control and Prevention, 2002 (http://www.cdc.gov/HIV/graphics(.
- 17 Eggar M ,May M ,Clere G et al . ART cohort collaboration. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies .*Lancet* 2002; 360: 119 29.

Global Incidence and Epidemiology of the AIDS Pandemic, Distribution of HIV Subtypes, and Epidemiology of Hepatitis C Infection Among HIV-Positive Individuals

Karen T. Tashima and Aadia I. Rana

Introduction

It has been more than 25 years since the Centers for Disease Control and Prevention published a report in 1981 of *Pneumocystis* pneumonia in five previously healthy young men in Los Angeles, CA (1). These cases were later recognized as the f irst reported cases of acquired immunodeficiency syndrome (AIDS) in the United States (2). By the 1990s, an estimated 1 million people were infected with HIV globally. Since that time, the disease has become one of the greatest global public health challenges of our time, resulting in an estimated 65 million infections and claiming the lives of more than 25 million people (UN AIDS). The proportion of indi viduals worldwide infected with HIV is just under 1% and has been stable since 2001; however, population growth and longer survival of infected persons have resulted in the continuous rise of the number of people living with HIV. A reduction in the number of annual ne w HIV infections globally is a positive trend noted in 2007.

The HIV pandemic is believed to have started with a cross-species transmission from primates to humans in Central Africa. Threestrains of HIV have been described based on the differences in their encoding proteins: M, N, and O. Group M strain is the most prevalent and is divided into subtypes (or clades), based on the whole genome, which are geographically distinct. HIV-1 group M strain is responsible for the vast majority of infections (see Chapter 15 for a comprehensive review of clade subtypes). HIV-1 subtype B is the predominant subtype in North America, Western Europe, and Australia but represents only about 12% of the global HIV pandemic. A complete understanding of global epidemiologic trends and the distribution of HIV subtypes is needed for future prevention and treatment efforts (3–9). An overview of the findings of the 2007 global UNAIDS HIV report, global distribution of

A.I. Rana (🖂)

Infectious Disease Research Fellow, Warren Alpert Medical School of Brown University, The Miriam Hospital, Providence, RI, USA arena@lifespan.org

HIV subtypes, and recent epidemiologic trends highlighting popula tions at risk of acquiring HIV infection is presented in this chapter. Because hepatitis C infection among HIV-infected individuals may pose an additional risk to neurocogniti ve health, current estimates and epidemiologic trends of dually infected persons has also been reviewed.

Global Epidemiology

In 2007, an estimated 33.2 million people were living with HIV infection; approximately 2.5 million people were ne wly infected, and 2.1 million lost their li ves to AIDS (10). The number of children under 15 years li ving with HIV in 2007 is estimated to be 2.5 million. 420,000 children were ne wly infected with HIV and 330,000 children died of AIDS in 2007. 90% of all HIV -infected children live in sub-Saharan Africa. The UN AIDS/WHO 2007 report noted tw o patterns to the epidemic; first, the generalized epidemics continue in the general populations in many sub-Saharan African countries; and second, epidemics in the rest of the world are primarily concentrated among populations most at risk, such as men who ha ve sex with men, injection drug users, sex workers, and sexual partners of these populations at risk. The most prevalent viral strains globally are HIV-1 group M subtypes A, B, C, D, CRF01_AE, and CRF02_A G (figure from (11)). Subtype A is found primarily in East Africa and in former So viet Republics. Subtype B predominates in infections found in the Americas, W estern Europe, and Australia. Infections in Southern and East Africa, and in India are subtype C and account for 50% of all the HIV infections worldwide. Subtype D is mainly found in East Africa and in W est Africa. CRF01_AE and subtype B are the tw o subtypes found in southeast Asia, and CRF02 AG is found in West and West Central Africa. In South America, subtype B and BF recombinants, and subtype C are found (11).

Africa

The greatest HIV burden is in sub-Saharan Africa. 22.5 million people are li ving with HIV in this re gion, 1.7 million were ne wly infected in 2007, and more than three quarters of AIDS deaths in 2007 occurred here. In most other re gions of Africa, HIV infections have been concentrated in various high-risk populations, but the HIV epidemic has become more widespread, and is termed as *generalized epidemic* in sub-Saharan Africa. Only about 10% of the world population lives in sub-Saharan Africa, but this region is home to approximately 68% of the adults living with HIV and 90% of children living with HIV. In sub-Saharan Africa, transmission is primarily through heterosexual contact, with more w omen infected with HIV than men. About 61% of adults li ving with HIV in 2007 were w omen. On a verage, three women in sub-Saharan Africa are infected for every two men. Among young people

aged 15–24, the gap increases even more to three young women infected for every young man. Three-quarters of all women aged 15 and older living with HIV globally are in sub-Saharan Africa (10).

The subregion of southern Africa is the epicenter of the AIDS epidemic; eight countries in this region have an estimated adult HIV pre valence exceeding 15%, while in Botswana, Lesotho, Swaziland, and Zimbabwe the pre valence exceeds 20%. Zimbabwe showed significant declines in HIV pre valence, while the pre valence is stable in the other countries in the region. South Africa, with an HIV prevalence of 18.8%, has the highest b urden of HIV infections with 5.5 million persons living with HIV. In Southern Africa, 98% of HIV infections are caused by subtype C (11, 12).

There have been recent declines in HIV incidence rates in K enya, Zimbabwe, Cote d'Ivoire, Mali, and urban areas of Burkina Faso (10). This is likely related to a combination of behavioral changes (increased condom use, delayed sexual debut, increasing avoidance of casual se xual relations) and high mortality rates from AIDS. Some African countries report a decline in HIV pre valence among women attending antenatal clinics, notably in Zimbabwe, Botsw ana, and in urban areas of Zambia and Kenya.

Overall in the region of West Africa, 21% of infections are caused by subtype A, 35% by subtype G, and 28% by subtype CRF02_A G, and other recombinants account for 14% (12). In Nigeria, which has the lar gest number of infections in West Africa, subtypes A (29%) and G (54%) predominate. In east Africa, subtypes A, C, D, and unique recombinant forms are found. In Kenya and Rwanda, the majority of infections are caused by subtype A (57%, 79%, respectively); in the United Republic of Tanzania subtype C accounts for 44% and in Uganda subtype D for 46% of infections.

In Central Africa, subtype A is found in 38% of infections; otherwise, the greatest diversity of subtypes and recombinants are represented in this region.

There have been significant improvements in access to antiretro viral therapy in sub-Saharan Africa in the past se veral years. From 2003 to 2005, there w as an eightfold increase in the number of HIV-positive individuals receiving antiretroviral therapy, who were in need of it. Ho wever, that still represents less than 20% of the population in sub-Saharan Africa with indications for treatment.

Asia

The HIV epidemic in most Asian countries is attributable primarily to various highrisk behaviors, including unprotected intercourse with sex workers, injection drug use, and men who have sex with men. 29% of adults living with HIV in Asia are women. Of the approximately 4.9 million HIV-infected persons in Asia, 2.5 million of those live in India. New infections in 2007 are estimated at 340,000 adults and children, a decrease from 2001 when 450,000 ne w infections occurred in this region. While HIV prevalence has been declining in pre gnant women in antenatal clinics across Asia, HIV prevalence among men who have sex with men is increasing in countries such as Thailand. Declines in HIV prevalence were seen in Cambodia, Thailand, and Myanmar, whereas increases are noted in V iet Nam and Indonesia. 97% of HIV infections in India are subtype C, and in south and south-east Asia (Cambodia, Thailand, Viet Nam), subtype CRF01_AE accounts for 84% of infections and other recombinants 4%. The recombinant subtypes are somewhat less predominant in Myanmar, where subtypes B and C account for 24 and 12% of infections, respectively. In China, clades B', B, BC, and AE were found (13).

Recently updated reports from 2007 estimate that national adult HIV prevalence in India is approximately 0.36%, which corresponds to an estimated 2–3.1 million people living with HIV in the country. This is a reduction in previous estimates using better sampling methods across the country. These numbers show an epidemic that is stable over time with mar ginal decline in 2006 especially noted in the antenatal clinics in the southern states of Andhra Pradesh, amil Nadu, Maharashtra, and Karnataka, which have been the hardest hit by the epidemic. More than 80% of reported AIDS cases in India are due to unprotected heterose xual intercourse, and a significant portion of the new cases are in women. However, the 2006 surveillance figures showed an increase in HIV infection among several groups at higher risk of HIV infection, among people who inject drugs, and men who have sex with men. Injection drug use is the primary mode of transmission in the northeastern states of Manipur, Mizoram, and Nagaland as well as in major cities throughout India. There is a substantial overlap between those who inject drugs and those who engage in commercial sex.

In China, injection drug users account for almost one-half of the 650,000 people living with HIV. In certain areas of some pro vinces, owing to sharing needles and syringes, as well as high-risk se xual behavior among the drug users, HIV pre valence exceeds 50% among injection drug users. In China, subtype B is found in 38% of people li ving with HIV, CRF01_AE in 15%, and other recombinants account for 45% of infections. In Japan, subtype B causes 81% of infections (12).

In Thailand and Cambodia, the epidemics have been largely driven by commercial sex. In other countries in Asia, the overlapping risks of injection drug use and unprotected sex feature in several epidemics, including in V iet Nam. There have also been indications of epidemics among injection drug users in the past several years in Asian countries. There is a general decline in HIV prevalence in Asia in antenatal clinics, but along with other regions of the Asia and the world, there are increases in prevalence among men who have sex with men and injection drug users. HIV prevalence is increasing in China, Indonesia, and V iet Nam, with high rates in Pakistan and Bangladesh in the injection drug use population.

In Asia, like Africa, the number of people receiving antiretroviral therapy has increased significantly in the past several years. Nonetheless, only 16% of persons in need of treatment in Asia received it in 2005, with coverage in India still remaining below 10%. With the continuing expansion of the availability of generic antiretrovirals through manuf acturers in India and government support of first-line therapy, these numbers are expected to increase significantly with continued global support.

Eastern Europe and Central Asia

The HIV epidemic in Eastern Europe accounts for approximately twice the number of newly diagnosed HIV cases as in W estern Europe, and is primarily dri ven by injection drug use (IDU) (two-thirds) and secondarily through the heterosexual partners of these drug users (one-third of ne w infections). Approximately 1.6 million people are living with HIV in Eastern Europe and Central Asia and 150,000 people were newly infected in 2007. The majority of people li ving with HIV in this region live in the Russian Federation and in Ukraine. This is lik ely the result of the man y political and social changes confronting eastern Europe, including changes in drug trafficking routes and drug prices, leading to an increase in the size of the population using drugs and HIV transmission within drug-sharing and se xual networks. (14)

New diagnoses among injection drug users, female se x workers, and men who have sex with men are reported from testing in other Central Asian countries, including Republic of Moldo va, Georgia, Armenia, Azerbaijan, Uzbekisan, Kazakhstan, Tajikistan, and Kyrgyzstan. 79% of infections in the region are caused by subtype A and 15% by subtype B. CRF03_AB is found only in this re gion (12).

Latin America and the Caribbean

HIV infections in Latin America are reported mostly among men who ha ve sex with men, injection drug users, and sex workers, but has also increased among the women in the general population of Brazil and Uruguay. Brazil, the most populous country in Latin America, has an adult HIV pre valence of 0.5% and comprises almost 30% of the population living with HIV in South and Central America and the Caribbean. High-risk behavior is still widely reported among young Brazilians with almost one-third reporting se xual debut prior to age 15, and 20% of young Brazilians aged 15–24 reporting greater than ten se xual partners. Approximately 73% of the estimated 400,000 people in need of antiretro viral therapy in Latin America received it in 2005. Brazil provides free antiretroviral therapy to those in need of treatment, and approximately 83% of HIV-infected persons receive therapy. Subtype B infections predominate in Latin America, with a smaller representation of subtypes C and F and recombinants totaling about a quarter of infections overall (12, 15). Clade B/F recombinants were common (48%) in a surv ey of treatment failure patients in Buenos Aires, Argentina (16). Populations at highest risk for HIV infection in Latin American countries are men who have sex with men and female sex workers (17).

The Caribbean is the second most HIV-affected region of the world. About three quarters of the 230,000 people living with HIV infection in the region live in Haiti or the Dominican Republic. 43% of adults li ving with HIV in 2007 are w omen. Transmission is largely through heterosexual intercourse; injection drug use (except in the countries of Bermuda and Puerto Rico) plays a minor role in the Caribbean's epidemic. Sex between men is estimated to be responsible for 12% of infection in

the Caribbean. Haiti is the most burdened Caribbean country with a recent prevalence near 4%. HIV prevalence has declined in urban areas of Haiti by 2005 estimates, but remained constant in other areas of the Caribbean. Subtype B is responsible for 94% of infections in Haiti, Dominican Republic, and Trinidad and Tobago. In Cuba, 48% were caused by subtype B and 41% caused by recombinant forms (11, 12). With the exception of Cuba, antiretro viral treatment access is highly une ven. In Haiti and the Dominican Republic, for e xample, fewer than 20% of people needing antiretroviral treatment were receiving it in 2005.

North America and Western Europe

In the developed world, including the United States and Europe, the HIV incidence rate dropped every year until the late 1990s when it stabilized translating into about 65,000 new infections in North America and Western and Central Europe. A total of approximately 2.1 million people are living with HIV infection in these regions. The rate has not continued to decline lar gely in part to a rising pre valence rate among immigrants, migrants, ethnic minority groups, and men who ha ve sex with men. Men account for 74% of HIV infections in the United States. Half of ne w infections in the United States in 2005 were among men who have sex with men, 32% among women, and 18% among injection drug users (17). Racial and ethnic minorities, particularly African Americans and Latinos, represent 48 and 18% of new infections, respectively. There is a particular need for improved prevention, diagnosis, and treatment services in these populations. In the United States, there has been reported e vidence of resurgent risk behavior among men who have sex with men (18). In Canada and W estern Europe, new infections are significantly represented by immigrants who acquire the disease heterose xually. Spain, Italy, France, and the United Kingdom continue to have the largest HIV epidemics in the region. Fewer cases of new infections are attributed to injection drug users. Subtype B viruses predominate in North America and W estern Europe, but immigration of people from other parts of the w orld have increased representation of other subtypes (19).

Co-Infection with Hepatitis C

Hepatitis C is a blood-borne infection, transmitted through contaminated blood, injection drug use equipment, and, less ef ficiently, through se xual intercourse. Prevalence of hepatitis C among the HIV infected population is about 30% worldwide, but can vary from 10.4% in an Asian Recific cohort (TREAT Asia HIV Observational Database) (20) to 51% in a lar gely injection drug use population in Columbia, Canada (21). In the United States and Europe, estimates are that 25% of H IV-positive individuals have hepatitis C infection as well. More recently, acute hepatitis C

outbreaks are being reported among men who have sex with men (21, 22). Hepatitis C infection has emerged as an important cause of morbidity and mortality concomtant with the decline in HIV -related morbidity and mortality associated with effective antiretroviral treatment.

Conclusion

The advances in antiretroviral therapy in the last decade have reduced morbidity and mortality in the developed world, including neurocognitive impairment and AIDS dementia. Antiretroviral medications have variable penetration into the central nervous system, and adequate levels may be important in preventing or reversing the neurocognitive deficits related to HIV infection for some patients. Access to these life-saving medications has improved globally, although only to a fraction of those in need, but appears to have similar beneficial effects. Expansion of antiretroviral coverage will also lead to increased HIV drug resistance and antiretro viral toxicities globally. These issues will continue to require signif icant resources and research in order to improve the lives of everyone living with HIV infection.

References

- 1. CDC. Pneumocystis pneumonia-Los Angeles. MMWR 1981;30:250-252.
- 2. CDC. First report of AIDS MMWR 2001;50(21):429.
- Kantor Impactof HIV-1 pol diversity on drug resistance and its clinical implications. Curr Opin Inf Dis 2006; 19 (6): 594 – 606.
- 4 . KantoR KatzensteinDA , EfronB Caradho AP, Winhoven B etal. Impactof HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration . PloSMed 2005 ; 2 (4) : e112 .
- 5. Brander C Frahm N Warker BD Thechallenges of host and viral diversity in HIV vaccine design. CurrOpin Immunol 2006; 18 (4): 4 Boub 17 Jun 2006.
- 6 . Stebbing Myle G The clades of HIV: their origins and clinical significance . AIDS Rev 2003 ; 5 (4) : 205 – 213 .
- 7 . Maglion M Geotz M Wang Z Wagner G Hilton L et al . Antietroviral drug resistance in the developing world . Evid Rep Technol Assess (Full Rep) 2007 ; 156 : 1 – 74 .
- 8. ThomsonMM ,Najera R Molecular epidemiology of HIV-1 variants in the global AIDS pandemic: an update . AIDSRev 2005 ; 7 (4) : 210 214 .
- 9. Preisler W, Drexler JF, Drosten C. HIV -1 viral load assays for resource-limited settings: Clades matter. PloS Med 3(12): e358, doi:10.1371/journal.pmed.0030538.
- 10. UNAIDS/WHO. AIDS epidemic update: December 2007. UN AIDS, Geneva, 2007. UNAIDS/07.27E. ISBN 978 92 9 173621 8.
- 11 .McCutchanFE Globalepidemiology of HIV. JMed Virol 2006 ; 78 : S7 S12 .
- 12 . Hemelaar J ,Gouws E ,Ghys PD ,Osmano S Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004 . AIDS 2006 ; 20 : W130 W23 .
- 13 . Wing Y, Song AXuS LiX Chong H et al. Impactof HIV-1 genetic diversity in China on the measurement of viral load . JMed Virol 2008 ; 80 (1) : 1 8 .
- 14. Anne Johnson. What's Driving the European HIV Epidemic. CROI, Los Angeles 2007.

- 15 BarretoCC NishyiaA AraujoIV, FerreiraJE BuschMP etal.. Trends in antiretroviral drug resistance and clade distribution among HIV-1-infected blood donors in Sao Paulo, Brazil. J Acquir Immun Defic Syndr 2006; 41: 338 – 341.
- 16 Gomez-CarrilloM QuarleriJF, RubioAE CarobeneMG DilerniaD CarrJK SalomonH Drug resistance testing provides evidence of the globalization of HIV type 1: a new circulating recombinant form. AIDSRes Hum Retroviruses 2004; 20 (8): 885 – 888.
- World Health Organization, UNAIDS. 2007 AIDS Epidemic Update http://www.unaids.org/ en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/2007/default.asp
- 18. Jaffe HW, Valdiserri RO, De Cock KM. The reemer ging HIV/AIDS epidemic in men who have sex with men. JAMA 2007;298(20):2412–2414.
- 19 LospitaoE Alarez A SorianoV, HolguinA HIV1 subtypes in Spain; a retrospective analysis from 1995 to 2003. HIVMed 2005; 6 (5): 313 320.
- 20 ZhouJ DoreGJ ZhangF, LimPL ChenYA for the TREAT Asia HIV Observational Database. Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database. *J Gastro Hep* 2007 ; 22 (9) : 1510 – 1518 .
- 21 PuotiM MannoD NastaP, CarosiG Theburden of HIV and hepatitis C virus coinfection . CurrOpin HIV AIDS 2007; 2: 460 – 465 .
- 22 Danta M ,Brown D ,Bhagani S ,Pybs OG ,Sabin CA at., for the HIV and Acute HCV (HAAC) group. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21 (8): 983 991.

New Insights into HIV Neuropathogenesis

Tory P. Johnson and Avindra Nath

Introduction

Over the last two decades, substantial progress has been made to understand the pathophysiology of dementia due to HIV infection; yet neuroprotective drugs have shown little or no effect on the syndrome. Although there may be multiple reasons for these failures, it also be gs another look at our approach to ward studying HIV neuropathogenesis. Importantly, it is being recognized that innate immune responses that have been often targeted by therapeutic approaches may have important antiviral effects. Further, the effects of the virus on neurogenesis may be critically important, and in patients treated with antiretroviral therapy, T-cell infiltration within the brain may be an important mediator of neuronal injury. This chapter brings to light these newer developments in the pathophysiology of HIV infection and highlights these areas requiring closer attention and further in vestigation.

Early in the epidemic, once it was discovered that HIV was a retrovirus and that it could be found in macrophages, many in the field thought that the pathophysiology of neurological complications due to HIV infection w as obvious. As in other retroviruses that had been studied prior to HIV , such as visna virus that infects sheep causing an encephalopathy, it was thought that the infection of macrophages would be sufficient to drive all the glial and neuronal changes in the brain. However, the years since have proven that the neuropathogenesis of HIV infection is a tangled web. Over 20 years have passed since HIV dementia was first described, and even though we have learned a lot about some of the k ey elements of how HIV causes neuroglial dysfunction, there are other key questions that remain unanswered.

It is abundantly clear that the brain is an important reserv oir for the virus and the viruses may reside in several cell types besides the macrophages. The mechanisms of viral persistence and latency, however, remain unknown. As a result there are currently no drugs available that may impact these reserv oirs. Despite all the studies in

Nath (XXX)

Department of Neurology, Johns Hopkins University, Baltimore ,MD ,USA anath1@jhmi.edu

pathophysiology of this disease, currently there are no clinically a vailable surrogate markers for HIV-associated cognitive impairment. Further, to date all clinical trials with neuroprotective agents in HIV dementia ha ve failed to show any significant clinical benefit. Although there may be multiple reasons for such failures, it also means that we need to ree valuate the pathophysiology of HIV -associated cognitive impairment to help identify novel targets and approaches for therapeutic development. In this chapter, we have focused the discussion of some of these ne wer emerging concepts.

Innate Immune Responses: Friend or Foe

Most studies consider the induction of innate immune responses such as cytokines, chemokines, oxidative stress, and proteases to be detrimental to the neuron. This concept has been applied to most neurode generative diseases, including HIV -associated cognitive impairment (Fig. 1). However there are reasons to believe that in the setting of viral infections, such responses may not al ways be hostile to the host. Organisms that lack a cellular immune response often use such innate immune responses to protect themselves from invading pathogens. For example, plants, without a specific adaptive immune system, may use metalloproteinases, along with other innate defense mechanisms, to combat infection. F or example, the metalloproteinases-2 gene of the so ybean, Glycine max, is upre gulated in response to a variety of infections (1). Thus in circumstances where the cellular immune responses fail to control the pathogen such as persistent HIV infection of the CNS, the innate immune responses get activated. For example, it has been shown that matrix matalloproteinases (MMP), which are a f amily of structurally similar, zinc-containing endopeptidases, that are known to be increased in patients with HIV dementia can cleave the Tat protein of HIV and thus inactivate it and prevent the protein from causing neurotoxicity or from transactivating the HIV genome (2). Similarly, oxidative stress may be an attempt by the host to cause inactivation of viral proteins by modification by free radicals, nitric oxide, or reactive aldehydes released by lipid peroxidation. However, these types of of fensive mechanisms are nonspecif ic and can result in damage to the host cells (Fig. 1). This is particularly true when there is a chronic activation of the innate immune responses. Considering the same e xample of MMPs, it has been sho wn that these molecules can enzymatically de grade the extracellular matrix proteins and can thus disrupt the blood-brain barrier and neuronal synapses (3- 6)MMPs can also cleave other host proteins, such as chemokines (7), and these cleavage products can cause neurotoxicity. Further, MMPs may directly interact with integrin receptors on neurons, and initiate a cascade of events leading to neuronal cell death (8).

Further, innate immune responses may interact with one another . MMPs can become nitrosylated and persist in a hyperacti ve state, perhaps contributing to neurotoxicity under conditions of oxidative stress (9). Autopsy studies also confirm elevated levels of inducible nitric oxide synthase (iNOS) in patients with HIV dementia (10–11). iNOS is present in macrophages and microglia and its le vels




Fig. 1 Nonspecific antiviral effects of the immune system leads to CNS damage. Activated macrophages release free radicals and induce oxidative and nitrosative stress, which may directly interact with viral proteins and cause functional impairment. These cells also release proteases such as matrix metalloproteinases that may cleave viral proteins. However, these responses may also damage neurons and glial cells. Similarly, activated T cells may enter the brain in patients treated with antiretroviral drugs, leading to an immune reconstitution syndrome. These cells are unable to clear the virus from the brain, but in the process may release proteases such as granzyme, perforin, and granulolysin. These substances may also be toxic to other brain cells (*See Color Plates*)

correlate with the severity of HIV dementia (12–16). In a simian immunodeficiency virus model of HIV dementia, iNOS e xpression was found to correlate with dendritic injury (17). Nitric oxide and peroxynitrite are potently toxic to neurons and may mediate toxicity through the formation of iron–nitric oxide comple xes of iron-containing enzyme systems, oxidation of protein sulfhydryl groups, nitration of proteins, nitrosylation of nucleic acids, and DN A strand breaks (re viewed in (18)). In the presence of both free oxygen species and nitric oxide, peroxynitrite may be formed. Peroxynitrite is highly reacti ve and modifies tyrosine residues in proteins to form 3-nitro-tyrosine, although it may modify c ysteine and histidine residues as well. We found elevated levels of 3-nitro-tyrosine-modified proteins in

the CSF of individuals with progressive deterioration of neurocognitive dysfunction over several months, also termed *active HIV dementia*. 3-nitro-tyrosine levels are a much more sensitive indicator of nitrosative stress than nitrate and nitrite levels in CSF (Li et al., 2008).

Other forms of oxidative stress such as protein carbon yls, a measure of protein oxidation, and hydroxynonenol ester (HNE) levels, a measure of lipid peroxidation, are also ele vated in the CSF and brain of indi viduals with HIV dementia (20). Measurement of ceramide and sphingomyelin levels in CSF may also have a predictive value in identifying individuals at risk of HIV dementia, as these lipid products are also altered by oxidati ve stress (22). Studies in vitro also demonstrated that HIV proteins gp120 and Tat may induce neuronal death through induction of oxidati ve stress (23). Future studies need to address the precise proteins that are functionally altered as a consequence of oxidati ve stress and if production of ne w proteins by the cells can o vercome the posttranslational modif ications by oxidati ve stress of these proteins. Importantly, it needs to be determined if there is accompan ying alterations in chromosomal DNA or DNA repair enzymes by these processes, for it may have far-reaching consequences on cellular function.

Immune Reconstitution Syndrome: An Unrecognized Consequence of Antiretroviral Therapy

It has only recently been recognized that some patients may de velop a devastating neurological syndrome following the initiation of combined antiretro viral therapy. This occurs despite a drop in viral load and impro vement in CD4 cell counts. Although this syndrome may involve other organ systems, when it involves the CNS it may be fatal. The syndrome has been termed *immune reconstitution inflammatory* syndrome (IRIS) and is def ined as a continual clinical deterioration of a patient successfully treated with combined antiretroviral therapy (24). The lower the CD4 cell count at the time of initiation of antiretro viral therapy, the greater seems to be the risk of development of IRIS, as well as increased risk of f ailure to completely reconstitute the immune responses (24, 25). The reconstitution of the immune system after the initiation of combined antiretro viral therapy follows a predictable pattern of an initial increase in memory T cells, follo wed by an increase in thymic production of naive T cells, with an increase in the overall quantity of CD4+ T cells (25, 26). Other risk factors for development of IRIS include a high viral load at the onset of antiretroviral therapy, a prompt reconstitution of the immune system after initiation of therapy, and infection with an opportunistic pathogen prior to combined antiretroviral therapy (27).

Complications arising from reconstitution of the immune system are discernible in the CNS as well as in other regions, and can lead to a rapid neurological deterioration of the patient over days (28). This process is mediated by a rob ust immune response targeted at either an opportunistic infection present prior to the initiation of combined antiretroviral therapy, or to unknown antigens, possibly even self-antigens (24). IRIS occurs in approximately 15–35% of HIV patients initiating combined antiretroviral therapy, with similar percentages occurring in children (27, 29, 30). Some patients develop fulminant encephalitis once combined antiretroviral therapy is begun. Although the fulminant forms of CNS-IRIS have received attention, it is quite likely that, in the era of combined antiretro viral therapy, other milder forms of IRIS also exist.

Histology shows massive infiltration of T cells in the brain inpatients with CNS-IRIS, which leads to an increase in neuronal death, and break do wn of the blood-brain barrier (31-33). This impairment of the BBB can then in turn permit greater immune cell access to the brain. Importantly, studies have emerged that identify increased T cells in the brain of patients who came to autopsy or underwent a brain biopsy in the postcombined antiretro viral therapy era (33, 34). HIV dementia is largely driven by macrophage activation and HIV-infected macrophages, whereas T cells appear to mediate the detrimental effects of IRIS (34, 35) (Fig. 1).

The clinical manifestations of CNS-IRIS are diverse and depend on the presence or absence of, as well as the type of, opportunistic infections present. Se veral opportunistic infections play an established role in the de velopment of CNS-IRIS, such as *Mycobacterium* species, *Cryptococcus*, JC virus, and Cytome galovirus, each with diverse clinical symptoms and outcomes (28). Once CNS-IRIS is identified, treatments include the use of corticosteroids to suppress the immune system (24, 28). Preventive measures include careful screening for opportunistic infections prior to the onset of combined antiretro viral therapy and appropriate interv ening therapy if necessary to reduce antigen presentation.

The pathophysiology of IRIS is poorly understood, ho wever, the production of both the antibody response and the CTL response depends on the effective stimula-(37, 38). Apart from indirect control of anti viral tion by CD4+ helper T cells immune responses, CD4+ cells are capable of ef fector functions via the release of cytokines and induction of cell lysis. A robust CD4+ cellular response is correlated with a lower persisting viral load, as compared with patients with a reduced CD4+ T-cell response (37), highlighting the importance of CD4+ T cells in controlling HIV infection. Additionally, CD4+ T cells may play important roles in controlling pathogens in the CNS (39, 40), as indicated by both functional studies and by CD4+ T cells comprising a higher percentage of the total T -cell population in the CNS (41, 42). However, HIV preferentially infects HIV-specific CD4+ T cells, leading to a depletion of this subset of T cells (43), in conjunction with other mechanisms (44). The loss of IL-2-producing CD4+ T cells causes an o verall diminished immune response to HIV, as central memory T -cell (CCR7+, CD45RA-, IL-2producing) numbers decrease compared with ef fector memory T-cell numbers (CCR7-, CD45RA-, low proliferation) (45). The adaptive immune response to HIV is important in controlling viral replication; ho wever, the same response in the context of the CNS can be detrimental to a patient, as the neurons are not equipped to handle sustained and aggressive inflammation.

Much research is urgently needed to improve our overall understanding of the mechanisms that contribute to CNS-IRIS disease processes, especially in investigating the activation of T cells in the absence of opportunistic infections and in characterizing

the immune cells in volved in IRIS. The recent de velopment of a non-CNS-IRIS model in rabbits (46) should be a useful tool in dissecting, in part, the underlying mechanisms of aberrant T-cell activation, and should provide an insight into other nontuberculosis antigens the immune cells recognize. De velopment of an SIV model of CNS-IRIS would be advantageous, as this model could be used to test potential therapeutics. Until all f actors contributing to IRIS are fully understood, the contradictions to combined antiretroviral therapy will remain unpredictable, and potential interventions to prevent IRIS will remain elusive.

Modulation of Neurogenesis in HIV infection: A New Target for Neuroregenerative Therapies

Much attention has been focused on trying to protect the injured or dying neuron. Several detailed studies have clearly shown evidence of neuronal apoptosis and dendritic loss in the brain of HIV-infected patients, and experimental studies have implicated HIV proteins and substances released from activated glial cells in causing the damage. Despite this o verwhelming evidence, to date all clinical trials with neuroprotective therapies have shown little or no improvement in cognitive function in patients with HIV infection (47). These observations are not unique to HIV dementia but in most neurode generative diseases, such as Alzheimer's disease, Parkinson's disease, strok e, and amyotrophic lateral sclerosis, neuroprotecti ve therapies have been dismal f ailures. This has made us and others ree valuate the therapeutic targets. It is becoming abundantly clear that there is continuous replacement and regeneration of neurons during adulthood; hence, any impairment of neurogenesis may have far-reaching consequences on the brain. HIV has been sho wn to infect neural progenitor cells in vitro and in vivo. These cells express CXCR4, a coreceptor for HIV, and promote the dif ferentiation of these cells into astroc ytes instead of neurons (48, 49). Exposure of neural progenitor cells also results in decreased proliferation of these cells (50), causing an arrest in the G1 phase of the cell c ycle via a cascade that consists of p38 mitogen-activated protein kinase (51). Thus therapeutic strategies that are able to o vercome this block and promote neurore generation may be a new approach for treatment of HIV dementia and other neurodegenerative disorders. Renewed attention has thus been diverted toward growth factors such as erythropoietin and brain-derived growth factor as well as antidepressant drugs that promote growth factor production (52).

Regulation of HIV Reservoirs in Brain: Need for New Therapeutic Targets

HIV predominantly infects two cells types, the macrophages/microglia and perivascular astrocytes. The virus can reside in these cell types for e xtended periods of time. It leads to a productive or persistent infection in the macrophages; however, in astrocytes it forms a latent infection, whereby the early viral proteins are formed b ut infectious virus is not produced. In this state, transient viral replication maybe stimulated by exposure to cytokines (53, 54). Astrocytes also have a very low turnover rate and hence these cells are perfect reservoirs for the virus. Some groups have shown that neurons, endothelial cells, and neural progenitor cells are also capable of getting infected and, similar to astrocytes, form a nonproductive infection. That the virus is able to infect multiple cells types comes as no surprise; ho wever, eliminating these reservoirs is a formidable challenge. Mechanisms that regulate viral replication in these cell types or maintain them in this latent state are poorly understood. One study implicated the 68-kDa Src-associated protein that binds to Re v and is involved in its transport to the nucleus and is poorly expressed in astrocytes (55). Unpublished observations from our laboratory have shown that the promyeloc ytic leukemia protein is e xpressed at high levels in astrocytes compared with lymphocytes and macrophages and can bind to Tat proteins and thus prevent HIV replication (Galey and Nath, unpublished).

Role of Viral Strains and Clades in HIV Neuropathogenesis

The spectrum of viral genotypes or quasispecies are generated throughout the course of disease because of the lo w fidelity of reverse transcriptase, a lack of proofreading by the viral polymerase, high rates of viral production, and in vi vo selection pressures (56). Hence once the virus enters the brain, it may e volve acquiring sequence heterogeneity different from that in lymphoid organs due to the different selective pressures in the brain. Thus far, only a limited number of studies have looked at viral sequences from brain tissue and a fewer have tried to make any functional correlation of the viral sequences. However, available evidence suggests that the brain-derived viral sequences tend to favor its establishment as a reservoir, e.g., brain-derived *tat* sequences from HIV-demented patients are poor transactivators of the HIV-LTR, which permits the virus to stay latent and thus escape the immune system (57). At the same time, the y acquire more neurotoxic properties and both Tat and gp120 sequences from HIV -demented patients show increased neurotoxic potential (57, 58).

As the virus has e volved and spread to dif ferent regions of the w orld, it has become apparent that there are clear geographical dif ferences in the neurological manifestations of HIV infection. In regions of the world infected with HIV clade C, only milder forms of cogniti ve impairment have been recognized e ven in patients with advanced immunosuppression in the absence of antiretroviral therapy (28, 59). While it is possible that patient selection bias may in part be responsible for these differences, there is also evidence to suggest that genetic differences in the *tat* gene of the HIV clades may also alter the pathogenicity of the virus. F or example, the cysteine in position 31 of clade B virus is mutated to a serine in clade C virus. This mutation results in decreased chemotactic properties of clade C virus and decreased neurotoxicity (60, 61). Studies from Uganda suggest that indi viduals infected with clade D virus are more likely to develop dementia compared with those infected with clade A virus (62). The molecular determinants of these differences are unknown.

In summary, recent studies indicate that the pathophysiology of neurological complications are much more comple x than that previously thought. They likely occur in genetically susceptible populations and may be impacted by the strain and clade of the virus. The role of T cells and innate responses in mediating the syndromes have become increasingly important in the era of antiretro viral therapy. These insights will dictate new therapeutic approaches for this population.

Role of Host Genetic Factors in HIV Neuropathogenesis

The epidemiology of HIV dementia suggests that host genetic factors must contribute to the pathophysiology of HIV dementia. Some patients despite high viral loads and profound immunosuppression remain cognitively intact, while a smaller percentage of such patients develop a dementing illness. Despite this overwhelming evidence, only a handful of genes have been studied as a potential factor in HIV neuropathogenesis. One reason is that such studies require lage sample sizes. The Apo E genes have been best studied in this regard. Both population-based and experimental studies in vitro and in vivo suggest that individuals with ApoE4 gene are more likely to develop HIV dementia (63) in particular among older HIV+ indi viduals (64). Individuals with HIV infection and ApoE4 allele have increased oxidative stress in the brain and CSF (65, 66) and human neuronal cultures with the ApoE4 allele are more vulnerable to toxicity by HIV proteins (66). Further, human lipidated apoE3 greatly protects neurons from HIV T at protein-induced toxicity, whereas human lipidated apoE4 shows no protection (67). Other epidemiological studies suggest that macrophage chemoattractant factor-1 or CCL-2 mutations (68) and mutations in its receptor CCR2 (64-I allele) (69) correlate with the presence of dementia likely by influencing macrophage inf iltration. Tumor necrosis factor- α promoter polymorphisms also correlate with the presence of dementia lik ely by influencing levels of tumor necrosis factor- α production, which may induce neurotoxicity (70). Polymorphisms in the iNOS gene ha ve been found in humans. A functional CCTTT-repeat polymorphism in the promoter region of the gene was not found to affect HIV viral load or CD4 cell counts in HIV-infected individuals (71); however, its role in inducing nitrosative stress in the brain of HIV-infected individuals has not yet been studied .

References

- Liu ,Y , Dammann ,C. and Bhattacharyya ,M.K. The matrix metalloproteinase gene GmMMP2 is activated in response to pathogenic infections in so ybean. Plant Physiol, 2001. 127 (4)788 – 97 .
- 2 . Rumbaugh J. et al., Interaction of HIV Tat and matrix metalloproteinase in HIV neuropathogenesis: a new host defense mechanism . Faseb J , 2006 .20 (10) 736 8.

- 3 .Libby R.T ,etal., Disruptionof laminin beta2 chain production causes alterations in morphology and function in the CNS [In Process Citation]. JNeurosci, 1999.19 (219399 411.
- 4 . Rtton, B.L. Chiu A.Y and Sanes J.R. Synapticlaminin prevents glial entry into the synaptic cleft . Nature 1998 .393 (6686698 701 .
- 5. Nichol K.A. Schulz M.W and Bennett M.R. Nitricoxide-mediated death of cultured neonatal retinal ganglion cells: neuroprotective properties of glutamate and chondroitin sulfate proteoglycan. BrainRes, 1995.697 (1–2) = 16.
- 6 .Bozzo C. etal., Solubleintegrin ligands and growth factors independently rescue neuroblastoma cells from apoptosis under nonadherent conditions. ExpCell Res, 1997.237 (2326 – 37).
- 7 .Zhang K. et al., HIVinduced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration . NatNeurosci , 2003 .6 (10)064 71 .
- 8 .Conant K. etal., MMP-1 interacts with neuronal integrins and stimulates dephosphorylation of Akt . JBiol Chem , 2003 .279 (98056 - 62) .
- 9 .Gu Z. etal., S-nitrosylationof matrix metalloproteinases: signaling pathway to neuronal cell death . Science 2002 .297 (5584)186 90 .
- 10 . Haughe N.J. et al., Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia . AnnNeurol , 2004 .55 (22)57 67 .
- 11 . AdamsonD,C. et al., Immunologic NO synthase: Elevation in severe AIDS dementia and induction by HIV-1 gp41 . Science $1996\ 274\ 1917\ -\ 20$.
- 12 .Rostasy K. et al., Human immunodeficiency virus infection, inducible nitric oxide synthase expression, and microglial activation: pathogenetic relationship to the acquired immunodeficiency syndrome dementia complex. AnnNeurol, 1999 .46 (2207 16.)
- AdamsorD,C. etal., Mechanisms and structural determinants of HIV-1 coat protein, gp41induced neurotoxicity. JNeurosci, 1999. 19 (164: - 71).
- 14 . ZhaoM.L. etal., Expression f inducible nitric oxide synthase, interleukin-1 and caspase-1 in HIV-1 encephalitis . JNeuroimmunol , 2001 .115 (1–2)82 91 .
- 15 .iNcent, VA. ,etal., Nitricoxide synthase expression and apoptotic cell death in brains of AIDS and AIDS dementia patients. AIDS 1999 .13 (3317 – 26.
- 16 . Nuo, G.J. and Aférie, M.L. AIDS dementia is associated with massive, activated HIV-1 infection and concomitant expression of several cytokines. MolMed, 1996. 2 358 366.
- 17. LiX, "Tonstad, L. and Olsen I. Brain abscesses caused by oral infection. Endod Dent Traumatol, 1999. 15 (395: 101.
- 18 .at n_1 , R.and Singh I, Pharmacological strategies for the regulation of inducible nitric oxide synthase: neurodegenerative versus neuroprotective mechanisms. Neurochem Int, 2006 . 49 (2)70 - 82 .
- Li, W., et al., Nitrosative stress with HIV dementia causes decreased L-prostaglandin D synthase activity. Neurology, 2008. 10(19Ptz): 1753–62.
- 20 .ufchan, J. etal., Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants. Neurology, 2003 .60 (2307 - 14.
- 21 . Akseno M.Y ,etal., Oxidative damage induced by the injection of HIV-1 Tat protein in the rat striatum . NeurosciLett , 2001 .305 (15 \div 8 .
- 22 . KrumarI., Nath A. and Mattson M.P HIVprotein Tat induces apoptosis by a mechanism involving mitochondrial calcium overload and caspase activation. ExptNeurol, 1998.154 : 276 88.
- 23 . Mace, D.R. etal., Deltaopioid agonists attenuate TAT(1–72)-induced oxidative stress in SK-N-SH cells . Neurotoxicology, 2006 .27 (1)01 7 .
- Shallne, S.A. JII etal., Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore), 2002.
 81 (3)13 27.
- 25 . MooreR,D.and Kruly, J.C. CD4+cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis, 2007. 44 (3341 6).
- 26 . Roderly, WG., Landay A. and Lederman M.M. Recovery of the immune system with antiretroviral therapy: the end of opportunism? AMA, 1998. 280 (172: 7.

- 27 . Shallne, S.A. et al., Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005 .19 (4399 406 .
- 28 . RiedeD,J. etal., Therapy insight: CNS manifestations of HIV-associated immune reconstitution inflammatory syndrome. NatClin Pract Neurol, 2006.2 (10557 - 65.
- 29 . FrenchM.A. Disordersof immune reconstitution in patients with HIV infection responding to antiretroviral therapy . CurrHIV/AIDS Rep , 2007 .4 (1)6: 21 .
- Puthanakit T, etal., Hospitalizationand mortality among HIV-infected children after receiving highly active antiretroviral therapy. ClinInfect Dis, 2007.44 (4599 – 604.
- 31 .Langford TD. , etal., Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy . AIDS 2002 .16 (7)019 29 .
- 32 . MillerR.F ,et al., Cerebral CD8+ lymphocytosis in HIV-1 infected patients with immune restoration induced by HAART . ActaNeuropathol (Berl) , 2004 .108 (1)7: 23 .
- 33 PetitC,K. etal., BrainCD8+ and cytotoxic T lymphocytes are associated with, and may be specific for, human immunodeficiency virus type 1 encephalitis in patients with acquired immunodeficiency syndrome. JNeurovirol, 2006 .12 (4272 - 83).
- 34 .eWkataramana, A. etal., Immunereconstitution inflammatory syndrome in the CNS of HIVinfected patients. Neurology, 2006 .67 (3383 – 8.
- 35 . Elli R, Langford D. and Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair . NatRev Neurosci , 2007 .8 (133: 44 .
- 36 . Gonzalez-ScaranoE, and Martin-Garcia J. The neuropathogenesis of AIDS . Nat Rev Immunol, 2005 .5 (169: – 81).
- 37 . Gloste S.E. et al., Association of strong virus-specific CD4 T cell responses with efficient natural control of primary HIV-1 infection . AIDS 2004 .18 (5749 55 .
- 38 . Rosenber E.S. etal., Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997 .278 (5342)447 – 50.
- 39 .Gasser O. etal., HIVpatients developing primary CNS lymphoma lack EBV-specific CD4 + T cell function irrespective of absolute CD4 + T cell counts . PLoSMed , 2007 .4 (3)96 .
- 40 . SinclaiE. etal., Protective immunity to cytomegalovirus (CMV) retinitis in AIDS is associated with CMV-specific T cells that express interferon- gamma and interleukin-2 and have a CD8+ cell early maturational phenotype. JInfect Dis, 2006.194 (11)537 46.
- 41 . MukhtaM. etal., TCells and excitotoxicity: HIV-1 and other neurodegenerative disorders . NeuromolMed, 2005 .7 (3265 - 73.
- 42 .Sønningsson, A. etal., Iymphocyte phenotype and subset distribution in normal cerebrospinal fluid . JNeuroimmunol, 1995 .63 (139: 46 .
- 43 . DouekD,C. et al., HIV preferentially infects HIV-specific CD4+ T cells . Nature ,2002 . 417 (688495: - 8.
- 44 . RibeiroR,M. Dynamics of CD4+ T cells in HIV-1 infection. Immunol Cell Biol, 2007.
 85 (4387 94.
- 45 .aRner, B.E. ,Boritz E. and Wison, C.C. Efects of sustained HIV-1 plasma viremia on HIV-1 Gag-specific CD4+ T cell maturation and function. J Immunol, 2004 . 172 (5) : 3337 47.
- 46 . ManabeYC. ,etal., Theaerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome . Tuberculosis (Edinb) , 2007 .88 (3)87 196
- 47 . Tirchan , J. et al., Neuroprotective therapy for HIV dementia . Curr HIV Res , 2003 . (4) : 373 – 83 .
- 48 . Lwrence , D.M. et al., Human immunod eficiency virus type 1 infection of human brainderived progenitor cells . J Virol , 2004 . 78 (147319-28 .
- 49 . Rothenaigneil. et al., Long-termHIV-1 infection of neural progenitor populations . AIDS , 2007 .21 (17)271 - 81 .
- 50 .eWkatesan, A. et al., Adult hippocampal neurogenesis: regulation by HIV and drugs of abuse . CellMol Life Sci , 2007 .64 (162)120 32 .
- 51 .Okamoto S. etal., HIV/gp120decreases adult neural progenitor cell proliferation via checkpoint kinase-mediated cell-cycle withdrawal and G1 arrest. CellStem Cell, 2007 .1 (2230 – 6.

- 52 . KauM, and Lipton S.A. Experimental and potential future therapeutic approaches for HIV-1 associated dementia tar geting receptors for chemokines, glutamate and erythropoietin . NeurotoxRes , 2005 .8 (1–2)67 – 86 .
- 53 .offnatore, C. etal., PersistentHIV-1 infection in human fetal glial cells reactivated by T cell factor(s) or c ytokines tumor necrosis f actor- α and interleukin-1 beta. J Virol, 1991.65 : 6094 100.
- 54 .Brack-Wrner, R. Astroytes: HIV cellular reservoirs and important participants in neuropathogenesis [editorial]. AIDS 1999 .13 (1) = 22.
- 55 .Li J. etal., Expression fexogenous Sam68, the 68-kilodalton SRC-associated protein in mitosis, is able to alleviate impaired Rev function in astrocytes. JVirol, 2002 .76 (94526 - 35.)
- 56 .Gao F, etal., Molecularcloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. JVirol, 1996 .70 (3)651 – 67.
- Johnston J.B. etal., HIV1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors. AnnNeurol, 2001. 49 (2)30 – 41.
- 58. Reer, C. et al., Neuronal death induced by brain-derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients. J Virol, 1998.72 (119045 - 53.
- 59 . Gupta D. etal., Neuropsychological deficits in human immunodeficiency virus type 1 clade C-seropositive adults from South India . JNeurovirol , 2007 .13 (3)95 - 202 .
- 60 . RangaU, etal., Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine. JVirol, 2004.78 (53586 90.
- MishraM. et al., Clade-specifc differences in neurotoxicity of human immunodeficiency virus-1 B and C Tat of human neurons: significance of dicysteine C30C31 motif. Ann Neurol, 2008.63 (3366 - 76.
- 62 . SacktoN. etal., HIVassociated cognitive impairment in sub-Saharan Africa–the potential effect of clade diversity . NatClin Pract Neurol , 2007 .3 (8)36 43 .
- 63 . CordeE.H. etal., HIVinfected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy [see comments]. NatMed, 1998.4 (10)182 4.
- 64 .akour, V ,etal., Age,apolipoprotein E4, and the risk of HIV dementia: the Hawaii Aging with HIV Cohort . JNeuroimmunol , 2004 .157 (1–2)97 202 .
- 65 . Cutlet R.G. et al., Dysrgulation of sphingolipid and sterol metabolism by ApoE4 in HIV dementia . Neurology, 2004 .63 (4626 30 .
- 66 .uftchan-Cholewo, J. et al., Increased vulnerability of ApoE4 neurons to HIV proteins and opiates: protection by diosgenin and L-deprenyl. NeurobioIDis, 2006 .23 (1)09 19.
- 67 . PocernichC,B. et al., Efects of apolipoprotein E on the human immunodeficiency virus protein Tat in neuronal cultures and synaptosomes . JNeurosci Res , 2004 .77 (4532 9 .
- 68 . GonzaleÆ, etal., HIV1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci USA, 2002 .99 (21)3795 800 .
- 69 . SinghK,K. et al., CCR2 polymorphisms affect neuropsychological impairment in HIV-1-infected adults . JNeuroimmunol , 2004 .157 (1-2),85 92 .
- 70 . Quaspe M.W , et al., Increased frequency of the tumor necrosis factor- α -308 A allele in adults with human immunodeficiency virus dementia. AnnNeurol , 2001 .50 (2)57 62 .
- 71 . Hershær, M. etal., CCTTFrepeat polymorphism of the inducible nitric oxide synthase is not associated with HIV pathogenesis . ClinExp Immunol , 2004 .137 (3566 – 9.

Neuropathological Findings Associated with Long-Term HAART

Iain C. Anthony and Jeanne E. Bell

Introduction

The introduction of highly acti ve anti-retroviral therapy (HAART) in 1996/1997 had a profound impact on the course of HIV infection. The use of HAAR T results in a significant decrease in viral load, often below the limits of detection in serum. This, coupled with increased CD4 T lymphocyte counts and at least partial restoration of the immune system, provides protection for infected subjects from opportunistic infections, which were pre viously the major cause of morbidity and mortality in HIV. HAART is not a cure for HIV and the virus is ne ver fully eradicated, but for those subjects able to tolerate its toxic side ef fects, HAART has converted HIV infection into a long-term chronic disease with reasonable life e xpectancy.

Since the first reports of AIDS in the early 1980s, it has been clear that the central nervous system (CNS) is frequently a direct tar get of the disease. The disease manifestations that point to brain involvement include neurological dysfunction as well as neurocognitive deficits, which may progress to dementia. HIV-related dementia (HAD) was typically sub-cortical in that psychomotor slo wing and executive dysfunction in addition to memory loss were prominent features. HAD was common in the pre-HAART era, occurring in 10-20% of AIDS subjects. However the exact pathological basis of this dementia has proved difficult to elucidate. Although HIV can infect the brain directly by in vading microglial cells, the ensuing encephalitis (HIV encephalitis, HIVE) was not found to be present in all indi viduals who had developed HAD. To further complicate matters, some of the opportunistic conditions that affect the brain in untreated AIDS can also cause dementia and at autopsy nearly all AIDS cases proved to have some form of pathology in the CNS. Unfortunately, the problem of HAD has not been eclipsed since HAAR T became a vailable. Although the prognosis for HIV -infected individuals treated with HAAR T has changed immeasurably for the better, with a decline in the incidence of the more

I.C. Anthony (🖂)

Centre for Infectious Diseases, University of Edinburgh ,Edinburgh, Scotland, EH89AG ianthony@staffmail.ed.ac.uk

severe forms of HAD, neurocognitive disability in the form of mild neurocognitive disorder (MND) is still detectable in a significant proportion. The challenge remains to determine the cause of MND while accepting that HAD remains incompletely understood. Neuropathological investigation of the brain in HAART-treated individuals, including those with cogniti ve impairment, is lik ely to contribute in solving this problem so that pre ventive or protective strategies may be de vised for long-term HIV-infected survivors. To assess the pathological f indings in the brains of HAART-treated individuals, it is helpful to first consider the effects of HIV in the brain before HAART was introduced.

Neuropathology of HIV-Infected Subjects in the Pre-HAART Era

The mortality of untreated HIV infection is most often associated with symptomatic AIDS, resulting in man y published studies relating to the neuropathology of this novel condition. There are far fewer studies of the autopsy brain in the pre-symptomatic stages of HIV infection, but these should not be ne glected since there is e vidence that HIV enters the brain compartment quite soon after initial infection and before the onset of AIDS.

Neuropathology in Untreated Pre-Symptomatic HIV-Infected Individuals

HIV-infected pre-symptomatic subjects rarely die before the onset of AIDS, since they generally have CD4 lymphocyte counts above 400 cells/ μ l and are not then vulnerable to the range of infections seen in the end stages. Drug ab use and overdoses, accidental or otherwise, are the usual reason for death in pre-AIDS and have provided opportunities to investigate CNS involvement in the pre-symptomatic phase of HIV infection (1, 2). Studies of a unique cohort of HIV-infected intravenous drug abusers in Edinburgh (UK), who were known to have acquired their infection in late 1983/early 1984, showed relatively minor changes in comparison with those seen in AIDS (1). Characteristic AIDS-related conditions, including HIVE and CNS opportunistic infections, such as toxoplasmosis, cytomegalovirus (CMV), varcella zoster virus (VZV) or Cryptococcus neoformans were found to be absent in pre-AIDS brains. Despite this, there is evidence of inflammation in the CNS of many of these subjects, in the form of a low grade lymphocytic leptomeningitis and perivascular lymphocytic cuffing, particularly in the central white matter (1, 2). The perivascular cuffs are composed predominantly of CD8 positive lymphocytes, although significant numbers of CD20 positive B lymphocytes are also present (3). There is little evidence of CD4 T-lymphocytes within the infiltrates. In addition to lymphoc yte responses in the pre-symptomatic brain, microglial acti vation has also been demonstrated,

together with subtle gliosis (4, 5). Mild axonal damage can sometimes be observed in the brains of pre-symptomatic subjects (6). This is demonstrated by the accumulation of molecules such as β amyloid precursor protein (β APP), as a result of disrupted transport within affected axons. Axonal damage can be caused by a number of insults, including trauma, inflammation, and hypoxia, all of which may be operational in pre-symptomatic HIV-infected individuals.

These appearances are suggestive of a CNS response to viral infection, and there is evidence that HIV does enter the nerv ous system before the onset of AIDS (7). There is some evidence that the CD8 lymphocytic responses contribute to the control of viral infection in the early stages of the disease (8). It is unclear whether the activation of microglia and astroc ytes is a direct result of virus penetration of the CNS compartment or whether it is simply an indirect effect of a vigorous systemic response to infection, dri ven by aberrant release of c ytokines in the systemic compartment. In pre-symptomatic subjects, there is no evidence of productive HIV infection in any cell type. However, PCR studies have confirmed low levels of HIV in the brains of some pre-symptomatic subjects (2). There is still no conclusi ve evidence as to which brain cells are harbouring the virus in the early stages of infection. Analysis of the virus recovered from the brains of pre-symptomatic subjects reveals a genotype consistent with a normally macrophage (CCR5) tropic HIV v ariant. suggesting that microglia are the source (9).

Neuropathology of AIDS in the Pre-HAART Era

As HIV-infected subjects progressed into symptomatic AIDS before HAART became available, CD4 lymphocyte counts drop, leaving subjects vulnerable to opportunistic pathogens and tumour formation. Common opportunistic conditions observ ed in the CNS are shown in Table 1. The prevalence of opportunistic conditions v aries somewhat depending on the geographic location of the cohort studied and the risk group for HIV exposure. These opportunistic conditions may be found in isolation or together, but there is no convincing evidence to date of synergy between them. HIVE itself may be found in isolation or together with one or more opportunistic conditions in the brain.

Opportunistic condition	Pre-HAART (n=228)	Post HAART $(n=42)$
Cytomegalovirus (CMV) encephalitis	9%	5%
Primary Central Nervous System Lymphomas	6%	7%
(PCNSL) driven by Epstein Barr virus (EBV)		
Toxoplasmosis	5%	0%
Herpes simplex virus encephalitis	>1%	>1%
Progressive Multifocal Leukoencephalopathy	3%	3%
(PML) (associated with JC virus infection		
of oligodendrocytes)		
Varicella Zoster Virus encephalitis	>1%	>1%

CMV is promiscuous in its cellular tar gets and viral particles may be identified in endothelial cells, neurons and glial cells. T ypically, the infected cell sho ws enlargement of the nucleus and/or the cytoplasm and viral inclusions may be identified in both. Two major forms of CMV encephalitis are described. The f irst of these is a microglial nodular encephalitis in which CMV inclusions may be quite hard to find. The other form displays more florid inflammation and CMV inclusion-bearing cells are relatively frequent in association with polymorphonuclear leucoc ytic infiltration and foci of necrosis.

Toxoplasma gondii is a protozoan that can exist in the brain parenchyma as free organisms or in the form of characteristic c ysts. It can give rise to a necrotising encephalitis, particularly in the peri ventricular tissues, and the associated acute inflammatory exudate may spread to involve the ventricular cavities.

Cryptococcus is a fungus that, if it in volves the CNS, causes a meningitis with a characteristic gelatinous exudate. If the infection spreads to the brain there is a predilection for the basal ganglia where small punctate *ca*vities may become visible to the naked eye. The inflammatory reaction is usually quite sparse.

Progressive multifocal leucoencephalopathy (PML) results from the reactivation of a persistent papovavirus infection in the brain. This infection manifests itself as demyelinating lesions that are often peri ventricular or at the gray–white matter junction. The lesions may be necrotic and are associated with inclusion-bearing oligodendrocytes and enlarged, often bizarre astrocytes.

A few cases of herpes virus infections of the CNS other than CMV have been reported in AIDS. Herpes simplex virus (HSV) encephalitis is caused by infection with HSV1 or HSV2, initially latent within sensory ganglia and reactivated to target the limbic system causing a necrotising inflammation primarily in the temporal lobes. Inflammatory infiltrate may be diffuse in the meninges, and viral proteins and inclusion bodies can be identified in the affected areas. In a similar way, varicella zoster virus may spread from latently infected sensory ganglia to cause myelitis or encephalitis. However, these were rare complications of AIDS.

Primary central nervous system lymphomas (PCNSLs) are high-grade lymphomas of B-lymphocytic origin and are usually monoclonal. Epstein-Barr virus (EBV) is the aetiological agent that dri ves B-cell proliferation and e ventual neoplastic transformation. EBV is present in almost 100% of AIDS-related PCNSLs (10–12). In nearly all instances, there is expression of two key EBV oncogenes LMP-1 and EBNA-2. Expression of LMP-1 leads to upre gulation of anti-apoptotic genes such as BCL-2 in the infected B lymphoc yte, while EBNA-2 is responsible for dri ving the infected cell into S-phase of the cell cycle (13, 14). The expression of these two proteins plays a k ey role in the immortalisation of B lymphoc ytes. PCNSLs are often diffuse and multifocal, with tumour cells forming concentric layers around blood vessels (Fig. 1). The tumours can be found in almost any location in the CNS, including the brain stem and spinal cord.

The immune dysfunction that results from HIV infection permits the development of the opportunistic conditions described earlier . However, HIV itself can also establish a primary infection within the brain. The predominant CNS tar get cells are microglia. These cells e xpress low levels of CD4 antigen in addition to the




Fig. 1 Primary Central Nerv ous System L ymphoma in the brain of an AIDS patient. The Epstein-Barr Virus positive cells are of B lymphocyte origin and form in concentric rings around blood vessels

chemokine receptor CCR5 (15). Both perivascular and parenchymal microglia are capable of supporting productive HIV infection, giving rise to HIVE (16). The prevalence of HIVE in the pre-HAAR T era varied greatly between cohorts, ranging from 5 to 30% of cases (17–19).

During productive infection of the CNS a number HIV proteins may be detected immunohistochemically in microglia, including p24, gp41, gp120 and Nef(20-26). HIV-infected microglia may fuse to give rise to multinucleated giant cells (Fig. 2), which together with microglial nodules form the pathological hallmarks of HIVE (27, 28). A variable degree of macrophage infiltration and microglial activation is also present in HIVE, together with e vidence of astrocytosis and myelin pallor or white-matter damage (29). Foci of HIVE may be present in an y area of the brain, but the basal ganglia and central white matter are particularly af fected, while the neocortical grey matter and brainstem are sometimes involved. The severity of HIVE also varies from mildly affected cases in which only a fe w productively infected microglia and/or giant cells are seen, to florid cases with numerous giant cells, widespread inflammation and extensive tissue damage. The variations in severity of HIVE are likely to contribute to the range of cognitive symptoms in untreated AIDS. Neuroimaging of patients with HAD re veals generalized white-matter reduction, with additional gre y-matter loss, particularly in the basal ganglia and posterior cortex (30, 31). These findings fit with the general neuropathological findings in these cases. Neuronal loss has been described in HAD, and apoptotic cells are commonly found in the basal ganglia and to a lesser e xtent in other regions of the brain, including the hippocampus and frontal corte x (32, 33). Particular subsets of




Fig. 2 HIV infected microglia may fuse to give rise to multinucleated giant cells, which together with microglial nodules form the pathological hallmarks of HIVE

neurons may be particularly vulnerable in HIV-related CNS damage. Axonal damage is also evident, with myelin pallor and accumulation of β amyloid precursor protein (β APP) in axons, which displays focal axonal swellings and disruption of axonal transport. At a more subtle le vel, evidence of synaptic and dendritic damage has been reported in AIDS (34, 35). Animal models and in vitro systems have been used extensively to study the pathogenesis of HAD (36, 37).

There has been significant interest in the evidence of activated microglia and macrophages in the brain since the discovery that this was the feature that correlated most closely with the onset of HAD (38), irrespective of whether activated cells were actually HIV infected. Activation of microglia, particularly in the basal ganglia, and influx of macrophage/monocytes are prominent features in the brains of subjects with HAD and have been suggested by a number of authors to be the pathogenetic basis for the observed clinical symptoms (38–41). Although it is likely that neuronal loss and damage form the proximal substrate for cognitive impairment, the fact that microglial activation also correlates well with cognitive status engenders suspicion that these cells are the major source of neurotoxic molecules, such as pro-inflammatory cytokines, nitric oxide, free radicals and others, which lead to neuronal damage(42, 43). These microglia/macrophages display upre gulation of a v ariety of cellular markers, including CD14, CD16, CD45, CD68 and MHC class II (17, 38, 43-47). The degree of activation and upregulation is also related to the type of infection present, whether it be opportunistic or HIV itself. Thus CMV encephalitis induces upregulation of CD68 on microglia. In contrast, toxoplasmosis preferentially upregulates MHC class II, while HIVE provokes upregulation of both markers (48). In addition to changes in the phenotype of resident microglial cells, increased influx of monocytes and macrophages from the blood has been reported (39, 40), possibly facilitated by changes in the blood-brain barrier (49).

In most subjects with CNS opportunistic infections or HIVE focal inf iltrates of CD8 lymphocytes are present. However, it is unclear how effective these cytotoxic T cells are in late-stage AIDS when the systemic immune system is in a state of terminal dysfunction. The astrogliosis observed in AIDS may be more significant than just a reaction to neuronal and other damage in the CNS, since these cells are believed to be capable of supporting a restricted form of HIV infection (50, 51), which may cripple their neuronal glutamate b uffering functions. Ho wever the extent of astrocyte infection in vivo remains unknown since the evidence of productive infection is not detected in these cells.

In occasional AIDS patients, e ven at advanced stages of immunosuppression, there is little evidence of significant CNS disease, and HIV-related disorders may not be evident in the brain at autopsy. However, the brain is rarely entirely normal even if the changes are minor and non-specific.

Some Effects of Drug Abuse in the Brain Mimic Those of HIV

Drug abuse is clearly a confounding f actor in assessing the effects of HIV in the brains of pre-symptomatic and some AIDS subjects, and the influence of drug abuse on the CNS must be considered together with HIV in this context. The problem of drugs as possible co-f actors for AIDS progression has been e xplored in animal models and in vitro (52). Drug abuse is known to cause mild activation of microglia, possibly adding to the neuroinflammatory response observed in pre-symptomatic subjects (5). Axonal injury as shown by expression of β APP is also evident in the brains of HIV-negative drug abusers (53, 54) A number of studies have demonstrated other neuronal and dendritic damage in HIV-negative drug abusers (53–56). Some of this CNS damage is undoubtedly hypoxic/ischaemic in origin. Intra venous drug abusers are at risk of co-infection with hepatitis B or C. Liver dysfunction, particularly cirrhosis, can cause hepatic encephalopathy, contributing to cognitive problems in this group of subjects. Recently there has been gro wing interest in the possibility that hepatitis C can enter the CNS and infect the brain directly thus leading to signs and symptoms of brain dysfunction (57–59).

Neuropathological Findings in the Post-HAART Era

The introduction of HAART has resulted in a marked improvement in the prognosis for HIV-infected subjects, with HIV becoming a chronic disease in those who are compliant with long-term HAART. AIDS defining illnesses are no longer the major cause of death in HIV. Instead other factors such as hepatitis Cinfection are becoming important in HIV-related mortality. Drug abuse continues to contribute to mortality in these circumstances. The benefits of HAART are apparent not just in the systemic organ systems, but also in terms of CNS disorders despite the poor penetration of the brain by some of the drugs used in HAART (60). Since the effect of HAART is to limit disease progression and maintain treated subjects in a state of partial immune competence, it would seem logical to predict that post-HAART neuropathology would closely resemble that observed in pre-symptomatic subjects in the pre-HAART era. However, the evidence accumulated to date suggests that this is not the case. There is a continued concern that the CNS actsas a sanctuary site for viral persistence and for the emergence of drug resistant HIV and that HAART is not successful in eradicating HIV from the brain compartment (16, 61, 62).

Although the incidence of HAD has decreased since the introduction of HAA \mathbf{R} , there has been a rise in reports of more minor cognitive dysfunctions (63, 64). In addition clinical reports suggest that the regions of the brain maximally affected in HIV have altered (65). In the pre-HAART era subjects with HAD displayed primarily sub-cortical symptoms that correlated well with pathological f indings of damage and inflammation in the basal ganglia. Post-HAAR T, clinical symptomatology in some studies points to wards damage in the hippocampus and temporal lobe, although sub-cortical neurode generation characteristic of the pre-HAAR T era is still noted in some studies (66, 67). Dementia is reported as more common in older HIV-positive individuals, suggesting they are more at risk of this complication (68).

The success of HAART in reducing mortality rates has meant that opportunities for autopsy-related study of the effects of HIV on the brain have become much less common. Nevertheless small cohorts of clinically well characterised, HAART-treated subjects have been examined at post-mortem by a number of groups in the US and Europe. It is important to note that the cause of death in these cases may not be directly attributable to HIV or to a f ailure of HAART to control the virus. As noted above, both drug abuse and hepatitis may influence the neuropathological outcomes in these subjects. Others who have been treated with HAART may indeed die after failure of therapy, either because of viral resistance or more lik ely intolerance of the drug regime. If the period between withdrawal of therapy and death is relatively long, then any changes observed in the brain may not be representati ve of those to be found in well-treated subjects. These considerations underline the importance of pursuingstudies in clearly defined groups of patients with well-documented clinical details.

The incidence of most of the major CNS complications that were observed prior to the introduction of HAAR T has f allen. Table 1 sho ws the changes in the Edinburgh cohort since the introduction of HAAR T. There has been a mark ed decline in the incidence of CMV and of toxoplasmosis. The US Multicenter AIDS Cohort Study (MACS) has also sho wn a significant decrease in the incidence of cryptococcal meningitis and CNS lymphoma, with a non-signif icant decrease in toxoplasmosis. The incidence of PML dropped only marginally (69). Some studies have reported an actual increase in HIVE or more severe forms of HIV-related brain disease in HAART-treated individuals (70–73). Gray et al. ha ve shown that in the French cohort there is a decreased incidence of cerebral toxoplasmosis and CMV encephalitis, with the incidence of PML and PCNSL unchanged (72). Gray et al. also report an increase in varicella zoster encephalitis and herpes simplex encephalitis, both previously rare neurological complications of HIV. The decline in opportunistic conditions is undoubtedly due to the HAAR T-induced recovery of the systemic immune system, providing greater protection against common pathogens. Those opportunistic conditions that continue to pose problems may be due to the reactivation of persistent infections as in PML. Reports of HIV resistance to man y of the drugs used in the HAAR T combination are becoming increasingly common, causing concern about the return of rising opportunistic infections. Data from the Centers for Disease Control (USA) suggest that approximately 15.2% of new HIV diagnoses possess strains resistant to at least one antiretroviral drug, with 3.2% being resistant to two or more drugs (74).

One HAART-related effect that has attracted much comment is the emer gence of a new condition termed the *immune reconstitution syndrome* (IRIS). In IRIS cases a sudden and usually fatal episode of encephalopathy follows the commencement of HAART and is associated with extensive demyelination and white-matter damage (75, 76) The myelin damage is accompanied by marked CD8 lymphocytic infiltrate of the brain parenchyma, suggesting that an immunological pathogenesis (75). In most subjects HAART has a positi ve effect on the systemic immune system, resulting in increased CD4 counts and restoration of immune function. The subsequent upturn in the numbers of circulating CD4 and CD8 lymphocytes may result in sudden massive influx of these cells into the brain (75). No information is a vailable with regard to the viral load in brain tissue in these cases. Although there is an assumption that the observed demyelination is caused by the influx of auto-immune lymphocytes into the brain, it should be noted that CD8 lymphoc ytic infiltrate of the brain is also prominent in some pre-symptomatic indi viduals without obvious myelin damage. Equally, the majority of patients started on HAART do not display the signs and symptoms of IRIS, suggesting that those individuals who do develop this condition have additional factors that drive their recovering immune system in the direction of autoimmunity. The factors involved in this process are unclear but given the role of the thymus in the elimination of auto-immune cells during de velopment it seems possible that this organ may play a role in IRIS.

Even in the absence of o vert HIV-related pathology, significant changes have been observed in the brains of HAART-treated subjects, including neuroinflammation in the form of significant microglial upregulation of MHC class II and CD68 (17). This is particularly prominent in the hippocampus and temporal cortex. In contrast, the basal ganglia are relatively quiescent in this respect. This f inding highlights the shifting pathology in the HIV-infected brain since the introduction of HAART and correlates well with the clinical findings. Kusdra et al. showed a significant rise in CD14/CD69 cells in the blood of HAART-treated individuals with HAD as compared with non-demented HAART subjects (77).

It has been postulated for some time that those who survive long term with HIV in the HAART era will be predisposed to the early onset of neurodegenerative conditions, principally Alzheimer's disease (78). In part this relates to the view held by some that neuroinflammation may mak e a significant contribution to the early stages of Alzheimer's disease (79, 80). There is pathological e vidence to support this hypothesis. Gelman and Schuenk e (81) showed increased levels of ubiquitin– protein complexes and decreased synaptophysin in AIDS subjects compared with controls (81). Green et al. have shown elevated levels of β -amyloid in the brains of

HAART-treated subjects (82). However, this finding has not been replicated in other studies (83) although in vitro studies suggest that HIV proteins ele vate amyloid levels by inhibiting neprilysin(84). β -amyloid is one of the two key pathological proteins found in Alzheimer's disease, the second key protein is an aberrant version of the neuronal protein Tau.


Hyperphosphorylated Tau has been shown to accumulate at an accelerated rate in HIV-infected subjects treated with HAART (83). Tau is a microtubule associated protein mainly expressed in neurons of the CNS. It has a central role in the formation and stabilisation of microtubules, which are essential structural components of the cell and which also facilitate the traffic of organelles along axons and dendrites. Tau is phosphorylated and de-phosphorylated as part of the normal biology of the cell; the protein has multiple phosphorylation sites, which are utilised in this normal process (Fig. 3). Tau binding and the stabilisation of microtubules is controlled by the phosphorylation state of the T au protein. Phosphorylation of T au leads to dissociation of Tau from microtub ules, which promotes microtub ule instability. This is part of normal cell functioning for remodelling and gro wth. However, hyperphosphorylation of Tau is abnormal and can lead to the formation and deposition of paired helical f ilament (PHF) Tau in the form of insoluble neuritic threads, neurofibrillary pre-tangles and tangles.


In the adult human brain, six isoforms of Tau are expressed by alternative mRNA splicing from a single gene. Abnormalities in T au mRNA splicing are linked with frontotemporal dementia and parkinsonism link ed to chromosome 17, and similar alterations are suggested in sporadic tauopathies, such as progressi ve supranuclear palsy or corticobasal degeneration (85). Alterations in Tau mRNA have also been linked with alterations in neurofilament gene expression, suggesting that these structural support proteins of the neuron are intrinsically link ed to the degenerative process (85). In vitro studies have shown altered neurofilament gene expression in neuronal co-cultures exposed to supernatant from HAAR T-treated macrophages (77). Changes in neural cell signalling proteins as well as structural and functional proteins may represent subtle forms of cellular dysfunction rather than frank cell death (77).

Hyperphosphorylated versions of the Tau protein accumulate in the brain with increasing age at low to moderate levels. Higher (pathological) levels of Tau are observed in the tauopathies (86–88). Neurofibrillary tangles (NFTs) are one of two diagnostic pathological observations in Alzheimer's disease. NFTs fill the neuronal soma, leading to loss of structural inte grity in the affected neurons and eventually to cell death, while the presence of hyperphosphorylated PHF T au in neurites may interfere with structural inte grity of the axon or dendrite in addition to disrupting axonal or dendritic transport.

The phosphorylation state of T au is controlled by a series of kinases and phosphatases, several of which can potentially be influenced by both direct and indirect effects of HIV and/or HAART. Enzymes that play a part in controlling Tau phosphorylation includes glycogen synthase kinase 3β (GSK- 3β), cyclin dependant kinase 5 (CDK-5) protein phosphatase 1 (PP-1) and PP2b.

The predominant regions of the HAART-treated brain in which Tau accumulations occur are the hippocampus, temporal cortex and frontal cortex. The thalamus is also





affected though to a lesser degree. Interestingly there is little evidence of Tau deposition in the basal ganglia or in the brain stem. Evidence of T au pathology includes the presence of neurof ibrillary tangles and pre-tangles (Fig. 4). Ho wever, the most prominent feature is the accumulation of hyperphosphorylated T au in neuritis (Fig. 5 and 6). These Tau-related changes show a strong correlation with the expression of the enzymes GSK-3ß and CDK-5. The HIV protein T at has the potential to upregulate GSK-3ß activity in vitro (89). Tau-related changes are not observed in



Fig. 4 Hyperphosphorylated Tau in the Neuronal Cell Body





Fig. 5 Hyperphosphorylated Tau Accumulating in Distal Neurites

pre-HAART subjects, thus raising the question of whether HAART itself is inducing this pathology. Other potential confounding factors include drug abuse and hepatitis C as before. Ho wever, while drug ab use alone has been sho wn to induce similar Tau-related changes (53), elevated levels of hyperphosphorylated Tau are found in HIV-infected HAART-treated subjects in both drug ab users and non-drug abusers.




Hyperphosphorylated Tau in neurites (Hippocampus)

Fig. 6 Quantitation of Hyperphosphorylated Tau in Neurites

Equally, while hepatitis C is highly prevalent in HIV-infected subjects, co-infection does not correlate well with the presence of hyperphosphorylated T au. HAART is well recognised for its toxicity, particularly to mitochondria, and it may be that mitochondrial damage plays a k ey role in the upre gulation of GSK-3 β , which in turn promotes Tau phosphorylation (Fig. 7). It is of interest that sodium v alproate, which inhibits GSK-3 β , is under investigation as a therapeutic agent to achieve this in the clinical setting (90).

A recent study has sho wn that levels of Tau are increased in the cerebrospinal fluid (CSF) in HIV-infected individuals while the levels of β amyloid were reduced, showing similarity to the CSF findings in Alzheimer's disease (91).

In addition to the accumulation of neurode generative proteins, other mechanisms may be contributing to cumulative brain damage. Although there is little understanding at present of how neural progenitor cells contribute to the normal **Fig. 7** Potential Mechanisms for T au De-regulation and Dysfunction during HIV infection



maintenance of the human brain if at all, it is noted that these cells e xpress high levels of chemokine receptors, are vulnerable to neuroinflammatory c ytokines, undergo apoptosis, and are capable of being infected with HIV (92–94).

Conclusions

The brain represents a viral sanctuary in HAART-treated individuals, and developing an understanding of how the virus persists and evolves at this site is critical to further improving the treatment for infected subjects.

The incidence of common CNS complications such as HIV-associated dementia, HIVE and many CNS opportunistic infections has declined since the introduction of HAART, but none have been completely eliminated. As the number of HIV-infected subjects rises year on year, the prevalence of many of these conditions is actually increasing despite the fall in incidence rates.

New forms of cogniti ve deficits have been identified in the HAAR T era and these are undoubtedly the result of new forms of pathology, which were not previously observed in HIV. Cognitive impairment is often more cortical than sub-cortical and this is reflected in a shift in pathology to neocortex rather than the basal ganglia. The major pathological changes are persistent and elevated levels of neuroinflammation coupled with the presence of neurodegenerative proteins such as hyperphosphorylated Tau. All of the current data point to progressi ve neurodegeneration in subjects maintained long term on HAART.

References

- 1 .Gray F, Scarailli F, Esrall I etal. Neuropathology of early HIV-1 infection. BrainPathol 1996 ; 6 (1) : 1 15 .
- BellJE BusuttilA IronsideJW, etal. Humanimmunodeficiency virus and the brain: investigation of virus load and neuropathologic changes in pre-AIDS subjects. JInfect Dis 1993; 168 (4): 818 – 24.
- 3 .Anthon IC ,Crawford DH ,Bell JE Blymphocytes in the normal brain: contrasts with HIV-associated lymphoid infiltrates and lymphomas . Brain 2003 ; 126 50Pt 1058 67 .
- 4 .AnSF, CiardiA GiomettoB Scarailli T, GrayF, Scarailli F Investigation on the expression of major histocompatibility complex class II and c ytokines and detection of HIV -1 DNA within brains of asymptomatic and symptomatic HIV -1-positive patients. Acta Neuropathol (Berl) 1996; 91 (5): 494 – 503.
- 5 . Tomlinson GS SimmondsP, BusuttilA ChiswickA BellJE Upregulation of microglia in drug users with and without pre-symptomatic HIV infection . Neuropathol Appl Neurobiol 1999 ; 25 (5) : 369 – 79 .
- 6 .AnSF, GiomettoB Groes M etal. Axonaldamage revealed by accumulation of beta-APP in HIV-positive individuals without AIDS . JNeuropathol Exp Neurol 1997 ; 56 (11) : 1262 8 .
- 7 .Duis LE HjelleBL MillerVE etal .Earlyviral brain invasion in iatrogenic human immunodeficiency virus infection . Neurology 1992 ; 42 (9) : 1736 – 9 .
- 8 .McCrossanM MarsdenM CarnieFW, etal. Animmune control model for viral replication in the CNS during presymptomatic HIV infection. Brain 2006 ; 129 20Pt 503 – 16.
- 9 . Peters PJ ,Bhattacharya J ,Hibbitts S et al. Biological analysis of human immunodeficiency virus type 1 R5 en velopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages. JVirol 2004; 78 (13): 6915 26.
- 10 . MacMahonEM GlassJD Hayword SD etal. Association Epstein-Barr virus with primary central nervous system lymphoma in AIDS . AIDSRes Hum Retroviruses 1992; 8 (5): 740 – 2.
- 11 .AuperinI Miklt J OksenhendlerE etal. Primarycentral nervous system malignant non-Hodgkin's lymphomas from HIV-infected and non-infected patients: expression of cellular surface proteins and Epstein-Barr viral markers. Neuropathol Appl Neurobiol 1994; 20 (3): 243 – 52.
- 12 .Jellinger KA , Rulus W .Primary central nervous system lymphomas-new pathological developments .JNeurooncol 1995 ; 24 (1) : 33 6 .
- 13 . Rove M Peng-PilonM HuenDS etal. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers. JVirol 1994; 68 (9): 5602 12.
- 14 .JayachandraS Lw KG ThlickAE etal. Threeunrelated viral transforming proteins (vIRF, EBNA2, and E1A) induce the MYC oncogene through the interferon-responsive PRF element by using different transcription coadaptors. ProcNatl Acad Sci USA 1999 ; 96 (20) : 11566 71 .
- 15 .ClaphamPR McKnightA HIV1 receptors and cell tropism . BrMed Bull 2001 ; **48** ÷ 59 .
- 16 .LambotteO Deia K Tardieu M HIV1 persistence, viral reservoir, and the central nervous system in the HAART era . BrainPathol 2003 ; 13 (1) : 95 103 .
- 17 . Anthon IC RamageSN CarnieFW, SimmondsP, BellJE Influenceof HAART on HIV-related CNS disease and neuroinflammation . JNeuropathol Exp Neurol 2005 ; 64 (6) : 529 36 .
- 18 .BellJE DonaldsonYK Lwrie S etal. Influenceof risk group and zidovudine therapy on the development of HIV encephalitis and cognitive impairment in AIDS patients. AIDS 1996 ; 10 (5) : 493 - 9 .
- 19 .MartinezAJ SellM Mitroics T, et al. The neuropathology and epidemiology of AIDS. A Berlin experience. A review of 200 cases . Bathol Res Pract 1995 ; 191 (5) : 427 - 43 .
- 20 . Anderson CE , Timlinson GS , Truly B et al . Relationship of Nef-positive and GFAPreactive astrocytes to drug use in early and late HIV infection . Neuropathol Appl Neurobiol 2003 ; 29 (4) : 378 – 88 .
- 21 .BagasraO Lui E BobroskiL etal. Cellularreservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry. AIDS 1996 ; 10 (6) : 573 85.

- 22 . BudkaH CostanziG CristinaS et al. Brain pathology induced by infection with the human immunodeficiency virus (HIV). A histological, immunocytochemical, and electron microscopical study of 100 autopsy cases. ActaNeuropathol (Berl) 1987; 75 (2): 185 98.
- 23 .RankiA Nyber M Qord V,etal. Abundant expression of HIV Nef and Rev proteins in brain astrocytes in vivo is associated with dementia . AIDS 1995 ; 9 (9) : 1001 8 .
- 24 . Tkahashi K Wesselingh SL Griffin DE McArthurJC JohnsonR Glass JD Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. AnnNeurol 1996 ; 39 (6) : 705 – 11.
- 25 . Wey CA SchrierRD NelsonA , LampertPW, OldstoneMB Celluhr localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients . ProcNatl Acad Sci USA 1986 ; 83 (18) : 7089 – 93 .
- 26. Kire K Widenheim KM Jaman WD DicksonDW Morphologyand distribution of HIV-1 gp41-positive microglia in subacute AIDS encephalitis. P attern of involvement resembling a multisystem degeneration. ActaNeuropathol (Berl) 1990; 80 (4): 393 – 400.
- 27 . SharerLR KapilaR Neuropathologicobservations in acquired immunodeficiency syndrome (AIDS) . ActaNeuropathol (Berl) 1985 ; 66 (3) : 188 98 .
- 28 .BudkaH Multinucleatedgiant cells in brain: a hallmark of the acquired immune deficiency syndrome (AIDS). ActaNeuropathol (Berl) 1986 ; 69 (3–4) : 253 8 .
- 29 .BellJE ArangoJC Anthon IC Neurobiology of multiple insults: HIV-1-associated brain disorders in those who use illicit drugs. JNeuroimmune Pharmacol 2006; 1 (2): 182 – 91.
- 30 . Alward EH HendererJD McArthurJC etal. Reducedbasal ganglia volume in HIV-1-associated dementia: results from quantitative neuroimaging . Neurology 1993 ; 43 (10) : 2099 104 .
- 31 . Alward EH BrettschneiderPD McArthurJC etal. Magneticresonance imaging measurement of gray matter volume reductions in HIV dementia. AmJ Psychiatry 1995 ; 152 (7) : 987 94 .
- 32 . Exerall IP, LuthertPJ LantosPL Neuronalloss in the frontal cortex in HIV infection . Lancet 1991; 337 (8750): 1119 21.
- 33 . Earall IP, LuthertPJ LantosPL Neuronalnumber and volume alterations in the neocortex of HIV infected individuals . JNeurol Neurosurg Psychiatry 1993 ; 56 (5) : 481 - 6.
- 34 . Masliah E ,Heaton RK ,Marcotte TD et al. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. AnnNeurol 1997 ; 42 (6) : 963 – 72.
- 35 . Earall IP, Heaton RK Marcotte TD et al. Cortical synaptic density is reduced in mild to moderate human immunodef iciency virus neurocogniti ve disorder. HNRC Group. HIV Neurobehavioral Research Center. BrainPathol 1999; 9 (2): 209 – 17.
- 36 .Persidsly Y, StinsM Wy D etal. Amodel for monocyte migration through the blood-brain barrier during HIV-1 encephalitis . JImmunol 1997; 158 (7): 3499 – 510.
- 37 .DemuthM CzubS SauerU etal. Relationshipbetween viral load in blood, cerebrospinal fluid, brain tissue and isolated microglia with neurological disease in macaques infected with different strains of SIV. JNeurovirol 2000; 6 (3): 187 201.
- 38 .Glass JD ,Fedor H ,Wesselingh SL ,McArthur JC Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia . Ann Neurol 1995 ; 38 (5) : 755 62 .
- 39 .FischerSmith T, CroulS Serstiuk AE et al. CNS invasion by CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: peri vascular accumulation and reservoir of HIV infection. JNeurovirol 2001; 7 (6): 528 – 41.
- 40 .FischerSmith T, RappaportJ Evolving paradigms in the pathogenesis of HIV-1-associated dementia . ExpertRev Mol Med 2005 ; 7 (27) : 1 26 .
- 41 . GartnerS HIVInfection and Dementia . Science 2000 ; 287 : 602 4 .
- 42 . Lwrence DM ,Major EO HIV1 and the brain: connections between HIV-1-associated dementia, neuropathology and neuroimmunology . MicrobesInfect 2002; 4 (3) : 301 8.
- 43 .Anderson E ,Zink W, Xiong H ,Gendelman HE HIV1-associated dementia: a metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes . JAcquir Immune Defic Syndr 2002; 31 (Subpl S43 – 54).

- 44 .Swindells S Zheng J ,Gendelman HE HIVassociated dementia: new insights into disease pathogenesis and therapeutic interv entions. AIDS Patient Care STDS 1999; 13 (3): 153 63.
- 45 . FischerSmith T, CroulS AdeniyiA etal. Macrophage/microglialaccumulation and proliferating cell nuclear antigen e xpression in the central nerv ous system in human immunodef iciency virus encephalopathy. AmJ Pathol 2004 ; 164 (6) : 2089 – 99 .
- 46 .BellJEAJ Anthony IC. The changing pathology of NeuroAIDS associated with drug abuse in the era of HAART. AmericanJournal of Infectious Diseases 2006; 2 (2): 39 – 48.
- 47 . Anthom IC RamageSN CarnieFW, SimmondsP, BellJE Doesdrug abuse alter microglial phenotype and cell turno ver in the context of advancing HIV infection. Neuropathol Appl Neurobiol 2005; 31 (3): 325 38.
- 48. Steggles K. Personal Communication 2007.
- 49 .KanmogneGD PrimeauxC GrammasP HIV1 gp120 proteins alter tight junction protein expression and brain endothelial cell permeability: implications for the pathogenesis of HIV-associated dementia. JNeuropathol Exp Neurol 2005 ; 64 (6) : 498 – 505 .
- 50 . Brack-Wher R Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis . AIDS 1999 ; 13 (1) : 1 22 .
- 51 .Brack-Wrner R ,Erfle V, Ranki A Signifcance of restricted HIV expression for HIV neuropathogenesis: still an unresolved issue . AIDS 1997 ; 11 (2) : 251 2 .
- 52 .DonahoeRM Multipleways that drug abuse might influence AIDS progression: clues from a monkey model .JNeuroimmunol 2004 ; 147 (1–2) : 28 32 .
- 53 .RamageSN Anthon IC CarnieFW, BusuttilA RobertsonR BellJE Hyperphosphorylated tau and amyloid precursor protein deposition is increased in the brains of young drug abusers. NeuropatholAppl Neurobiol 2005 ; 31 (4) : 439 – 48.
- 54 .ButtnerA RohrmoserK MallG PenningR Wris S Widespread axonal damage in the brain of drug abusers as evidenced by accumulation of beta-amyloid precursor protein (beta-APP): an immunohistochemical investigation . Addiction 2006 ; 101 (9) : 1339 46 .
- 55 .ButtnerA MallG PenningR Was S The neuropathology of heroin abuse. For ensic Sci Int 2000 ; 113 (1–3) : 435 – 42 .
- 56 . FerrerAlcon M ,Garcia-Seilla A , Jaquet PE et al. Regulation of nonphosphorylated and phosphorylated forms of neurof ilament proteins in the prefrontal corte x of human opioid addicts . JNeurosci Res 2000 ; 61 (3) : 338 49.
- 57 .LaskusT, Radawski M AdairDM , Mikinson J Scheck AC, Rakila J Emeging evidence of hepatitis C virus neuroinvasion. AIDS 2005 ; 19 (Suppl S140 4.
- 58 . Fron DM ThomasHC MurphyCA etal. HepatitisC and cognitive impairment in a cohort of patients with mild liver disease . Hepatology 2002 ; 35 (2) : 433 9 .
- 59 . Frton DM AllsopJM MainJ Fster GR ThomasHC Tylor-Robinson SD Evidencefor a cerebral effect of the hepatitis C virus . Lancet 2001 ; 358 (9275) : 38 9 .
- 60 . Kandanearatchi A Miliams B Esrall IP Assessing the efficacy of highly active antiretroviral therapy in the brain . Brain Pathol 2003 ; 13 (1) : 104 – 10 .
- 61 . SmitTK Brev BJ Jourtellotte W, Mogello S GelmanBB SaksenaNK Independentevolution of human immunodeficiency virus (HIV) drug resistance mutations in di verse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol 2004 ; 78 (18) : 10133 – 48.
- 62 .LangfordD Marquie-BeckJ deAlmeida S etal. .Relationshipof antiretroviral treatment to postmortem brain tissue viral load in human immunodef iciency virus-infected patients. JNeurovirol 2006 ; 12 (2) : 100 - 7 .
- 63 .SacktorN McDermottMP, MarderK etal. HIVassociated cognitive impairment before and after the advent of combination therapy. JNeurovirol 2002 ; 8 (2) : 136 42 .
- 64 .McArthur JC ,Haughe N ,Gartner S et al. Human immunodeficiency virus-associated dementia: an evolving disease . JNeurovirol 2003 ; 9 (2) : 205 21 .
- 65 . Brev BJ Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of ne w forms of AIDS dementia comple x. AIDS 2004 ; 18 (Suppl S75 8.

- 66 . StoutJC EllisRJ JerniganTL etal. Progressive cerebral volume loss in human immunodeficiency virus infection: a longitudinal v olumetric magnetic resonance imaging study . HIV Neurobehavioral Research Center Group .Arch Neurol 1998; 55 (2) : 161 8.
- 67 . MooreDJ MasliahE RippethJD etal. Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment . AIDS 2006 ; 20 (6) : 879 – 87 .
- 68 . Mcour V, Shikuma C, Shiramizu B et al . Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort . Neurology 2004 ; 63 (5) : 822 7.
- 69 . Sacktor N , Jules RH , Shalasky R et al. HIVassociated neurologic disease incidence changes:: Multicenter AIDS Cohort Study, 1990–1998. Neurology 2001 ; 56 (2) : 257 – 60 .
- 70 .LangfordD AdameA GrigorianA etal. Patterns of selective neuronal damage in methamphetamine-user AIDS patients . JAcquir Immune Defic Syndr 2003 ; 34 (5) : 467 – 74 .
- 71 .LangfordTD LetendreSL LarreaGJ MasliahE Changingpatterns in the neuropathogenesis of HIV during the HAART era . BrainPathol 2003 ; 13 (2) : 195 210 .
- 72 .Gray F, Chretien F, Matt-Decouvelaere AV, Scarwilli F.The changing pattern of HIV neuropathology in the HAART era. JNeuropathol Exp Neurol 2003; 62 (5): 429 40.
- 73 .Gray F, Kohane C The neuropathology of HIV infection in the era of Highly Active AntiRetroviral Therapy (HAART) . BrainPathol 2003 ; 13 (1) : 79 83 .
- 74. Bennett D, McCormick L, Kline R, et al. U.S. Surv eillance of HIV Drug Resistance at Diagnosis Using HIV Diagnostic Sera. 12th Conference on Retro viruses and Opportunistic Infectious; Foundation for Retrovirology 2005.
- 75 . Miller RF, Isaacson PG, Hall-Craggs M et al. Cerebral CD8+ lymphocytosis in HIV-1 infected patients with immune restoration induced by HAAR T. Acta Neuropathol (Berl) 2004 ; 108 (1) : 17 23 .
- 76 . Whkataramana A , Pardo CA , McArthur JC et al. Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients . Neurology 2006 ; 67 (3) : 383 8 .
- 77. Kasdra L McGuireD PulliamL Changesin monocyte/macrophage neurotoxicity in the era of HAART: implications for HIV-associated dementia. AIDS 2002; 16 (1): 31 8.
- 78 . Alisk JM The coming problem of HIV-associated Alzheimer's disease . Med Hypotheses 2007 ; 69 (5) : 1140 – 3 .
- 79 . McGeerPL McGeerEG Local neuroinflammation and the progression of Alzheimer's disease . J Neurovirol 2002 ; 8 (6) : 529 – 38 .
- 80 .McGeerPL ItagakiS Byes BE McGeerEG Reactive microglia are positive for HLA-DR in the substantia nigra of P arkinson's and Alzheimer's disease brains. Neurology 1988; 38 (8): 1285 – 91.
- 81 .Gelman BB ,Schuenk K Brain aging in acquired immunodeficiency syndrome: increased ubiquitin-protein conjugate is correlated with decreased synaptic protein b ut not amyloid plaque accumulation. JNeurovirol 2004 ; 10 (2) : 98 108 .
- 82 .Green DA, Masliah E, Miters HV, Beizai P, Moore DJ, Achim CL Brain deposition of beta-amyloid is a common pathologic feature in HIV positi ve patients. AIDS 2005; 19 (4): 407 11.
- 83 . Anthon IC RamageSN CarnieFW, SimmondsP, BellJE Accelerated Tau deposition in the brains of individuals infected with human immunodef iciency virus-1 before and after the advent of highly active anti-retroviral therapy. ActaNeuropathol (Berl) 2006 ; 111 (6) : 529 – 38.
- 84 .Rempel HC ,Pulliam L HIV1 Tat inhibits neprilysin and elevates amyloid beta. AIDS 2005 ; 19 (2) : 127 35 .
- 85 .UmedaY, Thiguchi S ArimaK et al. Alterations in human tau transcripts correlate with those of neurofilament in sporadic tauopathies . NeurosciLett 2004 ; 359(3) : 151 4.
- 86 . BraakH BraakE Frequency of stages of Alzheimer-related lesions in different age categories. NeurobiolAging 1997; 18 (4): 351 – 7.
- 87 . Pollock NJ Mirra SS Binder LI Hansen LA Wood JG Filamentous aggregates in Pick's disease, progressive supranuclear palsy, and Alzheimer's disease share antigenic determinants with microtubule-associated protein, tau . Lancet 1986 ; 2 (8517) : 1211 .

- 88 .HuttonM LendonCL RizzuP,etal. Association of missense and 5' -splice-sitemutations in tau with the inherited dementia FTDP-17 . Nature 1998 ; 393 (6686) : 702 5 .
- 89 . Maggirwar SB Jong N RamirezS GelbardHA Devhurst S HIV1 Tat-mediated activation of glycogen synthase kinase-3beta contrib utes to Tat-mediated neurotoxicity. J Neurochem 1999 ; 73 (2) : 578 – 86 .
- 90. Devhurst S ,Maggirvar SB ,Schifto G ,Gendelman HE ,Gelbard HA Glycogen Synthase Kinase 3 Beta (GSK-3beta) as a Therapeutic Target in NeuroAIDS. J Neuroimmune Pharmacol 2007; 2 (1): 93 – 6.
- 91 .Brev BJ PembertonL Blennev K Wallin A Hagberg L CSFamyloid beta42 and tau levels correlate with AIDS dementia complex . Neurology 2005; 65 (9) : 1490 2.
- 92 . Ni HT, Hu S ,Sheng WS et al. High-level expression of functional chemokine receptor CXCR4 on human neural precursor cells. BrainRes Dev Brain Res 2004 ; 152 (2) : 159 69 .
- 93 . ShengWS HuS NiHT, Roven TN Lokinsgard JR PetersonPK .TNF-alpha-induced chemokine production and apoptosis in human neural precursor cells . JLeukoc Biol 2005 ; 78 (6) : 1233 41 .
- 94. Lawrence DM DurhamLC Schwartz L SethP, MaricD MajorEO Humanimmunodeficiency virus type 1 infection of human brain-derived progenitor cells. JVirol 2004; 78 (14): 7319 28.

Biomarkers of HIV-Related Central Nervous System Disease

Bruce James Brew and Scott Letendre

Introduction

Biomarkers are important, some w ould say essential, for the management of patients with HIV -related central nerv ous system (CNS) disease. Ho wever, at present there is much that still needs to be done. It would be premature to say that they have reached the point in their de velopment at which the y could, or e ven should, be used routinely. That said though, it should be stressed that an appreciation of the field is important: there are some areas that can be used in day to day clinical practice. In this re view, we have focused on HIV -related brain disease (HBD) in the form of dementia (HIV -associated dementia – HAD) as well as its less-severe manifestations namely Minor neurocognitive disorder (MND) and asymptomatic neurocognitive impairment. Biomarkers of opportunistic HIV-related brain complications are lar gely available, for example cryptococcal antigen. This review will be confined to biomarkers of HBD and will focus on those measured in the blood or cerebrospinal fluid (CSF). In addition, this chapter will focus on the older nomenclature for HIV-related cognitive disorders.

There are several reasons for the importance and need for biomarkers in HIV-CNS disease. First, an objective marker(s) that could diagnose or predict the presence and severity of HBD has been a critically important and largely unmet clinical need since the advent of the epidemic. Se veral markers have been evaluated to date, b ut they have been largely nonspecific for HAD or MND. The acuity of this need is link ed to the logistical challenges of diagnosing these conditions in resource-limited settings and to selection of the antiretro viral drugs that are most ef fective in the CNS. The specificity of a diagnostic mark er is essential in clinical situations that are increasingly complex and diverse. For example, affected patients often ha ve confounding conditions. In the pre-HAART era, these were opportunistic infections or tumors.

B.J. Brew (🖂)

Departments of Neurology and HIV Medicine,

St Vincent's Hospital Sydney, Australia

Brew@.unsw.edu.au

In the era of highly acti ve antiretroviral therapy (HAART), increasing numbers of patients are developing more chronic conditions, such as hypertension, v ascular disease, and viral hepatitis, that can potentially confound attribution of cognitive impairment to HIV. A marker of the severity of HBD could provide an objective measure of the quantum of the deficit that was related to HIV, as opposed to the confounding condition. This would inform the aggressiveness of the clinical intervention, obviating the need for a wait and see approach, which was used previously.

Second, recent data support the existence of different clinical phenotypes of HBD, including an inactive form, in which there is no ongoing brain damage, both at clinical and subclinical le vels. The ability to identify inactive disease *in real time* using a marker, as opposed to serial testing over weeks, is clearly desirable. Indeed, the identification of disease activity is clinically important for two reasons. Unrecognized inactive disease may mean that the patient is given new antiretroviral drugs needlessly with the consequent increased risk of toxicity. Further, the lack of recognition of disease activity in clinical trials could lead to the inclusion of a sizeable number of patients with inactive disease leading to the premature conclusion of a trial of a novel agent because of the misperception of the agent's inefficacy, when in fact the trial patients did not have active disease that would allow the agent to work.

Third, a marker(s) that can diagnose the presence and activity of HBD would be invaluable in clinical trials. It is becoming increasingly apparent that the trials of investigational drugs must be on a background of optimal HAAR T. In such a situation, the degree and rapidity of clinical improvement is likely to be small and slow. A sensitive surrogate marker could mean faster delivery of effective new agents to the pharmaceutical armamentarium.

Fourth, a reliable marker would be helpful at the level of the individual patient in assisting the assessment of response to antiretroviral drugs. While it is clear that such response can be assessed clinically, it is equally clear that clinical response can take weeks or even months. A marker that can predict clinical response w ould be valuable.

The approach tak en in this re view will deliberately be synthetic with a clear clinical practical orientation. We have not detailed every study of every biomarker that has been explored. Rather we have attempted to integrate the data into a cohesive whole that will either have direct clinical practicality or will at the v ery least provide the clinician with an appreciation of the area that will facilitate understanding of future markers.

Many biomarkers have been described; broadly these can be di vided into those related to pathogenesis and those related to the relevant cells. For example, monocyte chemotactic protein (MCP)-1 induces migration of replication-competentmonocytes across the blood-brain barrier, which may increase the production of neurotoxic HIV-encoded proteins in the CNS. The second category contains markers reflecting the state of cells (for example, activation or injury) that play roles in these processes but not thought to be in volved in pathogenesis: neurofilament-light reflects injury of neurons, but is not thought to reflect a mechanism of injury. We have chosen to meld the two categories using a pathogenetic frame work. Although it is true that the pathogenesis of HBD is not completely understood, the general features are

reasonably appreciated. In broad terms, the disorder can be divided into effectors (host cells or HIV), modulators, toxins, and target(s), and within these there are the mononuclear cells, microglia, astrocytes, neurons, endothelial cells, and the blood-brain barrier. In addition to this unidirectional schema of disease causation, there is also the reverse component, namely repair.

Principles

Several principles are critical to appreciate not only for the understanding of the potential for a mark er to be v aluable in management b ut also in relation to the interpretation of existing tests, especially those in the CSF.

The first is that HIV disease is heterogeneous. This may seem self-e vident but the concept extends beyond the issue of opportunistic conditions. HIV -infected individuals differ in their lik elihood of having brain disease according to se veral fundamental factors – the most important being CD4 cell count and HIV replication, at least in untreated patients. Disease duration may also be a f actor, although the evidence is less clear at present. Thus, studies must use appropriately matched controls to validate the efficacy of a particular marker.

Second, brain injury is not a uni versal complication of HIV infection e ven if patients have lived with HIV infection for an extended period. Consequently, studies must include sufficient subjects who have or who are likely to have HIV-related brain disease. In the pre-HAART era, approximately 20% of patients with advanced HIV disease would be expected to develop HIV-associated dementia. The proportion of subjects who will develop HAD, at least of moderate-to-severe intensity, in the HAART era is much smaller.

Third, it is important to appreciate that antiretro viral drugs differ in their distribution characteristics and neurologic effectiveness. Evidence is accumulating that at least three such neurologically effective drugs provide better treatment for HBD (1). Thus, accounting for interindi vidual differences in antiretro viral distribution characteristics, as well as the duration of therap y, may bias the results of mark er studies involving subjects on HAART.

Fourth, the blood-brain barrier can be injured during HIV infection and as such may not competently e xclude markers at the endothelial lumen from the CNS. Thus, accounting for interindi vidual differences in blood-brain barrier injury is probably important when interpreting the analyses of mark ers in the CSF, particularly if appropriate controls are not studied.

At the level of individual patient assessment, clinicians should be a ware of several concepts, each of which may potentially interfere with interpretation of the significance of a particular mark er (2). The first concept is that of "layering," that is to say, several abnormalities are frequently layered one upon another in HIV disease. This is especially true of CSF analyses and brain imaging. F or example, a mild mononuclear pleocytosis is often found in HIV disease and may be attributable to the disease itself without an y clear clinical significance. Furthermore, there is the concept of parallel tracking – several conditions occur in different parts of the

neuroaxis at the same time, sometimes leading to difficulties in clinical assessment as well as interpretation of test results. F or example, vacuolar myelopathy often occurs with HAD at least in the pre-HAAR T era, thereby making the diagnostic interpretation of biomarkers associated with white-matter damage potentially difficult. Finally, clinicians should be a ware of the increasingly important issue of confounding conditions, especially as patients live longer. Such conditions may be difficult to diagnose and may compound e xisting predispositions to brain injury. New biomarkers should be cautiously applied in such patients – the y may have limited utility because of the confounding conditions.

Overview

Biomarkers associated with HBD should confirm the diagnosis and, when possible, exclude other disorders that may be playing a contrib utory role. This review first discusses markers from a pathogenic perspective – categorizing markers as reflecting effector cells, modulators of pathogenesis, toxins, or tar get cells – and then discusses markers that are practical for confirmation of HBD followed by those that are exclusionary. Finally, there is a brief discussion of the probable future for biomarkers.

Effector Cells

Lymphocytes

CD4Cell Count

While the CD4 cell count per se is not a direct mark er of the effector cells or toxins associated with HBD, it is a useful indirect mark er. At least in the pre-HAART era and in untreated patients, HAD occurred most often in patients with advanced HIV disease – usually at the time of vulnerability to opportunistic conditions, namely CD4 counts below $200/\mu L$ (3). Indeed, the lower the CD4 count the greater the risk of development of HAD (3). This probably reflected impaired immune control with increased viral replication and compensatory but ineffective immune activation.

In HAART-treated patients the association has changed. The CD4 count in treated patients now is much higher and indeed in some cases it is normal (4, 5). There are several potential explanations for this change, including a greater number of survivors due to the effects of HAART, as well as the presence of inactive disease in some. Increasing evidence now points to the value of the nadir, rather than the current, CD4 cell count (5–7).

β-2-Microglobulin

β-2 microglobulin ($β_2$ M) is the invariant light chain of the major histocompatibility complex class I. It is constitutively expressed on the surface of all nucleated cells with the exception of neurons and is particularly highly expressed on lymphocytes, thus serving as a marker of such cells. In the case of HIV disease, it seems that CSF $β_2$ M dominantly reflects cytotoxic T cells. Again it is not surprising that ele vated concentrations are nonspecific, with raised concentrations being found in both inflammatory and lymphoproliferative conditions (8). CSF $β_2$ M correlates well with the severity of HAD (8). A cutoff value for CSF $β_2$ M at 3.8 mg/L had a sensitivity for HAD diagnosis of 44%, specificity of 90%, and a positive predictive value of 88% in the pre-HAART era (9). CSF $β_2$ M levels also fall with successful treatment of HIV (8, 10), including in HAD patients. Raised CSF $β_2$ M concentrations confer an increased risk of HAD in patients with adv anced HIV disease (11).

Monocytes

CD14+/CD69+Monocytes

Most investigators consider the monoc yte/macrophage to be important in HBD pathogenesis. Increased numbers of the subset CD14lo/CD69hi in the peripheral blood appear to be important (12), but they are nonspecific as they can be elevated in the presence of coe xisting infection. Pulliam et al. were the f irst to describe increased numbers of the subset and their correlation with HAD(12). The prognostic significance of an elevation of this subset in asymptomatic patients is presently unknown. HAART reduced this subset in one study (13).

One group (14) measured this subset in a lar ge number of patients, although none was demented. Patients who were on a HAART regimen containing a protease inhibitor were most likely to have significant elevations in this monocyte subset in the CSF. Both the reason for this and its prognostic significance are unknown.

SolubleCD14 (sCD14)

Soluble CD14 is found principally on human monocytes, exists in both membrane and soluble forms (15), and is released by stimulated monocytes in vitro. Ele vations in serum are associated with HIV disease progression in vivo (16, 17). Ryan reported that sCD14 concentrations were higher in plasma in cognitively impaired compared with those from unimpaired subjects taking combination antiretro viral therapies (18). An important distinction from other mark ers of macrophage activation may be that in the CNS; sCD14 may derive primarily from trafficking monocytes and perivascular macrophages, rather than native microglia (19). As such, sCD14 may indicate interindividual differences in infiltration of immune cells into the CNS. If levels of sCD14 correlate with those of CD14+/CD69+, the y may be a more clinically accessible

indicator of CD14+/CD69+ cell numbers, since the y can be measured by simple ELISA rather than specialized flow cytometry. Although HAART can decrease sCD14 levels (13), detection of high levels may identify those at risk for subsequent neurological injury, although no validation of this concept yet exists.

Neopterin

Neopterin is a product of guanosine triphosphate metabolism (20). It is mainly produced by activated monocytes, macrophages, and microglia (21), and as such serves as a marker for such cells. Consequently, it is not surprising that high CSF concentrations are found in patients with opportunistic CNS infections as well as HAD. Furthermore, the CSF concentrations correlate with HAD severity (21). Elevated CSF concentrations increase the risk of HAD at least in patients with adv anced HIV disease (11). The CSF neopterin levels decrease with antiretro viral therapy (21). However, after 2 years of virologic suppression, only 55% had normal CSF neopterin le vels (22). What this means in terms of the risk of later de velopment of HAD is unknown.

QuinolinicAcid

Quinolinic acid (QUIN) is a product of the kynurenine pathway, the principal degradative pathway for tryptophan metabolism (23). It is produced by monocytes after stimulation by a number of agents, especially by interferon- γ (IFN- γ) and HIV proteins. It is important as it not only reflects monocyte activation but is a toxin in itself: QUIN is an agonist of *N*-methyl-D-aspartate receptors and so can lead to excitotoxic cell death. Furthermore, it can cause cell death through lipid peroxidation and the generation of free radicals (24). At present, Q UIN can be measured only by gas chromatography/mass spectrometry.

Increased CSF QUIN concentrations may be seen in opportunistic conditions as well as HAD (25). CSF QUIN levels are correlated with the severity of HAD (23). There is only one small study showing that elevated CSF concentrations confer an increased risk of HAD through increased psychomotor slowing (25). CSF QUIN is also relatively unique in that it reflects disease acti vity within the brain – Q UIN cannot cross an intact blood–brain barrier at least in the short term, so elevated CSF concentrations usually indicate an intrathecal process (26). Only CSF S100b, neurofilament-light (NFL), and tau ha ve such brain specificity. CSF QUIN levels fall rapidly with antiretroviral treatment (23, 26).

Microglia

At present there is no specific marker of microglia. The development of such a marker would be of considerable benefit given the fact that the degree of activation of microglia is the best correlate of the presence and severity of HAD in neuropathological

terms (27). Thus, for the moment, CSF markers of microglia are inferred from those previously discussed in relation to monocytes.

Astrocytes

S-10**B**

S-100 is an acidic calcium-binding protein that e xists in dimer forms of α and β subunits. S100 β is virtually exclusively found in astrocytes (28). As such it is one of the few biomarkers that reflects brain damage with astroc ytosis. S100 β may be more than just a marker of astrocytosis as high concentrations may lead to neuronal apoptosis (29). Elevated CSF S100 β concentrations occur in an y condition that causes astrocytosis. Raised levels occur in patients with either moderate or se vere HAD and predict rapid progression to death (28). There are no published data on response to HAART.

Glial Fibrillary Acid Protein (GFAP)

GFAP is another protein produced by astrocytes, but its levels in CSF do not appear to have a role in HBD or at least HAD (30).

Modulators

HIV primarily targets cells of the immune system, and so measuring modulators of immune activation or suppression are rational foci for biomark er investigations. Many critical interactions among cells of the immune system are controlled by soluble mediators called cytokines, a diverse group of intercellular signaling peptides and glycoproteins. Each is produced by particular cell types in response to a variety of stimuli and produces characteristic ef fects on the growth, mobility, differentiation, or function of tar get cells. Collectively, they regulate immune and inflammatory responses as well as healing, hematopoiesis, angiogenesis, and many other biologic processes (31).

Interleukins

The most studied interleukins are produced by tw o types of cells, helper T lymphocytes, the primary targets of HIV, and macrophages, the cells that play a central role in HIV neuropathogenesis. The interleukins produced by helper T lymphogtes are typically categorized as being produced by Th1 cells (for example, IL-2), which generally activate macrophages, or Th2 cells (for e xample, IL-6, IL-10), which generally activate B lymphocytes. Others, such as IL-1, are not produced by Th1 or Th2 lymphocytes but instead are produced by macrophages and other antigen presenting cells and can promote inflammation.

The interleukin family is large and diverse but most interleukin studies in neuroAIDS focused on just three members, IL-1, IL-2, or IL-6. Among six studies that measured IL-1, four identified a relationship with HBD, either in adults (32, 33) or in children (34, 35). Most of the nine studies that measured IL-6 also identified associations with brain injury, in either adults (32, 33, 36, 37) or children (34, 35). In contrast, none of the studies of IL-2 identified associations with neurologic disease. In fact, only three studies e ven compared IL-2 or its soluble receptor to a measure of brain injury (32, 38, 39). Of the interleukins measured in other studies (40–42), only IL-10 was associated with HBD, which was identified by one of the two largest studies in this series (43).

As IL-1 β , IL-6, and IL-10, b ut not IL-2, are produced by antigen presenting cells, such as macrophages, these f indings are consistent with the central role of macrophages, but not Th1 lymphoc ytes, in HIV neuropathogenesis. Th2 lymphocytes can also produce IL-6 and IL-10, and so the f indings may also implicate these cells in HIV neuropathogenesis.

TNF Superfamily Proteins

Tumor necrosis factor (TNF) is the prototype of a f amily of molecules that are involved with immune re gulation and inflammation (44, 45). Receptors for TNF and other proteins, such as soluble F as and CD30, constitute a superf amily of related proteins (46–50). The prototypical member of the superf amily, TNF- α , is produced by activated macrophages and microglia and plays a central role in se v-eral pathologic processes. In HIV disease, TNF- α can upregulate HIV replication (51). Indeed, mRNA expression of TNF- α is elevated in the brain tissue of individuals with HAD (52–54).

Most studies that measured TNF- α in CSF identified associations with measures of brain injury, including clinical staging, HIV RNA levels in CSF, and focal CNS damage (33, 36, 53, 55–60). Most of the studies that reported no association with brain injury were unable to detect TNF- α in most or all of the specimens.

Among studies of other TNF superf amily proteins, five reported that levels of soluble TNF receptors (sTNFRs) were elevated in CSF in HIV-infected individuals and both studies that compared these levels to a neurological outcome identified an association (61, 62). Of interest, one study identified persistently elevated levels of sTNFR-II in CSF despite effective antiretroviral therapy, supporting persistent neuroinflammation in these individuals (63).

Three studies measured levels of the apoptosis-associated proteins, soluble F as (sFas)/TNFRSF6, and F as ligand (F asL)/TNFSF6, and identified associations between higher levels of sFas and HAD (64–66). In a recent analysis, the HNRC GROUP measured ten biomarkers, including sFas, in 29 HIV-infected, cognitively impaired subjects before and 12 weeks after a change in antiretroviral therapy (67).

In multivariate analyses, cognitive improvements were associated with reductions in sFas, even after adjusting for multiple, potentially confounding conditions.

Thus, a preponderance of the studies that have reported on TNF superfamily proteins in CSF to date have identified links with HBD. These findings are most consistent for proteins other than TNF- α , though, perhaps because endogenous regulation of this potent proinflammatory c ytokine makes it difficult to measure in body fluids. Strong evidence exists that sTNFRs (63) and sFas (67) can be detected in body fluids despite antiretroviral therapy, supporting that these proteins might be useful biomarkers of ongoing neuroinflammation in treated individuals.

Interferons and Interferon-Inducible Proteins

The interferons (IFNs) are a f amily of cytokines that can be cate gorized into two major subgroups, type I (IFN- α , β , ω , and κ) and type II (IFN- γ), based on their properties and cellular receptors. In the brain, astrocytes and microglia in particular can produce IFN- α . This endogenous IFN- α may help to protect the brain from viral infections, b ut with prolonged e xposure and/or high concentrations, may injure the brain. For example, transgenic mice that overproduce IFN- α in astrocytes have a high incidence of severe neuropathology, manifesting as intractable seizures and early death (68). The expression of IFN- α is also ele vated in the brains of patients with HIV encephalitis and correlates with the severity of antemortem cognitive impairment. IFNs can induce the e xpression of o ver 300 different genes, some of which may be the actual mediators of the antiviral and antitumor effects of IFNs (69). Some, however, may also promote pro-apoptotic actions (70) that could lead to neurodegeneration.

Three studies have measured IFN- α and three others have measured IFN- γ in CSF. All three studies of IFN- α in CSF identified that higher levels were associated with HAD (71–73). Two of these also link ed higher IFN- α levels to higher HIV RNA levels in CSF (71, 72), indicating ineffectual antiviral activity. Two of the three studies of IFN- γ identified higher levels in HIV-infected individuals (74, 75), although a third was unable to detect IFN- γ in CSF (76) and none of the studies identified links to HBD.

Four studies reported le vels of the interferon-inducible protein, IP-10. T wo compared IP-10 le vels to HIV RN A levels in CSF and identified statistically significant correlations (63, 77). Gisolf et al. identified that IP-10 was elevated in some subjects despite apparent control of HIV replication in CSF , similar to their f indings with sTNFR-II (63). The two studies that compared IP-10 to brain injury both identifed links between higher levels and adverse neurologic outcomes (41, 78).

These studies implicate IFN- α and IP-10 more than IFN- γ in HIV neuropathogenesis. Notably, all three studies that measured IFN- γ were published prior to 1992, whereas nearly all of the studies on IFN- α and IP-10 were performed after 1996. Thus, the advent of HAART in 1996 and its resulting impact on the neurologic complications of HIV could account for important differences in the findings of these studies.

Chemokines

Multiple lines of evidence support the role of chemokine receptors and chemokines in HIV neuropathogenesis. For example, in vitro studies first recognized that HIV could induce expression of MCP-1/CCL2 from astrocytes (79) and that MCP-1 can potently induce chemotaxis of monocytes across endothelial barriers (80). Human studies corroborated these observations, identifying MCP-1 on brain macrophages of subjects dying with HIV encephalitis (81) and genetic associations with HAD (82). Fifteen published studies ha ve reported le vels of MCP-1 in CSF in HIV infected individuals, making it one of the most studied biomark ers of the HAART era. Of the nine studies that compared levels to a neurologic outcome, eight identified associations between higher MCP-1 le vels and worse outcomes (40, 60, 79, 83–87).

A smaller number of studies compared the le vels of CC chemokines, MIP-1 α , MIP-1 β , and RANTES to neurologic outcomes. These chemokines bind to CCR-5, the most commonly used receptor by HIV for entry into lymphoytes and microglia (88). These chemokines ha ve been implicated in HIV neuropathogenesis by the identification that their mRN A levels are high in brain tissue from subjects with HIV or SIV-encephalitis (89–92). The findings of the four published CSF studies, however, are inconsistent, identifying only that levels of RANTES/CCL5 (40) and perhaps MIP-1 α /CCL3 (93) were elevated in subjects with ADC, although others have had difficulty detecting these three chemokines in CSF (41), particularly in treated individuals.

Fractalkine, a chemokine that binds to CX3CR1, appears to be important in reducing the neurotoxicity associated with activated microglia (93). Two published studies measured fractalkine in CSF in HIV -infected individuals, demonstrating nonspecific elevations in those with neurologic complications, including HAD (95, 96). These findings seem contrary to the in vitro data, as a neuroprotecti ve chemokine would be expected to be lo wer in HBD, not higher . Perhaps the ele vated levels reflect the host's attempt at neuroprotection, b ut the levels are not high enough. Indeed, the MRS Consortium Group demonstrated that lo wer fractalkine levels in CSF were associated with lo wer neuronal pattern scores on proton magnetic resonance spectroscopy, arguing for a loss of neuroprotection in subjects with evidence of neurodegeneration (97).

Other Modulators

Transforming Growth Factor (TGF)-β

TGF- β is involved in down regulation of T-cell and macrophage activation, modulation of proinflammatory cytokines, and protection against HIV-mediated excitotoxicity (98). As such it may not only set the stage for reparative processes to be gin, but also participate in such processes. In HIV disease, TGF- β is produced by CD8 cells, microglia, and astroc ytes. CSF TGF- β concentrations are ele vated in mild HAD and undetectable in more severe disease (72, 99). The effect of HAART and the prognostic significance are not known.

Urokinase Plasminogen Activator Receptor (uPAR)

Soluble urokinase plasminogen activator receptor (suPAR) is the receptor for the urokinase plasminogen activator (uPA), or urokinase. These two molecules are the main components of the uPA system, which regulates extracellular proteolysis and intracellular signaling for chemotaxis. Raised CSF suPAR levels are seen in HAD (100) and decline signif icantly with HAAR T. The prognostic signif icance is unknown.

Toxins

Viral Toxins

HIVRNA

Quantitative measurement of HIV RN A reflects productive viral replication. Plasma HIV RNA levels are generally of limited use as a biomark er for HBD. Plasma HIV RNA levels are not specific or sensitive to HBD. That said, there is some clinical utility in the significance of a plasma HIV RN A, which is below detection – HAD is unlikely to be present at least as an active process in HAART naive patients. However, in HAART-treated patients, an undetectable plasma RNA level seems to occur more often in HAD for reasons that are unclear (101).

CSF HIV RNA is also nonspecific, with elevated levels in asymptomatic patients and those with opportunistic infections as well as HAD (102, 103). But CSF HIV RNA levels do correlate well with the se verity of HAD in HAAR T naive patients (101, 102) and fall with HAART (104). HAD developing in the context of HAART is not related to CSF HIV RNA (60). Also, elevated CSF viral loads (\geq 200 copies/ mL) in HAAR T-treated patients may predict progression to neuropsychological impairment after a median follow-up of approximately 1 year (105).

HAD can occur in the absence of an elevated HIV RNA in CSF (6, 60, 106), but it is uncommon. One e xplanation for this is the occurrence of HAD that has not fully responded to HAAR T, so that there is a residual def icit that reflects permanently damaged tissue (inactive HAD) (6). A second explanation is that the clinical expression of the deficit may be driven not by HIV but by a confounding condition, such as hepatitis C disease (107, 108). Third, the disorder may have been initiated by HIV, but have subsequently become independent – autonomous uncheck ed immune activation (60). Fourth, the virologic response in the CSF may occur sooner than the neurologic response in some patients, although there is little e vidence at present to support this. Finally, some patients may experience an immune restoration disorder after the initiation of HAAR T (109), which may mitigate the beneficial effects of treatment.

HIVDNA

HIV DNA levels can be measured and reflect latent infection. Not une xpectedly, plasma HIV DNA is nonspecific, but it does appear to have some sensitivity to the presence of HAD. Interestingly, HIV DNA levels are still elevated significantly in HAD patients (110). Thus far, there are no published data on CSF HIV DNA.

HIVEncoded Proteins

The HIV-encoded proteins gp120, nef, tat, gp41, and vpr are all neurotoxic in vitro. Their measurement in blood or CSF has been problematic because of the v ery low concentrations that appear to be present. Vpr has been assayed in the CSF, but it is not clear whether the results reflected cell-free or cell-associated vpr (111). More sensitive techniques are in de velopment that will hopefully allo w more accurate measurement of vpr as well as the other HIV neurotoxins.

Host Toxins

Host toxins include arachidonic acid metabolites/prostaglandins, nitric oxide, and platelet activating factor (PAF). Other host neurotoxins, including Q UIN, S100- β , interferons, interleukins, and TNF- α , have been discussed in previous sections.

Arachidonic Acid Metabolites and Prostaglandins

The lipids in macrophages are highly enriched in arachnidonic acid, which can be metabolized to prostaglandin products (prostaglandin E2, F2 α , and thromboxane B2) by the cyclooxygenase pathway. These are highly correlated with the presence and severity of HAD, as well as with β 2M and neopterin. Studies were performed before the introduction of HAAR T but nonetheless, there w as no appreciable decrease in patients treated with antiretroviral drugs. The prognostic significance of elevated concentrations is unknown (112).

NitricOxide

Nitric oxide is considered to be an important neurotoxin in HBD, where it is dominantly produced by macrophages and microglia. CSF le vels of nitric oxide and its metabolites are, ho wever, not raised in HAD despite the presence of increased activity of its associated enzyme in HAD brain tissue(113). CSF concentrations are raised in opportunistic complications of HIV disease that affect the CNS (114), and indeed there is some e vidence that they reflect damage to the blood–brain barrier (115). Its role as a CSF biomark er of HAD therefore seems doubtful.

PlateletActivating Factor

PAF is a product of infected or acti vated monocytes. While it is pleiotropic in its actions, there is convincing evidence of its neurotoxicty, which at least in part is mediated by *N*-methyl D-aspartate receptor activation (116–119). PAF levels are elevated in HAD, but they do not appear to correlate with severity. The prognostic significance and the response to HAART are unknown (120).

Target Cell

Neuron

Neuroflament-Light (NFL)

The neurofilament is a major structural element of neurons, mainly found in lage myelinated neurons. It is composed of a triplet protein, of which the light subunit (NFL) is the essential component of the neurofilament core (121). Its main function is to maintain the axonal caliber . CSF NFL le vels are significantly but nonspecifically raised in HAD and rise with HAAR T interruption (122, 123). Recent data also show that levels fall to normal in the majority of patients commenced on HAART (124). CSF neurof ilament heavy chain concentrations may be elevated in the conte xt of significant neuropathies such as Guillain-Barré syndrome (125), but thus far this does not seem to be the case for NFL in HIV neuropathy. Some asymptomatic patients with advanced HIV disease have raised CSF NFL concentrations; this seems to carry a significant risk of HAD over the next 2 years (126).

Tau

Tau is a structural neuronal protein. There are two o dominant forms that can be measured: total tau (t-tau) and phosphorylated tau (p-tau). Both reflect neuronal damage nonspecifically, though p-tau is more often ele vated in patients with Alzheimer's disease (127). In HIV disease, however, both are elevated in the CSF even in a proportion of otherwise normal patients (128). There is no relationship to HAD severity. Other studies have found varied results, possibly because of the

effect of age. The precise relationship between tau and NFL in HBD is yet to be determined, but broadly the two neuronal markers reflect damage to different types of neurons, with NFL dominantly indicating damage to large myelinated axons.

Endothelial Cells/Blood-Brain Barrier

Albumin, Immunoglobulin G, and Total Protein

Albumin, immunoglobulin G (IgG), and other lar ge proteins are normally excluded from the CNS by an intact blood-brain barrier. When the BBB is injured, ho wever, its permeability to lar ge molecules may increase. Thus, le vels of these proteins in CSF may reflect the severity of BBB injury and exposure of normally protected brain tissues to extraneural toxins. Elovaara et al., for e xample, reported that the alb umin ratio was increased in patients with neurological "deficits" (129), although Marshall et al. reported that the albumin ratio increased over time even in neuroasymptomatic individuals (130). Hall et al. reported that "disturbances" in the albumin ratio in 30% of 59 subjects were greater in those with more adv anced HIV disease (131) and Singer et al. confirmed this finding in 139 subjects (132). In 2001, Andersson et al. reported increased albumin ratios in only 15% of 110 neuroasymptomatic, HIV infected subjects (133). More recently, elevations were identified in just 5% of asymptomatic individuals, although 56% still had an abnormal IgG inde x that persisted in 41% e ven after antiretro viral treatment (134). Few, if an y, studies have identified correlations between total protein le vels and HBD. Some what unexpectedly then, the HNRC Group identified strong associations between changes in total protein levels in CSF and cognitive improvements before and 12 weeks after changes in antiretroviral therapy (67). Until others confirm this finding, however, total protein levels in CSF should not be considered a reliable mark er of HBD.

Serum Vascular Endothelial Growth Factor (VEGF)

Vascular endothelial growth factor (VEGF) is a potent angiogenic and mitogenic peptide. Thus far, there is one report of CSF and serum le vels in HIV disease. Serum but not CSF le vels were nonspecifically, significantly increased in HIV infection especially in HAD and decreased with HAAR T, although the numbers were small. Interestingly, even with effective viral suppression, serum VEGF levels were increased (135).

IntercellularAdhesion Molecules

HIV gp120 and pro-inflammatory c ytokines can upregulate adhesion molecules, including intercellular adhesion molecule (ICAM)-1, on the luminal surf ace of brain microvascular endothelial cells (136). Rieckmann et al. measured a soluble

form of ICAM-1 (sICAM-1) in CSF, finding that levels were higher in individuals with meningeal inflammation than in HIV -seropositive subjects and were associated with BBB damage (137). Heidenreich et al. compared sICAM-1 levels in HIV-seropositive patients with a different group (HIV-seronegative patients without neuroinflammatory disorders) and found that CSF levels were, in fact, higher among HIV-seropositive patients. The highest levels were found in individuals who had "HIV encephalopathy" (138).

MatrixMetalloproteinases

Matrix metalloproteinases (MMPs) are a family of neutral proteases that are important in normal development and have been implicated in man y pathological processes, including neuroinflammation. In the CNS, MMPs can de grade components of the basal lamina, leading to disruption of the BBB (139). Sporer et al. (140) found that active MMP-9 was detected more frequently in HIV -infected subjects with neurological deficits or CNS opportunistic infections and was associated with higher CSF-to-serum albumin ratios. Conant et al. (141) confirmed that MMP-9 (along with MMP-2) activity was more frequently detectable in the CSF of subjects with HIV dementia (9/16), compared with nondemented seropositi ve (2/11) or seronegative (0/11) controls. Liuzzi et al. (142) reconfirmed this f inding more recently in 138 HIV-infected individuals.

Biomarkers of Repair

At present almost no studies have addressed this area, yet it is important and clinically relevant. As discussed earlier, clinical evidence of improvement can tak e weeks or even months. A biomarker that predicts improvement would be valuable. Unfortunately, imaging does not appear to be particularly helpful in this re gard at least in relation to magnetic resonance spectroscopy.

The study by Albrecht et al. (143) is interesting. It did show that CSF levels of nerve growth factor were raised in HAD patients, while brain-derived nerve growth factor levels were low. However, more data are needed on the relationship to HAD severity, prognostic significance, and the effect of HAART.

What Biomarkers Should Be Measured to Confirm HBD?

The diagnosis of HAD and its less-severe forms is still primarily a clinical diagnosis. Nonetheless, there are three biomark ers in current clinical practice that can be of supportive value: CD4 cell count, CSF HIV RNA, and CSF protein.

In untreated patients, the CD4 cell count can be helpful in determining the likelihood of HAD. If the CD4 cell count is above 200 cells/ μ L, a diagnosis of HAD is

unlikely. In resource limited countries, the lymphoc yte count derived from the full blood count may be used – a normal lymphocyte count is unusual for HAD. On the other hand if the patient is on HAAR T or has f ailed therapy, the nadir CD4 cell count is probably more useful than the current value, which may be near-normal in a substantial proportion of patients. The same can be said for the lymphocyte count in resource-limited settings.

The second biomark er that is potentially helpful is the CSF HIV RN A level. Again its utility is chiefly in those with untreated HIV disease or in those who have failed HAART. In such patients, the CSF HIV RN A is almost al ways elevated above 50 copies/mL. In HAART-treated patients, the CSF HIV RNA load is much less reliable and just as is the case with CD4 cell count, a sizeable proportion of patients may have undetectable or minimally raised concentrations.

The third biomarker that can be clinically helpful is the CSF protein. Almost all HAD patients have a raised CSF protein.

Is There a Biomarker to Indicate Inactive HAD?

Intuitively, one would consider that HAD was inactive if markers of activity were absent. However, given that there are so man y markers, it is not clear at present which is most sensitive. Furthermore, it is unknown whether there may be an effect that we have termed *stunning*. A biomarker such as NFL or t-tau may reflect neuronal damage, the cause of which is no longer operative – a "hit and run" phenomenon. If this is the case, then therapy directed at the presumed inciting agent would be inappropriate.

Recent data from Sacktor et al. (144) have raised the possibility that raised CSF concentrations of sphingomyelin may serve as markers of inactive HAD. However, it is not clear yet how long sphingomyelin concentrations remain elevated.

What Biomarkers Should Be Measured to Exclude HBD?

There are several simple biomarkers in the blood and CSF should be measured to exclude other diseases that may mimic HAD and its more minor forms.

B12, Red-Cell Folate, and Thyroid Function

These are commonly used tests in the screening of patients with dementia. They are also entirely appropriate for HAD. Some of the symptoms associated with B12 and red-cell folate deficiency can mimic those associated with HAD, especially the combined involvement of cognitive deficit and myelopathy, sometimes with neuropathy. Similarly, hypothyroidism on occasion can have symptoms and signs not dissimilar from those of HAD, especially the psychomotor slowing.

This simple biomarker has considerable utility in an e xclusionary sense. A CSF white-cell count in excess of 50 cells/ μ L is unlikely to be due to HIV alone, especially when the CD4 count declines belo w 200/ μ L (145) and suggests another disease process, for example cryptococcal meningitis. In addition to the total count being helpful, the dif ferential is also useful. F or example, a polymorphonuclear pleocytosis is unlikely with HAD and raises the possibility of c ytomegalovirus encephalitis.

What Biomarkers are Likely in the Near Future?

There are two clear developments in the field of biomarkers. First, since HBD is multifaceted and unlikely to be diagnosed by a single biomarker, a combination of markers will likely be required to address specific questions. Such a combination would ideally incorporate representative biomarkers of the pathogenic schema presented in this review. One such combination that has been forw arded is CSF HIV RNA, CSF neopterin, and NFL (146). This combination, ho wever, is not readily available in the clinic and its utility is yet to be tested. Furthermore, this combination does not assess an important arm of pathogenesis, namely regenerative/reparative markers.

Second, the application of proteomics to the CSF is an important de velopment. This is a powerful tool to uncover a more specific marker or combination of markers of HBD (147–149). However, it must be judiciously applied. Approximately 50% of patients with minor and mild cognitive deficits remain unchanged over the subsequent months (6). Studying large numbers of patients with HAD and HBD to ensure that there are sufficient numbers with active disease may, however, be practically difficult. Despite this challenge, the de velopment of a biomark er of inactive disease is critical for the advancement of the field.

Conclusions

The field of biomark ers is rapidly maturing, especially in relation to HBD. However, the process of v alidating the clinical utility of pathogenesis-focused biomarkers has been complicated by the multitude of biomark ers implicated in HIV neuropathogenesis and the mark ed shifts in disease that follo wed the introduction of HAART. Despite this, we consider it best to continue to approach this challenge from a pathogenic perspective, as this ultimately facilitates the clinical application of these markers. Furthermore, this approach fosters the development of new markers and encourages the use of combinations of mark ers appropriate to the diagnosis of current HBD and the prediction of the risk for its development in the future.

References

- 1. Cysique LA, Maruff P, Brew BJ. Antiretroviral therapy in HIV infection: are neurologically active drugs important? Archives of neurology 2004;61:1699–704.
- 2 .Brev BJ Principles of HIV Neurology.In: Bree BJ ed. HIV Neurology. New York :Oxford University Press ; 2001 : 32 5 .
- 3 .Brev BJ AIDS Dementia Complex .In: Bree BJ ed. HIV Neurology . New York : Oxford University Press ; 2001 : 53 90 .
- 4 .DoreGJ McDonaldA LiY, KaldorJM Brev BJ Marked improvement in survival following AIDS dementia complex in the era of highly acti ve antiretroviral therapy. AIDS 2003 ; 17 (10) : 1539 45 .
- Valcour V, Yee P, Williams AE, et al. Lo west ever CD4 lymphocyte count (CD1 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type, Infection – The Hawaii Aging with HIV Cohort. J Neuro virol 2006;12(15):387–91.
- 6 .Cysique LA ,Maruff P, Brev BJ Variable benefit in neuropsychological function in HIVinfected HAART-treated patients . Neurology 2006 ; 66 (9) : 1447 – 50 .
- 7 . Tozzi V, BalestraP, LorenziniP, et al . Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. JNeurovirol 2005; 11 (3): 265 73.
- 8 .Brev BJ BhallaRB Pul M etal .Cerebrospinalfluid beta 2-microglobulin in patients with AIDS dementia complex: an expanded series including response to zido vudine treatment. AIDS 1992 ; 6 (5) : 461 − 5 .
- 9. McArthur JC ,Nance-Sproson TE ,Griffin DE et al . The diagnostic utility of elevation in cerebrospinal fluid beta 2-microglobulin in HIV-1 dementia. Multicenter AIDS Cohort Study. Neurology 1992 ; 42 (9) : 1707 – 12 .
- 10 EntingRH Fudraine NA, LangeJM etal .Cerebrospinalfluid beta2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis f actor alpha receptors before and after treatment with lami vudine plus zido vudine or sta vudine. J Neuroimmunol 2000 ; 102 (2) : 216 - 21.
- Brav BJ DunbarN PembertonL KaldorJ Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin. JInfect Dis 1996 ; 174 (2) : 294 - 8.
- 12 PulliamL GasconR StubblebineM McGuireD McGrathMS Unique monocyte subset in patients with AIDS dementia . Lancet 1997 ; 349 (9053) : 692 5 .
- 13 Ksdra L McGuireD PulliamL Changesin monocyte/macrophage neurotoxicity in the era of HAART: implications for HIV-associated dementia . AIDS 2002; 16 (1): 31 8.
- 14 Neuenbrg JK Furlan's Bacchetti'P, PriceRW, GrantRM Enrichment of activated monocytes in cerebrospinal fluid during antiretroviral therapy. AIDS 2005; 19 (13): 1351 – 9.
- 15 Landmann R ,Muller B ,Zimmerli W .CD14, new aspects of ligand and signal diversity. Microbesand infect 2000 ; 2 (3) : 295 – 304 .
- 16 Lien E Aukrust P, Sundan A Muller F, Froland SS Espeik T Elevated levels of serumsoluble CD14 in human immunodef iciency virus type 1 (HIV -1) infection: correlation to disease progression and clinical events. Blood 1998 ; 92 (6) : 2084 – 92 .
- 17 NockherWA, Begmann L ScherberichJE Increasedsoluble CD14 serum levels and altered CD14 expression of peripheral blood monocytes in HIV-infected patients. Clin Exp Immunol 1994 ; 98 (3) : 369 - 74 .
- 18 RyanLA ZhengJ BresterM etal .Plasmalevels of soluble CD14 and tumor necrosis factoralpha type II receptor correlate with cogniti ve dysfunction during human immunodeficiency virus type 1 infection . JInfect Dis 2001 ; 184 (6) : 699 – 706 .
- 19 CauwelsA FreiK SansanoS etal .Theorigin and function of soluble CD14 in experimental bacterial meningitis . JImmunol 1999 ; 162 (8) : 4762 – 72 .
- 20 HamerlinckFF Neopterin:a review. ExpDermatol 1999 ; 8 (3) : 167 76 .

- 21 .Brw BJ BhallaRB Rul M etal .Cerebrospinalfluid neopterin in human immunodeficiency virus type 1 infection . AnnNeurol 1990 ; 28 (4) : 556 60 .
- 22 AbdulleS Hagber L Sennerholm B FuchsD GisslenM Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS 2002 ; 16 (16) : 2145 - 9.
- 23 Hyes MP, Brev B Martin A et al .Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome . AdvExp Med Biol 1991 ; 294 : 687 – 90 .
- 24 BehanWM McDonaldM DarlingtonLG StoneTW Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and depren yl. Br J Pharmacol 1999 ; 128 (8) : 1754 – 60.
- MartinA Hyes MP, SalazarAM etal .Progressive slowing of reaction time and increasing cerebrospinal fluid concentrations of quinolinic acid in HIV -infected individuals. J Neuropsychiatry Clin Neurosci 1992; 4 (3): 270 9.
- 26 Mile M PriceRW, NilssonA Hyes M Vortta D CSFquinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy. Brain 2004; 127 50Pt 1047 - 60.
- 27 .Glass JD ,Fedor H ,Wesselingh SL ,McArthur JC Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia . Ann Neurol 1995 ; 38 (5) : 755 62 .
- 28 Pemberton LA ,Brev BJ Cerebrospinal fluid S-100beta and its relationship with AIDS dementia complex . JClin Virol 2001 ; 22 (3) : 249 53 .
- 29 HuJ Ferreira A Min Eldik LJ S100beta induces neuronal cell death through nitric oxide release from astrocytes. JNeurochem 1997 ; 69 (6) : 2294 301 .
- 30 SporerB MisslerU MagerkurthO Kedel U Wesmann M Hister HW Evaluation of CSF glial fibrillary acidic protein (GF AP) as a putati ve marker for HIV-associated dementia. Infection 2004; 32 (1): 20 3.
- 31 .OppenheimJJ RuscettiFW Cytokines In: arslow TG StitesDP, Frr AI ImbodenJB eds. MedicalImmunology, 10thed. New York : LangeMedical Books/McGraw-Hill; 2001.
- 32 .GalloP, Freik RordorfC LazdinsJ avolato B Entana A Humanimmunodeficiency virus type 1 (HIV-1) infection of the central nervous system: an evaluation of cytokines in cerebrospinal fluid. JNeuroimmunol 1989 ; 23 (2) : 109 – 16.
- 33 Perrella O ,Carrieri PB ,Guarnaccia D ,Soscia M Cerebrospinal fluid cytokines in AIDS dementia complex . JNeurol 1992 ; 239 (7) : 387 8 .
- 34 .GalloP, Luerda AM DeRossi A etal .Immunologicalmarkers in the cerebrospinal fluid of HIV-1-infected children . ActaPaediatr Scand 1991 ; 80 (6–7) : 659 66 .
- 35 Luerda AM GalloP, DeRossi A etal .Cerebrospinalfluid analysis in HIV-1-infected children: immunological and virological f indings before and after AZT therap y. Acta Paediatr 1994 ; 83 (10) : 1038 42 .
- 36 RieckmannP, AlbrechtM EhrenreichH Weber T, MichelU Semiquantitative analysis of cytokine gene expression in blood and cerebrospinal fluid cells by reverse transcriptase polymerase chain reaction. ResExp Med (Berl) 1995 ; 195 (1) : 17 29.
- 37 Torre D ZeroliC FerraroG et al .Cerebrospinal fluid levels of IL-6 in patients with acute infections of the central nervous system . ScandJ Infect Dis 1992 ; 24 (6) : 787 91 .
- 38 .Griffin DE McArthurJC CornblathDR Soluble interleukin-2 receptor and soluble CD8 in serum and cerebrospinal fluid during human immunodef iciency virus-associated neurologic disease. JNeuroimmunol 1990 ; 28 (2) : 97 – 109 .
- 39 For WR GlassJD Grffin JW, et al .Cytokineexpression in the brain during the acquired immunodeficiency syndrome. AnnNeurol 1992 ; 31 (4) : 349 60 .
- 40 Kilder W, McArthur JC, Nance-Sproson T, McClernon D, Griffin DE Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. AnnNeurol 1998; 44 (5): 831 – 5.

- 41 Kilb SA Sporer B Lahrtz F, Kedel U Pfster HW, Entana A Identification of a T cell chemotactic factor in the cerebrospinal fluid of HIV -1-infected individuals as interferongamma inducible protein 10. JNeuroimmunol 1999 ; 93 (1-2) : 172 - 81.
- 42 son Giesen HJ JanderS Killer H ArendtG Serumand cerebrospinal fluid levels of interleukin-18 in human immunodeficiency virus type 1-associated central nervous system disease. JNeurovirol 2004 ; 10 (6) : 383 - 6 .
- 43 GalloP, Suieri S RinaldiL et al .Intrathecal synthesis of interleukin-10 (IL-10) in viral and inflammatory diseases of the central nerv ous system. J Neurol Sci 1994; 126 (1): 49 - 53.
- 44 .Cosman D Hematopoietic Cell Growth Factors and Their Receptors . In: WhettenAD , GordonJ eds. BloodCell Biochemistry , Vol 7 . New York : Plenum :1996 .
- 45 GrussHJ Dover SK Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas . Blood 1995 ; 85 (12) : 3378 404 .
- 46. TNF Superfamily. R&D Systems Catalog 1998; 1998.
- 47 . Armitage RJ Tumor necrosis factor receptor superfamily members and their ligands . Curr Opin Immunol 1994 ; 6 (3) : 407 – 13 .
- 48 Bakr SJ ReddyEP Transducers of life and death: TNF receptor superfamily and associated proteins . Oncogene 1996 ; 12 (1) : 1 9 .
- 49 Lotz M , Trkeltaub R , Miger PM Cartilage and joint inflammation. Regulation of IL-8 expression by human articular chondrocytes .J Immunol 1992 ; 148 (2) : 466 73 .
- 50 Ware CF, WanArsdale S, WanArsdale TL Apoptosis mediated by the TNF-related cytokine and receptor families. JCell Biochem 1996; 60 (1): 47 55.
- 51 Zoumpourlis V, Eliopoulos AG, Spandidos DA. Transcriptional activation of the human immunodeficiency virus long terminal repeat sequences by tumor necrosis factor. Anticancer Res 1992; 12 (6B): 2065 – 8.
- 52 Achim CL ,Hyes MP, Wey CA Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains . J Clin In vest 1993 ; 91 (6) : 2769 - 75 .
- 53 MastroianniCM Poletti F, Valenti C, Valo V, Jirillo E, Deli S Tumour necrosis factor (TNF-alpha) and neurological disorders in HIV infection. J Neurol Neurosurg Psychiatry 1992; 55 (3): 219 – 21.
- 54 Wysselingh SL GlassJ McArthurJC Griffin JW, Griffin DE Cytokine dysregulation in HIVassociated neurological disease . AdvNeuroimmunol 1994 ; 4 (3) : 199 – 206 .
- 55 .Calo ME ArranzGF, Sánchez-PortocarreroJ et al. [Alphatumor necrosis factor in central nervous system disease associated with HIV infection]. AnMed Interna 1995; 12 (6): 263 6.
- 56 FranciottaDM Melzid'Eril GL BonoG BrustiaR RubertoG Rgani I Tumor necrosis factor alpha le vels in serum and cerebrospinal fluid of patients with AIDS . Funct Neurol 1992; 7 (1): 35 8.
- 57 .Gendelman HE Zheng J ,Coulter CL et al .Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. JInfect Dis 1998 ; 178 (4) : 1000 – 7 .
- 58 LafeuilladeA PoggiC Pellgrino P, CortiK Prciži N Sayad C HIV1 replication in the plasma and cerebrospinal fluid. Infection 1996 ; 24 (5) : 367 71.
- 59 MastroianniCM Roletti F, MassettiAP, Elciano M Milo V Hevated levels of tumor necrosis factor (TNF) in the cerebrospinal fluid from patients with HIV -associated neurological disorders. ActaNeurol (Napoli) 1990 ; 12 (1) : 66 - 7.
- 60 .Seigny JJ AlbertSM McDermottMP,etal .Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia . Neurology 2004 ; 63 (11) : 2084 90 .
- 61 Portgies P, GodfriedMH HintzenRQ etal .Low levels of specific T cell activation marker CD27 accompanied by elevated levels of markers for non-specific immune activation in the cerebrospinal fluid of patients with AIDS dementia comple x. J Neuroimmunol 1993 ; 48 (2) : 241 7.

- 62 Mllo V, Mastroianni CM Lichtner M Mengoni F, Delia S Increased cerebrospinal fluid levels of soluble receptors for tumour necrosis factor in HIV-infected patients with neurological diseases. AIDS 1995; 9 (9): 1099 – 100.
- 63 GisolfEH an Praag RM JurriaansS et al .Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RN A in HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Def ic Syndr 2000; 25 (5): 426 33.
- 64 Sabri F, DeMilito A Pirskanen R et al .Elevated levels of soluble Fas and Fas ligand in cerebrospinal fluid of patients with AIDS dementia comple
 x. J Neuroimmunol 2001 ; 114 (1-2) : 197 206 .
- 65 SporerB Kedel U GoebelFD Pheter HW Increasedlevels of soluble Fas receptor and Fas ligand in the cerebrospinal fluid of HIV -infected patients. AIDS Res Hum Retro viruses 2000 ; 16 (3) : 221 6.
- 66 Jowfighi A Skalasky RL SHillaire C ConantK McArthurJC CSF soluble Fas correlates with the severity of HIV-associated dementia . Neurology 2004 ; 62 (4) : 654 6.
- 67. Letendre S, Buzzell M, Marquie-Beck J, et al. The Ef fects of Antiretro viral Use on Cerebrospinal Fluid Biomarkers and Neuropsychological Performance. In: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; 2006.
 - 68 .Campbell IL ,Krucker T, Steffensen S et al . Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha. BrainRes 1999 ; 835 (1) : 46 61 .
 - 69 StarkGR Kerr IM Williams BR Silerman RH SchreiberRD How cells respond to interferons . AnnuRev Biochem 1998 ; 67 : 227 – 64 .
 - 70 .Chwla-Sarkar M LindnerDJ LiuYF, et al .Apoptosis and interferons: role of interferonstimulated genes as mediators of apoptosis . Apoptosis 2003; 8 (3): 237 - 49.
 - 71 Kriine A Force G Serson J etal .MeasuringHIV-1 RNA and interferon-alpha in the cerebrospinal fluid of AIDS patients: insights into the pathogenesis of AIDS Dementia Complex. JNeurovirol 1999 ; 5 (5) : 500 - 6 .
 - 72 PerrellaO CarreiriPB PerrellaA etal .Transforming growth factor beta-1 and interferonalpha in the AIDS dementia complex (ADC): possible relationship with cerebral viral load ? EurCytokine Netw 2001 ; 12 (1) : 51 – 5.
 - 73 RhoMB Wesselingh S GlassJD etal .Apotential role for interferon-alpha in the pathogenesis of HIV-associated dementia . BrainBehav Immun 1995; 9 (4) : 366 77 .
 - 74 Fuchs D , Forsman A , Hagberg L et al . Immune activation and decreased tryptophan in patients with HIV-1 infection . JInterferon Res 1990 ; 10 (6) : 599 603 .
 - 75 .Griffin DE ,McArthur JC ,Cornblath DR Neopterin and interferon-gamma in serum and cerebrospinal fluid of patients with HIV -associated neurologic disease . Neurology 1991 ; 41 (1) : 69 74 .
 - 76 .GalloP, PiccinnoMG Igni S etal .Immuneactivation in multiple sclerosis: study of IL-2, sIL-2R, and gamma-IFN le vels in serum and cerebrospinal fluid . J Neurol Sci 1989 ; 92 (1) : 9 − 15 .
 - 77 ShacklettBL CoxCA Wikens DT,etal .Increasedadhesion molecule and chemokine receptor expression on CD8+ T cells traf ficking to cerebrospinal fluid in HIV-1 infection. J Infect Dis 2004 ; 189 (12) : 2202 12 .
 - 78 .CinqueP, BestettiA MarenziR etal .Cerebrospinalfluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection . JNeuroimmunol 2005 ; 168 (1–2) : 154 – 63 .
 - 79 .ConantK Garzino-DemoA NathA etal .Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci USA 1998 ; 95 (6) : 3117 - 21 .
 - 80 Wriss JM NathA MajorEO BermanJW HIV1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-re gulates CCR5 e xpression on human monoc ytes. J Immunol 1999 ; 163 (5) : 2953 – 9.

- 81 . Sanders VJ , Pittman CA , White MG , Wing G , Wiley CA , Achim CL . Chemokines and receptors in HIV encephalitis . AIDS 1998 ; 12 (9) : 1021 6 .
- 82 . GonzalezE Røin BH SenL etal .HIV1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. ProcNatl Acad Sci USA 2002 ; 99 (21) : 13795 – 800 .
- 83 . Aison MJ NathA Greene-Aison R etal .Inflammatorychanges and breakdown of microvascular integrity in early human immunodef iciency virus dementia . J Neurovirol 2004 ; 10 (4) : 223 – 32 .
- 84 . Bernasconis CinqueP, PeriG etal .Selective elevation of monocyte chemotactic protein-1 in the cerebrospinal fluid of AIDS patients with c ytomegalovirus encephalitis. J Infect Dis 1996; 174 (5): 1098 – 101.
- 85 .Cinque P, Ygo L ,Mengozzi M et al .Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV -1 encephalitis and local viral replication . AIDS 1998 ; 12 (11) : 1327 32 .
- 86 . Monteirede Almeida S Letendre S Zimmerman J Lazzaretto D McCutchan A Ellis R Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. JNeuroimmunol 2005; 169 (1–2): 144 – 52.
- 87 . SozzaniS IntronaM BernasconiS etal .MCP-1and CCR2 in HIV infection: regulation of agonist and receptor expression . JLeukoc Biol 1997 ; 62 (1) : 30 3 .
- 88 .HeJ ,Chen Y, Firzan M et al .CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia . Nature 1997; 385 (6617): 645 – 9.
- 89 . HesselgesserJ HorukR Chemokineand chemokine receptor expression in the central nervous system . JNeurovirol 1999 ; 5 (1) : 13 26 .
- 90 . Sasseille VG, SmithMM MackayCR etal .Chemokineexpression in simian immunodeficiency virus-induced AIDS encephalitis . AmJ Pathol 1996 ; 149 (5) : 1459 – 67 .
- 91 . Schmidtmayerøa H ,Nottet HS ,Nuøo G et al . Human immunodeficiency virus type 1 infection alters chemokine beta peptide e xpression in human monoc ytes: implications for recruitment of leuk ocytes into brain and lymph nodes . Proc Natl Acad Sci USA 1996; 93 (2): 700 4.
- 92 Wistmoreland SV, Rottman JB, Williams KC, Lackner AA, Sasseille VG. Chemokine receptor expression on resident and inflammatory cells in the brain of macaques with simian immunodeficiency virus encephalitis. AmJ Pathol 1998; 152 (3): 659 – 65.
- 93 .LetendreSL LanierER McCutchanA Cerebrospinalfluid beta chemokine concentrations in neurocognitively impaired individuals infected with human immunodeficiency virus type 1. JInfect Dis 1999 ; 180 (2) : 310 – 9.
- 94 . Re DB , Przedborski S Fractalkine: moving from chemotaxis to neuroprotection . Nat Neurosci 2006 ; 9 (7) : 859 61 .
- 95 .ErichsenD LopezAL PengH etal .Neuronalinjury regulates fractalkine: relevance for HIV-1 associated dementia .JNeuroimmunol 2003 ; 138 (1-2) : 144 55 .
- 96 . Sporer B ,Kastenbauer S ,Keedel U ,Arendt G ,Hister HW Increased intrathecal release of soluble fractalkine in HIV -infected patients. AIDS Res Hum Retro viruses 2003 ; 19 (2) : 111 6 .
- 97. Letendre S, Zheng J, Yiannoutsos C, et al. Chemokines Correlate with Cerebral Metabolites on Magnetic Resonance Spectroscop y: A Sub-study of A CTG 301 and 700. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; 2004.
- 98 . Scorziello A ,Florio T, Bajetto A ,Thellung S ,Schettini G TGFbeta1 prevents gp120induced impairment of Ca2+ homeostasis and rescues cortical neurons from apoptotic death JNeurosci Res 1997 ; 49 (5) : 600 – 7 .
- 99 . Johnson MD , Kim P, Tourtellotte W, Federspiel CF. Transforming growth factor beta and monocyte chemotactic protein-1 are elevated in cerebrospinal fluid of immunocompromised patients with HIV-1 infection. JNeuroAIDS 2004; 2 (4): 33 – 43.
- 100 . CinqueP, Nebloni M Santoito ML etal .Theurokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations . AnnNeurol 2004 ; 55 (5) : 687 94 .

- 101 McArthurJC McClernonDR CroninMF,etal .Relationshipbetween human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997; 42 (5): 689 98.
- 102 Brev BJ PembertonL CunninghamP, Lev MG Levels of human immunodeficiency virus type 1 RN A in cerebrospinal fluid correlate with AIDS dementia stage . J Infect Dis 1997; 175 (4): 963 - 6.
- 103 EllisRJ HsiaK SpectorSA etal .Cerebrospinalfluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobeha vioral Research Center Group . Ann Neurol 1997; 42 (5): 679 – 88.
- 104 EllisRJ GamstAC, CapparelliE etal .Cerebrospinalfluid HIV RNA originates from both local CNS and systemic sources . Neurology 2000 ; 54 (4) : 927 36 .
- 105 Ellis RJ Moore DJ Childers ME et al .Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA . ArchNeurol 2002 ; 59 (6) : 923 – 8 .
- 106 Shiramizu B J.au E Jamamoto A J.Uniatowski J J. Toelstrup D Fassibility assessment of cerebrospinal fluid from HIV-1-infected children for HIV proviral DNA and monocyte chemoattractant protein 1 alleles. JInvestig Med 2006 ; 54 (8) : 468 – 72.
- 107 ChernerM LetendreS HeatonRK etal .HepatitisC augments cognitive deficits associated with HIV infection and methamphetamine . Neurology 2005 ; 64 (8) : 1343 7 .
- 108 LetendreSL ChernerM EllisRJ etal .Theeffects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease . AIDS 2005 ; 19ugpl 3): S72 - 8 .
- 109 . Riedel DJ , Brdo CA , McArthur J , Nath A Therapy Insight: CNS manifestations of HIVassociated immune reconstitution inflammatory syndrome . NatClin Pract 2006 ; 2 (10) : 557 – 65 .
- 110 Shiramizu B ,Gartner S ,Wiliams A et al . Circulating proviral HIV DNA and HIV-associated dementia . AIDS 2005 ; 19 (1) : 45 52 .
- 111 Tingaturthi PK , Swaya BE , Singh SP, et al . Role of HIV-1 Vpr in AIDS pathogenesis: relevance and implications of intra virion, intracellular and free Vpr. Biomed Pharmacother 2003 ; 57 (1) : 20 - 4 .
- 112 Griffin DE Wesselingh SL McArthurJC Elevated central nervous system prostaglandins in human immunodeficiency virus-associated dementia. AnnNeurol 1994; 35 (5): 592 – 7.
- 113 Milstien S Sakai N Brow BJ et al. Cerebrospinal fluid nitrite/nitrate levels in neurologic diseases. JNeurochem 1994; 63 (3): 1178 80.
- 114 .Giøannoni G MillerRF, HealesSJ LandJM HarrisonMJ ,Thorpson EJ Elevated cerebrospinal fluid and serum nitrate and nitrite le vels in patients with central nerv ous system complications of HIV-1 infection: a correlation with blood-brain-barrier dysfunction . J Neurol Sci 1998 ; 156 (1) : 53 – 8.
- 115 .Giøannoni G HealesSJ Silør NC etal .Raisedserum nitrate and nitrite levels in patients with multiple sclerosis . JNeurol Sci 1997 ; 145 (1) : 77 81 .
- 116 BazanNG Reckard MG Father L AllanG Bioactive lipids in excitatory neurotransmission and neuronal plasticity. NeurochemInt 1997; 30 (2): 225 31.
- 117 BitoH NakamuraM HondaZ etal .Platelet-activating factor (PAF) receptor in rat brain: PAF mobilizes intracellular Ca2+ in hippocampal neurons . Neuron 1992; 9 (2) : 285 – 94 .
- 118 EpsteinLG GelbardHA HIV1-induced neuronal injury in the developing brain . JLeukoc Biol 1999 ; 65 (4) : 453 7 .
- 119 FranconiF, MiceliM DeMontis MG Crisaf EL BennardiniFTagliamonte A NMDA receptors play an anti-aggregating role in human platelets. ThrombHaemostasis 1996; 76 (1): 84 – 7.
- 120 Gelbard HA, Nottet HS, Swindells S et al. Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin. JVirol 1994 ; 68 (7) : 4628 35.
- 121 Nogren N Rosengren L Stigbrand T Elevated neurofilament levels in neurological diseases. BrainRes 2003; 987 (1): 25 31.
- 122 AbdulleS MellgrenA Brev BJ etal .Cerebrospinalfluid neurofilament protein (NFL) a marker of AIDS dementia complex . JNeurol 2006 ; 254 (8) : 1026 32 .

- 123 Gisslen M ,Rosengren L ,Hagbeg L ,Deeks SG ,Price RV .Cerebrospinal fluid signs of neuronal damage after antiretro viral treatment interruption in HIV -1 infection. AIDS Res Ther 2005 ; 2 : 6 .
- 124. Mellgren A, Price RW, Hagberg L, Rosengren L, Brew BJ, Gisslen M. Antiretro viral treatment reduces increased CSF neurof ilament protein (NFL) in HIV -1 infection. Neurology 2007;69:1536–41.
- 125 Petzold A ,Hinds N ,Murray NM et al .CSF neurofilament levels: a potential prognostic marker in Guillain-Barre syndrome . Neurology 2006 ; 67 (6) : 1071 3 .
- 126. Gisslen M, Hagberg L, Brew BJ, Cinque P, Price RW, Rosengren L. Elevated cerebrospinal fluid neurofilament light protein concentrations predict the de velopment of AIDS dementia complex. J Infect Dis 2007;195:1774–8.
- 127 Andreasen N ,Sjogren M ,Blennw K CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42. World J Biol Psychiatry 2003 ; 4 (4) : 147 55.
- 128 Brev BJ ,Pemberton L ,Blennev K ,Willin A ,Hagbeg L CSF amyloid beta42 and tau levels correlate with AIDS dementia complex . Neurology 2005 ; 65 (9) : 1490 2 .
- 129 Eløaara I Jianainen M Jule SL SuniJ Ærvo T, Lahdæirta J CSFprotein and cellular profiles in various stages of HIV infection related to neurological manifestations. J Neurol Sci 1987; 78 (3): 331 – 42.
- 130 MarshallDW, Bry RL ButzinCA Lucy DR AbbadessaSM BoswH RN CSFchanges in a longitudinal study of 124 neurologically normal HIV-1-infected U.S. Air Force personnel. JAcquir Immune Defic Syndr 1991 ; 4 (8) : 777 – 81.
- 131 HallCD Suder CR RobertsonKR etal .Cerebrospinalfluid analysis in human immunodeficiency virus infection . AnnClin Lab Sci 1992 ; 22 (3) : 139 – 43 .
- 132 SingerEJ Syndulk K Phy-Chandon B SchmidP, ConradA Tourtellotte WW Intrathecal IgG synthesis and albumin leakage are increased in subjects with HIV-1 neurologic disease. JAcquir Immune Defic Syndr 1994; 7 (3): 265 – 71.
- 133 Andersson LM, Hagber L, Fuchs D, Sønnerholm B, Gisslen M, Increased blood-brain barrier permeability in neuro-asymptomatic HIV -1-infected individuals-correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels. JNeurovirol 2001; 7 (6): 542 – 7.
- 134 AbdulleS Hagber L GisslenM Effects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patients. HIVMed 2005; 6 (3): 164 9.
- 135 Sporer B Kedel U Paul R Eberle J Arendt G Pifster HW Vascular endothelial growth factor (VEGF) is increased in serum, b ut not in cerebrospinal fluid in HIV associated CNS diseases. JNeurol Neurosurg Psychiatry 2004 ; 75 (2) : 298 300.
- 136 HuangSH JongAY Cellularmechanisms of microbial proteins contributing to invasion of the blood-brain barrier. Cellmicrobiol 2001; 3 (5): 277 87.
- 137 RieckmannP, Nunk K BurchhardtM et al .Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: an indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier. JNeuroimmunol 1993 ; 47 (2) : 133 40.
- 138 HeidenreichF, ArendtG JanderS Jablonwski H StollG Semm and cerebrospinal fluid levels of soluble intercellular adhesion molecule 1 (sICAM-1) in patients with HIV-1 associated neurological diseases. JNeuroimmunol 1994 ; 52 (2) : 117 – 26.
- 139 Rosenber GA Matrixmetalloproteinases in neuroinflammation. Glia 2002 ; 39 (3) :9279 -
- 140 Sporer B , Rul R , Kedel U et al . Presence of matrix metalloproteinase-9 activity in the cerebrospinal fluid of human immunodef iciency virus-infected patients. J Infect Dis 1998; 178 (3): 854 7.
- 141 Conant K McArthur JC Griffin DE Sjulson L Whl LM Jrani DN Cerebrospinal fluid levels of MMP-2, 7, and 9 are ele vated in association with human immunodef iciency virus dementia. AnnNeurol 1999 ; 46 (3) : 391 – 8.
- 142 LiuzziGM MastroianniCM SantacroceMP,etal .Increasedactivity of matrix metalloproteinases in the cerebrospinal fluid of patients with HIV-associated neurological diseases. JNeurovirol 2000 ; 6 (2) : 156 - 63 .

- 143 AlbrechtD GarciaL CartierL etal . Trophic factors in cerebrospinal fluid and spinal cord of patients with tropical spastic paraparesis, HIV, and Creutzfeldt-Jakob disease. AIDS Res Hum Retroviruses 2006 ; 22 (3) : 248 – 54.
- 144 SacktorN Haughy N CutlerR etal .Novel markers of oxidative stress in actively progressive HIV dementia . JNeuroimmunol 2004 ; 157 (1–2) : 176 84 .
- 145 MarshallDW, Brg RL CahillWT, HoukRW, ZajacRA BoswellRN Spectrumof cerebrospinal fluid findings in various stages of human immunodef iciency virus infection. Arch Neurol 1988 ; 45 (9) : 954 – 8.
- 146 Gisslen M ,Hagber L, Rosengren L et al . Defining and Evaluating HIV-Related Neurodegenerative Disease and Its T reatment Targets. J Neuroimmune Pharmacol 2006; 2 (1): 112 – 9.
- 147 .Beger JR Axison M MootoorY, BeachC Cerebrospinalfluid proteomics and human immunodeficiency virus dementia: preliminary observations . JNeurovirol 2005; 11 (6): 557 – 62 .
- 148 LuoX CarlsonKA Wijna V, et al .Macrophageproteomic fingerprinting predicts HIV-1associated cognitive impairment . Neurology 2003 ; 60 (12) : 1931 – 7 .
- 149 .Wijna V, CarlsonKA LuoX etal .Proteomicfingerprinting of human immunodeficiency virus type 1-associated dementia from patient monocyte-derived macrophages: A case study. JNeurovirol 2004 ; 10 (Subpl 74 – 81 .

Neuroimaging Among HIV-Infected Patients: Current Knowledge and Future Directions

David F. Tate, Jared J. Conley, Dominik S. Meier, Bradford A. Navia, Ronald Cohen, and Charles R.G. Guttmann

Early in the human immunodef iciency virus (HIV) pandemic, in vi vo medical imaging methods (computed tomography (CT) and magnetic resonance imaging (MRI)) were used to e xamine the impact of HIV on the central nerv ous system (CNS), including HIV-associated opportunistic infections (OIs). Ov er the years, additional studies have led to many key findings that have furthered our understanding of HIV's effect on the brain, as well as pro vided better clinical prognosis. It is expected that future studies will continue to add to our gro wing understanding of the evolution and progression of HIV -associated CNS injury, such that surrogate imaging markers of treatment ef ficacy can be established and routinely implemented in the care of HIV-infected patients. In this chapter, we highlight much of the current literature in an attempt to pro vide the reader with a summary of HIV neuroimaging studies conducted within the past decade, as well as identify future directions that we belie ve will provide valuable insights into HIV -associated neurological injury.

Examining the CNS for injury in HIV-infected patients is important for several reasons (see Table 1). More generally, there is signif icant neuropathological evidence of CNS injury associated with HIV infection. F or example, common pathological findings in HIV-infected patients include microglial nodules containing multinucleated giant cells, myelin v aculation, astrocyte proliferation, cortical neuronal loss, and reduction in synaptic density (1–3). The potential of neuroimaging to provide proxy markers of common pathological processes in HIV infection is particularly relevant because HIV activity and its translation to CNS involvement can differ greatly among individuals. Clinical markers of disease e volution and progression are therefore essential for e xamining host and viral v ariables that might affect disease progression and/or treatment ef ficacy. Though not al ways

D.F. Tate (🖂)

Instructor in Radiology and Psychiatry, Center for Neurological Imaging, Brigham and Women's Hospital, Harvard Medical School, Boston ,MA, USA dtate1@partners.og

Screen or rule out the	possibility of ne	urologic opporti	inistic infections

Understand disease etiology/pathogenesis

Assess disease severity (a single MRI exam allows to assess the amount of CNS involvement) Monitor progression (serial MRI provides markers of progression-translation of HIV activity

into neurodegeneration)

Evaluate treatment effect (both CNS-specific treatment as well as generic treatment to the extent that neurodegeneration is a covariate of general progression)

etiologically specific in isolation, multiple imaging modalities used in combination demonstrate improved ability to discern specif ic processes of HIV -associated pathological injury.

Additionally, since the be ginning of the pandemic, there has been a subset of patients who developed significant cognitive symptoms consistent with a diagnosis of dementia (4). Though the number of patients e xperiencing frank dementia has declined in the era of highly acti ve antiretroviral therapies (HAARTs), there is evidence that the number of mild cognitive symptoms has increased (5, 6). These findings continue to suggest the CNS in volvement. These CNS findings combined with neuroimaging surrogate studies will greatly improve our ability to predict clinical and cognitive progression over time as well as improving treatment decisions.

Another general reason for examining HIV-associated CNS injury is that despite the improvements in HIV medication regimens, there continues to be pathological evidence of CNS involvement. In fact, when examining the postmortem samples (7, 8), the incidence of HIV encephalitis continues to gro w regardless of treatment improvements. This finding is perhaps the most important reason for conducting imaging studies, as it will be imperative to understand why these symptoms persist and what effects treatment does or does not have on CNS preservation.

By way of organizing the direction of the chapter, we have discussed the following topics. First, we be gin by briefly discuss the quantitati ve clinical and research neuroimaging findings. This section of the chapter is divided into specific imaging modalities (e.g., structural MRI, magnetic resonance spectroscop y, diffusion imaging, etc.) for easy na vigation. Our discussion of these v arious modalities is limited to findings primarily from the last decade (though we have included earlier study findings in some places to provide relevant contextual information). This was done in order to limit studies to patient populations that were more lik ely to be on HAART regimens, as treatments of this type are thought to alter the natural progression of HIV and, therefore, could present differently in the CNS. Finally, we have concluded the chapter by summarizing the literature and suggesting future directions for HIV neuroimaging research, including longitudinal/prospecti ve methods as well as multimodal imaging methods that have been used successfully to examine other CNS diseases.

Qualitative and Quantitative Structural Neuroimaging

CT and MRI have been used since the beginning of the HIV pandemic to examine a host of clinical and structural complications associated with HIV infection. Early imaging was often used to identify common comorbid opportunistic infections (OIs) and/or tumors (e.g., lymphoma, meningitis, toxoplasmosis, progressi ve multifocal leukoenchephalopathy). Generally these neurologic OIs present with well-def ined space occupying lesions and/or have readily recognizable imaging findings (9–11).

This early literature is still v ery useful in more immunologically compromised and/or treatment-resistant patient populations where the prevalence of these comorbid disorders is much higher. Additionally, the gross structural changes as observed in Fig. 1 and the clinical ramifications of these changes underscore the importance of monitoring HIV disease progression and the prevention of neurologic OIs through early diagnosis and thorough treatment.

Clinical research of OIs w as followed by examination of the direct ef fects of HIV on the CNS. Initial studies have shown general atrophy in both cortical (See Fig. 2) and subcortical regions of the brain (12), often related to the regional concentrations of HIV (13). More specifically, these regions include frontal white matter and basal ganglia (14, 15), with alterations in these areas becoming more prominent in later stages of HIV infection.

In particular, tissue volume reduction in the caudate nucleus is repeatedly cited as a common HIV quantitative imaging finding (15–17). These findings are clinically important, as the y are often associated with measures of cognitive function and/or disease burden. For example, reduction of various brain volume measures has been significantly associated with measures of cognitive function (18), including global measures of cognition (19–22), cognitive speed (23, 24), executive function (25), fine motor tests (26, 27), verbal fluency (25), and memory (28), with the most consistent findings associated with measures of cognitive speed and executive function.

The relationship between quantitative MRI findings and HIV disease burden has not been consistent across studies, making it difficult to understand the true nature of the relationship between these v ariables. For example, there are several studies demonstrating significant associations between CD4 cell-count decline, global atrophy (22, 29), caudate atrophy (29, 30), putamen atrophy (31), and cortical thickness (22). Yet other researchers do not find associations with CD4 or viral load (20) or they simply do not report associations (32, 33). Importantly, there are several methodological and sampling-related issues that may provide an explanation for these equivocal findings. One important caveat to these results is the lack of longitudinal studies that could be used to model the potentially dynamic nature of HIV infection (see discussion at the end of this chapter). An exception to this criticism is the longitudinal imaging study conducted by Stout et al. (30), where they examined the prospective imaging data for 86 HIV+ men and 23 serone gative controls. Measures for total CSF, total brain volume, white-matter volume, gray-matter cortical volume, and subcortical gray-matter nuclei v olumes were examined separately for symptomatic and asymptomatic HIV+ patients (30). Though all the HIV+




Fig. 1 Composite image of common opportunistic infections (OIs) MRI findings. (**a**) and (**b**) are T1 and T2 axial images of the anterior half of the brain from a patients with progressi ve multifocal leukoencephalopathy (PML). The T2 image (**b**) demonstrates the diffuse, asymmetrical whitematter injury commonly observed in PML (see *white arrow*) while the T1 image (**a**) demonstrates the hypointense area (see *arrow*) within lesion. The combination of these two findings together is diagnostic of PML. (**c**) is a T2 image of a patient with cryptococcal meningitis with bilateral infarctions in the caudate nuclei. (**d**) is a T1 image of a patient with toxoplasmosis. *Arrows* illustrate the frank lesions as well as edema (dark hypointense area surrounding the bright ringed lesion) resulting from injury. Images courtesy of Peter Hildenbrand, MD

patients were free of CNS OIs, the symptomatic patients demonstrated increases in CSF volume that was significantly different from HIV+ asymptomatic patients and controls. Significant reductions in white-matter volume were also noted in symptomatic HIV+ patients. Of the subcortical gray matter nuclei e xamined, only the caudate demonstrated accelerated atrophy, though this atrophy w as only significant for patients at the most adv anced CDC stage. Furthermore, though the size of the caudate and CSF v olume were unrelated to CD4 counts at either time point individually, patients experiencing the most decline in CD4 cells demonstrated the most change in quantitative MRI measures. This f inding is significant in that it




Fig. 2 T1-weighted image of an HIV patient with enlarged lateral ventricles (general a non-specific sign of atrophy). Images courtesy of Peter Hildenbrand, MD

provides evidence that the association between immunological function and MRI measures may be more evident in prospective studies and can be effectively modeled to examine the progression of CNS injury relative to clinical measures of immuno-logical function.

Another important caveat to these early MRI research findings is that many were conducted in the early/middle 1990s before the introduction of HAAR T. Since the introduction of HAART, there has been an alteration in the natural progression of HIV as well as mark ed improvement in the life e xpectancy of patients (34, 35). With these improvements in immunological function and life e xpectancy, renewed interest in e xamining the structural neuroimaging f indings associated with HIV infection has been generated (32, 36) with similar findings of global atrophy (32, 36) yentricular enlargement (29, 36) reduction in caudate volume (29, 36) corpus callosum (22), and even cerebellar atrophy (37, 38).

Additionally, recent modifications of MRI sequences and postprocessing methods have improved the clinical utility of imaging as well as improved the cost effectiveness of large-scale MRI studies of HIV-associated CNS injury. Advances in digital image processing and increased automation have not only enabled researchers to effectively and efficiently query vast amounts of MRI data, but also have opened up new avenues for studying neurode generation (i.e., data-dri ven approaches to test for structural changes without an a priori hypothesis). For example, Thompson et al. (39) have used the T1-weighted MRI sequence, along with 3D cortical surf acing software, to determine the areas and amount of thinning in the cerebral corte x of HIV/AIDS patients. Their analysis of the cortical maps of 26 AIDS subjects and 14 controls generated results of significant cortical thinning in primary sensorimotor, premotor, and visual areas of AIDS patients (39). These regions of cortical thinning are in stark contrast to those areas affected by other common noninfectious dementias, such as Alzheimer's disease where it is the medial temporal, limbic, and association cortices that are affected first (40). They also found that atrophy le vels in the prefrontal and parietal cortices predicted cognitive impairment, and that cortical thinning of the language areas and frontal poles of both hemispheres w as an accurate predictor of CD4 cell counts. In addition, this group assessed the role of HAART, comparing AIDS patients on and of f treatment, and disco vered evidence that suggested limited utility of HAART in mediating the severe pattern of cortical thinning.

A year later, Thompson et al. published another study, which evaluated corpus callosum atrophy and v entricular expansion in an HIV/AIDS cohort, and utilized similar 3D statistical anatomic maps methods (22). Fifty-one patients were selected, including 30 AIDS patients and 21 serone gative controls. The T1 sequence scans were used to create 3D surface mesh reconstructions of the CC and lateral ventricles, with structural alterations then being correlated with viral load, T -cell counts, and cognitive impairment. Their results sho wed thinning throughout the CC, with the frontal three-fifths having the greatest sustained atrophy (25% reduction), which correlates well with the caudate nucleus volume reductions and increased viral load seen in other studies (30). This CC thinning was strongly linked to CD4 counts in both traditional volumetric measurements and mapping, suggesting that CC thickness can potentially be applied as an MRI-based mark er of white-matter integrity in AIDS patient populations. Additionally, the study established a 3D pattern for ventricular expansion in AIDS patients, with the frontal horn maps pro viding the greatest distinction between AIDS subjects and controls. These 3D entricular changes were again significantly linked with CD4 counts, as well as cognitive impairment.

In another v ery sophisticated analysis of HIV -associated structural imaging abnormalities in HIV+ patients, Lepore et al. (41) examined 26 AIDS patients and 14 seronegative controls using a tensor -based morphometry approach (TBM). Using this method, very precise volumetric differences can be mapped and correlated to clinical and/or cogniti ve measures. Significant reduction in v olume was noted bilaterally in the primary and sensory association areas and subcortical areas of the brain for HIV+ patients. The v olumetric reduction (especially reduction in white matter) significantly correlated with cognition and declines in CD4 cell counts(41). This method appeared to impro ve the sensitivity of volumetric findings capturing significant amounts of atrophy that have not been observed utilizing less sophisticated methods. The findings from this study emphasize the importance of frontal–subcortical areas in the de velopment of cognitive dysfunction observed in more immunosuppressed HIV+ patients.

Although not a signif icant defining MRI feature of HIV+ encephalopathy , another common imaging finding worth mentioning is the presence of T2-weighted hyperintensities or signal abnormalities (see Fig 3.) in and about the white matter of the CNS (white-matter signal abnormalities, WMSAs) (12, 42, 43).

In the HIV Neuroimaging Consortium multisite imaging study , we found that 25% of the HIV+ patients had a measurable degree of WMSAs, which is similar to other studies (36, 42, 44). These findings may be important in HIV patient populations due to the association they have with pathological findings in HIV encephalopathy




Fig. 3 Set of T2-weighted images illustrating the range of WMSAs seen among HIV patients. *White arrows* point to areas of WMSAs. P atient (**a**) has a single small circumscribed WMSA. Patient (**b**) has several areas of WMSAs with necrotic centers. Patients (**c**) and (**d**) have more diffuse WMSAs with less defined boundaries (often called dirty white matter). Images courtesy of NIH funded (RO1NS03624) HIV Neuroimaging Consortium

(1, 3). For example, increasing WMSA load or volume was shown to be related to a pathological diagnosis of HIV encephalitis, including dendritic pruning (45). However, in a recent study by V alcour et al. (46), WMSAs were also shown to be related to vascular risk factors among an older aging HIV cohort, emphasizing the need to examine in additional detail the role and pathological correlates of these signal abnormalities (46). With regard to cognition, there does not appear to be any relationship between WMSA and cognition among HIV -infected patients (44). However, to date, this relationship has not been e xamined thoroughly and as such may provide a unique line of investigation.

In summary, structural imaging findings appear to be more sensitive to changes at later stages of HIV infection, with the most common findings being global atrophy and caudate volume atrophy. These MRI f indings are often (though not al ways) associated with performance on cogniti ve tests and, as such, are thought to be useful in e xamining the brain–beha vior relationships among HIV patients. Associations with immunological function (CD4) or disease se verity (viral load) are not always found, though longitudinal prospective imaging studies may improve our understanding of progressive CNS involvement among HIV+ cohorts.

Proton Magnetic Resonance Spectroscopy

Magnetic resonance spectroscopy (MRS) has been proven to be particularly useful in examining HIV-associated CNS abnormalities. This MRI method allo ws researchers to measure chemicals/metabolite concentrations in the brain noninvasively, without removing any tissue or using radioactive tracers. It is based on the principle that different chemicals resonate at different frequencies when stimulated by a static magnetic field. In this manner, MRS is capable of identifying and quantifying a specific set of various neurochemicals.

As illustrated in Fig. 4, different chemical metabolites appear at v arious points along the *x*-axes (termed the chemical shift), with the shift being measured in parts per million (ppm). MRS signal intensity (*y*-axes) or height of the peak is related to the concentration of the metabolite. By examining the area under the chemical shift peak for each metabolite, the amount of metabolite can be estimated for analysis. This method has been used extensively to evaluate disorders of the CNS with a high degree of success.

Though MRS is capable of quantifying many chemical compounds (see Table 2 for a list of common metabolites captured by MRS), the most commonly reported chemical spectra in the assessment of HIV+ patients include *N*-acetylaspartate (NAA), myo-inositol (mI), Choline (Cho), and creatine (Cr). Ne xt to water, NAA represents the largest peak of proton signal in the CNS. It has been found almost exclusively in neurons and is considered a measure of neuronal inte grity (47–49). NAA is reduced in tissue where neurons are being destro yed in a disease process and, as might be expected, exists in higher concentrations in the gray matter (48). In contrast to NAA, mI is found almost e xclusively in glial-cell populations. It is




Fig. 4 Typical placement of regions of interest and a common spectra output from an HIVinfected patient. Images courtesy of NIH funded (R O1NS03624) HIV Neuroimaging Consortium (*See Color Plates*)

Table 2 Common metabolites measured with MRS and their ppm peak location

ppm	Metabolite	Properties
1.3	Lactate	Marker of cell death and necrosis
2.0	NAA	Neuronal integrity
2.1-2.4	Glutamine/GABA	Neurotransmitters
3.0	Creatine	Energy metabolism
3.2	Choline	Cell-membrane turnover
3.5	Myo-inositol	Glial-cell marker

often found in higher concentrations in the gray matter and is considered a mark er of glial-cell proliferation. Cho is associated with cell-membrane synthesis, since phosphocholines are released during myelin breakdown (48). Thus, Cho is particularly useful in examining the white mater of HIV+ patients where pathology evidence is suggestive of myelin abnormalities. The Cr signal in the MRS spectra is often used as a reference peak against which to normalize metabolite concentrations. This is generally an accepted method because the Cr signal is relati vely constant across subjects, though this method is not without contro versy.

There are a couple of technological caveats worth mentioning. Technical challenges in MRS arise from spatial resolution limits because of rapid loss of signal with smaller field of view. A reliable signal requires f airly large quantities of tissue, which limit studies to the most abundant metabolites and relatively large anatomical regions of interest, though as higher field strength magnets become more mainstream, there will be some improvements. Higher field strength will also enable additional metabolites to be studied because of the impro ved separation of chemical shift peaks. Another qualification is that the determination of absolute concentration measures from the observed spectra requires careful calibration and complex spectral fitting algorithms. Self-normalizing ratios, such as N AA/Cr, have often been used as surrogates of absolute NAA concentrations. The rationale is that Cr is a principal energy metabolite, and therefore assumed to be e venly and constantly distributed throughout the brain. There are concerns, however, that naturally occurring fluctuations of Cr would render it unf it as a variable for normalization. Astroc ytes also have higher Cr levels than neurons, which could explain Cr rises in areas of gliosis (50, 51). Since glial-cell proliferation is a possible pathological factor in HIV, the use of Cr as a variable for normalization may be questionable. Additionally, Cr and Cho levels appear to correlate with age (52), requiring proper normalization and control in longitudinal and cross-sectional studies, especially in aging HIV+ populations.

Despite these limitations, MRS has generally been more sensiti ve to changes in the brain at earlier stages of HIV infection when compared with other imaging modalities and as such may represent an important method in understanding early neurochemical mechanisms of HIV -associated CNS injury. Findings using MRS have been generally consistent, with the pattern of metabolites demonstrating elevations in Cho, mI, and occasionally Cr in frontal areas and in the basal ganglia(53–57). Elevations in these metabolites are often interpreted to be a sign of increased glial activation, astrocytosis, and/or inflammation, all of which are readily observed in postmortem neuropathology studies (1). Additionally, decreases in NAA have also been observed in advanced disease (49, 54, 58), signaling the loss of neurons.

Given the significant effects of HAART on the progression of clinical symptoms and HIV viremia, investigators have sought to examine the effects of these medications on common MRS spectra. Unfortunatlely, the research is mix ed with some studies demonstrating improved metabolite function in HIV+ patients (59, 60) while others have only demonstrated partial or no reco very of metabolite ratios (56, 61). For example, the Chang et al. (61) study of 33 HIV+ patients and 26 serone gative controls demonstrated no significant improvement in the metabolite function of the HIV+ cohort, despite improvements in CD4 cell counts and viral loads (measured in the plasma and CSF) after 3 months of treatment (61). The persistent abnormalities were interpreted to represent mechanisms of ongoing repair of reactive inflammatory processes in the areas sampled. T arasow et al. (56) noted modest improvements in NAA/Cho ratios approximately 6 months into treatment suggesting impro ved neuronal integrity in the frontal/subcortical areas of the brain (56). Similarly, Stankoff et al. (60) examined the effect of HAART on 22 AIDS patients, half of whom exhibited cognitive impairment. At baseline, AIDS patients with cogniti ve impairment exhibited reduced NAA levels in the frontal white matter. After 9 months of therapy with HAART, the severity of cognitive difficulties and the magnitude of NAA abnormalities improved among patients with cognitive impairments at baseline (60). Taken together, these findings have led many to postulate that MRS might be an important method for examining treatment efficacy, albeit the small cohort sizes (with potential selection bias from subgroups of patients who might be nested within larger samples who experience improvement), short follow-up intervals, and various methodological differences (i.e., different ROIs, different metabolite ratios reported, etc.) should be considered when interpreting results.

MRS findings associated with cognitive function have also been a topic of interest among HIV-infected patient populations. Worsening metabolite ratios are generally associated with cognitive decline across studies, especially when there are N AA reductions in the basal ganglia or cerebral white matter (62, 63). For example, in the recent paper by Paul et al. (64) associations between NAA/Cr and mI/Cr ratios in the frontal white matter and basal ganglia and cogniti ve performance were particularly robust, especially with measures of motor function and processing speed. In contrast, metabolite ratios in the parietal corte x were not associated with any cognitive measure suggesting regional significance of metabolites in these areas of the brain and their specific impact on commonly observed cognitive abnormalities in HIV-infected patients (64).

Similar to structural imaging f indings, MRS investigators have also examined several potential confounds known to confer additional neurological risks, including alcohol abuse, drug abuse, and aging. In the Pfefferbaum et al. (49) study, the authors compared the metabolite findings of four experimental groups: HIV+ plus alcoholism (n = 15), HIV+ only (n = 9), alcoholism only (n = 8), and 23 controls. Importantly, HIV+ groups were matched for CD4 cell counts and alcoholic patients were matched for self-reported lifetime alcohol consumption. Metabolites measured in the parietal–occipital region of the brain demonstrated signif icant findings for the HIV+ alcoholic group only with nearly a full standard deviation reduction in NAA and Cr regardless of HAART status (49). Though there was no significant alteration of these metabolites for the HIV+ or alcoholic only groups, this may be the result of sampling the parietal–occipital re gion only rather than areas known to be affected in both excessive alcohol use and HIV infection.

In the Chang et al. (65) study, the effects of methamphetamine (meth) drug abuse on MRS measured metabolite ratios were examined. The results of this study demonstrated significant additive effects of chronic meth use by examining four experimental groups: HIV+ meth user (n = 24), HIV+ only (n = 44), meth users only (n = 36), and controls (n = 39). Importantly, Chang et al. attempted to quantify the actual amount of meth used during their lifetime with a meth use history questionnaire which was used in the analyses as a covariate. Regions of interest placed in the frontal gray matter, frontal white matter, and basal ganglia demonstrated several significant differences in metabolites between the groups. Specifically, NAA was reduced in the frontal regions of the brain for chronic meth users, HIV+ only, and HIV+/meth user groups compared with controls with the HIV+/meth user group having the most decline. In f act, the HIV+/meth users group demonstrated significant declines in NAA for all three regions compared to the other groups with an average 7.2% decline for the three R OIs demonstrating a significant additive effect of comorbid methamphetamine use among HIV+ patients (65).

Aging is another potential confounding factor in HIV+ research settings. We know that in normal aging, there are observ able metabolite changes, including slow but steady increases in the glial mark er mI (66). Some studies ha ve demonstrated increases in Cho and Cr as well (66–68) though others have not (69, 70). Age is becoming an increasingly important topic of research among HIV+ cohorts as the introduction of HAART has vastly improved the life expectancy of HIV+ patients. In the multicenter HIV MRS Consortium study by Chang et al. (71), 100 HIV+ patients underwent assessment of metabolites in the frontal white matter , basal

ganglia, and parietal cortex. These patients were stratified into three groups according to disease-associated cognitive performance (61 AIDS Dementia Complex (ADC), 39 neuroasymptomatic (NAS), and 37 seronegative controls(SN)). Results demonstrated worse metabolite ratios, particularly for Cho/Cr and mI/Cr ratios, for the ADC group with aging interacting with group status (71). In another study by Ernst and Chang (72), 46 HIV+ patients and 58 serone gative controls were e xamined using MRS. Measurements of metabolites in the frontal white matter and basal ganglia were shown to be worse in older HIV+ patients (72). When examining this cross-sectional data by decade, there were notable increases in glial mark es, Cho, and mI such that the percentage of increase in these metabolites was approximately >10% per decade for HIV+ patients compared with <3% for seronegative controls. NAA also showed decreases in the basal ganglia across decades though the decline was not as significant as the increases in other metabolites (<4% per decade). One important caveat was that this finding was in HAART naïve patients, which might have resulted in worse findings.

There have also been attempts to look at different combinations of MRS metabolites that have proven useful. For example, Yiannoutsos et al. (73) examined factor groupings of metabolite ratios using a statistical f actor analysis approach. The results from this study of 100 HIV+ participants identif ied three coherent factors (inflammatory, basal ganglia, and neuronal) that were associated with unique patterns or combinations of metabolite ratios (73). Specifically, the inflammatory factor was associated mainly with elevations of mI/Cr in all three regions (frontal, parietal, and basal ganglia) and Cho/Cr increases in the frontal and parietal white matter. The basal ganglia f actor was associated with NAA/Cr decreases and Cho/ Cr increases in the basal ganglia R OI. The neuronal f actor was associated with reductions in the NAA/Cr ratio in the frontal and parietal white matter. These factors were found to be useful in discriminating between the groups of cogniti vely impaired and unimpaired participants, with the neuronal pattern being strongly associated with ADC staging. Such a statistical approach could greatly improve our understanding of the combination of these factors.

In summary, there is signif icant evidence of altered metabolic function in HIV-infected patients, early in the course of disease progression. This is especially true for metabolic markers of glial proliferation (mI) and membrane turnover (Cho) suggesting a clear metabolic reaction to HIV infection. Ov er time, neuronal integrity is compromised, signaled by a reduction in NAA especially in frontal and subcortical areas of the brain. There is equivocal evidence of metabolite improvement with the introduction of HAAR T, though this important issue requires further examination. Importantly, there are clear associations between cognitive performance and abnormal metabolite function with more rob ust association s being observ ed when NAA is reduced in frontal and subcortical ROIs. This finding emphasizes the known pathological spatial distribution of HIV throughout the CNS and the subcortical cognitive presentation so often observ ed in HIV infection. F or these reasons, researchers have emphasized the utility of MRS in examining the temporal evolution and progression of HIV-associated CNS injury.

Diffusion Magnetic Resonance Imaging (DTI)

Diffusion MRI sequences are relati vely new developments in the MR arsenal of imaging tools. Diffusion imaging examines the rate and direction of gross thermal molecular water movement (Brownian motion) at each imaging v oxel. As water molecules move about in the tissue of interest, they encounter the physical barriers of cell membranes, myelin sheaths, and other tissues that restrict the otherwise random nature of their mo vement. This anisotropic mo vement may be quantified providing both vector and velocity information at each imaging v oxel. Thus, the amount of mo vement and the direction of the mo vement can provide unique information regarding structural tissue organization and coherence at a microscopic scale well beyond typical imaging resolution (74).

Though there are a v ariety of ways for quantifying diffusion data, researchers have focused on two primary metrics (or some deri vation of these two indices). These two metrics include the mean diffusivity (75) and fractional anisotropy (FA). MD is a measure of the magnitude of water diffusion at a particular imaging voxel and produces values that range from 0 to 1 (values closer to 0 representing reduced water movement and values closer to 1 indicating unrestricted w ater movement). FA as a metric includes information about diffusion directionality and reflects a difference between isotropic diffusion and linear diffusion. Values for FA range from 0 to 1 with 0 reflecting more random diffusion and 1 indicating more directional linear diffusion.

Examination of HIV-associated CNS injury using DTI began shortly after 2000 as researchers realized its clinical utility in the f ield. Though axonal membranes are generally sufficient to cause anisotrop y (76–78), there is e vidence that changes in myelin density (79, 80) and/or axonal degradation (81) can also alter FA values such that a reduction reflects altered myelin and/or reduction in white-matter volume. This ability to examine subtle changes in white-matter micro-architecture makes diffusion imaging particularly attractive when examining white matter inte grity among HIV-infected patients. Despite this ability , there are a limited number of studies in the general HIV literature to date. Belo w, we provide a short review of the DTI studies and then finish with a summary of our own developing research in this field.

General DTI findings demonstrate consistent reductions in F A measures and intermittent increases in MD. These altered scalar metrics are interpreted as an indication of white-matter damage. F or instance, a study in 2001 conducted by Pomara et al. evaluated DTI metrics among a cohort of six HIV+ patients and nine controls utilizing a regions of interest (ROIs) approach in the several white-matter areas of the CNS. The analyses of ROIs indicated a statistically significant decrease in FA for the frontal lobes of HIV patients, but no significant group differences for the parietal lobes, temporal lobes, or the tw o corpus callosum ROIs. At the same time, FA was significantly increased in the internal capsule of the HIV cohort, while MD values were not significantly different among the groups, re gardless of the ROI. In 2004, Ragin et al. studied the whole-brain fractional anisotropy differences amongst a small HIV cohort (six) and healthy controls (nine). The results demonstrated

whole-brain FA measures that were significantly reduced in the patients with HIV (82). Yet, whole-brain ADC (a v ariant of MD) v alues indicated no significant differences between the two groups.

Beyond these general findings, some researchers have sought to assess the impact of clinical measure of disease se verity (i.e., viral load and CD4) in the context of DTI metrics. In 2002, Filippi et al. related diffusion tensor metrics to viral load in the white matter of a small HIV+ cohort. In this small study , the results of ten HIV patients showed significantly lower FA values in HIV patients with higher viral loads (44,000–200,000), particularly in the splenium and genu of the corpus callosum (CC) (83).

In addition to these viral load associations, se veral groups began assessing DTI measures with respect to cognitive variables. For instance, the Ragin et al. (82) study not only demonstrated that FA was reduced in the whole brain of HIV+ patients, but that it was also significantly associated with the degree of dementia of these patients (84). In 2005, Ragin et al. again showed that DTI metrics were significantly related with loss of function in specif ic cognitive domains (85). Significant relationships were identified between measures for putamen and v erbal memory (75), visual memory (FA), working memory (FA), and overall cognitive impairment (75). The caudate only demonstrated a significant correlation between FA and visual memory, whereas metrics for the centrum semiovale showed significant correlation with visual memory deficits (75) and visuoconstruction (FA). In 2006, W u et al. e valuated diffusion alterations in the CC and associations with cogniti ve performance and motor skills. Utilizing the same cohort as Ragin et al. (85), they found a significant reduction of FA in the splenium of HIV patients, which correlated with dementia severity and deficits in motor speed (86). Likewise, there were also increases in MD measures that correlated with deficits in motor speed. F A values in the genu were also significantly correlated with performance on measures of visual memory.

Throughout all the pre vious DTI-HIV studies, the issue of small sample size (generally approximately ten patients and ten controls) presents itself, demanding a more thorough re view. One interesting e xception to this criticism is the 2005 Thurnher et al. study of 60 HIV patients and 30 healthy controls (87). In this study, the results indicated a significant difference in DTI measures (FA and MD) only in the genu of the corpus callosum. No statistically significant differences were found in the splenium, but an *increase* in FA was noted among the controls compared to HIV+ patients. In addition, there w as no correlation found between plasma viral load and FA/MD values, nor between CD4 counts and FA/MD.

Modest discrepancies in these studies may in part reflect differences in design and/ or the effects of possible confounds. While differences in technical design are sometimes difficult to assess, revealing potential confounds amongst these various studies has proven to be some what easier. The largest confound has been elucidated by the research of Pfefferbaum and Sullivan, who have shown the importance of controlling for patient comorbid neurologic injury risks such as alcohol consumption. For example, in their recent study (2007), they assessed four patients groups: alcoholism alone (n = 87), HIV infection alone (n = 42), alcoholism and HIV infection comorbidity (n = 52), and non-affected controls (n = 88) matched for lifetime alcohol consumption histories and CD4+ counts and viral loads. Results sho wed that, compared to con trols, each group had lower FA and higher MD in the genu and splenium, b ut the effects were only significant in the two groups with alcoholism (with the genu more affected than the splenium). Evidence also demonstrated a compounded alcoholism-HIV ef fect – when the HIV+ groups were separated by disease se verity (an AIDS-defining event or CD4+ counts < 200), the HIV/alcoholism comorbid group exhibited an increased significance in FA and MD abnormalities compared to more immunologically intact patients (88). In this study, the associations between motor def icits and low FA and high MD supported the functional relevance of the microstructural abnormalities. The study concluded that the strong DTI f indings in HIV-alcoholism comorbidity underscore the role of white-matter abnormalities as HIV infection progress to AIDS, and that DTI's sensitivity to such white-matter disruption may provide an early diagnosis of HIV-associated dementia. Most importantly, this study clarified the need to control for potential neurologic risk factors often present in HIV-infected cohorts.

Recently, our group (T ate et al. submitted) (89) sought to further clarify whitematter abnormalities in the CC of HIV+ subjects utilizing DT -MRI. Twenty HIV+ subjects on HAART and 20 seronegative controls were selected and matched in alcohol consumption histories using a brief questionnaire that quantif ies frequency, quantity, and duration of alcohol use (Kreek-McHugh-Schleger-Kellogg (KMSK)).

The results demonstrated gross CC F A values that were reduced for HIV - infected patients when comparing the two groups (see Fig. 5). In addition to gross difference, FA values were significantly different for all regions of the CC examined, even when considering corrections for multiple comparisons. The a verage percent reductions in FA values were highest for the genu and the splenium (27 and 32% reduction respectively), similar to other studies. These reductions in F A were observed despite relatively intact immune functioning (average CD4 of 461.3) and reduced plasma viral loads (80% of patients with less than 10,000 copies per ml) suggesting CNS injury despite improved immunological function.




Fig. 5 This figure depicts the divisions of the corpus callosum with bars demonstrating the difference between HIV+ participants and controls. Colored bars represent mean values with standard error (*See Color Plates*)

We also investigated unique global quantitative tractography methods to examine the difference between 22 HIV-infected patients and 6 serone gative controls. Each participant underwent 12-direction diffusion imaging with sufficient resolution for deriving global tractography maps utilizing methods described else where (90). When deriving tractography maps for other analyses, it became apparent that there were consistent qualitative differences between HIV-infected patients and the seronegative controls. For example, as seen in Fig. 6 there is a clear reduction




Fig. 6 This illustrates the gross qualitative differences between an HIV+ participant and control using more stringent FA criterion ((a) *lowest* FA value, (b) *middle* FA value, (c) *highest* FA value) in the generation of the tractography models. This clearly illustrates the reduction of tract generation in the frontal, subcortical, and cerebellar re gions (*white arrows*) when higher FA constraints are used to generate tracts. This may be an indication of increased disoganization and/or diffusion coherence in these areas (*See Color Plates*)

in the number of tracts generated by the tractography algorithm in the frontal, subcortical, and cerebellum, though the same parameter constraints (namely FA) were used to generate each model.

With such unique qualitative observations, we sought to develop unique tractography metrics that might capture relevant information about the coherent organization of the white matter among HIV -infected patients (i.e., number of tracts, length of tracts, average FA along the tracts, etc; for a full description see the Correia, et al. (2008) paper) (91).

In preliminary analyses of these two experimental groups, we examined several metrics including number of tracts generated, total length of tracts, and average linear FA along the length of the tracts. Results demonstrated no significant differences for number of tracts generated or the total length of tracts (though both were reduced in HIV-infected patients). There was a significant difference for the average linear FA along the length of the tracts with lower FA found for HIV-infected patients. The total length of the tracts and the average FA values for the HIV+ patients were significantly associated with the plasma viral load, b ut not CD4 cell counts. Furthermore, there were several significant associations between the tractography metrics and cognitive tests (e.g., estimate of IQ, short-term memory , speed of processing, and mental flexibility). We interpreted these findings to indicate the usefulness of tractography in examining HIV-associated CNS injury, as there was a trend to significant differences between the groups for the measures as well as man y significant associations with measures of disease severity and cognitive performance.

In conclusion, as the literature suggests, there is a significant amount of evidence that DTI is sensiti ve in revealing subtle white-matter abnormalities in the HIV+ cohort. General reductions in F A and increases in MD are apparent in multiple white-matter regions, especially in the frontal white matter and the CC, as compared to healthy controls. Continued research in this f ield must be done to further elucidate the role of HIV in disrupting white-matter integrity. Particularly, it will be imperative for researchers to control for the confounding influence of alcoholism, as well as increase the number of patients in future DTI-HIV studies. One additional current limitation in the HIV+ literature is the lack of specif ic pathological correlates with diffusion metrics. This limitation is being examined in several other disease modalities in postmortem studies though no specif ic studies have been conducted in HIV+ patients. Until such time, such results should be interpreted cautiously until we can fully clarify the specif ic etiological pathologies that are associated with each of the specific diffusion metrics. Nonetheless, it is important to push forward with these DTI methods, as there appears to be both clinical and cognitive utility being established in the CNS of HIV+ patients.

Functional Magnetic Resonance Imaging (fMRI)

Functional MRI (fMRI) aims to observ e neural activity during predefined tasks conducted while in the scanner. Contrast for this imaging method is based on the differences between the magnetic susceptibility of oxygenated and nonoxygenated

blood (termed the blood oxygen-level dependent or BOLD response). This BOLD signal reflects increases blood oxygenation associated with a particular task conducted while in the scanner, locating individual or functionally-related brain areas participating in the given task.

Research using fMRI in HIV -infected patients is limited though there have been a few studies examining attention, working memory, and/or motor function in HIV patients. The Chang et al. (90) study of 11 HIV-infected patients and 11 seronegative controls demonstrated an increase parietal acti vation for subjects participating in a simpler task of attention, a simple reaction time task (92). As the task demands were increased, additional acti vation of frontal lobes w as required to accomplish the task with the HIV-infected patients exhibiting significantly more activation in these areas compared to controls. Ernst et al. (2002) demonstrated a similar finding among asymptomatic HIV-infected patients (93). These results extend the Chang et al (92) findings by demonstrating abnormal activation pattern earlier in the disease process (92). However, the additional activation differences were only noted in the lateral prefrontal corte x during the more complex attention task, while the simpler attention task did not demonstrate any differences in this cohort of patients.

Studies of working memory also suggest an overall increase in cerebral blood volume (CBV) in se veral of the deep gray matter structures of HIV -infected patients when compared to serone gative controls (94) despite the lack of evidence for cognitive function deficits as measured by neuropsychological testing. More recent studies of working memory have also demonstrated similar findings among HIV+ patients. The Chang et al (92) and the Ernst et al (93) studies also examined working memory (92, 93). Both of these studies found additional areas of activation for HIV+ symptomatic and asymptomatic patients when participating in the working memory tasks (n-back task paradigm). Specifically, additional areas of activation were observed in the lateral prefrontal and supplementary motor areas of the brain. Interestingly, the Ernst et al. (93) examined the relationship between MRS and fMRI f indings without finding a significant association between measures of N-acetylaspartate (NAA) (a marker of neuronal integrity) and increased activation. However, other glial metabolites, especially frontal metabolites, were associated with increased recruitment for w orking memory tasks. These f indings were interpreted to mean that inflammatory factors associated with glial activation were decreasing the efficiency of cortical connections, and thereby requiring the recruitment of additional neural networks (93). These additional areas of acti vation regardless of the task (attention or working memory) are interpreted as abnormal and as a sign of reduced cortical efficiency (HIV+ patients require additional areas of brain activation in order to complete the task).

It is important to realize that fMRI relies on several assumptions about the shape and duration of the BOLD response or the basic hemodynamic response function (HRF) and there may be reason for proceeding cautiously with future studies. Juengst et al. (95) examined the HRF of HIV+ patients for dif ferences that might be associated with age, brain hemisphere, or e ven disease status (95). fMRI data from 16 seronegative controls and 30 HIV+ patients were examined. There were no significant findings associated with age, hemisphere, or HIV status, though there was a notable delay in the time it took the HRF to return to normal in patients with more severe cognitive difficulties. So, the basic shape of the HRF for HIV+ patients is not different from controls and studies e xamining the fMRI results among HIV+ patients can move forward. However, there will be need for future studies to e xamine the HRF in more adv anced disease stages to completely understand the reason for the delay in returning to normal. Thus, fMRI studies relying on longer e vent-related paradigms may be af fected by this slo w HRF return and studies using fMRI in more advanced disease should still consider the potential difference in HRF shape as a possible confounder of group comparison.

Positron Emission Tomography (PET) Imaging and Single Positron Emissions Computed Tomography Imaging (37)

PET and single positron emissions computed tomography (23) are similar in that they depend on intravenous injection of the specific radioisotopes used to tag specific chemicals in the brain. They differ in their complexity of use, the amount of specialized equipment required to acquire images, and the types of brain processes the y are capable of capturing. SPECT is a relatively simpler (i.e., often at lower resolution) technique that provides general information regarding cerebral blood flow (CBF). PET requires the use of a cyclotron thereby increasing its cost, but through a set of specific radioactive tracers is capable of capturing more specific ic brain functions (e.g., CBF and glucose metabolism).

SPECT imaging: From the very beginning of the pandemic, SPECT has been useful in detecting global alterations in CBF (96–98). It was demonstrated through these studies that CBF changes were often observ able before any measurable structural changes). Consistently, these studies demonstrated reductions in CBF in the frontal, temporal, and parietal areas of the brain, the se verity of which w as shown to be associated with se verity of cognitive symptoms. Importantly, however, reductions in CBF were shown to be improved through treatment, with CBF reductions returning to near normal levels (99).

More recently, there have been additional studies using SPECT imaging. F or example, Ernst et al. (100) examined the SPECT measured CBF and metabolite measure for a cohort of 24 HIV+ patients and 34 HIV– controls(100). SPECT CBF was shown to be significantly reduced in the temporoparietal white matter for the HIV+ cohort. These findings were interpreted in the context of abnormal metabolite measures using MRS, where the abnormal MRS f indings appeared to precede abnormal SPECT f indings. This suggested that MRS, as a measure of HIV - associated CNS in volvement, is more sensiti ve than SPECT. In a similar study , Chang et al. (101) compared the f indings from SPECT and perfusion MRI in a small cohort of patients with HIV-cognitive motor complex (101). Nineteen patients

with HIV and 15 healthy serone gative controls were e xamined. HIV-infected patients demonstrated reduced CBF bilaterally in the inferior lateral frontal lobes and the inferior medial parietal lobes. These reductions correlated significantly with measures of disease se verity including CD4 count, plasma viral load, Karnosfsky score, and HIV-dementia scale measures. There were no significant differences between the perfusion MRI and SPECT measures of CBF.

Among HIV-infected patients, SPECT abnormalities ha ve also been sho wn to generally worsen over time. A 46-month prospecti ve/longitudinal study by Christensson et al. (102) found a reduction of SPECT perfusion and cogniti ve performance in HIV+ subjects (102). Results of the repeated SPECT scanning demonstrated a group reduction of CBF over time. At the same time, cognitive testing was also shown to progressively worsen, though none of the patients de veloped dementia. However, patients with the worst cognitive functioning showed increased tracer uptake indicating hyperperfusion in se veral regions of the brain including several cortical and subcortical regions, which was interpreted to be an indication of a specific HIV-induced inflammatory response and that this increase in a subset of patients may obscure reductions in HIV-infected patients.

PET imaging: In the early years of the HIV pandemic, PET w ork primarily focused on cerebral glucose metabolism. These studies often demonstrated hypermetabolism in the basal g anglia (103, 104) or thalamus (105), as well as in the temporal and parietal lobes (103, 106). These changes were often observed early in the disease with changes in metabolism demonstrated well before the onset of any cognitive dysfunction (104). Though the reasons are still relatively obscure, the pattern of hypermetabolism early in the disease process appears to e volve into hypometabolism for cortical and subcortical gray matter (107) in more advanced disease. For example, the van Giesen et al. (57) cross-sectional study of 19 HIV-infected patients demonstrated hypermetabolism in the basal ganglia that was associated with intact motor performance. In the patients who demonstrated moderate motor slowing, the metabolism levels began to diminish toward hypometabolism. Patients who had the most severe motor slowing had the most widespread hypometabolism throughout the basal ganglia. This study, regardless of the small sample size, provides evidence for the evolution and progression of metabolism abnormalities beginning with early hypermetabolism that progressi vely worsens into hypometabolism in more advanced disease stages.

PET imaging may still prove useful in future HIV studies. There are man y new and novel tracers developed over the past se veral years that have the potential to examine very specific metabolites and/or neurotransmitters. F or example, the use of the PET ligand [11C]-PK11195 might provide a window into active areas of inflammatory processes in HIV infection. Examination of multiple sclerosis (MS) patients using this ligand has demonstrated increased sensitient vity of MS activity, often extending into normal appearing white matter, especially during active clinical phases of the MS activity (Vowinckel, Banati, Debruyne). Thus, there may be additional opportunities to examine the effects of HIV-associated CNS injury using PET technology.

Other Neuroimaging Modalities (e.g., Perfusion MRI, MTR)

There are several other MRI imaging modalities that have been used to examine HIV-associated CNS effects though these studies are limited. In this section, we have discussed a couple of methods that have demonstrated interesting results including, perfusion MRI, magnetization transfer imaging, and postcontrast enhancement imaging.

Perfusion MRI (pMRI) is an MRI imaging method capable of measuring the rate of arterial blood flow. One of the major advantages of pMRI is the fact that it uses no radioactive tracers to capture this information. It captures cerebral blood flow (CBF), cerebral blood volume (CBV), and the mean transit time it tak es blood to flow from one part of the brain to another . Complex mathematical algorithms and corrections schemes are used to quantify pMRI metrics and it has been used successfully in a couple of studies to examine the effects of HIV infection on pMRI metrics.

One study by Chang et al. (101), demonstrated significant decreases in CBF in a group of HIV+ patients with early cognitive and motor complex problems (101). These decreases in CBF appeared predominately in the lateral frontal lobes and medial parietal lobes. There were also notable increases in CBF in the posterior parietal white matter when compared to age match controls. The alterations in CBF were also found to be associated with CD4 cell counts, HIV disease scale, and other measures of disease severity. In a study by Wenserski et al. (108), 32 HIV+ patients with varying degrees of minor motor deficits were examined using pMRI and MRS (reviewed above). Patients were divided into three groups based on motor exam with one group having normal function (n = 10), eight patients with their f irst altered motor slowing in a series of the tests, and 14 patients who had been e xperiencing motor slowing on objective testing for at least 6 months (108). There were increased CBF findings that were primarily relegated to the basal ganglia of the eight patients with initial motor findings. This is similar once again to the recent f indings of the Ances et al. (109) study of 42 HIV+ patients and 17 serone gative controls using continuous arterial spin labeled (CASL) MRI. There w as a stepwise reduction in caudate blood flow for HIV+ patients with increasing worse neurocognitve function, with the most cognitive impaired patients having the most reduced caudate blood flow (109). Blood flow in the caudate and caudate v olume were poorly correlated though there were general decreases in v olume related to cognitive severity. So, measures of CBF as captured with various pMRI methods has the ability to discriminate between HIV+ patients and seronegative controls. It is also noteworthy that the basal ganglia is the area where the most change is observed and may provide another unique surragate marker of HIV-associated CNS involvement.

Magnetization transfer (MT) attempts to obtain a signal from macromolecules, which are otherwise invisible to MRI, because the T2 relaxation times of their protons (less than 200 μ s) are orders of magnitude belo w that of free w ater. MTI applies an extra off-resonance saturation pulse intended to resonate with the bound protons in macromolecules, yielding a signal once the magnetization is transferred to the surrounding free w ater. Hence MTI is considered to have partial sensitivity

towards macromolecules of cell membranes, such as the cholesterol and galactocer ebroside found in myelin (110). MTI has been successfully applied for clinical assessment in several neurodegenerative diseases, such as MS (111–113) and other conditions (114, 115).

As with MRS or DTI, a potential confound to MTI is the diluti ve effect of edema, where the additional w ater also causes a reduction in MT . Longitudinal changes of MT ha ve also been prof fered as complements to help distinguishing edema and different forms of pathology in MS (112), suggesting that MTI may indeed be sensitive to tissue destruction (116). A principal contribution of MTI lies with its potential specificity to demyelination and its alle ged sensitivity to detect diffuse disease. In MS, se veral findings point to ward MT sensitivity regarding damage of normal appearing white matter (N AWM) (117, 118). A technical confounder in MTI is the of f-resonance pulse, which varies between scanners and is difficult to calibrate well, possibly biasing comparisons and multicenter trials.

Despite these limitations, the Ragin et al. (2004) e xamined nine HIV+ patients and nine healthy controls using whole-brain MTR (82). Additionally, the MTR results were compared to DTI metrics. Results from this study demonstrated reductions in MTR for HIV+ patients that were related to measures of psychomotor speed. MTR was also found to be related to the apparent dif fusion coefficient (ADC) by measures of fractional anisotropy (FA). Though accomplished in a small cohort of patients, this study demonstrated the utility of MTR in distinguishing between experimental groups. This f inding was essentially equivalent to an earlier MTR study of HIV patients. In the Ge et al. (119) study of 15 HIV+ symptomatic patients, eight HIV+ asymptomatic patients, and ten serone gative controls, both HIV+ groups demonstrated significant reductions in the mean and median v alues for whole-brain MTR (119). Differences for the two HIV+ patient groups included a downward shift in the mean when compared to the control group as well as a significant reduction in the height of the histogram peak for the symptomatic patients. Furthermore, this study also demonstrated that MTR was modestly related (r > 0.50) to a measure of brain atrophy (BPF) such that when MTR w as reduced there was a reduction in BPF. So, global and regional MTR measures have the ability to discriminate between HIV+ patients and healthy controls early in the disease suggesting possible pathological changes in axonal membranes.

Another interesting line of research in HIV neuroimaging studies is the use of contrast agents to e xamine blood-brain barrier (BBB) permeability . Given the many significant volumetric, metabolite, and perfusion abnormalities in the basal ganglia a few researchers have focused MRI methods at understanding the mechanism of injury in this area associated with HIV+ infection. Of note in particular is the study by Avison et al. (2004), where the y examined gadolinium (gd) enhanced imaging findings (120). In this study, HIV-infected patients were injected with gd and examined for areas of enhancement. In this cohort of HIV+ patients, there were several areas of enhancement in and about the basal ganglia indicating increased permeability of the BBB in these areas. This f inding is particularly interesting as there is evidence that infection with HIV leads to BBB permeability. This study provides direct evidence of permeability in the case of HIV infection.

Summary and Future Research

Despite the adv ances in MRI and the man y important findings in HIV-infected patients to date, improvements can be made in se veral key areas. One significant improvement in future research studies might be in participant selection. Generally, HIV-infected patients present with additional neurological risks that might be better controlled through patient selection and/or the addition of supplementary control groups with different conditions. As already illustrated, Pfefferbaum/Sullivan have demonstrated the significant contribution of alcohol abuse among commonly presenting HIV-infected populations. Much has also been written about other subpopulations within HIV-infected cohorts such as drug ab use (71, 121, 122), hepatitis C (HCV) coinfection (75, 123, 124), etc. The use of more controlled research designs will not only broaden our understanding of the neurological effects of these additional factors, but will impro ve our understanding of the specific ic mechanisms of HIV - associated CNS injury.

Another significant improvement that will advance the HIV infection literature will be larger, prospective studies. To date, the vast majority of imaging studies are cross-sectional in design. There are a few notable exceptions, though these studies are often limited to smaller cohorts and limited time points (not more than two time points). One major adv antage of prospective studies is the improved statistical power when using participants as their own controls. There has been much work recently reported in the literature, regarding time series analyses of prospective imaging data among several different patient populations (125, 126). The interest in this type of imaging data has resulted in a growing set of methods for dealing with longitudinal data, including subtraction imaging (see Fig. 7), our own time series analysis (see Fig. 8), etc. For example, in a study of multiple sclerosis patients (an interesting possible archetype for HIV -associated neurodegeneration) the level of disease activity varies greatly among individuals, as does the severity




Fig. 7 Example of structural change detected by serial MRI. A subtraction of co-re gistered and intensity-normalized baseline and follow-up exam reveals both new and resolving pathology, visible as hyper- and hypointensity, respectively, relative to the neutral gray. Changes are highlighted as all stable anatomy cancels in the subtraction




Fig. 8 Example of time series analysis examination of a MS lesion in a single patient. The three images represent three types of MRI sequences (gadalinium enhanced (red), proton density (*green*), and T2 weighted (*blue*)). The graph below represents the intensity of the v oxel marked by the *red* x over the time course of the study. In this manner the variability and magnitude of the lesion can be examined (*See Color Plates*)

and rate of progression. Morphological change is reflected in focal lesions as well as global and regional atrophy, with both brain and spinal cord afected. Occurrence, duration and residual of indi vidual MS lesions are often stochastic in nature (see Fig. 9) potentially confounding associations with clinical outcomes. Additionally, emerging longitudinal studies of Alzheimer's disease have revealed significant variability in the rate and progression of neuroimaging abnormalities. Morphological alteration in AD is reflected in global and regional atrophy as well as specific anatomical abnormalities such as hippocampal atrophy. Despite the complexity, there has been encouraging success in modeling lesion v ariability in MS patients (126) and global/regional atrophy rates in AD patients (127, 128) that might also be applied to HIV-infected patients. Monitoring the literature for advances in longitudinal methods among other patient populations will most certainly reveal additional ways of examining HIV-associated CNS injury and/or treatment efficacy.

What should be clear from the current neuroimaging research literature is the fact that MRI variables in isolation provide limited pathological specificity. Future studies of HIV-associated CNS injury would benefit from the use of multimodal imaging methods that exploit the complimentary and unique sensitivities of different imaging modalities (see Fig. 10). For example, the combination of MRS and structural





Fig. 9 Example of the dynamics of an MS lesion captured in serial T2-weighted MRI. A ne w lesion appeared in week 17, undergoing rapid edematous changes over the next 5 weeks



Inflammation

Demyelination

Fig. 10 MRI specificity matrix illustrating the complimentary and unique pathological correlates of different MRI sequences described in the te xt for four common pathological f indings in HIV encephalitis. *Gd-DTPA* gadolinium enhanced; *MRS:NAA N*-acetylaspartate; *T2* T2-weighted sequences (*See Color Plates*)

MRI has the potential to distinguish between tw o different pathways of injury among HIV-infected patients – inflammatory and noninflammatory (129). Studies designed to maximize the dissociative qualities of different imaging modalities have the best potential of establishing pathological specificity not afforded by clinical and/or cognitive variables. Though there is still much to be learned about HIV - associated CNS injury (see T able 1), it is obvious that MRI and other associated imaging modalities hold significant promise for evaluating the evolution, progression, and treatment effects among HIV-infected patients.

References

- 1. BellJ Theneuropathology of adult HIV infection. Rev Neurol 154 (12)816 829998.
- 2 . BudkaH Multinucleated giant cells in brain: a hallmark of the acquired immune deficiency syndrome (AIDS). Acta Neuropathol 69 (3-4)253 - 258986.
- 3 . GonzalesM Duis R Neuropathologyof acquired immunodeficiency syndrome . Neurpathol Appl Neurobiol 14 (5)345 363988 .
- 4 . Naia B Jordan B Price R The AIDS dementia complex: I. Clinical features . Ann Neurol 19 (6)517 524986 .
- 5 . Cysique L Maruff P, Brev B Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly acti ve antiretroviral therapy eras: a combined study of two cohorts. JNeurovirol 10 (6)350 352004.
- 6 . Tozzi V, BalestraP, LorenziniP, BellagambaR GalganiS Corphongo A VlassiC Larussa D ZaccarelliM NotoP, Vsco-Comandini U GiulianelliM IppolitoG Antinori A Narciso P. Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observ ational cohort. J Neurovirol 11(3): 265 – 272005.
- 7 . LangfordT, LetendreS LarreaG MaliahE Changingpatterns in the neuropathogenesis of HIV during the HAART era . BrainPathol 13 (2)195 210003 .
- MasliahE De&resa R MalloryM HansenL Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS 14 (1)69 – 72000.
- 9 . PostMD Beger J DuncanR QuencerR Pdl L Whifield D. Asymptomaticand neurologically symptomatic HIV-seropositive subjects: results of a long-term MR imaging and clinical follow-up. Radiology 188 727 733993.
- 10 .PostMJ Jannoutsos C SimpsonD BoossJ Clifford DB CohenB McArthurJC HallCD Progressive multifocal leuk oencephalopathy in AIDS: are there any MR findings useful to patient management and predicti ve of patient survi val? AIDS Clinical T rials Group, 243 Team. AJNRAm J Neuroradiol 20 (10)1896 – 906999 .
- 11 .Ruiz A ,Post MJ ,Bundschu CC Dentate nuclei involvement in AIDS patients with CNS cryptococcosis: imaging findings with pathologic correlation. JComput Assist Tomogr 21 (2): 175 182997 .
- 12 .Hwkins CP, McLaughlinJE Kindall BE McDonaldWI Pathological findings correlated with MRI in HIV infection . Neuroradiology 35 (4)264 268993 .
- 13 .Brw BJ ,Rosenblum M ,Cronin K ,Price RW .AIDS dementia complex and HIV-1 brain infection: clinical-virological correlations . AnnNeurol 38 (4)563 570995 .
- 14 Alward EH HendererJD McArthurJC BrettschneiderPD HarrisGJ BartaPE Pearlson GD. Reduced basal ganglia volume in HIV-1-associated dementia: results from quantitative neuroimaging. Neurology 43 (10)2099 – 2104993.

- 15 .JerniganTL ArchibaldS HesselinkJR AtkinsonJH Min RA McCutchan A, ChandlerJ, GrantI Magneticresonance imaging morphometric analysis of cerebral volume loss in human immunodeficiency virus infection. The HNRC Group. ArchNeurol 50 (3)250 – 255993.
- 16 .HallM Whalp R RobertsonK HambyS Wikins J HallC. The correlation between neuropsychological and neuroanatomic changes o ver time in asymptomatic and symptomatic HIV-1-infected individuals. Neurology 46 (6)1697 1702996 .
- 17 .Raininka R Elwaara I , Mata A , Manne L , Haltia M , Male SL Radiological study of the brain at various stages of human immunodef iciency virus infection: early de velopment of brain atrophy. Neuroradiology 34 (3)190 – 196992.
- 18 Rul R CohenR Nuia B Ishima K Relationshipsbetween cognition and structural neuroimaging findings in adults with human immunodeficiency virus type-1. Neurosci Biobehav Rev 26 (3)353 352002.
- 19 .Pedersen C ,Thomsen C ,Arlien-Sobog P, Praestholm J ,Kjaer L Boesen F, Hansen HS , Nielsen JO Central nervous system involvement in human immunodeficiency virus disease. A prospective study including neurological e xamination, computerized tomography, and magnetic resonance imaging. DanMed Bull 38 (4)374 – 379991.
- 20. Pfderbaum A Rosenbloom MJ Rohling T, Adalsteinsson E Kamper CA, Deresinski S, Sullian EV Contribution of alcoholism to brain dysmorphology in HIV infection: effects on the ventricles and corpus callosum. Neuroimage 33 (1)239 – 252006.
- Portgies P, EntingRH Toost D BoschDA [Indications for brain biopsy in the diagnosis of intracerebral lesions in patients with AIDS]. NedTijdschr Geneeskd 137 (20)999 – 1002993.
- 22 .ThompsonPM DuttonRA HayashiKM LuA LeeSE LeeJY LopezOL AizensteinHJ , Tga AW , Beckr JT 3Dmapping of ventricular and corpus callosum abnormalities in HIV/ AIDS . Neuroimage 31 (1)12 22006 .
- 23 .Grant I ,Atkinson JH ,Hesselink JR ,Kinnedy CJ ,Richman DD ,Spetor SA ,McCutchan A . Evidence for early central nerv ous system in volvement in the acquired immunodef iciency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging . AnnIntern Med 107 (6)828 – 836987 .
- 24 .PoutiainenE Elwaara I Rainink R Mkki J Lahdwirta J ilvanainen M Cognitive decline in patients with symptomatic HIV-1 infection. No decline in asymptomatic infection. Acta Neurol Scand 93 (6)421 – 427996.
- 25 .HestadK McArthurJH DaPan GJ SelnesOA, Nance-SprosonTE Aylward E Mathews VP, McArthurJC Regional brain atrophy in HIV-1 infection: association with specific neuropsychological test performance. ActaNeurol Scand 88 (2)112 – 118993.
- 26 .Kiebrtz K ,Konen L ,Cox C ,Grossman H ,Hollway R ,Booth H ,Hicky C ,Feigin A , Caine E Cognitive performance and regional brain volume in human immunodeficiency virus type 1 infection . ArchNeurol 53 (2)155 – 158996 .
- 27 .Syndulk K SingerEJ Nogales-GaeteJ ConradA SchmidP, Turtellotte WW Laboratory evaluations in HIV-1-associated cognitive/motor complex . PsychiatrClin North Am 17 (1) : 91 123994 .
- 28 .Kiebrtz KD ktonen L ZettelmaierAE KidoD CaineED SimonJH Magneticresonance imaging findings in HIV cognitive impairment. ArchNeurol 47 (6)643 – 645990.
- 29 .ChiangM DuttonR HayashiK LopezO AizensteinH Joga A , Beckr J ThompsonP 3D pattern of brain atrophy in HIV/AIDS visualized using tensor based morphometry . Neuroimage 34 44 - 60007 .
- Stout JC, Ellis RJ, Jernigan TL, Archibald SL, Abramson I, Wilfson T, McCutchan A, Willace MR AtkinsonJH GrantI Progressive cerebral volume loss in human immunodeficiency virus infection: a longitudinal v olumetric magnetic resonance imaging study. HIV Neurobehavioral Research Center Group. ArchNeurol 55 (2)161 – 168998.
- 31 .Castelo JM ,Courtne MG ,Melrose RJ ,Stern CE Putamen hypertrophy in nondemented patients with human immunodef iciency virus infection and cogniti ve compromise. Arch Neurol 64 (9)1275 – 1280007 .

- 32. Rel S Kilson D GlosserG MatozzoI GeY, BabbJ Mannon L GrossmanR Correlation between percentage of brain parenchymal v olume and neurocognitive performance in HIVinfected patients. AmJ Neuroradiol 23 543 – 542002.
- 33 .SamuelssonK Pirskanen-MatellR BremmerS HindmarshT, NilssonBY, PerssonHE The nervous system in early HIV infection: a prospective study through 7 years. Eur J Neurol 13 (3)283 - 292006.
- 34 Fing C , Chang Y, Hsu H , Wu S , Chen K , Lin C , Huang L , Chen M , Hwang J , Wang J , Chuang C Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. QJM 100 (2)97 1020007.
- 35 .LimaV, HoggR HarriganP, MooreD Jp B JWod E Montaner J Continuedimprovement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 21 (6)685 - 692007.
- 36 .DSclafani V, MackayRD Myerhoff DJ NormanD Weiner MW, Fin G Brainatrophy in HIV infection is more strongly associated with CDC clinical stage than with cogniti ve impairment. JInt Neuropsychol Soc 3 (3)276 287997.
- 37 .KinzelN Strik D ClarkH Cuert W Cerebellopontinedegeneration as an immune restoration disease in HIV infection . AIDS 18 (17)2348 – 2350004 .
- 38 . Tigliati M SimpsonD Mogello S Clifford D Schwrtz R Beger J Cerebellardegeneration associated with human immunodeficiency virus infection . Neurology 50 (1)2:44 – 251998 .
- 39. Thompson PM Dutton RA Hayashi KM Joga AW, Lopez OL Aizenstin HJ Beckr JT. Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline. ProcNatl Acad Sci USA 102 (43)15647 – 15652005.
- 40 .ThompsonP, HayashiK DuttonR ChiangM Lew A Swell E, ZubicarayGD Beckr J , Lopez O ,Aizenstein H ,Joga A Tracking Alzheimer's disease . Ann NY Acad Sci 1097 : 183 – 212007 .
- 41 .LeporeN BrunC ChouYY, ChiangMC DuttonRA HayashiKM, LudersE LopezOL, AizensteinHJ Joga AW, Beckr JT, ThompsonPM Generalizedtensor-based morphometry of HIV/AIDS using multivariate statistics on deformation tensors. IEEE Trans Med Imaging 27 (1)129 - 142008.
- 42 .McArthurJC Kimar AJ JohnsonDW, SelnesOA, Beckr JT, HermanC CohenBA, Saah A. Incidental white matter hyperintensities on magnetic resonance imaging in HIV -1 infection. Multicenter AIDS Cohort Study. JAcquir Immune Defic Syndr 3 (3)252 – 259990.
- 43 .PomaraN CrandallDT, ChoiSJ JohnsonG LimKO Whitematter abnormalities in HIV-1 infection: a diffusion tensor imaging study. PsychiatryRes 106 (1)15 22001.
- 44 .BornsteinRA Chakres D BroganM NasrallahHA Fess RJ Fra M WhitacreC Magnetic resonance imaging of white matter lesions in HIV infection. J Neuropsychiatry Clin Neurosci 4 (2)174 178992.
- 45 .ArchibaldS MasliahE Fennema-NotestineC MarcotteT, EllisR McCutchanJ HeatonR, GrantI MalloryM MillerA JerniganT Correlationof in vivo neuroimaing abnormalities with postmortem human immunodef iciency virus encephalitis and dendretic loss. Arch Neurol 61 369 – 378004.
- 46 Mcour VG, Sithinamsuwan P, Nidhinandanas Thitiichianlert S Ratto-Kin S Apateerapong W, ShiramizuBT, DesouzaMS ChitpatimaST, Wtt G ChuenchitraT, Rbertson KR Rul RH McArthurJC KimJH ShikumaCM Neuropsychologicalabnormalities in patients with dementia in CRF 01_AE HIV-1 infection. Neurology 68 (7)525 - 522007.
- 47. MartinE ,Capone A ,Schneider J ,Hennig J ,Thiel T Absence of N-acetylaspartate in the human brain: impact on neurospectroscopy ? AnnNeurol 49 (4)518 522001 .
- 48 .McRobbieD MooreE Graes M PrinceM MRIFrom Picture to Proton .Cambridge, UK : CambridgeUniversity Press , 2003 .
- 49 .Pfderbaum A AdalsteinssonE Sullian E CorticalNAA deficits in HIV infection without dementia: Influence of alcoholism comorbidity. Neuropsychopharmacology 30 :1392 - 1399, 2005.
- UrenjakJ Wiliams SR GadianDG NobleM Protonnuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. JNeurosci 13 (3)981 – 989993.

- 51 .xn Walderveen MA BarkhofF, PouwelsPJ xn Schijndel RA PolmanCH, CastelijnsA. Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vi vo using proton magnetic resonance spectroscopy. AnnNeurol 46 (1)79 – 87999.
- 52 .LearySM Bræ PA, MacManusDG Perker GJ Barker GJ MillerDH ThompsonAJ A(1) H magnetic resonance spectroscopy study of aging in parietal white matter: implications for trials in multiple sclerosis. MagnReson Imaging 18 (4)455 - 452000 .
- 53 .ChangL ErnstT, Leonido-Ye M Walot I SingerE Cerebralmetabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex . Neurology 52 (1)100 108999 .
- 54 .SacktorN Sklasky R ErnstT, MaoX SelnesO PomperM ChangL ZhongK Shungu D MarderK ShibataD Schifto G BoboL Barker P Amulticenter study of two magnetic resonance spectroscopy techniques in individuals with HIV dementia. J of Magn Reson Imag 21 325 - 332005 .
- 55 .Suvanwelaa N PhanuphakP, PhanthumchindaK Suvanwela N antivatana J ,RuxrungthamK , Suttipan J ,Wangsuphachart S ,Hawanich M Magnetic resonance spectroscopy of the brain in neurologically asymptomatic HIV-infected patients . MagnReson Imag 18 (7)859 – 862000.
- 56 . Tarasow E , Wercinska-Drapalo A , Jaroszwicz J , Orzechowska-Bobkiewicz A Dzienis W , Probapowicz D , Malecki J Antiretroviral therapy and its influence on the stage of brain damage in patients with HIV – 1H MRS evaluation . MedSci Monit 10 (Suppl): 101 – 106004 .
- 57 .on Giesen HJ Antk C HefterH Winserski F, SeitzRJ ArendtG Potentialtime course of human immunodeficiency virus type 1-associated minor motor def icits: electrophysiologic and positron emission tomography findings. ArchNeurol 57 (11)1601 1602000.
- 58 Aylor M Schweinsbrg B AlhassoonO Gongatana A Brwn G Mung-Casey C Letendre S GrantI Group.H Effects of human immunodeficiency virus and methamphetamine on cerebral metabolites measured with magnetic resonance spectroscopy. JNeurovirol 13 (2): 150 – 152007.
- 59 .Chang L ,Ernst T, Leonido-Ye M ,Wit M ,Speck O ,Wolot J Miller EN Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia . Neurology 53 (4)782 - 7899999 .
- 60 .Stankoff B Jourbah A SuarezS Torell E Stivenart JL Payan C CoutellierA HersonS Baril L Bricaire F, Caloz V, Cabanis EA Lacomblez L Lubetzki C Clinical and spectroscopic improvement in HIV-associated cognitive impairment. Neurology 56 (1)112 – 112001.
- 61 .ChangL ErnstT, Wit MD AmesN Wolt I Juicich J DeSilar M Tivedi N SpeckO, MillerEN Persistentbrain abnormalities in antiretroviral-naive HIV patients 3 months after HAART. Antivir Ther 8 (1)17 – 20003.
- 62 .Myerhoff D BloomerC CardenasV, NormanD Winer M FeinG Elevated subcortical choline metabolites in cogniti vely and clinically asymptomatic HIV+ patients . Neurology 52 (5)995 1003999 .
- 63 .NelsonJ DouH EllisonB UbertiM XiongH AndersonE MellonM GelbardH Boska M GendelmanH Corgistration of quantitative proton magnetic resonance spectroscopic imaging with neuropathological and neurophysiological analyses defines the extent of neuronal impairments in murine human immunodef iciency virus type-1 encephalitis. J Neurosci Res 80 (4) 562 - 572005.
- 64 .Rul RH Laidlaw DH ate DF, LeeS HothKF, GunstadJ ZhangS Lawrence J FlaniganT. Neuropsychological and neuroimaging outcome of HIV-associated progressive multifocal leukoencephalopathy in the era of antiretroviral therapy. JIntegr Neurosci 6 (1)191 – 202007.
- 65 .ChangL ErnstT, SpeckO GrobC Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities . AmJ Psychiatr 162 361 362005 .
- 66 .ChangL ErnstT, PolandRE JendenDJ Invivo proton magnetic resonance spectroscopy of the normal aging human brain . LifeSci 58 (22)2049 2056996 .
- 67 .Pfderbaum A Adalsteinsson E Spielman D Sullian EV, Lim KO Invivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging . MagnReson Med 41 (2)276 284999 .
- 68 .SoherBJ an Zijl PC DuynJH Barker PB Quantitative proton MR spectroscopic imaging of the human brain . MagnReson Med 354 (3) 356 363996 .

- 69 .BrooksJC RobertsN Kemp GJ Gosny MA Le M WhitehouseGH Aproton magnetic resonance spectroscopy study of age-related changes in frontal lobe metabolite concentrations. CerebCortex 11 (7)598 – 602001.
- 70 .Schuff N Ezekiel F, Gamst AC, Amend DL Capizzano AA Maudsly AA Winer MW. Region and tissue dif ferences of metabolites in normally aged brain using multislice 1H magnetic resonance spectroscopic imaging. MagnReson Med 454 (5) 899 – 902001.
- 71 .ChangL LeePL ,Yannoutsos CT, ErnstT, MarraCM RichardsT, Kilson D ,Schifto G , JarvikJG ,MillerEN ,Lenkinski R ,Gonzalez G , Nuia BA A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age . Neuroimage 23 (4) : 1336 – 1342004 .
- 72 .Ernst T, Chang L Efect of aging on brain metalism in antiretroviral naive HIV patients . AIDS 18 (Suppl): S61 – S62004 .
- 73 .Yannoutsos C ErnstT, ChangL LeeP, RichardsT, MarraC, Myerhoff D JarvickJ Kilson D Schifto G Ellis R Swindles S Simpson D Miller E Gonzalez R Nuia B Regional pattern of brain metabolites in AIDS dementia complex. Neuroimage 23 928 – 932004.
- 74 .LeBihan D ManginJF, PouponC ClarkCA Apprata S Molk N ,ChabriatH Difusion tensor imaging: concepts and applications. JMagn Reson Imaging 13 (4)534 – 548001.
- 75 .Perry W, Carlson M, Barakat F, Hilsabeck R, Schiehser D, Mathevs C, Hassanein T. Neuropsychological test performance in patients co-infected with hepatitis C virus and HIV. AIDS 19 (Suppl): S79 S82005.
- 76 .BeaulieuC AllenPS Water diffusion in the giant axon of the squid: implications for diffusion-weighted MRI of the nervous system . MagnReson Med 32 (5)579 583994 .
- 77 .HuppiPS MaierSE PeledS ZientaraGP, BarnesPD JoleszFA, Wipe JJ Microstructural development of human ne wborn cerebral white matter assessed in vi vo by diffusion tensor magnetic resonance imaging. PediatrRes 44 (4)584 – 590998.
- 78 .NeilJJ ShiranSI McKinstryRC Scheff GL Søder AZ AlmliCR Akbdak E Aronøitz A, Miller JP, Lee BC Conturo TE Normal brain in human newborns: apparent diffusion coefficient and dif fusion anisotropy measured by using dif fusion tensor MR imaging . Radiology 209 (1)57 – 66998.
- 79 .GulaniV, Webb AG, DuncanID Lauterbr PC Apparent diffusion tensor measurements in myelin-deficient rat spinal cords. MagnReson Med 45 (2)191 – 192001.
- 80 .SchmiererK WheeleiKingshott CA BoulbyPA , Scarwilli F , AltmannDR , Barker GJ Ffts PS MillerDH Difusion tensor imaging of post mortem multiple sclerosis brain . Neuroimage 35 (2)467 - 472007 .
- 81 .BeaulieuC The basis of anisotropic water diffusion in the nervous system – a technical review . NMRBiomed 15 (7-8)435 - 452002 .
- 82 .RaginAB Story P, CohenBA, EpsteinLG EdelmanRR Wholebrain diffusion tensor imaging in HIV-associated cognitive impairment. AJNRAm J Neuroradiol 25 (2)195 – 200004.
- 83 .FilippiM DoussetV, McErland HF, MillerDH GrossmanRI Rob of magnetic resonance imaging in the diagnosis and monitoring of multiple sclerosis: consensus report of the White Matter Study Group. JMagn Reson Imaging 15 (5)499 – 502002.
- 84 .RaginA Story P, CohenB EdelmanR EpsteinL Diseaseburden in HIV-associated cognitive impairment: a study of whole-brain imaging measures . Neurology 63 2293 2292004 .
- 85 .RaginAB ,W Y, Story P, CohenBA , EdelmanRR EpsteinLG .Difusion tensor imaging of subcortical brain injury in patients infected with human immunodef iciency virus. J Neurovirol 11 (3)292 – 298005.
- 86 .W Y, Story P, Cohen BA, Epstein LG Edelman RR Ragin AB. Difusion alterations in corpus callosum of patients with HIV. AJNRAM J Neuroradiol 27 (3)656 60006.
- 87 .ThurnherMM CastilloM StadlerA Riger A SchmidB Sundgra PC Difusion-tensor MR imaging of the brain in human immunodef iciency virus-positive patients. AJNR Am J Neuroradiol 26 (9)2275 – 2282005.
- 88 . Pfefbaum A ,Rosenbloom MJ ,Adalsteinsson E ,Sullian EV Difusion tensor imaging with quantitative fibre tracking in HIV infection and alcoholism comorbidity: syner gistic white matter damage . Brain 130 (Pt): 48 62007.

- 89. Tate DF, Zhang S, Sampat M, Conle y J, Russel T, Kertesz K, Paul RH, Coop K, Laidla w DH, Guttmann CRC, Navia B, Tashima K, and Flanig an T (submitted). Altered fractional anisotropy and tractography metrics in the corpus callosum is associated with measures of HIV infection disease burden and cognitive performance. Submitted to Journal of Neuro virology.
- 90 .ZhangS DemiralpC Laidlw D Vsualizing diffusion tensor MRI images using streamtubes and streamsurfaces. IEEE Transaction on Visualization and Comuter Graphics 9 (4) : 454 - 46200.
- Correia S, Lee SY, Voorn T, Tate DF, Paul RH, Zhang S, Salloway SP, Malloy PF, Laidlaw DH (2008). Quantitative tractrography metrics in white matter integrity in diffusion tensor MRI. Neuroimage, 42(2): 568–581.
- 92 .ChangL SpeckO MillerEN BraunJ Jøicich J Koch C, IttiL ErnstT Neuralcorrelates of attention and working memory deficits in HIV patients. Neurology 57 (6)1001 – 1002001.
- 93 .ErnstT, ChangL ArnoldS Increasedglial metabolites predict increased working memory network activation in HIV brain injury. Neuroimage 19 1686 1692003 .
- 94. Tacey I ,Hambeg LM ,Guimaraes AR ,Hunter G ,Chang I ,Nuia BA , Gonzalez RG Increased cerebral blood v olume in HIV-positive patients detected by functional MRI . Neurology 50 (6)1821 – 1826998 .
- 95 .JuengstS AizensteinH FigurskiJ LopezO Beckr J Alteratons in the hemodynamic response function in cognitively impaired HIV/AIDS subjects. JNeurosci Meth 163 208 – 212007.
- 96 .CostaDC EllPJ BurnsA PhilpotM Ley R CBFtomograms with [99mTc-HM-PAO in patients with dementia (Alzheimer type and HIV) and P arkinson's disease–initial results. JCereb Blood Flow Metab 8 (6)S:109 – S115988.
- 97 .HolmanBL GaradaB JohnsonKA MendelsonJ HallgringE Toh SK Wirth J Nuia B A comparison of brain perfusion SPECT in cocaine ab use and AIDS dementia complex. J Nucl Med 33 (7)1312 – 1315992.
- 98 .Rosci MA ,Pigorini F, Bernabei A ,Pu FM ,Mpini V, Merigliano DE ,Meligrana MF . Methods for detecting early signs of AIDS dementia comple x in asymptomatic HIV -1infected subjects. AIDS 6 (11)1309 – 1316992 .
- 99. Tozzi V, NarcisoP, GalganiS SetteP, BalestraP, Geract , Ru FM PigoriniF, Mpini V, CamporiondoMP, et al .Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex . AIDS 7 (5)683 – 692993 .
- 100 .ErnstT, IttiE JttiL ChangL Changes in cerebral metabolism are detected prior to perfusion changes in early HIV -CMC: A coregistered (1)H MRS and SPECT study. J Magn Reson Imaging 12 (6)859 – 862000.
- 101 .ChangL ErnstT, Leonido-Ye M SpeckO PerfusionMRI detects rCBF abnormalities in early stages of HIV-cognitive motor complex . Neurology 54 (2)389 – 396000 .
- 102 ChristenssonB Ljungbeg B RydingE Sønson G RosenI SPECT with 99mTc-HMPAO in subjects with HIV infection: cogniti ve dysfunction correlates with high uptak e. Scand J Infect Dis 31 (4)349 – 354999.
- 103 HinkinCH an Gorp WG Mandelarn MA GeeM SatzP, HolstonS MarcotteTD Earns G Pz DH RopchanJR etal .Cerebralmetabolic change in patients with AIDS: report of a six-month follow-up using positron-emission tomography. J Neuropsychiatry Clin Neurosci 7 (2)180 – 187995 .
- 104 Rottenber DA, Sidtis JJ, Strother SC, Schaper KA, Anderson JR, Nelson MJ, Price RW. Abnormal cerebral glucose metabolism in HIV -1 seropositive subjects with and without dementia. JNucl Med 37 (7)1:133 – 1141996.
- 105 Rottenber DA, MoellerJR StrotherSC SidtisJJ Nuia BA, Ibawan V, GinosJZ PriceRV. Themetabolic pathology of the AIDS dementia complex. AnnNeurol 22 (6)700 – 706987.
- 106 an Gorp WG Mandelkrn MA GeeM HinkinCH SternCE Pz DK DixonW, Earns G, FlynnF, FrederickCJ etal .Cerebralmetabolic dysfunction in AIDS: findings in a sample with and without dementia. JNeuropsychiatr Clin Neurosci 4 (3)280 – 287992.
- 107 O'DohertyMJ BarringtonSF, CampbellM Lwe J BradbeerCS PET scanning and the human immunodeficiency virus-positive patient. JNucl Med 38 (10)1575 – 1583997.

- 108 Winserski F, GiesenHv, Witsack H AulichA ArendtG Humanimmundeficiency virus 1-associated minor motor disorders: perfusion weighted MR imaging and H MR spectroscopy. Radiology 228 185 – 192003.
- 109 Ances B ,Roc A ,Wang J ,Karczykowski M ,Okawa J ,Stern J, Kim J ,Walf R ,Jawler K , Kalson D Detre J Caudateblood flow and volume are reduced in HIV+ neurocognitively impaired patients. Neurology 66 826 – 868006 .
- 110 Kicharczyk W, MacdonaldPM StaniszGJ Henklman RM Relaxivity and magnetization transfer of white matter lipids at MR imaging: importance of cerebrosides and pHRadiology 192 (2)521 – 529994 .
- 111 LearySM Silør NC Steenson VL Barkr GJ MillerDH Thompon AJ Magnetisation transfer of normal appearing white matter in primary progressi ve multiple sclerosis. Mult Scler 5 (5)313 – 316999 .
- 112 RopeleS StrasserFuchs S AugustinM Stollberger R EnzingerC, HartungHP, Frzekas F. A comparison of magnetization transfer ratio, magnetization transfer rate, and the native relaxation time of water protons related to relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 21 (10)1885 1892000.
- 113 SantosAC, NarayananS destefano N Traglia MC FrancisSJ Arnaoutelis R Caramanos Z AntelJP, Pik GB ArnoldDL Magnetization transfer can predict clinical evolution in patients with multiple sclerosis. JNeurol 249 (6)662 – 668002.
- 114 McGwan JC , Yng JH , Plotkin RC , Grossman RI , Umile EM , Cecil KM , Bagly LJ Magnetization transfer imaging in the detection of injury associated with mild head trauma . AJNRAm J Neuroradiol 21 (5)875 – 880000 .
- 115 PriceG CercignaniM BagaryMS BarnesTR Barker GJ Joec EM RonMA Avolumetric MRI and magnetization transfer imaging follo w-up study of patients with f irst-episode schizophrenia. SchizophrRes 87 (1–3)100 – 108006.
- 116 KimuraH GrossmanRI LenkinskiRE Gonzalez-ScaranoF ProtonMR spectroscopy and magnetization transfer ratio in multiple sclerosis: correlati ve findings of active versus irreversible plaque disease . AJNRAm J Neuroradiol 17 (8)1539 1547996 .
- 117 Kalkers NF, Hintzen RQ an Waesberghe JH Lazeron RH an Schijndel RA , Ader HJ , Polman CH Barkhof F Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy. JNeurol Sci 184 (2)155 – 162001.
- 118 Lycklama a Nijeholt GJ ,Castelijns A , Lazeron RH an Waesberghe JH ,Phman CH , UitdehaagBM BarkhofF Magnetizationtransfer ratio of the spinal cord in multiple sclerosis: relationship to atrophy and neurologic disability. J Neuroimaging 10 (2) 67 - 72 , 2000 .
- 119 GeY, Kilson D BabbJ MannonL GrossmanR Wholebrain imaging of HIV-infected patients: quantitative analysis of magnetization transfer ratio histogram and fractional brain volume. AmJ Neuroradiol 24 82 – 82003.
- 120 Axison M NathA Greene-Axison R SchmittF, Greenber R Beger J Neruoimagingcorrelates of HIV-associated BBB compromise. JNeuroimmunol 157 140 – 146004.
- 121 MartinE NixonH PitrakD Weddington W, RainsN NunnallyG GrbesicS GonzalezR, Jacobs J BecharaA Characteristics of prospective memory deficits in HIV-seropositive substance-dependent individuals: preliminary observations. JClin Exp Neuropsychol 29 (5): 496 - 502007.
- 122 MartinE PitrakD Weddington W, RainsN NunnallyG NixonH GrbesicS Wessileva J, BecharaA Cognitive impulsivity and HIV serostatus in substance dependent males. JInt Neuropsychol Soc 10 (7)931 – 938004.
- 123 Cherner M, Letendre S, Heaton R, Durelle J, Marquie-Beck J, Gargg B, Grant I, Group HNRC. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology 64 (8)1343 – 1342005.
- 124 LetendreS ChernerM EllisR Marquie-BeckJ GraggB Marctte T, HeatonR McCutchan J GrantI Group.H Theeffects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS 19 (Suppl): S72 S78 2005.

- 125 .Lew A KlunderA JrCJ Jaga A DaleA BernsteinM Britson P, GunterJ Ward C, WhitwellJ Borowski B FleisherA Jax N Harosy D Jarnak J Shuff N Studholme C Absander G Wainer M ThompsonP, StudyAPP Longitudinalstability of MRI for mapping brain change using tensor-based morphometry. Neuroimage 31 (2)627 - 640, 2006.
- 126 MeierDS GuttmannCR MRItime series modeling of MS lesion development. Neuroimage 32 (2)531 – 532006.
- 127 Barnes J Levis E Scahill R Bartlett J Frost C Schott J, Rossor M J Ex N Automated measurement of hippocampal atrophy using fluid-registered serial MRI in AD and controls. JComput Assist Tomogr 31 (4)581 – 582007.
- 128. Bradley K, Bydder G, Budge M, Hajnal J, White S, Ripley B, Smith A. Serial brain MRI at 3–6 month intervals as a surrogate marker for Alzheimer's disease. Br J Radiol (75): 894, 2002.
- 129 Axison M NathA Beger J Understanding pathogenesis and treatment of HIV dementia: a role for magnetic resonance ? Trends Neurosci $25\ (9)468\ -\ 473002$.

The Assessment of HIV-Associated Neurocognitive Disorders: New Challenges in the HAART Era

Lucette A. Cysique and Bruce J. Brew

Introduction

The introduction of highly active antiretroviral therapy (HAART) in the mid-nineties has changed the global picture of HIV infection. From a life threatening illness, HIV/AIDS has become a chronic disease with a much-prolonged life e xpectancy. These marked changes have been also observed in the context of HIV-related neurological diseases with a decrease in the incidence of HIV -associated dementia (HAD) since 2001. The HAART era is now characterized by a higher prevalence of HIV-associated neurocognitive disorders (HAND) with predominantly a milder form of the disease. This higher prevalence was interpreted as reflecting at least in part an increased survival rate in individuals with HIV infection.

Associated with the increased survival are potentially new characteristics of the recently infected population and comorbidities in the longer-term infected population that may complicate both the assessment of HAND and its nature. In W estern countries, the epidemiological f igures of HIV infection have changed from a mainly Caucasian gay male population to a more diverse population where women of ethnic minority and of low socio-economic background are overrepresented and there are a significant number of individuals with a history of substance use disorder. This shift could also be interpreted as the old- and newly-infected population in the W estern countries. Importantly, the individuals who have been infected between 20 and 10 years ago are now aging and contribute to the global aging of the HIV population. It is currently unclear whether aging will be associated with a more severe or different form of HAND.

The newly-infected population in the eastern countries of Europe, for e xample, is overrepresented by intravenous drug users. In North America, a large proportion of drug users are often coinfected with Hepatitis C virus. Recent work has reported

L.A. Cysique (🖂)

University of New South Wales, Sydney, NSW, Australia

Department of Neurology, St. Vincent's Hospital, Victoria St. Darlinghurst, NSW, Australia lcysique@unsw.edu.au

a higher proportion of neurocogniti ve impairment in coinfected indi viduals in comparison with mono-infected indi viduals. Hepatitis C virus is therefore one of the most important comorbidities that HIV-infected population are facing.

Another complexity of chronic HIV-related neurological disease is the long-term therapeutic management involving optimization of HAART to counter side-effects, lower the pill burden to potentially improve adherence, and to minimize the resistance that most patients e ventually develop. Moreover, while more def inite evidence remains to be collected, there is the potential for neurotoxicity-related to some or all of the component drugs when patients are on long-term HAAR T. Lastly, there are controversial results regarding whether immune reconstitution syndrome may lead to the expression of HAND in what was previously subclinical disease.

In the last se veral years, research into HIV -related neurological diseases has extended from a mainly W estern population to an international one especially in developing countries, where the HIV epidemic is increasing such as in Asia and Sub-Saharan Africa. Importantly, in these developing countries, the HIV-infected population usually differs in terms of socio-economic status, gender, and sexual orientation compared with the original population in Western countries. More specifically, very large regional differences are possible within one country, for example, between the urban and the rural population. As in the ne wly-infected population in the Western countries, women of lower socio-economic background are often o verrepresented as well as drug users and se x workers. Related to this population is often a low level of education and sometimes illiteracy that challenges the conventional neuropsychological method which is often based on the assessment of some academic skills. In addition, extreme poverty or survival conditions affect all aspects of medical and neurological health. Furthermore, there are issues of cultural dif ferences and the frequent lack of local normative data again hindering the use of standard neuropsychological tests.

Moreover, some work suggests that regional differences in HIV clades may lead to variation in the expression and severity of HAND. Ho wever, more recent and more rigorous studies have tended not to support such clade related effects. Nonetheless, more work is needed. Lastly, HIV-related opportunistic infection remains common in some countries where ART access is still limited. In resourcelimited settings, the cause of HAND may be multiple and sometimes compounded by high rate of malaria or tuberculosis.

In light of these new findings and challenges, it appears important to be able to reevaluate the state of our knowledge regarding HAND. The complexities of the disease itself with a relapsing and remitting course, the complexities of HAART itself with its direct and indirect effect on the progression of the disease, and the complexities of the social characteristics of the population studies render the HAAR T era particularly challenging. Because HAND has become a chronic disease, when treatment is available, part of the focus of the research and the clinical evaluation need to be redirected to the long-term follow-up of the HIV-infected individuals. Moreover, because HIV/AIDS is a global disease, it is particularly important to try to understand whether the manifestations of HAND are similar across the world as well as developing pragmatic strategies to assess HAND in developing countries.

In this chapter, we have summarized the current knowledge regarding the use of neuropsychological method in HAND to detect cogniti ve impairment and change in cognitive functioning, emphasizing indi vidual case methods. We have also described what may be the new risk factors for HAND and how this may affect the pattern of neuropsychological dysfunctions usually observed in HAND. The discussion regarding the assessment of neuropsychological dysfunction in the developing countries is part of the chapter entitled "Impact of Clade Diversity of Neuropsychological outcomes".

The Assessment of Cognitive Functions in the HAART Era

The Typical Neuropsychological Assessment

The diagnosis HAND or HAD remains the decision of a neurologist because other neurological disorders need to be excluded as the cause of the cognitive impairment by neurological and neuroimaging evaluations. The assessment of neuropsychological functions is required to delineate whether the prof ile of impairment thought to be typical of the effect of HIV on the brain is present. Moreover, this assessment allows classifying the severity of the deficits in addition to the assessment of everyday life functioning.

Three main nomenclatures have been produced in the pre-HAART era to classify the cognitive, motor and neuropsychiatric manifestations of HAND. First, Price & Brew (1) established a framework of five stages for AIDS-Dementia Complex severity including a preclinical phase. Then, in 1991 (2) and 1996 (3), the American Academy of Neurology proposed a modif ied nomenclature to better delineate the mild and more severe forms of the disease because the mild neurocogniti ve deficits, observed commonly in advanced HIV infection, were not severe enough to be termed as dementia. The y defined two stages: HIV-1-Associated Minor Cognitive/Motor Disorder (MCMD) and HAD Complex respectively with the main difference between the two stages residing in the severity of cognitive symptoms impacting significantly on activities of daily living. Finally, Grant & Atkinson in 1999 (4), defined a partially revised nomenclature consisting of HIV-1-Associated Dementia-HAD and HIV-1-Associated Mild Neurocognitive Disorder (MND). The main distinction between the AAN criteria and the Grant & Atkinson's criteria for the diagnosis of HAD, resides in not requiring a disturbance in either motor functioning or moti vation, emotional control, or social behavior in addition to the cognitive deficit.

Recently, all these nomenclatures were updated and merged into a common one. This updated nomenclature (5, 6) defined an additional stage in HAND as "asymptomatic neurocognitive impairment" (ANI) which recognized the possibility of subclinical cognitive impairment. This updated nomenclature otherwise k eeps the Grant and Atkinson (4) definitional criteria which gives a greater priority to cognitive impairment as compared to motor and emotional dif ficulties. Central to these definitional criteria is the assessment of cognitive functions that is to be documented by a formal neuropsychological e xamination. Global impairment is def ined by a deficit of at least one standard de viation below the normative mean in a minimum of two cognitive domains. This cut-off is relatively strict and may be more relevant to the research context as there is a 15% f alse-positive classification rate for the ANI category. The assessment needs to be comprehensive enough to assess abilities of attention/working memory, speed of information processing, learning, delayed recall, verbal functioning, abstraction/problem solving and motor functions. While a step-down battery exists (7) as well as brief cogniti ve scales such as the HIV - dementia scale (8, 9), it is recommended to use these instruments either as screening tools or as part of a more comprehensi ve assessment. It is also important to use demographically-corrected norms even for these screening tools (10). However, it should be said that these brief instruments maybe of practical importance in limited-resource settings.

Because HAND is thought to mainly represent HIV brain injury to the striatofrontal neuronal networks (11), the neuropsychologist expects that areas of speed of information processing, attention/working memory, learning and active retrieval (as opposed to recognition in memory tests) will be primarily affected (for a recent review of the neuropsychological prof ile in HIV-infection, see (12)). Any focal deficits such as agnosia, apraxia or aphasia would be indicative of another diagnosis depending on neurological and neuroimaging results. The presence of focal neurological and neuropsychological f indings may indicate that an HIV -related brain opportunistic infection is present. Although this is less frequent in the HAART era, the neurological and the neuroimaging investigation should be able to provide this differential diagnosis. In addition, any rapid forgetfulness in memory tests, anomia, and semantic paraphasia in language tests as seen in Alzheimer's disease would signal the need for further in vestigation. Gross visuo-spatial def icits as seen in Alzheimer's disease, P arkinson's disease, and Huntington's disease are also unlikely, but may not exclude a diagnosis of HAND in the absence of identification of other pathology by neuromedical e xamination. Overt dysexecutive functioning especially when accompanied by gross frontal type of beha vior is unusual except in the advanced stage of HAD. However, milder forms of abstraction and problem solving disturbances are often observable on neuropsychological tests.

The exact composition of the neuropsychological battery for the assessment of HIV-infected individuals suspected or at risk for cognitive impairment may vary, but the clinical neuropsychologist can f ind some guidance from several sources. Currently, neuropsychological test compendia such as Lezak et al. (13) provide recommendations for selecting a number of neuropsychological test measures. There is also the Halstead-Reitan battery (14) for which, some of the tests have been recommended in the use of HIV-infection (15, 16). International experts during a National Institute of Mental Health (NIMH) workshop have also outlined recommendations for what is named the NIMH battery (17, 18). Lastly, Maj et al. (19) have provided recommendations for a testing battery in international settings.

Theoretically, the neuropsychologist should have the same number of tests in each cognitive domain to mak e a statistically sound decision regarding domain-specific level of cognitive impairment (20). It is often the case that research

over-represents tests of processing speed and attention (see 21, 22 for reviews). Nevertheless, the aim of the clinical assessment is to represent as comprehensively as possible the current neurocognitive abilities of one individual.

In addition to the neuropsychological tests, it is also recommended to briefly assess the level of depressive complaints using a validated psychiatric scale as well as anxiety and cognitive complaints (for more information see 23, 24). Importantly, the assessment should be complemented by an e xamination of activities of daily living (25) as this assessment serv es to ascertain the presence of dementia vs. milder stages of HAND (5, 6). In the context of HIV/AIDS, a caregiver is not often available to provide a more objective assessment of everyday life functioning. Self-reported everyday functioning is used on scales such as the Instrumental Activities of Daily Living Scale (IADL, 26), the direct assessment of functional status instrument (DAFS, 27). The current research in this area sho ws that the reports of cogniti ve complaints, depressive complaints and IADL should be interpreted together, as the different types of complaints may be inter-related while they do remain for the most part independent of the neuropsychological le vel of impairment at least in mildly impaired individuals (24, 25, 28).

Because of the increasing o verlap between HIV-infection and substance use disorders, assessment of substance use history is of particular importance (see also 12 for recent re view). Preferably validated psychiatric structured intervie ws or scales should be used, rather than open questions to the examinee (for an extended and recent review of psychiatric disorders in HIV -infection, see 23). The type of drugs, length of use, mode of use, and dosage should be recorded as the y help to interpret the current level of neurocognitive abilities. Lastly, medication adherence should always be monitored as it has been shown to be associated with severity of cognitive impairment in HIV-infection (29). A recent article provides an overview of the instruments that are available (30). They conclude that even a brief assessment of medication adherence is recommended.

It is common that a comprehensive assessment will require at least 2 h of testing and 1 h to collect other information. Depending on the instruments used, the assessment will vary in length. It is likely that the clinician will be a ware of the current HIV diagnosis of the examinee. More importantly, the clinician will pay attention to the degree of fatigue that may interfere with the test results. Patients at the AIDS stage are more likely to demonstrate fatigue-related cognitive deficits often observable by a decrease le vel of sustained attention. This is why most clinicians opt for a focused battery of tests lik ely to detect HAND which will lik ely be applicable to most of the patients in an HIV clinic. Ne vertheless, the neuropsychologist should remain open to test additional cogniti ve domains when an atypical pattern is detected. Fortunately, a lot of the tests used in HAND are also used in degenerative diseases allowing the clinician to detect atypical deficits that would be indicative of a differential diagnosis. However, focal deficits such as agnosia, or hemi-ne glect will need the addition of specific tests. Psychiatric features other than mild depressive and anxiety complaints should be thoroughly investigated by a psychiatrist. Finally sensory deficits whether related to HIV/AIDS should temper the interpretation of the results. The most common in the conte xt of HIV/AIDS is se vere peripheral

neuropathy in the upper limbs, which can sometimes signif icantly reduce motorcoordination abilities. Lastly, effort, cooperation, and motivation ought to be constantly monitored during the testing session. Instruments aimed at detecting lack of ef fort and or motivation will help the interpretation (12, 31).

The Importance of Appropriate Norms for a Given Population (Effect of Age, Education, Ethnicity, and Gender)

The effect of age and education and gender to a lesser e xtent has been long recognized in neuropsychological testing (32). The proper use of neuropsychological instruments demands the corrections of at least these two factors on the raw results obtained by an indi vidual. Unsurprisingly, the most commonly used tests and the most trusted by the neuropsychologists are also tests that have been amply validated and that have also normative data based on lar ge samples. Some of these tests have already a large pool of cross-cultural data and the best e xamples are the Wechsler adult intelligence scale (WAIS-III, 33) and Wechsler memory scale (WMS-III, 34) already translated in many languages. However, their application in developing countries is till sparse – this has been addressed in the chapter entitled "Impact of Clade Diversity of Neuropsychological Outcomes" Importantly, the data from the crosscultural validation within Western countries of the well-known batteries tend to demonstrate a "universal" effect of age and education on the neuropsychological abilities (35). When gender norms are available, the clinician is encouraged to use them. The same logic applied to ethnicity where it has been sho wn in some countries to af fect the neuropsychological performance (36). Some neuropsychologists also recommend the use of reading levels to account for quality of education differences between ethnic groups within the same country (37). However, the clinician should remain aware that these corrections are probably the proxies of comple x and multifactorial effects on the brain. Therefore it is the current socio-cultural and socio-economic as well as historical context that will render these v ariables and their interactions (e.g., gender and ethnicity) more or less pertinent (38). Some authors also recommend the assessment of levels of acculturation by taking into account specifically designed measures of acculturation (39) as well as v erbal fluency in the nonnative language, length of residence in the adoptive country, socio-economic status, and persistence of po verty (40, 41). As e xplained in more detail in "Impact of Clade Di versity of Neuropsychological Outcomes" one aspect that is less like ely to affect testing performance in Western countries is the effect of rural or urban di vision although this may not have been true in the past. In developing countries, this distinction is of particular importance and may be complicated by its interaction with gender (42).

Altogether, clinicians should a void using tests with poor normati ve standards. Despite the fact that the procedure for de veloping neuropsychological norms corrected for demographic factors is a demanding and arduous process in a globalizing world, this method still represent the most validated approach to determine level of cognitive impairment. The dif ficulties of neuropsychological norms de velopment

are that the y need to be rede veloped approximately every decade (i.e., "Flinn effect"). This process is costly and needs to be done on a lar ge scale. More fundamentally, the relevant demographic factors between one population and another may differ and change overtime in different ways (43). This inherently hampers the development of "universal" normative data, and implies that local normative data are by definition relative and transient.

The application to the de veloping countries is even more challenging because some of the factors impacting on neuropsychological function need to be ingenuously investigated. The effect of age, education, and gender may be different from the developed countries because of une xpected interactions between these factors especially, in poorer settings. Lastly, the comparison of one individual to a group encompasses some theoretical limitations as well as statistical limitations due to the Gaussian assumptions that the reference population has to respect (44). Here, the rapid progression of the research in statistical psychology is hoped to develop complementary mathematical tools to address the inherent complexity of this type of behavioral data. One way to partially overcome this problem is to focus on the longitudinal assessment of cognitive functions, when one individual becomes his/ her own normative standard. However, repeated assessments of cognitive functions also need normative standards in order to correct for practice effect and define what may be significant change.

The Importance of Long-Term Follow-Up

The course of HIV -associated neurocognitive impairment is v ariable and almost any pattern of progression can be seen with phases of relapse and remission of unknown duration (45). In addition to this, the natural course of HIV -associated neurocognitive impairment has potentially been altered by the widespread use of HAART. There has been an increase in patients' survival (46) leading to the emergence of the concept of inactive disease (47). Brew (48) and McArthur et al. (49) have proposed that HAND may be now subdivided in four categories depending on the disease evolution and the response to treatment: acti ve HAND happens with no antiretroviral treatment, inactive HAND happens with successful treatment but is a "burnt out" form of the disease where some irreversible brain injury remains stable, chronic HAND where slow brain HIV replication pro vokes a low level of neuroinflammation and a transformed HAND where age, Hepatitis C virus in the brain, direct and indirect toxicity of antiretro viral drugs, increased cerebro vascular risks in long-term HIV-infection, and immune reconstitution syndrome may change the clinical profile of HAND. The ultimate comple xity comes also from the f act that these different types of HAND may happen at different times in the life of a single HIV-infected individual and may even overlap to a certain extent.

Because these new definitions of illness are based on the e volution of HAND and the recovery, partial recovery, progression, or stabilization of cognitive deficits, it is clear that a strategy for repeated assessments is becoming crucial. As in other slowly progressing diseases, a yearly e valuation appears to be suitable. Ho wever when HAD has occurred before or in between antiretro viral therapy, a follow-up assessment should be gi ven 6 months after treatment initiation as this has been shown to be the probable time window for HAART benefit (50).

The follow-up neuropsychological assessment should comprise the same tests as the baseline assessment and include alternate versions of test measures when these have been shown to provide equivalent results. The neuropsychologist should be aware of the reliability data on the NP test measures used to facilitate the interpretation of change. Information regarding disease evolution, change in any comorbid factors, drug use should be recorded. Evaluation of depressive, anxiety and cognitive complaints as well as activities of daily living should be also reassessed.

It should be noted now that no systematic criteria have been published for what may be normal and abnormal cogniti ve change. Therefore, in most published works, the cross-sectional criteria have been applied to data collected on each followup session and abnormality is def ined when these are outside normal ranges. However, this method does not take deterioration in cognitive function overtime as the core definition for HAND, but instead requires that the patient's neuropsychological performance be compared to the performance of the normati ve sample. There are at least two main problems with this approach. First, practice ef fects are well-known to occur with repeated administration of neuropsychological tests (51). Therefore, normative data should contain modifications for this practice effect, or better still, also provide data from normal individuals or clinically stable individuals who have been assessed repeatedly. Second, the requirement that abnormality be defined when performance data fall outside some normal range means that patients who show significant deterioration in cognitive function, but whose performance is still normal, will not be classified as abnormal, or worse still, not considered for special CNS related therapy.

There have been fe w studies that ha ve evaluated the long-term outcome of HAART on cognitive function have been conducted in patients who met the criteria for neurocognitive impairment at their initial visit (before HAAR T initiation) and were then reassessed up to $2.\frac{1}{2}$ (52), and 4 years (50) later. These studies observed improvement in complex attention/psychomotor speed (52) and in motor-coordination (50) and interpreted such improvement to reflect a HAAR T-related CNS benefit. Tozzi et al. (50) showed that 57.3% of their 16 patients had v aried neurocognitive improvement after a median time of 45 months of HAART (range 36–52), although sustained improvement was found only for the Stroop interference subtest and for the grooved pegboard dominant hand task. None w as found for attention, simple processing speed, verbal memory, or visuo-construction functions. However, neither of these prospective studies compared the cognitive change observed in the advanced HIV group to any control group. Thus it is possible to conclude that the performance change observed in either study reflected in part a practice ef fect: the HIV-infected individuals became more practiced at performing the tests and the magnitude of such an effect was unknown. Another limitation is that while T ozzi et al. (50) used a relatively comprehensive range of neuropsychological tests, Sacktor et al. (52)included only the Trail Making and Symbol Digit Modalities tests in their battery.

In addition to these studies, our longitudinal observ ational study conducted in 2006 (53) in Australia tended to address some of the limitations of these pre vious studies. We used a comprehensi ve neuropsychological assessment o ver a 4-year period. We developed norms for change in an HIV -sample and used the reliable change index (RCI) method to determine cogniti ve change in each indi vidual. In this study we found that a majority of HIV+ participants stabilize their performance (between 76 and 66% from first to last visit, while 7.5–29% improved), independent of the attrition rate. However, neuropsychological decline does occur in a minority (between 16.5 and 5% from f irst to last visit): it is not linear in that se veral years may pass between symptoms of progressive neurocognitive impairment.

Several studies have been published in normal controls and clinical groups other than HIV/AIDS to address cognitive change. We have summarized below the most important guidelines that come out of these studies.

Practice Effect and Regression Toward the Mean

Repeated neuropsychological assessment is subject to a learning effect that differs depending on the test measure used and on the initial le vel of impairment of the individual. The psychometric property of the tests will interfere with the ability to observe change. Indeed, tests that ha ve a skewed distribution of measures and a restricted range of responses will not perform as well as measures that ha ve an infinite number of potential measures and/or with a normal distribution. This is one of the reasons why time-based tests perform better than measures of verbal learning for example. Moreover, by nature, some cognitive abilities will remain more stable than others and this is why language tests, in healthy population, are usually less subject to improvement compared to executive function based tests (54) and memory measures (55). Keeping this in mind, the clinical neuropsychologist is encouraged to evaluate potential cognitive change in a comprehensi ve number of cognitive abilities and use tests on which test releast reliability and practice ef fect data have been published. When data are sk ewed, the normalization of the data distrib ution may be approximated using appropriate statistical transformation (see 56). Moreover, one strategy has been to use a battery approach in the evaluation of cognitive change (57). This method has se veral advantages in HIV infection: the use of a composite score on which to base change computations improves the reliability of the observed change and it appears to be clinically rele vant in the diffuse type of neurocognitive disorders where the decline or improvement is likely to affect a range of cognitive functions. However, when decline is expected in specific areas of cognitive functioning, individual measures need to be explored.

The interval between assessments has not been sho wn to be a major f actor on the magnitude of the practice effect in some studies (58, 59), but not in others (60-62); while others have found that it does not affect all tests to the same extent (63). It is often that the largest practice effect is observable at the second assessment (64) although this may depend on the age, the education, and the initial level of

impairment of a given individual (65, 66). To circumvent this effect, some authors have proposed the use of a dual baseline assessment (67). Although this method may correct for part of the lar gest effect of practice, it appears to be more easily applicable when using brief screening battery (58, 59). The current pragmatic attitude in research is to include a statistical correction for the number of assessments given (53). Some have also suggested to monitor change in cogniti ve functions using practice effect itself (68). More work is currently made which hopefully will provide clearer guidelines for clinicians.

To account for practice effect, it is required to include a correction of the test retest difference that can be derived from a normative or reference sample. Several computational methods to derive change scores which tak e into account practice effect have been developed and we have outlined them below. These methods also allow correcting for re gression towards the mean. Re gression towards the mean results in an increment for lo wer average baseline score or decrement for higher average baseline score of the retest score to ward the group mean due to the least square method of the regression prediction (69).

We chose to present only the most contemporary methods because the theoretical detail of longitudinal statistics is be yond the scope of this chapter . However, we provide ample citations to which a more interested reader can refer. In addition, we will not discuss research statistical methods that have been developed to look at cognitive change overtime in groups because we are interested in change at the level of the individual in the clinical setting. However, the reader can find examples of these methods in NeuroAIDS research in Sacktor et al. (70) using the generalized estimating equations (GEE – 71). There is also the possibility of using the mixed effect regression models (72), which has been also used in NeuroAIDS research (e.g., Ferrando 73). This last method can provide both group and individual analyses as well as the modelized the drop out effect, which is common in this type of studies.

Defining What is Significant Change

Below, we present three statistical methods that have been validated for interpreting change overtime in individuals. The reader is encouraged also to refer to the original publications for an y application of these statistical procedures that have been briefly described here. These three methods have been outlined in T emkin et al. (63) and Heaton et al. (65). The first method was originally described by Jacobson and Truax (73) and is the RCI method. Since then modified RCIs have been produced to better account for practice effect, and variability of performance overtime. (see 74, 75 for reviews). This has been developed further below.

The second method is based on the use of linear regression of the retest scores on the baseline scores in a control or reference sample to de velop a formula for predicting a follow-up score from any baseline score (63, 76). The third method is the use of a stepwise linear regression in which f actors such as demographic and overall baseline level of cognitive performance are accounted for in a stepwise fashion according to the prediction formula (63).

A crucial process in the determination of norms for change is the use of an index to standardize the performance overtime which is ideally derived from an appropriate normative sample. In the case of the Temkin's RCI (63), this is the standard deviation of the difference; others have used the within standard deviation (53, 75, 77). In the simple linear regression model, the residual standard de viation is used (63), while the corrected residual standard de viation is used in the multiple linear regression model (63, see also formulas 1 & 2). Importantly, Heaton et al. (65) have found that the RCI corrected for practice effect provided similar results to the more comple x regression models mentioned in a mixed clinical sample. Authors have traditionally used the 90% confidence interval which indicates that in the reference or control sample, it is expected that 5% of the individuals will significantly improve and 5% will significantly decline. Additional research is needed in this area to be able to define systematic criteria for change that will help clinical neuropsychologists. Itshould be noted that most of the well-known standard neuropsychological batteries such as the WAIS, WMS, and HRB have published test retest reliability data, ne vertheless these data are unequal in quality and authors are still debating on what are the best indices for standardization (55).

Formula 1: Reliable change index (RCI) with practice effect correction

$$RCI = (X_2 - X_1) - (U_2 - U_1)/SD$$
 diff

where X_2 = individual time 2 performance (or any follow-up); X_1 = individual time 1 performance; U_2 = reference or control mean time 2 performance (or any relevant follow-up); U_1 = reference or control mean time 1 performance; and SD dif f = standard deviation of the difference (other have used the within standard deviation; see (74, 75) for reviews).

Significant change can be defined using a 90% confidence interval. This corresponds to 5% of a normative sample improving (i.e., RCI \ge 1.64) and 5% of a normative sample declining (i.e., RCI \ge -1.64).

Formula 2: Regression-based change score (RCS)

$$RCS = (actual X_2 - Predicted X_2)/SD$$
 residual

where actual X_2 = actual individual performance at time 2 (or an y follow-up); predicted X_2 = predicted individual at time 2 (or an y follow-up); and SD residual = residual standard deviation of the control or reference sample (or corrected residual standard deviation in the stepwise regression model).

Significant change can be defined using a 90% confidence interval. This corresponds to 5% of a normati ve sample improving (i.e., RCI or RCS \geq 1.64) and 5% of a normative sample declining (i.e., RCI or RCS \geq -1.64).

Lastly and very importantly, Heaton et al. (65) noted that the initial le vel of impairment or performance is crucial to understand the e xpected change (i.e., change is expected to be larger in low performing individuals). They recommend that the reference group used to de velop norms for change have the same baseline performance level as the clinical groups that are tested. In the clinical context, this

often represents groups with a specif ic disease that remain stable (i.e., with no significant clinical or treatment changes) rather than "only" healthy controls. Another method is to use multiple reference groups as suggested by McCaf frey & Westervelt (69). This method may be particularly useful in the clinical setting, while in the research setting the choice of the type of reference group should be guided by the scientific questions that the study is investigating. Besides the clinical similarity between the sample used to develop norms for change and the sample on which the norms will be applied, f actors such as age, education, gender, and other demographic variables should also be considered. Indeed, recent work suggests that these factors may affect the methods used to detect change in a comple x manner (see (78) for further details).

Again this area of research is in constant e volution and it is anticipated that the criteria and guidelines for cognitive change will be formalized in the future. A multidisciplinary effort is currently underway in NeuroAIDS research and other clinical areas where change contributes to the definition of the disease (e.g., postoperative cognitive related deficits, (75)).

Is the Neurocognitive Profile of HAND Changing, and What Are the Effects of Age, HCV, and Gender?

Evidence for neuropsychological changes in the pattern of HAND with HAAR T introduction came from studies demonstrating that HAAR T was associated with significant improvement in neuropsychological functioning and in particular psychomotor slowing (50, 52, 70, 79–83). Historically, the extent of improvement in neurocognitive functioning had no parallel, with some patients fully recovering from mild to moderate degrees of dementia.

Most of the neuropsychological in vestigations conducted in the HAAR T era assessed a relatively comprehensive range of neuropsychological functions and most have demonstrated a positive significant impact associated with HAAR T on psychomotor speed tests and/or motor tests. However, not all demonstrated sustained effects on learning, memory, visuo-spatial functions, and v erbal fluency (50, 80). This may indicate that improvement on HAART is not equal for all cognitive domains. Alternatively or additionally, the extent of improvement may be dependent on the initial severity of cognitive impairment. It is now recognized that the overall effect of HAART is that the se verity of the cognitive disturbances has decreased (49). Cysique et al. (84) have attempted to address whether the detailed pattern of cognitive performance has changed by comparing cohorts of adv anced HIVinfected individuals in the post-HAART and pre-HAART era who were comparable in terms of demographics, socio-economic background, HIV risk factors, and disease severity. They found a similar prevalence of cognitive impairment before and after HAART supporting previous results from the MACS and NEAD cohorts in the U.S. (85). However, a potential change in the neuropsychological profile was not explored between the two American cohorts because of the substantial difference in demographic and HIV risk factors. Because this was not the case in the Australian cohorts, Cysique et al. (84) compared their two cohorts on nine cognitive domains and noted that the pattern of neuropsychological impairment had changed across pre-HAART and HAART eras with a reduction in attention, visuo-spatial, and psychomotor speed deficits but with a trend to ward greater memory impairment and a progression of executive deficits. This change remained even in patients with an undetectable plasma viral load, although the se verity was partially diminished. This study and our longitudinal results (53) implied first that patients still had deficits either because of "carry o ver" of pre-HAART residual deficits, that is an inactive disease component, and/or ne w deficits from "grumbling" chronic disease. The prospective study however, showed that approximately 50% were stable on HAART implying that inactive disease can only account for some of the lack of change between pre- and post-HAART cohorts. It also implies that there must be a dynamic flux between no deficit and deficit in HAART-treated patients.

However, direct cohort comparison is potentially fraught with dif ficulty in interpretation. Some authors ar gue that the interpretation of a dif ference may be due to unknown factors. Nevertheless, because of the intrinsic complexity of the disease, historical cohort comparisons should remain a potential strategy coupled with prospective studies in the HAAR T era. Factors, such as rapidly e volving treatment, significant changes in demographic characteristics of the HIV epidemic including more w omen and more minorities, aging, and HCV coinfection render the interpretation of HAND profile change in longitudinal data in the HAART era very complex as well.

Is the Pattern of HAND Changing with Aging?

There have been se veral publications demonstrating an increase in cogniti impairment in older HIV-infected individuals compared to younger HIV -infected individuals (86–88). Interestingly, a relatively old publication by Hinkin et al. (89) demonstrated a similar level and pattern of deficit between young individuals with HAD and older healthy indi viduals as compared with healthy young indi viduals. This pattern was characterized by a predominance of psychomotor slowing, working memory, and complex attention deficits. The authors hypothesized that HAD was a form of premature aging and this hypothesis rebounded in the HAART era with the increasing aging of the HIV-infected individuals (90). Some authors have suggested that an additive or interactive effect of age on HIV may amplify some minor neurocognitive disturbances (91). However, the exact neuropsychological consequences remain to be thoroughly e xplored. Normal aging is mainly associated with decreased cognitive speed (92) and this is thought to be related to striato-frontal dysfunction. HAND has also been interpreted as resulting from striato-frontal injury, although other parts of the brain are also affected (93). Aged HIV+ individuals could potentially show an overall worsening of their cogniti ve ability driven by decreased psychomotor speed. Ho wever, comorbid factors associated with aging may complicate this picture.

Indeed, aging itself is the primary risk factor for neurodegenerative diseases (94) of which the most frequent is Alzheimer's disease (95). Therefore a logical axis of research is now to find potential corroboration of the possibility for neurodegenerative pathological development in HIV-infected individuals (48). There have been now several reports demonstrating the existence of neuropathological mechanisms pertaining to Alzheimer's disease in HIV-infection, such as increased *B*-amyloid brain deposits (96, 97); CSF amyloid β 42 and tau le vels paralleling those in Alzheimer's disease (98) and complex neuro-inflammatory pathways (99). As mentioned earlier, the neuropsychologist is advised to use a comprehensi ve assessment of cognitive abilities. If so, unusual features such as rapid forgetting on memory tests, gross verbal disturbances in naming tests could alert that a patient who is HIV+ is also developing Alzheimer's disease. Some have also suggested that the progression of HAND may be more rapid with the copresence of a neurode generative disease (90), but more research will be needed in this area. If this happens it will be important to discover which pattern of neuropsychological deficits is predictive of disease progression. Other neurode generative disorders that are less common than Alzheimer's disease could also be more prevalent in long-term HIV-infected individuals, such as Parkinson's disease which shares a common dopaminer gic neuropathogenesis with HAD affecting mainly the basal g anglia (100). Here, gross visuospatial and motor deficits should alert the clinician that a differential diagnosis may be needed.

Older HIV-infected individuals may be also at higher risk for cerebro vascular insults due to a combination of aging factors (increased incidence of cardiovascular, cerebrovascular, metabolic diseases such as diabetes and hypercholerostemia), HIV disease factors (decreased immune competence that is accelerated with aging) and HAART-related toxicity (lipodysytophy, immune reconstitution syndrome) (90). From a neuropsychological perspective, focal cerebrovascular events of subcortical areas in older indi viduals with HAND may precipitate dementia with additional psychomotor slowing as a predominant feature. It may also translate into increased deficits in learning and memory as well as e xecutive functions. More work is also needed in this area to understand whether some white matter diseases commonly seen in HIV-infected individuals (101) and vascular cognitive impairment (102) are the result of low-grade cerebrovascular injury and how they may affect the pattern of cognitive deficits in older HIV+ individuals.

Lastly, it has been shown that psychiatric disorders have a greater prevalence in older HIV-infected individuals as compared to younger HIV -infected individuals. This is the case not only for depressi ve symptoms, but also alcohol ab use and dependence as well as drug abuse and dependence. While depressive disorders have been demonstrated to be independent from HAND (28, 103), this was shown in relatively young individuals and needs to be fully explored in older individuals. Contemporary nonacute drug use in HIV-infection is known to worsen the overall cognitive deficits (104), but the chronic effects of such drugs are less clear (105). It has been shown that lower socio-economic status in HIV+ drug users had more influence on neuropsychological performance than the drug use status per se (106).

Therefore, these characteristics should be kept in mind when investigating how age may affect cognitive performance in HIV-infection.

The Potential Additive Effect of HCV and HIV on the Brains

There is evidence that approximately 30% of HCV+ individuals with mild liver disease present at least mild neuropsychological dysfunction that is independent of substance use and other comorbid f actors such as depression and f atigue (107). From a series of six studies (104, 108–112), it appears that the most robust cognitive dysfunction was found in domains of sustained attention and comple x attention as well as motor functions compatible with fronto-striatal models of neurocognitive impairment (113). An additive or synergistic effect of HCV in HIV-infected individuals has been hypothesized and there is an emerging evidence that coinfected subjects are more likely to be neuropsychologically impaired, (104, 114)particularly in tests of executive functions (111, 115) and psychomotor speed (114).

Are Female Gender and Sex Hormones Associated with a Higher Prevalence of HAND?

There are currently no data in the HAART era to support that women are more at risk for HAND or at more at risk for more rapid progression (116), but studies addressing this question have been rare. A European epidemiological study from the pre-HAAR era noted that women were more likely to be diagnosed with HAD as compared with men (117). However, as with drug users, the effect of basic demographics should be carefully reviewed to evaluate such data. Because the gender distribution is changing in the developed countries and now includes more women especially from minority backgrounds, and that women represent the largest pool of individuals in developing countries (118), studies addressing a potential difference in HAND between genders are needed. Cohen et al. (81) noted that in the HIV epidemiological research study (HERS) cohort, HIV+ w omen receiving HAART also sho wed neurocognitive improvement in domains of verbal fluency, psychomotor speed, and executive functions especially after 18 months, while untreated w omen worsened in the same cognitive abilities areas. Nonetheless, more specif ic studies are needed. Indeed, such studies should be coupled with other factors such as hormonal status and corrected for other potential discrepant factors such as economic status.

The influence of sex hormones particularly testosterone on cognition is comple x. Endocrine abnormalities are common in HIV-1 infected patients (119) and testosterone deficiency has been reported as the most common one (120–122). Usually, testosterone level is in vestigated in HIV-infected men, but recent data, using a more sensitive measure have shown that HIV-infected women also had lower free testosterone than seronegative women (123). Symptoms include depressed mood, decrease libido and energy, loss of weight, and muscle mass (124). Testosterone deficiency has been associated with higher occurrence of opportunistic infections, a CD4 cell count below 200 cells/mm³ and treatment with megestrol acetate (125). However, other studies did not replicate these results and could not find any relation with HIV illness markers (126). Testosterone supplementation in HIV-1 infected individuals induces a positi ve effect on depression (127), libido, ener gy and weight, and muscle mass (124.127-129) as well as improved quality of life (130). So far, no studies have addressed whether testosterone deficiency could lead to cogniti ve deficits in HIV-infected subjects. However, recent data suggest that testosterone deficiency contributes to the occurrence of Alzheimer's disease (131, 132) and that testosterone supplementation may have a neuro-protective effect (133). The question remains also open for the female hormone estrogen, which has been shown in some studies to have a beneficial effect on cognitive functions in women with Alzheimer's disease (134). Although, recent advances demonstrate that it is a combination of select neuro-protective estrogens that could provide an increased and clinically meaningful efficacy (135). Promising results come from recent studies showing a protective effect of estradiol on neurotoxins that have been implicated in HIV neuropathogenesis (136).

New Risk Factors for HAND?

Nadir CD4

There are now several reports that have shown that the nadir CD4 cell count may be a new risk factor for HAND in the HAART era (53, 137, 138). The fact that the worst historical impairment of immune function accounts for the current neurocognitive status, while current traditional markers of HAND such as plasma viral load and CSF viral load are less effective as markers of the disease (139), confirm that the neuropathogensis of HAND has shifted from an acute process to a more chronic process (48). It should be noted that there is some evidence that the combination of low nadir CD4 and previous HAD is a risk factor for further neurocognitive decline, even if years had passed between episodes of HAND (53). Potential new markers of this chronic neuro-inflammation have been in vestigated in several studies. MCP-1 which was a potential candidate (140) appears to be now less likely to be associated with HAND in long-term treated patients. Indeed, recent in vestigations showed that increased levels of the vitamin E and triglyceride C52 predicted the onset or worsening of HAD (141). Moreover the authors showed that elevated levels of sphingomyelin were associated with inacti ve HAD and that ele vated levels of ceramide and the accumulation of 4-hydroxynonenals were associated with active HAD. But, it is perplexing that inactive HAD should be associated with active process that elevates sphingomyelin. In this re gard, it should be noted that approximately half of these patients were intra venous drug users, raising the possibility that this elevation may be related to drug use. Others have found that HIV proviral DNA was

associated with baseline neuropsychological performance, but was not predictive of HAND decline (142).

Duration of HIV

There are no clear data showing that the duration of HIV affects the occurrence and progression of HAND. However, this may need to be reconsidered for two reasons. First, it is possible that an effect of HIV disease duration will only sho w after the second decade and the oldest surviving patients are now for the most part in their first decade with the disease. Secondly, the current tools to capture the duration of the disease are poor. What may be necessary is the de velopment of an algorithm that takes into account the nadir CD4, the response to treatment and resistance, and comorbidities. Therefore additional work is needed in this area.

Is Neuro HAART Important?

There have been several reports demonstrating that HAAR T composed of agents able to cross the blood–brain barrier (BBB) is more ef fective at improving neurocognitive deficits in HIV-infected individuals with HAND (143, 144). In a longitudinal study of 15 months in average, and using the RCI method, Cysique et al.(53) reproduced their initial findings (143) of better neurocognitive performance in HIV+ individuals receiving at least three antiretro viral drugs with good CNS-penetrance. More longitudinal studies are necessary in a wide range of HIV+ infected indi viduals who differ in terms of their HAND se verity at baseline. Correction for pre vious antiretroviral history is ideally needed. Moreo ver, as we outlined in the pre vious paragraph, robust longitudinal design taking into account practice ef fect, baseline performance, and a reference range of cogniti ve fluctuation is needed to correctly infer cognitive change in long-term treated indi viduals. Lastly, it should be noted that a detailed scoring system for CNS-penetrance has been proposed by Letendre et al. (145).

Immune Reconstitution Inflammatory Syndrome (IRIS)

Following HAART initiation some HIV+ indi viduals can de velop a paradoxical neurological deterioration, despite improvements in HIV viral load and CD4+ T-cell counts (146). This IRIS has been reported in se veral case studies which observ ed severe worsening of brain opportunistic infections as well as the occurrence of a severe dementing illness (147, 148). Although these studies suggest that IRIS may be responsible for HAND w orsening in some cases, a recent longitudinal study

demonstrated that long-term immune reconstituted HIV+ individuals had improved neuropsychological functioning over a 96 weeks period (149). The authors also showed that improved cognitive functioning corrected for practice ef fect was not associated with higher CD4 cell count, but was associated with plasma viral suppression. Finally, as mentioned earlier, the role of IRIS in aging patients may dif fer from the role of IRIS in younger HIV+ individuals. More longitudinal studies will be necessary to thoroughly address these questions, but it appears that IRIS is a v ery uncommon cause of HAND expression or deterioration.

References

- 1 . PriceRW, Brev BJ TheAIDS dementia complex. JInfect Dis 1988 ; 158 : 1079 8
- 2 Janssen R ComblathD HopkinsJ etal .Nomenclatureand research case definitions for neurological manifestations immunodeficiency virus type-1 (HIV-1): reports of a Working group of the American Academy of Neurology AIDS Task Force . Neurology 1991; 41 : 778 85.
- 3. American Academy of Neurology, Dana Consortium. Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. Neurology 1996;47:1247–53.
- 4 Grant I AtkinsonJH Neuropsychiatricaspects of HIV infection and AIDS .In: SadocBJ , Sadock A eds. Kaplanand Sadock's comprehensive Textbook of Psyhiatry/VII. Baltimore : Williams & Wilkins; 1999 : 308 – 35 .
- 5 Antinori A ArendtG Beckr JT, etal .Updatedresearch nosology for HIV-associated neurocognitive disorders . Neurology 2007; 69: 1789 – 99.
- 6 Cherner M CysiqueL HeatonRK etal .Neuropathologicconfirmation of definitional criteria for human immunodeficiency virus-associated neurocognitive disorders . JNeurovirol 2007; 13: 23 8.
- 7 Carey C Wods S RippethJ et al .Initial validation of a screening battery for the detection of HIV-associated cognitive impairment . ClinNeuropsychol 2004; 18: 234 48.
- 8 Davis H Skilasky RJ SelnesO Bugess D McArthurJ AssessingHIV-associated dementia: modified HIV dementia scale versus the Grooved Pegboard . AIDSRead 2002 ; 12 : 32 – 3 .
- 9 Power C SelnesO GrimJ McArthurJ HIVDementia Scale: a rapid screening test. JAcquir Immune Defic Syndr Hum Retrovirol 1995; 8: 273 – 8.
- 10 Mogan EE Wods SP, ScottJC etal .Predictive validity of demographically adjusted normative standards for the HIV dementia scale . JClin Exp Neuropsychol 2007 ; 20 : 1 - 8 .
- 11 Rul R Cohen R Nuia B Ashima K Relationshipsbetween cognition and structural neuroimaging findings in adults with immunodef iency virus type-1. Neurosci Biobehav Rev 2002; 26: 353 9.
- Woods SP, Grant I. Neuropsychology of HIV. In Gendelman HE, Grant I, Ev erall I, Lipton SA, and Swindells, S. Eds. The Neurology of AIDS, 2nd Ed (pp. 607–616). London: Oxford University Press. 2005.
- 13 LezakM Hwieson D LoringD HannayJ FischerJ Neuropsychological Assessment . 4th ed. Oxford OxfordUniversity Press ; 2004 .
- 14 HeatonRK GrantI Matthews CG Comprehensive norms for an expanded Halstead-Reitan battery: demographic corrections research f indings, and clinical applications. Odessa: FL: PsychologicalAssessment Resources; 1992.
- 15 GrantI SacktorN McArthurJ HIVneurocognitive disorders .In: GendelmarHE GrantI , Esrall I LiptonSA SwindellsS eds. The Neurology of AIDS . 2nded. London Oxford University Press; 2005 :pp357 – 73 .
- 16 HeatonR GrantI ButtersN etal .TheHNRC 500-neuropsychology of HIV infection at different disease stages . JInt Neuropsychol Soc 1995; 1:231 51.

- 17 McCaffey RJ ,Westervelt HJ ,Haase RF .Serial neuropsychological assessment with the National Institute of Mental Health (NIMH) AIDS abbre viated neuropsychological battery. ArchClin Neuropsychol 2001 ; 16 : 9 18 .
- 18 .ButtersN GrantI haxbyJ Assessmentof AIDS-related cognitive changes: Recommendations of the NIMH W orkgroup on neuropsychological assessment approaches. J Clin Exp Neuropsychol 1990; 12: 963 – 78.
- 19 MajM SatzP, JanssenR etal .WHOneuropsychiatric AIDS study, cross-sectional phase II . ArchGen Psychiatry 1994 ; 51 : 51 – 61 .
- 20 IngrahamL Aikn C Anempirical appraoch to determining criteria for abnormality in test batteries with multiple measures. Neuropsychology 1996; 10: 120 4.
- 21 Cysique L Maruff P, Brev B The neuropsychological profile of symptomatic, AIDS and ADC patients in the pre-HAAR T era: a meta-analysis J Int Neuropsychol Soc 2006; 12:1 15.
- 22 Rger M Wish R RazaniJ MartinDJ BooneKB Ameta-analysis of the neuropsychological sequelae of HIV infection. JInt Neuropsychol Soc 2002; 8: 410 24.
- 23 AtkinsonJH PersonC Mung C DeitchD Teisman G Theneurology of AIDS: psychiatric disorders .In: GendelmanHE GrantI Exerall I LiptonSA SwindellsS eds. TheNeurology of AIDS . London OxfordUniversity Press; 2005 :pp553 66.
- 24 CarterSL Rourk SB MurjiS ShoreD Rourk BP Cognitive complaints, depression, medical symptoms, and their association with neuropsychological functioning in HIV infection: a structural equation model analysis. Neuropsychology 2003 ; 17 : 410 – 9.
- 25 HeatonR MarcotteTD Riera Mindt M etal .Theimpact of HIV-associated neuropsychological impairment on everyday functioning . JInt Neuropsychol Soc 2004 ; 10 : 317 31 .
- 26 Lwton MP, BrodyEM Assessmentof older people: self-maintaining and instrumental activities of daily living . Gerontologist 1969 ; 9 : 179 86 .
- 27 Lowenstein DA, BatesBC Manual for administration and scoring the Direct Assessment of Functional Status scale for older adults (D AFS) Miami Beach, FL: Mount Sinai Medical Center; 1992.
- 28 .CysiqueLA DeutschR AtkinsonJH etal .Incidentmajor depression does not affect neuropsychological functioning in HIV-infected men . JInt Neuropsychol Soc 2007 ; 13 : 1 – 11 .
- 29 HinkinCH HardyDJ MasonKI etal .Medicationadherence in HIV-infected adults: effect of patient age, cognitive status and substance . AIDS 2004 ; 18 : S19 S25 .
- 30 SimoniJM Kirth AE PearsonCR Rentalone DW, MerrillJO Frik PA Self-reportmeasures of antiretroviral therapy adherence: a re view with recommendations for HIV research and clinical management. AIDSBehav 2006; 10: 227 45.
- 31 HiscockM HiscockCK Refning the forced-choice method for the detection of malingering . JClin Exp Neuropsychol 1989 ; 11 : 967 – 74 .
- 32 .Wechsler D WAIS-R manual . New York : ThePsychological Corporation ; 1981 .
- 33 Wechsler D Wechsler Adult Intelligence Scale-Third Edition Manual . San Antonio : The Psychological Corporation ; 1997 .
- 34 Wechsler D Wechsler Memory Scale Third Edition Manual . SanAntonio : ThePsychological Corporation ; 1997 .
- 35 .Grgoire J Factor structure of the French version of the Wechsler Adult Intelligence Scale-III . EducationalPsychol Measurement 2004 ; 64 : 463 – 74 .
- 36 HeatonRK MillerSW, Tylor MJ GrantI Revised comprehensive norms for an expanded Halstead-Reitan Battery: Demographically adjusted neuropsychological norms for African American and Caucasian adults Scoring Program . Odessa: FL: Psychological Assessment Resources; 2004.
- 37 ManlyJJ JacobsDM Juradji P, SmallSA SternY Readinglevel attenuates differences in neuropsychological test performance between African American and White elders . J Int Neuropsychol Soc 2002; 8: 341 – 8.
- 38 ManlyJJ EchemendiaRJ ManlyJJ etal .Race-specifc norms: using the model of hypertension to understand issues of race, culture, and education in neuropsychology . Arch Clin Neuropsychol 2007 ; 22 : 319 25 .

- 39 Manly JJ Byrd DA, Touradji P, et al. Acculturation, reading level, and neuropsychological test performance among African American elders. ApplNeuropsychol 2004; 11: 37 46.
- 40 .Gasquoine PG Variables moderating cultural and ethnic differences in neuropsychological assessment: the case of Hispanic Americans . ClinNeuropsychol 1999; 13: 376 83.
- **4**. Perez-Arce P . The influence of culture on cognition . Arch Clin Neuropsychol 1999 ; 14 : 581 92 .
- 42 ZhangZ Genderdifferentials in cognitive impairment and decline of the oldest old in China . JGerontol B Psychol Sci Soc Sci 2006; 61: S107 – 15.
- 43 GrantBF, StinsonFS HasinDS Dwson DA, ChouSP, AndersonK Immigrationand lifetime prevalence of DSM-IV psychiatric disorders among Me xican Americans and non-Hispanic whites in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. ArchGen Psychiatry 2004; 61: 1226 – 33.
- 44. Carello C, Moreno M. Why nonlinear methods? In: Rile y MA, Van Orden GC, eds. Tutorials in contemporary nonlinear methods for the behavioral sciences. Retrieved 15 May 2007, from http://www.nsf.gov/sbe/bcs/pac/nmbs/nmbs.jsp; 2005:pp. 353–400.
 - 45 BouwmanFH Skalasky RL HesD etal .Variable progression of HIV-associated dementia . Neurology 1998 ; 50 : 1814 – 20 .
- 46 . DoreGJ McDonaldA LiY, KaldoJM Brev BJ Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 2003; 17: 1539 45.
- 47 Brev BJed. AIDSDementia Complex. In: HIV Neurology . Oxford OxfordUniversity Press ; 2001 : 53 90 .
- 48 .Brw BJ Evidencefor a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of ne w forms of AIDS dementia comple x. AIDS 2004 ; 18 : S75 - 8.
- 49 McArthur JC , Haughy N , Gartner S et al . Human immunodeficiency virus-associated dementia: an evolving disease . JNeurovirol 2003 ; 9 : 205 21 .
- 50 Jozzi V, BalestraP, GalganiS et al .Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years . JAcquir Immune Defic Syndr 2001 ; 28 : 19 27 .
- 51 Læine A MillerE Beckr J SelnesO CohenBA Normative data for determining significance of test-retest dif ferences on eight common neuropsychological instruments . Clin Neuropsychol 2004 ; 18 : 373 – 84 .
- 52 SacktorN Shalasky RL Trwater PM etal .Response systemic HIV viral load supression correlates with psychomotor speed performance . Neurology 2003; 61: 567 9.
- 53 Cysique LA ,Maruff P, Brev BJ Variable benefit in neuropsychological function in HIVinfected HAART-treated patients. Neurology 2006; 66: 1447 – 50.
- 54 Basso M ,Bornstein R ,Lang J Practice effects on commonly used measures of executive function across twelve months . ClinNeuropsychol 1999 ; 13 : 283 92 .
- 55 .DikmenS HeatonR GrantI Timkin N Test-retest reliability and practice effects of expanded Halstead-Reitan neuropsychological test battery. JInt Neuropsychol Soc 1999; 5: 346 56.
- 56 Hwell D Statistical Methods for Psychology. 5thed. Pacific Grove, California : Thomson Learning ; 2002 .
- 57 Woods SP, Childers M, Ellis RJ, Guaman S, Grant I, Heaton RK. A battery approach for measuring neuropsychological change. ArchClin Neuropsychol 2006; 21: 83 9.
- 58 Basso MR , Carona FD , Lovery N , Aclrod BN Practice effects on the WAIS-III across 3- and 6-month intervals . ClinNeuropsychol 2002 ; 16:57-63 .
- 59 Fileti MG ,Maruff P, Collie A ,Darby DG Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals. JClin Exp Neuropsychol 2006 ; 28 : 1095 112.
- 60 BornsteinRA Bakr GB DouglassAB Short-termretest reliability of the Halstead-Reitan battery in a normal sample . JNerv Ment Dis 1987 ; 175 : 229 32 .
- 61 .CatronDW, ThompsonCC Est-retest gains in WAIS scores after four retest intervals . JClin Psychol 1979 ; 35 : 352 7 .
- 62 DodrillCB Toupin AS Effects of repeated administrations of a comprehensive neuropsychological battery among chronic epileptics. JNerv Ment Dis 1975; 161: 185 – 90.

- 63 Æmkin N HeatonR GrantI DikmenS Detectingsignificant change in neuropsychological test performance: a comparison of four models. JInt Neuropsychol Soc 1999; 5: 357 69.
- 64 Collie A ,Maruff P, Darby D ,McStephen M The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. J Int Neuropsychol Soc 2003; 9:419 28.
- HeatonR #mkin N DikmenS etal .Detectingchange: a comparison of three neuropsychological methods, using normal and clinical samples
 Arch Clin Neuropsychol 2001 ; 16 : 75 91 .
- 66 Rabbitt P, Diggle P, Holland F, McInnes L Practice and drop-out effects during a 17-year longitudinal study of cognitive aging. JGerontol B Psychol Sci Soc Sci 2004; 59B: 84 – 97.
- 67 Duff K Westervelt H McCaffrey R Haase R Practice effects, test-retest stability, and dual baseline assessments with the California v erbal learning test in an HIV sample . Arch Clin Neuropsychol 2001 ; 16 : 461 76 .
- 68 Duff K Bglinger LJ SchultzSK etal .Practiceeffects in the prediction of long-term cognitive outcome in three patient samples: a no vel prognostic index Practice effects, test-retest stability, and dual baseline assessments with the California v erbal learning test in an HIV sample . ArchClin Neuropsychol 2007 ; 22 : 15 – 24 .
- 69 McCaffrey R Westervelt H Issuesassociated with repeated neuropsychological assessment. NeuropsycholRev 1995; 5: 203 – 21.
- 70 .SacktorNC Isles RH Stalasky RL etal .Combinationantiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men . Neurology 1999; 52: 1640 – 7.
- 71 Zger SL ,Liang KY .Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986 ; 42 : 121 – 30 .
- 72 .DigglePJ LiangK Zger SL Analysis of Longitudinal Data . Oxford; New York: Oxford University Press ; 2002 .
- 73 JacobsonN,S. , Tuax P Clinical significance: a statistical approach to defining meaningful change in psychotherapy research . JConsult Clin Psychol 1991 ; 59 : 12 – 9 .
- 74 . CollieA DarbyDG Falleti MG SilbertBS Maruff P Determining the extent of cognitive change after coronary surgery: a review of statistical procedure . AnnThorac Surg 2002; 73 : 2005 11 .
- 75 Levis MS Maruff P, SilbertBS Exred LA ScottDA Theinfluence of different error estimates in the detection of postoperati ve cognitive dysfunction using reliable change indices with correction for practice effects. ArchClin Neuropsychol 2007 ; 22 : 249 57 .
- 76 McSween AJ NaugleRI CheluneGJ LudersH "Tscores for change": an illustration of a regression approach to depicting change in clinical neuropsychology . Clin Neuropsychol 1993 ; 7 : 300 – 12 .
- 77 MollicaC Maruff P, Vince A Development of a statistical approach to classifying treatment response in individual children with ADHD. HumPsychopharmacol 2004; 19:445 56.
- 78 Leine AJ HinkinCH MillerEN Beckr JT, SelnesOA, CohenBA Thegeneralizability of neurocognitive test/retest data derived from a nonclinical sample for detecting change among two HIV+ cohorts. JClin Exp Neuropsychol 2007 ; 29 : 669 – 78.
- 79 FerrandoSJ RabkinJG an Gorp WG LinS-H McElhing M Longitudinal improvement in psychomotor processing is associated with potent antiretroviral therapy in HIV-1 infection. JNeuropsychiatry Clin Neurosci 2003; 15: 208 – 14.
- 8 0 ozzi V, BalestraP, GalganiS etal .Positive and sustained effects of highly active antiretriviral therapy on HIV-1 associated neurocognitive impairment . AIDS 1999 ; 13 : 1889 – 97 .
 - 81 . Cohei R , Boland R , Brul R et al . Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women . AIDS 2001 ; 15 : 341 5.
 - 82 . RoberstorK ,Roberston TW, Frd S et al . Highly active antiretroviral therapy improves neurocognitive functioning . JAcquir Immune Defic Syndr 2004 ; 36 : 562 6 .
- 83 . Ferrand**S** Yan Gorp W, McElhing M GogginK Swell M RabkinJ Highlyactive antiretroviral treatment in HIV infection: benefits for neuropsychological function . AIDS 1998 ; 12 : F65 70 .
- 84Cysique L Maruff P, Brev B Prevalence and pattern of neuropsychological impairment in HIV/AIDS-infection across pre and post- highly active antiretroviral therapy eras: a combined study of 2 cohorts. JNeurovirol 2004 ; 10 : 350 7.

- 85. Sackton McDermott MMarderK et al. HIVassociated cognitive impairment before and after the advent of combination therapy. JNeurovirol 2002; 8: 136 42.
- 86. Beek JT, LopezOL Dev MA AizensteinHJ Prevalence of cognitive disorders differs as a function of age in HIV virus infection . AIDS 2004; 18: S11 18.
- 87. Chernel EllisRJ LazzarettoD etal .Efects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings . AIDS 2004 ; 18 : S27 – 34 .
- 88. alkour V, ShikumaC Watters M etal .Higherfrequency of dementia in older HIV-1 individuals. The Hawaii aging with HIV-1 cohort . Neurology 2004 ; 63 : 822 7 .
- HinkinCH , Cummings JL am Gorp WG , Mitrushina M Erontal-subcortical features of normal aging: an empirical analysis . CanJ Aging 1990 ; 9 : 104 – 19 .
- 90.Valcour V, Rul R HIV infection and dementia in older adults. Clin Infect Dis 2006; 42: 1449 54.
- Goodkik Wikie FL ConchaM etal .Agingand neuro-AIDS conditions and the changing spectrum of HIV-1 associated morbidity and mortality. JClin Epidemiol 2001; 54: S35 – 43.
- 92. MazauM DartiguesJF, LetenneurL etal . Visuo-spatial attention and psychomotor performance in elderly community residents: effects of age, gender, and education. J Clin Exp Neuropsychol 1995; 17: 71 – 81.
- 93 . MoorDJ MasliahE RippethJD etal .Corticaland subcortical neurodegeneration is associated with HIV neurocognitive impairment . AIDS 2006 ; 20 : 879 87 .
- 94. LiddeBJ Rul RH ArnsM etal .Ratesof decline distinguish Alzheimer's disease and mild cognitive impairment relative to normal aging: inte grating cognition and brain function . JIntegr Neurosci 2007; 6: 141 – 74.
- 95. Byte PA, Wison RS Aggarwal NT, Tang Y, BennettDA Mildcognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology 2006; 67: 441 5.
- 96 . Esir
MM ,BiddolphSC ,MorrisCS Prevalence of Alzheimer plaques in AIDS . J
Neurol Neurosurg Psychiatr 1998 ; 65 : 29 33 .
- 97 . GreeDA, MasliahE Jhters HV, BeizaiP, MooreDJ AchinCL Braindeposition of betaamyloid is a common pathologic feature in HIV positive patients. AIDS 2005; 19: 407 – 11.
- 98. Bree BJ Pemberton L Blennov K Jullin A Hagberg L CSFamyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology 2005; 65: 1490 2.
- 99. FinctCE Mogan TE Systemicinflammation, infection, ApoE alleles, and Alzheimer disease: a position paper. CurrAlzheimer Res 2007; 4 : 185 – 9.
- 100 .Beger JR NathA Greenbeg RN etal .Cerebrovascular changes in the basal ganglia with HIV dementia . Neurology 2000 ; 54 : 921 6 .
- 101 . Axison MJ NathA Beger JR Understandingpathogenesis and treatment of HIV dementia: a role for magnetic resonance . Trends Neurosci 2002 ; 25 : 468 – 73 .
- 102 . SelnesOA, Wheres HV Mascular cognitive impairment. NatClin Pract Neurol 20062;: 538 47.
- 103 .GogginKJ ZisookS HeatonRK etal .Neuropsychologicalperformance of HIV-1 infected men with major depression . JInt Neuropsychol Soc 1997 ; 3 : 457 64 .
- 104 .ChernerM LetendreS HeatonRK etal .HepatitisC augments cognitive deficits associated with HIV infection and methamphetamine . Neurology 2005 ; 64 : 1343 7 .
- 105 .ConchaM GrahamNM MunozA etal .Efect of chronic substance abuse on the neuropsychological performance of intravenous drug users with a high prevalence of HIV-1 seropositivity . AmJ Epidemiol 1992 ; 136 : 1338 – 48 .
- 106 . ConchaM SelnesOA , Vlaho D etal .Comparisonof neuropsychological performance between AIDS-free injecting drug users and homose xual men. Effect of chronic substance abuse on the neuropsychological performance of intra venous drug users with a high prevalence of HIV-1 seropositivity . Neuroepidemiology 1997 ; 16 : 78 – 85 .
- 107 . From DM ThomasHC Tylor-Robinson SD Centralnervous system involvement in hepatitis C virus infection . MetabBrain Dis 2004 ; 19 : 383 – 91 .
- 108 .CasatoM SaadounD MarchettiA etal .Centralnervous system involvement in hepatitis C virus cryoglobulinemia vasculitis: a multicenter case-control study using magnetic resonance imaging and neuropsychological tests. JRheumatol 2005 ; 32 : 484 8.
- 109. Mogello S EstanislaoL RyanE etal .Efects of hepatic function and hepatitis C virus on the nervous system assessment of advanced-stage HIV-infected individuals. AIDS 2005; 19 (Suppl: S116 22.

- 110 .Perry W, Carlson MD ,Barakat F, et al .Neuropsychological test performance in patients co-infected with hepatitis C virus and HIV. AIDS 2005 ; 19 (Suppl S79 84 .
- 111 .RyanEL Mogello S IsaacsK NaseerM GeritsP Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 2004; 62: 957 – 62.
- 112 . Wissenborn K KrauseJ Bokmeyer M etal .HepatitisC virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy . JHepatol 2004; 41: 845 51.
- 113 .GrantI MarcotteTD HeatonR Neurocognitive complications of HIV Disease . Psychol Sci 1999 ; 10 : 191 – 5 .
- 114 .Hilsabeck RC Castellon SA Hinkin CH Neuropsychological aspects of coinfection with HIV and hepatitis C virus . ClinInfect Dis 2005 ; 41 (Subpl S38 44 .
- 115 .MartinEM Noak RM FendrichM etal .Stroopperformance in drug users classified by HIV and hepatitis C virus serostatus . JInt Neuropsychol Soc 2004 ; 10 : 298 300 .
- 116 .RobertsonKR KapoorC RobertsonWT, FiscusS Frd S HallCD Nogender differences in the progression of nervous system disease in HIV infection. J Acquir Immune Defic Syndr 2004 ; 36 : 817 – 22 .
- 117 .Chiesi A , Ila S , Dally LG et al .Epidiemology of AIDS dementia complex in Europe. HNRG Group. HIV Neurobehavioral Research Center. J Acquir Immune Defic Syndr Hum Retrivirol 1996 ; 11 : 39 – 44 .
- 118 . Wyjna V, Skolasky RL Hechnarria R etal .Prevalence of human immunodeficiency virusassociated cognitive impairment in a group of Hispanic w omen at risk for neurological impairment . JNeurovirol 2006 ; 12 : 356 – 64 .
- 119 .DobsAS Dempsy MA LandesonPW, PolkBF Endocrinedisorders in men infected with human immunodeficiency virus . AmJ Med 1988 ; 84 : 611 6 .
- 120 .BashinS BremmerW Emeging issues in androgen replacement therapy. JClin Endocrinol Metab 1997 ; 82 : 3 - 8 .
- 121 .Laudat A BlumL GuechotJ et al .Changes in systemic gonadal and adrenal steroids in asymptomatic human immunodeficiency virus infected men: relationships with CD4 cell counts . EuropJ Endocrinol 1995 ; 133 : 418 – 24 .
- 122 .Raff F, Brisseau J, Remi J, Barrier J, Grolleau J Endocrine function in 98 HIV-infected patients: a prospective study. AIDS 1991 ; 5 : 729 33 .
- 123 .Sinha-HikimI Arer S BeallG etal .Theuse of a sensitive equilibrium dialysis method for the measurement of free testosterone levels in healthy, cycling women and in human immunodeficiency virus-infected women . JClin Endocrinol Metab 2001 ; 83 : 1312 – 8.
- 124 . RabkinJ Wagner GJ RabkinR Adouble-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms . ArchGen Psychiatry 2000 ; 57 : 141 – 7 .
- 125 .Kopicko JJ Momodul AdedokunA Hoffman M ClarkRA Kissinge P Characteristics of HIV-infected men with lo w serum testosterone le vels. Int J STD AIDS 1999 ; 10 : 817 – 20 .
- 126 .FerrandoSJ RabkinJG Porestsk L Dehydropiandrosteronesulfate (DHEA) and testosterone: relation to HIV illness stage and progression o ver one year. J Acquir Immune Defic Syndr 1999 ; 22 : 146 – 54 .
- 127 .GrinspoonS CorcoranC Stanly T, BaajA BasgozN KlibanskiA Effects of hypogonadism and testosterone administration on depression indices in HIV -infected men. J Cln Endocrinol Metab 2000 ; 85 : 60 - 5 .
- 128 . RabkinJ Wagner GJ RabkinR Treatment of depression in HIV+ men: literature review and report of an ongoing study of testosterone replacement therapy. AnnBehavior Med 1996; 18: 24 – 9.
- 129 .RabkinJ Wagner GJ RabkinR Testosterone therapy for HIV+ men with and without clinical hypogonadism . JClin Psychompharmacol 1999 ; 19 : 19 – 27 .
- 130 .GrinspoonS CorcoanC AskariH et al .Efects of androgen administration in men with AIDS wasting syndrome. A randomized, double-blind, placebo controlled trial . Ann Intern Med 1998 ; 129 : 18 - 26 .
- 131 .GourasGK XuH GrossRS etal .Æstosterone reduces neuronal secretion of Allzheimer's beta-amyloid peptides . ProcNatl Acad Sci USA 2000 ; 97 : 1202 5 .
- 132 . Hogerørst E Williams J BudgeM BarnestonL CombrinckM Srith AD Serumtotal testosterone is lower in men with Alzheimer's disease . NeuroEndocrinol Lett 2001 ; 22 : 163 – 8 .

- 133 .HammondJ LeQ GoodyerC Geland M Jifiro M LeblancA Testosterone-mediated neuroprotection trough the androgen receptor in human primary neurons . J Neurochem 2001 ; 77 : 1319 - 26 .
- 134 .CholertonB GleasonCE Bakr LD AsthanaS Estrogenand Alzheimer's disease: the story so far. DrugsAging 2002 ; 19 : 405 - 27 .
- 135 .ZhaoL BrintonRD Selectestrogens within the complex formulation of conjugated equine estrogens (Premarin) are protecti ve against neurode generative insults: implications for a composition of estrogen therap y to promote neuronal function and pre vent Alzheimer's disease . BMCNeurosci 2006 ; 7 : 24 .
- 136 . Willace DR DodsonS NathA BoozeRM Estrogenattenuates gp120- and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function. Synapse 2006; 59: 51 - 60.
- 137 . Tzzi V, BalestraP, LorenziniP, et al . Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort . JNeurovirol 2005 ; 11 : 265 - 73 .
- 138 . Mcour V, Ye P, Williams AE etal . Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection-The Hawaii Aging with HIV Cohort. JNeurovirol 2006 ; 12 : 387 - 91.
- 139 .Cysique LA Brev BJ ,Halman M et al .Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inacti ve AIDS dementia comple x in highly acti ve antiretroviral therapy-treated patients. JAcquir Immune Defic Syndr 2005; 39:426-9.
- 140 . Seigny JJ , Albert SM , McDermott MP, et al . Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia . Neurology 2004 ; 63 : 2084 - 90 .
- 141 . Bandaru VV, McArthur JC, Sacktor N et al . Associative and predictive biomarkers of dementia in HIV-1-infected patients . Neurology 2007 ; 68 : 1481 - 7 .
- 142 . ShiramizuB Rul R , Miliams A etal .HIV proviral DNA associated with decreased neuropsychological function. JNeuropsychiatry Clin Neurosci 2007 ; 19 : 157 - 63 .
- 143 .CysiqueL Maruff P, Brev B Antiretroviral therapy in HIV infection: are neurologically active drugs important? ArchNeurol 2004 ; 61 : 1699 - 704 .
- 144 .Letendre S McCutchan J Childers M et al .Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. AnnNeurol 2004 ; 56 : 416 - 23 .
- 145 .Letendre S ,Marquie-Beck J ,Capparelli E et al . Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. ArchNeurol 2008 ; 65 : 65 - 70 .
- 146 .RiedelDJ Ardo CA McArthurJ NathA Therapy Insight: CNS manifestations of HIVassociated immune reconstitution inflammatory syndrome . Nat Clin Pract Neurol 2006 ; 2 : 557 - 65 .
- 147 .GrayF, BazilleC Adle-BiassetteH Mikel J MoulignierA Scravilli F Centralnervous system immune reconstitution disease in acquired immunodef iciency syndrome patients receiving highly active antiretroviral treatment. JNeurovirol 2005; 11 (Suppl 16 - 22.
- 148 . Whkataramana A , Perdo CA , McArthur JC et al . Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology 2006 ; 67 : 383 - 8.
- 149 .McCutchanA, W JW, RobertsonK etal .HIVsuppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. AIDS 2007; 21: 1109 - 17.

The Changing Face of HIV-Associated Cognitive and Neuropsychiatric Disturbance

Ron Cohen

Over 25 years have passed since the first descriptions in the weekly report of Centers for Disease Control and Prevention of five homosexual men in Los Angeles, California, with a rare pneumonia seen only in conjunction with weak ened immune systems (1). They turned out to be the f irst recognized cases of acquired immune d efficiency syndrome (AIDS (2, 3)). In addition to opportunistic infections and physical wasting observed in these early cases (4, 5), mental status changes were evident, with some patients showing severe functional impairments indicati ve of dementia (6–8) Since then, a remarkable number of scientific advances have occurred with respect to the viral mechanisms underlying AIDS, its clinical e xpression, and available treatment approaches (9, 10). Despite these adv ances, the possibility of de veloping brain dysfunction remains a major concern for people infected with HIV.

In this chapter, I have considered the neuropsychology of HIV from a historical perspective, reviewing the cognitive and neuropsychiatric disturbances that were first described prior to the availability of antiretroviral treatments through some of the major developments in the field to the present. This will be followed by discussion of some of the major f actors that influence the neuropsychological symptoms of HIV, as well as ho w the cognitive and behavioral effects of the illness relate to associated brain changes. The chapter concludes with discussion of some potentially important considerations for the future.

Clinical Cases

Three cases are presented below from the author's clinical experience. These cases illustrate the transformation in the neuropsychological manifestations of HIV that have occurred over the past 25 years.

R. Cohen (🖂)

Department of Psychiatry, Brown University ,Providence, RI 02903 rcohen@lifespan.org

Case 1 (1982): As a neuropsychology intern on the psychiatry consultation service at UCLA in 1981, I assessed my f irst patient with AIDS. At that time, HIV had not been recognized as the cause for AIDS, and in f act there was considerable disagreement over the v ery nature of the disease. The patient, a 36-year -old homosexual male was quite ill, with severe pneumonia, from which he was slowly resolving. He also had an unusual skin disorder that was being worked up for possible cancer. The nursing staff was quite concerned about his mental status and behavior. He was poorly oriented and had great difficulty maintaining his attention. He waxed and waned between periods of relative clarity and other periods in which he w as extremely disinhibited and emotionally labile. On several occasions, he undressed and was found wandering in the halls. An assessment w as conducted at bedside with great difficulty, in part because of the patient's circumstantial and tangential thinking and poor attentional capacity.

An evaluation was completed over the course of three separate days with results suggesting severe and global cogniti ve dysfunction (Modif ied Mini Mental Examination, MMSE = 15). However, his presentation was also remarkable in several ways. Although he had difficulty staying on task and e xpressing his thoughts in a coherent and fluent manner, his comprehension and v erbal reasoning abilities appear relatively intact. His performance on a test of confrontation naming was also only very slightly below expectancy, and he showed the ability to hold information in memory on recognition testing, though this was not consistent over time. In contrast, the patient showed severe impairments of learning and memory recall, along with severe impairments on almost e very measure of e xecutive functioning, including the Wisconsin card sorting test, Porteus mazes, trail making, the stroop interferencetest, and verbal fluency (controlled oral word association test, COWAT). His dementia is quite evident from his performance on clock drawing, and his copy and recall of a complex figure (see Fig. 1). He had difficulty in maintaining set on even the trail making A test. Performance w as even severely impaired on simple beha vioral inhibition tests, such as the Go-No-Go. Basic ADLs were impaired. Approximately 1 month after this e valuation was completed, the patient died of complications associated with a recurrence of pneumonia. At the time of his death, he sho wed severe wasting, with a body weight that was below 90 lbs.

Case 2 (1993): The patient, a 28-year-old woman with a history of injection drug use (heroin and cocaine), was referred for outpatient neuropsychological assessment. She was asymptomatic without an y prior AIDS-associated infection, b ut with impaired immune function (CD4 < 200). She was examined prior to the availability of combined highly acti ve antiretroviral therapy (HAART), but was being treated with an early re verse transcriptase inhibitor (zido vudine). She had stopped using injection drugs 2 years earlier and w as trying to return to emplo yment. However, she was experiencing great difficulty learning new information in the classes she was taking. She also reported problems with focusing on tasks and sustaining attention with considerable distractibility. Her family described her as being v ery apathetic. There was some concern about depression, though she denied sadness and most other depressive symptoms. The evaluation revealed that she was not demented on the MMSE (MMSE = 27), but was having mild problems with learning and recall,




Fig. 1 (**a–c**) are the drawings of Case 1; a patient with AIDS–dementia. The drawing depict a level of performance commonly seen in patients with middle-stage dementia (e.g., Alzheimer's disease) with strong evidence of frontal lobe dysfunction. (**a**) Copy of a complex figure was poorly organized with lack of attention to detail and spatial distortion; (**b**) clock drawing within a presented circle; performance is severely impaired; (**c**) rampart figures are impaired with evidence of both perseveration and breaks in response set

along with mild impairments on e xecutive measures (Stroop and T rail Making). The most notable finding was extreme slowing on motor tasks and also on cognitive tasks requiring information processing speed.

Case 3 (2005): The patient, a 49-year -old college educated homosexual male, underwent neuropsychological evaluation 2 years ago on the request of his physician who had noticed for getfulness and the patient's inability to recall certain current information and details of recent events in his life. The patient had been symptomatic with pneumonia secondary to AIDS 8 years before. His CD4 nadir had been below 100, and he had experienced a viral load of greater than 20,000 copies at the time. However, he was treated successfully with HAART and has consistently had CD4 levels of greater than 400 o ver the past 5 years as well as viral loads that were almost undetectable. He was admitted for increased forgetfulness that was affecting his work as an accountant. The e xamination revealed an MMSE = 27. He only recalled one of three w ords on short delay and no w ords on longer delay . He

showed impaired recall and recognition performance on the California V erbal Learning Test (CVLT). Motor slowing was evident, along with belo w average performance on attention and executive measures.

The Transformation of HIV-Associated Brain Dysfunction

The three cases described earlier assessed at dif ferent time points over the course of 25 years demonstrates the e volution of HIV-associated neuropsychological disturbance in the United States. It is some what ironic that as better treatments for AIDS became available, concern about the cognitive sequelae of HIV have increased. Treatments were not a vailable in early years of AIDS, and so mortality w as very high, with most patients dying within a few years of diagnosis. Dementia was quite common among patients who were symptomatic, though it usually w as not the primary concern, as the critical issue was to simply keep patients alive. By the mid to late 1980s a number of drugs became a vailable, and patients were beginning to survive longer with AIDS. Consequently, AIDS-associated dementia became increasingly prevalent. As treatments became more effective in the 1990s, a decline in cases of AIDS-dementia was seen, particularly following the advent of HAART in the late 1990s. Increasingly, patients were not de veloping the opportunistic infec tions associated with AIDS and were remaining largely asymptomatic. As it is discussed in greater detail subsequently, patients were presenting with less se vere cognitive problems, though continued reports of cognitive difficulties have remained. One key feature of the illness remains unchanged. Despite all of the available treatments and advances in the field, to date the infection is not curable. Once infected, people must live with the virus in their body, with a possibility of AIDS occurring at some later point. Consequently, people infected with HIV experience all of the psychological, social, and economic problems that go along with other chronic diseases. In sum, there has been a marked increase in the number of people infected with HIV reaching advanced age, who have lived with the infection for man y years. The effects of chronic HIV in the aging brain are yet to be fully understood, though there is reason to believe that these effects are continuing to evolve. In the following sections, factors that influence HIV-associated neuropsychological disturbances are discussed.

Mechanisms Underlying Brain Dysfunction

The neuropathology and mechanisms underlying brain dysfunction of HIV is reviewed in "Co-occurrence of HIV, hepatitis C, and substance use disorders: effects on brain functioning." A few key points have been highlighted that provides insights into its neurocognitive manifestations. Neuropathological studies have consistently demonstrated that HIV has a particular predilection for the basal ganglia and white-matter pathways (11–18). Why these selective regional neuropathological effects occur is not fully understood, though the virus seems to cross the blood-brain barrier most effectively in the parenchyma surrounding the basal ganglia. There is some evidence that gp120 associated with HIV alters the blood-brain barrier , which facilitates the central nervous system (CNS) penetration (19). The virus directly infects supportive cells of the brain, including mononuclear phagocytes such as microglial cells, astrocytes, and macrophages (20– 22)Strong evidence for viral replication within neurons does not exist, but markers of HIV have been found in neurons, microvascular endothelial cells, cells of the choroid plexus, and oligodendrocytes (21) .Once cerebral mononuclear phagocytes are infected, a paracrine-amplified inflammation occurs, which seems to persist throughout the infection (23). Cellular disturbances result, which appear to be associated with proinflammatory cytokines, (e.g., interleukin-8), nitric oxide, quinolinic acid, progeny virions, and re gulatory proteins (24). With ongoing viral replication in the brain, greater neuropathology develops.

HIV infection af fects the brain both directly and indirectly (25, 26). Brain abnormalities are considered to be directly caused by HIV if the y can be due to neuropathological factors attributable directly to the effects of virus in the brain. Alternatively, secondary brain abnormalities occur because of opportunistic infections, and other diseases develop as HIV infection progresses to AIDS. Evidence of direct CNS effects comes from cases in which there has been no opportunistic infection of the brain; yet there is significant neurocognitive impairment, not attributable to other neurological brain diseases. In such cases, there are often brain neuroimaging abnormalities evident by neuroimaging on MRI, as well as e vidence of HIV-RNA in the cerebral spinal fluid (CSF), and in brain tissue (27–29). Human and animal studies have both demonstrated that the virus can be detected in the brain within 2 weeks of initial infection, where it remains presumably until death (27, 29, 30). Elevated free calcium is thought to occur directly from HIV ef fects, such as the enveloping of proteins (e.g., gpl20), with calcium influx via ionic channels causing neuronal damage (26). Excitatory amino acids and receptor antagonists, such as quinolinic acid, also seem to play a direct role. Although all of the direct mechanisms underlying HIV neuropathology have not been resolved, there is compelling evidence that HIV infection directly disrupts normal brain functioning.

HIV infection also indirectly causes opportunistic infections, tumors, and cerebrovascular disturbances, which can produce dramatic brain dysfunction(25, 26). Both viral (e.g., JC virus (progressive multifocal leukoencephalopathy, PML), cytome-galovirus, herpes simplex) and nonviral infections (e.g., toxoplasmosis, cryptococcus) may occur (31–44). For example JC virus is associated with PML, a rapidly progressive and fatal disease that is characterized by the de velopment of multiple subcortical white-matter lesions (43, 45). PML causes severe cognitive impairment associated with the extensive white-matter pathology, and the prognosis of these patients is very poor. It is important to note that the overall impact of opportunistic infections is relatively minimal compared with the direct effects of the virus. The impact of HIV-1 on cognitive and behavioral functions cannot be fully accounted for by the secondary effects of opportunistic infections that affect the brain. In the era of new treatments for HIV, only a small percentage of HIV -infected individuals have secondary brain infections; yet neurocogniti ve dysfunction occurs in 30–87% of

infected individuals (46). They are less common now, though they still occur. For the most part, these infections are treatable and a majority of patients are no w able to recover (36). Yet, there continues to be reason for some concern as infections such as cytomegalovirus may induce T-cell-independent apoptosis in brain (47).

A retrospective autopsy study of HIV between 1988 and 1996 re vealed brain lesions in 79% of patients (48). Both focal and diffuse brain lesions were evident, with various types of pathology present, including multifocal myelin loss (21%), microglial nodules (18%), inf arcts-hemorrhage (15%), angiocentric pallor (6%), and calcification (5%). At a cellular level, multinucleated giant cells, macrophagic subcortical infiltration, myelin pallor, and gliosis may occur. Leukoencephalopathy (myelin loss, nucleated macrophages/microglia, reactive astrogliosis) is very common. Vacuolar leukoencephalopathy is associated with deep white-matter swelling. Damage to axons, myelin, and lar ge astrocytes may occur as either a direct ef fect of HIV and due to encephalitis or othersecondary infections. Vasculitis may develop in patients, and this is associated with increased risk of inf arctions secondary to hemorrhage in subcortical regions of the brain.

To summarize the above literature, brain function is compromised early in the course of the disease both directly through infection of macrophages and in some cases indirectly through opportunistic infections (49–54). HIV encephalitis occurs following the accumulation of peri vascular accumulations of microglia cells, monohistocytes, and macrophages. Leuk oencephalopathy often occurs follo wing diffuse myelin loss, proliferation of astroglial cells, and inf iltration by mono- and multinucleated macrophages (25–47).

HIV-Associated Neurocognitive Dysfunction

As discussed earlier, the prevalence and to some extent the nature of HIV-associated neurocognitive dysfunction has changed since AIDS was first recognized approximately 25 years ago and HIV was identified. It is likely that in the early days of the epidemic, a majority of patients may have eventually developed dementia if the y lived long enough, though most patients died prior to sho wing this degree of functional impairment. As treatments became a vailable, the prevalence of severe cognitive dysfunction declined, such that by the mid-1990s approximately 15% of patients with AIDS were diagnosed with dementia, though man y more seemed to have milder forms of cognitive dysfunction (55, 56). In the past, the prevalence of neurocognitive impairments was less in asymptomatic patients, though impairments occurred among patients with v ery impaired immune functions and sustained elevations of viral load (57). Currently, estimates of the prevalence of dementia and neurocognitive impairment vary depending on the criteria that are used for defining impairment. In the current NIH supported studies being conducted by my group in the Brown University Center for AIDS Research (CF AR), approximately 30% of HIV-infected patients have some cognitive impairments, though some what less than 5% have severe impairments that meet dementia criteria. These f indings are

consistent with rates described in multicenter studies of HIV-associated brain disease, suggesting that the incidence of AIDS–dementia in this country has declined from what was observed in the early years of the disease (7, 11, 58, 59).

HIV-associated dementia is diagnosed when there is e vidence of mark ed declines in function across more than one cognitive domain, along with evidence of functional deterioration affecting activities of daily living (ADLS) and self care. By definition, there must be evidence of significant declines from premorbid abilities. When first recognized among early cases, HIV -associated dementia differed substantially from the dementia associated with Alzheimer's disease (AD) and other cortical degenerative diseases (60). The neuropsychological profile associated with AIDS–dementia in volved impairments on measures of comple x attention, information processing speed, and verbal memory, and presented clinically as distinct from classic neurode generative dementias, such as Alzheimer's disease. As w as evident in Case 1, patients with dementia secondary to HIV tend to experience their dementia in the context of other AIDS symptoms. Many are physically ill and most have very compromised immune systems.

A large number of studies conducted over the past 20 years have supported the conclusion that the cogniti ve, behavioral, and functional presentation of AIDS -dementia differs from that of Alzheimer's disease and related neuronal dementias (56, 61–68). Tests sensitive to mental flexibility, motor and information processing speed, verbal fluency, and learning and memory recall tend to be affected (69, 70). This pattern is typical of "subcortical dementia," in which the neurocogniti ve presentation suggests functional disruption of subcortical-frontal brain systems (71–73). This differs from the severe primary amnesic disorder e vident in AD, in which there are usually also impairments across core cognitive functions (language, visual-spatial, conceptual abilities). The cogniti ve deficits found among patients with HIV-associated dementia tend to be greatest in the areas of informationprocessing speed and efficiency, attention-executive control, and psychomotor functions. The dominant finding is usually marked slowing on a variety of tasks that require rapid processing speed. With respect to learning and memory, impairments also differ from those seen in Alzheimer's and related cortical dementias. HIV -infected patients tend to have greatest problems with their ef ficiency for new learning and with retrieval of information from memory that has been learned. Y et, most patients continue to show the ability to store new memory, and often their recognition memory performance is stronger than recall, pointing to the f act that their primary memory systems (e.g., hippocampus) are more spared than is the case in Alzheimer's disease. In sum, most patients with dementia secondary to HIV do not exhibit primary amnestic disturbances.

While this "frontal–subcortical" pattern of impairment is most typical of AIDS –dementia, considerable heterogeneity in symptom presentation e xists, reflecting the variety of underlying neuropathology. Among some patients, se vere memory impairments affecting memory encoding and storage may e xist that are virtually impossible to distinguish from AD. In general, HIV –associated dementia differs from degenerative dementias such as AD with respect to temporal consistenc y. Patients with HIV are more likely to show significant variations in functional abilities

in association with their disease status. Yet, the functional impact of HIV-dementia is devastating, as patients experience major cognitive and behavioral problems that affect daily living.

Patients with dementia who have opportunistic brain infections are particularly variable in their cognitive presentation. Furthermore, their dementia severity often fluctuates with changes in their infection. Many patients show marked improvements as their brain infection resolves.

HIV-associated cognitive-motor disorder (CMD) is the diagnosis given to HIV-infected patients with milder functional impairments not meeting the criteria for diagnosis of dementia (53). The prevalence of AIDS–dementia complex (ADC) has declined since the introduction of effective antiretroviral therapies (50, 74, 75). Though less severe than dementia, CMD still often af fects daily functioning and quality of life (49– 54,65, 66, 76– 87)Mirroring AIDS–dementia, HIV-associated CMD tends to have greatest impact on attention, executive, and psychomotor functions (88–112). The most commonly observe ed finding involves slowing on tasks requiring rapid information processing and on tasks requiring motor or sensory-motor response. Such slowing is rather ubiquitous in HIV and can beobserved on a wide range of neuropsychological tests, including simple motor tasks (e.g., Finger Tapping, Grooved Pegboard), simple and choice reaction time, and more complex cognitive tasks that require information processing (e.g., digit symbol, trail making). I have briefly discussed past findings regarding impairments of specific cognitive processes and domains.

Reaction Time and Information Processing Speed

Although there continues to be a debate about the extent to which slowing of cognitive processes secondary to HIV accounts for the variety of impairments associated with HIV, there can be little doubt that it is among the most common impairments among HIV-infected patients (53, 88, 90, 93, 99– 101,103, 107, 113– 116) Furthermore, impaired reaction time and reduced information processing speed likely account for many of the impairments of attention and executive function (117–120). Cognitive slowing presumably reflects the effects of HIV on subcortical white and the basal ganglia, most notably the caudate nucleus. The caudate has been sho wn to be particularly vulnerable to HIV (95, 113, 121– 139).

Executive Functioning and Attention

When neuropsychological functioning is impaired, the cogniti ve domains most commonly affected are those of attention and executive functioning (6, 53, 65, 66, 78, 80, 84, 140– 142)Impairments of executive functioning and attention in HIV must be considered in the context of the psychomotor and information processing

speed deficits, as impairments in these domains in past studies often occur against the backdrop of cogniti ve slowing (116). Two primary f actors account for the effects of diminished speed of information processing on attention and executive control: (1) performance on attention and executive measures is often time dependent so that a person's scores on tests will be negatively affected by generalized slowing; and (2) slowed processing speed reduces the amount of information that can be handled at any given time resulting in diminished processing capacity and increased effortful demands on tasks requiring controlled focused attention (95, 114–116). In effect, reducing processing speed capacity tends to also reduce information processing efficiency, a necessary element of effective attention and executive control. The first factor can be partially controlled for by selecting tasks to assess these functions that do not require rapid processing and responding. However, the second factor is more critical as reduced processing capacity associated with cogniti ve slowing may affect performance on any attention and executive control task that is demanding enough to be sensitive to impairments in these domains.

Slowed cognitive processing does not account for all of the attention and e xecutive impairments that occur among people infected with HIV . Symptomatic patients who have not progressed to the point of AIDS–dementia may have problems with response initiation, inhibition, alternation, and control that extend beyond what can be explained by cognitive slowing. Furthermore, impairments of higher -order executive processes that involve problem solving, abstraction, and planning may also occur, and are difficult to explain solely on the basis of slowing. Several studies have demonstrated attention and executive impairments in humans and other HIV -infected primates that are not attributable to generalized slowing (89, 107, 116). Although severe impairments of executive functioning and attention that e xtend beyond the effects of slowing are not universal among all HIV-infected patients with CMD, they represent an important basis for functional impairments among some patients. Be yond the general effects of slowing, these attention and executive impairments are most likely attributable to disrupted frontal–subcortical pathways (65, 143– 150).

Psychomotor Functioning

It has long been recognized that man y HIV-infected patients show impaired performance on motor tasks when other cognitive functions are relatively intact (141). Typically this involves slowing on reaction time measures and tasks requiring fine motor speed and de xterity (e.g., Grooved Pegboard), though among some people impairments may in volve more substantial problems with motor control (58, 151) The presence of motor problems along with other cognitive problems is one of the key factors that distinguished AIDS-dementia from Alzheimer's disease and related dementias (53). Clinically, psychomotor slowing makes interpretation of more generalized cognitive slowing somewhat difficult, as it is difficult to disentangle slowing solely attributable to motor dysfunction from more pervasive slowing affecting information processing. Impaired psychomotor functioning is thought

to reflect the proclivity of the HIV to af fect basal ganglia systems, including the caudate and putamen.

Learning and Memory

Historically, primary amnesic disorders have been uncommon among HIV-infected patients. Even patients with AIDS-dementia do not sho w a failure to store new information similar to that seen in Alzheimer's disease. For example, the patient with AIDS-dementia who was described earlier (Case 1) had major impairments of new learning and encoding and poor recall of material that he had tried to learn. Yet, he had the ability to retain information once learned, and sho wed relatively intact recognition memory performance. Learning and memory performance were not significantly impaired among w omen in our CDC-HERS cohort, whereas performance on the tests of attention-executive functioning and psychomotor function (Grooved Pegboard) was reduced in HIV-infected patients, and worsened in those not treated with HAART (69, 152). This pattern of results corresponds with past evidence that at least in the past, HIV did not af fect hippocampal and related temporal lobe systems involved in primary memory. Instead learning and memory difficulties seemed to reflect dysfunction resulting from subcortical-cortical interactions (79, 121, 139, 153-156).

When learning and memory problems occur among patients with CMD, the y tend to involve learning efficiency and retrieval, particularly on tasks requiring the processing of large quantities of new or complex information that is difficult to organize (e.g., California Verbal Learning Test, Complex Figure Test). However, other problems with specific processes associated with learning and memory have also been described. For example, working memory is often af fected in patients with CMD (137, 157, 158). Difficulties with semantic processes and priming associated with learning and memory have also been described (159). Yet, problems with semantic memory are not al ways evident (137, 157, 160) and relate more to e xecutive dysfunction than to memory encoding or storage per se when they occur (161). It should be noted however that there is recent evidence that in the current era of HAAR T, HIV may be causing greater hippocampal damage and hippocampal-associated memory impairments. Moore et al. found that hippocampal and putamen microtub ule-associated protein and synaptophysin in the hippocampus and putamen, reflecting neuronal cell body, dendritic, and presynaptic terminal health, were independently associated with overall HIV-associated neurocognitive impairment (87, 162-164).

Language

Primary language functions tend not to be greatly af fected in HIV (53, 165–168), except in some cases of advanced ADC. It is rare to encounter a patient with severe aphasia. Yet, problems with v erbal fluency are common, often e videnced by

reduced performance on the COWAT, with deficits on this test typically associated with executive dysfunction involving impaired response generation and persistence (168). Performance on verbal fluency for "action" words has even been shown to predict dependence of instrumental ADLs (159). Language-related problems involving semantic processing (e.g., semantic priming) also seem to often relate to executive dysfunction (158, 160, 167, 169). Yet, some studies have shown semantic impairments attributable to reduced acti vation of automatic semantic netw orks, particularly in children (170). The more mark ed impairments of psychomotor , attention, and executive functioning may mask more subtle ef fects of HIV on language functioning in the developing brain (87, 162–164).

Visual Functions

Primary visual perception and visual–spatial functioning are usually not se verely impaired by HIV (66, 171–176). Yet, past studies ha ve shown abnormalities of certain visual functions (173, 175–177). Abnormal visual contrast sensiti vity and color detection may occur (173, 175–177). Visual abnormalities ha ve tended to involve ocular abnormalities, as well as problems associated with ocular movement (66, 172, 174). However, problems with visual selective attention under dual-task or other demanding conditions also occur , and may account for some of the observed problems with primary visual perception (110).

The Importance of Preserved Neurocognitive Function

Besides the fact that cognition is a core element of the human e xperience, there is now considerable e vidence that preserving cogniti ve integrity is important for health, functional status, and o verall quality of life. HIV-infected patients without dementia who have milder cognitive impairments usually continue to function independently in their community, though often with much greater difficulty. Even mild neurocognitive effects have health ramifications. Clinical evidence suggests that patients with even mild neurocognitive impairment have an increased risk of mortality, and identification of mild neurocogniti ve disturbances may also be important in predicting disease course. Early HIV-associated cognitive impairments, specifically psychomotor slowing, is associated with an increased risk of mortality at a 3.5-year follow-up (110, 142, 178, 179). Patients with only a 25% reduction in processing speed have been found to be at 6.4 times the risk of mortality compared with those at the 75%. Psychomotor slowing in HIV infection has also been found to be a particularly strong predictor of subsequent dementia and death (180).Therefore, treating these neurocognitive impairments may have critical ramifications for overall health outcome. P atients with CMD are more likely to benefit from behavioral interventions to improve their functional capacity, and early detection of such impairments might ultimately enable interventions to prevent dementia.

Neurocognitive impairments have adverse effect not only on health status (181), but also on quality of life (OOL) and functional capacity (182). Support for this comes from a large number of studies involving a wide range of different medical disorders, such as heart disease (74). We have found that among HIV -infected women, neurocognitive performance was a strong correlate of OOL(50, 75). In this study of 44 HIV -infected women enrolled in psychosocial support groups, we examined neurocognitive functioning, along with depression severity, quality of life (MOOL-HIV), and immune function status (CD4). We found that neurocognitive status was strongly associated with QOL, measured by the MQOL-HIV (R = 0.60, p < 0.01) and perceived health status as measured by the SF-36 (R = 0.56), accounting for more variance than CD4 and depression se verity, though depression se verity contributed additional variance. The results reinforced the functional signif icance of neurocognitive impairments in HIV. Other studies have found a similar relationship between neurocognitive status, QOL, and health status among HIV-infected patients (50, 74, 183– 185HIV-associated neurocognitive impairments are associated with the need for independent living capacity, occupational performance, and ability to engage in ADLs (186). Recent findings suggest that in the current era of HAAR T, memory function may be an increasingly important predictor of ADLs, such as return to emplo yment, with youth also being an important f actor (187-195). Depression improved after return to work.

The Influence of Viral and Host Factors

Immunological Compromise

Efforts to characterize HIV-associated factors that contribute to the development of neurocognitive dysfunction initially led to the e xamination of markers of immune system disturbance. This was a logical starting point as HIV infection impairs the immune system, resulting in reduced CD4 cell count, and historically clinical outcome in HIV has been found to be associated with the integrity of immune system function (50, 61, 67, 134, 196–206).

Past studies have also shown a relationship between CD4 cell and neurocognitive functioning, as well as increased risk for dementia and cogniti ve abnormalities on EEG, MRI, and other indices of brain dysfunction(207, 208). This relationship was most obvious prior to the development of HAART. The risk of cognitive impairment associated with HIV is clearly greatest among symptomatic patients with AIDS who have CD4 cell counts belo w 200 (209). In one study, the risk of cogniti ve dysfunction was found to increase threefold in patients with CD4 counts below 200 mm³, and sevenfold among patients with CD4 counts below 100 mm³ (55) .We have observed the strongest association between neurocogniti ve performance and CD4 count among patients with CD4 levels below 100; with marked increases in impairment

the farther below this level, CD4 falls (53). There was also early evidence that rate of decline in CD4 was an important determinant of cognitive status (77, 204, 210–212).

Today a much more complex relationship exists between CD4 and neurocognitive functioning. Some studies continue to f ind reduced CD4 le vels to be associated with cognitive dysfunction, but others do not (213). There are several reasons for differences across studies: (1) the range of CD4 among patients in particular cohorts varies quite markedly; (2) the CD4 le vels used to group patients is often quite different; (3) CD4 nadir (i.e., lowest level of immune function during disease course), duration of CD4 suppression, and duration of infection vary across studies; (4) whether symptomatic patients are considered in a study; and (5) when treatments available at the time a particular study was conducted. In the post-HAART era, the relationship between CD4 cell count and cogniti ve impairment has become less clear cut. It is possible that plasma le vels of HIV-RNA and CD4 cell count may or may not fully reflect the de gree of viral suppression in the CSF, because of differential penetration of drugs across the blood–brain barrier.

While neurocognitive studies of impaired immune function ha ve primarily focused on the CD4, other lymphocytes have also been implicated in HIV infection, including CD8, CD14, CD16, and CD57. CD8 has been link ed to age-associated changes in T-cells (214), and both CD4 and CD8 appear to aggre gate in the brains of people with AIDS (215). Subsets of lymphocytes (e.g., CD8+CD57+) also occur in the context of viral infections, such as measles, which seem to be augmented in interaction with HIV (216). The significance of these lymphocytes with respect to HIV-associated neurocognitive function is still not fully understood, though.

Immune response genes (e.g., CCL5) have been identified, including CCL5, which remain upregulated throughout the course of HIV infection and over time can be found in infiltrating lymphocytes (217). These genes seem to affect multiple phenotypic responses and affect the brain during critical periods of viral and host interaction, likely damaging both immune cells and neurons in chronic infection. They also may play a role in linking T au protein, which has long been implicated in Alzheimer's disease to neuropathological brain changes in HIV (218). Accordingly, CD4 levels likely are only part of the story in accounting for brain changes secondary to HIV.

Although various issues remain unresolved regarding neurocognitive dysfunction in the context of immune system suppression, several conclusions can be reached:

- 1. Asymptomation with CD4 levels greater than 400 or 500 cells/ml typically have little cognitive impairment that can be attributed to HIV after other factors are accounted for.
- 2. Patients with CD4 levels below 100 are much more likely to have impairments.
- 3. When CD4 drops below 200 cells, a curvilinear relationship seems to e xist; as levels approach 0 cells, there is a mark ed increase in impairments. Greatest impairments occur among patients whose CD4 levels have fallen below 50.
- 4. (4) Both CD4 nadir and the duration of immunological suppression may be impotant factors that influence the likelihood that cognitive impairment will occur.

Viral Load and Neurocognitive Functioning

While CD4 cell count pro vides an index of immunological health, the b urden of HIV is ultimately a function of viral load, measured by the number of copies of virus detected in the blood plasma or cerebral spinal fluid (209, 219) Historically, plasma viral load was shown to be associated with the development of symptoms and HIV prognosis. Patients with plasma HIV-RNA > 50,000 copies/ml have 12–18 times the risk for developing and dying from AIDS than do patients with reduced viral load. Relative risk markedly increases between 500 and 50,000 (220, 221).

Plasma viral load prior to the initiation of antiretro viral therapy is associated with subsequent neurocognitive decline and the de velopment of AIDS–dementia (222). McArthur et al. e xamined over 1,600 patients from the MA CS cohort with baseline serum viral load collected o ver a decade ago (223). Plasma viral loads of greater than 50,000 copies/ml were predicti ve of subsequent dementia, with a relative hazard of 9.1 compared with those patients with viral loads of less than 500. Patients with lower CD4 cell counts at baseline also had increased risk for developing dementia. Similar findings have been reported by other groups (211). In sum, past studies suggested that sustained ele vated viral load and chronically suppressed CD4 levels predict subsequent functional status (224). However, there is evidence that this association may have changed in large part because of sustained viral suppression secondary to HAART.

HIV infection of the brain is characterized by replication of viral RN A in the CSF, as well as rapid turnover, suggesting that the CNS effects are caused by rapidly proliferating cells (67, 126, 221, 225– 234) Viral load measures taken from the CSF of HIV-infected patients provides one of the few ways of assessing HIV infection in the CNS, as direct brain biopsy is not generally feasible. The relationship between systemic CD4 cell count and plasma viral load and CSF viral load is complex, though, as one might expect, CSF viral load has tended to relate more strongly than plasma viral load with neurocognitive performance and the occurrence of AIDS–dementia (67, 234). The strength of relationship that is observed depends on (1) whether symptomatic or asymptomatic patients are examined, (2) the range of CD4 levels that are considered, and (3) the confounding v ariables that are controlled in a particular study. The CD4 threshold used to group patients appears particularly important. Also, results differ depending on whether plasma or CSF viral loads are analyzed. Strongest relationships between systemic and CNS viral load seem to e xist among patients with the greatest systemic viral load and impaired immune functions.

A relatively strong relationship e xists for patients with CD4 less than 200, whereas the relationship is weak for those with CD4 > 500. For example, when the relationship between cognitive performance and disease status as measured by CD4 cell counts, plasma, and CSF viral load w as examined in a study that grouped patients based on CD4 levels (<200, 200–500, >500 cells/mm³), CSF viral load, but not plasma viral load w as found to be a signif icant predictor of neurocogniti ve impairment. This relationship was particularly strong for patients with CD4 < 200 (235). Other studies have shown a significant relationship between HIV-RNA in the

CSF and severity of HIV-associated dementia and neurocognitive impairments in both adults and children (43, 48– 49,101– 106)McArthur et al. (58) found that HIV-RNA levels in CSF in the pre-HAART era were significantly higher in patients with dementia after adjusting for CD4 count (p < 0.01), whereas plasma levels did not correlate with the presence of dementia among these patients. There are some data suggesting that viral replication may occur in the brain even when it is suppressed systemically, as measured in the plasma viral load, as well as data suggesting that HIV in the CSF may be virologically dif ferent from HIV found in plasma, though these issues remain unresolved. Perhaps, a more critical issue stems from the f act that both cell-free plasma and CSF RN A levels are now typically well suppressed by HAART. This has led to the need to e xamine cell-associated viral b urden. Recent studies in HAART-experienced HIV-positive patients suggest no relationship between either plasma or CSF HIV -RNA levels and neurocognitive performance suggesting that HAART may attenuate HIV replication within the CNS (236).

Proviral DNA

In most patients, se veral months of HAART usually suppresses HIV-RNA to less than 50 copies/ml (237). Yet, there is considerable e vidence that HIV continues to replicate within cells, despite suppression of free virus, and that this may create a substantial b urden on the system over time (238, 239). Accordingly, quantitative methods were developed for measuring cell-associated "proviral" DNA among patients with HIV (240).

Against this backdrop, it is important that while incidence has declined, people continue to develop HIV-associated dementia despite HAART (241, 242). A significant relationship has been shown between levels of circulating provirus and HIV-associated dementia, not only in this country b ut in other parts of the w orld, where AIDS is less well-controlled (243). Recently, Shiramizu et al. demonstrated that circulating HIV proviral DNA is significantly associated with neurocognitive function as well (215). In fact, HIV-DNA levels correlated with performance across many different cognitive domains, including learning and memory, motor function, attention and working memory, executive functioning and language, independent of age, ethnicity, intellectual level, and plasma viral load. Yet, baseline HIV-DNA levels did not predict change in these cognitive functions over time. Therefore, it is lik ely that cognitive function varies in its relationship to changes in HIV proviral DNA over time.

Other Medical and Viral Conditions Exacerbate Brain Dysfunction

HIV infection almost always occurs against the backdrop of other medical conditions and preexisting exposure to other viruses. For example, the CD8+CD57+ interactions (244) that exist among patients with pre vious exposure to measles points to viral synergistic effects that may influence the effects of HIV on the brain. Hepatitis C virus (HCV) is a common coinfection occurring with HIV that af fects many infected patients, particularly those with history of intravenous drug use (IDU). HCV infection is characterized by chronic inflammation of the liver and development of hepatic cancer in many cases (245, 246). HCV has been associated with cognitive impairments and cognitive decline in its own right, with impairments extending beyond effects that can be attributed to comorbid medical and psychiatric conditions, adv erse effects of treatment effects, or hepatic cirrhosis by itself (247). Cortical electrophysiological changes have also been reported in this population, with HCV patients e xhibiting delayed P300 latencies, which correlated with the se verity of cognitive impairment (248, 249). Importantly, these cognitive changes were unrelated to treatment of HCV with interferon, a medication known to result in fatigue and cognitive compromise (53, 77, 134, 170, 185, 250–253). It is beyond the scope of this chapter to review the important interactions that may occur among HC, HIV, and other viruses (see "Co-occurrence of HIV, hepatitis C, and substance use disorders: effects on brain functioning"), though it seems clear that such conditions contrib ute to HIV-associated neurocognitive dysfunction, and likely augment the effects of HIV in the brain.

Symptomatic or Not?

One factor that consistently emerges as an important determinant of cognitive dysfunction among HIV-infected patients is whether they have been symptomatic with AIDS. There is little doubt that neurocognitive dysfunction is most common among patients who have been symptomatic and had CD4 le vels drop below 200 cells and been diagnosed with AIDS (66, 78, 212, 254), as discussed earlier. There are a number of reasons why cognitive dysfunction is more common among symptomatic patients. Opportunistic brain infections are more common among symptomatic patients. In fact, by definition such infections could not ha ve occurred in a patient considered to be asymptomatic. Furthermore, symptomatic patients are usually sick er and may experience functional problems as a result of systemic illnesses. Perhaps most importantly , symptomatic patients are lik ely to have experienced prolonged elevated viral loads with CNS penetration and severely impaired immune function, e xposing them to the direct effects of HIV on brain structural and functional inte grity.

The neuropsychological literature has been more ambiguous with respect to neurocognitive function among asymptomatic patients. In some studies conducted in the pre-HAART era, asymptomatic HIV-infected patients with CD4 cell counts above 200 were found to have impairments compared with seronegative controls (255). Yet, other studies have provided more mixed results. For example, in an initial well-controlled study of asymptomatic HIV-infected gay men, which controlled for various comorbid and demographic factors, Stern et al. found mild motor slo wing in the asymptomatic patients. Yet, in a subsequent study, Stern et al. again employed rigorous experimental control for age, education, and other clinical factors, and failed to show differences in sensitive information processing measures between asymptomatic HIV women compared with controls (77, 251). Similar findings of limited or no impair ments have been reported in other studies of asymptomatic patients (256). In a recent study comparing a lar ge sample from the MA CS cohort, there was no evidence of cognitive decline among the asymptomatic patients (257-259). Performance on two cognitive tests with kno wn sensitivity to brain functioning in HIV (Symbol Digit Modality Test, Trail Making Test) did not decline over an extended time period in three groups of asymptomatic HIV-infected homosexual men compared with serone gative controls. The results provide strong evidence that asymptomatic HIV-infected people can live for a relatively long time of period with low levels of HIV, without experiencing significant cognitive declines. By comparing three asymptomatic HIV patient subgroups, evidence is provided that etiological f actors, including the absence of recurring elevated HIV-RNA levels, lack of progression to AIDS, and preserv ation of CD4 above 200 cells/ul, are important for preserving cognitive function. Whether these results hold for patients who ha ve had more variable patterns of CD4 and viral load over time are still an open question, as well as the outcome for these patients as they reach more advanced age.

Chemokines and Inflammatory Processes

One of the presumed mechanisms by which HIV results in brain dysfunction is through the triggering of inflammatory processes in immunological response to the virus. Inflammatory processes are mediated by a v ariety of biochemical events in response to viral infiltration, including the release of chemokines, which mediate white-blood-cell activity (260). Chemokines such as CCRC5, CCR3, and CXCR4 serve as important cofactors, which in association with CD4 cells control the entry of HIV into target cells (211, 261–265). Cytokines, which are present in cerebral microglia and astrocytes, are believed to be important in the de velopment of neuropathological brain changes, neuronal dysfunction, including apoptosis and HIV-associated cognitive decline (266, 267). Cytokines generated in response to virus in the brain(21) are thought be an important actor underlying HIV-neurocognitive dysfunction (268). Various cytokines have been implicated, though MCP-1, MIP-18, and TNF- α appear particularly important, as these c ytokines correlated strongly with cognitive function in a large cohort of HIV patients (269). Further, a recent study conducted by the A CTG demonstrated subtle improvement in grooved pegboard function among HIV patients treated with CP1189, a compound that inhibits TNF- α , though no other cognitive benefits were observed (269, 270, 271). Strong relationships between elevated TNF levels and severity of cognitive function, and brain atrophy and brain metabolite abnormalities have been described in other studies as well in the pre-HAART era (272), providing further evidence for the role of c ytokines in HIV-associated brain dysfunction. However, a recent study in HAART-experienced patients found no relationship between either CSF or plasma immune acti vation markers and HIV-dementia, again suggesting an attenuated CNS inflammatory response in HAART-experienced HIV-positive patients (236).

Cognitive Reserve May Provide Some Functional Protection

The construct of cognitive reserve was developed to explain the clinical observation that people with strong premorbid cognitive abilities seemed to have greater preservation of neuropsychological functioning following brain injury (273, 274). Evidence for this phenomenon came from studies of Alzheimer's disease (275). Both educational and occupational attainment reduced AD risk. Both environmental and innate factors seem to contribute to cognitive reserve. Cognitive reserve also seems to influence neuropsychological status in HIV (272). Stern et al. found that well-educated people (>12 years) have less HIV-associated neurocognitive impairment (15.8%) than less well-educated people (38.1%). When a cognitive reserve score was derived based on demographic and clinical f actors, patients with the lo west scores had the greatest functional impairment.

Cognitive reserve implies that people ha ve different capacities to withstand functional decline in the context of the amount of brain injury, and there may be a number of reasons for this. Cognitive reserve presumably reflects cognitive and/or brain capacity, which in turn sets the threshold for neurocognitive dysfunction after brain injury (276, 277). The fact that cognitive reserve is associated with educational and occupational attainment may either point to the benef its of en vironmental enrichment. Alternatively, greater educational and occupational accomplishment reflects stronger premorbid cognitive abilities and greater intrinsic functional brain capacity. This second possibility is supported by the evidence that cognitive reserve is associated with increased brain size and weight, increased dendritic arborization and length, and improved neuronal efficiency. Genetic predisposition also influences neuronal development and ultimately the amount of brain reserve that exists. Prior brain injuries or disease, and de velopmental brain disorders that af fect brain functioning, may also reduce this reserve. For example, prior stroke and head injury have been shown to be risk f actors for the development of AD. Also psychiatric problems such as chronic substance abuse, affective disorder, or schizophrenia may reduce reserve. Clinically, it may be e xtremely difficult to disentangle the e xact basis for reduced cogniti ve reserve among HIV-infected patients with multiple comorbidities, which may include psychopathology , substance ab use problems such as chronic injection drug use, prior head trauma, and neurological conditions, together with effects of limited education and environmental impoverishment.

Psychiatric Comorbidity in HIV

It is well recognized that certain comorbidities common among people infected with HIV affect neurocognitive and functional status in their own right, perhaps in part by reducing cogniti ve reserve. That HIV and psychiatric comorbidity often interact to affect behavior has made this an important area of in vestigation (278). Among the most significant psychiatric comorbidities among HIV-infected patients are substance abuse and major depression. When considering psychiatric comorbidity among patients with HIV it is important to distinguish between long-standing psychopathology predating the HIV infection vs. conditions that have developed after infection. Furthermore, psychiatric and behavioral problems that have developed following infection with HIV or the occurrence of AIDS may either represent a response to associated stress, uncertainty , and emotional pain, or may represent a direct neuropsychiatric manifestation of HIV in the brain. I have briefly discussed some of these distinctions in relationship to particular types of psychopathology in the sections that follow.

The Significance of Substance Abuse

One of the most common comorbid conditions associated with HIV is substance abuse, in particular IDU of opiates, cocaine, and methamphetamine. This is due in large part to the fact that IDU is the major mode of HIV transmission besides sœual activity. The proportion of patients having current or past substance abuse histories varies across clinics, though typically the y represent a sizeable number of the patients in most centers. The proportion of cases of HIV-infected people with IDU histories has increased in recent years lar gely due to greater success in pre vention of HIV through se xual activities. In our clinical setting, approximately 50% of cases have a history of IDU. Of this group, about 80% had heroin IDU, though the drug of choice varies greatly across the country.

The effects of substance abuse in the context of HIV are complex and difficult to disentangle fully, in part because effects differ depending on the drug of abuse. There is a little doubt that during acute periods of intoxication, people using opiates, alcohol, and other drugs of abuse experience diminished cognitive performance. For example, chronic cocaine use has been associated with brain dysfunction (279). However, the effects of chronic use are less clear cut and v ary depending on drug type. It is beyond the scope of this chapter to re view the research literature on this question, though there is strong e vidence that certain forms of long-term drug abuse are associated with chronic brain dysfunction, and chronic drug use can not be assumed as the basis of cognitive dysfunction among all past substance abusers (280).

Beyond the direct effects of drug of ab use on brain function, substance ab use tends to be associated with other beha viors that increase the risk of brain injury, including head trauma, poor health care utilization, and nutritional problems. Among patients enrolled in the Brown CFAR and HERS projects, we have found that those with current IDU had poorer adherence to HAAR T than those without current or past IDU. Furthermore, those with daily IDU had poorer adherence than those using less than four times a week, and patients with poly-substance ahuse had the poorest adherence. This observation is consistent with reports from other groups. Woods et al. found that while rates of viral suppression were similar among IDU and non-IDU patients after correcting for rates of HAART adherence, patients with current IDU had worse outcome, attributable to poorer adherence (163).

There is growing evidence that patients with severe poly-substance abuse problems fare the worse with respect to neurocognitive outcome. Our analysis of the Brown CFAR cohort has revealed that patients with active IDU (primarily heroin addiction) had weaker cognitive function than patients without substance ab use history. This finding is consistent with results from studies comparing HIV patients who are gay vs. injection drug users, with the IDU sho wing greater cognitive impairment prior to being symptomatic with AIDS (281, 282). In contrast, patients with former IDU involving a single drug did not differ greatly from those without IDU after controlling for age, education, and level of depression in our CFAR cohort. This observation is consistent with results from other studies that have found limited cognitive impairment among heroin addicts after detoxification (283–285).

The effects of chronic substance ab use on brain function appear to be more pronounced among HIV patients who have been poly-substance abusers. In our CFAR cohort, this subgroup sho wed poor neurocognitive outcome than did the others. Grant et al. have reported similar findings for people who abused multiple drugs. In a national collaborative study, greater cognitive impairments were observed on the Halstead Reitan battery among patients with poly-substance ab use problems immediately following treatment and after 3-month follow-up. This study suggested that while some long-term improvement occurred following successful abstinence, persisting impairments existed.

Major Depression

Problems with depression and emotional distress are e xtremely common among HIV-infected patients (283, 286–288), with the pre valence of concurrent major depressive diagnosis between 4 and 10% among patients diagnosed with HIV(289) The lifetime prevalence is estimated to be 22–45% (288, 290–292). A much larger proportion of infected patients have significant depressive symptoms, but have not been formally diagnosed with major depression, with estimates approaching 50% in our clinic. The risk of depression is elevated even among patients at risk for contracting HIV and also among people prior to being diagnosed first (290) ,and in the early stages of the disease, the prevalence of major depression in HIV-positive patients is similar to that of demographically similar HIV-negative individuals (288, 290, 293). It should be emphasized that people with HIV report a history of depressive symptoms prior to seroconversion (283). This suggests that many people who develop depression after diagnosis with HIV may be neurobiologically vulnerable to affective disturbance.

The likelihood of depression increases as the se verity of HIV illness increases (67, 294, 295), with a majority of patients (60–70%) reporting significant depressive symptoms over a 7-year period. As much as 20–30% of HIV -infected people with advanced disease experience severe depression (296–302). This is important given that patients with advanced HIV are 30 times more lik ely to commit suicide than are healthy controls, and depression has been implicated in as man y as 50% of suicides among HIV-infected people (276, 277).

Interactions of HIV and Depression

HIV and major depressive disorder (MDD) may interact in important w ays to affect disease progression (303–306). At a behavioral level, depressed patients have greater problems adhering to treatments (307–315). Poor treatment adherence has important implications, as beneficial effects from HAART appear dependent on sustained viral suppression and good clinical outcome (316–321). Failure to maintain adherence increases the possibility of treatment resistance and increased disease burden.

Depression and psychosocial stress has been associated with greater disease progression independent of adherence (322–338). While the extent to which the psychological state affects the viral replication in HIV is not resolv ed, there is a large body of research that demonstrates that it does have an adverse impact on immune system health (339–345). The mechanisms underlying this association are not fully understood, and considerable research effort has been focused on examining specific neurobiological factors. For example, studies have shown that cortisol may reduce immune system function by directly af fecting the CD4 cell or other lymphoc ytes (322). Antoni et al. (306, 346–353) demonstrated that immune reconstitution is preceded by a reduction in cortisol following psychotherapy and psychosocial intervention.

Overall, there is considerable e vidence that depression and psychosocial stress affect HIV-associated mortality and morbidity (354). There is e vidence that this association continues even in the HAART era (355), particularly with advanced age (356–358). On the other hand there is also evidence that the rates of depression are declining as a function of the availability of more effective treatments (358). Findings are mixed with respect to the association between depression and neurocognitive function in the HAART era. Some studies have suggested that these factors continue to be linked, and that improved neurocognitive function corresponds with decreases in depressive symptoms (359, 360), while others ha ve found either a weak er relationship between depression and neurocogniti ve function, or that the y are independent factors (361).

Neuropsychiatric Manifestations of HIV-Associated Brain Effects

The relationship between psychiatric comorbidity and HIV -associated brain dysfunction is made complicated by the f act that neuropsychiatric symptoms may occur as a direct result of the effect of HIV infection in the brain. These symptoms may occur early in the course of infection before o vert cognitive dysfunction or brain abnormalities are evident, and may mimic psychiatric symptoms that ha ve a more "functional" origin (283, 362–366). Because neuropsychiatric and behavioral problems may either reflect emotional and beha vioral response and adaptation to having a severe and stigmatizing disease or underlying brain disturbance, a careful assessment of the e volution of the psychiatric symptoms within the indi vidual patient is essential with an emphasis on determining prior history of depression or

other psychiatric conditions, as well as the immediate antecedents and psychosocial factors contributing to current symptoms.

Neuropsychiatric symptoms were relatively common among many of the patients with AIDS–dementia assessed in the early years of the epidemic (6, 364, 367). For example, the patient described earlier (Case 1) w as extremely disinhibited in his behavior. He would consistently try to remove his clothes while walking in the hospital corridors and w ould make inappropriate remarks to nurses and other patients on his unit. Furthermore, he sho wed evidence of pseudo b ulbar affect, characterized by rapid fluctuations in his e xpressed affect, and incongruence between his affective behavior and his described mood. This type of beha vioral presentation was not uncommon among many people with AIDS–dementia before treatments were available, and still occurs in a small subset of patients. Increased irritability and even agitation may also be observ ed. Apathy is among the most common neuropsychiatric manifestation of HIV, and was described in early studies of AIDS–dementia (91, 129).

Apathy

Symptoms of apathy, characterized by indifference, reduced motivation, and a lack of behavioral initiative continue to be common among HIV -infected patients (363, 368– 370)and may be attributable to several different factors in HIV (367, 369). Given that these symptoms also occur as a direct result of mood disturbance, the possibility of MDD needs to be given first consideration. However, patients without MDD may also describe apathy or e xhibit related behaviors. In such cases, the possibility of apathy as a neuropsychiatric manifestation of HIV in the brain should be considered.

That apathy should occur among HIV-infected patients is not altogether surprising considering the typical neurocognitive dysfunction associated with HIV, and the functional neuroanatomic systems known to be most vulnerable to the virus, most notably the basal ganglia (11, 371). The nucleus accumbens (N A) of the basal ganglia is of particular interest in this regard, as it is involved in the limbic regulation of mood, reward, and behavior. The NA is located adjacent to thehead of the caudate and has consistently been tied to the development of HIV-associated neurocognitive dysfunction. Neuropathology studies of the basal ganglia of patients who had HIV have indicated elevated viral load, along with the presence of gliosis and multinucleated giant cells (369). While caudate nucleus v olume has received the most attention, HIV aggre gates in other re gions of the basal ganglia, potentially affecting limbic structures, such as the NA.

Brain morphometric studies conducted by our group ha ve indicated the N A volume in HIV-infected patients; smaller NA volumes are associated with increased apathy (368). In contrast, caudate v olume was not significantly associated with apathy measured psychometrically. Apathy also w as associated with cogniti ve performance (69, 91, 129, 152, 367). Although apathy tends to be a symptom that affects work performance and other aspects of daily li ving, there is at least some

evidence that it may be less important than the broader constellation of MDD in accounting for quality of life among people infected with HIVHowever, NA volume is also significantly associated with clinical severity of MDD. Our findings regarding the NA are consistent with models of its role in emotional re gulation, as part of a broader frontal–striatal–limbic network (6, 372– 374).

Psychosis and Delirium

Severe psychopathology, such as psychosis and delirium, also occur among patients with HIV (372, 375–380). These symptoms are most common among patients with advanced disease who are symptomatic with AIDS (381–385) or as an adv erse reaction to pharmacotherapy (386).

Neurobiological Bases of Neuropsychiatric Symptoms

Apathy, depression, and other neuropsychiatric symptoms that occur secondary to HIV share much of the same pathophysiology that underlies HIV -associated neurocognitive impairments and brain dysfunction. As discussed earlier , limbic and mesolimbic areas are affected, including frontal–striatal systems, which raises the specter of dopamine dysregulation. Dopamine postsynaptic receptors are present in the basal ganglia, including NA. Laboratory animal studies have shown effects on dopamine regulation in both symptomatic and asymptomatic SIV-infected monkeys, with reductions in the dopamine metabolites homovanillic acid and 3, 4-dihydroxy-phenylacetic acid in the NA and other nuclei.

Various HIV-associated neuropathological processes may affect dopamine metabolism. For example, brain-derived neurotropic factor (BDNF) may play an important role. BDNF, a neurotrophin that appears to mediate CNS function and dysfunction (387), is widely distributed throughout the brain (388, 389) .BDNF has a number of important roles related to brain function as it influencesneurogenesis and neuronal survival and growth (390), and serves to both strengthen excitatory synapses and weaken inhibitory synapses (391–393). BDNF also enhances neuro genesis. Intraventricular infusion of BDNF results in an increase in neurons in the thalamus, septum, and basal ganglia. Notably, BDNF also regulates the release of dopamine in mesolimbic systems, and down-regulation of dopamine receptors occurs when BDNF is infused into NA (394), and BDNF levels are reduced by HIV (395). The fact that BDNF provides a link between dopamine regulation in the NA and basal ganglia and neuropathological effects of HIV in the brain makes it a factor for explaining how HIV may trigger neurobiological changes underlying neuropsychiatric symptoms such as depression and apathy.

Besides playing a significant role in neuronal function, BDNF levels also change in response to stress. Behavioral and physical stressors, such as immobilization and physical stress reduce BDNF le vels in the brain (396), whereas antidepressants increase BDNF indices (397), and BDNF delivery to the brain results in sprouting of serotonergic neurons in rats (398). It would be an oversimplication to focus entirely on BDNF, as disorders such as MDD are af fected by complex interactions involving the limbic hypothalamic pituitary adrenocortical axis in response to stress. These findings highlight the important role that BDNF plays in the regulation of mood and the symptoms associated with dysre gulation of this system. Such findings illustrate how BDNF and other factors of this type may become dysregulated in response to the psychosocial stress associated with living with HIV, and at the same time contrib ute to the neuropsychiatric presentation. In light of the comple x interrelationship between HIV -associated neuronal changes and the functional neuroanatomic impact of HIV on brain systems involved in emotional and behavioral control, along with the fact that living with HIV is associated with tremendous psychosocial stress and emotional challenge, it clear that careful assessment of neuropsychiatric status is essential for patients infected with HIV, and much more research is needed to fully understand these associations.

HIV in the Era of HAART

Effective treatment of HIV with combined therap y involving HAART was first reported in 1998 (9, 399–401). An essential feature of these treatments is the combined use of medications. HAAR T has proven to be remarkably effective in reducing plasma viral load to undetectable limits, increasing CD4 levels, preventing opportunistic infections from developing and greatly reducing AIDS-related mobidity and mortality (402–409). Until 1996, only a small percentage of infected patients were treated with combined therapy consisting of drugs that constitute HAART. For example, no participants of the CDC-HERS study were HAART-treated, and about half of the cohort w as HAART naïve by the f inal follow-up evaluation. In our Center for AIDS Research at Bro wn University, about 15% of ne wly referred patients are on HAART prior to their first clinic visit, but among patients followed in the clinic the percentage approaches 85%.

It is now well established that at least over the short-term HAART markedly reduces systemic viral load and that with sustained viral suppression, immune functionsrecover as well (410–415). However, there was initially greater concern over whether HAART would produce CNS benefits, in part because early studies suggested that nucleoside analogs crossed the blood–brain barrier to only a limited extent (224). Furthermore, there is evidence of rapid turno ver of the virus in the brain (221, 228, 236, 416–418). Fortunately, subsequent studies found that CSF viral load is reduced in patientstreated with HAART (419). Overall, recent studies have shown a reduction in CSF HIV-1 RNA levels, often to below detectable limits, with combinations of antiretroviral medications. In this context, there is also growing evidence that HAART improves survival associated with CNS opportunistic infections and diseases (221, 225, 230, 416, 420). These findings are encouraging, though it is possible that HIV-1 RNA in the CSF does not fully

reflect levels in actual brain tissue. Some patients seem to sho w persistent virus in the CNS and brain disturbances even with sustained treatment (53, 421–423).

HAART Improves Cognitive Function

Studies have also shown that HAART improves cognitive function (53). Our group examined a large cohort of women enrolled in the CDC-HERS study (423). Women who received HAART exhibited no decline in cognitive function. By contrast, women who did not receive HAART exhibited significant declines on tests of psychomotor speed and memory. Other groups ha ve reported similar f indings. Ferrando et al. examined 130 men with HIV on measures of attention, concentration, psychomotor speed, learning, and executive function (422). Individuals taking HAART exhibited lower viral loads, higher CD4 cell counts, and they performed better on most cognitive tests. Tozzi et al. prospectively examined 116 patients with advanced HIV (57, 122, 424–427). In this study , the pre valence of neurocognitive impairment decreased from 81 to 50% in the f irst 6 months of taking HAART, and then declined further to 22% after 15 months. Impro vements were greatest for information processing speed and verbal learning. Similar findings have been found in other recent studies of the neurocognitive effects of HAART (428), providing strong e vidence that HAART has been effective in reducing neurocognitive dysfunction in HIV.

Given these neurocognitive benefits of HAART, what are the costs of not being treated? It is some what difficult to do studies at this point in time to answer this question, given that most patients are treated with HAART when they have certain clinical criteria. However, data exist from the time period immediately following the advent of HAART. For example, in our analysis of the CDC-HERS cohort described earlier, women who were not treated with HAART showed a sharp divergence over time from those treated with HAART, with untreated patients worsening over time.

Even now, not all patients are treated with HAAR T, either because of problems tolerating the drugs or lack of adherence to treatment recommendations. Studies how that successful viral load reductions depend on adequate HAART adherence (429), and that when HAART is discontinued for 12 months, viral load returns to 1 evels similar to those seen in HAAR T-native patients (430, 431). Yet, heterogeneity in treatment response exists, and longer-term HAART-effects are still not well understood (432–434). Whether continuous HAART is required to prevent brain dysfunction is also unresolved; short-term treatment interruptions have produced accelerated CD4 declines and viral load increases in some studies (203). Postponing the initiation of HAART until CD4 drops to low levels may increase the likelihood of patients developing neurocognitive impairments, though conversely there is also some evidence that HAART use in patients with elevated CD4 levels may actually have detrimental effects on cognitive function (435, 436). Therefore, achieving optimal treatment outcome may be more complicated than that originally thought, although the b ulk of evidence to date suggests that failure to treat patients with compromised immune function and elevated viral loads tends to result in poor neurocogniti ve outcome.

Nosology of HIV-Associated Neurocognitive Disorders: 2007

In response to the changes that ha ve occurred in the prevalence and manifestations of HIV-associated neurocognitive dysfunction since the adv ent of HAAR T, the National Institutes of Health created a w orking group to critically re view the adequacy and utility of current def initions and diagnostic criteria and to identify the aspects in need of updating (437). The report provides a major view of the collective experience of the workgroup members with HIV-associated neurocognitive disorders (HAND). This nosology discusses the impact of comorbidities, and suggests inclusion of the term asymptomatic neurocognitive impairment to cate gorize

Table 1	Nosology of HIV	V-associated	neurocognitive	impairment	(437)

HIV-associated asymptomatic neurocognitive impairment (ANI)

Acquired impairment in two or more cognitive domains, with evidence of performance >1.0 SD below the mean for age- and education-appropriate norms on standardized neuropsychological tests

Cognitive impairment does not interfere with everyday functioning

Cognitive impairment does not meet the criteria for delirium or dementia

No evidence of another preexisting cause for the AHI

If prior ANI existed, but no longer does, a diagnosis of ANI in remission is made

Diagnosis deferred for patients with major depression or substance ab use on examination *HIV-associated mild neurocognitive disorder (MND)*

HIV-associatea mila neurocognitive aisoraer (MND)

Acquired impairment in two or more cognitive domains, with evidence of performance >1.0 SD below the mean for age- and education-appropriate norms on standardized neuropsychological tests

Typically, impairment staging corresponds to an MSK scale stage of 0.5 to 1

The cognitive impairment produces at least mild interference in daily functioning (at least one of the following): (a) self-report of reduced mental acuity, inefficiency in work, homemaking, or social functioning; (b) observation by knowledgeable others that the individual had undergone at least mild decline in mental acuity with resultant inefficiency in work, homemaking, or social functioning The cognitive impairment does not meet the criteria for delirium or dementia

No evidence of another preexisting cause for the MND

Remission and comorbid psychiatric disturbance criteria similar to that for ABI

HIV-associated dementia (HAD)

Marked acquired impairment in at least two cognitive domains. Typically impairments involve multiple domains, especially in learning of new information, slowed information processing, and defective attention/concentration

The impairments must be >2 SD below average on neuropsychological testing

Correspond to an MSK scale stage of 2.0 or greater

The cognitive impairment markedly interferes with daily functioning

The impairments do not meet the criteria for delirium

No evidence of another preexisting cause for dementia, such as CNS infection, neoplasm, etc., or severe substance abuse compatible with CNS disorder

Remission and comorbid psychiatric disturbance criteria similar to that for ABI and HAND. However, if dementia persists after one month on remission of major depression, a reassess-

ment should be conducted to reassess for dementia

individuals with subclinical impairment. An algorithm is proposed to assist in standardized diagnostic classification of HAND. The resulting nosology dif fers from earlier classification systems in that a cate gory is now included for mild cognitive problems that are lar gely asymptomatic. The nosology also recognizes the significance of comorbid factors and builds this into an algorithm for clinical decision making.

As shown in Table 1, this nosology distinguishes among (1) mild asymptomatic neurocognitive impairments (ANI), (2) HAND, in which greater cognitive impairments are evident that have mildly adverse effects on daily living, and (3) HIV-associated dementia (HAD), in which significant functional impairments are evident. Patients who had experienced HAD at some point in the past, but are no longer demented, are classified as "in remission." The clinical algorithms provided with this updated nosology give guidelines for decision making re garding (1) cognitive impairment, (2) functional decline, (3) f actoring in comorbidities, and (4) alternative approaches when full neurodiagnostic assessment capabilities are not available (437). This nosology has considerable potential clinical v alue for the post-HAART era.

HIV and the Aging Brain

The prevalence of older HIV-infected patients is increasing (9, 438–440), as treatment advances have led to major reduction in the progression of HIV infection and significantly improved survival (441-444). Patients over 50 years of age account for an increasing percentage of cases, as the lifespan of HIV -infected people is approaching that of the general population (424, 445–449). Mounting clinical and laboratory evidence suggest a significant relationship between aging and HIV infection (450, 451). Senescence of the immune system occurs with advanced age, af fecting T-lymphocytes and blood monoc yte-derived macrophages (452). In T-cells infected with HIV (both CD4 and CD8), shortened telomeres occur with adv anced age (193, 453-460), and T-cells show reduced proliferation and interleukin-2 production in both HIV-infected and elderly people. Thymus production also decreases with both age and in HIV -associated immunological impairment, which lik ely contributes to age-HIV interactions. Opportunistic infections have age-related response in older patients as well(461). Another important issue is that reconstitution of the immune system after treatment also appears diminished with adv anced age (441, 443, 449, 462). Agerelated immunological changes lik ely affect functional outcome for older HIV-infected patients (455, 458, 459). Furthermore, risk for comorbidity also increases with age (463). Neuropathological changes secondary to HIV may induce oxidative and inflammatory processes in the brain endothelium, f actors that may contribute to interactions between age-associated vascular changes and HIV effects in the brain (62, 464).

Advanced Age Appears to Aggravate Neurocognitive Symptoms of HIV

Although some evidence for age-associated differences in neurocognitive impairment in HIV has existed from the pre-HAART era (134, 355, 421, 441, 445–447, 449, 465–484), research on the effects of HIV on brain function as infected people reach advanced age has just recently be gun to emerge over the past several years (445). HIV affects the brains of young and old people dif ferently. Older patients (>50 years.) are more likely to be demented than are younger patients (446) (Table 2). Cherner et al. (468, 485) found age-related trends; older HIV -infected patients were more likely to have cognitive impairments than do younger patients, with greatest effects when CSF viral load w as in the detectable range. V alcour et al. found that older HIV -infected patients had greater impairments than younger patients on the Memorial Sloan-Kettering scale (355, 476, 486, 487). Others have reported similar age-associated findings, with interactions between age, HIV, and various clinical factors, including comorbid psychiatric status (478).

Our findings to date suggest that patients over age 45 have greater impairments and declines over time. In a pilot study of patients in the Bro wn CFAR, we com-

Cognitive task (baseline)	HIV-infected (age <45)	Controls (age <45 years)	HIV-infected (age >45 years)	Controls (age >45 years)
Trails A	23. 5 (7.2)	19.4 (6.6)	37.1 (12.4)	29.5. (9.2)
Trails B	62.2 (12.3)	40.33 (10.9)	124.7 (12.1)	86.2 (7.6)
COWAT	45.3 (8.8)	41.8 (7.6)	29.5 (10.4)	40.2 (8.6)
GPB-D	73.5 (12.5)	68.4 (10.3)	114.2 (18.6)	86.1 (16.3)
Stroop	38.7 (7.4)	42.2 (8.6)	25.5 (8.3)	38.4 (7.6)
HVLT-total	25.7 (4.4)	28.2 (5.5)	17.6 (7.0)	24.5 (5.7)
HVLT-delay	9.4 (2.2)	10.3 (2.5)	6.8 (3.3)	8.3 (2.7)
24 months	Performance	Performance	Performance	Performance
	change	change	change	change
Trails A	2.6 (2.3)	-4.3 (3.6)	10.2 (7.5)	3.3 (6.2)
Trails B	2.4 (5.5)	0.6 (5.5)	12.8 (9.6)	4.7 (8.5)
COWAT	0.2 (2.1)	0.4 (2.1)	-1.5(4.0)	3.3 (4.5)
GPB-D	-3.2(4.1)	-6.3 (4.7)	14.0 (5.3)	2.3 (4.4)
Stroop	3.8 (8.5)	5.2 (7.5)	-3.3 (6.9)	4.0 (5.7)
HVLT-total	-0.3 (2.8)	1.3 (2.5)	-3.4 (2.1)	1.8 (2.4)
HVLT-delay	0.5 (1.3)	1.3 (1.5)	-1.1 (2.0)	0.6 (1.2)

 Table 2
 Comparison of neurocognitive performance between young (<45 years) and older (>45 years)

 HIV-infected patients and seronegative controls

Baseline raw score performance is given in the top half of the table; change scores between the baseline and 24-month assessment is given in the lower half of the table. All HIV patients included in this analysis had a CD4 nadir < 400 cells. **Bold:**p < 0.05

Trails A trail making test (s); *Trails B* trail making test (s); *COWAT* controlled oral word association test (number of w ords); *GPB-D* grooved pegboard-dominant hand (s); *Stroop* stroop color word interference test – interference trial (number of w ords); *HVLT* hopkins verbal learning test (words recalled)

pared the change in performance across these same measures between baseline and 24-month follow-up in 40 HIV-infected patients (young = 16, older = 24) and 20 seronegative controls (young = 10, older = 10). The mean age of the older group was 53.3 ± 5.4 years; the mean age of the younger group was 34.6 ± 7.3 years. All the HIV-infected patients had exhibited a past decline in CD4 to belo w 200 cells. At baseline, the older patients sho wed weaker cognitive performance compared with older seronegative controls than did younger HIV-infected patients relative to the younger controls. Change scores were computed to compare performance at 24-month follow-up to baseline (see Table 1).

As is evident from these data, older HIV patients showed greater decrements in performance over 24 months compared with younger patients. It is noteworthy that older HIV-infected patients showed some decline in memory performance over 24 months, whereas the younger patients showed little change. This finding suggests that the cognitive change occurring with HIV in the context of aging may differ from that historically found with HIV -CMD, an intriguing f inding given the reports of cortical thinning in patients with chronic infection (476). However, it is important to note that not all studies have shown interactions of age by HIV status with respect to cognitive function. For example, Kissel et al. (447) reported independent effects for age and HIV on cognitive function, but not a significant interaction age by HIV status after controlling for education, concluding that people are not at an increased risk for HIV -related cognitive impairment when normal age-related cognitive changes are taken into account. Clearly the question of HIV-associated neurocognitive effects in the context of the aging brain remains an unresolved issue.

Aging in the Context of Chronic Infection

HIV effects on the aging brain are potentially amplif ied by a variety of host and viral factors. Perhaps, the most obvious and important factor is that as HIV-infected patients age, the y experience chronic infection of increasing duration. Ev en among patients whose infection is well managed with HAART, there is the potential for periods of increased viral activity, thereby increasing the risk of brain dysfunction. While these conclusions are intuitive, there is still relatively little data directly addressing the interaction between adv anced age and chronic infection, though research supporting this conclusion is emer ging. Goodkin (446) provided data supporting this assumption, suggesting that older patients had a longer duration of known infection. Cherner et al. (421, 466) found that older HIV patients (>50) had duration of infection 4 years greater than younger patients. Our data support this relationship as well, as infection duration accounted for some but not all age-related effects (421). This has clinical implications, as improved cognitive function secondary to HAART may not persist, as there is some data suggesting that within 2 years of achieving undetectable viral levels, 40-50% of previously treated patients develop increased viral load (424, 468, 485, 488, 489) Despite declines in rates of ADC (56), chronic HIV infection in the context of an aging brain remain an important question (478). Whether the prevalence of dementia will increase as HIV -infected patients live longer remains an open question.

The Changing Face of HIV-Associated Brain Dysfunction

There is a little doubt that the nature of HIV -associated brain dysfunction has changed markedly over the past decade since the advent of HAART, particularly in the United States. AIDS-dementia is less common, and fewer patients are experiencing encephalopathy due to opportunistic infections, such as PML and toxoplasmosis. Yet, the possibility of de veloping severe cognitive impairment continues to be a significant concern for many people infected with HIV, particularly given the prospect of growing old with chronic viral infection of the brain.

The third case vignette discussed earlier provides an illustration of this change. This patient who was almost 50-years old e xhibited what appeared to be a more primary amnestic disorder. He also had greater cortical atrophy than would be expected at his age. In many ways he presented like that of much older people who are commonly seen in memory disorder clinics with mild cognitient verimpairment, suggesting prodromal AD. Of course, it would be impossible to draw conclusions from a single patient (Case 3); it is possible that this patient was actually experiencing early AD, completely independent of their HIV status. Yet, HIV may eventually contribute to cortical atrophy, even though the subcortical pathology once seen is less striking. In the past, cortical atrophy occurred in many patients with advanced HIV, and some degree of global cognitive decline would likely to have occurred if patients lived long enough. Now people are living many years with a lower grade of infection.

As HIV has changed from a subacute often fatal illness to one that is more indolent, though still disruptive to the quality of life of HIV-infected persons, there has been a corresponding increase in the complexity of factors that determine whether a particular patient will develop neurocognitive dysfunction. As illustrated in Fig. 2, viral factors likely interact with an aging brain to influence the e xtent to which neuropathological processes occur. While HAART is effective in reducing cognitive impairment and improving functional status over the short term, and perhaps e ven over the long term when viral control is maintained (490), there is also mounting evidence from studies of proviral DNA that HIV may continue to have detrimental neuronal influences, e ven when plasma viral load has been reduced to almost undetectable levels. Furthermore, there is emer ging evidence that the nature of cognitive impairments in older patients with chronic HIV may dif fer from that observed in the early years of the AIDS epidemic, with greater in volvement of the hippocampus and mesial temporal systems, as well as the possibility of cortical thinning (491-493). This raises the specter of older HIV-infected patients developing memory problems beyond the psychomotor and information processing slowing that has been characteristic of HIV -CMD in the past. Furthermore, data from recent




Fig. 2 Factors implicated in HIV-associated neurocognitive dysfunction

neuroimaging studies employing proton magnetic resonance spectroscop y (MRS) and other highly sensitive brain imaging methods demonstrate that brain metabolic abnormalities may have developed prior to the time that neurocognitive impairments becomes evident, even in the setting of stable disease.

Many questions remain. Are cortical changes in f act occurring in the context of chronic HIV that cannot be explained by normal aging or an independent neurodegenerative process such as? Do basal ganglia effects of HIV evident in past studies evolve into a more cortical presentation over time? Is there a diaschesis at work such that abnormal subcortical white-matter projections to cortical areas lead to associated cortical changes? Alternatively, are cortical changes occurring that are largely independent of basal ganglia abnormalities previously observed? Undoubtedly, answering these questions will require longitudinal studies in which infected patients are followed over an extended time period to examine the interactive effects of the various host and viral factors that influence chronic HIV infection as patients reach more advanced age. Recent advances in structural and functional brain neuroimaging (e.g., dif fusion tensor imaging, functional MRI), as well in vivo measurement of brain metabolic function (MRS) should greatly facilitate these efforts.

References

- 1. CDC. Pneumocystis pneumonia–Los Angeles. MMWR Morb Mortal Wkly Rep 1981;30 (21):250–2.
- 2. CDC. First report of AIDS. MMWR Morb Mortal Wkly Rep 2001;50(21):429.
- CDC. HIV and AIDS–United States, 1981–2000. MMWR Morb Mortal Wkly Rep 2001;50(21):430–4.
- 4 .SmallCB KleinRS FriedlandGH MollB EmesonEE SpiglandI Community-acquired opportunistic infections and defecti ve cellular immunity in heterose xual drug ab users and homosexual men. AmJ Med 1983 ; 74 (3) : 433 41.
- 5 . Kermani E DrobS AlpertM Oganic brain syndrome in three cases of acquired immune deficiency syndrome . ComprPsychiatr 1984 ; 25 (3) : 294 7 .
- 6 . Nuia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol 1986; 19 (6): 517 24.
- 7 . Nuia BA, Price RW The acquired immunodeficiency syndrome dementia complex as the presenting or sole manifestation of human immunodef iciency virus infection. Arch Neurol 1987 ; 44 (1) : 65 9.
- 8 . PriceRW, Nuia BA, ChoES AIDSencephalopathy. NeurolClin 1986; 4:(285 301.
- 9 .CarpenterCC CooperDA , FischIMA etal .Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel .AMA 2000 ; 283 (3) : 381 90 .
- 10 HammerSM SaagMS SchechterM etal .Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel .AMA 2006 ; 296 (7) : 827 43 .
- 11 Naia B ChoE PetitoC etal .TheAIDS dementia complex II. Neuropathology. AnnNeurol 1986 ; 19 : 525 35 .
- 12 Budka H Neuropathology of human immunodeficiency virus infection . Brain Pathol 1991 ; 1 (3) : 163 75 .
- 13 . BudkaH Waey C KleihuesP,etal .HIVassociated disease of the nervous system: review of nomenclature and proposal for neuropathology-based terminology. BrainPathol 1991; 1 (3): 143 – 52.
- 14 Esrall I LuthertP, LantosP Areview of neuronal damage in human immunodeficiency virus infection: its assessment, possible mechanism and relationship to dementia . J Neuropathol Exp Neurol 1993 ; 52 (6) : 561 – 6 .
- 15 Escrall IP, LuthertPJ LantosPL Neuronalnumber and volume alterations in the neocortex of HIV infected individuals. JNeurol Neurosurg Psychiatr 1993 ; 56 (5) : 481 6.
- 16 Wey CA AchimCL ChristophersonC et al . HIV mediates a productive infection of the brain . AIDS 1999 ; 13 (15) : 2055 – 9 .
- 17 Mey CA Masliah E Mory M etal . Neocortical
damage during HIV infection . Ann
Neurol 1991 ; 29 (6) : 651 - 7 .
- 18 Adward E HendererB McCarthurJea Reducedbasal ganglia volume in HIV-1 associated dementia: results from quantitative neuroimaging. Neurology 1993; 43: 2099 104.
- 19 Joneatto S FincoO and der Putten H Abrigannis Annunziata P Evidence of blood-brain barrier alteration and activation in HIV-1 gp120 transgenic mice . AIDS 1999 ; 13 (17) : 2343 – 8 .
- 20 MerrillJE ChenIS HIV1, macrophages, glial cells, and cytokines in AIDS nervous system disease. Faseb J 1991; 5 (10) : 2391 7.
- 21 Brack-Wrner R Astroytes: HIV cellular reservoirs and important participants in neuropathogenesis . AIDS 1999 ; 13 (1) : 1 22 .
- 22 Zink WE Zheng J. Persidsky Y, Poluektøa L. Gendelman HE. The neuropathogenesis of HIV-1 infection. FEMSImmunol Med Microbiol 1999; 26 (3–4): 233 41.
- 23 .Anderson E ,Zink W, Xiong H ,Gendelman HE HIV1-associated dementia: a metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes. JAcquir Immune Defic Syndr 2002 ; 39uppl2: S43 54.
- 24 . Poluektwa L MoranT, Zekiyanskaya M SwindellsS etal .Theregulation of alpha chemokines during HIV-1 infection and leuk ocyte activation: relevance for HIV-1 associated dementia. J Neuroviroimmunol 2001; 1: 112 – 28.

- 25 . Clifford DB Primaryneurologic complications of HIV infection . International AIDS Society-USA 1997 ; 5 : 4 - 7 .
- 26 . Price RW, Brev B Sidtis J Rosenblum M Scheck AC, Cleary P The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 1988; 239 (4840): 586 92.
- 27 .GoulsmithJ DeWlf F, Rul DA, etal .Expressionof human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection . Lancet 1986 ; 11 : 177 80 .
- 28 Ho DD ,Sarngadharan MG ,Resnick L ,Dimarzøeronese F, Rota TR Hirsch MS Primaryhuman T-lymphotropic virus type III infection . AnnIntern Med 1985 ; 103(R61)) : 880 3.
- 29 Dais LE HjelleBL MillerVE etal .Earlyviral brain invasion in iatrogenic human immunodeficiency virus infection . Neurology 1992 ; 42 (9) : 1736 – 9 .
- 30 RImer D HjeelleB Wey C etal .HIV1 infection despite immediate combination antiretroviral therapy after infusion of contaminated white cells . AmJ Med 1994 ; 97 : 289 – 95 .
- 31 Bernick C ,Grgorios JB Progressive multifocal leukoencephalopathy in a patient with acquired immune deficiency syndrome . ArchNeurol 1984 ; 41 (7) : 780 2 .
- 32 EberweinP, HansenLL AgostiniHT Genotypesof JC virus, DNA of cytomegalovirus, and proviral DNA of human immunodeficiency virus in eyes of acquired immunodeficiency syndrome patients. JNeurovirol 2005 ; 11 (1) : 58 65.
- Gonzales MF, Dais RL Neuropathology of acquired immunodeficiency syndrome. NeuropatholAppl Neurobiol 1988; 14 (5): 345 – 63.
- 34 Kralnik IJ Withrich C DangX etal .JCvirus granule cell neuronopathy: a novel clinical syndrome distinct from progressi ve multifocal leuk oencephalopathy. Ann Neurol 2005 ; 57 (4) : 576 – 80 .
- 35 LeeMH ChenYZ Wing LS Ym PS HsuYH Progressive multifocal leukoencephalopathy in an AIDS patient. JFormos Med Assoc 2007; 1065(()ppl): S24 – 8.
- 36 LeportC Raff F, MatheronS etal .refatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodef iciency syndrome. Efficacy of long-term continuous therapy. AmJ Med 1988 ; 84 (1) : 94 100 .
- 37 McMurtrayA NakamotoB ShikumaC Mcour V Small-essel vascular disease in Human Immunodeficiency Virus infection: The Ha waii aging with HIV Cohort Study. Cerebrovasc Dis 2007; 24 (2-3): 236 41.
- 38 Mobly K RotterdamHZ LernerCW, Topper ML Autopsyfindings in the acquired immune deficiency syndrome. Rathol Annu 1985 ;(20Pt1)): 45 65.
- 39 Rul RH Laidlw DH ate DF, etal .Neuropsychologicaland neuroimaging outcome of HIVassociated progressive multifocal leukoencephalopathy in the era of antiretro viral therapy. JIntegr Neurosci 2007; 6 (1): 191 – 203.
- 40 Post MJ ,Chan JC ,Hensly GT, Hoffman TA , Moslowitz LB ,Lippman S Toxoplasma encephalitis in Haitian adults with acquired immunodef iciency syndrome: a clinical-pathologic-CT correlation. AJRAm J Roentgenol 1983 ; 140 (5) : 861 – 8.
- 41 Ramsy RG GeremiaGK CNS complications of AIDS: CT and MR findings . AJR Am J Roentgenol 1988 ; 151 (3) : 449 54 .
- 42 SchmidbauerM BudkaH Okda R CristinaS LechiA Tabattoni GR Multifocalvacuolar leucoencephalopathy: a distinct HIV -associated lesion of the brain . Neuropathol Appl Neurobiol 1990; 16 (5): 437 – 43.
- 43 Xgo L CinqueP, SalaE etal .JCVDNA and BKV-DNA in the CNS tissue and CSF of AIDS patients and normal subjects. Study of 41 cases and review of the literature. J Acquir Immune Defic Syndr Hum Retrovirol 1996 ; 12 (2) : 139 46.
- 44 Lanjøvar DN Surør KV, Maheshwari MB Shenø BP, HiraSK Toxoplasmosis of the central nervous system in the acquired immunodef iciency syndrome. Indian J P athol Microbiol 1998 ; 41 (2) : 147 – 51 .
- 45 Albrecht H ,Hoffmann C Dgen O et al .Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS 1998 ; 12 (10) : 1149 – 54 .

- 46 CinqueP, Vgo L BryttingM etal .Cytomegalovirus infection of the central nervous system in patients with AIDS: diagnosis by DNA amplification from cerebrospinal fluid. J Infect Dis 1992; 166 (6): 1408 - 11.
- 47 ReuterJD Cytomgalovirus induces T-cell independent apoptosis in brain during immunodeficiency. JClin Virol 2005; 32 (3): 218 – 23.
- 48 Lanjæar DN JainPP, ShettyCR Profle of central nervous system pathology in patients with AIDS: an autopsy study from India . AIDS 1998 ; 12 (3) : 309 13 .
- 49 .HeatonR ↓ In R McCutchanJ Neuropsychologicalimpairment in human immunodeficiency virus-infection: implications for employment . PsychosomaticMed 1994 ; 56 : 8 17 .
- 50 HeatonRK MarcotteTD MindtMR etal .Theimpact of HIV-associated neuropsychological impairment on everyday functioning . JInt Neuropsychol Soc 2004 ; 10 (3) : 317 31 .
- 51 .GrantI AtkinsonJH HesselinkJR etal .Evidencefor early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. Ann Intern Med 1987 ; 107 (6) : 828 – 36.
- Grant I, Heaton RK, Ellis RO, et al. Neurocognitive complications in HIV (Abstract 32208). In: 12th World AIDS Conference; Geneva, Switzerland; 1998.
 - 53 CohenRA BolandR Rul R etal .Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women . AIDS 2001 ; 15 (3) : 341 5 .
 - 54 .BornsteinRA NasrallahHA Para MF, etal .Neuropsychological performance in asymptomatic HIV infection . JNeuropsychiatry Clin Neurosci 1992 ; 4 (4) : 386 94 .
 - 55 .BornsteinRA NasrallahHA Para MF, Fiss RJ WhitacreCC RiceRR Jr Rateof CD4 decline and neuropsychological performance in HIV infection. ArchNeurol 1991; 48 (7): 704 – 7.
 - 56 BornsteinRA NasrallahHA Pra MF, WhitacreCC Fiss RJ Duration of illness and neuropsychological performance in asymptomatic HIV infection . J Neuropsychiatry Clin Neurosci 1994; 6 (2): 160 4.
 - 57 SacktorN McDermottMP, MarderK etal .HIVassociated cognitive impairment before and after the advent of combination therapy . JNeurovirol 2002 ; 8 (2) : 136 42 .
 - 58 Nuia BA, ChoE CKP, Price RW The AIDS dementia complex: I. Clinical features . Ann Neurol 1996 ; 19 : 517 – 24 .
 - 59 Toss S PriceR Nuia B Neuropsychological characterization of the AIDS dementia complex; preliminary report . AIDS 1988 ; 2 : 81 8 .
 - 60 Brw BJ PembertonL CunninghamP, Lw MG Levels of human immunodeficiency virus type 1 RN A in cerebrospinal fluid correlate with AIDS dementia stage
 J Infect Dis 1997; 175 (4): 963 6.
 - 61 Beckr JT, SanchezJ Dev MA LopezOL DorstSK BanksG. Neuropsychologicalabnormalities among HIV-infected individuals in a community-based sample. Neuropsychology 1997; 11 (4): 592 – 601.
 - 62 xm Gorp WG MillerEN MarcotteTD et al .Therelationship between age and cognitive impairment in HIV-1 infection: findings from the Multicenter AIDS Cohort Study and a clinical cohort . Neurology 1994 ; 44 (5) : 929 – 35 .
 - 63 MitrushinaM SatzP, DrebingC etal .The differential pattern of memory deficit in normal aging and dementias of different etiology. JClin Psychol 1994 ; 50 (2) : 246 52 .
 - 64 xm Gorp WG Julin SJ Exms G SatzP Incidence of the WAIS-R Fuld profile in HIV-1 infection. JClin Exp Neuropsychol 1990 ; 12 (5) : 807 11 .
 - 65 Min Gorp WG SatzP, HinkinC Exans G MillerEN The neuropsychological aspects of HIV-1 spectrum disease . PsychiatrMed 1989 ; 7 (2) : 59 78 .
- 66 Martin EM ,Sorensen DJ ,Robertson LC ,Edelstein HE ,Chirugi VA .Spatial attention in HIV-1 infection: a preliminary report . JNeuropsychiatr Clin Neurosci 1992; 4 (3): 288 – 93.
- 67 . HeatonRK GrantI ButtersN etal .TheHNRC 500–neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center . JInt Neuropsychol Soc 1995 ; 1 (3) : 231 – 51 .
- 68 Portgies P, EntingRH deGans J etal .Presentationand course of AIDS dementia complex: 10 years of follow-up in Amsterdam, The Netherlands . AIDS 1993; 7 (5): 669 75 .

- 69 CummingsJL Subcortical dementia. Neuropsychology, neuropsychiatry, and pathophysiology. BrJ Psychiatr 1986 ; 149 : 682 97 .
- 70 Cummings JL ,Benson DF .Subcortical dementia. Review of an emerging concept. Arch Neurol 1984 ; 41 (8) : 874 9 .
- 71 MaxwellJ EganV, ChiswickA etal .HIV1 associated cognitive/motor complex in an injecting drug user. AIDSCare 1991; 3 (4): 373 – 81.
- 72 SaykinAJ JanssenRS SprehnGC KaplanJE SpiraTJ O'ConnorB Longitudinalevaluation of neuropsychological function in homose xual men with HIV infection: 18-month follow-up. JNeuropsychiatr Clin Neurosci 1991; 3 (3): 286 – 98.
- 73 .GoodkinK , Wikie FL ConchaM etal .Subtleneuropsychological impairment and minor cognitive-motor disorder in HIV-1 infection. Neuroradiological, neurophysiological, neuroimmunological, and virological correlates. NeuroimagingClin N Am 1997; 7 (3): 561 – 79.
- 74 .Oswiecki DM CohenRA Morrw KM etal .Neurocognitive and psychological contributions to quality of life in HIV-1-infected women . AIDS 2000 ; 14 (10) : 1327 – 32 .
- 75 .MindtMR ChernerM MarcotteTD etal .Thefunctional impact of HIV-associated neuropsychological impairment in Spanish-speaking adults: a pilot study
 J Clin Exp Neuropsychol 2003 ; 25 (1) : 122 - 32 .
- 76 MillerV, SabinC PhillipsA RottmanC etal .Theimpact of protease inhibitor containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load . AIDS 2000 ; 14 : 2129 – 36 .
- 77 Miller EN ,Selnes OA , McArthur JC et al . Neuropsychological performance in HIV-1infected homosexual men: The Multicenter AIDS Cohort Study (MA CS). Neurology 1990 ; 40 (2) : 197 – 203 .
- 78 Martin EM Robertson LC Edelstein HE et al .Performance of patients with early HIV-1 infection on the Stroop Task . JClin Exp Neuropsychol 1992 ; 14 (5) : 857 68 .
- 79 MartinEM PitrakDL PursellKJ MullaneKM Nøak RM Delayedrecognition memory span in HIV-1 infection . JInt Neuropsychol Soc 1995 ; 1 (6) : 575 80 .
- 80 Martin EM, Pitrak DL, Pursell KJ, Andersen BR, Mullane KM, Nøak RM Information processing and antiretro viral therapy in HIV -1 infection. J Int Neuropsychol Soc 1998 ; 4 (4) : 329 – 35.
- MartinE SorensonD EdelsteinH etal .Decision-makingspeed in HIV-infection: a preliminary report. AIDS 1992; 6: 109 – 13.
- 82 Martin E ,Pitrak D ,Rains N et al . Delayed nonmatch-to-sample performance in HIV-seropositive and HIV-seronegative polydrug abusers . Neuropsychology 2003 ; 17 (2) : 283 8 .
- 83 MartinE Nøak R FendrichM etal .Stroopperformance in drug users classified by HIV and hepatitis C virus serostatus . JInt Neuropsychol Soc 2004 ; 10 (2) : 298 300 .
- 84 .MartinA Hyes M SalazarA etal .Progressive slowing of reactin time and increasing cerebral spinal fluid concentrations of quinolinic acid in HIV -infected individuals. J Neuropsychiatry Clin Neurosci 1992 ; 4 : 270 – 9 .
- 85 xm Gorp W, MillerE MarcotteT, DixonP, № D SelnesO. Therelationship between age and cognitive impairment in HIV -1 infection: findings from the Multicenter AIDS Cohort Study and Clinical Cohort. Neurology 1994 ; 44 : 929 – 35.
- 86 xm Gorp W, SatzP, HinkinC Exms G MillerE Theneuropsychological aspects of HIV-1 spectrum disease. PsychiatrMed 1989; 7:59 - 78.
- 87. Yn Gorp WG MillerEN SatzP, Vsscher B Neuropsychologicalperformance in HIV-1 immunocompromised patients: a preliminary report. JClin Exp Neuropsychol 1989; 11 (5): 763 – 73.
- 88 AmadorF, MayoiRios J delCastillo-Martin N [Cognitive slowing in asymptomatic individuals who are seropositi ve for human immunodef iciency virus type 1]. Rev Neurol 2006; 42 (3): 132 6.
- 89 . AmadorF, Pelgrina M MayoRios J Cognitive slowing in cognitive-motor disorder associated to type 1 human immunodeficiency virus: TR and P300. ActasEsp Psiquiatr 2007; 35 (4): 221 – 8.
- 90 . Arendt G , Hefter H , Jablonwski H Acoustically evoked event-related potentials in HIV-associated dementia . ElectroencephalogrClin Neurophysiol 1993 ; 86 (3) : 152 60 .

- 91 . CastellonSA HinkinCH Wood S Yarema KT Apathy depression, and cognitive performance in HIV-1 infection . JNeuropsychiatr Clin Neurosci 1998 ; 10 (3) : 320 – 9 .
- 92 . ConnollyS ManjiH McAllisterRH etal .Long-latency event-related potentials in asymptomatic human immunodeficiency virus type 1 infection . AnnNeurol 1994 ; 35 (2) : 189 – 96 .
- 93 . FeinG BigginsCA MacKayS. Delayedlatency of the event-related brain potential P3A component in HIV disease. Progressive effects with increasing cognitive impairment. Arch Neurol 1995; 52 (11): 1109 18.
- 94 . Handelsman L ,Horwth T, Aronson M et al . Auditory event-related potentials in HIV-1 infection: a study in the drug-user risk group. JNeuropsychiatr Clin Neurosci 1992 ; 4 (3) : 294-302.
- 95 . Hardy DJ ,Castellon SA ,Hinkin CH Perceptual span deficits in adults with HIV. J Int Neuropsychol Soc 2004 ; 10 (1) : 135 40 .
- 96 .HardyDJ HinkinCH Reactiontime slowing in adults with HIV: results of a meta-analysis using brinley plots . BrainCogn 2002 ; 50 (1) : 25 34 .
- 97 . Hinkin
CH CastellonSA HardyDJ Frinpour R Novton T, Singe E Methylphenidate
improves HIV-1-associated cognitive slowing .
 JNeuropsychiatr Clin Neurosci 2001 ; 13 (2) : 248 – 54 .
- 98 . HinkinCH CastellonSA HardyDJ GranholmE Sigle G Computerized and traditional stroop task dysfunction in HIV-1 infection . Neuropsychology 1999 ; 13 (2) : 306 16 .
- 99 . Karlsen NR Reinang I Froland SS Slowed reaction time in asymptomatic HIV-positive patients . ActaNeurol Scand 1992 ; 86 (3) : 242 6 .
- 100 LopezOL Wess J SanchezJ Dev MA Beckr JT Neurobehavioral correlates of perceived mental and motor slo wness in HIV infection and AIDS . J Neuropsychiatr Clin Neurosci 1998; 10 (3): 343 – 50.
- 101 MartinEM Nøak RM FendrichM etal .Stroopperformance in drug users classified by HIV and hepatitis C virus serostatus . JInt Neuropsychol Soc 2004 ; 10 (2) : 298 300 .
- 102 MartinEM PitrakDL Nøak RM PursellKJ MullaneKM Reaction times are faster in HIV-seropositive patients on antiretro viral therapy: a preliminary report . J Clin Exp Neuropsychol 1999 ; 21 (5) : 730 – 5 .
- 103 Martin EM Sorensen DJ Edelstein HE Robertson LC Decision-making speed in HIV-1 infection: a preliminary report. AIDS 1992; 6 (1): 109 13.
- 104 . Messenheimer A, Robertson KR, Wilkins JW, Kalkwski JC HallCD Event-related potentials in human immunodeficiency virus infection. A prospective study. ArchNeurol 1992; 49 (4): 396 – 400.
- 105 .MillerEN SatzP, Vescher B Computerized and conventional neuropsychological assessment of HIV-1-infected homosexual men . Neurology 1991 ; 41 (10) : 1608 – 16 .
- 106 .Ogunrin AO , OdiaseFE , Ogunniyi A Reaction time in patients with HIV/AIDS and correlation with CD4 count: a case-control study. Trans R Soc Trop Med Hyg 2007 ; 101 (5) : 517 – 22 .
- 107 Pul RH CohenRA SternRA Neurocognitive manifestations of Human Immunodeficiency Virus . CNSSpectr 2002 ; 7 (12) : 860 – 6 .
- 108 PeredaM Auso-Mateos JL GomezDel Barrio A etal .Factors associated with neuropsychological performance in HIV -seropositive subjects without AIDS . Psychol Med 2000 ; 30 (1) : 205 - 17 .
- 109 PoutiainenE Elwaara I Rainink R etal .Cognitive performance in HIV-1 infection: relationship to severity of disease and brain atrophy. ActaNeurol Scand 1993; 87 (2): 88 – 94.
- 110 SacktorNC BacellarH Hower DR etal .Psychomotorslowing in HIV infection: a predictor of dementia, AIDS and death . JNeurovirol 1996; 2 (6) : 404 10 .
- 111 SassoonSA Fima R RosenbloomMJ O'ReillyA Pfefferbaum A Sullivan EV Component cognitive and motor processes of the digit symbol test: dif ferential deficits in alcoholism, HIV infection, and their comorbidity. AlcoholClin Exp Res 2007; 31 (8): 1315 – 24.
- 112 .WhiteJL Darb DF, Brown SJ etal .Earlycentral nervous system response to HIV infection: sleep distortion and cognitive-motor decrements . AIDS 1995 ; 9 (9) : 1043 50 .
- 113 .Gonzalez R , Jassileva J , Bechara A et al . The influence of executive functions, sensation seeking, and HIV serostatus on the risky sexual practices of substance-dependent individuals. JInt Neuropsychol Soc 2005; 11 (2): 121 31.

- 114 JasiukaitisP, FeinG Differential association of HIV-related neuropsychological impairment with semantic versus repetition priming. JInt Neuropsychol Soc 1999; 5 (5): 434 – 41.
- 115 Stout JC ,Salmon DP, Butters N et al Decline in working memory associated with HIV infection. HNRC Group . PsycholMed 1995 ; 25 (6) : 1221 32 .
- 116 .CohenRA. Neuropsychologyof attention . New York : Plenum 1993 .
- 117 NishiyoriA MinamiM OhtaniY,etal Localizationof fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia? FEBS Lett 1998 ; 429 (2) : 167 72 .
- 118 Sardar AM , Czudek C , Renolds GP .Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS . Neuroreport 1996 ; 7 (4) : 910 2 .
- 119 MiszkielKA Pley MN Wikinson ID etal .Themeasurement of R2, R2* and R2' in HIV-infected patients using the prime sequence as a measure of brain iron deposition . Magn Reson Imaging 1997 ; 15 (10) : 1113 9 .
- 120 Mankwski JL ,Queen SE ,Kirstein LM et al . Alterations in blood-brain barrier glucose transport in SIV-infected macaques . JNeurovirol 1999 ; 5 (6) : 695 – 702 .
- 121 ChangL SpeckO MillerEN etal .Neuralcorrelates of attention and working memory deficits in HIV patients . Neurology 2001 ; 57 (6) : 1001 7 .
- 122 CysiqueLA Maruff P, Brev BJ Prevalence and pattern of neuropsychological impairment in human immunodef iciency virus-infected/acquired immunodef iciency syndrome (HIV/ AIDS) patients across pre- and post-highly acti ve antiretroviral therapy eras: a combined study of two cohorts. JNeurovirol 2004; 10 (6): 350 – 7.
- 123 Fron DM AllsopJM CoxIJ etal .Areview of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection . AIDS 2005 ; 19uppl3 : S53 - 63 .
- 124 Grohman K Donnelly K Strang J Kleiner J Neuropsychological impairment in veterans who are HIV-positive . BrainCogn 2002 ; 49 (2) : 194 – 8 .
- 125 Klusman LE ,Moulton JM ,Hornbostel LK ,Picano JJ ,Beattie MT Neuropsychological abnormalities in asymptomatic HIV seropositi ve military personnel. J Neuropsychiatr Clin Neurosci 1991 ; 3 (4) : 422 – 8 .
- 126 . MarcotteTD HeatonRK , Wilson T, et al Theimpact of HIV-related neuropsychological dysfunction on driving behavior. The HNRC Group . JInt Neuropsychol Soc 1999; 5 (7): 579 – 92 .
- 127 Marcotte TD Lazzaretto D Scott JC Roberts E Woods SP, Letndre S Visual attention deficits are associated with driving accidents in cognitively-impaired HIV-infected individuals. JClin Exp Neuropsychol 2006; 28 (1): 13 – 28.
- 128 PerryW, CarlsonMD BarakatF, et al Neuropsychological test performance in patients coinfected with hepatitis C virus and HIV. AIDS 2005 ; ISuppl3 : S79 – 84.
- 129 Rabkin JG Ferrando SJ an Gorp W, Rieppi R McElhing M Swell M Relationships among apathy, depression, and cognitive impairment in HIV/AIDS. J Neuropsychiatr Clin Neurosci 2000; 12 (4): 451 – 7.
- 130 Robertson KR ,Nakasujja N ,Wing M et al . Pattern of neuropsychological performance among HIV positive patients in Uganda . BMCNeurol 2007; 7:8.
- 131 . Schulte T, Muelle Oehring EM ,Rosenbloom MJ ,Pfeferbaum A ,Sulkian EV .Differential effect of HIV infection and alcoholism on conflict processing, attentional allocation, and perceptual load: evidence from a Stroop Match-to-Sample task . BiolPsychiatr 2005; 57 (1): 67 75.
- 132 ShorPosner G Cognitive function in HIV-1-infected drug users. JAcquir Immune Defic Syndr 2000; 25uppl1: S70 – 3.
- 133 .Vlla G MonteleoneD MarraC etal .Neuropsychologicalabnormalities in AIDS and asymptomatic HIV seropositive patients . JNeurol Neurosurg Psychiatr 1993 ; 56 (8) : 878 84 .
- 134 Wikie FL GoodkinK KhamisI etal .Cognitive functioning in younger and older HIV-1infected adults .JAcquir Immune Defic Syndr 2003 ; 3Suppl2 : S93 – 105 .
- 135 MannLS Westlake T, Wes TN BeckmanA BeckmanP, PortezD Executive functioning and compliance in HIV patients . PsycholRep 1999 ; 84 (1) : 319 22 .
- 136 Selnes OA Neurocognitive aspects of medication adherence in HIV infection. J Acquir Immune Defic Syndr 2002; 31 (Suppl S132 – 5.

- 137 Care CL Woods SP, RippethJD HeatonRK GrantI Prospective memory in HIV-1 infection. JClin Exp Neuropsychol 2006 ; 28 (4) : 536 – 48.
- 138 GrayRA Micox KM ZinkMC Wed MR Impaired performance on the object retrievaldetour test of e xecutive function in the SIV/macaque model of AIDS . AIDS Res Hum Retrovir 2006; 22 (10): 1031 – 5.
- 139 Wrk MK FranksJJ HenryRR HamiltonWJ Verbal working memory storage and processing deficits in HIV -1 asymptomatic and symptomatic indi viduals. Psychol Med 2001 ; 31 (7) : 1279 – 91 .
- 140 Martin EM Robertson LC ,Sorensen DJ Jagust WJ ,Mallon KF, Chrurgi W Speed of memory scanning is not af fected in early HIV -1 infection. J Clin Exp Neuropsychol 1993 ; 15 (2) : 311 – 20 .
- 141 SacktorN BacellarH Hower D et al .Psychomotorslowing in HIV infection: a predictor of dementia, AIDS & death . JNeurovirol 1996 ; 2 (6) : 404 10 .
- 142 DunlopO BjorklundR BruunJN etal .Earlypsychomotor slowing predicts the development of HIV dementia and autopsy-v erified HIV encephalitis . Acta Neurol Scand 2002 ; 105 (4) : 270 5 .
- 143 .Baldweg T, GruzelierJH StygallJ etal .Detectionof subclinical motor dysfunctions in early symptomatic HIV infection with topographical EEG. IntJ Psychophysiol 1993 ; 15 (3) : 227 – 38 .
- 144 .SternRA SingerNG Silar SG etal .Neurobehavioral functioning in a nonconfounded group of asymptomatic HIV-seropositive homosexual men . AmJ Psychiatry 1992 ; 149 (8) : 1099 – 102 .
- 145 MurrayEA RauschDM Lendary J SharerLR EidenLE Cognitive and motor impairments associated with SIV infection in rhesus monkeys. Science 1992; 255 (5049) : 1246 9.
- 146 DiamondGW, KaufmanJ BelmanAL CohenL CohenHJ Rubinstei A Characterization of cognitive functioning in a subgroup of children with congenital HIV infection. Arch Clin Neuropsychol 1987; 2 (3): 245 – 56.
- 147 ArendtG HefterH Neuen-JacobE etal .Electrophysiologicalmotor testing, MRI findings and clinical course in AIDS patients with dementia . JNeurol 1993 ; 240 (7) : 439 45 .
- 148 ArendtG Maeckr HP, Jablonwski H Homber V Magnetic stimulation of motor cortex in relation to fastest voluntary motor activity in neurologically asymptomatic HIV-positive patients. JNeurol Sci 1992 ; 112 (1–2) : 76 80.
- 149 CurrieJ BensonE RamsdenB PerdicesM CooperD Eyemovement abnormalities as a predictor of the acquired immunodef iciency syndrome dementia comple x. Arch Neurol 1988 ; 45 (9) : 949 – 53 .
- 150 FitzgibbonML CellaDF, HumfleetG Griffin E SheridanK Motor slowing in asymptomatic HIV infection . PerceptMot Skills 1989 ; 68(R62)): 1331 – 8.
- 151 PriceRW, Brev BJ TheAIDS dementia complex. JInfect Dis 1988; 158 (5)9:-103.
- 152 Alæander GE ,DeLong MR ,Strick PL Parallel organization of functionally segregated circuits linking basal ganglia and cortex . AnnuRev Neurosci 1986 ; 9 : 357 – 81 .
- 153 MartinEM PitrakDL RainsN et al .Delayed nonmatch-to-sample performance in HIVseropositive and HIV-seronegative polydrug abusers . Neuropsychology 2003 ; 17 (2) : 283 – 8 .
- 154 Lw WA, MartinA MapouRL et al. Working memory in individuals with HIV infection. JClin Exp Neuropsychol 1994 ; 16 (2) : 173 – 82.
- 155 HinkinCH HardyDJ MasonKI et al . Verbal and spatial working memory performance among HIV-infected adults . JInt Neuropsychol Soc 2002 ; 8 (4) : 532 8 .
- 156 ErnstT, ChangL Juicich J AmesN ArnoldS Abnormalbrain activation on functional MRI in cognitively asymptomatic HIV patients. Neurology 2002; 59 (9): 1343 – 9.
- 157 Peny G JacobsD SalmonDP,etal .Verbal memory performance of patients with human immunodeficiency virus infection: evidence of subcortical dysfunction. The HNRC Group . JClin Exp Neuropsychol 1994 ; 16 (4) : 508 – 23 .
- 158 Nielsen-BohlmanL Byle D BigginsC EzekielF, FeinG Sematic priming impairment in HIV. JInt Neuropsychol Soc 1997; 3 (4): 348 – 58.
- 159 .WhiteDA, Taylor MJ ButtersN etal .Memoryfor verbal information in individuals with HIVassociated dementia complex. HNRC Group . JClin Exp Neuropsychol 1997; 19 (3): 357 – 66 .

- 160 Brouwers P, an Engelen M Lalonde F, et al . Abnormally increased semantic priming in children with symptomatic HIV-1 disease: evidence for impaired development of semantics? JInt Neuropsychol Soc 2001; 7 (4): 491 501.
- 161 . MooreDJ MasliahE RippethJD etal .Corticaland subcortical neurodegeneration is associated with HIV neurocognitive impairment . AIDS 2006 ; 20 (6) : 879 – 87 .
- 162 Kribrian R WrobelAJ Cognitive impairment in HIV infection. AIDS 1991 ; 5 (12)501 7 .
- 163 Willman MC Neuropsychologicalimpairment among intravenous drug users in pre-AIDS stages of HIV infection . IntJ Neurosci 1992 ; 64 (1–4) : 183 94 .
- 164 Maruff P, CurrieJ MaloneV, McArthudackson C MulhallB Bonson E Neuropsychological characterization of the AIDS dementia comple x and rationalization of a test battery . Arch Neurol 1994 ; 51 (7) : 689 95.
- 165 Rul R Cohen Stern R Neurocognitive manifestations of human immunodeficiency virus. CNSSpectrums 2003 ; 7 (12) : 860 6.
- 166 JudicelloJE Woods SP, Persons TD MoranLM Care CL Grantl Verbal fluency in HIV infection: a meta-analytic review. JInt Neuropsychol Soc 2007; 13 (1): 183 9.
- 167 MossHA , Wilters PL ,Brouwers P, Hendricks ML ,Pizzo A Impairment of expressive behavior in pediatric HIV-infected patients with evidence of CNS disease. J Pediatr Psychol 1996; 21 (3): 379 – 400.
- 168 Rul Woods S Mogan EE Davson M CobbScott J GrantI Action (verb) fluency predicts dependence in instrumental activities of daily living in persons infected with HIV-1. J Clin Exp Neuropsychol 2006 ; 28 (6) : 1030 – 42.
- 169 HodsonA MokJ DeanE Speechand language functioning in paediatric HIV disease. Int J Lang Commun Disord 2001; 35uppl: 173 – 8.
- 170 Walters PL BrouwersP, Guitello L MossHA Receptive and expressive language function of children with symptomatic HIV infection and relationship with disease parameters: a longitudinal 24-month follow-up study. AIDS 1997 ; 11 (9) : 1135 – 44.
- 171 GeierSA Kronwitter U BognerJR et al Impairment of colour contrast sensitivity and neuroretinal dysfunction in patients with symptomatic HIV infection or AIDS . Br J Ophthalmol 1993 ; 77 (11) : 716 – 20 .
- 172 HinkinCH CastellonSA HardyDJ Dualtask performance in HIV-1 infection . JClin Exp Neuropsychol 2000 ; 22 (1) : 16 24 .
- 173 Jázak LC ,Bullimore MA Visual changes in human immuno-deficiency virus infection . OptomVis Sci 1994 ; 71 (9) : 557 - 61 .
- 174 Maruf P, MaloneV, McArthudackson C MulhallB BensonE furrie J Abnormalities of visual spatial attention in HIV infection and the HIV-associated dementia complex. JNeuropsychiatr Clin Neurosci 1995; 7 (3): 325 – 33.
- 175 QuicenoJI CapparelliE SadunAA etal . Vsual dysfunction without retinitis in patients with acquired immunodeficiency syndrome . AmJ Ophthalmol 1992; 113 (1) : 8 13 .
- 176 Shah KH ,Holland GN , № F, № Natta M ,Nusinwitz S Contrast sensitivity and color vision in HIV -infected individuals without infectious retinopathy . Am J Ophthalmol 2006 ; 142 (2) : 284 92 .
- 177 Griffin WC III MiddaughLD CookJE For WR Thesevere combined immunodeficient (SCID) mouse model of human immunodef iciency virus encephalitis: deficits in cognitive function. JNeurovirol 2004 ; 10 (2) : 109 15.
- 178 PessinH RosenfeldB BurtonL BreitbartW Therole of cognitive impairment in desire for hastened death: a study of patients with adv anced AIDS. Gen Hosp Psychiatr 2003; 25 (3): 194 9.
- 179 ArendtG on Giesen HJ Humanimmunodeficiency virus dementia: evidence of a subcortical process from studies of fine finger movements. JNeurovirol 2002; Suppl2: 27 32.
- 180 .MayeuxR SternY, Ting MX etal .Mortalityrisks in gay men with human immunodeficiency virus infection and cognitive impairment. Neurology 1993 ; 43 (1) : 176 – 82 .
- 181 ReicksC MooreD Dwson L MarcotteT, HeatonR GrantI, etal .Neuropsychological performance predicts everyday functioning in HIV+ individuals . JINS 1999 ; 5 : 155 .

- 182 Cohen RA ,Moser DJ ,Clark MM et al .Neurocognitive functioning and improvement in quality of life following participation in cardiac rehabilitation . Am J Cardiol 1999 ; 83 (9) : 1374 8.
- 183 Rosenbloom MJ ,Sullian EV, Sassoon SA et al . Alcoholism, HIV infection, and their comorbidity: factors affecting self-rated health-related quality of life. J Stud Alcohol Drugs 2007; 68 (1): 115 25.
- 184 BuchananRJ Wing S HuangC Analyses of nursing home residents with HIV and dementia using the minimum data set. JAcquir Immune Defic Syndr 2001; 26 (3): 246 – 55.
- 185 an Gorp WG ,Baerwald JP, Ferrando SJ ,McElhing MC ,Rabkin JG The relationship between employment and neuropsychological impairment in HIV infection . J Int Neuropsychol Soc 1999 ; 5 (6) : 534 – 9 .
- 186 an Gorp WG RabkinJG FerrandoSJ etal .Neuropsychiatricpredictors of return to work in HIV/AIDS . JInt Neuropsychol Soc 2007; 13 (1): 80 – 9.
- 187. Flanigan T, Jesdale B, Zierler S, et al. F all in CD4 count among HIV infected w omen: A comparison of injection drug use and heterose xual transmission groups (Abstract No. PoC4367). International Conference on AIDS 1992;8(2):C306.
- 188 JanssenRS Nwmyanwu OC SelikRM StehrGreen JK Epidemiologyof human immunodeficiency virus encephalopathy in the United States . Neurology 1992 ; 42 (8) : 1472 - 6 .
- Mayer K, Jesdale B, Flanigan T, et al. The prevalence of specific illnesses in HIV-infected US women with associated CD4 counts (Abstract No. PoC4371). International Conference on AIDS 1992;8(2):C306.
 - 190 NockherWA, Bermann L ScherberichJE Increasedsoluble CD14 serum levels and altered CD14 expression of peripheral blood monocytes in HIV-infected patients. Clin Exp Immunol 1994; 98 (3): 369 – 74.
 - 191 ThieblemontN Weiss L Şadghi HM EstcourtC Haeffner-Cavaillon N CD14lovCD16high: a cytokine-producing monocyte subset which e xpands during human immunodef iciency virus infection. EurJ Immunol 1995 ; 25 (12) : 3418 – 24.
 - 192 DragicT, LitwinV, Allway GP, etal .HIV1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996 ; 381 (6584) : 667 - 73.
 - 193 Wugelers PJ StrathdeeSA KaldorJM etal .Associationsof age, immunosuppression, and AIDS among homosexual men in the Tricontinental Seroconverter Study. J Acquir Immune Defic Syndr Hum Retrovirol 1997 ; 14 (5) : 435 – 41 .
 - 194 Pella FJ Jr, Delany KM MoormanAC, etal .Decliningmorbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. NEngl J Med 1998; 338 (13): 853 – 60.
 - 195 LilloFB Ciuffeda D Vglia F, et al . Vral load and burden modification following early antiretroviral therapy of primary HIV-1 infection . AIDS 1999 ; 13 (7) : 791 6 .
 - 196 Egan VG, Chiswick A, Brettle RP, Goodwin GM The Edinburgh cohort of HIV-positive drug users: the relationship between auditory P3 latency, cognitive function and self-rated mood. PsycholMed 1993; 23 (3): 613 – 22.
 - 197 GruzelierJ Bugess A Baldweg T, etal .Prospective associations between lateralised brain function and immune status in HIV infection: analysis of EEG, cognition and mood over 30 months . IntJ Psychophysiol 1996 ; 23 (3) : 215 – 24 .
 - 198 Ellis RJ Deutsch R Heaton RK et al .Neurocognitive impairment is an independent risk factor for death in HIV infection. San Die go HIV Neurobehavioral Research Center Group. ArchNeurol 1997 ; 54 (4) : 416 – 24 .
 - 199 Harrison MJ, Næman SP, Hall-Craggs MA et al. Evidence of CNS impairment in HIV infection: clinical, neuropsychological, EEG, and MRI/MRS study . J Neurol Neurosur g Psychiatr 1998 ; 65 (3) : 301 7.
- 200 Walace MR MossRB BeechamHJ 3rd etal .Earlyclinical markers and CD4 percentage in subjects with human immunodef iciency virus infection. J Acquir Immune Def ic Syndr Hum Retrovirol 1996 ; 12 (4) : 358 – 62 .
- 201 BouwmanFH Skalasky RL HesD etal . Variable progression of HIV-associated dementia . Neurology 1998 ; 50 (6) : 1814 – 20 .

- 202 Brev BJ DunbarN PembertonL KaldorJ Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin. JInfect Dis 1996 ; 174 (2) : 294 – 8.
- 203 LetendreS AncesB GibsonS EllisRJ Neurologic complications of HIV disease and their treatment . Top HIV Med 2007 ; 15 (2) : 32 -9 .
- 204 . MarcotteTD DeutschR McCutchanA ,etal .Predictionof incident neurocognitive impairment by plasma HIV RN A and CD4 le vels early after HIV serocon version. Arch Neurol 2003 ; 60 (10) : 1406 – 12 .
- 205 .Wallace MR HeatonRK McCutchanA ,etal .Neurocognitive impairment in human immunodeficiency virus infection is correlated with se xually transmitted disease history. Sex Transm Dis 1997 ; 24 (7) : 398 – 401 .
- 206 DeRonchi D Jaranca I BerardiD etal .Riskfactors for cognitive impairment in HIV-1infected persons with different risk behaviors . ArchNeurol 2002; 59 (5) : 812 - 8.
- 207 ClarkRA BessingerR Clinical manifestations and predictors of survival in older women infected with HIV. JAcquir Immune Defic Syndr Hum Retrovirol 1997; 15 (5): 341 – 5.
- 208 OdiaseF, OgunrinO OgunniyiA Effect of progression of disease on cognitive performance in HIV/AIDS . JNatl Med Assoc 2006 ; 98 (8) : 1260 – 2 .
- 209 MellorsJ MunozA Giogi J etal .Plasmaviral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection . AnnIntern Med 1997 ; 126 (12) : 946 – 54 .
- 210 . Trainie Construction and the second second
- 211 . McArthurJC McClernonDR CroninMF,etal .Relationshipbetween human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain
 Ann Neurol 1997 ; 42 (5) : 689 98 .
- 212 Mla G SolidaA MoroE etal .Cognitive impairment in asymptomatic stages of HIV infection. A longitudinal study. EurNeurol 1996; 36 (3): 125 33.
- 213 Bfros RB CaiZ LintonPJ CD8T cells and aging . CritRev Immunol 2003, 23 (1-2): 45 64 .
- 214 PetitoCK AdkinsB McCarthyM RobertsB KhamisI CD4+and CD8+ cells accumulate in the brains of acquired immunodeficiency syndrome patients with human immunodeficiency virus encephalitis. JNeurovirol 2003; 9 (1): 36 – 44.
- 215 Aronsson B , Toye-Blomberg M , Smedman L Increase of circulating CD8+CD57+ lymphocytes after measles infection b ut not after measles v accination. J Clin Lab Immunol 2004 ; 53 : 1 12.
- 216 RobertsES Huitron-ResendizS affe MA etal .Hostresponse and dysfunction in the CNS during chronic simian immunodeficiency virus infection . JNeurosci 2006 ; 26 (17) : 4577 85 .
- 217 KimBO LiuY, ZhouBY, HeJJ Induction C chemokine XCL1 (lymphotactin/single C motif-1 alpha/activation-induced, T cell-derived and chemokine-related cytokine) expression by HIV-1 Tat protein . JImmunol 2004 ; 172 (3) : 1888 95 .
- 218 Geskus RB Miedema A, Goudsmit J Reiss P, Schuitema kr H Cotinho RA Prediction of residual time to AIDS and death based on markers and cofactors. J Acquir Immune Defic Syndr 2003 ; 32 (5) : 514 – 21 .
- 219 Mellors JW . Vral load and clinical outcome . International AIDS Society-USA 1997 ; 5 : 8 10 .
- 220 .Gonzalez R Heaton RK Moore DJ et al .Computerized reaction time battery versus a traditional neuropsychological battery: detecting HIV-related impairments. J Int Neuropsychol Soc 2003 ; 9 (1) : 64 – 71 .
- 221 Miello B GoodkinK AshtanaD etal .HIV1 RNA concentration and cognitive performance in a cohort of HIV-positive people . AIDS 2007 ; 21 (11) : 1415 22 .
- 222 Childs EA Jules RH Selnes OA, et al . Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999 ; 52 (3) : 607 13.
- 223 Dallin G Frzadegan H Selness O et al . Sustained cognitive decline in HIV infection: Relationsip to CD4 cell count, plasma viremia & p24 antigenemia . J Neurovirol 1998 ; 4 (1) : 95 - 9 .

- 224 EggersCC an Lunzen J BuhkT, StellbrinkHJ HIVinfection of the central nervous system is characterized by rapid turno ver of viral RN A in cerebrospinal fluid. J Acquir Immune Defic Syndr Hum Retrovirol 1999 ; 20 (3) : 259 – 64.
- 225 ChangL ErnstT, Wtt MD et al . Persistentbrain abnormalities in antiretroviral-naive HIV patients 3 months after HAART. Antivir Ther 2003 ; 8 (1) : 17 – 26 .
- 226 .ChangL ErnstT, Leonido-¥e M ,₩lot I SingerE Cerebralmetabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex . Neurology 1999 ; 52 (1) : 100 8 .
- 227 RobertsonK FiscusS KapoorC etal .CSF plasma viral load and HIV associated dementia . JNeurovirol 1998 ; 4 (1) : 90 – 4 .
- 228 ChristoPP, GrecoDB AleixoAW, Liramento A HIV1 RNA levels in cerebrospinal fluid and plasma and their correlation with opportunistic neurological diseases in a Brazilian AIDS reference hospital. ArqNeuropsiquiatr 2005; 63 (4): 907 – 13.
- 229 Bandaru VV, McArthur JC, Sacktor N et al. Associative and predictive biomarkers of dementia in HIV-1-infected patients. Neurology 2007; 68 (18): 1481 – 7.
- 230 Cysique LA ,Brw BJ ,Halman M et al .Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inacti ve AIDS dementia comple x in highly acti ve antiretroviral therapy-treated patients . JAcquir Immune Defic Syndr 2005 ; 39 (4) : 426 – 9 .
- 231 Kriine A Force G Serran J etal .MeasuringHIV-1 RNA and interferon-alpha in the cerebrospinal fluid of AIDS patients: insights into the pathogenesis of AIDS Dementia Complex . JNeurovirol 1999 ; 5 (5) : 500 - 6 .
- 232 Wey CA SoontornniyomkijV, RadhakrishnanL et al . Distribution of brain HIV load in AIDS . BrainPathol 1998 ; 8 (2) : 277 – 84 .
- 233 LetendreSL McCutchanA , ChildersME etal .Enhancingantiretroviral therapy for human immunodeficiency virus cognitive disorders . AnnNeurol 2004 ; 56 (3) : 416 23 .
- 234 EllisRJ HsiaK SpectorSA etal .Cerebrospinalfluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobeha vioral Research Center Group . Ann Neurol 1997 ; 42 (5) : 679 – 88 .
- 235 GulickRM MellorsJW, Hulir D etal . Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. NEngl J Med 1997; 337 (11): 734 – 9.
- 236 .McArthurJC McDermottMP, McClernonD etal .Attenuatedcentral nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol 2004 ; 61 (11) : 1687 – 96 .
- 237 .ChunTW, NickleDC JustementJS etal .HIVinfected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reserv oir. J Clin Invest 2005 ; 115 (11) : 3250 - 5 .
- Coombs RW. Preliminary e valuation of HIV -1 proviral DNA quantification assay. In: Conference on the Laboratory Science of HIV; 1998.
- 239 . Inther LA CoombsRW, AungSA delaRosa C GretchD Cory L Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro. JMed Virol 1999 ; 58 (2) : 165 73.
- 240 .GartnerS HIVinfection and dementia . Science 2000 ; 287 (5453) : 602 4 .
- 241 Shiramizu B ,Gartner S ,Williams A et al . Circulating proviral HIV DNA and HIV-associated dementia . AIDS 2005 ; 19 (1) : 45 52 .
- 242 Shiramizu B Ratto-Kim S , Sithinamsuwan P, et al . HIVDNA and dementia in treatment-naive HIV-1-infected individuals in Bangkok, Thailand . IntJ Med Sci 2007 ; 4 (1) : 13 8.
- 243 ShiramizuB Rul R Williams A etal .HIVproviral DNA associated with decreased neuropsychological function . JNeuropsychiatry Clin Neurosci 2007 ; 19 (2) : 157 63 .
- 244 MoriishiK MatsuuraY Mechanismsof hepatitis C virus infection . Antivir Chem Chemother 2003 ; 14 (6) : 285 97 .
- 245 HilsabeckRC HassaneinTI CarlsonMD Zigler EA PerryW Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C . J Int Neuropsychol Soc 2003 ; 9 (6) : 847 – 54 .

- 246 Hilsabeck RC ,Perry W, Hassanein TI Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002 ; 35 (2) : 440 6 .
- 247 KramerL BauerE FunkG etal .Subclinicalimpairment of brain function in chronic hepatitis C infection . JHepatol 2002 ; 37 (3) : 349 – 54 .
- 248 DieperinkE "Wilenbring M HoSB Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. AmJ Psychiatry 2000; 157 (6): 867 76.
- 249 KameiS SakaiT, MatsuuraM etal .Alterationsof quantitative EEG and mini-mental state examination in interferon-alpha-treated hepatitis C. EurNeurol 2002; 48 (2): 102 – 7.
- 250 . CysiqueLA Maruff P, Brev BJ Theneuropsychological profile of symptomatic AIDS and ADC patients in the pre-HAART era: a meta-analysis . JInt Neuropsychol Soc 2006; 12 (3) : 368 82 .
- 251 OdiaseFE OgunrinOA, OgunniyiAA Memoryperformance in HIV/AIDS-a prospective case control study. CanJ Neurol Sci 2007; 34 (2): 154 9.
- 252 GrassiMP, PerinC BorellaM MangoniA Assessmentof cognitive function in asymptomatic HIV-positive subjects. EurNeurol 1999 ; 42 (4) : 225 – 9.
- 253 BlancheS Trdieu M Dulige A etal .Longitudinalstudy of 94 symptomatic infants with perinatally acquired human immunodef iciency virus infection. Evidence for a bimodal expression of clinical and biological symptoms . AmJ Dis Child 1990 ; 144 (11) : 1210 – 5 .
- 254 Bornstein RA Nasrallah HA Bra MF, Whitacre CC Ess RJ Change in neuropsychological performance in asymptomatic HIV infection: 1-year follow-up. AIDS 1993; 7 (12): 1607 11.
- 255 SternRA ArrudaJE Somerville A, et al .Neurobehavioral functioning in asymptomatic HIV-1 infected women . JInt Neuropsychol Soc 1998 ; 4 (2) : 172 – 8 .
- 256. Cole MA, Margolick JB, Cox C, Li X, Selnes O A, Martin EM, et al. Longitudinally preserved psychomotor performance in long-term asymptomatic HIV -infected Individuals. Neurology 2007;69(24):2213–220.
- 257 Kilder W, McArthur JC, Nance-Sproson T, McClernon D, Griffin DE Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. AnnNeurol 1998 ; 44 (5) : 831 – 5.
- 258 Sasseille VG, SmithMM MackayCR etal .Chemokineexpression in simian immunodeficiency virus-induced AIDS encephalitis . AmJ Pathol 1996 ; 149 (5) : 1459 – 67 .
- 259 GrayF, Scarailli F, Earall I etal .Neuropathologyof early HIV-1 infection . BrainPathol 1996 ; 6 (1) : 1 15 .
- 260 . Lui E Kilson D UlrichA FuL Chemokinereceptors in the human brain and their relationship to HIV infection . JNeurovirol 1998 ; 4 : 301 11 .
- 261 Persidsk Y, ZhengJ MillerD GendelmanHE Mononuclearphagocytes mediate blood-brain barrier compromise and neuronal injury during HIV -1-associated dementia. J Leukoc Biol 2000 ; 68 (3) : 413 − 22 .
- 262 Brev BJ BhallaRB Rul M etal .Cerebrospinalfluid beta 2-microglobulin in patients with AIDS dementia complex: an expanded series including response to zido vudine treatment. AIDS 1992 ; 6 (5) : 461 - 5 .
- 263 HesselgesserJ HorukR Chemokineand chemokine receptor expression in the central nervous system . JNeurovirol 1999 ; 5 (1) : 13 26 .
- 264 HesselgesserJ Jub D BaskarP, Greenbeg M HoxieJea Neuonal apoptosis induced by HIV-1 ap 120 and the chemokine SDF-1 alpha is mediated by the chemokine receptor CXCR4. CurrBiol 1998 ; 7 : 595 – 8.
- 265 LetendreSL LanierER McCutchanA Cerebrospinalfluid beta chemokine concentrations in neurocognitively impaired individuals infected with human immunodeficiency virus type 1. JInfect Dis 1999; 180 (2): 310 – 9.
- 266 AndersonE ZinkW, XiongH GendelmanH HIVassociated dementia. A metabolic encephalopathy perpetraded by virus-infected and imune-competent mononuclear phagocytes. J Acquir Immuno Defic Syndr 2002; 1: S43 – 54.
- 267 Poluektøa IY, Munn DH, Persidsky Y, Gendelman HE Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV -1 encephalitis. JImmunol 2002; 168 (8): 3941 – 9.

- 268 LetendreS Marquie-BeckJ SinghKK etal .Themonocyte chemotactic protein-1 -2578G allele is associated with ele vated MCP-1 concentrations in cerebrospinal fluid . J Neuroimmunol 2004 ; 157 (1–2) : 193 6 .
- 269 Clifford DB McArthurJC Schifto G et al .Arandomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment . Neurology 2002 ; 59 (10) : 1568 – 73 .
- 270 RyanLA CotterRL ZinkWE II GendelmanHE ZhengJ Marophages, chemokines and neuronal injury in HIV -1-associated dementia. Cell Mol Biol (Noisy-le-grand)
 2002 ; 48 (2) : 137 - 50 .
- 271 RyanLA Zheng J ,Brester M et al . Plasma levels of soluble CD14 and tumor necrosis factor-alpha type II receptor correlate with cognitive dysfunction during human immunode-ficiency virus type 1 infection . JInfect Dis 2001 ; 184 (6) : 699 706 .
- 272 SternY Whatis cognitive reserve? Theory and research application of the reserve concept . JInt Neuropsychol Soc 2002 ; 8 (3) : 448 60 .
- 273 SternY Cognitive reserve and Alzheimer disease. AlzheimerDis Assoc Disord 2006; 20 (3 Suppl 2): S69 – 74.
- 274 SternY, AlbertS Ting MX TsaiWY Rateof memory decline in AD is related to education and occupation: cognitive reserve? Neurology 1999 ; 53 (9) : 1942 7.
- 275 SternRA Silar SG ChaissonN Earns DL Influenceof cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus-1 infection. Arch Neurol 1996; 53 (2): 148 53.
- 276 . Kepnisky KL BaoJ LinYW Neurobiologyof HIV, psychiatric and substance abuse comorbidity research: workshop report . BrainBehav Immun 2007; 21 (4) : 428 41 .
- 277 .Kepnisky KL Stoff DM RauschDM Workshop report: The effects of psychological variables on the progression of HIV-1 disease . BrainBehav Immun 2004 ; 18 (3) : 246 61 .
- 278 O'Mally S AdamseM HeatonRK Gwin FH Neuropsychologicalimpairment in chronic cocaine abusers . AmJ Drug Alcohol Abuse 1992 ; 18 (2) : 131 44 .
- 279 MillerL Neuropsychological assessment of substance abusers: review and recommendations . J Subst Abuse Treat 1985 ; 2 (1) : 5 – 17 .
- 280 Wood E MontanerJS Jp B etal .Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV -1 infected injection drug users . CMAJ 2003 ; 169 (7) : 656 61 .
- 281 ConchaM GrahamNM MunozA etal .Efect of chronic substance abuse on the neuropsychological performance of intravenous drug users with a high prevalence of HIV-1 seropositivity. AmJ Epidemiol 1992 ; 136 (11) : 1338 – 48 .
- 282 Guerra D , Sole A , Cami J , Jobena A Neuropsychological performance in opiate addicts after rapid detoxification . Drug Alcohol Depend 1987 ; 20 (3) : 261 70 .
- 283 Atkinson JH ,Grant I Natural history of neuropsychiatric manifestations of HIV disease . PsychiatrClin North Am 1994 ; 17 (1) : 17 – 33 .
- 284 Sigel JM AnguloFJ DetelsR Wesch J MullenA AIDSdiagnosis and depression in the Multicenter AIDS Cohort Study: the ameliorating impact of pet o wnership. AIDS Care 1999; 11 (2): 157 – 70.
- 285 Judd FK , Mijch AM Depressive symptoms in patients with HIV infection . Aust N Z J Psychiatry 1996 ; 30 (1) : 104 – 9 .
- 286 Brøn G Rundell J McManisSea Prevalence of psychiatric disorders in early stages of HIV infection . PsychsomMed 1992 ; 54 : 588 – 601 .
- 287 Perry SW, 3rd HIV related depression . Res Publ Assoc Res Nerv Ment Dis 1994 ; 72 : 223-38 .
- 288 Williams JB RabkinJG RemienRH GormanJM EhrhardtAA Multidisciplinary baseline assessment of homosexual men with and without human immunodeficiency virus infection. II. Standardized clinical assessment of current and lifetime psychopathology . Arch Gen Psychiatry 1991; 48 (2): 124 30.
- 289 Penzak SR ,Reddy YS ,Grimsly SR Depression in patients with HIV infection. Am J Health Syst Pharm 2000 ; 57 (4) : 376uiz885-9.

- 290 .AtkinsonJH Jr, Grant I Jánnedy CJ RichmanDD SpectorSA McCutchanJA Prevalence of psychiatric disorders among men infected with human immunodeficiency virus. A controlled study. ArchGen Psychiatry 1988; 45 (9): 859 – 64.
- 291 PerryS Jacobsbeg L CardCA AshmanT, FrancesA FishmanB Severity of psychiatric symptoms after HIV testing. AmJ Psychiatry 1993 ; 150 (5) : 775 – 9.
- 292 PerryS Jacobsber LB FishmanB FrancesA BoboJ Jacobsber BK Psychiatric diagnosis before serological testing for the human immunodef iciency virus. Am J Psychiatry 1990; 147 (1): 89 – 93.
- 293 Rosenbeger PH BornsteinRA NasrallahHA etal .Psychopathologyin human immunode-ficiency virus infection: lifetime and current assessment . Compr Psychiatry 1993 ; 34 (3) : 150 8 .
- 294 AtkinsonJH GrantII Mooddisorder due to human immunodeficiency virus: Yes, No, or Maybe? SeminClin Neuropsychiatry 1997 ; 2 (4) : 276 – 84 .
- 295 Heaton RK , In RA , McCutchan A , et al . Neuropsychological impairment in human immunodeficiency virus-infection: implications for emplo yment. HNRC Group. HIV Neurobehavioral Research Center. PsychosomMed 1994 ; 56 (1) : 8 17 .
- 296 AlfonsoCA CohenMA AladjemAD et al .HIV seropositivity as a major risk factor for suicide in the general hospital . Psychosomatics 1994 ; 35 (4) : 368 73 .
- 297 Carrico AW, Johnson MO, Morin SF, et al. Correlates of suicidal ideation among HIV-positive persons. AIDS 2007; 21 (9): 1199 203.
- 298 .GielenAC, McDonnellKA Q'CampoPJ Burk JG Suiciderisk and mental health indicators: Do they differ by abuse and HIV status? Womens Health Issues 2005; 15 (2): 89 – 95.
- 299 .GrassiL MondardiniD Avanati M Şighinolf L ŞerraA Ghielli F Suicideprobability and psychological morbidity secondary to HIV infection: a control study of HIV -seropositive, hepatitis C virus (HCV)-seropositive and HIV/HCV-seronegative injecting drug users. J Affect Disord 2001 ; 64 (2–3) : 195 – 202 .
- 300 Kelly B Raphael B Judd F, et al . Suicidal ideation, suicide attempts, and HIV infection. Psychosomatics 1998 ; 39 (5) : 405 - 15.
- 301 NandakumarR Depression, suicidality, and HIV. AmJ Psychiatry 1999 ; 156 (5) 2 801 -
- 302 Ry A Characteristics of HIV patients who attempt suicide. Acta Psychiatr Scand 2003 ; 107 (1) : 41 4.
- 303 HolzemerW, CorlessI Noks K etal .Predictorsof self-reported adherence in persons living with HIV disease . AidsPatient Care STDS 1999 ; 13 : 185 – 97 .
- 304 KalichmanS RompaD CageM Distinguishingbetween overlapping somatic symptoms of depression and HIV disease in people li ving with HIV -AIDS. J Nerv Ment Dis 2000 ; 188 : 662 - 70 .
- 305 Singh N ,Berman SM ,Swindells S et al . Adherence of human immunodeficiency virusinfected patients to antiretroviral therapy. ClinInfect Dis 1999 ; 29 (4) : 824 - 30 .
- 306 SinghN SquierC Siek C Wegener M NguyenMH № VL Determinantsof compliance with antiretroviral therapy in patients with human immunodef iciency virus: prospective assessment with implications for enhancing compliance. AIDSCare 1996; 8 (3): 261 – 9.
- 307 HaubrichR etal .Selfreported treatment adherence and drug/alcohol use are associated with virologic outcomes in CCTG 570: A clinical strategy trial of HIV RNA antiretroviral (ARV) monitoring . InternationalConference on AIDS 1998 ; 12 : 597 .
- 308 .ChenLF, Hø J Lwin SR En years of highly active antiretroviral therapy for HIV infection . MedJ Aust 2007 ; 186 (3) : 146 - 51 .
- 309 LucasGM Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven . JAntimicrob Chemother 2005; 55 (4) : 413 6.
- 310 Rris D ,Ledegrerber B ,Weber R et al .Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort . AIDS Res Hum Retro vir 1999 ; 15 (18) : 1631 – 8 .
- 311 Retel AK Petel KK Futureimplications: compliance and failure with antiretroviral treatment. JPostgrad Med 2006 ; 52 (3) : 197 – 200 .

- 312 . PotterSJ Chav CB SteainM DwyerDE SaksenaNK Obstacles to successful antiretroviral treatment of HIV-1 infection: problems & perspectives . IndianJ Med Res 2004 ; 119 (6) : 217 – 37 .
- 313 Jashima KT, FlaniganTP Antiretroviral therapy in the year 2000. InfectDis Clin North Am 2000 ; 14 (4) : 827 49.
- 314 Timer BJ Adherenceto antiretroviral therapy by human immunodeficiency virus-infected patients. JInfect Dis 2002; 1850 uppl2: S143 51.
- 315 With LM Novak MA Adherence and drug resistance: predictions for therapy outcome . ProcBiol Sci 2000 ; 267 (1445) : 835 – 43 .
- 316 Antoni MH ,Schneiderman N ,Fletcher MA ,Goldstein DA , Ironson G ,Laperriere A Psychoneuroimmunologyand HIV-1 . JConsult Clin Psychol 1990 ; 58 (1) : 38 49 .
- 317 CruessDG PetittoJM LesermanJ etal .Depressionand HIV infection: impact on immune function and disease progression . CNSSpectr 2003 ; 8 (1) : 52 8 .
- 318 Eans DL LesermanJ PerkinsDO et al .Severe life stress as a predictor of early disease progression in HIV infection . AmJ Psychiatry 1997 ; 154 (5) : 630 4 .
- 319 LesermanJ Theeffects of depression, stressful life events, social support, and coping on the progression of HIV infection. CurrPsychiatry Rep 2000; 2 (6): 495 502.
- 320 Leserman J HIV disease progression: depression, stress, and possible mechanisms. Biol Psychiatry 2003 ; 54 (3) : 295 306 .
- 321 LesermanJ WhettenK Love K StanglD Swrtz MS ThielmanNM How trauma, recent stressful events, and PTSD af fect functional health status and health utilization in HIV infected patients in the south . PsychosomMed 2005 ; 67 (3) : 500 7 .
- 322 AntoniMH CruessDG KlimasN etal .Increasesin a marker of immune system reconstitution are predated by decreases in 24-h urinary cortisol output and depressed mood during a 10-week stress management intervention in symptomatic HIV-infected men. J Psychosom Res 2005 ; 58 (1) : 3 - 13 .
- 323 DantzerR Cytokine, sickness behavior, and depression . NeurolClin 2006 ; 24 (3)-:6041
- 324 .Gorman JM , Krtzner R P.sychoneuroimmunology and HIV infection . J Neuropsychiatry Clin Neurosci 1990 ; 2 (3) : 241 52 .
- 325 Grippo AJ, Francis J, Beltz TG, Felder RB, Johnson AK, Neuroendocrine and cytokine profile of chronic mild stress-induced anhedonia. PhysiolBehav 2005; 84 (5): 697 706.
- 326 Hayly S MeraliZ AnismanH Stressand cytokine-elicited neuroendocrine and neurotransmitter sensitization: implications for depressive illness. Stress 2003; 6 (1): 19 – 32.
- 327 KanitzE Tichscherer M PuppeB Tichscherer A Stabentow B Consequences of repeated early isolation in domestic piglets (Sus scrof a) on their beha vioural, neuroendocrine, and immunological responses. BrainBehav Immun 2004; 18 (1): 35 45.
- 328 KiankC HoltfreterB Stark A MundtA Wike C SchutC Stresssusceptibility predicts the severity of immune depression and the failure to combat bacterial infections in chronically stressed mice. BrainBehav Immun 2006 ; 20 (4) : 359 68.
- 329 LeonardBE TheHPA and immune axes in stress: the involvement of the serotonergic system . EurPsychiatry 2005 ; 230uppl3 : S302 6.
- 330 Leonard BE HPA and Immune Axes in Stress: Involvement of the Serotonergic System . Neuroimmunomodulation 2006 ; 13 (5–6) : 268 – 76 .
- 331 McDonoughKH Jrag JI Sepsis-inducedmyocardial dysfunction and myocardial protection from ischemia/reperfusion injury. FrontBiosci 2006 ; 11 : 23 32 .
- 332 . O'BrienSM ScottIV , DinanTG Cytokines:abnormalities in major depression and implications for pharmacological treatment . HumPsychopharmacol 2004 ; 19 (6) : 397 – 403 .
- 333 .O'LearyA Stress, emotion, and human immune function . PsycholBull 1990 ; 108 (3)-: 8263
- 334 Rec TW, HuF, MillerAH Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression.
 BrainBehav Immun 2007; 21 (1): 9 19.
- 335 ReicheEM MorimotoHK NunesSM Stressand depression-induced immune dysfunction: implications for the de velopment and progression of cancer . Int Rev Psychiatry 2005; 17 (6): 515 27.

- 336 ReicheEM NunesSO MorimotoHK Stress, depression, the immune system, and cancer. LancetOncol 2004 ; 5 (10) : 617 25 .
- 337 SteinM Stress, depression, and the immune system . JClin Psychiatry 1989 ; 50 uppl 35 40 ; discussion 1-2.
- 338 Sternbeg EM ChrousosGP, Wider RL GoldPW Thestress response and the regulation of inflammatory disease. AnnIntern Med 1992; 117 (10): 854 – 66.
- 339 RadhakrishnaPillai M BalaramP, BinduS HareendranNK Rdmanabhan TK NairMK Interleukin 2 production in lymphocyte cultures: a rapid test for cancer-associated immunodeficiency in malignant cervical neoplasia. CancerLett 1989 ; 47 (3) : 205 – 10.
- 340 Nair PK Rodriguez S Ramachandran R et al .Immunestimulating properties of a novel polysaccharide from the medicinal plant T inospora cordifolia. Int Immunopharmacol 2004 ; 4 (13) : 1645 – 59 .
- 341 NairMPN MahajanS HouJ SweetAM Schwrtz SA Thestress hormone, cortisol, synergizes with HIV-1 gp-120 to induce apoptosis of normal human peripheral blood mononuclear cells. CellMol Biol (Noisy-le-grand) 2000 ; 46 (7) : 1227 – 38.
- 342 Nair A Hunzekr J Bonneau RH Modulation of microglia and CD8(+) T cell activation during the development of stress-induced herpes simple x virus type-1 encephalitis. Brain Behav Immun 2007; 21 (6): 791 – 806.
- 343 NairA BonneauRH Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation . JNeuroimmunol 2006 ; 171 (1–2) : 72 85 .
- 344 ClericiM MerolaM FerrarioE etal .Cytokineproduction patterns in cervical intraepithelial neoplasia: association with human papilloma virus infection. J Natl Cancer Inst 1997; 89 (3): 245 – 50.
- 345 AbdeljaberMH NairMP, SchorkMA Schwrtz SA Depressednatural killer cell activity in schizophrenic patients. ImmunolInvest 1994 ; 23 (4–5) : 259 – 68.
- 346 . AntelmanG KaayaS Wi R etal .Depressive symptoms increase risk of HIV disease progression and mortality among women in Tanzania . JAcquir Immune Defic Syndr 2007 ; 44 (4) : 470 − 7 .
- 347 ColeSW, Kemeny ME Jaylor SE Jascher BR Jahey JL Accelerated course of human immunodeficiency virus infection in gay men who conceal their homose xual identity. PsychosomMed 1996 ; 58 (3) : 219 31.
- 348 CruessDG DouglaSD PetittoJM etal .Associationof resolution of major depression with increased natural killer cell acti vity among HIV-seropositive women. Am J Psychiatry 2005; 162 (11): 2125 30.
- 349 JohnsonJE Finne JW, MoosRH Predictors of 5-year mortality following inpatient/residential group treatment for substance use disorders. AddictBehav 2005; 30 (7): 1300 16.
- 350 Kemeny ME DeanL Effects of AIDS-related bereavement on HIV progression among New York City gay men. AIDSEduc Prev 1995 ; 75 (φpl): 36 – 47.
- 351 Lyketsos CG Hover DR GuccioneM Depressionand survival among HIV-infected persons.
 AMA 1996 ; 275 (1) : 35 6 .
- 352 Lyketsos CG Hower DR GuccioneM etal .Depressive symptoms as predictors of medical outcomes in HIV infection. Multicenter AIDS Cohort Study. AMA 1993 ; 270 (21) : 2563 – 7 .
- 353 MayneTJ Mitinghoff E Chesny MA BarrettDC CoatesTJ Depressive affect and survival among gay and bisexual men infected with HIV. ArchIntern Med 1996 ; 156 (19) : 2233 8.
- 354 Erinpour R MillerEN SatzP,etal .Psychosocialrisk factors of HIV morbidity and mortality: findings from the Multicenter AIDS Cohort Study (MA CS). J Clin Exp Neuropsychol 2003 ; 25 (5) : 654 – 70 .
- 355 Justice AC, McGinnis KA, Atkinson JH et al. Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS 2004 ; Suppl1: S49 – 59.
- 356 CookA, Grg D Burk-Miller J etal .Efects of treated and untreated depressive symptoms on highly active antiretroviral therapy use in a US multi-site cohort of HIV-positive women. AIDSCare 2006; 18 (2): 93 – 100.

- 357 JuddFK CockramAM Kimiti A MijchAM Hy J BellR Depressive symptoms reduced in individuals with HIV/AIDS treated with highly active antiretroviral therapy: a longitudinal study. AustN Z J Psychiatry 2000; 34 (6): 1015 – 21.
- 358 GibbieT, MijchA EllenS etal .Depressionand neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up . HIVMed 2006 ; 7 (2) : 112 21 .
- 359 CastellonSA HardyDJ HinkinCH et al .Components of depression in HIV-1 infection: their differential relationship to neurocogniti ve performance. J Clin Exp Neuropsychol 2006 ; 28 (3) : 420 – 37 .
- 360 SadekJR Jgil O GrantI HeatonRK Theimpact of neuropsychological functioning and depressed mood on functional complaints in HIV-1 infection and methamphetamine dependence. JClin Exp Neuropsychol 2007 ; 29 (3) : 266 – 76.
- 361 PerrySW, Toss S Psychiatricproblems of AIDS inpatients at the New York Hospital: preliminary report. PublicHealth Rep 1984; 99 (2): 200 – 5.
- 362 SternRA PerkinsDO Exms DL Neuropsychiatric manifestations of HIV-1 infection and AIDS. In: BloomFE, Kepfer DJ eds. Psychopharmacology: The fourth generation of progress. New York: Raven Press; 1995 : 1545 – 58.
- 363 Rul R Cohen RA Stern R Neuropsychiatric and neurobehavioral functioning in human immunodeficiency virus. CNSSpectrums 2003; 7: 860 – 6.
- 364 CastellonSA HinkinCH MyersHF Neuropsychiatric disturbance is associated with executive dysfunction in HIV-1 infection . JInt Neuropsychol Soc 2000 ; 6 (3) : 336 47 .
- 365 .Brwn GR RundellJR McManisSE Kendall SN JenkinsRA Neuppsychiatric morbidity in early HIV disease: implications for military occupational function. Vaccine 1993; 11 (5): 560 – 9.
- Beckett A. Neuropsychiatric manifestations of HIV infection. Ne w Dir Ment Health Serv 1990(48):33–42.
- 367 Bøger JR ArendtG HIV dementia: the role of the basal ganglia and dopaminergic systems . JP sychopharmacol 2000 ; 14 (3) : 214 – 21 .
- 368 Rul R FlaniganTP, Tshima K etal .Apathycorrelates with cognitive function but not CD4 status in patients with human immunodef iciency virus. J Neuropsychiatry Clin Neurosci 2005; 17 (1): 114 8.
- 369. Rul RH ,Brickman AM ,Nuia B et al . Apathy is associated with volume of the nucleus accumbens in patients infected with HIV. JNeuropsychiatry Clin Neurosci 2005; 17 (2): 167 71.
- 370 Tate D Paul RH FlaniganTP, etal . The impact of a pathy and depression on quality of life in patients infected with HIV. AIDSPatient Care STDS 2003; 17 (3): 115 20.
- 371 Bruce-Keller AJ Chauhan A DimayugaFO GeeJ Keller JN Nat A Synaptictransport of human immunodeficiency virus-Tat protein causes neurotoxicity and gliosis in rat brain . JNeurosci 2003 ; 23 (23) : 8417 – 22 .
- 372 Lowenstein RJ ,Sharfstein SS Neuropsychiatric aspects of acquired immune deficiency syndrome . IntJ Psychiatry Med 1983 ; 13 (4) : 255 – 60 .
- 373 .ThomasCS SzabadiE Paranoid psychosis as the first presentation of a fulminating lethal case of AIDS . BrJ Psychiatry 1987 ; 151 : 693 5 .
- 374 Mgel-Scibilia SE ,Mulsant BH ,Msshavan MS HIV infection presenting as psychosis: a critique . ActaPsychiatr Scand 1988 ; 78 (5) : 652 6 .
- 375 KleihuesP, LangW, Buger PC etal .Progressive diffuse leukoencephalopathy in patients with acquired immune def iciency syndrome (AIDS) . Acta Neuropathol (Berl) 1985 ; 68 (4) : 333 - 9 .
- 376 Detmer WM , Lu FG Neuropsychiatric complications of AIDS: a literature review . Int J Psychiatry Med 1986 ; 16 (1) : 21 9 .
- 377 KalyoncuOA, Tan D MirsalH PektasO Brazyurek M Majordepressive disorder with psychotic features induced by interferon-alpha treatment for hepatitis C in a polydrug abuser. JPsychopharmacol 2005; 19 (1): 102 – 5.
- 378 Sgreti J ,Harris AA ,Kessler HA ,Busch K Neuropsychiatric complications of human immunodeficiency virus infection . ComprTher 1988 ; 14 (7) : 9 15 .
- 379 Wo SK The psychiatric and neuropsychiatric aspects of HIV disease . J Palliat Care 1988 ; 4 (4) : 50 3 .

- 380 Swell DD JesteDV, McAdamsLA etal .Neuroleptictreatment of HIV-associated psychosis. HNRC group . Neuropsychopharmacology 1994 ; 10 (4) : 223 – 9 .
- 381 Lechin F, and der Dijs B ,Benaim M Benzodiazepines: tolerability in elderly patients. PsychotherPsychosom 1996; 65 (4): 171 – 82.
- 382 . Sekine Y, Minabe Y, Kwai M et al . Metabolite alterations in basal ganglia associated with methamphetamine-related psychiatric symptoms. A proton MRS stud Neuropsychopharmacology 2002 ; 27 (3) : 453 – 61 .
- 383 Ester R ,Olajide D , Exerall IP Antiretroviral therapy-induced psychosis: case report and brief review of the literature . HIVMed 2003 ; 4 (2) : 139 44 .
- 384 Halstead S ,Riccio M ,Harlw P, Oretti R ,Thompson C Psychosis associated with HIV infection . BrJ Psychiatry 1988 ; 153 : 618 23 .
- 385 ArendtG deNocker D øn Giesen HJ NoltingT Neuropsychiatricside effects of efavirenz therapy. ExpertOpin Drug Saf 2007 ; 6 (2) : 147 54.
- 386 PezetS MalcangioM Brain-derived neurotrophic factor as a drug target for CNS disorders. ExpertOpin Ther Targets 2004; 8 (5): 391 – 9.
- 387 ZhouXF, SongXY, ZhongJH BaratiS ZhouFH JohnsonSM. Distribution and localization of pro-brain-derived neurotrophic factor-like immunoreactivity in the peripheral and central nervous system of the adult rat. JNeurochem 2004; 91 (3): 704 – 15.
- 388 Huang EJ ,Reichardt LF .Trk receptors: roles in neuronal signal transduction . Annu Rev Biochem 2003 ; 72 : 609 – 42 .
- 389 HuangW, ZhangC ChenSL etal .[Brain-derived neurotrophic factor induces rat bone marrow stromal cells to differentiate into neuron-like cells in vitro]. Di Yi Jun Yi Da Xue Xue Bao 2004 ; 24 (8) : 854 8.
- 390 BinderDK ScharfmanHE Brain-derived neurotrophic factor. Growth Factors 200422 (3) : 123 - 31.
- 391 BustosG AbarcaJ CampusanoJ BustosV, Noriga V, AliagaE Functional interactions between somatodendritic dopamine release, glutamate receptors and brain-deri ved neurotrophic factor expression in mesencephalic structures of the brain. Brain Res Brain Res Rev 2004 ; 47 (1-3) : 126 - 44 .
- 392 GuillinO Griffon N DiazJ etal .Brain-derived neurotrophic factor and the plasticity of the mesolimbic dopamine pathway. IntRev Neurobiol 2004 ; 59 : 425 44 .
- 393 NaritaM AokiK Takagi M Yijima Y, SuzukiT Implication brain-derived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine. Neuroscience 2003; 119 (3): 767 – 75.
- 394 .Noshen RL BachisA AdenSA DeBernardi MA Mocchettil Intrastriatal administration of human immunodeficiency virus-1 glycoprotein 120 reduces glial cell-line derived neurotrophic factor levels and causes apoptosis in the substantia nigra. JNeurobiol 2006; 66 (12): 1311 – 21.
- 395 Smith MA, Makino S, Køtnansky R, Post RM Efects of stress on neurotrophic factor expression in the rat brain . AnnN Y Acad Sci 1995 ; 771 : 234 9 .
- 396 DiasBG BanerjeeSB DumanRS Midya W Differential regulation of brain derived neurotrophic factor transcripts by antidepressant treatments in the adult rat brain . Neuropharmacology 2003; 45 (4): 553 - 63.
- 397 MamounasLA AltarCA BlueME KaplanDR #ssarollo L fxons WE BDNFpromotes the regenerative sprouting, but not survival, of injured serotoner gic axons in the adult rat brain. JNeurosci 2000; 20 (2) : 771 – 82.
- 398 Cameron DW, Heath-Chiozzi M, Danner S et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritona vir Study Group. Lancet 1998 ; 351 (9102) : 543 – 9.
- 399 Casado JL ,Perez-Elias MJ ,Marti-Belda P, et al .Improved outcome of cytomegalovirus retinitis in AIDS patients after introduction of protease inhibitors . J Acquir Immune Defic Syndr Hum Retrovirol 1998 ; 19 (2) : 130 – 4 .
- 400 AndreP, GroettrupM KlenermanP, etal .Aninhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses . Proc Natl Acad Sci U S A 1998 ; 95 (22) : 13120 4 .

- 401 ZennouV, MammanoF, Rulous S MathezD Chael F Lossof viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. JVirol 1998 ; 72 (4) : 3300 - 6.
- 402 . Training the second seco
- 403 Gibb DM ,Nwberry A ,Klein N ,deRossi A ,Grosch-Werner I ,Baiker A Immune repopulation after HAAR T in pre viously untreated HIV-1-infected children. P aediatric European Network for T reatment of AIDS (PENT A) Steering Committee . Lancet 2000 ; 355 (9212) : 1331 – 2 .
- 404 Cu-UvinS Caliendo AM ReinertS et al . Efect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA . AIDS 2000 ; 14 (4) : 415 – 21 .
- 405 Ruia E Antonelli G Solmone MC et al .Significant reduction in HIV-1 plasma viral load but not in proviral infected cells during sub-optimal antiretro viral therapy. J Biol Re gul Homeost Agents 2000; 14 (1): 1 3.
- 406 DanielV, SusalC MelkA etal .Reductionof viral load and immune complex load on CD4+ lymphocytes as a consequence of highly acti ve antiretroviral treatment (HAART) in HIVinfected hemophilia patients . ImmunolLett 1999 ; 69 (2) : 283 – 9 .
- 407 HoenB DumonB HarzicM etal .Highlyactive antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial . J Infect Dis 1999 ; 180 (4) : 1342 6 .
- 408 MaggioloF, BotturaP, CapraR PiraliA Zafaroni P, SuterF Changesin plasma HIV-RNA and CD4 lymphocyte counts in patients receiving highly active antiretroviral therapy. AIDS 1999 ; 13 (12) : 1594 5.
- 409 LucasGM ChaissonRE MooreRD Highlyactive antiretroviral therapy in a large urban clinic: risk f actors for virologic f ailure and adv erse drug reactions. Ann Intern Med 1999 ; 131 (2) : 81 - 7.
- 410 AbdulleS Hagber L GisslenM Efects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patients. HIVMed 2005; 6 (3): 164 – 9.
- 411 AntinoriA CingolaniA GiancolaML Erbici F, DeLuca A Peno CF Clinicalimplications of HIV-1 drug resistance in the neurological compartment. Scand J Infect Dis Suppl 2003 ; 35uppl106 : 41 – 4.
- 412 Antinori A ,Giancola ML ,Grisetti S et al . Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of adv anced HIV-1-infected patients. AIDS 2002 ; 16 (14) : 1867 76 .
- 413 KandanearatchiA Williams B Escrall IP Assessing the efficacy of highly active antiretroviral therapy in the brain. BrainPathol 2003; 13 (1): 104 – 10.
- 414 Kilson DL Neuropathogenesis of central nervous system HIV-1 infection. ClinLab Med 2002; 22 (3): 703 - 17.
- 415 StrazielleN BelinMF, Ghersi-EgeaJF Choroidplexus controls brain availability of anti-HIV nucleoside analogs via pharmacologically inhibitable organic anion transporters. AIDS 2003 ; 17 (10) : 1473 – 85 .
- 416 ArendtG NoltingT, FrischC etal .Intrathecalviral replication and cerebral deficits in different stages of human immunodeficiency virus disease . JNeurovirol 2007 ; 13 (3) : 225 – 32 .
- 417 Corti ME , Mafane MF, Bare P, et al . [Cerebrospinal fluid viral load in HIV-1 positive hemophilic patients treated with HAART]. Medicina(B Aires) 2001; 61 (6): 821 4.
- 418 GisslenM Sønnerholm B NorkransG etal .Cerebrospinalfluid and plasma viral load in HIV-1-infected patients with various anti-retroviral treatment regimens. Scand J Infect Dis 2000 ; 32 (4) : 365 – 9 .
- 419 SkiestDJ CrosbyC Survial is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma . AIDS 2003 ; 17 (12) : 1787 93 .
- 420 CinqueP, PresiS BestettiA etal .Efect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid . AIDS Res Hum Retro viruses 2001; 17 (5): 377 – 83.

- 421. Cohen R. HAART enhanced cognitive performance among elderly HIV-infected women. In: Graylyn Conference on W omen's Cognitive Health; W ake Forest University, Winston-Salem, North Carolina; 2001.
- 422 Totzi V, NarcisoP, GalganiS et al. Effects of zidovudine in 30 patients with mild to endstage AIDS dementia complex . AIDS 1993 ; 7 (5) : 683 – 92 .
- 423 Ferrando S an Gorp W, McElhing M ,Goggin K ,Swell M ,Rabki J Highly active antiretroviral treatment in HIV infection: benef its for neuropsychological function. AIDS 1998 ; 12 (8) : F65 - 70 .
- 424 Brev BJ Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of ne w forms of AIDS dementia comple x. AIDS 2004 ; [Stupp11: S75 8.
- 425 Jozzi V, Balestra P, Galgani S et al .Neurocognitive performance and quality of life in patients with HIV infection . AIDSRes Hum Retroviruses 2003 ; 19 (8) : 643 52 .
- 426 SacktorN NakasujjaN Skalsky R etal .Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa . Neurology 2006 ; 67 (2) : 311 4 .
- 427 McCutchanA, W JW, RobertsonK etal .HIVsuppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients . AIDS 2007; 21 (9) : 1109 17 .
- 428 Gibb DM ,Goodall RL ,Giacomet V, McGee L ,Compagnucci A Juall H Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. PediatrInfect Dis J 2003; 22 (1): 56 62.
- 429 DesquilbetL GoujardC RouziouxC etal .Doestransient HAART during primary HIV-1 infection lower the virological set-point? AIDS 2004 ; 18 (18) : 2361 9 .
- 430 Jacobson MA ,Khayam-Bashi H ,Martin JN ,Black D ,Ng V Efect of long-term highly active antiretroviral therapy in restoring HIV-induced abnormal B-lymphocyte function. J Acquir Immune Defic Syndr 2002 ; 31 (5) : 472 – 7 .
- 431 KaufmannDE LichterfeldM AltfeldM etal .Limiteddurability of viral control following treated acute HIV infection . PLoSMed 2004 ; 1 (2) : e36 .
- 432 Arnedo-Mero M GarciaF, GilC etal .Riskof selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection . Clin Infect Dis 2005 ; 41 (6) : 883 – 90 .
- 433 Mgel M LichterfeldM KaufmannDE etal .Structuredtreatment interruptions following immediate initiation of HAAR T in eight patients with acute HIV -1 seroconversion. Eur J Med Res 2006 ; 11 (7) : 273 – 8 .
- 434 PriceRW, DeeksSG Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the central nerv ous system. JNeurovirol 2004 ; ISuppl1: 44 - 51.
- 435. Centers for Disease Control. AIDS among persons aged greater than 50 years-United States, 1991–1996; 1998.
 - 436 MackK OryM AIDS and older Americans at the end of the twentieth century. JAcquir Immune Defic Syndr 2003 ; 33 (2) : 568 72 .
- 437 AntinoriA ArendtG Beckr JT, etal .Updatedresearch nosology for HIV-associated neurocognitive disorders . Neurology 2007 ; 69 (18) : 1789 99 .
- 438. Centers for Disease Control. The HIV/AIDS epidemic in the United States, 1997–1998. HIV/AIDS Surveillance Report 1999;11(1):1–43.
- 439. Center for Disease Control and Prevention. HIV/AIDS Surveilance. 2001;13(2).
- 440 Cassado J ,Perez-Elias M ,Antela A et al . Predictors of long-term response to protease inhibitor therapy in an unselected cohort of HIV-infected patients . AIDS 1997 ; 11 : F113 6 .
- 441 Manfredi R HIV disease and advanced age: an increasing therapeutic challenge. Drugs Aging 2002 ; 19 (9) : 647 69 .
- 442 Manfredi R Nanetti A Mentini R CalzaL ChiodoF Frequercy, epidemiology, risk factors, clinical and bacteriological features of enterococcal disease in patients with HIV infection in a decade survey. New Microbiol 2002 ; 25 (2) : 179 – 86.
- 443 ManfrediR Evolution of HIV disease in the third millennium: clinical and related economic issues . IntJ Antimicrob Agents 2002 ; 19 (3) : 251 – 3 .

- 444. World Health Organization. The World Health Organization Report; 1999.
- 445 Beckr JT, LopezOL Dev MA AizensteinHJ Prevalence of cognitive disorders differs as a function of age in HIV virus infection . AIDS 2004 ; \$\$upl1:\$11 8.
- 446 ChernerM EllisR LazzarettoD etal .Efects of HIV-1 infection and aging on neurobehavioral functioning: Preliminary data . AIDS 2004 ; 18 (Suppl S19 – S26 .
- 447 .GoodkinK ShapshakP, AsthanaD ZhengW, ConchaF, etal Older age and plasma viral load in HIV-1 infection. AIDS 2004 ; 18 (Subpl S87 – S98 .
- 448 GoodkinK AsthanaD ShapshakP, ConchaM Wikie F, KhamisI Neurocognitive symptoms and immunological and virological correlates in older HIV -1 seropositive individuals. The Gerontologist 2002 ; 42 (speissule 1): 81 - 2.
- 449 GoodkinK Wikie FL ConchaM etal .Agingand neuro-AIDS conditions and the changing spectrum of HIV-1-associated morbidity and mortality. J Clin Epidemiol 2001; 58uppl 1: S35 – 43.
- 450 Biros RB DagaragM Menzuela HF Invitro senescence of immune cells. ExpGerontol 2003 ; 38 (11-12) : 1243 9.
- 451 Trazona R CasadoJG DelarosaO etal .Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-nai ve HIV-1-seropositive individuals . JClin Immunol 2002 ; 22 (3) : 176 – 83 .
- 452 Menzuela HF, Biros RB Divergent telomerase and CD28 expression patterns in human CD4 and CD8 T cells following repeated encounters with the same antigenic stimulus. Clin Immunol 2002 ; 105 (2) : 117 25.
- 453 PhillipsAN LeeCA ElfordJ etal .Morerapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts . JAcquir Immune Defic Syndr 1991 ; 4 (10) : 970 5 .
- 454 FerroS SalitIE HIV infection in patients over 55 years of age. JAcquir Immune Defic Syndr 1992 ; 5 (4) : 348 - 53 .
- 455 Bfros RB Impactof the Hayflick Limit on T cell responses to infection: lessons from aging and HIV disease . MechAgeing Dev 2004 ; 125 (2) : 103 6.
- 456 DorrucciM SerrainoD RezzaG Theeffect of aging on the incidence of Kaposi's sarcoma among HIV-positive individuals with kno wn dates of serocon version. Int J Cancer 2003 ; 104 (2) : 251 4 .
- 457 Tarazona R SolanaR OuyangQ Pewelec G Basicbiology and clinical impact of immunosenescence. ExpGerontol 2002; 37 (2–3): 183 – 9.
- 458 EngelsEA Humanimmunodeficiency virus infection, aging, and cancer. JClin Epidemiol 2001 ; 58uppl1: S29 34 .
- 459 LiebermanR HIVin older Americans: an epidemiologic perspective . JMidwifery Womens Health 2000 ; 45 (2) : 176 82 .
- 460 HaynesBF, HaleLP Thehuman thymus. A chimeric organ comprised of central and peripheral lymphoid components. ImmunolRes 1998; 18 (2): 61 78.
- 461 Sempwski GD HaynesBF Immune reconstitution in patients with HIV infection . Annu Rev Med 2002 ; 53 : 269 84 .
- 462 SmolaS Justice AC, Wegner J RabeneckL Waissman S Rodrigez-Barradas M Veterans aging cohort three-site study (VACS 3): overview and description. JClin Epidemiol 2001; 54 Suppl1: S61 – 76.
- 463 Joborek M LeeYW, PuH etal .HIVTat protein induces oxidative and inflammatory pathways in brain endothelium . JNeurochem 2003; 84 (1): 169 79.
- 464 ArendtG HefterH NellesHW, HilperathF, Strohmær G Agedependent decline in cognitive information processing of HIV -positive individuals detected by event-related potential recordings. JNeurol Sci 1993 ; 115 (2) : 223 – 9.
- 465 Mince DE Cortical and subcortical dynamics of aging with HIV infection . Percept Mot Skills 2004 ; 98 (2) : 647 - 55 .
- 466 CohenR DrugAbuse, Aging, and HIV Disease in the Brain .In: Societyfor Neurosciences ; SanDiego, California 2001.
- 467. Chang L, Lee PL, Yiannoutsos CT, Ernst T, Marra CM, Richards T, et al. A multicenter in vivo proton MRS study of HIV-associated dementia and its relationship to age. Neuroimage 2004;23(4):1336–47.

- 468 Mccour V, ShikumaC Waters M SacktorN Cognitive impairment in older HIV-1 seropositive individuals: prevalence and potential mechanisms. AIDS 2004 ; 18 (Suppl S79 – 86.
- 469 DanielsonME Justice AC Veterans Aging Cohort Study (VACS) meeting summary. JClin Epidemiol 2001; 58uppl1: S9 – 11.
- 470 HinkinCH CastellonSA AtkinsonJH GoodkinK Neuropsychiatricaspects of HIV infection among older adults . JClin Epidemiol 2001 ; 5%uppl1 : S44 – 52 .
- 471 IngramF, Ketonen L Par D Avery E Memoryimplications of a "fornix white line" in HIV infection. JNeuroAIDS 2002; 2 (3): 83 90.
- 472 ChernerM EllisRJ LazzarettoD etal .Efects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings . AIDS 2004 ; Suppl1 : S27 - 34 .
- 473 Stoff DM Mentalhealth research in HIV/AIDS and aging: problems and prospects . AIDS 2004 ; ISauppl1: S3 10 .
- 474 Mcour V, ShikumaC , Shiramizu B et al . Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort . Neurology 2004 ; 63 (5) : 822 7.
- 475 Mccour VG, ShikumaCM Matters MR SacktorNC Cognitive impairment in older HIV-1seropositive individuals: prevalence and potential mechanisms. AIDS 2004 ; 1\$uppl 1: S79 - 86.
- 476 KisselEC Pukay-MartinND BornsteinRA Therelationship between age and cognitive function in HIV-infected men. JNeuropsychiatry Clin Neurosci 2005; 17 (2): 180 4.
- 477 SelnesOA Memoryloss in persons with HIV/AIDS: assessment and strategies for coping. AIDSRead 2005; 15 (6): 2894–.92,
- 478 .ThompsonPM DuttonRA HayashiKM etal .Thinningof the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphoc yte decline. Proc Natl Acad Sci U S A 2005 ; 102 (43) : 15647 - 52 .
- 479 ThompsonPM DuttonRA HayashiKM etal .3Dmapping of ventricular and corpus callosum abnormalities in HIV/AIDS . Neuroimage 2006 ; 31 (1) : 12 – 23 .
- 480 Valcour V, Rul R HIV infection and dementia in older adults. Clin Infect Dis 2006; 42 (10): 1449 54.
- 481 Mccour V, & P, Wiliams AE etal .Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection–The Hawaii Aging with HIV Cohort . JNeurovirol 2006 ; 12 (5) : 387 91 .
- 482 Mcour VG, Sacktor NC, Rul RH et al .Insulin resistance is associated with cognition among HIV-1-infected patients: the Hawaii Aging With HIV cohort. J Acquir Immune Defic Syndr 2006 ; 43 (4) : 405 – 10 .
- 483 . Where D BurrageJ Chemosensory declines in older adults with HIV: identifying interventions . J Gerontol Nurs 2006 ; 32 (7) : 42 – 8 .
- 484 . Wrice DE Areview of metacognition in aging with HIV. Percept Mot Skills 2006 ; 103 (3) : 693-6 .
- 485 Mcour V, SacktorN HIVassociated dementia and aging. JMent Health Aging 20028; 295 - 306.
- 486 . Justice AC, Whalen C Aging in AIDS; AIDS and aging . JGen Intern Med 1996 ; 110)(: 645 7 .
- 487 RabkinJ McElhing M FerrandoS Moodand substance abuse in older adults with HIV/ AIDS: methodological issues and preliminary evidence. AIDS 2004 ; **(Suppl1)**: S43 – S8.
- 488 .ThurnherMM SchindlerEG ThurnherSA PernerstorferSchon H Kleibl-Ppov C Riger A Highly active antiretroviral therapy for patients with AIDS dementia complex: effect on MR imaging findings and clinical course. AJNRAm J Neuroradiol 2000 ; 21 (4) : 670 8 .
- 489 DoreG CorrellP, LiY, KaldorJ CooperD Brev B Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 1999 ; 13 : 1249 53.
- 490 ColeM Magolick JB CoxC LiX SelnesOA, MartinEM Ph.D.5 Beckr JT, Aronw HA CohenB SacktorN MillerEN and the Multicenter AIDS Cohort Study. Longitudinally Preserved Psychomotor Performance in Long-term Asymptomatic HIV-infected Individuals. Neurology 2007; 69 (24): 2213 – 20.
- 491 ChangL LeePL Mannoutsos CT, etal .Amulticenter in vivo proton-MRS study of HIVassociated dementia and its relationship to age . Neuroimage 2004 ; 23 (4) : 1336 – 47 .

- 492 Yannoutsos CT, ErnstT, ChangL et al .Regional patterns of brain metabolites in AIDS dementia complex . Neuroimage 2004 ; 23 (3) : 928 35 .
- 493 Nuia BA, Rostasy K The AIDS dementia complex: clinical and basic neuroscience with implications for novel molecular therapies . NeurotoxRes 2005 ; 8 (1-2) : 3 24.

Youth with HIV/AIDS: Neurobehavioral Consequences

Susannah Allison, Pamela L. Wolters, and Pim Brouwers

Epidemiological Data on Children and Adolescents with HIV Globally and Within the US

While HIV/AIDS is primarily considered a disease that af fects adults, there are a substantial number of children and adolescents li ving with the disease throughout the world. At the end of 2007, it was estimated that there were 2.5 million children (those less than 15 years) li ving with HIV around the world (1). An additional 10 million adolescents and young adults (2) (15–24-years old), also are living with HIV. Just under half a million children became ne wly infected with HIV in 2007 (1) and almost 6,000 young people become infected every day (3). The majority of children living with HIV reside in sub-Saharan Africa; ho wever, large numbers of children with HIV also live in the Caribbean, Latin America, and South/South East Asia.

The numbers of infants becoming infected in the United States have decreased substantially over the past 15 years due to breakthroughs in the prevention of mother-to-child transmission using antiretro viral therapy and increased access to care (4). In 1991, the number of estimated perinatal HIV-infections reached a peak at 1,650 (5) and declined to an estimated range of 144–236 in 2002 (CDC, unpublished data, 2006). Among adolescents, v ery little change has occurred in new infections of HIV from 1994 through 2002 (6). An estimated 4,883 youth were diagnosed with HIV-infection or AIDS in 2004, representing about 13% of the persons given a diagnosis during that year(7). In developing countries where access to HIV testing and the prevention of mother -to-child transmission (PMTCT) prophylaxis therapy is not widely available and breast feeding is almost universal,

S. Allison (\boxtimes)

Infant, Child, & Adolescent Research Programs, Center for Mental Health Research on AIDS, Division of AIDS & Health and Behavior Research, National Institute of Mental Health, NIH, Bethesda, MD USA allisonsu@mail.nih.gov

rates of mother-to-child transmission remain high (4). PMTCT coverage remains low with less than 10% of pre gnant women offered services worldwide, resulting in an increasing pediatric HIV epidemic (8).

The majority of children living with HIV (around 90%) acquired the virus via mother-to-child transmission (vertical transmission), either in utero, intrapartum, or through breastfeeding (9). Other routes of transmission during childhood and adolescence include exposure in a medical setting (the use of unsterilized needles or a blood transfusion), through risk y sexual behavior, either v oluntary or coerced, or from drug use. Lastly, some children are e xposed through sexual abuse or rape.

Given the numbers of children and adolescents li ving with HIV in the world, and the fact that HIV is a neuro virulent virus, it is important to understand the impact that HIV/AIDS and its treatment ha ve on the developing central nervous system (CNS).

Overview of Impact of HIV on the CNS in Children

Infants and children infected with human immunodef iciency virus-type 1 (HIV-1) are at increased risk for de veloping CNS disease, that may impact cogniti ve, language, motor, and behavioral functioning. The severity of HIV-related CNS manifestations in children range from subtle impairments in one or two specific domains to severe deterioration of global developmental skills.

Neuropathology

In high resource environments, severe CNS dysfunction in children with HIV disease is typically the result of HIV-1 infection in the brain (10, 11). HIV-1 has been isolated from the CNS tissue of fetuses (12) and the cerebral spinal fluid (CSF) of adults soon after infection (13-15) suggesting early CNS in vasion. The timing of CNS infection for inf ants is variable and likely influences neuropathology and neurodevelopmental effects (12, 16-18). Astrocytes, macrophages, and microglia may be infected with HIV -1, while neurons seem to remain lar gely uninfected. Various neurotoxic factors released by the virus and host cells are postulated as the main cause of neurologic damage (11, 19, 20). Secondary CNS complications due to immune deficiency, such as brain tumors, other infections such as Cytongalovirus (21), or cerebrovascular diseases, also may cause CNS manifestations b ut are less common in de veloped countries and usually occur in older children (22).Coinfections, however, are more common in infants in the developing world, even among those that are not yet immunocompromized (23, 24) and can result in significant CNS manifestations (25, 26).

Prevalence of HIV-Related CNS Disease

Prior to the introduction of antiretro viral therapy, approximately 50–90% of children with HIV-1 infection exhibited severe CNS manifestations (27, 28) termed HIV encephalopathy. Subsequent studies, when combination therap y was standard of care, ha ve reported HIV encephalopathy prevalence rates of approximately 13–23% (29–32). The prevalence rates in the era of highly active antiretroviral therapy (HAART) have not yet been determined, but probably are e ven lower. Children exhibit CNS disease more frequently than adults (16 vs. 5%) (32) with new pediatric cases of encephalopathy occurring primarily during the first 2 years after birth (32) and often as the initial AIDS-defining symptom (32, 33). When adults as well as older children and adolescents develop CNS complications it tends to be more common during the advanced stages of the disease (33, 34). Some of the key similarities and differences in the impact of HIV-1 on the CNS between adults and children are listed in T able 1.

The decline in the prevalence of severe HIV-related CNS manifestations may be related in part to the earlier and more generalized use of combination antiretroviral treatment (ART), including HAART that combines various agents with at least one protease inhibitor (PI) or nonnucleoside re verse transcriptase inhibitor (35–38). HAART is effective in suppressing systemic viral replication (39), which in turn may reduce the number of HIV-infected cells entering the CNS (40). However, the CNS is a separate compartment from the rest of the body and it may serv e as a reservoir for persistent HIV-1 infection (41). Many antiretroviral agents, including

Adults	Children
CNS HIV-1 invasion during primary infection, often followed by compart- mentalization	CNS HIV-1 invasion during primary infection, likely also often followed by compartmen- talization
Target cells include macrophages, micro- glia, and to a lesser degree astrocytes	Same target cells, but astrocytes may play a more central role and neurons may also be actively infected
Long latent period between infection and neurological manifestations	Neurological disease more often the first AIDS- defining illness, even before important immunodeficiency
Deterioration of mature CNS with brain atrophy	Impairment of immature CNS and impaired brain growth
Both motor and cognitive functions deteriorate	Motor, cognitive, and language functions are impaired
CNS opportunistic infections and cerebrov- ascular disease are common	Cerebrovascular disease and CNS opportunistic infections are rare, but the latter may be more frequent in developing countries
ART reduces incidence and can reverse neu- rological manifestations present at the start of treatment	Similar preventive and therapeutic effects of antiretroviral treatment on CNS manifestations

Table 1 Key features of HIV-1 neuroAIDS in children and adults (42)

PIs, do not penetrate well into the CNS (43, 44). Since HAART has become available, a proportional increase in AIDS dementia complex compared to other AIDSdefining illnesses has occurred in adults with HIV -1 disease (45). In a pediatric study of children being treated with HAART, IQ scores were significantly different between patients with encephalopathy, CNS compromise, and no apparent CNS disease; however, the absolute CD4 counts and viral loads of the three groups were not significantly different (46). These studies suggest that combination AR T may provide systemic benefits, but not be as effective in treating the CNS (47) so that HIV-infected patients with well-controlled systemic disease may still be at risk for developing CNS manifestations.

In addition to the effects of HIV-1 on the developing brain, infected children also may have other medical and environmental risk factors that can contribute to neurobehavioral abnormalities. Thus, assessment of neurobehavioral functioning throughout childhood and adolescence is important for identifying and monitoring the effects of HIV-1 on the CNS o ver time, evaluating response to antiretro viral therapy, making treatment decisions, and planning educational and rehabilitati ve interventions. Neuropsychological test scores also can provide information, beyond that obtained from medical surrogate markers of HIV status that is predictive of later disease progression (48, 49).

Clinical Presentation of HIV-Related CNS Disease in Children

Pediatric HIV-related encephalopathy has characteristic features and distinct patterns, although the clinical presentation varies in onset, severity, and prevalence in different subgroups. Factors associated with variations in the presentation of HIVrelated CNS manifestations include age of infection, route and timing of transmission, maternal and child disease status, genetic factors, treatment history, and other medical and environmental conditions.

Infants and young children tend to exhibit the highest rates of HIV-related CNS disease and the most severe neurodevelopmental impairments (50–52), while older children and adolescents tend to ha ve the lowest rates and less se vere manifestations of CNS disease (29, 52, 53). The greatest risk for encephalopathy occurs during the first year of life, when it is often the initial AIDS-def ining symptom (30–33, 54). Children with early onset of HIV encephalopathy , before the age of 1 year, have smaller head circumference and lower body weight at birth, suggesting a different pathophysiology compared to later occurring encephalopathy (32).

Major factors determining the risk for the de velopment of encephalopathy seem to be the timing of the infection as well as maternal and inf ant characteristics. Earlier infection seems to be associated with higher risk for CNS disease and more severe CNS manifestations. Vertically-infected children with apparent utero transmission (positi ve HIV-1 cultures or polymerase chain reaction positivity during the first week of life) more often display se vere HIV disease (55) and poorer neurode velopmental function (18) compared to children with presumed intrapartum infection (ne gative cultures at birth), who in turn are more affected than children infected through blood or blood products in early childhood (33, 56). Adolescents infected with HIV, often through sexual transmission, also appear to have less CNS symptoms, with a clinical presentation resembling that seen in adults (34).

The in-utero environment also seems to moderate the risk of encephalopathy; it is highest in HIV-infected children born to mothers with more advanced disease as measured by CD4 cell count and viral load (57) and is lo west in children also infected in the perinatal period through blood or blood products b ut born to uninfected mothers (33, 56). Infant factors associated with a high risk for the de velopment of CNS disease are high plasma viral loads (31, 32, 58, 59), more severe immunodeficiency early in life (30–32, 55), and host genetic f actors in the child (60–62). ART may prevent the development of HIV-associated CNS manifestations as HIV-infected children who are nai ve to ART (52) or who are on monotherap y (53) appear to be at greater risk than children on combination AIT, such as HAART (38, 63). Very early ART exposure, however, as in children with HIV -1 infection exposed to zidovudine in utero and for 6 weeks after birth, does not seem to provent encephalopathy or cognitive deficits (32, 64).

Finally, other medical and en vironmental conditions, such as maternal substance abuse during pregnancy, low birthweight, preterm birth, e xposure to toxic substances (i.e., lead), other CNS infections, impoverished socioeconomic and en vironmental background, and psychosocial difficulties, also may negatively influence the development of children with HIV-1 infection. As vertically-infected children live longer, such conditions may have a greater cumulative impact on neurobehavioral function and need to be considered when assessing the effects of HIV-1 on the developing CNS.

Patterns of HIV-Related CNS Disease in Children

Despite variations in the presentation of CNS disease among different subgroups of children with HIV-1 infection, three main patterns have been described: encephalopathy, CNS compromise, and apparently not affected (65, 66).

HIV-related encephalopathy is characterized by perv asive and severe CNS dysfunction. Children with HIV-related encephalopathy exhibit global impairments in cognitive, language, motor, and social skills as well as significant neurologic impairments that affect their day-to-day functioning. Although overall functioning tends to be globally impaired in encephalopathic children, dif ferential deficits may be observed in selective functions. For example, expressive language is often more severely impaired or may deteriorate more quickly than recepti ve language. HIVrelated encephalopathy can be progressive (subacute or plateau subtypes) or static (67–69). Subacute progressive encephalopathy, the most severe subtype, is characterized by progressive, global deterioration, and loss of previously-acquired abilities and skills. In the plateau course of progressi ve encephalopathy, the acquisition of new skills becomes slower compared to their pre vious rate of development or may stop, but previously-acquired milestones are not lost. Both subacute and plateau subtypes result in a significant decline in standardized scores on repeated neurode-velopmental testing. Children with static encephalopathy continue to consistently gain new skills and abilities but at a slower rate than their normally developing peers. Thus, their scores on standardized tests are belo w average but remain stable o ver time. The prevalence of encephalopathy appears to be declining in pediatric HIV disease, most likely due to earlier treatment and improved therapeutic options. New cases of encephalopathy are seen most often in inf ants and young children (29, 30, 32), particularly those naive to ART (52), and older children in adv anced stages of disease (34). Encephalopathy is listed as a Cate gory C condition in the CDC classification system for HIV infection in children less than 13 years (70).

HIV-related CNS compromise is characterized by o verall cognitive functioning that is within normal limits but with either significant decline in psychometric test scores in one or more areas of neurobeha vioral functioning, which remains abo ve the low average range, or significant impairments in selective neurodevelopmental functions (66). Patients who were functioning within normal limits b ut exhibited significant improvements after initiation or change in ART also are included in this category. Children with HIV-related CNS compromise continue to ha ve adequate functioning in school and activities of daily living. With the widespread availability of HAART, children displaying CNS disease are more lik ely to exhibit this more subtle form of CNS compromise rather than the more severe and pervasive encephalopathy that was frequently seen during the f irst decade of the AIDS epidemic. CNS compromise is not a condition listed in the CDC classification system for HIV infection in children (70) but is comparable with the HIV-1-associated mild neurocognitive disorder (MND) in the new revised research criteria for HIV -associated neurocognitive disorders among adults published in 2007 (71).

The CNS of children is considered to be apparently not af fected by HIV when their cognitive functioning is at least within the normal range and without e vidence of HIV-associated significant deficits, decline in functioning, neurological abnormalities that affect day-to-day functioning, or therapy-related improvements.

Children infected with HIV-1 also may have non-HIV-related CNS impairments. Some HIV-1-infected children may be at greater risk for these non-HIV -related CNS impairments because of their complicated medical histories and/or dif ficult social situations. It is possible for children to e xhibit both HIV- and non-HIVrelated impairments. Determining whether de velopmental deficits are related to HIV-1 disease or other etiologies is complex but is important for making treatment decisions particularly in low-resource settings.

Effects of Antiretroviral Treatment on Cognitive Function

ART may be pre ventative and/or therapeutic for HIV -associated CNS disease. Since 1996, patients with HIV disease in de veloped countries have been offered HAART, which contains at least three dif ferent antiretroviral agents. With the availability of

effective HAART, the prevention of CNS disease appears to be related to the suppression of systemic viral replication, which reduces or eliminates the in vasion of HIVcarrying cells into the CNS (40). However, the CNS is a separate compartment from the rest of the body and it may serv e as a reservoir for persistent HIV-1 infection (41) and there is evidence that HIV may invade the CNS shortly after systemic infection, and in infants even in the early stages of gestation (12). Some antiretroviral agents have been found to penetrate the blood–brain barrier (44, 72, 73), inhibit viral replication in the CNS (74, 75), and reduce the neurotoxic effects of the virus on the brain (19, 76). In children with evidence of HIV-associated CNS manifestations, treatment studies ha ve shown that some antiretro viral drugs, particularly used in combination (46), may improve neurobehavioral functioning (53, 77, 78) as well as reduce cortical atrophy (79). These improvements in CNS functioning are lik ely due to treatment-related decreases in viral replication in the brain (75, 80).

Findings regarding the impact of HAART on the neurodevelopmental functioning of children are somewhat mixed. Rates of progressive encephalopathy and static encephalopathy have declined since the advent of HAART, decreasing from 40.7 to 18.2% (81). Young children treated with HAAR T, including a protease inhibitor, exhibited limited improvements in neurode velopmental functioning when compared with a group of HIV-exposed but HIV- infants (63), but at 3 years there were no significant differences between the two groups any longer. Another study failed to find overall improvements in neuropsychological functioning in a large group of HIV+ children following a change in treatment to a PI based re gimen (82). The later study did not include a control group, but instead compared scores with established norms. In a study of twelv e relatively immunocompetent children receiving their first HAART regimen, there were no significant changes in cognitive functioning over the course of the 96-week follo w-up period (83). There were also no changes noted in the mean rating of CT brain scan abnormality at weeks 24 and 48. However, one child, also described in a case series (84), evidenced declines in her performance IQ score at week 24. The patient's regimen was changed to include zidovudine instead of stavudine and her IO score improved back to baseline level. Within the French Perinatal Cohort (84), none of the infants born since 1996 and who initiated HAART before 6 months of age (n = 40) developed encephalopathy, whereas 3 of the 43 inf ants who started HAAR T after age 6 months de veloped encephalopathy during the first 2 years of life. In summary, findings indicate that children with HIV-related neurobehavioral deficits should be gi ven ART that includes at least one agent that has adequate CNS penetration, such as zido vudine (ZDV) or stavudine, in order to reduce HIV replication in the CNS.

Neuroimaging Findings

Previous research and clinical observations have indicated a reasonable correspondence between the findings from brain imaging studies and current le vel of neurocognitive functioning in children with HIV CNS disease, particularly in children prior to ART (17, 86) and increasingly in those receiving ART (87, 88). Cortical atrophy (seen either as v entricular dilatation and/or sulcal enlar gement) is a good indicator of degree of compromise (86, 89) and has been correlated with CSF viral load (89). Moreover, significant changes in cortical atrophy are associated with comparable changes in neurocognitive functioning (17, 90). Intracerebral calcifications also indicate significant HIV-related CNS compromise. Such lesions are most frequently seen in young vertically-infected children and have been associated with poor prognosis and encephalopathy, particularly when moderate to se vere cortical atrophy is also noted (91). Minor white matter abnormalities detected on MRI brain imaging are frequently transient and have not been associated with altered cognitive function (92, 93). However, more severe white matter lesions that are apparent on CT brain scans ha ve been related to cogniti ve impairments (94). While more advanced brain imaging techniques, such as diffusion tensor imaging and multisectoral structural imaging, have been used in adults to evaluate the impact of HIV on white matter (95, 96), studies using these techniques in children have not yet been published.

Proton magnetic resonance spectroscopy (¹HMRS), which allows for noninvasive measurement of brain metabolites associated with different aspects of neural cell function (97), provides markers of the effects of HIV in the brain that are different from changes seen on structural neuroimaging (98, 99). In children with HIV-associated CNS disease, studies demonstrated a decrease in N-acetyl aspartate (NAA) signal or in the N AA/Cr (creatine) ratio suggesting a decrease in neuronal density. These studies also noted an increase in the lactate signal, which may indicate active inflammation or severe tissue damage causing impaired blood perfusion and resulting ischemia (100–102). Moreover, normalization was seen in these parameters with ART; an increase in the NAA/Cr ratio and a decrease in the lactate peak was evident after the initiation of therap y in two children with progressive encephalopathy (102). Another study of children with MRS abnor malities stable on HAART (103) failed to note changes in ¹HMRS metabolites over time. A decreased choline creatine ratio (CHO/Cr), which could be indicative of demyelination has also been found in pediatric patients without encephalopathy when compared with control children (100). Recent research also suggests that HIV-infected children do not demonstrate a normal age-associated increase in NAA in the frontal white matter and hippocampus (104). Children with more cell loss in the hippocampus and resultant lo wer choline concentrations appeared to have poorer spatial skills. ¹HMRS is not a standard component of the clinical evaluation of children with HIV b ut clearly offers possibilities to further monitor HIV-associated CNS disease, evaluate the effects of therapy, and investigate the neuropathogenesis of neurobeha vioral manifestations. Future studies need to in vestigate whether ¹HMRS can be used in children with HIV infection as early indicators of brain abnormalities or delays in normal de velopment. In children who continue to have HIV-associated encephalopathy but who have shown a decrease in structural brain imaging ¹HMRS abnormalities, improvements may reflect incomplete functional recovery.

Neurodevelopmental Functioning in Specific Domains Among Children in Developed Countries

General Cognitive Function

As noted earlier, children with HIV CNS disease can present with a wide range of neurodevelopmental sequelae. In children with HIV encephalopathy, the effects of the disease on the CNS tend to be generalized with cogniti ve function and brain structures severely and globally affected (66, 90, 105) although some domains (i.e., receptive/expressive language, gross/fine motor) may be dif ferentially impaired. Furthermore, measures of general cognitive functioning are sensitive to HIV-related changes in CNS function and correlate well with information obtained through other studies, such as brain imaging (86, 94) cerebrospinal fluid analysis (10, 91) and virological and immunological parameters (105). However, in children with less severe CNS manifestations, the abnormalities may be less generalized (17) and neurobehavioral functions may be differentially affected by HIV.

Infants infected with HIV generally score lo wer than serore verters on several measures of early development (106–109). Mean developmental test scores ranged from the borderline to low average range (107, 108). However, in a study, where the children diagnosed with an AIDS-def ining diagnosis (with the e xception of lymphoid interstitial pneumonia) were e xcluded (109), HIV-infected infants did not differ from the group of serore verters. More recent data suggest that inf ants with more severe HIV symptomatology may remain at risk for compromised neurode-velopmental outcomes (110), while infants who are treated effectively (62) or are considered long-term nonprogressors may evidence neurodevelopment comparable to uninfected children from similar backgrounds and f amilies.

During the past 10–15 years, research has increasingly focused on the neurodevelopmental functioning of HIV -infected school-aged children gi ven that lar ger numbers of children are surviving into adolescence and adulthood (87, 88, 111– 114). Earlier in the epidemic, children who survived to be over the age of 6 exhibited significantly less evidence of CNS disease when compared with children under the age of 3 (52, 115). Children who survi ved into childhood and adolescence tended to have slower disease progression and experience lower rates of opportunistic infections and encephalopathy early in life. Ov erall, performance on global cognitive measures of intelligence in school-aged HIV+ children ha ve been found to fall in the average to low average range (47, 87, 111, 114, 116-118) with some children presenting with severe neurocognitive impairments as well as neurologic and neuroimaging abnormalities (52, 88, 114). See Fig. 1 for a graphical representation of the relationship between neuroimaging abnormalities and composite cognitive scores in children treated with HAAR T, based on data from Martin and colleagues (88). This figure illustrates that the group with CT scans that are within normal limits have IQ scores that follow the normal curve, while the scores of the group with mild-moderate CT scan abnormalities are more positi vely skewed.




Fig. 1 Full scale IQ distributions for the within normal limits (WNL) computed tomography (CT) brain scan group, the minimal to moderate abnormalities (MMA) CT brain scan group, and the theoretical normal curve (87)

Children and adolescents infected as a result of hemoglobin treatment also e xhibit cognitive functioning that generally is within the normal range. Minimal differences in functioning were evident between HIV+ and HIV– hemophilia patients (119–121). The prevalence of neurological dysfunction w as low and generally limited to participants in adv anced stages of immunodef iciency (122) (CD4+ cell counts below 200). Given that there is now almost universal access to HAART for children living in developed countries, more children ha ve access to effective treatment from an early stage and therefore are less likely to experience severe immunosuppression and CNS disease. Dif ferences in neurocogniti ve functioning associated with immune dysfunction may become less pronounced while other relationships between CNS manifestations and f actors unrelated to prior disease or HAAR T exposure may become more important. Gi ven that global cogniti ve measures may not detect subtle deficits (123), it is important to e valuate specific areas of neuropsychological functioning for potential deficit areas as described below.

Language

Language deficits are a major characteristic of neurobehavioral dysfunction in pediatric HIV disease, which marks a signif icant difference with the impact of HIV on adults as language skills are generally left intact (124). Among children with symptomatic HIV-1 infection, speech and language abnormalities are frequently present (28, 125–127). These abnormalities may appear prior to declines in cogniti ve function (125, 128) and even when receiving antiretroviral therapy (128). Expressive language tends to be significantly more impaired than receptive language in pediatric HIV disease. Children with HIV -1 encephalopathy exhibit more deficient overall language skills than do nonencephalopathic children; ho wever, the degree of discrepancy between receptive and expressive language is similar for both these groups (127). Furthermore, uninfected siblings score higher than their HIVinfected siblings on tests of both expressive and receptive language and do not show a discrepancy between these two language components (127) suggesting that the deficit is related to HIV disease and not en vironmental factors. In a study of children who were neurologically asymptomatic (CT or MRI were normal), there were no dif ferences in language functioning between HIV+ children and a group of seroreverters (111). HIV-related language deficits may be due in part to an impoverished representation of words and objects likely related to reduced neural netw orks in the brain (129). The differential deficit in expressive language also may reflect a more general HIV-associated impairment of expressive behavior (130), including motor function and emotional language (131).

Executive Functioning

Executive functioning has been attracting more attention as an important domain to study among children and adolescents. In this section, only research that involves the direct assessment of executive functions will be reviewed. Research that focuses on caregiver and child self-reports of beha vior and attentional def icits have been included in the section on behavioral, psychosocial, adaptive and family functioning. Executive functioning has many components, such as the ability to sustain or fle xibly redirect attention, the inhibition of inappropriate beha vioral or emotional responses, the planning of strategies for future behavior, the initiation and execution of these strategies, and the ability to flexibly switch among problem-solving strategies. These various abilities may be differentially affected in pediatric HIV disease. In one small study, both asymptomatic and symptomatic HIV+ children e videnced deficits on executive functioning measures when compared with a group of seroreverters (111). In a study of attention among children and adolescents with hemophilia (132), children and adolescents with HIV-1 and hemophilia exhibited greater difficulty sustaining attention over time on a continuous performance task when compared to the children with hemophilia who were HIV-. In another small study comparing school-aged children with HIV with age-appropriate norms, the only differences between groups were on neuropsychological tests assessing attentional flexibility, visuospatial working memory, and processing speed (113). Koekkoek and colleagues found significant relationships between w orking memory functioning and a higher percentage of CD4 cells at initiation of HAART as well as longer treatment duration and attentional control. Similarly, Martin and colleagues (88) found that higher CD4+ percentages were related to higher working memory and processing speed scores in children treated with HAART. Furthermore, scores on measures of global cognitive functioning and tasks in volving executive functions (88) were significantly lower in HIV-infected children with minimal to moderate brain scan abnormalities compared with children with normal CT brain scans. These studies suggest that relationships between immune functioning and subtle neuropsychological functions may exist.

Memory

In general, studies of children with v ertically acquired HIV-1 infection have documented memory impairments (112, 133, 134) while studies of children with transfusion-acquired HIV infection, either for hemophilia or neonatal problems, ha ve not found deficits in memory function (56, 120, 121, 135). More recently, however, declines in memory functioning o ver time were found in HIV -infected hemophiliacs with low CD4 counts (136). In addition, children with evidence of HIV CNS compromise exhibited significantly poorer performance on v erbal learning and recall trials compared with children without CNS compromise, while these two groups performed similarly on a recognition task (137, 138). Such a pattern suggests a retrie val deficit, which is similar to findings from studies of memory in HIV -infected adults, and may indicate subcortical pathology (139–141). Given that children with neurologic abnormalities (134, 137, 138) and poorer immune function (111, 136) exhibit more frequent and severe memory deficits, the etiology is likely related to HIV infection rather than other factors.

Motor Functioning

Children with HIV-1 CNS disease frequently e xhibit motor impairments, which often coexist with cognitive deficits (51, 107, 142)). In a large multicenter clinical trial, approximately 23% of symptomatic children who were naive to antiretroviral therapy exhibited some type of motor dysfunction (51). Infants less than 1 year of age developed motor impairments more frequently than school-age children (51) (45 vs. 9%, respectively). Children with encephalopathy and/or abnormal CT scans exhibit the most severe motor involvement and may lose previously attained motor milestones (67, 143). Gross motor function, particularly running speed and agility, tends to be more impaired than f ine motor skills when compared with the normal reference population (144). In a small study comparing HIV+ children to a control group of siblings of children with HIV infection, subtle motor impair ments were documented in the HIV+ group. Scores for both groups fell within the average range, however, children with HIV had lower performance on measures of fine motor skill and motor strength (87). Oral-motor functioning also may be affected resulting in articulation problems, expressive language deficits, and feeding and swallowing difficulties (126). Motor deficits may interfere with developmental progress and the performance of everyday living skills. Furthermore, motor dysfunction is highly predictive of later disease progression (48).

Behavioral, Psychosocial, Adaptive, and Family Functioning

In addition to cognitive deficits, children with HIV-1 infection may also present with behavioral and emotional difficulties. Psychosocial functioning may be negatively influenced by the effects of HIV disease on the CNS, prenatal insults, the psychological stresses of living with a chronic illness, exposure to additional stressors of living in a f amily exposed to HIV/AIDS (parental death, substance use, poverty), prolonged exposure to antiretroviral therapy, and other f amilial genetic factors. In some studies, certain beha viors have been linked to immune status and the presence of encephalopathy. As assessed by a standardized parent report scale, children with encephalopathy e xhibited more severe impairments in e veryday behaviors, such as daily living skills and socialization skills, compared with children without encephalopathy (144). Furthermore, deficits in adaptive behavior were associated with CT brain scan abnormalities (94) and immune status (144).Improvements in adaptive functioning were noted after the initiation of ART (145) suggesting that impairments in adaptive functioning are related to the effects of HIV-1 on the CNS.

Approximately two out of every five (40%) children with HIV disease meet the criteria for attention deficit/hyperactivity disorder (145-148, ADHD). This rate is higher than expected, given that the rate within the general population is thought to be between 3 and 7% (150). It is unclear, however, whether this increased pre valence of attention problems are directly attrib utable to HIV (121, 147, 148). Such attention deficits in children with HIV -1 may contribute to school and learning problems and may respond to stimulant medication.

In terms of beha vioral and emotional problems, children and adolescents with HIV appear to have higher rates compared with established national norms (117, 151) but similar rates to those among HIV -exposed but uninfected children (147, 148, 152) and/or with a demographically-matched non-HIV-exposed control group (147, 153). Behavior in these studies w as assessed on beha vior checklists completed by the primary care giver. Another study (46) found that rates of psychiatric diagnosis reported by parents were not significantly different between patients with or without CNS disease. Additionally among HIV+ adolescents, those who have lost a parent were more likely to report a history of depression (151). These findings suggest that some behavior problems are not related to the effects of HIV on the CNS but rather to other etiologies, such as environmental conditions, biological factors, or psychosocial difficulties.

Little has been published on the pre valence of more se vere psychiatric illness among HIV-infected children. Gaughn and colleagues (146) documented higher rates of psychiatric admissions among perinatally-infected youth in the P ACTG 219C cohort. Rates were compared to both the general pediatric population as well as a group of HIV- b ut HIV-exposed children. Out of 1,808 participants, 32 had been hospitalized at some point in their life for psychiatric manifestations. Fifteen of the 32 had been hospitalized more than once. Common reasons for admission included depression (n = 16) and behavioral disorders (n = 8).

Neurodevelopmental Outcomes Among Children in Developing Countries

The majority of research on the neurodevelopment of children living with HIV disease has been conducted in de veloped countries such as the US, France, Italy, and the UK; however, a small number of studies have been conducted in developing countries. This line of research is particularly important gi ven that the majority of HIV+ children currently are being born and living in these settings. While there are many lessons to be learned from research within de veloped countries, there are a number of factors that distinguish these populations. Children gro wing up in de veloping countries face different challenges than children in de veloped countries that may impact their neurode velopment, including the a vailability and quality of prenatal care, increased prevalence of coinfections (cerebral malaria, tuberculosis, and bacterial meningitis), access to medical treatment, and appropriate nutrition (zinc def iciency and protein malnutrition) and v ariability in the access to and quality of education. Malaria as well as other common comorbidities such as malnutrition or micronutrient deficiencies may interact with HIV and result in w orse neurocognitive outcomes among children (25). Lastly, some of the children studied in the United States ha ve also been exposed to drugs of ab use in utero, such as crack cocaine and heroin. Therefore, it is unclear if the findings from the US will generalize to populations of vertically-infected children that have not been exposed to the same types of drugs. While, studies have been conducted in a number of high prevalence countries including Uganda, Thailand, and Brazil, there are still man y questions that remain to be answered about the neurodevelopment of children within these environments.

The majority of neurode velopmental studies in de veloping countries ha ve focused on early child de velopment, predominantly within the first 2 years of life (133, 154–157). Two important domains of functioning during this time period are a child's cognitive and motor development. Significant differences begin to emerge between HIV– and HIV+ children in these domains during their first 2 years of life. Overall, cognitive development appears less af fected than motor de velopment among HIV+ infants (133, 155–158); however, HIV+ infants demonstrate earlier onset of cognitive impairment when compared with uninfected inf ants (154, 155). While the mean scores on a measure of cogniti ve ability for both HIV+ and HIV– but exposed children were found to f all in the average range, scores for the HIV+ children were significantly lower (154). Additionally, higher percentages of HIV+ children have been found to f all within the deficient range, when compared with children who seroreverted (159).

Even fewer studies have focused on the neurode velopment of school-aged children in developing countries (160, 161). As a result of increased access to testing and antiretro viral therapy, more children in late childhood and adoles-cence are being identified with HIV (162) and greater numbers of HIV+ children will be surviving into late childhood and be yond. In a school-aged sample of HIV+, ART naïve children in Uganda, cogniti ve and academic functioning w as in the normal range. No dif ferences were noted between the HIV+ children and

two control groups (one of serore verters and one group of age and gender matched HIV- children). This sample of HIV+ children is unique in that these children were most likely long-term nonprogressors. The majority of the studies described within developing countries have focused on children who were not taking ART due to a lack of access to medications. A recent study from Thailand highlights how access to AR T for children is be ginning to increase in v arious parts of the developing world (161). This small study of 34 HIV+ children compared three groups with different treatment histories: (1) those starting HAAR T, (2) those who had been treated with HAART for at least 1 year, and (3) those who remain untreated. The children were follo wed for a year and their psychomotor functioning was monitored during that time. Psychomotor performance deteriorated in all three groups o ver the course of the study, even in those treated with HAART. In another study (163), Thai children with HIV did not evidence higher rates of emotional or behavioral problems as assessed by the Thai version of the child behavioral checklist when compared with children with hematologic/oncologic diseases, or children from similar socioeconomic backgrounds. The authors report high levels of emotional and behavioral problems within these groups; half of the children in each group had signif icant problems, with adolescent females being the most at risk.

Some of the limitations that plague research on the neurode velopmental functioning of children li ving with HIV disease in de veloped countries also apply to research in developing countries. Limitations include the lack of neurodevelopmental assessment instruments that are culturally appropriate and ha ve local norms, small sample sizes, lack of an appropriate control group, use of screening measures instead of more comprehensive assessment tools, and studying only asymptomatic children thus limiting the generalizability of the findings.

The study of the neurode velopment of children living with HIV in de veloping countries is in its inf ancy. More research needs to be undertak en to address a number of questions, including determining the best methods for assessing neurodevelopment in these varying contexts, the impact of other medical conditions on a child's neurodevelopment (e.g., malaria, malnutrition/diarrhea, TB, etc.) and whether these other conditions may actually compound the effects of HIV, and lastly the role of contextual variables in a child's neurodevelopment (e.g., maternal health, family functioning, stigma in the community).

Issues Regarding Neurodevelopmental Assessment of Children with HIV Disease

As the research reviewed in this chapter indicate the approach taken when evaluating a child's neurodevelopment is crucial. Within the developed world, children are experiencing lower rates of encephalopathy; however, more subtle, domain specific deficits are being identified. Detecting more subtle deficits requires the administration of a more comprehensi ve battery that includes man y different domains of functioning so that patterns of functions that are differentially affected can be determined in children and adolescents with HIV.

In resource poor settings, conducting comprehensi ve neurodevelopmental assessments can be almost impossible and even administration of screening batteries can be challenging. Barriers to an adequate assessment include lack of access to appropriate neurodevelopmental tests, due to lack of availability in the child's language or those that are culturally appropriate, scarcity of indi viduals trained to conduct neurodevelopmental assessments, and not enough resources to support the inclusion of neurodevelopmental testing within a clinic or hospital setting. More efforts are needed to de velop valid and reliable assessment tools and approaches that can be used in these settings. Lastly, both within de veloped and developing countries, the use of appropriate norms and control groups for comparisons are essential. As has been demonstrated in multiple studies within the US, high pre valence rates of neurobehavioral abnormalities in HIV+ youth have been found to be similar to control groups when appropriate matched controls were used (e.g., HIVexposed but not infected children; (147, 152). Studies making comparisons to general population norms or controls that are not matched on important factors such as socioeconomic status may lead to incorrect conclusions, specif ically attributing differences to HIV status instead of other factors such as the environment.

Conclusions

Advances in ART has made a signif icant impact in reducing the pre-valence and severity of CNS disease in children and adolescents in de veloped countries; however, much research remains to be done. In the ne xt decade, pediatric research in HIV disease will likely focus on infants and children born in developing countries and adolescents with either perinatal or beha viorally-acquired HIV infection in higher resource environments. Studies conducted so f ar can provide guidance for addressing neurobehavioral issues in certain neurodevelopmental domains (general intellectual functioning, language functioning); ho wever, data are lacking in other areas (executive functioning, memory). The numbers of youth with beha viorallyacquired HIV and adolescents and young adults with perinatally-acquired HIV are increasing and represent important groups to study. However, at this time, no studies of cognitive functioning specifically in behaviorally HIV-infected youth have been identified in the literature; in articles in which these groups were included, numbers were small and the subsample otherwise w as not characterized. Finally, CNS disease continues to be evident in a subset of patients, even those treated with HAART. Thus, research investigating the neuropathogenesis of HIV CNS disease and specific treatments and interventions for those affected is still needed.

The authors would like to thank Ari Silbermann for his e xtensive literature review focusing on international research and Staci Martin and Annelies v an Rie for allowing us to use their materials. The views expressed in this chapter do not necessarily represent the views of the NIMH, NIH, HHS, or the United States Go vernment.

References

- 1. UNAIDS/WHO. AIDS Epidemic Update. New York: UNAIDS/WHO; 2007.
- 2. UNAIDS. 2004 Report on the Global AIDS Epidemic. New York: UNAIDS; 2004.
- 3. UNAIDS. 2002 Report on the Global HIV/AIDS Epidemic. New York: UNAIDS; 2002.
- Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. *Cochrane Database Syst Rev.* 24 Jan 2007;(1):CD003510.
- 5 . Lindgren ML ByersRH Jr, ThomasP, etal . Tends in perinatal transmission of HIV/AIDS in the United States. JAMA . 11Aug 1999; 282 (6) : 531 538 .
- 6 . BiddlecomAE Trends in sexual behaviours and infections among young people in the United States .*Sex Transm Infect*. Dec2004; 8(Suppl2: ii 74 79).
- 7. CDC. CDC HIV/AIDS Surveillance Report, 2004. Vol. 16. Atlanta: US Department of Health and Human Services, CDC; 2005.
- USAID U, WHO, UNICEF POLICY Project. Coverage of selected services for HIV/AIDS prevention, care and support in low and middle income countries in 2003. Washington, DC: Policy Project; 2004.
- 9. UNAIDS. AIDS Epidemiology Update 2006. New York: UNAIDS; 2006.
- 10 SeiS Stwart SK Frley M etal .Evaluation of human immunodeficiency virus (HIV) type 1 RNA levels in cerebrospinal fluid and viral resistance to zido vudine in children with HIV encephalopathy *J Infect Dis* . Dec1996 ; 174 (6) : 1200 1206 .
- 11 ZhengJ GendelmanHE TheHIV-1 associated dementia complex: a metabolic encephalopathy fueled by viral replication in mononuclear phagoc ytes. *Curr Opin Neurol*. Aug 1997; 10 (4): 319 325.
- 12 Juman WD Tanaka KE KressY, RashbaumWK RubinsteinA SoeiroR Zidovudine concentrations in human fetal tissue: implications for perinatal AIDS . Lancet. 26 May 1990; 335 (8700) : 1280 – 1281.
- 13 Duis LE HjelleBL MillerVE etal .Earlyviral brain invasion in iatrogenic human immunodeficiency virus infection. *Neurology* . Sep1992 ; 42 (9) : 1736 – 1739 .
- 14 .GarciaF, NieblaG RomeuJ etal .Cerebrospinalfluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV -1 infection: support for the hypothesis of local virus replication .*AIDS* . 20Aug 1999; 13 (12) : 1491 1496 .
- 15 HoD RotaT, Schooly R etal .Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodef iciency syndrome .N Engl J Med . 1985; 313 (24): 1493 1497.
- 16 .Giitello L BrouwersP, DeCarliC PizzoP Calcification of the basal ganglia in children with HIV infection .*Ann Neurol* . 1994 ; 36 : 506 .
- 17 DeCarli C , Giitello LA Brouwers P, Pizzo A. The prevalence of computed tomographic abnormalities of the cerebrum in 100 consecutive version ver
- 18 SmithR MaleeK CharuratM etal .Timing of perinatal human immunodeficiency virus type 1 infection and rate of neurodevelopment. The Women and Infant Transmission Study Group. *Pediatr Infect Dis J*. Sep2000 ; 19 (9) : 862 – 871.
- 19 Gendelman HE Zheng J ,Coulter CL et al . Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodef iciency virus-associated dementia. *J Infect Dis*. Oct1998; 178 (4): 1000 – 1007.
- 20 KaulM LiptonSA Mechanisms of neuronal injury and death in HIV-1 associated dementia . Curr HIV Res . Jul 2006 ; 4 (3) : 307 – 318 .
- 21 Kvacs A SchluchterM Easle K etal .Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric Pulmonary and Cardio vascular Complications of Vertically Transmitted HIV Infection Study Group . N Engl J Med . 8 Jul 1999; 341 (2): 77 84 .

- 22 Sharer L , Mintz M Neuropathology of AIDS in children . In: Scarailli F, ed AIDS: The Pathology of the Nervous System .Berlin SpringerVerlag; 1993 : 201 - 214 .
- 23 Grimwde K FrenchN MbathaDD ZunguDD DedicoatM GilksCF Childhoodmalaria in a region of unstable transmission and high human immunodef iciency virus prevalence. Pediatr Infect Dis J. Dec2003; 22 (12): 1057 - 1063.
- 24 Alatela SP, MateeMI MunubhiEK Seroprevalence of hepatitis B and C viral co-infections among children infected with human immunodef iciency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar -es-Salaam, Tanzania. BMC Public Health . 2007 ; 7 (147) : 338 .
- 25 . Noton CR Interaction between Plasmodium falciparum and human immunodef iciency virus type 1 on the central nervous system of African children. J Neurovirol. 2005; ISuppl3: 45 - 51.
- 26 Wimshurst JM Bugess J Hartly P, Ely B Specifc neurologic complications of human immunodeficiency virus type 1 (HIV -1) infection in children . J Child Neurol. Sep 2006: 21(9): 788 - 794.
- 27 BelmanAL DiamondG DicksonD etal .Pediatricacquired immunodeficiency syndrome. Neurologic syndromes .Am J Dis Child . Jan 1988; 142 (1) : 29 - 35 .
- 28 EpsteinLG SharerLR Olesk JM etal .Neurologicmanifestations of human immunodeficiency virus infection in children. Pediatrics. Oct1986; 78 (4): 678 - 687.
- 29 . BlancheS Nevell ML MayauxMJ etal .Morbidityand mortality in European children vertically infected by HIV-1. The French Pediatric HIV Infection Study Group and European Collaborati ve Study J Acquir Immune Defic Syndr Hum Retrovirol . 15Apr 1997; 14 (5): 442 - 450.
- 30 Lobato MN Caldwell MB NgP, Oxtoby MJ Encephalopathy in children with perinatally acquired human immunodeficiency virus infection. Pediatric Spectrum of Disease Clinical Consortium .J Pediatr . May 1995 ; 126 P5 1) : 710 - 715 .
- 31 CooperER HansonC DiazC etal .Encephalopathyand progression of human immunodeficiency virus disease in a cohort of children with perinatally acquired human immunodef iciency virus infection. W omen and Inf ants Transmission Study Group . J Pediatr . May 1998; 132 (5) : 808 - 812 .
- 32 Trdieu M LeChenadec J Persoz A Meer L Blanche S Mayaux MJ HIV1-related encephalopathy in infants compared with children and adults. French Pediatric HIV Infection Study and the SEROCO Group. Neurology. 14Mar 2000; 54 (5): 1089 - 1095.
- 33 Mintz M Clinical comparison of adult and pediatric NeuroAIDS . Adv Neuroimmunol. 1994 ; 4 (3) : 207 - 221 .
- 34 MitchellW Neurologicaland developmental effects of HIV and AIDS in children and adolescents .Ment Retard Dev Disabil Res Rev . 2001 ; 7 (3) : 211 - 216 .
- 35 Brodt HR Kamps BS Gute P, Knupp B Staszwski S Helm EB Changing incidence of AIDS-defining illnesses in the era of antiretro viral combination therapy. AIDS. 15 Nov 1997; 11 (14): 1731 - 1738.
- 36 d'Arminio-MonforteA DucaP, Vgo L GrassiM MoroniM Decreasing incidence of CNS AIDS-defining events associated with antiretroviral therapy. Neurology 2000 ; 54 : 1856 - 1859 .
- 37 Pella FJ Jr, Delane KM MoormanAC, et al. Declining morbidity and mortality among patients with adv anced human immunodef iciency virus infection. HIV Outpatient Study Investigators .N Engl J Med . 26Mar 1998; 338 (13): 853 - 860 .
- 38 Tardieu M Boutet A HIV1 and the central nervous system . Curr Top Microbiol Immunol. 2002 ; 265 : 183 - 195 .
- 9. Deeks S, Smith M, Holodniy M, Kahn J HIV1 Protease Inhibitors. JAMA 1997 ; 277 (2) : 145 - 153 .
- 40 McCrossanM MarsdenM CarnieFW, etal .Animmune control model for viral replication in the CNS during presymptomatic HIV infection. Brain. Feb2006; 129 (Pt: 503 - 516.
- 41 SonzaS Crove SM Reservoirs for HIV infection and their persistence in the face of undetectable viral load. AIDS Patient Care STDS. Oct2001; 15 (10): 511 - 518.
- 42. Van Rie A, Harrington PR, Dow A, Robertson K. Neurologic and neurodevelopmental manifestations of pediatric HIV/AIDS: a global perspecti ve. Eur J Pediatr Neurolo 2007;11(1):1-9.

- 43 Aveeka F, Jaywaardene A StapranaS etal . Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex. J Acquir Immune Defic Syndr Hum Retrovirol . 1999 ; 20 : 39 – 43 .
- 44 SwindellsS Therapy of HIV-1 Infection: A practical guide for providers .New York : Chapman & Hall ; 1998 .
- 45 DoreG CorrellP, LiY, KaldorJ CooperaD Brev B Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. *AIDS*. 1999; 13: 1249 1253.
- 46. Wolters P, Martin S, Tamula MA, Zeichner S, Civitello L, Hazra R. Classification of pediatric HIV central nervous system (CNS) disease: comparison of CNS and systemic disease markers fo children treated in the HAART era. *Conference on HIV Infection and the Central Nervous System: Developed and Resource Limited Settings*. Rome, Italy; 2005:32.
 - 47 RaskinoC PearsonDA, Bakr CJ etal .Neurologic,neurocognitive, and brain growth outcomes in human immunodef iciency virus-infected children recei ving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical T rials Group 152 Study T eam. *Pediatrics*. Sep1999; 104 (3) : e32.
 - 48 LlorenteA BrouwersP, CharuratM etal .Earlyneurodevelopmental markers predictive of mortality in infants infected with HIV-1. *Dev Med Child Neurol*. Feb2003; 45 (2) : 76 84 .
 - 49 PearsonDA, McGrathNM NozyceM etal .PredictingHIV disease progression in children using measures of neuropsychological and neurological functioning. Pediatric AIDS clinical trials 152 study team. *Pediatrics* . Dec2000 ; 106 (6) : E76 .
 - 50 ChaseC , Webert M PeltonSI CoulterDL CabralH Earlyneurodevelopmental growth in children with vertically transmitted human immunodef iciency virus infection. Arch Pediatr Adolesc Med. Aug1995; 149 (8): 850 – 855.
 - 51 Chase C Ware J Hittelman J et al . Early cognitive and motor development among infants born to women infected with human immunodeficiency virus. Women and Infants Transmission Study Group .*Pediatrics*. Aug2000; 106 (2) : E25.
 - 52 Englund JA, Baker CJ, Raskino C et al. Clinical and laboratory characteristics of a lar ge cohort of symptomatic, human immunodeficiency virus-infected infants and children. AIDS Clinical Trials Group Protocol 152 Study T eam. *Pediatr Infect Dis J*. Nov 1996; 15 (11): 1025 1036.
 - 53 McKinny RE Jr, JohnsonGM Stanly K etal .Arandomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. *J Pediatr*. Oct1998; 133 (4) : 500 – 508.
 - 54 ScottGB HuttoC Makuch W, etal .Survival in children with perinatally acquired human immunodeficiency virus type 1 infection. N Engl J Med . 28Dec 1989; 321 (26) : 1791 – 1796 .
 - 55 MayauxMJ Bugard M Jaglas JP,etal .Neonatalcharacteristics in rapidly progressive perinatally acquired HIV-1 disease. The French Pediatric HIV Infection Study Group . JAMA . 28 Feb 1996; 275 (8): 606 610.
 - 56 CohenSE MundyT, KarassikB LiebL LudwigDD Wird J Neuropsychologicalfunctioning in human immunodeficiency virus type 1 seropositive children infected through neonatal blood transfusion. *Pediatrics*. Jul1991; 88 (1): 58 – 68.
 - 57 BlancheS MayauxMJ RouziouxC etal .Relation of the course of HIV infection in children to the se verity of the disease in their mothers at deli very. N Engl J Med. 3 Feb 1994; 330 (5): 308 312.
 - 58 Lindsy JC HughesMD McKinny RE etal .Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RN A and CD4 cell counts as predictors of weight growth failure, cognitive decline, and survival in HIV-infected children. *J Infect Dis*. Nov 2000; 182 (5): 1385 – 1393.
 - 59 Pollack H Kichuk A , Cwan L et al . Neurodevelopment, growth, and viral load in HIVinfected infants .*Brain Behav Immun* . Sep1996 ; 10 (3) : 298 – 312 .
 - 60 JustJJ Abrams E Louie LG et al .Influence of host genotype on progression to acquired immunodeficiency syndrome among children infected with human immunodeficiency virus type 1 .J Pediatr . Oct1995; 127 (4) : 544 549 .

- 61 LlorenteA BrouwersP, ThompsonB etal .Efects of polymorphisms of chemokine receptors on neurodevelopment and the onset of encephalopathy in children with perinatal HIV-1 infection .Appl Neuropsychol . 2006 ; 13 (3) : 180 – 189 .
- 62 . Ses BolerAM NguyenGT, etal .Protective effect of CCR5 delta 32 heterozygosity is restricted by SDF-1 genotype in children with HIV -1 infection. *AIDS* . 27 Jul 2001; 15 (11) : 1343 1352 .
- 63. Lindsey JC, Malee KM, Brouwers P, Hughes MD. Neurodevelopmental functioning in HIVinfected infants and young children before and after the introduction of Protease inhibitor based highly active antiretroviral therapy. *Pediatrics*. 12 Feb 2007.
- 64 CulnaneM Fwler M LeeSS etal .Lackof long-term effects of in utero exposure to zidovudine among uninfected children born to HIV -infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA . 13Jan 1999; 281 (2): 151 – 157 .
- Force WGotAAoNAT. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 infection. *Neurology* 1991;41:778–785.
- 66 Wolters P, BrouwersP Evaluation of neurodevelopmental deficits in children with HIV infection .In: GendelmarH LiptonS EpsteinL SwindellsS eds. *The Neurology of AIDS* .New York : Chapman& Hall; 1998 : 425 442 .
- 67 BelmanAL HIV1-associated CNS disease in infants and children *.Res Publ Assoc Res Nerv Ment Dis* . 1994 ; 72 : 289 – 310 .
- 68 BrouwersP, MossH Witers P, SchmittA Developmental Deficits and Behavioral Change in Pediatric AIDS .In: Grant MartinA eds. *Neuropsychology of HIV Infection* .New York : OxfordUniversity Press; 1994 : 310 – 338 .
- 69 EpsteinLG SharerLR JoshiVV, Bjas MM Kenigsberger MR Odske JM Progressive encephalopathy in children with acquired immune def iciency syndrome. *Ann Neurol*. May 1985; 17 (5): 488 – 496.
- CDC. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age; Official authorized addenda: human immunodeficiency virus infection codes and official guidelines for coding and reporting ICD-9-CM. *MMWR*. 1994;43(RR-12):1–10.
- Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. *Neurology*. 30 Oct 2007;69(18):1789–1799.
 - 72 HaasDW, StoneJ CloughLA etal .Steady-statepharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodef iciency virus type 1 infection . *Clin Pharmacol Ther*. Oct2000; 68 (4) : 367 – 374 .
 - 73 .Hworth SJ ,Christoflo B ,Anderson RD ,Dunkle LM A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults . J Acquir Immune Defic Syndr Hum Retrovirol . 1Mar 1998; 17 (3) : 235 238 .
 - 74 Budraine NA, HoetelmansRM LangeJM etal .Cerebrospinal-fluidHIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. *Lancet*. 23May 1998; 351 (9115) : 1547 – 1551.
 - 75 McCoigC CastrejonMM CastanoE etal .Efect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy. *J Pediatr* . Jul2002; 141 (1) : 36 – 44 .
 - 76 MuellerB PizzoP Antiretroviral therapy for HIV infection of the central nervous system in children .In: GendelmanH LiptonS EpsteinL SwindellsS eds. *The Neurology of AIDS*. New York : Chapman& Hall ; 1998 : 486 495 .
 - 77 .Brouwers P, Moss H, Wilters P, et al. Effect of continuous-infusion zidovudine therapy on neuropsychologic functioning in children with symptomatic human immunodef iciency virus infection .J Pediatr . Dec1990; 117 (6): 980 – 985.
 - 78 Pizzo PA, Eddy J Enloon J et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection . N Engl J Med. 6 Oct 1988; 319 (14) : 889 896.
 - 79 DeCarliC FugateL Filoon J et al .Brain growth and cognitive improvement in children with human immunodeficiency virus-induced encephalopathy after 6 months of continuous infusion zidovudine therapy. *J Acquir Immune Defic Syndr*. 1991; 4 (6): 585 592.

- 80 Archoan R Beg G BrouwersP, etal .Preliminaryobservations in the response of HTLV-III/ LAV (Human Immunodeficiency Virus) – associated neurological disease to the administration of 3-azido-3-deoxythymidine. *Lancet* 1987 ; i : 131 – 135.
- 81 ShanbhagMC RutsteinRM ZaoutisT, ZhaoH ChaoD Radclife J Neurocognitive functioning in pediatric human immunodef iciency virus infection: ef fects of combined therap y. *Arch Pediatr Adolesc Med*. Jul2005; 159 (7): 651 – 656.
- 82 JeremyRJ KimS NozyceM etal .Neuropsychologicalfunctioning and viral load in stable antiretroviral therapy-experienced HIV-infected children. *Pediatrics*. Feb 2005; 115 (2): 380 - 387.
- 83 Hazra R Jankelevich S Mackall CL et al .Immunologic, virologic, and neuropsychologic responses in human immunodef iciency virus-infected children recei ving their first highly active antiretroviral therapy regimen. *Viral Immunol*. Spring2007; 20 (1) : 131 141 .
- 84 Jimula MA Wolters PL Walsek C ZeichnerS Quitello L Cognitive decline with immunologic and virologic stability in four children with human immunodef iciency virus disease. *Pediatrics*. Sep2003; 112 P\$ 1): 679 – 684.
- 85 Frye A ChenadecJL DollfusC etal .Earlyversus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. *Clin Infect Dis*. 2004; 39 (11): 1692 1698.
- 86 BrouwersP, DeCarliC Quitello L MossH Walters P, PizzoP Correlationbetween computed tomographic brain scan abnormalities and neuropsychological function in children with symptomatic human immunodeficiency virus disease. *Arch Neurol*. Jan1995; 52 (1): 39 – 44.
- 87 BlanchetteN SmithML KingS Fernandes-Penny A ReadS Cognitive development in school-age children with v ertically transmitted HIV infection . Dev Neuropsychol. 2002 ; 21 (3) : 223 – 241 .
- 88 Martin SC , Wilters PL , Jiedo-Tamula MA Zeichner SL , Hazra R Civitello L Cognitive functioning in school-aged children with vertically acquired HIV infection being treated with highly active antiretroviral therapy (HAART). *Dev Neuropsychol*. 2006; 30 (2): 633 657.
- 89 BrouwersP, Gütello L DeCarliC Wilters P, SeiS Cerebrospinal fluid viral load is related to cortical atrophy and not to intracerebral calcif ications in children with symptomatic HIV disease *J Neurovirol*. Oct2000; 6 (5): 390 – 397.
- 90 BrouwersP, DeCarliC Todor-Williams G Guitello L MossH Pzzo P Interrelationsamong patterns of change in neurocognitive, CT brain imaging and CD4 measures associated with anti-retroviral therapy in children with symptomatic HIV infection . *Adv Neuroimmunol*. 1994; 4 (3): 223 231.
- 91 BrouwersP, Hyes MP, MossHA etal .Quinolinicacid in the cerebrospinal fluid of children with symptomatic human immunodef iciency virus type 1 disease: relationships to clinical status and therapeutic response. *J Infect Dis*. Dec1993; 168 (6) : 1380 1386.
- 92 Nelson MD Jr, Wison DA, Kiskr CT, et al . Incidence of focal white matter lesions in a population of hemophiliac children and their normal siblings. Hemophilia Gro wth and Development Study. *Pediatr Radiol*. Oct2000; 30 (10) : 705 709.
- Tardieu M, Blanche S, Brunelle F. Cerebral magnetic resonance imaging studies in HIV -1 infected children born to seropositive mothers. *Satellite Conference of Seventh International Conference on AIDS*. Padova, Italy; 1991:60.
- 94 BrouwersP, VlugtHvd MossH Witters P, PizzoP Whitematter changes on CT brain scan are associated with neurobehavioral dysfunction in children with symptomatic HIV disease. *Child Neuropsychology*. 1995; 1 (2): 93 – 105.
- 95. Gongvatana A, Schweinsburg B, Taylor M, et al. HIV-associated white matter tract injury and neurocognitive impairment in the HAAR T era. *Thirty-Sixth Annual International Neuropsychological Society Meeting. Vol 145.* Waikoloa, Hawaii; 2008.
- 96. Harrison T, Schweinsburg B, Jacobus J, et al. Abnormal white matter signal and lo wer CD4 nadir independently predict lower white matter fracional anisotropy in HIV-infected individuals. *Thirty-Sixth Annual International Neuropsychological Society Meeting*. Waikoloa, Hawaii; 2008:146.
- 97 Kauppinen R , Wilimas S Nuclear magnetic resonance spectroscopy studies of the brain . *Prog Neurobiol* . 1994 ; 44 : 87 – 118 .

- 98 . McConnellJ SwindellsS OngC etal .Prospective utility of cerebral proton magnetic resonance spectroscopy in monitoring HIV infection and its associated neurological impairment. AIDS Res Hum Retrovir . 1994 ; 10 (8) : 977 – 982 .
- 99. Salam A Lamoureux S MichelG Confort-Goun S Cozzone P, Von-Dury J Localized proton magnetic resonance spectroscopy of the brain in children infected with human immunodeficiency virus with and without encephalopathy. *Pediatr Res*. 1998; 44: 755 – 762.
- 100 LuD Prvlakis S Frank Y, et al . Proton MR spectroscopy of the basal ganglia in healthy children and children with AIDS. *Radiology* 1996; 199 : 423 428 .
- 101 Invlakis S, Lu D, Frank Y, et al. Magnetic resonance spectroscopy in childhood AIDS encephalopathy. *Pediatr Neurol*. 1995; 12 (4): 277 282.
- 102 Invlakis SG LuD Frank Y, et al .Brain lactate and N-acetylaspartate in pediatric AIDS encephalopathy .AJNR Am J Neuroradiol . Feb1998; 19 (2) : 383 – 385 .
- 103 Jáller MA Jánkatraman TN ThomasMA etal .Cerebralmetabolites in HIV-infected children followed for 10 months with 1H-MRS. *Neurology*. 28Mar 2006; 66 (6): 874 – 879.
- 104 Killer MA, Wakatraman TN, Thomas A et al. Altered neurometabolite development in HIV-infected children: correlation with neuropsychological tests . *Neurology*. 25 May 2004; 62 (10) : 1810 – 1817.
- Brouwers P, Tdor-Williams G, DeCarli C et al . Relation between stage of disease and neurobehavioral measures in children with symptomatic HIV disease . *AIDS*. Jul 1995; 9 (7): 713 720.
- 106 CondiniA AxiaG CattelanC etal .Development of language in 18–30-month-old HIV-1infected but not ill children. *AIDS*. Jun1991; 5 (6) : 735 – 739.
- 107 FishkinPE ArmstrongFD RouthDK etal .Briefreport: relationship between HIV infection and WPPSI-R performance in preschool-age children . J Pediatr Psychol . Jul–Aug 2000; 25 (5) : 347 – 351 .
- 108 GayCL ArmstrongFD CohenD etal .Theeffects of HIV on cognitive and motor development in children born to HIV -seropositive women with no reported drug use: birth to 24 months .*Pediatrics* . Dec1995; 96 (6) : 1078 1082 .
- 109 NozyceM HittelmanJ MuenzL Durab SJ FischerML Muloughby A Effect of perinatally acquired human immunodef iciency virus infection on neurode velopment in children during the first two years of life. *Pediatrics*. Dec1994; 94 P61): 883 – 891.
- 110 .SmithR MaleeK LeightyR etal .Efects of perinatal HIV infection and associated risk factors on cognitive development among young children. *Pediatrics* . Mar2006; 117 (3) : 851 862 .
- 111 Bisiacchi PS, Suppiej A, Luerda A Neuropsychological evaluation of neurologically asymptomatic HIV-infected children. *Brain Cogn*. Jun–Aug2000; 43 (1–3): 49 52.
- 112 FundaroC MiccinesiN BaldieriNF, Genøese O RendeliC Sgni G Cognitive impairment in school-age children with asymptomatic HIV infection AIDS Patient Care STDS. Feb 1998; 12 (2): 135 140.
- 113. Koekkoek S, de Sonne ville LM, Wolfs TF, Licht R, Geelen SP. Neurocognitive function profile in HIV-infected school-age children. *Eur J Paediatr Neurol.* 17 Oct 2007.
- 114 Tardieu M ,Mayaux MJ ,Seibel N et al . Cognitive assessment of school-age children infected with maternally transmitted human immunodeficiency virus type 1. J Pediatr . Mar 1995; 126 (3) : 375 – 379 .
- 115 Blanche S ardieu M Dulige A et al .Longitudinal study of 94 symptomatic infants with perinatally acquired human immunodeficiency virus infection. Evidence for a bimodal expression of clinical and biological symptoms. Am J Dis Child. Nov 1990; 144 (11) : 1210 – 1215.
- 116 FrankEG Filey GM Kichuk A Cognitive functioning in school-age children with human immunodeficiency virus *.Percept Mot Skills* . Aug1997; 85 (1) : 267 272 .
- 117 NozyceML LeeSS Wiznia A etal .Abehavioral and cognitive profile of clinically stable HIV-infected children .*Pediatrics* . Mar2006 ; 117 (3) : 763 770 .
- 118. Nichols S, Montepiedra G, Malee K, Sirois P, Kammerer B, Garvie P. Developmental outcomes of perinatally-acquired HIV in late childhood and adolescence: relationship of cognitive, academic, and beha vioral functioning with disease status. *Thirty-Fifth Annual Meeting of the International Neuropsychological Society*. Portland, OR; 2007.

- 119 HooperSR WhittJK Tennison MB BurchinalM GoldSH HallCD HIVinfected children with hemophilia: one- and tw o-year follow-up of neuropsychological functioning. *Pediatr AIDS HIV Infect*. Apr1997; 8 (2): 91 – 97.
- 120 Loeland KA , Stehbens J , Contant C et al . Hemophilia growth and development study: baseline neurodevelopmental findings. J Pediatr Psychol . Apr1994 ; 19 (2) : 223 239 .
- 121 .WhittJK HooperSR #nnison MB etal .Neuropsychologicfunctioning of human immunodeficiency virus-infected children with hemophilia. J Pediatr . Jan1993; 122 (1) : 52 – 59 .
- 122 BaleJF, Jr, ContantCF, Gag B Ilton A KaufmanDM Wasiewski W Neurologichistory and examination results and their relationship to human immunodef iciency virus type 1 serostatus in hemophilic subjects: results from the hemophilia growth and development study. *Pediatrics*. Apr1993; 91 (4): 736 – 741.
- 123 Lezak M Neuropsychological Assessment, 3 rded. New York: Oxford University Press; 1995.
- 124 AncesBM EllisRJ Dementiaand neurocognitive disorders due to HIV-1 infection .Semin Neurol. Feb2007; 27 (1): 86 – 92.
- 125 Coplan J ,Contello KA ,Cunningham CK et al .Early language development in children exposed to or infected with human immunodeficiency virus. *Pediatrics*. Jul1998; 102 (1) : e8 .
- 126 Pressman H Communication disorders and dysphagia in pediatric AIDS . ASHA . Jan 1992 ; 34 (1) : 45 47 .
- 127 Waters PL BrouwersP, MossHA PizzoPA Differential receptive and expressive language functioning of children with symptomatic HIV disease and relation to CT scan brain abnor malities *.Pediatrics* . Jan1995; 95 (1): 112 – 119 .
- 128 Wilters PL BrouwersP, Gütello L MossHA Receptive and expressive language function of children with symptomatic HIV infection and relationship with disease parameters: a longitudinal 24-month follow-up study. *AIDS*. 15Jul 1997; 11 (9) : 1135 – 1144.
- 129 Brouwers P, an Engelen M Lalonde F, et al . Abnormally increased semantic priming in children with symptomatic HIV-1 disease: evidence for impaired development of semantics? *J Int Neuropsychol Soc*. May2001; 7 (4): 491 – 501.
- 130 MossH Wilters P, BrouwersP, HendricksM PizzoP Impairment of expressive behavior in pediatric HIV-infected patients with e vidence of CNS disease. *Journal of Pediatric Psychology*. 1996 ; 21 (3) : 379 – 400.
- 131 RoelofsK Witers P, Fernandez-CarolC ,VlugtHvd MossH Bouwers P Impairmentsin expressive emotional language in children with symptomatic HIV infection: Relation with brain abnormalities and immune function. *J Int Neuropsychol Soc*. 1996; 2 : 193.
- 132 . Watkins JM ,Cool VA , Usner D et al . Attention in HIV-infected children: results from the Hemophilia Growth and Development Study. J Int Neuropsychol Soc . May2000; 6 (4) : 443 – 454 .
- 133 Boiin MJ GreenSD Duies AG, GiordaniB MokiliJK CuttingWA Apreliminary evaluation of the cognitive and motor effects of pediatric HIV infection in Zairian children *Health Psychol*. Jan1995; 14 (1): 13 – 21.
- 134 Leenson RL Jr, MellinsCA Zavadzki R KairamR SteinZ Cognitive assessment of human immunodeficiency virus-exposed children. Am J Dis Child. Dec 1992; 146 (12): 1479 – 1483.
- 135 SmithM MindenD Netly C ReadS KingS BlanchetteV.Longitudinalinvestigation of neuropsychological functioning in children and adolescents with hemophilia and HIV infection .Dev Neuropsychol. 1997; 13 (1): 69 – 85.
- 136 Loeland KA Stehbens A, Mahong EM et al .Declining immune function in children and adolescents with hemophilia and HIV infection: ef fects on neuropsychological performance. Hemophilia Growth and Development Study. J Pediatr Psychol. Jul–Aug2000; 25 (5): 309 – 322.
- 137 KlaasP, Wilters P, MartinS Quitello L ZeichnerS Verbal learning and memory in children with HIV. Int Neuropsychol Soc. 2002 8: 187.
- 138 PerezL Witters P, MossH Quitello L BrouwersP Verbal learning and memory in children with HIV infection. J Neurovirol. 1998 ; 4 : 362.
- 139 BrouwersP, MohrE HildebrandK etal .Anovel approach to the determination and characterization of HIV dementia. *Can J Neurol Sci* . May1996 ; 23 (2) : 104 – 109 .

- 140 Stout JC Salmon DP, Butters N et al .Decline in working memory associated with HIV infection. HNRC Group. *Psychol Med*. Nov 1995; 25 (6) : 1221 1232.
- 141 .WhiteD Taylor M ButtersN etal .Memoryfor verbal information in individuals with HIVassociated dementia complex. J Clin Exp Neuropsychol . 1997; 19 (3) : 357 – 366 .
- 142 Alward EH ButzAM HuttonN Joner ML Migelhut JW Cognitive and motor development in infants at risk for human immunodeficiency virus. Am J Dis Child. Feb1992; 146 (2): 218 222.
- 143 BlanchetteN SmithML Fernandes-Penny A KingS ReadS Cognitive and motor development in children with v ertically transmitted HIV infection . *Brain Cogn* . Jun–Jul 2001 ; 46 (1–2) : 50 – 53 .
- 144 Brks RA Dandf JV Motorperformance changes in children testing positive for HIV over 2 years *Am J Occup Ther*. Sep–Oct1999; 53 (5) : 524 528 .
- 145 .Wilters P, BrouwersP, MossH PizzoP Adaptive behavior of children with symptomatic HIV infection before and after Zidovudine therapy. *J Pediatr Psychol*. 1994; 19 (1): 47 61.
- 146 GaughanDM HughesMD Olesk JM MaleeK GoreCA NachmanS Psychiatrichospitalizations among children and youths with human immunodef iciency virus infection. *Pediatrics*. Jun2004; 113 (6): e544 – 551.
- 147 Huens J Whitakr A FeldmanJ EhrhardtA Psychiatricmorbidity in school-age children with congenital human immunodeficiency virus infection: A pilot study. *Dev Behav Pediatr.* 1994 ; 15 (3) : S18 – S25 .
- 148. Harris L, Brouwers P, Chu C, et al. Attentional problems in young children with v erticallyacquired HIV-infection. *Thirty-fifth Annual International Neuropsychological Society Meeting*. Portland, Oregon; 2007.
- 149 Mellins CA ,Brackis-Cott E ,Dolezal C ,Abrams EJ P.sychiatric disorders in youth with perinatally acquired human immunodef iciency virus infection. *Pediatr Infect Dis J*. May 2006; 25 (5): 432 437.
- 150.APA. *Diagnostic and Statistical Manual of Mental Disorders*, 4th ed, T ext Revision. Washington, DC: American Psychiatric Association; 2000.
- 151 Battles HB ,Wener LS From adolescence through young adulthood: psychosocial adjustment associated with long-term survival of HIV. J Adolesc Health. Mar 2002; 30 (3): 161 168.
- 152 MellinsCA SmithR O'DriscollP, et al . Highrates of behavioral problems in perinatally HIV-infected children are not linked to HIV disease. *Pediatrics* . Feb2003; 111 (2) : 384 393 .
- 153 Bachanas PJ Killgren KA Schwartz KS et al. Predictors of psychological adjustment in school-age children infected with HIV. J Pediatr Psychol. Sep2001; 26 (6): 343 352.
- 154 BruckI ahan TT, CruzCR etal .Developmental milestones of vertically HIV infected and seroreverters children: follow up of 83 children . Arq Neuropsiquiatr . Sep 2001; 59 (3-B) : 691 – 695 .
- 155 DrotarD OlnessK Wiznitzer M etal .Neurodovelopmental outcomes of Ugandan infants with human immunodeficiency virus type 1 infection. *Pediatrics* . Jul1997; 100 (1) : E5 .
- 156 DrotarD QlnessK Waznitzer M et al .Neurodevelopmental outcomes of Ugandan infants with HIV infection: an application of growth curve analysis. *Health Psychol*. Mar1999; 18 (2) : 114 121.
- 157 Msellati P, Lepage P, Hitimana DG, Yn Goethem C, Yn de Perre P, Dabis F. Neurodevelopmental testing of children born to human immunodeficiency virus type 1 seropositive and seronegative mothers: a prospective cohort study in Kigali, Rwanda. *Pediatrics*. Dec1993; 92 (6): 843 – 848.
- 158. Abubakar A, Van Baar A, Van de Vijver FJ, Holding P, Newton CR. Paediatric HIV and neurodevelopment in sub-Saharan Africa: a systematic re view. *Trop Med Int Health*. 31 Mar 2008.
- 159 Jahan TT, BruckI Buger M CruzCR Neurological profile and neurodevelopment of 88 children infected with HIV and 84 seroreverter children followed from 1995 to 2002. Braz J Infect Dis. Oct2006; 10 (5): 322 326.

- 160 BagendaD NassaliA Kalyesubla I etal .Health,neurologic, and cognitive status of HIVinfected, long-surviving, and antiretro viral-naive Ugandan children . *Pediatrics* . Mar 2006; 117 (3) : 729 – 740 .
- 161 Keekkoek S ,Eggermont L ,DeSonneville L et al .Effects of highly active antiretroviral therapy (HAART) on psychomotor performance in children with HIV disease . J Neurol. 2006 ; 253 (12) : 1615 – 1624 .
- 162 LauferMK sm Oosterhout JJ PerezMA etal . Observational cohort study of HIV-infected African children . *Pediatr Infect Dis J*. Jul2006 ; 25 (7) : 623 - 627 .
- 163 Ananwaranich J Jupimai T, Mekmullica J Sosothikul D Ancharoen C. Behavioral and Emotional Problems in Thai Children W ith HIV Infection Compared to Children W ith and Without Other Chronic Diseases . J Int Assoc Physicians AIDS Care (Chic Ill). Mar 2008; 7 (1): 52 - 53.

Co-Occurrence of HIV, Hepatitis C, and Substance Use Disorders: Effects on Brain Functioning

Raul Gonzalez, Phillip J. Quartana, and Eileen M. Martin

Detrimental effects of HIV on brain systems and neurobehavioral functions remain a primary focus of neuropsychological and biomedical research. The neuropathological changes and neuropsychological dysfunction that often accompanies HIV, as well as its detrimental effects on instrumental activities of daily living and quality of life have become increasingly well-characterized and have been discussed at length by other contributors in this volume. The neurocognitive consequences of HIV are particularly pressing for HIV -seropositive (HIV+) individuals who have co-occurring medical and psychiatric conditions that also are kno wn to impinge upon neurocognitive functioning. Most notably, substance use disorders (SUDs) and Hepatitis C (HCV) are the two conditions that commonly co-occur with HIV and share in common a number of neuropathological and neurocognitive sequelae. In this chapter, we present and e valuate research that e xamines neurocognitive functioning among HIV-infected persons who are also infected with HCV and/or have a SUD. As we highlight throughout, the presence of an SUD and/or HCV in concert with HIV infection may increase the vulnerability to neurocogniti ve dysfunction. In the process, we also devote some attention to unique challenges in the study of these vulnerable populations and briefly touch upon some treatmentrelated issues.

Co-Occurrence of HIV, HCV, and SUDs

There are several factors that contribute to the common co-occurrence of HIV, HCV, and SUDs. For instance, risky injection drug use behaviors, such as sharing dirty needles or used syringes, are a prominent vector for blood-borne viruses, such

R. Gonzalez (🖂)

Department of Psychiatry, University of Illinois at Chicago, Chicago, IL 60612USA rgonzalez@psych.uic.edu

as HCV and HIV. The World Health Organization estimated that approximately one-third of new HIV infections worldwide are transmitted through injection drug use, with sub-Saharan Africa e xcluded (1). In Central Asia and Eastern Europe, injection drug use w as reported to account for approximately 80% of ne w HIV cases (1). Moreover, the occurrence of HIV among injection drug users has continued to increase in many developed countries (2).

HCV mono-infection (i.e., without comorbid HIV) is relatively common among injection drug users, with the estimated pre valence rates as high as 70% for acute cases (3) and as high as 60–90% for chronic infection (4). HCV infection among HIV+ injection drug users is also pre valent, with recent estimates indicating that approximately 25–30% of urban HIV+ injection drug users are co-infected with HCV (5, 6). However, rates of co-infection may v ary depending on pre valence of various risky behaviors. For example, Sherman et al. (7) reported a 16.1% pre valence rate for HCV infection among HIV+ indi viduals in the United States, b ut rates varied drastically when groups were stratif ied as "high risk" and "low risk" based on the beha viors they endorsed. Rates of co-infection were roughly 72.6% among those who engaged in "high-risk" behaviors (e.g., unprotected sex and injection drug use), but only about 3.5% among those who did not. Rates of HCV infection among HIV+ persons has become an increasingly important issue, as end-stage liver disease has been identified as a leading cause of mortality among HIV-infected individuals in developed countries (8, 9).

Although rates of HCV and HIV co-infection appears to be more common among injection drug users, it is important to note that the co-occurrence of HIV and HCV is not limited to this population. Rates of HCV and HIV co-infection ha ve ranged from 2 to 35.3% among noninjection drug users (10). The mechanisms for transmission of HIV and HCV among noninjection drug users are man y, but may include higher prevalence of risk y sexual practices (such as unprotected anal se x) during intoxication, sharing of some types of drug paraphernalia (e.g., cocaine "straws"), and sharing of tattoo needles (most commonly in prison settings) (11–13).

A recent study conducted by Danta et al. (14) underscores the importance of risky behaviors in the co-occurrence of HIV, HCV, and SUDs. They examined HCV infection among HIV+ men in London, England, who have sex with men (MSMs). Their findings pointed more directly to permucosal vs. percutaneous transmission of HCV infection, with a greater number of HCV -infected individuals reporting more frequent high-risk sexual behavior (e.g., "barebacking" and group sex participation) compared with HCV-seronegative (HCV-) individuals. Recreational drug use in this population, although a predictor of HCV -infected cases in uni variate analyses, was no longer a significant predictor in more complex multivariate models. The authors concluded that drug use lik ely leads to HCV transmission indirectly through increased high-risk se xual behaviors. It is interesting to note that risky sexual practices among HIV-infected MSMs have increased since the advent of HAART (15, 16). The reasons for this increase are man y, but often include the misguided belief that HIV is no longer a life-threatening illness, or more pointedly, that HAART can "cure" HIV infection (17). Thus, high-risk sexual and drug use practices appear to be important vectors for both HIV and HCV.

There is substantial evidence for common neurobehavioral deficits among individuals with HIV, HCV, and SUDs, which we review in this chapter. The neuropathology and neurocognitive deficits associated with HIV alone are discussed in detail by others in this book. The specif ic effects of various classes of controlled substances and effects of HCV alone are well beyond the scope of this chapter, but we note that SUDs and HCV may exacerbate brain dysfunction through overlap in some of the neural pathways they disrupt, namely prefrontal-striatal systems. That said, each of these conditions is associated with damage and dysfunction that extend beyond these systems. Systematic examination of the interactions between HIV, HCV, and SUDs remain a relatively recent endeavor. However, we underscore the pressing attention this research area has received: for example, despite a fairly limited pool of existing studies, the literature on effects of HCV on neuropsychological function has been reviewed by many (18-22). A more detailed understanding on how these frequently co-occurring conditions may together af fect neurobehavioral functioning is critical for de veloping appropriate treatments and improving patients' quality of life.

Challenges in Studying Comorbid Consequences of HIV, HCV, and SUDs

Before providing an overview of the literature on possible neurobeha vioral consequences of HIV, HCV, and SUD comorbidity, it is crucial that we ackno wledge some of the challenges inherent to conducting such investigations. First, it must be kept in mind that findings may often be disparate, in part because participant samples may differ across studies on a number of key parameters. For example, studies that examine HIV may use participant samples that differ in their risk for infection (e.g., MSMs, injection drug users, heterose xual men and women), length of HIV infection, and disease severity (e.g., varying CD4 counts, HIV viral burden in CSF or plasma, presence of opportunistic infection, AIDS diagnosis). As with HIV individuals with HCV may also dif fer in their disease se verity, as manifest by degree of liver disease, current treatment re gimen (i.e., interferon treatment), and whether there are neurological problems due to liver disease (e.g., hepatic encephalopathy). Studies that e xamine the effects of substance use on neurobeha vioral function may employ subject samples that dif fer significantly in their drugs of choice, amounts of drug use, length of abstinence, and comorbid psychopathology. Consequently, differences in the myriad combinations of parameters that def ine participants with HIV, HCV, or SUDs across studies may serve to yield conflicting results and make comparisons across studies difficult.

The study of HIV, HCV, and SUDs is necessarily challenging because of the high likelihood of comorbidity between these disorders and a number of other potentially confounding psychopathological and medical f actors that may also affect neurocognitive functioning, such as depression, ADHD, antisocial personality disorder, and liver disease. As outlined in Gonzalez et al. (20), a number of steps

can be taken to reduce the impact of these man y confounds, such as (1) e xcluding potential subjects with conditions judged to be signif icant threats to validity, such as schizophrenia or structural lesions of the CNS (e.g., strok e, gunshot wounds to the head, closed head trauma with significant loss of consciousness); (2) clear dissemination and rigorous enforcement of rules that a positi ve result on rapid urine toxicology screening or breathalyzer testing is automatic grounds for exclusion and nonpayment; (3) employing a carefully selected series of clinical tests and interviews to assure that groups are closely matched on substance ab use severity and diagnostic composition, current psychological distress, estimated IQ, personality traits such as antisociality and sensation seeking, and symptoms of additional psychiatric disorders such as ADHD. Attention to these potential confounds can strengthen inferences from study f indings and also, if carefully e xamined in data analyses, may yield interesting relationships between v ariables that would otherwise go undetected.

HIV and Substance Use Disorders

Neural Mechanisms for Interactions

Several mechanisms by which substance dependence and HIV may interf ace to impair brain functioning ha ve been put forth, and include disruption of immune function, cytokine regulation, cerebrovasculature, and excitatory neurotransmitters (23, 24). Specific drugs of ab use may e xacerbate HIV-associated brain injury through one or several of these mechanisms, thus presenting complex pathways for interactions.

Various drugs of abuse are known to increase severity of HIV through suppressing immune function, thus putati vely magnifying neurobeha vioral dysfunction through increased disease burden. For example, much evidence suggest that opioids may suppress immune function (25, 26), though the mechanisms are complex and remain somewhat enigmatic, particularly in the context of HIV (27, 28). Opioids have been shown to enhance viral replication (29–31) and reduce the effectiveness of CD4 (32) and CD8 T-lymphocyte cells in the presence of HIV (33). It should be noted that the interactions of these substances with HIV ha ve not al ways been shown to be deleterious; for example, in some circumstances opioids have exerted protective effects (24, 34). Some of the f actors that may account for conflicting findings have been discussed by others (35).

Similar to the findings with opioids, cocaine has also been sho wn to suppress immune response, as well as increase viral replication, and alter c ytokine production (e.g, TNF- α), which increases vulnerability to infection (24, 36, 37). Less is known about the impact of central nervous system (CNS) stimulant methamphetamine on the modulation of immune function in HIV, but animal studies suggest it is similar to cocaine in that it may also suppress immune function (38), increase

viral replication (39), and may adv ersely change c ytokine production (e.g., decreases in IL-2 and increases in TNF- α) (40).

There are other known mechanisms by which cocaine and methamphetamine may disrupt brain functioning, namely through direct effects on cerebrovasculature, which may include micro-infarcts and vasoconstriction (41–44). Cocaine has been shown to disrupt blood–brain barrier function, thus causing cerebro vascular complications and allowing greater virus traf ficking into brain (45–47). Finally, both cocaine and methamphetamine are known to be neurotoxic and may interact with HIV proteins (e.g., Tat and gp120) to potentiate damage to neurons. These proteins may interact with cocaine and/or methamphetamine to damage neurons through oxidative stress, mitochondrial dysfunction, and inflammation. Indeed, se veral investigations have suggested that both methamphetamine and cocaine can increase the neurotoxic effects of Tat, and that the striatum may be most vulnerable to such damage (48–53).

More controversy surrounds the impact of alcohol and cannabis on the neuropathogenesis of HIV (e.g., (54)). Not unlike the substances we have already discussed, some have suggested that alcohol may also w orsen the effects of HIV on brain through damage to the blood–brain barrier (55, 56), suppression of immune function, damage to immune cells, and modulation of c ytokines (37, 57, 58). Less research has been done on the impact of cannabis on immune function in HIV , despite substantial evidence for cannabinoids' ability to suppress immune response (59, 60). Some animal studies report decreased immune function and increased viral replication (61); but recent studies show no effects of cannabis (or THC) on the immune function of HIV+ human subjects (62, 63).

Neuropathology and Neuroimaging

Many neuropathological studies have been conducted to examine the effects of HIV on human brain tissue (e.g., (64–66)). However, there are substantially fewer studies that examine neuropathological changes that occur specifically as a result of comorbid HIV infection and substance use. Notably , examinations of varying cohorts of drug users have often revealed mixed results, and it remains difficult to describe definitively whether substance use exerts additive or synergistic damage to brain tissue. For example, among injection drug users (primarily heroin), investigators have reported greater rates of HIV encephalitis (67, 68). It is thought that HIV and injection drug use may interact synergistically to produce HIV encephalitis (35, 69, 70) and that increased activated microglia among injection drug users is a likely mechanism (71). However, other cohort studies ha ve not found increased pre valence of HIV encephalitis among injection drug users (72).

More recently, neuropathological changes that may occur because of the use of methamphetamine among HIV+ participants has become the subject of study Langford et al. (73) examined the brains of 28 HIV+ methamphetamine users and 49 HIV+ nonusers that were collected at autopsy . HIV+ methamphetamine users

were more likely to evidence ischemic damage in the neocortex and limbic systems. Further, among patients with HIV encephalitis, those who had histories of methamphetamine use also showed greater microgliosis. In a subset of HIV+ patients from the same cohort, Chana et al. (74) reported that patients with HIV encephalitis and a history of methamphetamine use sho wed the greatest loss of interneurons compared with those without HIV encephalitis or methamphetamine use. Further , interneuron loss was associated with poorer performance on measures of general neurocognitive function.

Neuroimaging techniques have been used to e xamine the combined effects of HIV and drug use on brain structure, metabolism, and function among patients, with results from such studies generally suggesting additi ve or synergistic actions across a variety of substances. For example, a thorough review of studies examining combined effects of alcohol use and HIV concluded that metabolic changes suggestive of neuronal injury were associated with more alcohol consumption among HIV+ persons, particularly within the periventricular white matter, subcortical grey matter, and brain stem (57). More recently, Pfefferbaum et al. (75) used magnetic resonance spectroscopy (MRS) to compare patterns of cerebral metabolites across three groups: HIV+ alcoholics (n = 15), HIV+ nonalcoholics (n = 9), and 23 healthy controls. HIV+ alcoholics sho wed significantly lower levels of *N*-acetylaspartate (NAA) and creatine compared with the other groups, suggesting neuronal injury in parietal–occipital grey matter and adjacent white matter. Alcoholism has also been shown to interact with HIV disease se verity, such that it may increase damage to corpus callosum among those with more advanced HIV (75).

Metabolic brain abnormalities have also been reported to be magnified by methamphetamine use among HIV+ indi viduals. Using a small sample of participants (n = 20), Taylor et al. (76) reported significantly lower levels of NAA, suggestive of neuronal injury, in the anterior cingulate of individuals with HIV and methamphetamine dependence compared with groups having only one risk factor (HIV or methamphetamine dependence) and healthy controls. Using similar methods, Chang et al. (77)examined brain metabolites in a lar ger sample (n = 143) across groups dif fering on history of methamphetamine use and HIV. They obtained evidence indicative of additive damage from HIV and methamphetamine, with the group of participants that had both risk factors demonstrating the lar gest differences from control participants in metabolites suggesting neuronal injury in frontal white and gre y matter, as well as basal ganglia. In contrast to the two o aforementioned investigations that provide evidence for additive damaging effects, Taylor et al. (78) did not f ind evidence of additive effects in another investigation they conducted where the y examined brain metabolites of 205 participants stratified into four groups based on history of HIV and methamphetamine dependence. Despite this, the y did report correlations between markers of immunosuppression and markers of neuronal dysfunction only among the group of participants with both risk factors.

Data from structural brain MRI studies have further complicated the interpretation of additive or synergistic effects from HIV and methamphetamine. Jernigan et al. (79) used MRI to examine the volume of various brain structures in groups of individuals who differed in their HIV serostatus and histories of methamphetamine dependence. Interestingly, they found that methamphetamine and HIV serostatus had opposing effects on brain volume, particularly in the caudate, with HIV being associated with decreased volumes and methamphetamine with increased volumes. Evidence for additive or interactive effects of methamphetamine and HIV on brain volume were not supported, but may have been obfuscated by the inverse morphological effects of these risk factors.

Neuropsychological Functioning

We have highlighted a few of many mechanisms that have been proposed by which HIV and various drugs of abuse may interact to affect brain functioning. The limited neuropathological and neuroimaging data a vailable lend some support for additive and syner gistic dysfunction. Y et, evidence from such studies do not directly inform whether changes in the brains of indi viduals translate to deficits in their neurocognitive functioning or their ability to function in their daily li ves. In this section, we review the neuropsychological investigations of HIV and substance use interactions, which rely on assessment techniques that allo w quantification of performance across v arious cognitive abilities sensiti ve to brain dysfunction. Furthermore, measures of neuropsychological functions can provide us with information about how a patient's daily functioning may be af fected as a consequence of brain dysfunction.

Over the past two decades, several groups have set out to document the neuropsychological impact of HIV infection among substance using populations and/ or the effects of substance use among HIV+ cohorts. Studies have often shown that HIV-associated neurocognitive dysfunction can be reliably detected among samples of injection and noninjection substance users (primarily cocaine and heroin). F or example, a series of in vestigations from Chicago have shown that in samples of individuals with substance dependence (primarily cocaine and heroin), those who are HIV+ demonstrate poorer performances on tests of general w orking memory capacity (80), verbal working memory (81), auditory working memory (82), and nonverbal working memory (83), suggesting that impaired working memory may represent a signature deficit among HIV+ substance-dependent indi viduals. Also, HIV+ substance users have been shown to demonstrate poorer performances on measures of decision-making (84). Thus, the evidence suggests that HIV worsens neurocognitive functioning among substance users. Ho wever, when the effects of substance use have been examined in HIV+ cohorts, the results have been equivocal. For example, some studies report no ef fects of injection drug use (85-87) or severity of multiple drug use (88) on the neurocognitive functioning of HIV+ participants. On the other hand, others ha ve reported that marijuana use is associated with poorer neuropsychological performance among HIV+ patients in adv anced disease stage (89).

The research designs of the aforementioned studies elucidate whether HIV infection worsens neurocognitive functioning among substance users and/or if

substance use e xacerbates neurocognitive dysfunction among HIV+ indi viduals. However, the research designs employed in such studies limit inferences that can be made about possible additive or synergistic effects of HIV and substance use as cofactors, and relatively few studies have employed designs to more conclusi vely detect such effects (90). To thoroughly investigate the possibility of syner gistic or additive effects, studies often include several subject groups: (1) a group with no risk f actors (e.g., no HIV and no SUD); (2) two groups with one risk factor each (e.g., a group with HIV but no SUD, as well as a group with SUD but no HIV); and (3) a group with both risk factors (e.g., with HIV and SUD). Such designs allow investigators to isolate the individual contribution of each condition to neurocognitive impairment and to assess if having both risk factors produces greater levels of impairment than what would be expected with one condition alone. It also allows one to determine if the degree of impairment observed in the dual-risk group is consistent with a simple aggre gate of the impairment in the single risk factor groups (i.e., additive effects) or if impairment surpasses such expectations. Below, we report results of se veral investigations conducted in recent years that make use of such designs.

Studies using the earlier-noted four-group design (or similar designs) to examine HIV and alcohol as cof actors generally support both additi ve and syner gistic effects, with groups that have both risk factors typically showing the most pronounced deficits. Green et al. (91) found evidence of additive effects of HIV and alcohol use on neuropsychological functioning, b ut no e vidence of syner gistic effects. Specifically, history of alcohol use w as not found to af fect neuropsychological functioning among HIV- participants, but did result in poorer performance among HIV+ participants on measures of v erbal IQ, verbal reasoning, and reaction time. In another investigation (92), HIV was not found to affect performance on a Stroop task, whereas history of alcohol use among HIV- participants w orsened performance; however, those with both HIV and history of alcohol use performed most poorly. Rothlind et al. (93) found no consistent e vidence of synergistic effects of HIV and alcohol. Ho wever, subgroup analyses pro vided some limited e vidence supporting synergistic effects of HIV and alcohol when alcohol users were stratified into current heavy drinkers and current very heavy drinkers. That is, current very heavy alcohol users with HIV showed impaired performances on measures of information processing speed relative to all other groups. Similar findings were also reported by Durvasula et al. (94) with a large sample of African-American men, such that heavy alcohol use had more pronounced ef fects on the neurocognitive functioning of HIV+ individuals compared with HIV- individuals, particularly on measures of psychomotor speed and reaction time. Thus, it appears that HIV+ individuals are more vulnerable to the negative effects of alcohol on neurocognitive functioning compared with their HIV-seronegative counterparts.

Less-consistent findings have emerged from investigations that have examined whether other substances (besides alcohol) interact in additive and/or interactive ways with HIV. For example, Durvasula et al. (95) found that history of cocaine use and history of HIV both accounted for unique verification are in the neuropsychological test performance of a large sample of African-American men. However, no evidence of additive or interactive effects from HIV and history of cocaine use were observed. Similarly, Basso and Bornstein (96) examined a large sample of HIV+ and HIV– individuals, with and without history of noninjection drug use and found no evidence of additive or interactive effects from substance use. P articipants were abstinent and had abused various substances, but the most frequently reported were marijuana and stimulants. In contrast, Rippeth et al.(97) found that participants with both methamphetamine dependence and HIV sho w greater prevalence of neuropsychological impairment than that observed among groups with only HIV or only methamphetamine dependence. Further , in a separate in vestigation, poorer immune status was associated with w orse neuropsychological functioning among HIV+ persons with methamphetamine dependence compared with those without methamphetamine dependence (98). It may be that methamphetamine and alcohol are more likely than other substances of abuse to compound neurocognitive impairments among HIV+ individuals.

HIV and Hepatitis C

Neural Mechanisms for Interactions

The CNS mechanisms by which HIV and HCV interact remain far from being fully understood, yet several possible avenues have been put forth. F or example, it has been argued, and to some extent substantiated, that co-infection with HIV can lead to accelerated progression of symptomatic liver disease and cirrhosis among those with HCV (99, 100). As such, subacute and acute hepatic encephalopathy may contribute to the neurocognitive problems observed. However, most of the studies we review attempt to control for severity of liver disease. Another possibility is that HCV may accelerate HIV-associated neurocognitive problems. Laskus et al. (101) found that HIV infection can augment HCV replication in human macrophages. Further, in a fashion akin to that proposed for HIV, some have presented evidence to suggest that HCV enters and replicates directly in brain (19, 101, 102), perhaps more so among those co-infected with HIV(103). HCV has been shown to replicate in bone marrow, as well as peripheral blood mononuclear cells (104, 105), which are known precursors for microglial cells and perivascular macrophages within the brain. As outlined in a recent review by Perry et al. (22), one manner in which HCV may be introduced into the CNS is through the migration of infected monoc vtes from the periphery into the brain. These cells then supplant white-matter microglial cells. This method of introducing infection into the brain through peripheral monocytes has been termed the Trojan horse mechanism (106). Thus, the brain may be both a reservoir for HCV and/or HIV, as well as a site for further replication. It is important to keep in mind, however, that HCV and HIV viral load (CSF- or serumbased) among patients on highly acti ve antiretroviral therapy (HAART) have not been consistently linked to decrements in neurocogniti ve performance, nor to the development of HIV-associated dementia (107-109) Hence, other neuropathological

mechanisms must be involved in the effects of HCV and HIV mono- and co-infection on neurobehavioral functioning.

A second neuropathological process that has received increased attention by which HIV and HCV share much in common is the modulation of stokines and pronounced inflammatory responses in the brain. HCV infection leads to rapid production of cytokines, which can remain ele vated for a number of years. Importantly, abnormal or prolonged cytokine production has been recognized as a partial determinant of neurocognitive function (110). One such cytokine, tumor necrosis factor- α (TNF- α), is commonly activated in response to both HCV and HIV infection. Hence, it is possible that increasing le vels of TNF- α associated with HCV–HIV co-infection can exert additive and/or syner gistic deleterious effects on neurobeha vioral function (111). HIV- and/or HCV-induced increases in TNF- α , or other mark ers of immune system functionality (e.g., MCP-1), may represent a viable pathw ay by which HCV and HIV can, in combination, exacerbate neurocognitive dysfunction. A comprehensive review of mechanisms for increased cogniti ve impairment among indi viduals co-infected with HIV and HCV is presented by P aul et al. (112).

Neuroimaging of HIV and HCV

There is a paucity of neuroimaging studies that e xamine specifically interactions between HIV and HCV, but in recent years a b urgeoning neurophysiological and neuroimaging research into the effects of HCV on neurocognition has shed some light on the potential for interactions with HIV . Specifically, electrophysiological study of cognitive impairments in HCV has revealed abnormal P300 event-related potentials among HCV-seropositive (HCV+) individuals relative to controls (113). These abnormalities may underlie the information processing speed and attention/ concentration deficits often observed among HCV+ indi viduals: deficits that are also common among individuals with HIV and SUDs. Similarly, studies employing MRS have revealed biochemical abnormalities in basal ganglia and white matter that are similar to those also reported with HIV (114, 115). Importantly, these abnormalities have been observed among HCV-infected individuals with and without a history of SUD, suggesting that they may be a consequence of HCV infection and not merely secondary to an SUD. In sum, these studies suggest that some of the brain abnormalities observed with HCV, in vivo, are similar to those observed with HIV; thus, brain dysfunction may be compounded when both are present. However, further research is certainly needed.

Neuropsychology of HIV and HCV

Several studies on neuropsychological effects of HCV and HIV co-infection have focused on comparing HIV+ groups with varying HCV serostatus. The overall findings suggest that a positive HCV serostatus can be an additional risk f actor for neuropsychological dysfunction. Studies of neurocognitive function among HCV+ individuals with varying HIV serostatus have generally but not universally demonstrated greater impairment among dually infected compared with mono-infected subgroups. For example, two recent investigations conducted with a cohort of individuals with advanced HIV disease reported that co-infected indi viduals tended to perform more poorly than mono-infected subjects, particularly on measures of executive functions (116, 117). Parsons et al. (118) also found poorer performance on tests of visual memory and f ine motor function among HIV+ participants who were also HCV-infected compared with those who were not. In contrast, others have found no differences in neuropsychological functioning between HCV+ and HCV– patients with HIV (21).

By using combinations of groups that differ both on HIV and HCV serostatus, several investigators have attempted to examine more conclusively the independent and combined effects of HCV and HIV on neuropsychological functioning. Martin et al. (119) examined performance on a reaction time v ersion of the Stroop task with 156 substance-dependent men with v aried HIV and HCV serostatus. They found no conclusive evidence for interactions between HIV and HCV on Stroop performance, but did observe that dually infected individuals performed worse than did mono- or uninfected individuals, consistent with additive effects. Richardson et al. (120) examined the neuropsychological functioning of 220 women stratified into four groups by HIV and HCV serostatus. The groups differed somewhat on several demographic characteristics and history of drug use; however, even when controlling for these factors, the highest odds for neuropsychological impairment was seen in the dually infected group. Controlling for age diminished the strength of these results, and an interaction effect between HIV and HCV was not observed. Similarly, Von Giesen et al. (121) compared the intellectual functioning, gross neurocogniti ve abilities, and electrophysiological motor performance of three patient groups dif fering on their HIV and HCV serostatus: individuals mono-infected with HIV (n = 43), or with HCV (n = 44), and a co-infected group (n = 44). They reported no significant difference between the three groups on measures of intellectual functioning and gross neuropsychological functioning, but did find that the groups dif fered from a control group of uninfected individuals on motor tests.

Reports of the relationships between se verity of HIV or HCV disease and neurocognition have been mixed. Richardson et al (120) reported that severity of HIV-associated immunosuppression as indexed by CD4 count mediated the relationship between disease status and neurocogniti ve function. Conversely, others have reported that markers of liver disease were not significantly predictive of neurocognitive performance (116, 117). These latter findings also suggest that effects of HCV on neuropsychological functioning may be independent of liver disease. However, recent studies of dually infected subjects indicate that neurocognitive function may improve with successful therap y for either disorder (118, 122).

HIV, HCV, and SUDs: Concurrently Examining All Three Risk Factors

Most of the investigations of HIV–HCV co-infection and neurocognition have by necessity included substance-dependent individuals, since injection drug use remains the strongest risk f actor for HCV infection. Ho wever, only a few studies have treated substance dependence as a systematic v ariable of interest and e xamined putative interactions between these three factors.

At present, available "three factor" studies have focused on methamphetamine use. Cherner et al. (123) reported on 430 dually, mono- or uninfected subjects with and without a history of methamphetamine use. The y reported that the prevalence of neurocognitive impairment varied according to the number of risk f actors, and these effects were most evident on measures of learning, recall, f ine motor speed, and abstraction/problem solving. When all three risk f actors (HIV, HCV, SUD) were entered into a regression model (along with several covariates), each accounted for unique variance in overall neuropsychological performance. However, the interactive effects of these v ariables were not systematically e xamined. A companion manuscript (124) examined the postmortem brain tissues of 25 HIV+ cases (12 with HCV and 13 without) from this cohort and reported that HCV in the CNS w as associated with a positive history of methamphetamine use and antemortem cognitive impairment.

To our knowledge, the aforementioned studies are the f irst to specifically and systematically examine the complex effects of substance use, HIV, and HCV on neuropsychological functioning. They make a valiant effort to tackle an important and complex issue; yet the y are also burdened by the challenges inherent in such investigations. Specifically, Cherner et al. (123) noted that some participant groups were not well represented in their sample (e.g., only 2 participants with HCV alone) and that the presence and se verity of some confounds were correlated with a number of risk f actors (e.g., more alcohol use). Further issues in this w ork have been highlighted by others (125). Much work remains to be done in this area.

Brief Comments on Treatment-Related Issues in this Population

There are a number of important treatment considerations in the conte xt of the neuropsychology of HIV, HCV, and SUDs that deserv e brief consideration. Exogenous administration of IFN- α , either alone or in combination with riba virin, is the most ef ficacious treatment choice for HCV infection (126). However, this treatment approach is often associated with subjective and objective complaints of neurobehavioral impairment, as well as depression, apathy, and a number of physical symptoms (e.g., influenza-like symptoms) (22, 126). More specifically, IFN- α treatment appears to be linked to prefrontal cortical hypometabolism, which raises apprehension regarding its effects on neurocognitive functioning (127). Due to the

effects of IFN- α treatment on neurobeha vioral and psychiatric status, there ha ve been concerns about employing such treatment among individuals with preexisting complications that already mak e them vulnerable to neurocogniti ve disturbances. More specifically, IFN- α therapy is contraindicated in the context of alcohol/ substance abuse, severe psychiatric disease, and uncontrolled hypertension. However, empirical evidence supporting such contraindications is far from conclusive (126). Recent studies have also highlighted the potential for drug–drug interactions between HAART, alcohol use, and other psychoacti ve substances (128). In fact, there is at least one documented report of a f atal interaction between MDMA use and ritonavir (129). Furthermore, co-infection with HIV appears to slow the beneficial effects of IFN treatment, although the reasons for this effect are not yet fully understood (130). Hence, successful treatment of HCV, as well as HIV, in the context of a co-occurring SUD requires special considerations, possibly requiring successful treatment of the SUD prior to implementation of pharmacotherap y.

Reasons for treating SUDs prior to or concurrently with treatment re gimens for HIV and HCV e xtend beyond risk of drug interactions. Indi viduals with SUDs often lead chaotic lifestyles when actively using that may interfere with almost all aspects of treatment. Compliance with doctor visits and medication re gimens would be challenging for such patients. As with AR T, adherence is an important predictor of response to IFN treatment among HCV -infected individuals (131). Active substance use w ould also likely interfere with cognitive functions such as memory and decision-making, which may be important underlying processes critical to successful adherence. Thus, patients with substance use disorders may require more attention, reminders, and moti vators to receive optimal benefit from their medical care.

Concluding Remarks

Based on the information presented in this chapter, it can be concluded that current data substantiates interactions between HIV, HCV, and SUDs to potentiate brain injury through a variety of complex pathways. Neurobehavioral disturbances in this population are thought to be in part driven by shared and unique impact from HIV, HCV, and SUDs on immune functioning, cytokine production, and cerebrovasculature. Although each of these conditions appears to affect widespread neural systems, it also seems that each overlaps to some extent in their proclivity to affect striatal structures and associated networks. Nonetheless, the evidence is far from conclusive regarding under which specific conditions co-occurrence of HIV, HCV, and SUDs may yield additive and/or interactive effects on neural systems and neurobehavioral manifestations. It is also important to k eep in mind that interactions among these conditions on neurobehavioral functioning extend beyond the molecular level. Indeed, not only do HIV and HCV affect neurobehavioral function, but there appear to be beha viors that are common to their transmission. Although we must make the seemingly obvious assertion that all substance users do not invariably

contract HIV or HCV, and that not all HIV+ or HCV+ indi viduals are substance users, these conditions do commonly co-occur . The many individuals who suffer from more than one of these conditions appear to be particularly vulnerable to neurobehavioral disturbances and may consequently experience significant difficulties in important aspects of their healthcare, such as maintaining medical appointments, maintaining abstinence, and adhering to prescribed beha vioral and pharmacologic treatment regimens. With the lifespan of HIV+ persons becoming progressively longer, the study of co-occurring conditions and their impact on patient health and quality of life become increasingly more important.

References

- 1. UNAIDS. Report on the Global AIDS Epidemic 2006. Joint United Nations Programme on HIV/AIDS.
- 2 . Stimson GV, Choopana K Global perspectives on drug injecting . In: StimsonGV, Des Jarlais DC BallA editors. DrugInjecting and HIV Infection: Global Dimensions and Local responses (Social Aspects of AIDS). London UCLPress, 1998 1 21.
- 3 . AlterMJ Prevention of spread of hepatitis C . Hepatology 2002 36 (Suppl 1): S93598 .
- 4 . ThomasDL Vlaho D SolomonL CohnS Tylor E GarfeinR etal .Correlates of hepatitis C virus infections among injection drug users . Medicine(Baltimore) 1995 74 (4) : 212 220 .
- 5 .HaganH DesJ HIVand HCV infection among injecting drug users . MtSinai J Med 2000 67 (5-6) : 423 - 428 .
- 6 . StrathdeeSA Reterson TL Behavioral interventions for HIV-positive and HCV-positive drug users . AIDSBehav 2006 ± 0 (2) : 115 130 .
- 7 .ShermanKE RousterSD ChungR , RajicicN HepatitisC Virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group . ClinInfect Dis 2002 34 (6) : 831 837 .
- 8 .BicaI McGovern B DharR StoneD McGovan K ScheibR etal .Increasingmortality due to end-stage liver disease in patients with human immunodef iciency virus infection. Clin Infect Dis 2001 32 (3) : 492 – 497 .
- 9 .PuotiM SpinettiA GhezziA DonatoF, ZaltronS PutzoliV etal .Mortalityfor liver disease in patients with HIV infection: a cohort study. JAcquir Immune Defic Syndr 2000 24 (3) : 211 217.
- 10 Scheinmann R Hagan H Lelutiu-Winberger C Stern R Des
J Fim PL etal .
Non-injection drug use and Hepatitis C Virus: a systematic review .
 Drug Alcohol Depend 2007 ;89 (1) : 1 – 12 .
- 11 Gyarmathy A, Neaigus A Miller M Friedman SR DesJ Riskcorrelates of prevalent HIV, hepatitis B virus, and hepatitis C virus infections among noninjecting heroin users . J Acquir Immune Defic Syndr 2002 30 (4) : 448 456 .
- 12 Hwe CJ FullerCM OmpadDC GaleaS Kolin B ThomasD et al Association of sex, hygiene and drug equipment sharing with hepatitis C virus infection among non-injecting drug users in New York city. DrugAlcohol Depend 2005 79 (3) : 389 – 395.
- 13 Gonzales R Marinelli-Case P, Shoptav S Ang A Rawson RA Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment. J Subst Abuse Treat 2006 31 (2): 195 – 202.
- 14 DantaM Brown D BhaganiS Pybs OG SabinCA NelsonM etal .Recentepidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours . AIDS 2007 21 (8) : 983 991 .

- 15 MacdonaldN DouganS McGarrigleCA BasterK RiceBD Exms BG etal .Recenttrends in diagnoses of HIV and other se xually transmitted infections in England and W ales among men who have sex with men . Sex Transm Infect 2004 80 (6) : 492 497 .
- 16 DoddsJP, Merce DE Prry JV, Johnson AM Increasingrisk behaviour and high levels of undiagnosed HIV infection in a community sample of homose xual men. Sex Transm Infect 2004 80 (3) : 236 – 240.
- 17 CrepazN HartTA, MarksG Highlyactive antiretroviral therapy and sexual risk behavior: a meta-analytic review. AMA 2004 292 (2) : 224 236.
- 18 .Clifford DB Xing Y, Exris S Neurologicconsequences of hepatitis C and human immunodeficiency virus coinfection. JNeurovirol 2005 \$11 (Suppl): 67 - 71.
- 19 Erton DM AllsopJM CoxIJ HamiltonG Wesnes K ThomaHC etal .Areview of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection . AIDS 2005 ;19 (Suppl): S53 – S63 .
- 20 .GonzalezR Jacobs J MartinEM Investigating neurocognitive features of hepatitis C virus infection in drug users: potential challenges and lessons learned from the HIV literature. Clin Infect Dis 2005 41 (Suppl): S45 S49.
- 21 Perry W, Carlson MD, Barakat F, Hilsabeck RC, Schiehser DM, Matews C et al. Neuropsychological test performance in patients co-infected with hepatitis C virus and HIV. AIDS 2005 ;19 (Suppl): S79 – S84.
- 22 PerryW, HilsabeckRC HassaneinTI Cognitive dysfunction in chronic hepatitis C: a review . DigDis Sci 2008 53 (2) : 307 – 321 .
- 23 FriedmanH ProssS KleinTW Addictive drugs and their relationship with infectious diseases . FEMSImmunol Med Microbiol 2006 47 (3) : 330 342 .
- 24 NathA HauserKF, Wijna V, BoozeRM MaragosW, Prendegast M etal .Molecularbasis for interactions of HIV and drugs of ab use. J Acquir Immune Defic Syndr 2002; 31(Suppl 2): S62 – S69 .
- 25 BrinkmanWJ HallDM SuoJL Weber RJ Centrally-mediatedopioid-induced immunosuppression. Elucidation of sympathetic nerv ous system involvement. Adv Exp Med Biol 1998; 437 : 43 - 49 .
- 26 Mlejo R Leon-Casasola O Benamin R Opioid
therapy and immunosuppression: a review . AmJ Ther 2004
 $\ddagger1~(5):354-365$.
- 27 .DonahoeRM ,Vlahø D Opiatesas potential cofactors in progression of HIV-1 infections to AIDS . JNeuroimmunol 1998 \$3 (1–2) : 77 \$7 .
- 28 PetersonPK MolitorTW, ChaoCC Theopioid-cytokine connection . JNeuroimmunol 1998 ; 83 (1-2) : 63 69 .
- 29 LiY, Wing X Jan S GuoCJ DouglasSD HoWZ Methadone enhances human immunodeficiency virus infection of human immune cells. JInfect Dis 2002 ;185 (1) : 118 - 122.
- 30 Peterson PK ,Gekkr G ,Hu S ,Loknsgard J ,Portoghese PS ,Chao CC Endomorphin-1 potentiates HIV-1 expression in human brain cell cultures: implication of an atypical muopioid receptor. Neuropharmacology 1999 38 (2) : 273 278 .
- 31 SchweitzerC Keller F, SchmittMP, JaeckD Adloff M SchmittC etal .Morphinestimulates HIV replication in primary cultures of human Kupffer cells. Res Virol 1991 ;142 (2–3) : 189 195 .
- 32 Quang-CantagrelND Willace MS AsharN Mathws C Long-termmethadone treatment: effect on CD4+ lymphocyte counts and HIV-1 plasma RNA level in patients with HIV infection. EurJ Pain 2001 5 (4): 415 – 420.
- 33 Wing X Jin N DouglasSD ZhangT, Wing YJ HoWZ Morphine inhibits CD8+ T cellmediated, noncytolytic, anti-HIV activity in latently infected immune cells. J Leukoc Biol 2005 78 (3): 772 - 776.
- 34 .Stefno GB Substance abuse and HIV-gp120: are opiates protective ? ArchImmunol Ther Exp 1999 47 (2) : 99 106 .
- 35 Exactli IP Interaction between HIV and intravenous heroin abuse ? JNeuroimmunol 2004 ; 147 (1–2) : 13 15 .

- 36 Pellgrino T, BayerBM Invivo effects of cocaine on immune cell function . JNeuroimmunol 1998 83 (1–2) : 139 147 .
- 37 For WR MiddaughLD Doalcohol and cocaine abuse alter the course of HIV-associated dementia complex ? JLeukoc Biol 1999 65 (4) : 475 481 .
- 38 InSW, SonEW, RheeDK PyoS Methamphetamineadministration produces immunomodulation in mice . JToxicol Environ Health A 2005 68 (23–24) : 2133 2145 .
- 39 Gurilin MA ,Mathes LE ,Podell M Methamphetamine enhances cell-associated feline immunodeficiency virus replication in astrocytes. JNeurovirol 2002 8 (3): 240 – 249.
- 40 M Q ZhangD Walston M ZhangJ LiuY, Walson RR Chronic methamphetamine exposure alters immune function in normal and retro virus-infected mice. Int Immunopharmacol 2002; 2 (7): 951 962.
- 41 Klonoff DC Andrews BT, ObanaWG Strole associated with cocaine use. ArchNeurol 1989 ; 46 (9) : 989 - 993 .
- 42 Rothrock JF, Rubenstein R Juden PD Ischemic stroke associated with methamphetamine inhalation. Neurology 1988 38 (4) : 589 592.
- 43 StricklandTL MillerBL Kewell A SteinR Neurobiologyof cocaine-induced organic brain impairment: contributions from functional neuroimaging. NeuropsycholRev 1998
 § (1): 1 − 9.
- 44 Wing AM SuojanenJN ColucciVM RumbaughCL Hollenber NK Cocaine- and methamphetamine-induced acute cerebral v asospasm: an angiographic study in rabbits . Am J Neuroradiol 1990 ;11 (6) : 1141 – 1146 .
- 45 FialaM GanXH ZhangL HouseSD Novton T, Graes MC etal .Cocaineenhances monocyte migration across the blood-brain barrier . Cocaine's connection to AIDS dementia and vasculitis ? AdvExp Med Biol 1998 437 : 199 – 205 .
- 46 FialaM EshlemanAJ CashmanJ LinJ Lossinsk AS SuarezV et al .Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells. JNeurovirol 2005 11 (3): 281 – 291.
- 47 ZhangL Loong D Tub D ChangSL Wy D Write MH et al .Cocaine opens the bloodbrain barrier to HIV-1 invasion . JNeurovirol 1998 4 (6) : 619 - 626 .
- 48 Aksenø MY, Aksenøa MV, NathA RayPD MactutusCF, BoozdRM Cocaine-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidati ve stress and D1 dopamine receptor. Neurotoxicology 2006 27 (2): 217 – 228.
- 49 .CassWA, HarnedME PetersLE NathA MaragosWF HIV1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat. BrainRes 2003 984 (1–2) : 133 142.
- 50 LangfordD GrigorianA HurfordR AdameA Crews L MasliahE Therole of mitochondrial alterations in the combined toxic ef fects of human immunodeficiency virus Tat protein and methamphetamine on calbindin positive-neurons. JNeurovirol 2004 10 (6): 327 – 337.
- 51 MaragosWF, Vung KL Tirchan JT, Gusva M Pauly JR NathA etal .Humanimmunodeficiency virus-1 Tat protein and methamphetamine interact syner gistically to impair striatal dopaminergic function. JNeurochem 2002 §3 (4) : 955 – 963.
- 52 NathA AndersonC Jones M Maragos W, Booze R Mactutus C et al .Neurotoxicity and dysfunction of dopaminer gic systems associated with AIDS dementia . J Psychopharmacol 2000 14 (3) : 222 – 227 .
- 53 .TheodoreS CassWA , MaragosWF Methamphetamineand human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum . Neuroscience 2006 ± 37 (3) : 925 935 .
- 54 DingleGA QeiTP Isalcohol a cofactor of HIV and AIDS? Evidence from immunological and behavioral studies . PsycholBull 1997 122 (1) : 56 71 .
- 55 Acheampong E ,Mukhtar M ,Arveen Z ,Ngoubilly N ,Ahmad N ,Atel C et al . Ethanol strongly potentiates apoptosis induced by HIV-1 proteins in primary human brain micro vascular endothelial cells . Virology 2002 304 (2) : 222 234 .
- 56 Joborek M LeeYW, FloraG PuH AndrasIE Wlegala E etal .Mechanismsof the bloodbrain barrier disruption in HIV-1 infection . CellMol Neurobiol 2005 25 (1) : 181 – 199 .

- 57 Myerhoff DJ Efects of alcohol and HIV infection on the central nervous system . Alcohol Res Health 2001 25 (4) : 288 298 .
- 58 Wing Y, Witson RR Isalcohol consumption a cofactor in the development of acquired immunodeficiency syndrome ? Alcohol 1995 ;12 (2) : 105 – 109 .
- 59 Cabral GA ,Staab A Effects on the immune system. Handb Exp Pharmacol 2005 ; 168 : 385 423 .
- 60 .MassiP, Vccani A Prolaro D Cannabinoids, immune system and cytokine network . Curr Pharm Des 2006 ;12 (24) : 3135 3146 .
- 61 Roth MD , Tshkin DP, Whittakr KM , Choi R , Baldwin GC Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL-SCID mouse. Life Sci 2005 77 (14) : 1711 1722.
- 62 AbramsDI HiltonJF, LeiserRJ ShadeSB ElbeikTA, Aveeka FT etal .Short-termeffects of cannabinoids in patients with HIV -1 infection: a randomized, placebo-controlled clinical trial . AnnIntern Med 2003 \$139 (4) : 258 266 .
- 63 Bredt BM Higuera-Alhino D Shade SB Hebert SJ McCune JM Abams DI Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J Clin Pharmacol 2002 42 (Suppl1): 82S 89S.
- 64 .BellJE An update on the neuropathology of HIV in the HAART era . Histopathology 2004 ; 45 (6) : 549 – 559 .
- 65 Esrall IP, HansenLA MasliahE Theshifting patterns of HIV encephalitis neuropathology. NeurotoxRes 2005 8 (1-2): 51 - 61.
- 66 LangfordTD LetendreSL LarreaGJ MasliahE Changingpatterns in the neuropathogenesis of HIV during the HAART era . BrainPathol 2003 13 (2) : 195 – 210 .
- 67 BellJE DonaldsonYK Lwrie S McKnzie CA EltonRA Chiswik A etal .Influenceof risk group and zido vudine therapy on the de velopment of HIV encephalitis and cogniti ve impairment in AIDS patients . AIDS 1996 10 (5) : 493 499 .
- 68 Duies J Evrall IP, Wich S McLaughlin J Scarwilli F, Lams PL HIVassociated brain pathology in the United Kingdom: an epidemiological study. AIDS 1997;11 (9): 1145 - 1150.
- 69 Anthon IC RamageSN CarnieFW, SimmondsP, BellJE Does drug abuse alter microglial phenotype and cell turno ver in the context of advancing HIV infection? Neuropathol Appl Neurobiol 2005 31 (3): 325 – 338.
- 70 BellJE ArangoJC RobertsonR BrettleRP, LeenC SimmondsP HIVand drug misuse in the Edinburgh cohort . JAcquir Immune Defic Syndr 2002 31 (Suppl): S35 S42 .
- 71 .Arango JC ,Simmonds P, Brettle RP, Bell JE Does drug abuse influence the microglial response in AIDS and HIV encephalitis ? AIDS 2004 18 (Suppl): S69 S74.
- 72 Mogello S ,Mahboob R , Maboob R , Mague K Autopsy findings in a human immunodeficiency virus-infected population over 2 decades: influences of gender, ethnicity, risk factors, and time. ArchPathol Lab Med 2002 ;126 (2) : 182 – 190.
- 73 LangfordD AdameA GrigorianA GrantI McCutchanA, EllisRJ etal .Rtterns of selective neuronal damage in methamphetamine-user AIDS patients J Acquir Immune Defic Syndr 2003 34 (5) : 467 – 474 .
- 74 ChanaG Esrall IP, Crevs L LangfordD AdameA GrantI et al. Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users. Neurology 2006; 67 (8): 1486 – 1489.
- 75 Pfderbaum A AdalsteinssonE Sullian EV CorticalNAA deficits in HIV infection without dementia: influence of alcoholism comorbidity. Neuropsychopharmacology 2005; 30 (7): 1392 – 1399.
- 76 Aylor MJ AlhassoonOM Schweinsbrg BC Jdeen JS GrantI MR spectroscopy in HIV and stimulant dependence HNRC Group. HIV Neurobeha vioral Research Center. J Int Neuropsychol Soc 2000 6 (1): 83 – 85.
- 77 ChangL ErnstT, SpeckO GrobCS Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities . AmJ Psychiatry 2005 162 (2) : 361 369 .

- 78 Aylor MJ Schweinsbrg BC AlhassoonOM Gongatana A Brwn GG Young-Casey C et al. Effects of human immunodeficiency virus and methamphetamine on cerebral metabolites measured with magnetic resonance spectroscopy. JNeurovirol 2007 13 (2): 150 – 159.
- 79 JerniganTL GamstAC, ArchibaldSL Fennema-NotestineC MindtMR MarcotteTD etal. Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am J Psychiatry 2005 ;162 (8) : 1461 1472.
- 80 Bartok A, Martin EM, Pitrak DL, Nøak RM, Pursell KJ, Mullane KM et al. Working memory deficits in HIV -seropositive drug users. J Int Neuropsychol Soc 1997; 3 (5): 451 456.
- 81 Frinpour R Martin EM Seidenberg M Pitrak DL Pursell KJ Milane KM et al . Verbal working memory in HIV -seropositive drug users . J Int Neuropsychol Soc 2000; 6 (5) : 548 – 555 .
- 82 MartinEM Sullian TS ReedRA Fletcher A , Pitrak DL , Weddington W et al . Auditory working memory in HIV-1 infection . JInt Neuropsychol Soc 2001 7 (1) : 20 26 .
- 83 MartinEM PitrakDL RainsN GrbesicS PursellK NunnallyG etal .Delayednonmatchto-sample performance in HIV -seropositive and HIV -seronegative polydrug ab users. Neuropsychology 2003 17 (2) : 283 – 288 .
- 84 Martin EM ,Pitrak DL ,Weddington W, Rains NA , Nunnally G ,Nixon H et al .Cognitive impulsivity and HIV serostatus in substance dependent males . J Int Neuropsychol Soc 2004; 10 (7) : 931 – 938 .
- 85 .ConchaM GrahamNM MunozA , Vlaho D Royal W, III Updik M etal .Effect of chronic substance abuse on the neuropsychological performance of intravenous drug users with a high prevalence of HIV-1 seropositivity . AmJ Epidemiol 1992 ;136 (11) : 1338 1348 .
- 86 .ConchaM SelnesOA, Vlahø D Nance-SprosonT, Updik M Røal W etal .Comparison of neuropsychological performance between AIDS-free injecting drug users and homose xual men . Neuroepidemiology 1997 ;16 (2) : 78 – 85 .
- 87 SelnesOA, McArthurJC Ryal W, III Updik ML Nance-SprosonT, ConchaM etal .HIV1 infection and intravenous drug use: longitudinal neuropsychological e valuation of asymptomatic subjects. Neurology 1992 42 (10) : 1924 1930.
- 88 . Bornstein RA Jema R Rosenbeger P, Whitacre CC Jera MF, Nasallah HA et al .Drug and alcoholuse and neuropsychological performance in asymptomatic HIV infection/Neuropsychiatry Clin Neurosci 1993 5 (3): 254 259.
- 89 .CristianiSA Pukay-MartinND BornsteinRA Marijuanause and cognitive function in HIVinfected people . JNeuropsychiatry Clin Neurosci 2004 16 (3) : 330 – 335 .
- 90 .BassoMR BornsteinRA Neurobehavioural consequences of substance abuse and HIV infection. JPsychopharmacol 2000 14 (3): 228 237.
- 91 .GreenJE Sueanu RV , BornsteinRA Theeffect of previous alcohol abuse on cognitive function in HIV infection . AmJ Psychiatry 2004 161 (2): 249 – 254 .
- 92 SchulteT, MuelleiOehring EM RosenbloomMJ Pfderbaum A Sullian EV Differential effect of HIV infection and alcoholism on conflict processing, attentional allocation, and perceptual load: e vidence from a Stroop Match-to-Sample task . Biol Psychiatry 2005; 57 (1): 67 – 75.
- 93 Rothlind JC, Greeniëld TM, Bruce AV, Myerhoff DJ, Flenniken DL, Lindgren A, et al. Heavy alcohol consumption in individuals with HIV infection: effects on neuropsychological performance. JInt Neuropsychol Soc 2005 ;11(1): 70 83.
- 94 Durasula RS MyersHF, MasonK HinkinC Relationshipbetween alcohol use/abuse, HIV infection and neuropsychological performance in African American men J Clin Exp Neuropsychol 2006 28 (3) : 383 404 .
- 95 Durasula RS MyersHF, SatzP, MillerEN Mogenstern H Richadson MA et al .HIV1, cocaine, and neuropsychological performance in African American men. J Int Neuropsychol Soc 2000 6 (3) : 322 335.
- 96 BassoMR BornsteinRA Effects of past noninjection drug abuse upon executive function and working memory in HIV infection. JClin Exp Neuropsychol 2003 25 (7): 893 903.

- 97. Rippeth JD , Heaton RK , Carge CL , Marcotte TD , Moore DJ , Gonzalze R et al . Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons . JInt Neuropsychol Soc 2004 ;10 (1) : 1 – 14 .
- 98 . Cary CL , Wods SP, Rippeth JD , Gonzalez R , Heaton RK , Grant I Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection . AIDSBehav 2006 ;10 (2) : 185 190 .
- 99 .Benhamou Y, Bochet M, Di M, V, Charlotte F, Azria F, Coutdier A et al .Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999 30 (4) : 1054 – 1058.
- 100 KramerJR GiordanoTP, SouchekJ El-SeragHB HepatitisC coinfection increases the risk of fulminant hepatic f ailure in patients with HIV in the HAAR T era. J Hepatol 2005; 42 (3) : 309 - 314.
- 101 LaskusT, Radowski M JablonskaJ KiblerK Wikinson J Adir D etal .Humanimmunodeficiency virus facilitates infection/replication of hepatitis C virus in nati ve human macrophages . Blood 2004 ;103 (10) : 3854 – 3859 .
- 102 LaskusT, Radowski M AdairDM Mikinson J ScheckAC, Rada J Emeging evidence of hepatitis C virus neuroinvasion. AIDS 2005 19 (Suppl): S140 - S144.
- 103 Laskus T, Operskalski EA, Radowski M, Wikinson J, Mack WJ, dGiacomo M et al. Negative-strand hepatitis C virus (HCV) RN A in peripheral blood mononuclear cells from anti-HCV-positive/HIV-infected women. JInfect Dis 2007 ;195 (1): 124 – 133.
- 104 Cribier B Schmitt C ,Bingen A ,Kirn A ,Kiler F In vitro infection of peripheral blood mononuclear cells by hepatitis C virus . JGen Virol 1995 76 (10) : 2485 2491 .
- 105 SansonnoD JacobelliAR CornacchiuloV, IodiceG DammaccoF Detection of hepatitis C virus (HCV) proteins by immunofluorescence and HCV RN A genomic sequences by non-isotopic in situ hybridization in bone marro w and peripheral blood mononuclear cells of chronically HCV-infected patients. ClinExp Immunol 1996 103 (3): 414 421.
- 106 Flugel A ,Bradl M ,Kreutzbeg GW, Graeber MB Transformation of donor-derived bone marrow precursors into host microglia during autoimmune CNS inflammation and during the retrograde response to axotomy. JNeurosci Res 2001 66 (1) : 74 82.
- 107 Hilsabeck RC ,Perry W, Hassanein TI Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002 35 (2) : 440 446 .
- 108 HilsabeckRC HassaneinTI CarlsonMD Zigler EA PerryW Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C . J Int Neuropsychol Soc 2003 9 (6) : 847 – 854 .
- 109 McAndrevs MP, Fercnik K CarlenP, Damyanoich A Mrkenjic M Jones S et al. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005 41 (4): 801 – 808.
- 110 .MIson CJ FinchCE CohenHJ Cytokinesand cognition-the case for a head-to-toe inflammatory paradigm. JAm Geriatr Soc 2002 50 (12) : 2041 – 2056.
- 111 RostasyK MontiL LiptonSA HedreenJC GonzalezRG Naia BA HIVleucoencephalopathy and TNF alpha expression in neurones . J Neurol Neurosur g Psychiatry 2005; 76 (7) : 960 – 964 .
- 112. Paul R, Letendre S, Dearborne J. Cognitive function in patients co-infected with hepatitis C and human immunodeficiency virus. Current Hepatitis Reports. In press.
- 113 KramerL BauerE FunkG HoferH JessnerW, Steindl-MundaP etal .Subclinicalimpairment of brain function in chronic hepatitis C infection . JHepatol 2002 37 (3) : 349 – 354 .
- 114 Erton DM AllsopJM MainJ Ester GR ThomasHC Tylor-Robinson SD Evidencefor a cerebral effect of the hepatitis C virus. Lancet 2001 358 (9275) : 38 – 39.
- 115 Erton DM Tylor-Robinson SD ThomasHC Reduced quality of life in hepatitis C-is it all in the head ? JHepatol 2002 36 (3) : 435 – 438 .
- 116 Mogello S EstanislaoL RyanE GeritsP, SimpsonD Jerma S et al. Effects of hepatic function and hepatitis C virus on the nerv ous system assessment of adv anced-stage HIVinfected individuals. AIDS 2005 ;19 (Suppl): S116 – S122.

- 117 RyanEL Mogello S IsaacsK NaseerM GeritsP Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 2004 62 (6) : 957 – 962.
- 118 Persons TD Tacker KA HallCD RobertsonWT, EronJJ FriedMW etal .Neurocognitive functioning and HAAR T in HIV and hepatitis C virus co-infection . AIDS 2006; 20 (12) : 1591 – 1595 .
- 119 MartinEM Nøak RM FendrichM Jøssileva J GonzalezR Grbsic S etal .Stroopperformance in drug users classified by HIV and hepatitis C virus serostatus J Int Neuropsychol Soc 2004 ;10 (2) : 298 – 300 .
- 120 Richardson JL , Nwicki M , Danly K , Martin EM , Cohen MH , Gonzlez R et al . Neuropsychological functioning in a cohort of HIV – and hepatitis C virus-infected women. AIDS 2005 ;19 (15) : 1659 – 1667 .
- 121 on Giesen HJ HeintgesT, Abbasi-BoroudjeniN Kacukkoylu S Kaller H ,HaslingerBA etal .Psychomotorslowing in hepatitis C and HIV infection . JAcquir Immune Defic Syndr 2004 35 (2) : 131 137 .
- 122 TheinH Maruff P, KrahnM KaldorJ Korey D Brev B etal .Improved cognitive function as a consequence of hepatitis C virus treatment . HIVMed 2007 § (8) : 520 528 .
- 123 ChernerM LetendreS HeatonRK DurelleJ Marquie-BeckJ mag B et al .HepatitisC augments cognitive deficits associated with HIV infection and methamphetamine Neurology 2005 64 (8) : 1343 1347 .
- 124 LetendreSL ChernerM EllisRJ Marquie-BeckJ GraggB Marotte T etal .Theeffects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease . AIDS 2005 19 (Suppl) : S72 S78 .
- 125 an Gorp WG , Hinkin CH Triple trouble: cognitive deficits from hepatitis C, HIV, and methamphetamine . Neurology 2005 64 (8) : 1328 - 1329 .
- 126 CroneC GabrielGM Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therap y complications. J Psychiatr Pract 2003 9 (2): 93 110.
- 127 JuenglingFD EbertD GutO EngelbrechtMA RasenackJ Nitsche EU etal .Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology 2000 152 (4) : 383 – 389 .
- 128 .Wnn GH ,Cozza KL ,Zapor MJ ,Wirtmann GW, Armstrong SC Med-pych drug-drug interactions update. Antiretrovirals, part III: antiretrovirals and drugs of abuse. Psychosomatics 2005 46 (1): 79 – 87.
- 129 Henry A, HillIR Fatal interaction between ritonavir and MDMA. Lancet 1998; 352 (9142): 1751 – 1752.
- 130 ShermanKE ShireNJ RousterSD PetersMG JamesKM ChungR etal .Vral kinetics inhepatitis C or hepatitis C/human immunodidiency virus-infected patients Gastroenterology 2005 128 (2): 313 – 327 .
- 131 McHutchisonJG MannsM Rtel K Ponard T, LindsayKL Tepo C et al .Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002 123 (4) : 1061 1069.

The Functional Impact of HIV-Associated Neuropsychological Decline

Matthew J. Wright, Ellen Woo, Terry R. Barclay, and Charles H. Hinkin

Unlike the relative paucity of research e xamining the functional impact of HIV associated neurocognitive decline, there is a mature body of literature with regards to the neuropsychological sequelae of HIV infection (see chapters 7, 8, 9, 15, & 18 in this volume for a thorough review). Briefly, HIV infection is associated with neuropsychological deficits in attention/working memory, motor abilities, memory, and executive functioning (1-5), which are often attributed to disruptions in frontal-striatal circuitry (3, 6). These HIV-associated deficits generally worsen with infection staging (3), and decline in psychomotor speed appears to be the most robust (5, 7). Although dementia occurs in a relatively small number of HIVinfected individuals, between 30 and 50% of those with HIV e vidence milder neuropsychological deficits (3, 8). That said, the number of newly diagnosed cases of HIV, in tandem with increased life e xpectancies resulting from treatment with highly active antiretroviral therapy (HAART), is driving up the mean age of the HIV-infected population (9, 10); older HIV+ individuals have been shown to demonstrate disproportionately greater neuropsychological decline and are about three times more likely to develop HIV-related dementia than are their younger counterparts (11, 12).

Data indicate that activities of daily living (ADLs; e.g., bathing, dressing) and instrumental activities of daily living (IADLs; e.g., financial management, cooking) decline in cases of HIV infection, although these declines tend to be specific to the individual and are some what variable (9, 13). Most of the functional declines are observed in IADLs (10). Heaton et al. at the UCSD HIV Neurobehavioral Research Center (HNRC) completed the groundbreaking w ork in this area via the use of

M.J. Wright (🖂)

Department of Psychiatry, Psychology Division,

Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA,

1000 W. Canson St. D-2 Annex, #5, Box 495

Torrance, CA 90509, USA

mwright@labiomed.org

laboratory-based functional measures, which indicated that HIV -related IADL declines are predicted by neuropsychological status (9, 14-16) although physical (e.g., fatigue, neurologic symptoms, GI disease) and af fective variables (e.g., depression) also play a role in HIV-related functional outcome (17). For example, HIV-associated neuropsychological impairment is predictive of vocational difficulties (e.g., unemployment rates, difficulties completing work-related duties) above and beyond HIV infection itself (18). Furthermore, neuropsychological impairment is predictive of laboratory-based measures, real-w orld indicators, and self-report questionnaire endorsements of IADLs among HIV-infected individuals (see Table 1 for suggested functional measures) (14). Specifically, HIV-associated deficits in executive abilities (related to declines in vocational, financial, and medication management skills), learning and memory (linked with declines in medication management, shopping, and cooking skills), and language and attention (associated with v ocational ability decrements) predict performances on laboratory-based measures of IADLs. Moreover, neuropsychological deficits, poor performance on laboratory measures of IADLs, and depression are predictive of self-reported IADL dependencies in HIV+ persons. Laboratory-based IADL performances and depressed mood are predictive of cognitive complaints and, along with AIDS status, predict declines in real-world measures of vocational functioning.

In summary, HIV infection is associated with neuropsychological def icits, which are predictive of laboratory and real-w orld measures of functional ability. The current review will focus on medication adherence, driving, and employment, three particular salient areas of everyday functioning.

Medication Adherence

Medication adherence can be assessed via a number of methods, all of which are characterized by unique strengths and weaknesses. These methods f all on a continuum ranging from those that are more objecti ve (e.g., plasma drug le vels) to those that are more subjective (e.g., patient self-reports). In this section, methods of assessing medication adherence are briefly outlined and followed by a review of the relationship between medication adherence and neuropsychological function in HIV+ individuals.

Medication Adherence: Methods of Measurement

Although laboratory-based measures can quantify medication management abilities (e.g., Medication Management T est – Re vised; see Table 1) (14), accurate realword measures of actual adherence are dif ficult to design. Self-report is probably the most widely used methodology for assessing medication adherence in clinical practice. Strengths of self-report include its ne gligible cost and the simplicity of

Performance Measures	Self-Report Measures
 Modified Direct Assessment of Functional Status A modified DAFS for use with HIV+ individuals that includes: Financial Skills (from the DAFS): currency calculation and checkbook balancing. Advanced Finances (from Heaton & colleagues): involves paying three bills, recording a deposit, and active account management to retain needed currency. Shopping (from the DAFS): selection of goods from a grocery list. Cooking (from Heaton & colleagues): involves utilizing two recipe cards and completing steps required for preparing pasta and warming bread. Medication Management Test-Revised The MMT was designed for application with HIV+ individuals. It was later modified by Heaton and colleagues (MMT-R) and entails: Referencing mock medication inserts. Sorting, organizing, and making inferences about three fictitious medications (e.g., refill needs). MESA SF2* & COMPASS*: computer administered measures of vocationally relevant aptitudes such as: Academic skills (writing, reading, vocabulary, and mathematical ability) Cognition (problem solving, short-term nonverbal memory, visual discrimination, and placing and tracking). Notes. For more detail please (14). 	 Patient self-reported work history* This can vary form informal interview questions to use of structured questionnaires. Patient's Assessment of Own Functioning: self-report questionnaire reflecting an individuals perception of their functional level with regard to: Cognition (general intellect, memory, language) Sensory-perceptual ability Motor function in hands Work and recreational activities Modified IADL Scale: assesses current and previous level of IADL dependence on tasks such as: Financial management Household repairs & chores Medication use Grocery shopping Telephone use Use of transportation Bathing and grooming Reading and TV comprehension

 Table 1
 Suggested Functional Measures for HIV Infected Individuals

IADL=instrumental activity of daily li ving; DAFS=Direct Assessment of Functional Status; MESA SF2=Microcomputer Evaluation and Screening Assessment Short Form 2; COMPASS = Computerized Adaptive Placement Assessment & Support System.

* These can be used in conjunction with published vocational profiles to determine level of occupational decline (see 9, 14).

data collection. Ho wever, many patients o verstate their actual adherence rates. Moreover, research with HIV-infected adults has revealed that patient self-report, relative to electronic monitoring techniques (see belo w), tends to be accurate among patients who candidly admit to poor adherence but may over-estimate actual adherence rates by approximately 10–20% among the majority of patients who claim perfect or near-perfect adherence (18–20).

Pill counts are a relati vely straightforward technique that can be utilized to assess adherence rates. Considering the number of pills dispensed to a patient on a particular date, in conjunction with how many pills they should have ingested in the intervening time period, it is simple to calculate the number of pills that should remain at the end of the study period. Excess doses are therefore considered to reflect doses not taken as prescribed. For example, consider a patient on a 2 pills/ day regimen who begins with 60 pills and returns to clinic 20 days later. If 20 pills remain, that w ould be interpreted as perfect adherence $(60 - (20 \times 2) = 20)$. Although it is easy for the researcher/clinician to calculate, a decided dra wback is that this is also easy for patients to calculate. Accordingly, prior to their return to clinic, patients may remove extra doses from their pill bottle and thus appear more adherent than is actually the case.

Bansberg et al. at UCSF de veloped an innovative approach to o vercome this limitation (21). They conducted "unannounced pill counts" at participants' residences. They found that this approach correlates well with biologic outcomes (e.g., HIV viral load). Although this methodology w orks well within dense urban communities (e.g., San Francisco), it w ould be cumbersome to utilize in sparsely populated rural settings or in a sprawling metropolis. Unannounced pill counts can also be conducted via telephone, an adaptation that at least partially ob viates the logistical difficulties introduced by geographical sprawl.

Similar to pill counts, pharmac y refill records have also proven to be a costeffective measure of medication adherence. This method presumes that patients refilling their medication prescriptions in a timely f ashion are more lik ely to be taking their medication as prescribed in comparison with individuals who are tardy in refilling their prescriptions. This approach w orks best in settings where phar macy records are centralized and easily accessed (e.g., in V eterans Administration Medical Centers).

An alternate approach that also minimizes reliance on patient self-report and utilizes electronic monitoring is the use of MEMS caps [e.g., Medication Ev ent Monitoring System (MEMS), Apre x Corp, Union City, California]. MEMS caps employ a microchip embedded in a pill bottle cap that automatically records the date, time, and duration of pill bottle openings. Although electronic monitoring devices may have their own limitations, accumulating data suggest that the y often are more accurate than pill counts or self-report, both of which appear to signif icantly overestimate adherence rates. One disadvantage of this method is the bulky nature of the MEMS cap bottle, which precludes inconspicuous transportation of one's medications. This can lead to "pock et-dosing," where patients remo ve extra doses from their pill bottle and place them in their pock et (or another less-conspicuous container) to consume at a later time. Also, the use of MEMS devices has precluded the use of daily/weekly pill or ganizers, which can contrib ute to

poorer adherence rates. Technological advances are now emerging that will help to overcome this limitation.

Medication Adherence: Neuropsychological Correlates in HIV Infection

The introduction of HAAR T has led to mark ed improvement in mortality, functional level, and quality of life among HIV+ indi viduals (22, 23). However, unless patients are adherent to their HAAR T regimen (i.e., at least 90–95% of doses taken), viral replication may ensue and drug-resistant strains of the virus can emerge. As mentioned earlier, memory and e xecutive abilities are predictive of performances on objective laboratory measures of medication management (14). Our group has engaged in se veral studies designed to elucidate the v ariables that are associated with medication adherence in HIV disease, with a particular emphasis on neurocognitive factors. Below we present an overview of the primary findings from these studies to illustrate how neurocognitive dysfunction can adversely affect medication adherence.

Our laboratory recently conducted an in vestigation of neuropsychological functioning and medication adherence in 137 HIV -infected adults (24). HIV+ participants were classified as neuropsychologically intact or impaired via a methodology developed by Heaton and colleagues at the UCSD HNRC. Here, neuropsychological test scores were con verted to demographically corrected *T*-scores (M = 50, SD = 10) and grouped by cogniti ve domain. A cut-point of 1 standard deviation below the mean (i.e., T < 40) was used to classify participants as cognitively compromised. We determined HAART adherence via MEMS caps over a one-month time frame. P articipants who took at least 95% of their prescribed doses were classified as good adherers.

The mean adherence rate across all participants was 80.2%; only 34% of participants demonstrated good adherence (95% adherence). Further analysis indicated that neuropsychologically compromised participants' mean adherence was 70% in comparison with cognitively intact participants, who demonstrated a mean adher ence of 82%. Logistic re gression analyses revealed that neuropsychologically compromised individuals were twice as lik ely to demonstrate poor adherence. A more detailed inspection of neuropsychological performances revealed that deficits in executive abilities, attention/working memory, and verbal memory were associated with poorer HAART adherence.

Medication Adherence: Neuropsychological Dysfunction and Regimen Complexity

Historically, effective pharmacological management of HIV/AIDS involved adherence to an extremely demanding, often comple x, medication re gimen [often upwards of 20–30 pills/day, many with specific, compound instructions (e.g., "Take




Fig. 1 Relationship between global neurocogniti ve functioning, re gimen complexity, and HAART adherence among HIV-infected participants. Adapted from Hinkin et al. (24)

three times per day on an empty stomach")]. Although considerable progress has been made in simplifying HIV medication re gimens, many regimens remain complex and likely pose difficulties for the cognitively compromised patient. Using the data set mentioned above, we explored the relationship between neuropsychological dysfunction, regimen complexity, and adherence. We found that HAART regimen complexity (1–2 daily doses vs. 3 daily doses) adv ersely affects adherence among neuropsychologically impaired HIV+ indi viduals (see Fig. 1). Complex medication regimens were not significantly problematic for the neuropsychologically normal participants. Follow-up analyses revealed that cognitive compromise in executive abilities and working memory interacted with re gimen complexity to produce these marked declines in adherence.

Medication Adherence: Aging and Neuropsychological Impairment

As mentioned earlier, older HIV+ indi viduals evidence disproportionately higher rates of neurocognitive impairment (11, 12). Given these findings, we hypothesized that older HIV+ participants (\geq 50-years old) would demonstrate lower adherence than would their younger counterparts (25). However, we found that the older participants were actually f ar more adherent than younger participants. 53% of our older HIV+ participants demonstrated good adherence, whereas only 26% of younger HIV+ participants indicated good adherence. Using a more liberal cutpoint of 90% to define good adherence, 71% of the older HIV+ group were found to be adherent vs. only 37% of the younger HIV+ group.

Nevertheless, a closer inspection of the interaction between adv ancing age and neuropsychological compromise presented a dif ferent picture. When we grouped participants by medication adherence (using the 95% adherence cut-point) and age (using age 50 as a cut-point) and then compared these groups' neuropsychological test performances, we found little dif ference in neuropsychological functioning between the good adherers. Ho wever, the older HIV+ subjects who were poor adherers performed far worse on neuropsychological testing than did the younger HIV+ subjects who were poor adherers. In f act, 83% of older adult participants demonstrating poor adherence indicated global cogniti ve impairment. Further analyses showed that this effect was driven by deficits in executive skills, psychomotor functioning, and verbal memory.

This suggests that adv ancing age in conjunction with neuropsychological decline poses particular challenges re garding medication management for HIV+ persons. Additionally, it must be noted that we have presented these data under the assumption that cognitive dysfunction causes poorer adherence. It is equally plausible that poor adherence results in neuropsychological impairment. In all lik elihood, a bidirectional relationship exists, with neuropsychological deficits adversely affecting patients' ability to adhere to their HAART regimen, which in turn results in increased disease progression and a worsening of neurocognitive function.

Medication Adherence: Drug Use/Abuse

Given the high comorbidities between substance ab use and HIV infection, we undertook a longitudinal study e xamining the impact of drug use and ab use on medication adherence among 150 HIV -infected individuals, 102 of whom were revealed by urinalysis to have recently used illicit drugs (26). Medication adherence was tracked over a 6-month period using MEMS caps. Our data indicated that drug-positive participants demonstrated signif icantly worse medication adherence than did drug-negative participants (63% vs. 79%, respectively). Logistic regression analysis revealed that drug use was associated with over a fourfold greater risk of poor adherence. Further, stimulant use (i.e., cocaine or methamphetamine) proved to be particularly deleterious to adherence, as participants who tested positive for stimulants were seven times more lik ely to be poor adherers than those without positive urines (see Fig. 2).

We also compared adherence rates for time periods when subjects were and were not using stimulants. From these data, we computed 3-day adherence rates for visits at which participants tested stimulant-positive as well as adherence rates for visits at which the same participants tested stimulant-ne gative. The 3-day mean adherence rate for participants who tested positi ve for recent stimulant use w as 51.3% in contrast to the 3-day mean adherence rate of 71.7% for the same participants when they had tested ne gative for recent stimulant use. These f indings suggest that the impact of stimulant use on HAART adherence is a function of state rather than trait. In other words, our findings imply that it is the acute effects of intoxication, rather than stable features, which may be characteristic of the drug-using populace, which adversely affects medication adherence. Related data from our laboratory comparing HIV+ participants who recently used stimulants (cocaine or methamphetamines;




Fig. 2 Medication adherence rates among stimulant using, nonstimulant drug using, and drug abstinent HIV-infected participants over a 6-month period. Adapted from Hinkin et al. (26)

n = 17) with those who did not recently use stimulants (n = 23) suggest a possible neuropsychological mechanism by which stimulant use decreases adher ence (27). In this study, despite similar global cognitive functioning between both groups, we found that recent stimulant use w as associated with declines in sustained visual attention as indexed by a computerized continuous performance task. Although we did not assess medication adherence in this e xperiment, this finding, taken together with other data from our laboratory, suggests that stimulant intoxication impairs attentional abilities, which in turn may result in reduced HAAR T adherence. Indeed, other w ork in our laboratory indicates that neurocognitive impairments are predictive of poor medication adherence in older HIV+ participants (28) as well as in stimulant using HIV+ persons (29).

Overall, our work suggests that attention, memory, and executive abilities are particularly important to successful medication adherence in HIV+ individuals (24, 29). One cogniti ve operation that requires all of these processes and that may account for medication adherence rates among neuropsychologically impaired HIV+ persons is prospective memory (ProMem). ProMem is the ability to remember and correctly execute an intended action in the future at either a specified time (time-based ProMem; e.g., tak e medication at 5 p.m.) or in conjunction with an event (event-based ProMem; e.g., tak e medication with dinner). In general, most individuals indicate that time-based ProMem tasks are more dif ficult to complete than are event-based ProMem tasks. Interestingly, Woods et al. at UCSD HNRC have shown that HIV+ participants demonstrated time and e vent-based ProMem deficits in comparisons with healthy controls (30). Additionally, these investigators have found evidence suggesting that HIV-related ProMem failures may be due to macrophage activation and axonal injury (31).

Driving

Like medication adherence, dri ving ability can be assessed in numerous w ays. Methods for assessing driving include patient self-report, review of driving history (e.g., records of traffic violations and accidents), dri ving simulator performances, and on-road e valuations. As mentioned earlier, self-reports can be biased for a number of reasons (e.g., motivation, cognitive impairment). Although state driving records may provide an objective indicator of traffic infractions and accidents, these likely grossly underestimate overall driving difficulties. Driving simulator performances and on-road evaluations almost certainly provide more accurate data on driving ability, although both of these methodologies lik ely elicit somewhat artificial representations of true driving behavior.

Neuropsychological deficits have been shown to be associated with declines in driving across a number of these methodologies (32–35), although the neuropsychological profile indicative of poor dri ving is yet to be determined because of methodological and def initional differences among studies. The majority of research regarding the neuropsychology of dri ving ability in HIV+ persons has been conducted by Marcotte et al. at the UCSD HNRC via the use of dri ving histories, driving simulators, and on-road e valuations. In the first study of HIV and driving ability, a link between neuropsychological impairments and driving simulator performance was demonstrated (see Fig. 3) (36). Participants evidencing mild




Fig. 3 Percentage of driving simulator failure for neuropsychologically normal and impaired HIV-infected participants. *TOPS* Truck Operator System; a program that assesses maintenance of speed, a straight trajectory, and infrequent divided visual attention. Reproduced with permission from Cambridge University Press (36)

neuropsychological deficits were shown to fail driving simulations at a rate f ive to six¹ times greater than cognitively intact participants. Also, neuropsychological performances in attention/w orking memory and f ine motor abilities predicted performance across driving simulations (simple and e vasive), although visuoconstructive abilities (simple dri ving) and nonverbal memory (evasive driving) were also found to be predictive.

A later study by Marcotte et al. that included 40 HIV+ participants and 20 healthy controls utilized a comprehensive neuropsychological test battery and two driving simulations to assess navigational abilities and evasive driving: an on-road driving evaluation and the Useful Field of View test (UFOV; a computerized measure of visual processing and attention) (37). Of the HIV+ participants, 11 were neuropsychologically impaired. These impaired HIV+ participants demonstrated increased simulator accidents, reduced simulator driving efficiency (i.e., they drove unnecessary distances to complete a specified task), greater fail rates in on-road driving tests, and decreased visual processing and di vided attention on the UFOV in comparison with the neuropsychologically intact HIV+ and HIV- participants. For the whole sample, global neuropsychological functioning, simulator accidents, and simulator driving efficiency accounted for 47.6% of the v ariance in on-road pass/fail performance. With regard to specific neuropsychological domains, only executive abilities emerged as a significant predictor of on-road pass-f ail rates, although attention/working memory, memory, and v erbal abilities approached significance.

More recently, Marcotte et al. e xamined the relationship between visual attention and dri ving in HIV+ participants more closely (38). In this study, which included 42 HIV+ and 21 HIV– participants, UFO V performances, neuropsychological status, and detailed self-reported driving history were collected. With regard to neuropsychological functioning, 45% (n = 19) of the HIV+ group e videnced impairments (mostly mild-moderate), while only 4.8% (n = 1) of the HIV– participants showed mild deficits. Overall, the HIV+ participants demonstrated greater difficulties on the divided attention subtest of the UFO V in comparison with controls. In fact, the HIV-infected participants had an 11-fold greater risk of performing in the abnormal range on the UFO V's divided attention subtest than the control participants (36% vs. 17%, respecti vely). In terms of predicting automobile accidents, high-risk status² on the UFO V predicted self-reported accidents, while neuropsychological status approached significance as a predictor. However, when both

¹Five times worse for simulations of simple driving (i.e., driving on a straight highway at a constant speed with occasional competing responses). Six times w orse for simulations of e vasive driving (i.e., variable speed driving requiring turns, passage of other v ehicles, and avoidance of potential accidents).

²Performances across the three UFO V subtests (Processing Speed, Di vided Attention, and Selective Attention) are analyzed with re gard to an algorithm that classifies risk level (39). Participants in Marcotte et al. (38) with a level five classification (High to Very High risk) were considered high risk.

neuropsychological impairment and UFO V high-risk status were considered together, 93% (39/42) of the HIV+ participants who reported automobile accidents in the past were classified correctly.

In sum, the relationship between neuropsychological functioning and dri ving ability in HIV-1-infected individuals is complex, but deficits in attention/working memory (particularly in the visual modality), in addition to declines in e xecutive and memory abilities, lik ely contribute to reduced dri ving performance in this population. These data argue for driving ability assessments of patients suffering from both HIV and neuropsychological impairments, with a particular focus on deficits in visual attention/working memory. However, it is very important to note that the majority of HIV -infected individuals do not e xhibit neuropsychological deficits that would impair their ability to drive.

Employment

Assessment of vocational status in HIV+ persons is of "real w orld" significance, given that transient employment as well as unemployment is associated with a greater risk of hospitalization and death compared to stable emplo vment (40). Several mechanisms have been proposed to explain the association between poor employment and health status in HIV participants. One mechanism includes the direct physiological effects of stress related to poor employment on the neuroendocrine and immune systems, leading to progression of HIV disease. The second mechanism involves increased risky health behaviors and poor treatment adherence in those without stable employment. Another mechanism is adv erse work conditions, such as low control over work scheduling, which can impact health. Finally, participants with a poor v ocational situation may have had poorer health prior to HIV infection. Poor employment histories are related to greater overall disability in ADLs (i.e., dressing and grooming, eating, hygiene), IADLs (i.e., reaching, gripping, shopping, and household chores), and mobility (w alking, arising) (9), which would have a significant impact on the ability to work.

Employment has been e valuated using a number of dif ferent methodologies. One method includes using the Computerized Adapti ve Placement Assessment and Support System (COMPASS; Valpar, Inc.). The COMPASS is an objective measure of vocational abilities that can also estimate premorbid work functioning based on a participant's work history. Multiple domains of work functioning are assessed: placing (e ye-hand coordination), color discrimination, reading, size discrimination, shape discrimination, short-term visual memory, spelling, vocabulary, mathematics, development/editing (sequentially ordering sentences), problem solving, e ye-hand-foot coordination, alignment and dri ving, machine tending, and wiring (fine motor tasks). Work histories have also been evaluated. Self-report regarding employment status (40, 41) or changes in vocational functioning have also been utilized (14, 40). Current vocational functioning can also be assessed by rating participants' jobs by the skills that the jobs require (14). The ratings include general educational development (i.e., reasoning, mathematic, and language) and aptitudes (i.e., job-specif ic skills; learning, v erbal, numerical, spatial, form perception, clerical perception, motor coordination, f inger dexterity, manual dexterity, eye-hand-foot coordination, and color discrimination). These ratings are used to derive a Department of Labor "W orker Qualifications Profile." These ratings help to determine the number of jobs that people can perform. Heaton et al. (42) suggested that this type of assessment is limited, as the y do not account for job-related experience, which can lessen the adverse effect of neuropsychological impairment on occupational performance.

Heaton et al. (42) found that medically asymptomatic HIV-infected patients who exhibited neuropsychological impairment were more than two times as likely to be unemployed (i.e., w ork less than half-time) than were patients who were not impaired, despite the lack of active HIV symptomatology. In addition, most of these participants were in the earlier stages of HIV infection, suggesting that medical illness was not the primary cause of the lack of employment. Regardless of employment status, HIV+ patients who e videnced neuropsychological impairment per - ceived themselves to have greater difficulties in vocational functioning than their unimpaired cohorts. The relationship between neuropsychological impairment and employment difficulties could not be explained by depression.

In the HAART era, employment loss is common during the early years of post-HIV infection (40). One out of f ive patients lose a job after a median time of 2.5 years after infection, e ven though physical declines are more limited. Dray-Spira et al. (40) found se veral risk f actors that increase the chances of losing employment. These variables include female gender, having a nonpermanent job, poor housing accommodations, and poor health [i.e., adv anced HIV disease (viral load > 10,000 copies/mL) and/or hospitalization in the past 6 months]. It was suggested that female gender is already a disadv antage for employment, and this is further compounded by low socioeconomic status (e.g., poor li ving accommodations) and HIV disease. Other barriers to employyment include advanced age and longer duration of unemployment (43). Heaton et al. (42) found that HIV+ persons who were neuropsychologically impaired were more like ely to be unemployed. Furthermore, global functional impairment (i.e., on an objecti ve laboratory-based assessment of everyday functioning, self-report of functioning outside the laboratory, and a laboratory assessment of v ocational functioning) and depression were more common in unemployed participants. It was suggested that neuropsychological testing and functional assessments could be used together to determine if HIV+ individuals suffer from "syndromic neurocognitive" disorders.

van Gorp et al. (43) found several predictors of return to employment in HIV+ persons who had stopped working after learning of their diagnosis. Effortful learning and memory was a robust predictor of return to work, beyond IQ and health. In addition, motor speed predicted return to work. Taken together, van Gorp et al. suggest that HIV+ indi viduals seek workplace accommodations while maintaining some employment, as patients who return to employment report less depression and improved quality of life. Furthermore, patients who returned to w ork often maintained their previous occupational levels. Having a high occupational position (e.g., managers, executives, craftsmen) decreased the risk of employment loss (40). Furthermore, employed HIV+ participants tend to hold more cognitively demanding jobs and have higher levels of lifetime job skills (44).

In general, loss of employment is common following an HIV diagnosis, and this phenomenon cannot be entirely explained by physical barriers or mood. There are numerous risk factors for unemployment: female gender, temporary employment, poor housing, health problems, older age, an AIDS diagnosis, and increased duration of unemployment. Of note, impairment in neuropsychological skills and e veryday functioning should be assessed in HIV+ patients, given that these are the major risk factors for unemployment. Neuropsychological assessments can also help to predict who will more likely return to work, based on higher performances on measures of learning, memory, and motor skills. W ith the proper w orkplace accommodations, return to work can be benef icial for HIV patients, as re gaining employment can enhance mood and quality of life.

Conclusion

HIV can give rise to neuropsychological def icits in attention/w orking memory, motor abilities, memory, and executive abilities. Between 30 and 50% of those with HIV evidence such deficits. HIV-infected individuals who demonstrate neuropsychological impairments also tend to e xhibit functional declines on real-w orld and laboratory measures. With regard to the majority of the domains of functional outcome reviewed herein (laboratory ADL/IADL simulations, medication adherence, driving ability, employment status), attention/w orking memory, memory, and executive deficits tend to be most predictive of functional decline. A complicating factor is depressive symptoms, which interact with cognitive declines and adversely influence the functional abilities of HIV-infected persons. In terms of specific functional effects, deficits in attention/w orking memory are associated with poorer medication adherence and dri ving ability (particularly visual attention/w orking memory); memory impairments correlate with reduced medication adherence (particularly verbal memory), driving ability (particularly non verbal memory), and employment status (chiefly v erbal memory); e xecutive problems are related to inferior medication adherence (especially for older adults and complex medication regimens) and driving ability. Additionally, fine motor deficits are predictive of impairments medication adherence (for older participants) and employment status. Overall, research indicates a link between functional outcome and neurocogniti ve status in HIV+ individuals and strongly suggests the need for repeated neuropsychological evaluations to optimize treatment planning (e.g., tracking cognitive status and diagnostic classif ication, vocational planning, and recommendations for performance enhancing beha vioral and en vironmental modifications) for HIVinfected persons.

Although our understanding of the functional impact of HIV -associated neuropsychological decline has grown, there are still critical gaps in the literature.

In particular, studies linking structural and functional neural systems known to be affected by HIV disease with their real-w orld functional correlates are yet to be performed. Such data may not only improve our scientific understanding regarding the neuroanatomy of functional abilities in HIV, but might also suggest neuroanatomical targets for novel pharmacologic and neurocognitive therapies. Additionally, studies deconstructing the neuropsychological def icits (e.g., attention/w orking memory, memory, and executive deficits) most often associated with functional decline in HIV disease could lead to insights informing neurocogniti ve rehabilitation strategies (e.g., cognitive strategy use, environmental support, behavioral and environmental modifications) with utility for prolonging functional independence.

References

- Miller EN ,Selnes OA , McArthur JC et al . Neuropsychological performance in HIV-1infected homosexual men: The Multicenter AIDS Cohort Study (MA CS). *Neurology* 1990 ; 40 : 197 – 203 .
- 2 .HinkinCH CastellonSA an Gorp WG SatzP Neuropsychological features of HIV disease. New York, NY, US : GuilfordPress ; 1998 .
- 3 .HeatonRK GrantI ButtersN et al .TheHNRC 500-neuropsychology of HIV infection at different disease stages HIV Neurobeha vioral Research Center. J Int Neuropsychol Soc 1995; 1 : 231 – 51.
- 4 .HardyDJ HinkinCH Leine AJ CastellonSA LamMN Risky decision making assessed with the gambling task in adults with HIV. *Neuropsychology* 2006; 20: 355 60.
- 5 .Selnes OA , Galai N , Bacellar H et al .Cognitive performance after progression to AIDS: a longitudinal study from the Multicenter AIDS Cohort Study. *Neurology* 1995 ; 45 : 267 75 .
- 6 . Woods SP, Carg CL , Foster AI , Grant I Action (verb) generation in HIV-1 infection . *Neuropsychologia* 2005 ; 43 (8) : 1144 - 51 .
- 7 .MarderK LiuX SternY et al .Neurologicsigns and symptoms in a cohort of homosexual men followed for 4.5 years. *Neurology* 1995 ; 45 : 261 7.
- 8 .McArthurJC Selnes OA , Glass JD Hover DR BacellarH HIV dementia. Incidence and risk factors .*Res Publ Assoc Res Nerv Ment Dis* 1994 ; 72 : 251 72 .
- 9 .HeatonRK MarcotteTD ,WhiteDA et al .Nature and vocational significance of neuropsychological impairment associated with HIV infection. *Clin Neuropsychol* 1996 ; 10 : 1 – 14 .
- 10 .O'DellMW, HubertHB LubeckDP, O'DriscollP Pre-AIDS physical disability: data from the AIDS T ime-Oriented Health Outcome Study . Arch Phys Med Rehabil 1998; 79: 1200 - 5.
- 11 ChernerM EllisRJ LazzarettoD etal .Efects of HIV-1 infection and aging on neurobehavioral functioning:preliminary findings. *AIDS* 2004 ; Suppl1: S27 – 34 .
- 12 Mcour V, ShikumaC ShiramizuB etal .Higherfrequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. *Neurology* 2004; 63: 822 7.
- 13 .Crystal S ,Sambamoorthi U Functional impairment trajectories among persons with HIV disease: a hierarchical linear models approach. *Health Serv Res* 1996; 31: 469 88.
- 14 HeatonRK MarcotteTD MindtMR etal .Theimpact of HIV-associated neuropsychological impairment on everyday functioning. *J Int Neuropsychol Soc* 2004 ; 10 : 317 31 .
- 15 MindtMR ChernerM MarcotteTD etal Thefunctional impact of HIV-associated neuropsychological impairment in Spanish-speaking adults: a pilot study . J Clin Exp Neuropsychol 2003 ; 25 : 122 – 32 .
- 16 Min RA HeatonRK GrantI Everyday functioning and its relationship to cognitive impairment in HIV disease . Nev York, NY, US : OxfordUniversity Press ; 1994 .

- 17 MJson IB ClearyPD Clinicalpredictors of declines in physical functioning in persons with AIDS: results of a longitudinal study . J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 343 9.
- 18 ArnstenJH DemasPA, Frzadegan H etal .Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring *Clin Infect Dis* 2001; 33: 1417 23.
- 19 Læine AJ HinkinCH CastellonSA etal . Variations in patterns of highly active antiretroviral therapy (HAART) adherence. *AIDS Behav* 2005; 9: 355 62.
- 20 Læine AJ HinkinCH MarionS etal .Adherenceto antiretroviral medications in HIV: differences in data collected via self-report and electronic monitoring . *Health Psychol* 2006 ; 25 : 329 – 35 .
- 21 Bangsber DR HechtFM CharleboisED Chesne M MossA Comparing objective measures of adherence to HIV antiretro viral therapy: electronic medication monitors and unannounced pill counts. AIDS Behav 2001; 5: 275 81.
- 22 Persons TD BraatenAJ HallCD RobertsonKR Betterquality of life with neuropsychological improvement on HAART. *Health Qual Life Outcomes* 2006; 4 : 11.
- 23 ClericiM SeminariE MaggioloF etal .Earlyand late effects of highly active antiretroviral therapy: a 2 year follo w-up of antiviral-treated and antiviral-naive chronically HIV-infected patients .AIDS 2002 ; 16 : 1767 – 73 .
- 24 HinkinCH CastellonSA Durasula RS et al .Medication adherence among HIV + adults: effects of cognitive dysfunction and regimen complexity. *Neurology* 2002 ; 59 : 1944 50 .
- 25 HinkinCH HardyDJ MasonKI CastellonSA etal .Medicationadherence in HIV-infected adults: effect of patient age, cogniti ve status, and substance ab use. AIDS 2004 ; 18uppl 1 : S19 - 25.
- 26 HinkinCH BarclayTR CastellonSA etal .Druguse and medication adherence among HIV-1 infected individuals .AIDS Behav 2007; 11: 185 – 94.
- 27 Læine AJ Hardy DJ Miller E Çastellon SA Longshore D Hinkin CH Theeffect of recent stimulant use on sustained attention in HIV -infected adults. J Clin Exp Neuropsychol 2006; 28: 29 42.
- 28 Barclay TR, Hinkin CH, Castellon SA, Mason KI, Reinhard MJ, Maion SD, Leine AJ, Durasula RS Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status. *Health Psychol* 2007; 26: 40 – 9.
- 29. Reinhard MJ, Hinkin CH, Barclay TR, Le vine AJ, Marion S, Castellon SA, Longshore D, Newton T, Durvasula RS, Lam MN, Myers H. Discrepancies between self-report and objecti ve measures for stimulant drug use in HIV : cognitive, medication adherence and psychological correlates. Addict Beha v 2007; http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VC9-4NGRRYG-9&_user=10&_coverDate=04%2F14%2F2007&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10 &md5=8e9daedf1baeb3b45c74afb410be9fe2
- 30 Woods SP, Mogan EE ,Marquie-Beck J ,Carg CL ,Grant I ,Letender SL The HIV Neurobehavioral Research Center (HNRC) Group. Mark ers of macrophage acti vation and axonal injury are associated withprospective memory in HIV-1 disease. *Cogn Behav Neurol* 2006; 19: 217 21.
- 31 Carp CL , Wods SP, Rippeth JD , Heaton RK , Grant I HIV Neurobehavioral Research Center (HNRC) Group. Prospecti ve memory in HIV -1 infection. J Clin Exp Neuropsychol 2006 ; 28 : 536 – 48 .
- 32 Fitten LJ Perryman KM Mkinson, CJ etal .Alzheimerand vascular dementias and driving: a prospective road and laboratory study. JAMA 1995; 273360 – 1365.
- 33 .OdenheimerGL BeaudetM JetteAM AlbertMS GrandeL Minakr KL Performancebased driving evaluation of the elderly dri ver: safety, reliability, and v alidity. J Gerontol 1994 ; 49 : M153 – 159 .
- 34 RebokGW, BylsmaFW, Kyl PM BrandtJ Filstein SE Automobiledriving in Huntington's disease .Mov Disord 1995; 10: 778 – 787.

- 35 RizzoM ReinachS McGeheeD Dwson J Simulated car crashes and crash predictors in drivers with Alzheimer Disease. *Arch Neurol* 1997; 54 : 545 51.
- 36 .Marcotte TD ,Heaton RK , Wilfson T et al . The impact of HIV-related neuropsychological dysfunction on driving behavior. The HNRC Group. J Int Neuropsychol Soc 1999 ; 5 : 579 92 .
- 37 MarcotteTD Wilfson T, RosenthalTJ et al .Amultimodal assessment of driving performance in HIV infection. *Neurology* 2004 ; 63 : 1417 – 22 .
- 38 MarcotteTD LazzarettoD ScottJC etal .Vsual attention deficits are associated with driving accidents in cogniti vely-impaired HIV-infected individuals. J Clin Exp Neuropsychol 2006 ; 28 : 13 – 28 .
- Visual Resources. UFO V Useful field of view manual. Chicago, IL: The Psychological Corporation; 1998.
- 40 Dray-SpiraR Guguen A PersozA etal . Emporary employment, absence of stable partnership, and risk of hospitalization or death during the course of HIV infection *J Acquir Immune Defic Syndr* 2005; 40: 190 7.
- 41 Dray-SpiraR PersozA Bourssa F et al .Employment loss following HIV infection in the era of highly active antiretroviral therapies. *Eur J Public Health* 2006 ; 16 : 89 95 .
- 42 .HeatonRK Min RA McCutchanA etal .Neuropsychologicalimpairment in human immunodeficiency virus-infection: implications for employment HNRC. Group. HIV Neurobehavioral Research Center .Psychosom Med 1994; 56: 8 – 17.
- 43 sm Gorp WG RabkinJG FerrandoSJ etal .Neuropsychiatricpredictors of return to work in HIV/AIDS .J Int Neuropsychol Soc 2007 ; 13 : 80 9 .
- 44 Wramley EW, Narwez JM SadekJR JesteDV, GrantI HeatorRK Work-related abilities in schizophrenia and HIV infection. J Nerv Ment Dis 2006; 194: 268 74.

Adjunctive Therapy for Long-Term Support of Cognitive Impairment

Joshua T. Dearborn, Susan E. Maloney, Nicole Hicklin, Elizabeth M. Lane, and Robert Paul

The neurological complications associated with human immunodef iciency virus (HIV) continue to be a problem despite the introduction of highly acti ve antiretroviral therapy (HAART). Current antiretroviral therapies have changed this formerly fatal illness into a chronic disease, allo wing HIV-infected individuals to live much longer. But, with increased age and duration of disease, the pre valence of neuro-logical conditions among these individuals has also increased (1).

Before the advent of HAART, dementias related to HIV were common occurrences within the infected population with a prevalence of about 30% (2). The HAART era has shown an initial improvement in cognitive function following treatment (3, 4). However, an increase in the rate of mild and moderate encephalopathy has been reported (5) in the post-HAAR T era. Autopsy reports sho w that about 90% of infected individuals have neurological evidence of disease (6).

HAART has altered the e xpression of dementia associated with HIV, and the nosology for HIV-1-associated neurocognitive disorders (HAND) has recently changed to reflect these dif ferences from pre- to post-HAAR T era (7). The new criterion has been shown to be more sensitive to diagnosis and better reflective of the state of the brain in patients with HAND (8). As noted in Chaps. 7 and 8, the three types of HIV-associated neurocognitive dementia are asymptomatic neuro-cognitive impairment (ANI), HIV-associated mild neurocognitive disorder (MND), and HIV-associated dementia (HAD). ANI, the mildest form of HIV dementia, is characterized by impairment in at least two cognitive domains that are one standard deviation below the mean on neuropsychological testing; ho wever, these impairments do not interfere with the activities of daily living (ADLs). The diagnosis of MND includes the same criteria as the diagnosis of ANI, but these cognitive deficits mildly interfere with ADLs. The diagnosis of HAD is made when there is an impairment in at least two o areas of cognitive functioning that f all two standard

R. Paul (🖂)

Department of Psychology, Behavioral Neuroscience, University of Missouri – St. Louis, One University Blvd St. Louis, MO 63121, USA paulro@umsl.edu deviations below the mean on neuropsychological tests. These cognitive deficits result in a striking reduction in ADL function.

There are currently no effective treatments for the neurological deficits associated with HIV. While several adjunctive therapies have been considered, the outcomes have not been remarkably positi ve. In addition, there are no reliable biological assays to monitor the efficacy of the drugs being tested. Current research has focused on interfering with the inflammatory cascade, reducing viral replication, neurotoxin release, oxidative stress, and apoptotic effects, as well as providing neuroprotection. Treatments focusing on prevention early in the course of infection may offer more benefit than attempting to repair damage after it had been done. This chapter provides an overview of the different approaches to adjunctive therapies for cognitive impairment associated with HIV.

Adjunctive Pharmacological Therapies in HAD

HAART has led to significant reductions in symptomology in HIV patients suffering from HAD, as well as the number of patients with HIV who declop these cognitive and motor deficits. However, in those who sho w cognitive benefit from HAART, the positive effects are often transient and do not wholly ameliorate symptoms. Furthermore, HAART has been shown to exert neurotoxic effects itself (9). As such, HAD remains prominent in the HIV patient population despite the adv ancements found with HAART (10).

Interestingly, high viral le vels in the brain do not represent a v alid marker of potential cognitive impairment. In studies conducted before the advent of HAART, CNS viral loads ha ve been lo w among patients with clinical characteristics of HAD, while patients with lo w viral loads exhibit significant cognitive impairment (11). The strongest correlation between viral load and HAD relates to peripheral levels in that controlled viral load as seen with HAART is associated with improved cognitive performance. Further, this suggests that brain tissue acts as a reservoir for the HIV virus (12). These findings are consistent with the theory that the development of HAD results from immunological reactions to the presence of HIV as well as direct virus-associated byproducts such as glycoprotein (gp120) and transregulatory protein (Tat) rather than absolute levels of the virus itself. Below we describe different such targeted therapeutic approaches and their findings.

Psychostimulants

HIV patients suffer from a hypoactive dopaminergic system (13). Specifically, dysfunction is noted in the basal ganglia, where these deficits often manifest as movement disorders in HIV patients. Further, the particular pattern of dopaminergic insult in the subcortical area along with the cognitive profile associated with HIV

infection is remarkably similar to that seen in Arkinson's disease. Psychostimulants are one class of drugs that serve as dopamine agonists and have therefore been investigated as possible adjunct therap y for HIV-related cognitive impairments. Studies have investigated the possible therapeutic effects of clinical psychostimulants on cognitive function in HIV patients. Early studies reported that psychostimulants improve cognitive function in HIV patients. Holmes et al. administered either methvlphenidate or de xtroamphetamine to 17 patients presenting with HIV -related cognitive declines evident through neuropsychiatric evaluation (14). Both stimulants were clinically effective at improving scores on the Efficacy Index of the Clinical Global Impressions in 13 of the 17 patients. Ho wever, these results were often short-lived, leading to the interpretation that improvement was perhaps tied to an alleviation of depressive symptoms when considering that four of those patients were diagnosed with major depression. Angrist et al. also found a similar improvement with methylphenidate and dextroamphetamine in seven patients experiencing HAD (15). However, improvement was interpreted as a function of practice effects rather than drug treatment given that the study employed an ABAB design in which the patients did not return to baseline after treatment was withdrawn. More recently, Hinkin et al. found that cognitive processing speed increased following administration with methylphenidate, and these effects were evident in the absence of significant improvement in mood among the subjects (16). As such there appears to be some level of empirical support for the utility of stimulants to improve cognitive function in HIV patients, b ut as noted by others the pragmatics of this approach need to be weighed in light of common histories of substance ab use in this population.

Selegiline

Selegiline is a monoamine oxidase-B inhibitor appro ved for the treatment of Parkinson's disease, dementia, and depression. It is speculated that selegiline exerts these effects via reducing oxidative stress. The Dana Consortium conducted a randomized double-blind, placebo-controlled trial e valuating the efficacy of selegiline's neuroprotective actions in 36 patients with mild HAD (17). Selegiline was well tolerated with a fe w adverse events, and those recipients receiving treatment showed significant improvement on tests of v erbal memory. Sacktor et al. then conducted a pilot trial in which nine randomly-assigned HAD patients were gi ven 3.0 mg of selegiline over 24 h via a transdermal patch and five were given placebo (18). The treatment group sho wed trends toward improvements in delayed recall and psychomotor speed as measured at 4 and 10 weeks. Unfortunately, more recent findings in which the same research group conducted a lar ger, placebo-controlled, three-arm study across 17 sites yielded less-encouraging results (19). One hundred and twenty eight HAD patients with mild to moderate dementia were gi ven transdermal selegiline in either 3-mg or 6-mg doses, or placebo, over 24 weeks. At the end of the treatment, neuropsychological e valuations revealed no significant differences between doses in terms of cognitive performance and in fact individuals

taking placebo demonstrated some what higher improvement scores. The authors contemplated that perhaps the trial was not of sufficient duration to identify clinical improvements associated with selegiline. However, the results did reveal that cognitive abilities did not worsen among treated patients over the trial period and this was interpreted as a possible neuroprotective effect.

Antioxidants

The presence of HIV in the brain instigates a proinflammatory response. Unfortunately this natural immune reaction cannot eradicate the virus, and the excessive inflammation itself becomes neurotoxic. Further, this reactive activation of macrophages to HIV infiltration and its products may create an uninhibited positi ve-feedback loop that further feeds HIV replication, which in turn increases neuro-inflammation in a positive-feedback fashion (20). Specifically, macrophage activation is associated with the release of cytokines, including tumor necrosis factor- α (TNF- α). These free radicals trigger excitotoxicity and subsequent cell death.

Treatment approaches involving antagonism of TNF- α include antioxidants that protect the brain from the resulting oxidative stress. CPI-1189 is one such antioxidant that scavenges superoxide radicals (21) and has been shown to exert neuroprotective effects on aggregate brain-cell cultures against TNF- α as well as gp120 (22) and block TNF- α -related deficits such as learning and memory impairments in an animal model of HAD (21). Tested in a randomized and double-blind, placebo-controlled human trial with 64 HAD patients, a 100-mg dose of CPI-1189 was associated with improvement in Grooved Peg-Board Test scores (23). Other compounds with similar antioxidant qualities such as the vitamins α -tocopherol (vitamin E) (24) and selenium (25) have been tested in patients with HAD and shown likewise trends for cognitive improvements. OPC-14117, particularly, is a vitamin E-like antioxidative synthetic that has shown trends toward improvement in memory and timed gait function in HIV patients (26). Recently green tea-derived EGCG has been observed to inhibit neuronal damage by Tat and gp120 in both in vivo and in vitro treated cells (27). Direct, clear-cut evidence of cognitive improvement with antioxidant therapy in HAD patients has ho wever proven elusive to establish lar gely because of methodological issues such as small sample sizes, primary outcome v ariables that included only safety and tolerability, and the lack of placebo-controlled studies. Interestingly, in at least one instance an antioxidant has been sho wn to worsen cognitive impairment. Thioctic acid, along with deprenyl, was evaluated by the Dana Consortium to reveal any effects on HIV-associated cognitive impairment (17). While deprenyl was associated with cognitive improvement, particularly in the domain of verbal memory, thioctic acid was associated with significantly worse performance on the Rey Auditory Verbal Learning Test total score and delayed recall. Additionally the direction of the effects of thioctic acid on the other measures of neuropsychological performance, including the Digit Symbol test, the Groo ved Pegboard test, Timed Gait, and Cal Cap, w as consistently negative. Still, antioxidant treatment results

overall have reliably been shown to be well tolerated and provide hope for efficacy in additional clinical trials (28).

Valproic Acid

Studies have shown that v alproic acid (VP A) inhibits the apoptosis-inducing GSK-3B that is activated by platelet-activating factor (PAF, an inflammatory instrument stimulated by HIV) (29) and protects brain tissue from neuronal and dendritic loss (30). Schifitto et al. recently conducted a small placebo-controlled study and found that 10 weeks of 250-mg VPA treatment in 16 HAD patients induced trends toward cognitive improvement in HIV patients showing cognitive disruptions as measured through neuropsychological evaluations and global screening measures, w as well tolerated, and did not affect viral load or CD4 counts(31). Further, magnetic resonance spectroscopy (MRS) re vealed a significant increase in brain metabolism in the frontal white matter of those impaired patients receiving treatment. However, concerns remain that while VPA facilitates neurogenesis and acts as a neuroprotectant, it may increase HIV replication in microglial cells, which is the speculated mode of degenerative action in HAD (32, 33).

Lexipafant

Another substance that seeks to act on P AF is lexipafant. Lexipafant inhibits PAF directly, and using a randomized, double-blind, placebo-controlled clinical trial, Schifitto et al. hypothesized that the substance could beneficially affect the cognitive performance of HIV infected people (34). Thirty subjects with HIV infection, evidence of cognitive impairment, and who were on a stable antiretro viral regimen for 6 weeks were enrolled in the study and assigned to receive either placebo or 250 mg of lexipafant twice a day, approximately 12 h apart. The trial w as primarily to assess the safety and tolerability of le xipafant, and secondarily to assess cognitive effects as measured by a neuropsychological battery.

Results indicated that the PAF antagonist was as tolerable as placebo, as indicated by similar rates of trial completion, similar incidences of adverse side effects, and similar compliance rates. At week 6 and week 10 after baseline evaluations, the lexipafant group showed trends toward improvement on the Rey Auditory Verbal Learning test as well as the timed gait test. There were no significant differences between the treatment group and placebo on global impression of cognitive verbal treatment, especially in verbal memory, may be viewed as encouraging particularly given the short duration and size of the trial. Schifitto et al. argue that in the view that it is important to develop an adjunctive therapy that can intervene in the inflammatory cascade triggered by HIV, these results warrant a larger and longer efficacy trial of lexipafant (34).

Calcium Channel Blockers

Other treatment approaches have targeted the prevention of excitotoxicity through mediation of the glutamater gic system reactions. Both immunoreaction macrophage stimulation and direct viral products such as Tat and gp120 bind to the glutamate receptors NMDA and AMPA. This "overstimulation" results in cell loss, most commonly recognized as the mechanism by which ischemia results in brain injury . Nimodipine was one of the earliest of these classes of drugs tested in clinical trials with seropositive patients. Nimodipine is a calcium channel blocker that in preliminary studies demonstrated an ability to block HIV -gp120 and Tat, thereby attenuating over-activity and cell death (35). Navia et al. conducted small phase I and II clinical trials, including 41 mild to moderate HAD patients (36). Nimodipine at 300 mg or 900 mg daily, or placebo, given for 16 weeks resulted in no signif icant change in neuropsychological Z-scores, although trends for impro vement were suggested in the high-dose group. The researchers note that larger sample sizes could have given the power needed to detect any possible significant effects due to nimodipine.

Memantine

The Alzheimer's disease drug memantine, an NMDA antagonist, has shown positive effectiveness in double-blind clinical trials in patients with HIV . Nath et al. ha ve reported blockade of gp120 and Tat-induced neuronal death by memantine in vitro (37). Anderson et al. also found similar results in a murine model specifically outlining neuroprotection in hippocampal cells (38). However, Schifitto et al. conducted a large-scale, double-blind, placebo-controlled multicenter trial testing the effectiveness of memantine in 140 mild to moderate HAD patients on neuropsychological functioning and MRS of frontal white matter and the parietal cortex (39). Results showed that the memantine group did not o verall significantly differ than did the placebo group on any measure. Although positive effects of memantine have been reported, conflicting results as well as tolerability issues surrounding memantine warrant cautionary use and more extensive trials.

Minocycline

Minocycline is a broad-spectrum antibiotic belonging to the tetracycline family that has been shown to exhibit anti-inflammatory effects alongside its antimicrobial ability. Studies have shown a neuroprotective component as well in terms of multiple sclerosis (40), ischemia (41), Huntington's disease (42), and other brain insults. Contemporary research has shown that minocycline effectively crosses the blood– brain barrier and decreases the severity of encephalitis (43), inhibits HIV replication in microglia while sparing normal healthy function (44), inhibits microglial activation (45), and even exerts antioxidative properties (46) and neuroprotective properties by inhibition of the p38 MAPK pathw ay (43). The long-time proven safety, tolerability, and purported neuroprotective eminence of the antibiotic leave many hopeful that current clinical trials will pro ve minocycline as an effective and inexpensive adjunct therapy for the treatment of HAD. Minocycline is currently under investigation as part of a large, multisite trial supported by NIH. This study focuses on patients with progressive cognitive decline rather than individuals with static brain involvement. Results from this study will be available shortly.

Lithium

Lithium salts, while traditionally prescribed for resistant and recurrent depression as well as bipolar disorder, have been shown to be beneficial against HIV and HAD. Lithium was first studied as an agent to alleviate neutropenia associated with AIDS (47). Lithium has furthermore been observed to carry antiviral properties of its own against HIV, although unfortunately the le vel required to yield such an effect is much larger than safe therapeutic doses (48). Lithium also boosts the immune system via agonism of T-cell growth factor (49), interleukin-2 and interferon (50), TNF- α (51), and antagonism of glycogen synthase kinase-3 β (GSK-3 β), the enzyme activated by Tat involved in the regulation of apoptosis (52). Furthermore, lithium has been shown to protect against neurotoxicity directly from HIV-gp120 (53). Visca et al. have shown this neuroprotective effect specifically in HIV-infected patients with a 900 mg-daily dose significantly increasing CD8+ le vels after 4 weeks (54). Clinical trials of lithium in terms of mood disorders have also shown neuroprotective qualities as assessed by increased N AA levels in MRS and MRI analyses in bipolar patients (55), reduced Tau protein production (56), and amyloid-related degeneration (57) in regards to Alzheimer's disease. One small open-label, 12-week pilot study in which eight HAD patients received doses that were titrated to maintain 12-h trough concentrations between 0.4 and 0.8 mEq/L sho wed improved performance on global neuropsychological tests in all eight indi viduals after 12 weeks, and became unimpaired in six (58). Furthermore, given the prevalence of depression in HIV patients, lithium's effectiveness against mood dysfunction together with its proven neuroprotective effects lends itself as an appropriate target for more extensive, much-needed clinical trials testing both the safety and efficacy of lithium on cognition in HAD patients.

Treatment of Comorbid Psychiatric Disorders and Its Effects on Cognition

Depression is the most common comorbid psychiatric condition present with HIV infection, affecting between 5 and 25% of the seropositi ve population (59). Even with this high pre valence, the contributions of depression to neuropsychiatric

impairment in HIV infection have yet to be clearly defined (60). Many empirical studies have found that depression has effects independent of HIV infection in the CNS, and that these effects do not include neuropsychological decline. The relevance of reviewing this literature in the current chapter is related to the question of whether cognitive function can be supported via concomitant treatment of depression and related mood disorders.

Millikin et al. reported that depressive symptoms in HIV-seropositive individuals were not significantly associated with phonemic or semantic fluenc y performance as measured by the FAS and Animals tests, respectively (61). Cohen et al. conducted a study with HIV infected w omen, which sho wed no influence of se verity of depressive symptoms on HAART effects with respect to neurocognitive performance in general (4). Cysique et al. evaluated the effects of incident major depression on neuropsychological functioning in HIV infected men (62). They examined 227 HIV+ men and e valuated them for lifetime and current major depressi ve disorder as well as performance on tests of attention, speed of information processing, lauguage skills, learning efficiency, and motor skills. Results showed no cognitive differences between the depressed and nondepressed HIV+ men, thus supporting the theory that depression is not responsible for neuropsychological impairment in HIV infection. This is a finding that is generally well-supported in the current literature (62).

Yet there are a number of studies that continue to f ind depression as an influential factor in neuropsychological performance when e valuating HIV+ populations. Vázquez-Justo et al. concluded that seropositi ve subjects with depressi ve symptoms performed significantly worse than those without depressive symptoms on measures of attention, v erbal and visual memory, motor speed, and frontal functions (60). Chandra et al. state that depression is kno wn to have a role in the causation of neurocognitive problems, particularly in areas of f ine motor speed and information processing (59). Over a 2-year study, Gibbie found that only a group of HIV+ individuals without depression, and not one with depression, showed improvement in measures of neuropsychological performance (63). Those individuals without depression at the baseline examination showed significant improvement in cognitive performance following HAART; those with depression at baseline did not sho w significant improvement. Judd et al. reported a correlation between spatial working memory and subjects' scores on the Beck Depression In ventory (BDI), concluding that HIV may affect the later prefrontal corte x, an area that is in volved in working memory and is implicated in major depression (64). Another study, comparing a sample of 47 HIV+ men with concurrent depression against an equal-sized group without depression, reported that the depressed participants showed greater detriment in the domains of memory, attention, and learning (65). More recently, Castellon's group took a no vel approach to the evaluation of the BDI by subjecting the test to a factor analysis in order to further determine the specific involvement of depression in cognitive function in HIV infection. The analysis produced three f actors: one encompassing apath y items, one encompassing mood and moti vation items, and one with somatic items. The mood and motivation factor from the BDI factor analysis was most closely related to neurocognitive performance on verbal memory, executive functioning, and motor performance. The other two factors were not associated with cognitive performance (66).

Clearly there are conflicting results in e valuating the effects of depression on cognition in HIV infection, which raises the question as to whether treating this disorder will result in a signif icant improvement in cognitive function. The literature cited above is only a sampling of the myriad experiments aimed at determining the true nature of depression's contribution to declining neurocognitive function in HIV seropositive individuals. A complicating factor in many of these papers is the acknowledgement that numerous studies using the same samples and measures have not found significant effects of depression and ha ve, in fact, concluded that depression and HIV infection should be viewed as separate pathologies, with HIV as the major contributing factor to declining cognitive abilities. Still, the discrepant results merit that the issue remains a contro versial one.

Even within the established body of research cited abo ve, Gibbie noted that improving symptoms of depression did not improve neuropsychological impairment (63), Goggin explained that depression severity scores did not correlate with an y of their cognitive measures (65), and Vázquez-Justo's work revealed that a study performed under the same parameters yielded qualitati vely different results from their own (60). Although not definitive, these studies do contribute to the acceptance of the current predominant hypothesis that depression is a disorder commonly occurring in HIV+ individuals, but its contribution to declining cognition is minimal at best (62). As such, treatment for depression has yet to be shown to improve cognition in HIV+ populations, and experiments looking at any such possible effects are a few and far in between. The a vailable evidence indicates that although depression is often present, it is not necessary for cogniti ve impairment in HIV infection (67). Depressive symptoms and cognitive detriments are currently addressed and treated as separately occurring phenomena and will lik ely continue to be so.

A somewhat different picture emerges when looking at the domains of apathy and fatigue in HIV infected individuals. Though smaller in number, the studies addressing these sequelae of CNS infection provide more consistent results. Apathy refers to a group of symptoms that include both lack of motivation and reduction in activity in motor, emotional, and cogniti ve domains (67, 68). Phenomenologically apathy appears similar to depression, but the two constructs can be differentiated and the criteria for HAD define apathy rather than depression as a core feature. Supporting this idea are results from Castellon et al., which showed that apathy, and not depression, was associated with w orking memory deficits in HIV (69). This led them to conclude that apathy may, on its own, indicate CNS involvement in HIV infection. In later studies, Castellon et al. would produce results showing that apathy is likely to be associated with impairments in working memory and executive functioning; in contrast, depression did not correlate with these two domains (66). On the level of brain organization, Paul et al. state that apathy often occurs in the context of damage to subcortical regions, presumably as a result of the disruption of the flo w of information between the frontal lobes and the striatum (70). Importantly, in another study conducted by Paul's lab (2005), apathy as measured by the Marin Apathy Scale correlated with lower volume of the nucleus accumbens (68). Since HIV is found in highest concentrations in deep subcortical nuclei, it is possible that the virus af fects the frontal-subcortical circuits, and that this is beha viorally manifested as a deficit

in working memory, executive function, and related cognitive domains. Treatment of apathy in HIV has been minimally examined at the present time.

Like the evidence for apathy, many studies have found that f atigue is significantly associated with depressive symptoms in HIV infection. Fatigue is present in between 2 and 27% of HIV+ individuals, and it is likely present in between 30 and 54% of individuals with AIDS (71). It is widespread among HIV+ patients, but very few studies have assessed effective treatments for it (72). Although there is a limited literature on fatigue as it pertains to cognition, there are many studies explaining its relation to depression in CNS pathology. This body of research has yielded mixed results; some studies have shown no relationship between f atigue severity and cognitive performance (73) while others report that there is an association between the two (74). In 1995, Perkins and colleagues found that there w as no relationship between f atigue and neuropsychological function in HIV infection (75). Still, fatigue remains an area of research interest when it comes to alle viating cognitive impairment.

One of the most recent promising a venues of research in this area comes from preliminary studies using modaf inil (Provigil). Modafinil is an FD A-approved medication that generally promotes w akefulness. According to Minzenber g and Carter it may improve cognitive function in such psychiatric disorders as depression, attention deficit/hyperactivity disorder, and schizophrenia (76). These authors explain that modafinil acts on catecholamines, serotonin, glutamate, andy-aminobutyric acid. In particular, though, its primary action may be on the catecholamines, and it appears to be selective for cortical over subcortical sites of action. Though this may not appear to fit with the subcortical profile of HIV-associated dementia, it would help to explain the alleviation of declining working memory and episodic memory shown by the drug. Preliminary results lead Minzenburg and Carter to conclude that modafinil is an excellent candidate for the remediation of cogniti ve dysfunction across psychiatric disorders, including HIV infection (76). In another study of the drug, Randall et al. (77) elucidated limited e vidence for modafinil as enhancing cognition in healthy, middle-aged subjects. A particularly relevant pilot study of the drug was performed by Rabkin et al.in 2004. Of 30 HIV+ patients, 24 were characterized as "responders" to modafinil; this group of responders showed significant improvement on measures of f atigue, depression, verbal memory, and executive function. The authors used these results as e vidence for modafinil's potential in alleviating fatigue and related cognitive dysfunction in HIV infection (72).

Potential Targets for Adjunctive Therapy for HIV-1-Associated Dementia

Proinflammatory cytokines, and among them chemokines and chemokine receptors, are currently being investigated for their therapeutic actions in HIV cohorts. When a chemokine binds to its receptor, an induction of calcium ion flux occurs within the cell, which in turn causes intracellular signaling cascades. In the CNS, chemokine

receptors, CCR5, CCR3, and CXCR4, along with the surf ace receptor CD4, are used by HIV-1 to enter and infect microphages and microglia. Inhibition of HIV -1 entry by antagonists of these receptors is being in vestigated in clinical trials (78). The novel CXCR4 antagonist neomycin B hexa-arginine has been demonstrated to cross the blood–brain barrier and reduce CXCR4-mediated gp120-induced neuro-toxicity (79).

These chemokine receptors, CXCR4 and CCR5, are also found on neurons and astrocytes, and even though the HIV-1 virus itself does not enter these cells, evidence exists that CXCR4 is involved in HIV-associated neuronal damage while CCR5 may actually have a protective role (as discussed in (78)). The CXCR4 receptor–ligand complex activates p38 mitogen-activated protein kinase (p38 MAPK), which has been shown to promote neuronal death (80). The protective actions induced by the CCR5 receptor–ligand complex involve the activation of the cellular serine–threo-nine protein kinase, Akt–protein kinase B (Akt/PKB), which has been demonstrated to promote cell survi val. Agents that stimulate cell survi val through the Akt/PKB pathway and those that inhibit p38 MAPK, e.g., minocycline, have been considered by Kolson to be one of the ne xt investigational steps in HIV-1-associated dementia therapies (80), and development is already underway for p38 MAPK inhibitors for several inflammatory- and stress-related conditions (78).

The HIV-1 protein gp120 can bind to CXCR4 receptors to induce apoptosis in that neuron. Ho wever, Kaul and Lipton (as cited in (78)) found that the CCR5 chemokine ligands MIP-1 α , MIP-1 β , and RANTES could protect against the gp120-induced toxicity at CCR5 receptors. These CCR5 ligands have been shown to suppress HIV-1 infection in the periphery. Individuals with higher cerebrospinal fluid concentrations of these chemokines, relative to those with low or undetectable amounts, have performed better on neurological measures. Some β-chemokines, the designation of the group of chemokines to which the CCR5 ligands belong, have also been shown to improve NMDA receptor-mediated neurotoxicity; another chemokine, fractalkine, has been shown in vitro to prevent gp120-induced neuronal apoptosis (as discussed in (78)). Selected chemokines may be a potential treatment for HAD, and, as reported in Kaul and Lipton, ef forts are underway to develop modified CCR5 ligands that will have the same therapeutic benefits without the adverse inflammatory side effects that have been seen with the administration of these agents (78).

The cytokine erythropoietin (EPO) has also been shown to have neuroprotective properties. Receptors for EPO are found on neurons, and when stimulated by EPO, activate survival pathways that lead to the increased transcription of inhibitors of apoptosis and other pro-survival factors (as discussed in (78)). EPO has been shown in vitro to pre vent neuronal death directly caused by HIV -1 through its protein gp120 and indirectly by NMDA receptor stimulation. EPO is already approved for the treatment of anemia, indicating easier passage through clinical trials for the treatment of HAD (78).

Another avenue under investigation for use as adjunctive therapy to HAD is neurotrophic factors. Nerve growth factor (NGF) mRNA and β -fibroblast growth factor (FGF) mRNA levels are elevated in individuals with HIV-1 infection present in the CNS, suggesting that NGF and FGF are not suf ficient by themselves as mechanisms for the prevention of HAD due to the f act that an effective immune action is not seen from the ele vation of these agents (81). Brain-derived neurotrophic factor (BDNF) is not elevated in these individuals, yet does show immune reactivity in the striatum and is e xpressed by neurites and somas in the corte x. As discussed in Noshenv et al., BDNF has been demonstrated to ha ve powerful neuroprotectant effects on the dopaminergic and serotonergic neurons in the basal ganglia and the neurons in the cortex in animal models of neurodegenerative disease (82). These neurons are hit hard by the degenerating effects of HIV-1 on the brain. A rodent model of HAD, created by injection of gp120 into the striatum, demonstrated a decrease in BDNF levels as early as 1 day after injection. Noshen y et al. suggested that this decrease in BDNF may be, in effect, a cause of neurodegeneration rather than a product of cell death (82). Pharmacological concentrations of BDNF demonstrated in vitro neuroprotectant ef fects in cortical neurons and cerebellar granule cells taken from the rat that were e xposed to gp120 for 12 h. BDNF has also been demonstrated to decrease CXCR4 le vels and block cell death mediated by the CXCR4 ligand stromal-derived factor $1-\alpha$. In effect, the decrease of CXCR4 receptors by BDNF could decrease the damage of gp120 proteins on the cells of the brain. These neuroprotectant influences of BDNF make it a potential candidate for investigation as an adjunctive therapy for HAD.

Lithium has been discussed in re gard to neuroprotective effects in HAD by increasing BDNF. However, Dou et al. demonstrated that this was not the mechanism for lithium's neuroprotectant role (83). Blockage of the T rkB receptor, a receptor with a high affinity for BDNF and believed to be involved in BDNF's promotion of cellular survival, did not inhibit the antiapoptotic influences of lithium. This study demonstrated in the mouse that lithium is a neuroprotectant at least in part through the inhibition of glycogen synthase kinase-3 β , an enzyme that is stimulated by HIV-1 mediated neuronal injury. Inhibition of this enzyme allows for the activation of the phosphatidylinositol 3-kinase (PI3-K)/Akt pathways, which have anti-apoptotic effects. These results led Dou et al. to suggest lithium as a possible future adjunctive therapy for HAD.

Another avenue of potential adjunctive therapies for HAD focuses on the mitochondria of neurons infected with HIV proteins. These organelles play an important role in metabolic activities associated with neurotoxicity of HIV-1, such as apoptosis, glutamate-mediated excitotoxic neuronal injury, and regulation of the cellular redox state. Hyperpolarization of the mitochondrial membrane potential in neurons infected by HIV proteins occurs prior to apoptosis (as discussed in (84)). Perry et al. suggest that these bioenergetic changes may be a subcellular mechanism for a reversible metabolic component of HAD. T olbutamide, an ATP-sensitive potassium (K+) channel antagonist, was found to reverse Tat-induced apoptosis of these neurons by blocking the efflux of K+ across the mitochondrial membrane. This antidiabetic drug has also been demonstrated to possess mitochondrial uncoupling properties, which allow for the inward leakage of protons across the membrane in the absence of ATP. Previous studies have demonstrated mitochondrial uncoupling to protect against ischemic damage in the brain. Perry et al. suggest that this uncoupling may protect neurons from apoptosis, and along with blockage of K+ channels, tolbutamide, and agents like it such as the β -adrenergic agonist CL-316,243, which e xpress endogenous uncoupling proteins, have potential as adjunctive therapies for HAD.

Estradiol, the most bioactive of the estrogens, has been observed in vitro to protect against the neurotoxic effects of HIV proteins by protecting the mitochondria of neurons through interactions with the mitochondrial enzyme A TP synthase, which is required for mo ving protons across the mitochondrial membrane, and, thus, normal mitochondrial functioning (81). This is perhaps the mechanism behind the estradiol-induced reduction of oxidati ve stress produced by gp120 and T at as described in Wallace (79). These therapeutic properties of estradiol are being considered in terms of HAD therapy. Plant estrogens and selective-estrogen receptor modulators may be therapeutic substitutions for estradiol due to its cancer causing side effects.

Opioid agents that are κ - and δ -receptor preferring have been demonstrated as neuroprotective; however, opioids that preferentially bind to the mu-receptor contribute to the neurotoxic effects of gp120 and Tat, which just happens to include the opioids that are most commonly ab used (79). For example, Wallace (79) describes U50,488, an agent that preferentially binds to the κ -receptor, as ultimately reducing excitotoxicity through the inhibition of NMD A receptors by suppressing quinolinic acid, an NMD A receptor agonist, released from microglia. Oxidati ve stress induced by Tat protein can be reduced by the δ - receptor agonist DPDPE. Research into δ and κ agonists may be a viable therapeutic option.

Kaul and Lipton describe nitroglycerin as a potential therapeutic agent (78). This substance produces nitric oxide-related molecules that can be converted chemically into a substance that resembles nitrosinium, which is one electron away from nitric oxide. This substance has been shown in animal models to protect neurons from NMDA receptor overstimulation and the resulting neuronal injury. However, more research into this potential adjunctive therapy would need to be conducted because of nitroglycerine's cardiovascular side effects.

Many of these potential adjunctive therapies for HIV-1-associated dementia are effective in their suppression of viral replication in the cells of the CNS or their direct protective actions on the neurons bombarded by the neurotoxic effects of HIV proteins. As researchers continue to understandthe neurodegenerative properties of HIV-1 in the CNS, more a venues for potential therapeutic interventions will be elucidated.

At a time when HAD is becoming continuously more pre valent in the HIV population, there are still no effective treatments specific to this complicating side effect of HIV. Current research has focused on stopping the neurodegenerative and inflammatory cascade that HIV initiates. Although once hopeful that drugs such as psychostimulants, selegiline, and valproic acid were going to be helpful in eliminating HAD, their results were found to be insignificant and in some instances potentially iatrogenic. New studies focusing on drugs, such as minoc ycline and a v ariety of antioxidants, are promising, but further research is necessary to determine the efficacy of these drugs. Other studies are e xploring the possibility of attacking the disease by focusing on chemokine receptors, neurotrophic f actors, the mitochondria of

cells, and hormone therapy, but all remain in the preliminary stages of development and assessment. Considerably, more research is necessary to effectively treat this debilitating aspect of HIV and fortunately numerous trials are currently underway and offer some hope and opportunities.

References

- Cysiqu&A Maruff P, Brev BJ Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly acti ve antiretroviral therapy eras: a combined study of two cohorts. Neurovirology 2004; 10: 350 – 357.
- 2. a Nour V, Rul R HIV infection and dementia in older adults. Clin Infect Dis 2006 ; 42 : 1449 – 1454 .
- 3 . Suarezs BarilL Stanloff B KhellafM DuboisB LubetzkiC etal .Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy. AIDS 2001 ; 15 : 195 200 .
- 4. Cohen RA ,Boland R ,Rul R ,Tshima KT, Schoenbaum EE ,Celentan DD et al . Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women . AIDS 2001 ; 15 : 341 – 345 .
- 5 . Neuenbrg JK BrodtHR HerndierBG Bickl M BacchettiP, Prie R et al .HIVrelated neuropathology, 1985 to 1999: Rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. JAcquir Immune Defic Syndr 2002 ; 31 : 171 177 .
- DouH Kingsly JD Mosly RL GelbardHA GendelmanHE Neuroprotective strategies for HIV-1 associated dementia . NeurotoxRes 2004; 6: 503 – 521.
- AntinorArendt G Beckr JT, Brw BJ ByrdDA, ChernerM, etal .Updatedresearch nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 1789 – 1799.
- Chernet Cysique L Heaton R Marcotte T, Ellis R Masliah E Grant I Neuropathologic confirmation of definitional criteria for human immunodeficiency virus-associated neurocognitive disorders. JNeurovirol 2007; 13: 23 – 28.
- 9 . Peltier AC , Russell JW Recent advances in drug-induced neuropathies . Curr Opin Neurol 2002 ; 15 : 633 – 638 .
- 10 Jozzi V, BalestraP, BellagambaR CorpolongoA Salatori MF, Visco-Comandini U etal . Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 2007 ; 45 : 174 – 182 .
- 11 Johnson RT, Glass JD, McArthur JC, Chesebro BW. Quantitation of human immunodeficiency virus in brains of demented and nondemented patients with acquired immunodeficiency syndrome. AnnNeurol 1996; 39: 392 395.
- 12 . ChunTW, Fuci AS Latent reservoirs of HIV: obstacles to the eradication of virus . ProcNatl Acad Sci U S A $1999\ ;\ 96\ :\ 10958\ -\ 10961\ .$
- 13 Beger JR , Kumar M , Kumar A , Fernandez JB , Lein B Cerebrospinal fluid dopamine in HIV-1 infection . AIDS 1994 ; 8 : 67 71 .
- 14 Holmes VF, Fernandez F, Ley JK Psychostimulant response in AIDS-related complex patients . JClin Psychiatry 1989 ; 50 : 5 8 .
- 15 AngristB d'HollosyM Sanifipo M SatrianoJ DiamondG Sinherkoff M etal .Central nervous system stimulants as symptomatic treatments for AIDS-related neuropsychiatric impairment. JClin Psychopharmacol 1992; 12; 268 272.
- 16 Hinkin CH ,Castellon SA ,Hardy DJ ,Jirinpour R ,Nevton T, Singe E Methylphenidate improves HIV-1–associated cognitive slowing . JNeuropsychiatry Clin Neurosci 2001 ; 13 : 2 .

- 17. Dana Consortium. A randomized, double-blind, placebo-controlled trial of depren yl and thioctic acid in human immunodef iciency virus-associated cognitive impairment. Neurology 1998;50:645-651.
- 18 SacktorN Schifto G McDermottMP, MarderK McArthurJC .Keburtz K Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology 2000 ; 54 : 233 - 235 .
- 19 Schifto G ZhangJ Eans SR SacktorN SimpsonD MillarLL etal .Amulticenter trial of selegiline transdermal system for HIV -associated cognitive impairment. Neurology 2007 ; 69 : 1314 - 1321 .
- 20 Richard MJ Guiraud P, Didier C See M Flores SC Fivier A Humanimmunodeficiency virus type 1 T at protein impairs selenoglutathione peroxidase e xpression and activity by a mechanism independent of cellular selenium uptak e: consequences on cellular resistance to UV-A radiation . ArchBiochem Biophys 2001 ; 386 : 213 - 220 .
- 21 BjugstadKB FlitterWD GarlandWA, SuGC ArendashGW Preventive actions of a synthetic antioxidant in a novel animal model of AIDS dementia . BrainRes 1998 ; 795 : 349 - 357 .
- 22 Pulliam L ,Irwin I ,Kasdra L ,Rempel H ,Flitter WD ,GarlandWA .CPI-1189 attenuates effects of suspected neurotoxins associated with AIDS dementia: a possible role for ERK activation . BrainRes 2001 ; 893 : 95 - 103 .
- 23 Clifford DB McArthurJC Schifto G Kiebrtz K McDermottMP, Letendre S etal . A randomized clinical trial of CPI-1189 for HIV -associated cognitive-motor impairment. Neurology 2002 ; 59 : 1568 - 1573 .
- 24 AllardJP, AghdassiE ChauJ Tim C Kavacs CM SalitIE etal .Effects of vitamin E and C supplementation on oxidati ve stress and viral load in HIV -infected subjects. AIDS 1998; 12: 1653 - 1659.
- 25 ShorPosner G MiguezMJ PinedaLM RodriguezA RuizP, Castlo G et al .Impactof selenium status on the pathogenesis of mycobacterial disease in HIV -1-infected drug users during the era of highly acti ve antiretroviral therapy. J Acquir Immune Def ic Syndr 2002 ; 29 : 169 - 173 .
- 26. Dana Consortium. Safety and tolerability of the antioxidant OPC-14117 in HIV -associated cognitive impairment. The Dana Consortium on the therap y of HIV dementia and related cognitive disorders. Neurology 1997;49:142-146.
- 27 GiuntaB Obrgon D HouH ZengJ SunN Niklic Vet al .EGCGmitigates neurotoxicity mediated by HIV-1 proteins gp120 and Tat in the presence of IFN-gamma: role of AK/STAT1 signaling and implications for HIV-associated dementia . BrainRes 2006; 1123: 216 - 225.
- 28 .McGuireD MarderK Pharmacological frontiers in the treatment of AIDS dementia. JPsychopharmacol 2000 ; 14 : 251 - 257 .
- 29 Jung N Sanchez JF, Maggirwr SB Ramirez SH GuoH Devhurst S etal Activation of glycogen synthase kinase 3 beta (GSK-3beta) by platelet activating factor mediates migration and cell death in cerebellar granule neurons. EurJ Neurosci 2001; 13: 1913 - 1922.
- 30 DouH BirusinghK Fraci J GorantlaS Poluektøa IY, etal. Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci 2003 ; 23 : 9162 - 9170 .
- 31 Schifto G PetersonDR ZhongJ NiH CruttendenK GaughM etal . Valproic acid adjunctive therapy for HIV -associated cognitive impairment: a f irst report. Neurology 2006 ; 66 : 919 - 921 .
- 32 Dragunw M Greenwood JM Cameron RE Narayan PJ O'Carroll SJ et al . Valproic acid induces caspase 3-mediated apoptosis in microglial cells Neuroscience 2006 ; 140 : 1149 - 1156 .
- 33 RobinsonB Trchan J AndersonC ChauhanA NathA Modulation of human immunodeficiency virus infection by anticonvulsant drugs. JNeurovirol 2006; 12: 1 - 4.
- 34 Schifto G ,Sacktor N ,Marder K ,McDermott MP, McArthur JC ,Keburtz K et al . Randomized trial of the platelet-acti vating factor antagonist le xipafant in HIV-associated cognitive impairment. Neurology 1999 ; 53 : 391 - 396 .

- 35 Dryer EB KaiserPK Offermann JT, LiptonSA HIV1 coat protein neurotoxicity prevented by calcium channel antagonists . Science 1990 ; 248 : 364 367 .
- 36 Nuia BA, DafniU SimpsonD Ticker T, SingerE McArthud C, etal .Aphase I/II trial of nimodipine for HIV-related neurologic complications . Neurology 1998; 51: 221 – 228.
- 37 NathA Haughe NJ JonesM AndersonC BellJE GeigerJD Synegistic neurotoxicity by human immunodeficiency virus proteins T at and gp120: protection by memantine . Ann Neurol 2000 ; 47 : 186 194 .
- 38 .AndersonER GendelmanHE XiongH Memantineprotects hippocampal neuronal function in murine human immunodeficiency virus type 1 encephalitis. JNeurosci 2004; 24: 7194 – 7198.
- 39 Schifto G Naia BA, Yannoutsos CT, MarraCM ChangL ErnstT, etal .Memantineand HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS 2007; 14 : 1877 1886.
- 40 BrundulaV, Rwcastle NB MetzLM BernardCC , Wing VW Targeting leukocyte MMPs and transmigration: minoc ycline as a potential therap y for multiple sclerosis . Brain 2002 ; 125 : 1297 1308 .
- 41 HeY, AppelS LeW Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. BrainRes 2001; 909: 187 193.
- 42 ChenM QnamVO, LiM FerranteRJ FinkKB ZhuS etal .Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease . NatMed 2000: 6; 797 – 801 .
- 43 ZinkMC UhrlaubJ DeWtt J Welker T, BullockB Mankwski J etal .Neuroprotective and anti-human immunodeficiency virus activity of minocycline . AMA 205 ; 293 : 2003 2011 .
- 44 SiQ CosenzaM KimMO ZhaoML Brønlee M GoldsteinH etal .Anovel action of minocycline: inhibition of human immunodeficiency virus type 1 infection in microglia . J Neurovirol 2004 ; 10 : 284 – 292 .
- 45 DheenST, KaurC LingEA Microglialactivation and its implications in the brain diseases . CurrMed Chem 2007 ; 14 : 1189 – 1197 .
- 46 KrausRL Resieczny R Lariosa-Wilingham K Tirner MS JiangA Trauger JW Antioxidant properties of minocycline: neuroprotection in an oxidati ve stress assay and direct radicalscavenging activity. JNeurochem 2005; 94: 819 – 827.
- 47 Perenti DM SimonGL ScheibRG Myer WA, SzteinMB Pexton H etal .Efect of lithium carbonate in HIV-infected patients with immune dysfunction. J Acquir Immune Defic Syndr 1998 ; 1 : 119 – 124 .
- 48 KinchingtonD RandallS Whither M HorrobinD Lithiumgamma-linolenate-induced cytotoxicity against cells chronically infected with HIV-1. FEBSLett 1993; 330: 219 – 221.
- 49 .Ocknfels HM ,Wgner SN ,Kim-Maas C ,Funk R ,Nussbaum G ,Goos M Lithium and psoriasis: cytokine modulation of cultured lymphoc ytes and psoriatic k eratinocytes by lithium . ArchDermatol Res 1996 ; 4 : 173 178 .
- 50 .W YY Modulationeffect of lithium on IL-2 and IFNr production by human peripheral blood mononuclear cells. Zhonghua Zhong Liu Za Zhi (Chinese Journal of Oncology) 1992 ; 14 : 337 – 339 .
- 51 .Bgaert R Schulze-Osthoff K ¼n Roy F, FiersW Synegistic induction of interleukin-6 by tumor necrosis factor and lithium chloride in mice: possible role in the triggering and exacerbation of psoriasis by lithium treatment. EurJ Immunol 1992 ; 22; 2181 2184.
- 52 Maggirvar SB Jong N RamirezS GelbardHA Davhurst S HIV1 Tat-mediated activation of glycogen synthase kinase-3beta contrib utes to Tat-mediated neurotoxicity. J Neurochem 1999 ; 73 : 578 – 586.
- 53 Esrall IP, BellC MalloryM LangfordD AdameA Rockstein E etal .Lithiumameliorates HIV-gp120-mediated neurotoxicity. MolCell Neurosci 2002; 21: 493 – 501.
- 54 Xsca U SantiG SpinaM Efects of lithium carbonate on lymphocyte subpopulations of healthy subjects and of asymptomatic HIV-positive patients .In: SchrauzerGN KlippelK-F, eds. Lithium in Biology and Medicine: Ne w Applications and De velopments. Weinheim, Germany: VCHPublishers; 1990: 75 – 79.

- 55 MooreGJ BebchukJM HasanatK ChenG Seraji-Bozogzad N Mds IB etal .Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neuro-trophic effects? BiolPsychiatry 2000 ; 48 : 1 8.
- 56 Løestone S Dais DR Webster MT, KaechS BrionJP, MatusA etal .Lithiumreduces tau phosphorylation: effects in living cells and in neurons at therapeutic concentrations . Biol Psychiatry 1999 ; 45 : 995 1003 .
- 57 . Alarez G Munoz-MontanoJR Satrustgui J Aila J BogonezE Diaz-Nido J Lithiumprotects cultured neurons against beta-amyloid-induced neurodegeneration . FEBSLett 1999 ; 453 : 260 264 .
- 58 LetendreSL Woods SP, EllisRJ AtkinsonJH MasliahE carden Brande G etal .Lithium improves HIV-associated neurocognitive impairment . AIDS 2006 ; 20 : 1885 188
- 59 . Chandra
PS DesaiG RanjanS HIV& psychiatric disorders . Indian
J Med Res 2005 ; 121 : 451-467 .
- 60 .Vázquez-JustoE RodríguezAlvarez R FerraceOtero MJ Influenceof depressed mood on neuropsychologic performance in HIV -seropositive drug users . Psychiatry Clin Neurosci 2003 ; 57 : 251 – 258 .
- 61 Millikin CP, Tépanier LL ,Rourk SB Vérbal fluency component analysis in adults with HIV/AIDS . JClin Exp Neuropsychol 2004 ; 26 : 933 942 .
- 62 .Cysique LA ,Deutsch R ,Atkinson JH ,Wung C ,Marcotte TD ,Dwson L et al .Incident major depression does not af fect neuropsychological functioning in HIV-infected men. J Int Neuropsychol Soc 2007; 13: 1 – 11.
- 63 .GibbieT, MijchA EllenS Hy J HutchisonC WrightE etal .Depressionand neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up . HIVMed 2006; 7: 112 121 .
- 64 JuddF, Kamiti A ChuaP, MijchA Hy J GrechP, et al .Nature of depression in patients with HIV/AIDS. AustN Z J Psychiatry 2005: 39 : 826 832.
- 65 .Goggin KJ ,Zisook S ,Heaton RK ,Atkinson JH ,Marshall S ,McCuthan A , et al . Neuropsychological performance of HIV -1 infected men with major depression . J Int Neuropsychol Soc 1997 ; 3 : 457 – 464 .
- 66 .CastellonSA HardyDJ HinkinCH SatzP, StenquistPK an Gorp WG etal .Components of depression in HIV-1 infection: their differential relationship to neurocognitive performance. JClin Exp Neuropsychol 2006 ; 28 : 420 – 437 .
- 67 Rabkin JG, Ferrando SJ, an Gorp W, Rieppi R, McElhing M, Swell M Relationships among apathy, depression, and cognitive impairment in HIV/AIDS. J Neuropsychiatry Clin Neurosci 2000; 12: 451 – 457.
- 68 Rul RH BrickmanAM Nuia B HinkinC Mallø PF, Jefferson AL etal .Apathyis associated with volume of the nucleus accumbens in patients infected with HIV. J Neuropsychiatry Clin Neurosci 2005; 17: 167 171.
- 69 CastellonSA HinkinCH Wood S Arema KT Apathy depression, and cognitive performance in HIV-1 infection. JNeuropsychiatry Clin Neurosci 1998; 10: 320 329.
- 70 Rul R Flanigan TP, Tshima K Cohen R Lwrence J AltE, et al .Apathy correlates with cognitive function but not CD4 status in patients with human immunodeficiency virus. JNeuropsychiatry Clin Neurosci 2005; 17: 114 – 118.
- 71 Millikin CP, Rourk SB ,Halman MH ,Pover C Fatigue in HIV/AIDS is associated with depression and subjective neurocognitive complaints but not neuropsychological functioning. JClin Exp Neuropsychol 2003 ; 25 : 201 – 215 .
- 72 RabkinJG McElhing MC RabkinR FerrandoSJ Modafnil treatment for fatigue in HIV+ patients: a pilot study. JClin Psychiatry 2004; 65: 1688 1695.
- Archibald CJ, Fisk JD. Information processing efficiency in patients with multiple sclerosis. J Clin Exp Neuropsychol 2000;22:686–701.
- Ravdin LD, Hilton E, Primeau M, Clements C, Barr WB. Memory functioning in L yme borreliosis. J Clin Psychiatry 1996;57:282–286.
- 75. Perkins DO, Leserman J, Stern RA, Baum SF, Liao D, Golden RN, et al. Somatic symptoms and HIV infection: Relationship to depressi ve symptoms and indicators of HIV disease. Am J Psychiatry 1995;152:1776–1781.

- 76. Minzenberg MJ, Carter CS. Modaf inial: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology Advance Online Publication, August 22, 2007.
 - 77 Randall DC ,Fleck NL ,Shneerson JM ,File SE The cognitive-enhancing properties of modafinil are limited in non-sleep-depri ved middle-aged v olunteers. Pharmacol Biochem Behav 2004 ; 77 : 547 – 555 .
 - 78 Kaul M ,Lipton SA Experimental and potential future therapeutic approaches for HIV-1 associated dementia tar geting receptors for chemokines, glutamate and erythropoietin . NeurotoxRes 2005; 8: 167 – 186.
 - 79 Wallace D HIV neurotoxicity: potential the rapeutic interventions . J Biomed Biotechnol 2006 ; XX : 1 – 10 .
 - 80 Klson DL Neuropathogenesis of central nervous system HIV-1 infection . Clin Lab Med 2002 ; 22 : 703 717 .
 - Strichan J Sacktorn Wojna V, ConantK NathA Neuroprotective therapy for HIV dementia. CurrHIV Res 2003; 1: 373 – 383.
 - 82 Noshen RL MocchettiI BachisA Brain-derived neurotrophic factor as a prototype neuroprotective factor against HIV -1-associated neuronal de generation. Neurotox Res 2005; 8: 187 – 198.
 - 83 DouH EllisonB Bradle J Kasiyano A Poluektoa IY, XiongH etal .Neuroprotective mechanisms of lithium in murine human immunodef iciency virus-1 encephalitis. J Neurosci 2005 ; 25 : 8375 – 8385 .
 - 84 Perry SW, Norman JP, Gelbard HA Adjunctive therapies for HIV-1 associated neurologic disease. NeurotoxRes 2005; 8: 161 – 166.

HIV-1 Genetic Diversity and Its Biological Significance

Michael M. Thomson

By means of high mutation and recombination rates, together with point introductions in different populations, HIV-1 pandemic strains have diversified extensively into numerous clades, including nine subtypes, at least 36 circulating recombinant forms (CRF), and di verse variants within subtypes and CRF. Differences between HIV-1 genetic clades on pathogenicity, transmissibility, and other biological features often have been difficult to prove, due to multiple factors, including large intrasubtype diversity, frequent recombination, and methodological issues. In spite of the dif ficulties and limitations of the studies, e vidence of some associations of HIV-1 clades with biological features has been found.

HIV-1, the fastest evolving of known human pathogens, has di versified rapidly since the introduction of the ancestor of the pandemic strains among humans from chimpanzees in West-Central Africa (1) in the first half of the twentieth century (2). Phylogenetic analyses based on full genome sequences ha ve allowed to classify HIV-1 pandemic viruses into discrete clades designated subtypes, subsubtypes, and CRF (3). Far from being constrained to a f ixed taxonomy, HIV-1 continues to increase its genetic diversity by generating new variants through interclade recombination and point introductions in dif ferent areas. The study of HIV -1 genetic variability may be useful not only to track the epidemic spread of HIV-1, but it also may be relevant for viral pathogenesis, transmission, antiretroviral therapy, or vaccine development. Although some biological correlations of HIV-1 genetic clades have been demonstrated, much of the biological significance of HIV-1 genetic diversity may still remain to be def ined. In this chapter, molecular mechanisms of HIV -1 genetic diversification, classification of HIV-1 genetic forms, geographical distribution of major clades, and their biological correlations, including dif ferences in disease progression, transmission, and in vitro biological features, are re viewed. Other implications of HIV-1 genetic diversity, such as those related to immune responses relevant for vaccines, or response and resistance to antiretro viral drugs, have been reviewed elsewhere (4-6), and are beyond the scope of this chapter.

M.M. Thomson (🖂)

Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain mthomson@isciii.es

Mechanisms of HIV-1 Variation

High genetic variability of HIV-1 derives from a combination of multiple mechanisms, including: (a) high mutation rates, deri ved from an error -prone viral reverse transcriptase (RT), which introduces mutations at an average of approximately one per genome per infection cycle (7), which remains uncorrected because of the lack of proof-reading activity of the viral enzyme; (b) elevated recombination rates, with an estimated average of nine template jumps by RT between both copackaged RNA genomes in T lymphocytes in a single round of replication (8); (c) rapid virus turnover all along the infection, with an estimated production of 10¹⁰ new virions each day and a mean generation time of 2–3 days (9). HIV-1 recombination rates in vivo are favored by the presence of tw o or more inte grated proviruses in most infected lymphoid cells (10), and may exceed those of mutations in some patients (11, 12).

Viral variants generated through these mechanisms are subject to selective ve forces, mainly exerted, in the absence of antiretroviral therapy, by the immune system, both by cytotoxic T lymphocytes (CTLs) (13, 14) and, in the envelope, also by neutralizing antibodies (15, 16), which drive the expansion of variants containing escape mutations able to evade selective pressures. CTL escape mutations can be transmitted and remain stable over years (14, 17, 18), and may have contributed to the generation of HIV-1 diversity at a population level (13, 19–21).

HIV-1 diversification in a typical infected individual follows through a series of defined stages. During primary infection, prior to the induction of immune responses, viral populations are usually highly homogeneous (22). Subsequent diversification is driven mainly by immune responses, with genetic diversity increasing linearly (approximately 1% annually in the *env* C2-V5 region) during the period of immune competence, while more homogeneous populations and, e ventually, lower diversification rates, develop at late stages, coinciding with the decline of efficient immune responses (23).

Classification of HIV-1 Genetic Forms

By means of high mutation and recombination rates, together with chance point introductions of variants in different populations (i.e., "founder events"), HIV-1 has diversified extensively into multiple genetic forms (3, 4, 24).

In the current classification (3), three phylogenetic groups, M (major), O (outlier) and N (non-M, non-O) are recognized, of whichgroup M is responsible for the global pandemic. Group O viruses circulate only in Central Africa (mainly Cameroon and some neighbouring countries), where the y represent a small minority (<1%) of HIV-1 infections (25). Only a few cases of group N infections, all in Cameroon, have been reported to date. The three HIV-1 groups derive from separate introductions from chimpanzees of the *Pan troglogdytes troglodytes* subspecies, inhabiting West-Central Africa (1, 26), although it is uncertain whether group O deri ves directly from West-Central chimpanzees, or gorillas, among which viruses related to group O have been found (27), served as an intermediate step in a transmission chain originating in chimpanzees. W ithin group M, nine subtypes are recognized,

designated A–D, F–H, J, and K. Initially subtype E was defined based on *env* sequences, although subsequently it w as shown to be a recombinant form (28), currently named CRF01 AE, containing segments of subtype A and an unkno wn subtype. All subtypes are thought to have originated in Central Africa, with the probable exception of subtype B, which initially propagated in Haiti (29). In phylogenetic trees, subtypes form clusters approximately equidistant with each other, separated by 30-35% amino acid distances in env. Within A and F subtypes, subclusters are distinguished, designated subsubtypes A1 through A4 (although the subsubtype status of A3 is controversial (24)), and F1 and F2, respectively. Similarly to subsubtypes, B and D clades are also more closely related to each other than to other subtypes, but their subtype designation has been retained for consistence v with earlier literature. Initial diversification of group M most lik ely occurred in the ter ritory of the Democratic Republic of Congo (DRC), where the greatest HIV1 group M diversity is found (30), and where the earliest HIV -1 specimens were collected (31, 32). Consistent with this hypothesis, phylogenetic trees of HIV-1 sequences from DRC




Fig. 1 Maximum likelihood tree of HIV-1 full-length genomes. Clusters corresponding to subtypes, subsubtypes, and geographic variants within subtypes and CRF01_AE are sho wn. The tree was constructed with Treefinder under the GTR + Γ + I substitution model, with assessment of reliability of tree topologies using 100 bootstrap replicates. Nodes signaled with a dot are supported by \geq 90% bootstrap values. In *parentheses* are names given to variants of HIV-1 subtypes. *BR* Brazil; *CD* Democratic Republic of Congo; *CF* Central African Republic; *CM* Cameroon; *CN* China; *CU* Cuba; *ES* Spain; *ET* Ethiopia; *FSU* countries from the former So viet Union; *IN* India; *KR* Korea; *NG* Nigeria; *TD* Chad; *ZA* South Africa

lack a well defined subtype structure, suggesting that HIV-1 subtypes derive from founder events involving early variants originating from DRC (33).

In areas in which multiple HIV-1 clades are cocirculating in the same population, intersubtype recombinant forms are frequently generated (24, 34), some of which have propagated epidemically. Recombinant forms identified in at least three epidemiologically unlinked individuals, characterized in full-length genomes, are designated CRF (3); these, in turn, may also generate other recombinant forms, including CRF by successive recombination events (35, 36). Currently, 36 CRF have been reported in the literature, and near full-length genome sequences of 7 more putati ve CRF have been submitted to the Los Alamos HIV Sequence Database (http://www.hiv.lanl.gov/content/hiv-db/mainpage.htmlp). Some CRF have propagated extensively, such as CRF02_A G in West Africa (37), CRF01_AE in Southeast Asia (38), CRF07_BC and CRF08_BC in China (39), or CRF12_BF in Argentina (40–42).

During the course of their expansion, some HIV-1 subtypes and CRF have entered certain geographic areas or populations through single introductions, generating variants recognizable in phylogenetic trees as subclusters within a subtype or CRF (24) (Fig. 1). Such is the case, for example, of the subtype B and CRF01_AE variants introduced in Thailand among injecting drug users in 1988 and promiscuousheterosexuals in 1989, respectively (43, 44), the subtype C variant introduced in the mid 1980s in south India among commercial sex workers (45), or the subtype A variant introduced in Ukraine among injecting drug users (IDU) in 1995(46, 47). These are variants that have propagated widely in the countries of introduction and in neighboring countries, although there are several others that have experienced a more limited propagation.

Geographic Distribution of HIV-1 Genetic Forms

Recently, a WHO/UNAIDS study estimating global distribution of HIV-1 genetic forms in 2004 has been published (48). The globally most pre valent clade was subtype C, responsible for approximately 50% infections worldwide, followed by subtypes A and B, representing 12% and 10% HIV -1 infections, respectively. Other genetic forms with more than 1% estimated global prevalences were subtype G (6%), CRF01_AE (5%), CRF02_AG (5%), and subtype D (3%). Recombinant forms collectively represented 18% infections. Globally less pre valent variants circulating as major clades in epidemics of some countries are CRF07_BC and CRF08_BC in China (39), CRF12_BF and related recombinants in Ar gentina and Uruguay (40–42), subtype F in Romania (49), CRF06_cpx in Estonia (50) and Burkina F aso (51), and CRF11_cpx in Central African Republic (52). A world map graphically representing the main HIV-1 clades circulating in each country is shown in Fig. 2.

Subtype C is predominant in Southern Africa, some countries of East Africa (Tanzania (53), Burundi (54), and Ethiopia (55)), India (56), and among Ethiopian immigrants in Israel (57), and is common in Southeast DRC (58), Sudan (59), Southern Brazil (60, 61), Myanmar (62), and Yemen (63). Subtype C viruses from India (56) (which have propagated to Nepal, Myanmar, and China), Brazil (60), and




Fig. 2 Geographic distribution of main HIV-1 genetic forms. Only most prevalent genetic forms circulating in each country are indicated with the corresponding color . *Hatched patterns* indicate that a second genetic form is circulating in the country at a prevalence of $\geq 20\%$, with *thinner bars* representing the less prevalent form when present in 20–40%, and *thicker bars* indicating >40% prevalences. Subtype or CRF prevalences were determined including URF containing segments of the circulating clades. *White color* indicates no available data from that country. The map is based on published papers, complemented in some cases with information from sequences deposited at the Los Alamos HIV Sequence Database (*See Color Plates*)

some from Ethiopia (55) form three respective monophyletic clusters within the subtype C radiation (Fig. 1), indicating that each represents a variant derived from a common ancestor. Subtype C viruses of Indian ancestry have recombined with subtype B viruses of Thai origin to generate the main clades circulating among IDU in China, CRF07_BC and CRF08_BC (64, 65), of which CRF07_BF, has also caused a recent explosive outbreak among IDU in Taiwan (66).

Within subtype A, there are two major variants, both of subsubtype A1; one has spread in East Africa (Kenya (67), Uganda (68), Tanzania (69), and Rwanda (70), with the highest prevalence in Kenya, where it frequently recombines with subtypes D and C, and the other in former Soviet Union (FSU) countries (71), where it was introduced among IDU in Southern Ukraine in 1995(46, 47), constituting the main HIV-1 genetic form in all FSU countries studied, except Estonia (where CRF06_cpx predominates (50)), propagating mainly among IDU. A third subtype A v ariant, designated subsubtype A3 by some authors (72), circulates as a minor form in Some W est African countries (73). Subtype A is the most pre valent genetic form in DRC (30, 58) and the Republic of Congo (74), where it is frequently found in recombination with multiple subtypes and CRFs circulating in this area. Recent reports indicate that subtype A viruses are responsible for HIV-1 outbreaks among IDU in Iran (75) and Pakistan (76), and are highly pre valent among sexually infected persons in Albania (77) and among recent diagnoses in Greece (78).

Subtype B is the HIV -1 clade with the earliest epidemic propagation outside Africa and with the widest global geographical dispersal. It is the major clade in the

Americas, although in Cuba multiple variants of African origin and locally generated recombinants collectively predominate over subtype B (79, 80), and in Argentina and Uruguay CRF12 BF and related recombinants are highly pre valent (40-42). The second major area of subtype B distrib ution is Western and Central Europe, where it was introduced from the USA early in the AIDS epidemic. A subtype B variant was introduced in late 1980s among IDU in Thailand (43), although, since the mid 1990s, it has been replaced by CRF01_AE as the main genetic form transnitted in this population (81). The Thai subtype B variant is predominant in some areas of Myanmar (82) and of the South Chinese Y unnan province (83), is common in Malaysia (84), and originated the epidemic among blood donors in Central China (85). A local subtype B variant is circulating in Korea (86), and in Brazil, a subtype B serotype with a distinctive V3 crown tetrapeptide (GWGR) forming a monophyletic cluster in env (87) represents approximately 40% of subtype B infections (88).Subtype B is also predominant in Japan, Australia, and Ne w Zealand, and among homosexual men in FSU and in South Africa.

Subtype G is the most prevalent clade in Northern Nigeria (89), the country with the largest HIV-1 infected population in West Africa. It is also relatively common in the Republic of Congo (74), and circulates as a minor form in other countries of Central and West Africa. A subtype G v ariant of monophyletic origin circulates widely in Portugal, transmitted via heterose xual contact and among IDU (90, 91), and also among a minority of IDU in Northwest Spain (92, 93). This variant has recombined with subtype B to generate CRF14_BG, which circulates at low prevalences in the Western Iberian peninsula (91–93).

Subtype D comprises two major variants, West-Central and East African (59, 94), of which the later has propagated to a greater e xtent, being predominant in Uganda (68) and relatively common in Kenya (67), Tanzania (69) and Sudan (59).

CRF01_AE, originating in Central Africa, circulates mainly in Southeast Asia, where, it was first introduced in Thailand among female prostitutes and their clients in 1989 (43, 44) and has subsequently spread widely to all countries of Southeast Asia, where it is the main circulating HIV -1 variant (38), and to areas of South China bordering Myanmar and Vietnam (95, 96). CRF01_AE viruses of Southeast Asian origin recently caused an outbreak among IDU in Finland (97).

CRF02_AG is the main genetic form circulating in most of West Africa (37), except northern Nigeria, where subtype G predominates (89), and some areas of Burkina Faso, where CRF06_cpx is more prevalent (51). CRF02_AG is also predominant in the West-Central African countries of Cameroon (98) and Equatorial Guinea (99).

In areas in which multiple HIV-1 genetic forms co-circulate in the same population, high frequencies of unique recombinant forms (URF) are found, generated in individuals infected with two or more of the locally circulating clades (24, 34, 100). The highest frequencies of URF (over 20%) have been reported in Central Africa, some countries of West Africa (Chad, Nigeria, Ghana, Niger , and Burkina Faso) and East Africa (Tanzania, Uganda, and Kenya), Argentina, Central Myanmar, and Yunnan province in South China. In Ethiopia, 40% viruses were reported to be intrasubtype recombinant between the local subtype C variant (C") and subtype C viruses of SouthernAfrican ancestry (C'). It should be noted that the proportions of URF reported in most studies

represent minimum figures, since usually only short genome segments are analyzed and only intersubtype recombination is examined. A recent study reporting intrasubtype recombination in 47% of South African sub type C genomes (101) indicates that recombination in HIV-1 may be much more common than previously estimated.

High prevalences of diverse HIV-1 African clades, mostly among heterosexually infected individuals, are found in several West European countries, such as United Kingdom (102), France (103), Belgium (104) or Portugal (90). However, except in Portugal, where subtype G circulates widely among the nati ve population, most non-B clades are found in African immigrants infected in their countries of origin or in Europeans infected from African individuals.

Correlations of HIV-1 Clades with In Vitro Biological Features

The study of in vitro biological correlations of HIV1 clades has not been undertaken in a systematic fashion, but rather has been focused on a fe w particular aspects of HIV-1 biology, mainly the activity of the transcriptional promoter at the 5 ' long terminal repeat (LTR) and coreceptor usage, with a more limited number of studies on Tat function and replicative capacity ("fitness").

Viral Promoter Activity

This has been one of the most intensely explored areas of HIV-1 in vitro biology regarding variation among clades. However, results often have been contradictory, which may derive from diverse factors, including the use of different lymphoid and nonlymphoid cell lines, use of promoters from a single or a few isolates from each clade (which may yield results reflecting isolate-specific, rather than clade-specific, differences), or of reconstructed clade consensus sequences (which may differ from actual isolate sequences). Examination of HIV-1 LTR sequences reveals interclade variation in binding motifs for cellular transcriptional f actors. One of the most notorious differences is in the number of NF- kB binding motifs just upstream of the transcriptional initiation site: while most clades contain tw o, most subtype C isolates have three, and CRF01_AE viruses ha ve only one (105). Several studies have suggested that these dif ferences result in dif ferent promoter acti vities. However, only one functional correlation has been uniformly reproducible by different authors in various T lymphoid cell lines, which is a reduced responsi veness of the LTR of CRF01_AE (L TR-E) to TNF a (106- 110) a cytokine which enhances HIV-1 transcription by activating NF-κB. Lower promoter activation is reflected in reduced viral replication rates of CRF01_AE in the lymphoid SupT1 cell line in the presence of TNFa (111). Decreased TNFa responsiveness of LTR-E appears to result from the presence of a single NF- kB site, since it w as also observed in response to intracellularly expressed Rel A/p65 subunit of NF-KB (105) and to other

stimuli known to activate NF- κ B (109), and the response was partially restored by reconstituting the second NF- κ B motif (106). Loss of the second NF- κ B motif in LTR-E is compensated by its conversion to a GABP binding site, which may promote Tat-induced LTR activation in some cell lines (110, 112). Some authors ha ve reported higher activation of LTR-C by TNF α (107) or NF- κ B (105) ,which would derive from the presence of 3 NF- κ B sites. It has been ar gued that this might contribute to higher efficiency of subtype C transmission through activation of viral replication by elevated TNF α levels in cervicovaginal secretions of w omen with sexually transmitted infections (107). However, others could not reproduce these results (108, 110). In fact, it was reported that the predicted e xtra NF- κ B site of LTR-C fails to bind NF- κ B, thus being functionally inacti ve (109, 113). Other reported associations of LTR activity with HIV-1 clades include greater responsiveness of LTR-B to NFAT compared with L TR-E or LTR-C (105, 110), and decreased responsiveness to Tat of the LTR-C relative to LTR-B or LTR-E (113).

Coreceptor Usage

Chemokine receptors CCR5 and CXCR4 are the major HIV-1 cellular coreceptors, with viruses using either CCR5, or CXCR4, or both (designated R5, X4, or R5X4 viruses, respectively) (114). Before the disco very of HIV-1 coreceptors, isolates were phenotypically characterized in MT-2 cell cultures as nonsyncytium inducing (NSI) or syncytium inducing (SI), which corresponds to CCR5-tropic or CXCR4tropic viruses respectively, since MT-2 cells only express CXCR4. In initial studies in subtype B-infected patients, it w as observed that in early and asymptomatic stages, viruses are almost uniformly of the SI (R5) phenotype, switching to the SI (X4 or R5X4) phenotype in late stages in approximately half of the patients (115). Subsequently, coreceptor switch was found to occur frequently also in other clades (116–118), except in subtype C isolates, among which this switch is uncommon (117–121) (although one study has reported 50% CXCR4-tropic subtype C viruses in antiretroviral treated – b ut not in untreated – patients in late stages (122)).Infrequent CXCR4 usage is a biological feature conserved in different subtype C variants from South Africa (120), India (121), Ethiopia (119) and Brazil (123). At the other extreme of subtype C, CRF14 BG viruses, which have a subtype B envelope inserted in an otherwise subtype G genome, and circulates as a minor form in Northwestern Spain and Portugal (91-93), are mostly X4 or R5X4 irrespective of disease stage (124), although longitudinal studies since serocon version would be needed to confirm this observation. Frequencies of SI viruses in late disease greater than those described in subtype B have been reported also for CRF01 AE in Thailand (117, 125) V3 sequence features associated with coreceptor usage in subtype C, CRF01_AE, and Romanian subtype F dif fer from those described in subtype B (126-129). In the FSU subtype A variant, the consensus V3 sequences of NSI and SI viruses are indistinguishable, with SI viruses lacking features typically associated with SI phenotype in subtype B (130).

Tat Function

As in the case of the LTR studies, contradictory results on HIV-1 clade correlations have been reported with Tat function, possibly derived from similar methodological limitations. Tat of CRF01_AE (Tat-E) has been reported to be the strongest L TR transactivator compared with T at from other subtypes (113, 131). Higher Tat-E efficiency was associated with longer half-life, more efficient interaction with TAR, and higher affinity to cyclin T1 compared with Tat-B or Tat-C (131). Other authors, however, have reported greater transactivating efficiency of Tat-C compared with Tat-B or Tat-E (132), or of Tat-C and Tat-B compared with Tat-E (133).

Clade-associated variability in some T at-mediated effects on cellular genes and functions have also been reported. It has long been known that Tat-B is secreted extracellularly and induces the expression of diverse inflammatory cytokines, among them TNF α by activating its promoter (134). However, recent observations indicate that T at-E inhibits TNF α gene transcription and protein expression in Jurkat T cells and has no effect on TNF α expression in a monocytic cell line, in contrast to Tat-B and Tat-C, which activate TNF α expression in both cell lines (135). This feature of T at-E was mapped to W32 residue present in most T at-E sequences. It was speculated that by inhibiting TNF α expression, and consequently NF- κ B activation, Tat-E could promote the recruitment of GABP to its binding site in the LTR-E, thus activating transcription from the viral promoter.

Tat has been implicated in HIV -1 neuropathogenesis through the induction of inflammatory cytokines and promotion of monocyte migration to the brain (136–138). With regard to these activities, Tat-C, compared with Tat-B, has been shown to be defective at induction of chemotactic activity in monocytes (139), correlated with decreased induction of TNF α and CCL-2 (previously known as monocyte chemotactic protein-1) secretion from monocytes and with lack of intracellular calcium flux in these cells (140). These functional defects were mapped to C31S substitution present in 90% Tat-C sequences. Based on these results, it w as proposed that the defective chemotactic monocyte activity of Tat-C could contribute to the reported low prevalence of HIV-1 associated dementia in India (141, 142). More recent studies, ho wever, have found frequencies of neurocognitive deficiency in HIV-1 infection in India (143–145) and in South Africa (146) similar to those of Western countries.

Replicative Capacity ("Fitness")

In in vitro pairwise competition assays using primary CD4+ T lymphoc ytes, R5 subtype C primary isolates from different geographic origins (Nigeria, South Africa, and India) consistently displayed slo wer replication kinetics than R5 subtype B viruses (147). No differences were found in cocultures of CD4+ T lymphoc ytes and skin-derived Langerhans cells. Viruses of subtypes A, B, and D, and CRF01_AE showed similar replication kinetics (148). The authors suggested that slo wer

replicative kinetics of subtype C in CD4+ lymphoc ytes might result in longer survival, thus increasing the chances of transmitting the virus and contributing to the greater global e xpansion of subtype C. Ho wever, disease progression has been reported to be similar between subtypes A and C in T anzania (149), and in South Africa, where subtype C predominates, survival in HIV-1 infected patients is similar to Western countries (150). In similar e xperiments, HIV-1 group O and HIV -2 viruses displayed typically 100-fold less replicative capacity than group M viruses, both in peripheral blood mononuclear cells and in cocultures of dendritic cells with primary quiescent T cells (148), a result which correlates with the much more limited propagation of the group O and HIV-2 viruses. In other studies, CRF02_AG viruses showed higher replicative capacity than subtype A or G viruses, independently of disease stage or coreceptor usage (151, 152), which correlates with the greater expansion in West Africa of CRF02_AG relative to its parental subtypes.

Correlations of HIV-1 Clades with In Vivo Viral Biology

Several studies have found associations of HIV -1 clades with plasma viral loads, disease progression, and transmission.

Plasma Viral Loads

Lower viral loads in the f irst month after serocon version have been reported in subtype C infections in Ethiopia compared with subtype B infections in Dutch individuals in the Netherlands, although the dif ference could be attrib utable to lower average CD4+ cell counts among HIV-1 seronegative Ethiopians, rather than to clade biological differences (153). In this study, postseroconversion viral loads were on average one log lower in infections with C' viruses (related to South Africanviruses) than with viruses of the local C" variant, as determined in the V3*env* region. In another study in Southern Africa, plasma viremia within the f irst 2 years of infection did not differ significantly from that found in subtype B (154).

Two studies have found higher plasma viral loads after serocon version in IDU infected with CRF01_AE than with subtype B. Inthe first study, in Thailand, median plasma viremia was three times higher in CRF01_AE than in subtype B infections in the first month after seroconversion (155). In Finnish IDU infected with CRF01_AE, higher viral loads were observed from 12 to 48 months postseroconversion, compared with subtype B infections among IDU from Amsterdam (156).

In Ghana, increased viral loads have been reported in early CRF02_AG infections compared to infections with other genetic forms circulating in the country (mostly subtypes A and G, and secondary recombinants of CRF02_AG) (157). Similarly, in Senegal, viral loads in primary infection were found to be higher in infections with CRF02_AG than with other clades (158).

Disease Progression

Infections with HIV-2, compared to HIV-1 infections, clearly result in slower disease progression (159), which is associated with lo wer plasma viral loads (160, 161), and reduced in vitro replicati ve fitness (148). By contrast, dif ferences between HIV-1 group M clades have been more difficult to prove.

Among seroprevalent infections, similar progression rates have been reported among different ethnic groups residing in one country and harboring diverse HIV-1 clades, such as sub-Saharan Africans and native Europeans in Sweden (162) and England (163), and Ethiopian immigrants and non-Ethiopians in Israel (164).

The first study reporting differences in disease progression between HIV-1 clades was done in Senegal among female sex workers followed since seroconversion (165) .The results indicated that infection with viruses bearing subtype A en velopes, compared to infections with viruses with en velopes of other subtypes (D, G, or C) considered collectively, was associated with an eightfold reduction in progression to AIDS. The results, however, may be considered as inconclusive because of the low numbers of women who developed AIDS and of infections with each of non-A subtypes. In addition, subsequent studies have shown that most A^{env} viruses in Senegal are in fact CRF02_AG viruses (37). A more recent study in Cameroon and Senegal (166), using a much larger number of patients with unknown dates of infection, failed to reveal significant differences in disease progression between CRF02_AG and other clades, adjusting for age, baseline CD4+ cell count, and clinical stage.

Several studies in East Africa have revealed evidence of faster disease progression in subtype D than in subtype A infections among adults. Differences were found in Uganda (167, 168), Tanzania (149), and Kenya (169). In two of the studies the subjects were followed since seroconversion (168, 169). In the Tanzanian study, progression in infections with subtype C and recombinant viruses did not dif fer from subtype A infections (149). In Kenya, differences in progression were not attributable to differences in viral load (169), whereas in Uganda faster disease progression in D^{env} infections was associated with earlier switch to CXCR4 coreceptor usage (170). In contrast to studies in adults, no differences between subtypes were found in survival among children in Uganda perinatally infected with subtypes A and D (171).

Three studies in Brazil have found slower disease progression among infections with viruses of the B_{Br} serotype, bearing GWGR in V3, than among infections withsubtype B viruses bearing the typical subtype B V3 cro wn tetrapeptide sequence GPGR (172–174), although in one study the association w as found only among w omen. However, in none of the studies infections were follo wed since seroconversion.

Transmission

Lower transmission rates have been demonstrated for HIV-2 than for HIV-1, both via heterosexual contact (175, 176) and from mother to child (177), which may be

related to lower viral loads (160, 178). However, differences in transmission among HIV-1 group M clades have not been demonstrated conclusively.

Heterosexual Transmission

Two reports from Thailand suggested higher rates of heterosexual transmission for CRF01 AE, compared with subtype B in W estern countries, both from female to male (among military conscripts mostly infected from female prostitutes)(179) and from male to female (among women infected from their male sexual partners), (180). The difference in both studies persisted in the absence of other sexually transmitted infections (STI). However, factors other than genotype could have influenced the results (181), such as frequency of condom use, of STI among prostitutes (in female to male transmission), or the incidence of acute infections (which is associated with increased HIV-1 transmission) during the study period. In another study in Thailand among heterosexual couples, CRF01 AE was associated with higher seroconcordance rates than subtype B. However, different clades in men were associated with different risk groups, with most CRF01 AE infections acquired from female prostitutes and subtype B found mostly among IDU. Presumed increased heterosexual transmission of CRF01 AE relative to subtype B w as attributed to differences in replication efficiency in Langerhan's cells (182), but this could not be reproduced by otherauthors (183, 184). In Uganda, a prospecti ve study among monogamous heterose xual HIV-discordant couples found no association between A and D serotypes and frequency of transmission per coital act (185). No study e xamining the relative efficiency of heterosexual transmission of subtype C, the globally most prevalent clade, has been published, although a higher frequency of vaginal shedding of HIV-1-infected cells among pregnant women in Kenya infected with subtype C than among those infected with subtypes A or D has been reported (186).

Transmission by Needle Sharing Among IDU

In Bangkok, Thailand, a significantly higher probability of transmission per needle sharing among IDU was associated with CRF01_AE compared to subtype B infections, controlling for behavioral risks (187). However, the authors could not e xclude the influence of nonviral factors, such as unequal distribution of HIV-1 genotypes among active needle-sharing networks or differences in incidence of acute infections with either genetic form during the study.

Mother to Child Transmission (MTCT)

The largest study on the correlation of HIV-1 subtype on MTCT was carried out in Kenya, involving 414 mothers, of which 80 transmitted HIV -1 infection (188). In multivariate analysis, adjusting for viral loads and other factors, subtype D or AD

recombinant viruses (as determined in gp41 and p24^{pag}), were associated with higher MTCT rates compared with nonrecombinant subtype A viruses. In another study in Kenya, however, no difference was found in MTCT between subtypes A and D, as determined in gp120 (189). In Tanzania, subtype C and intersubtype recombinant viruses, analyzed in p24-p7^{gag} and gp120 (190), or in LTR fragments (191), were associated with increased MTCT rates compared with subtypeD. In Brazil, no difference in MTCT rates was found between subtypes B and C (192). Other studies in Tanzania (193) and Ghana (194) failed to reveal associations of subtypes with MTCT rates, although the number of transmitted infections were too low for detection of minor differences. Timing of MTCT transmission and its correlation to subtype was examined in two studies in Tanzania. One revealed that subtype C^{env} was preferentially transmitted in utero (vs. *intrapartum*) compared to subtypes A or D (195). In the other study, intersubtype recombinant viruses were transmitted more frequently during breastfeeding than viruses of nonrecombinant subtype C, or of subtypes A, C, and D combined, as determined in fragments of *env* and the LTR (196).

Concluding Remarks

Biological differences between HIV-1 clades have often been difficult to prove, which seems counterintuitive in view of the great genetic di versity among HIV-1 subtypes. Difficulties in obtaining conclusive results derive from multiple factors, some related to virus genetics and others to methodological issues. Although HIV1 genetic diversity within group M is lar ge, and increasing over time, intersubtype biological differences do not increase in parallel with gro wing distances between viruses of different subtypes. These differences were already established at the time of origin of subtypes, and should not be expected to increase with time, since biological features characteristic of a subtype are those derived from its most recent common ancestor that have been preserved among a majority of viruses along subtype diversification. Thus, it is even possible that a clade-specific biological feature is lost if, as a consequence of stochastic events, such as transmission bottlenecks, it is lost in a major variant originated during clade diversification. In this respect, it is important to note, that, according to molecular clock estimates, current intrasubtype genetic distances might exceed intersubtype distances existing when subtypes originated (29, 101, 197). Another f actor to consider is the great frequence y of interclade recombination, particularly visible in areas in which multiple HIV -1 variants are cocirculating in the same population. These areas (such as East Africa) has frequently been used for studies on biological correlations of HIV -1 subtypes. One f actor complicating the interpretation of studies in these areas is that analyzing subtypes in only one or two short genome segments, as is usually done, may be insufficient for the genetic characterization of the virus, given the pervasiveness of recombination. In fact, in one study in Tanzania on HIV-1 transmission through breastfeeding, results were discordant when different genome segments were analyzed (196). A third factor to consider is the existence of different variants within subtypes, which may differ in their biological features. Some possible variant-specific biological features have been reported in subtype B in Brazil (172–174), subtype C in Ethiopia (153), and subtype A in FSU (130). With regard to studies on transmission, all have compared HIV-1 clades which ha ve spread widely, and which therefore are known to be transmitted efficiently. Differences would be expected to be more easily demonstrable by comparing globally predominant HIV-1 clades with others that have propagated little (such as subtypes H, J, and K, andsome "old" complex CRF of Central African origin). Since both transmission and progression correlate withviral loads (198, 199), a similar logic would be applicable to studies on HIV-1 progression. The difficulty in these studies is recruiting sufficient numbers of individuals infected with the genetic form of low prevalence.

With respect to published studies on in vitro biological correlations, there are other methodological issues that may limit the significance of results, as mentioned previously, such as the use of genes or re gulatory elements derived from only one or a few isolates from each clade, or differences between cell lines (111).

In spite of difficulties and limitations of the studies, there is reproducible evidence of some HIV-1 clade-associated biological features, such as the lower frequency of CXCR4 coreceptor usage among subtype C viruses, reduced responsi venes of the CRF01_AE transcriptional promoter to TNF α and NF- κ B, decreased replicative capacity of R5 subtype C viruses in primary CD4+ T lymphoc ytes, or more rapid disease progression in infections with viruses of East African subtype D (compared to East African subtype A) v ariants, which convincingly show that HIV-1 clades do differ in biological properties. Although be yond the scope of this chapter , correlations of HIV-1 subtypes with susceptibility to cellular (200–202) and humoral (203) immune responses and with de velopment of antiretro viral drug-associated resistance mutations (5) have also been reported. These results underscore the importance of continuing and expanding the studies on in vitro and in vivo biological correlations of HIV-1 genetic clades, an area of research which still remains insuficiently explored and in which a major scaling up of efforts would be necessary in the global combat against the disease and the pandemic.

References

- 1 .GaoF, BailesE RobertsonDL ChenY, Rodenbrg CM MichaeSF etal .Originof HIV-1 in the chimpanzee Pan troglodytes troglodytes . Nature 1999 397 : 436 441 .
- 2. Karber B MuldoonM TheilerJ GaoF, GuptaR LapedesA etal .Timing the ancestor of the HIV-1 pandemic strains . Science 2000 288 : 1789 1796 .
- 3 .Robertson DL ,Anderson JP, Bradac A , Carr JK , Eley B ,Funkhouser RK et al .HIV1 nomenclature proposal . Science 2000 288 : 55 56 .
- 4 . ThomsonMM Pérez-Álarez L NájeraR Molecularepidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. LancetInfect Dis 2002 2 : 461 471 .
- 5 .KantorR Impactof HIV-1 pol diversity on drug resistance and its clinical implications . Curr Opin Infect Dis 2006 19 : 594 606 .
- 6 .BranderC FrahmN Walker BD Thechallenges of host and viral diversity in HIV vaccine design . CurrOpin Immunol 2006 18 : 430 437 .

- 7. GaoF, ChenY, Ley DN Conwy A, Kepler TB HuiH Unselected mutations in the human immunodeficiency virus type 1 genome are mostly nonsynon ymous and often deleterious. JVirol 2004 78 : 2426 2433.
- Ley DN Aldrøandi GM Kitsch O Shw GM Dynamics of HIV-1 recombination in its natural target cells. ProcNatl Acad Sci U S A 2004 ;101 : 4204 – 4209.
- 9 .PerelsonAS NeumannAU , Markwitz M LeonardJM HoDD HIV1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time . Science 1996 271 : 1582 1586 .
- 10 .JungA MaierR Mattanian JP, Bocharw G JungV, FischerU etal .Multiplyinfected spleen cells in HIV patients . Nature 2002 418 : 144 .
- 11 .ShrinerD Rodrigo AG, NickleDC Mullins JI Pervasive genomic recombination of HIV-1 in vivo. Genetics 2004 167 : 1573 - 1583.
- 12 .Charpentier C ,Nora T, Thaillon O ,Chael F, Hance AJ Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients. JVirol 2006 80 : 2472 – 2482.
- 13 .AllenTM AltfeldM GeerSC KalifeET, MooreC O'Sullian KM etal .Selective escape from CD8 + T-cell responses represents a major dri ving force of human immunodef iciency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 2005 79 : 13239 – 13249 .
- 14 . LiuY, McNein J CaoJ ZhaoH Genwati I Wing K etal .Selectionon the human immunodeficiency virus type 1 proteome following primary infection . JVirol 2006 80 : 9519 – 9529 .
- 15. Wi X Deckr JM Wing S HuiH Kappes JC W X et al. Antibody neutralization and escape by HIV-1. Nature 2003 422 : 307 312.
- 16 .Frost SD ,Wrin T, Smith DM ,Kasakovsky Pond SL ,Liu Y, Rxinos E et al .Neutralizing antibody responses drive the evolution of human immunodef iciency virus type 1 en velope during recent HIV infection . ProcNatl Acad Sci U S A 2005 ;102 : 18514 – 18519 .
- 17 .GoulderPJ BranderC Ing Y, Temblay C ColbertRA AddoMM et al .Evolution and transmission of stable CTL escape mutations in HIV infection . Nature 2001 \pm 12 : 334 338 .
- 18 .Leslie AJ Pafferott KJ ChettyP, DraenertR AddoMM Feene M et al .HIV evolution: CTL escape mutation and reversion after transmission . NatMed 2004 10 : 282 – 289 .
- 19 . Moore CB John M James IR , Christiansen FT, Wtt CS , MallalSA Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population le vel. Science 2002; 296 : 1439 – 1443.
- 20. Wisim K Kasmir C GaschenB AddoMM AltfeldM BrunakS etal .Clusteringpatterns of cytotoxic T-lymphocyte epitopes in human immunodef iciency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation . JVirol 2002 76 : 8757 8768 .
- 21 .LeslieA Knanagh D Hongborne I Pffferott K Edwards C Pilay T etal .Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA . JExp Med 2005 201 : 891 – 902 .
- 22 . Delvart E ,Magierowska M ,Royz M ,Fley B ,Peddada L ,SmithR et al . Homogeneous quasispecies in 16 out of 17 indi viduals during very early HIV-1 primary infection. AIDS 2002 ;16 : 189 195 .
- 23 . Shankarappa R , Magolick JB , Gange SJ , Rodrigo AG , Upchurch D , Firzadegan H et al . Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection . JVirol 1999 73 : 10489 – 10502 .
- 24 . Thomson MM , Nájera R Molecular epidemiology of HIV-1 variants in the global AIDS pandemic: an update . AIDS Rev 2005 7 : 210 – 224 .
- 25. Vergne L ,Bougeois A ,Mpoudi-Ngole E ,Mougnutou R ,Mbagbaw J Liegeois F et al . Biological and genetic characteristics of HIV infections in Cameroon re veals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02_AG variant and disease stage . Verology 2003 310 : 254 – 266 .
- 26 . Kele BF, Vn Heuverswyn F, LiY, Bailes E, Akehisa J, Santiago ML et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006 313 : 523 526 .
- 27 . Yin Heuverswyn F, LiY, NeelC BailesE Keele BF, LiuW etal .Humanimmunodeficiency viruses: SIV infection in wild gorillas . Nature 2006 444 : 164 .

- 28 .GaoF, RobertsonDL MorrisonSG HuiH CraigS Deckr J etal .Theheterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin . JVirol 1996 70 : 7013 7029 .
- 29. Gilbert MT, Rambaut A, Wlasiuk G, Spira TJ, Pitchenik AE, Worobey M. The emergence of HIV/AIDS in the Americas and beyond. Proc Natl Acad Sci USA 2007; 104:18566–18570.
- 30. Ydal N, Peeters M, Mulanga-Kabya C, Nzilambi N, Robertson D, Junga W et al. Unprecedented degree of human immunodef iciency virus type 1 (HIV -1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV -1 pandemic originated in Central Africa. JVirol 2000 74 : 10498 – 10507.
- Worobey M, Gemmel M, Teuwen DE, Haselkorn T, Kunstman K, Bunce M et al. Direct e vidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature 2008; 455:661–664.
- 32 .ZhuT, Korber BT, NahmiasAJ HooperE SharpPM HoDD An African HIV-1 sequence from 1959 and implications for the origin of the epidemic . Nature 1998 391 : 594 597 .
- 33 .Rambaut A Robertson DL Pybs OG Peeters M Holmes EC Humanimmunodeficiency virus. Phylogeny and the origin of HIV-1. Nature 2001 #10 : 1047 1048.
- 34 .NájeraR DelgadoE Pérez-Álærez L ThomsonMM Geneticrecombination and its role in the development of the HIV-1 pandemic . AIDS 2002 16 Suppl4 : S3 S16 .
- 35 . SierraM ThomsonMM RíosM CasadoG CastroRO, DelgadoE etal .Theanalysis of near full-length genome sequences of human immunodef iciency virus type 1 BF intersubtype recombinant viruses from Chile, V enezuela and Spain re veals their relationship to di verse lineages of recombinant viruses related to CRF12_BF. InfectGenet Evol 2005 5 : 209 – 217.
- 36 . SierraM ,ThomsonMM PosadaD PérezL AragonesC GonzálezZ etal .Identification of 3 Phylogenetically Related HIV-1 BG intersubtype circulating recombinant forms in Cuba . JAcquir Immune Defic Syndr 2007 45 : 151 – 160 .
- 37 . Montuon C Jure-Kane C Ligeois F, MpoudiE Bougeois A Jorgen L etal .Mostenv and gag subtype A HIV-1 viruses circulating in W est and West Central Africa are similar to the prototype AG recombinant virus IBNG. JAcquir Immune Defic Syndr 2000 23 : 363 374.
- 38 .OelrichsRB Crove SM Themolecular epidemiology of HIV-1 in South and East Asia . Curr HIV Res 2003 ;1 : 239 248 .
- 39 . Saksena NK , Wang B , Steain M , Yang RG Zhang LQ Snapshot of HIV pathogenesis in China . CellRes 2005 15 : 953 – 961 .
- 40 . ThomsonMM Mahermosa ML Vázquezle Parga E Cueas MT, DelgadoE, ManjónN et al. Widespread circulation of a B/F intersubtype recombinant form among HIV -1-infected individuals in Buenos Aires, Argentina . AIDS 2000 14 : 897 899 .
- 41 .ThomsonMM DelgadoE HerreroI Mahermosa ML Vázquezde Parga E Cuevas MT et al. Diversity of mosaic structures and common ancestry of human immunodeficiency virus type 1 BF intersubtype recombinant viruses from Argentina revealed by analysis of near full-length genome sequences. JGen Virol 2002 83 : 107 – 119.
- 42 . Carr JK , Ávila M , Gómez Carrillo M , Salomon H , Hierholzer J , Watanaveeradej V et al . Diverse BF recombinants have spread widely since the introduction of HIV1 into South America . AIDS 2001 ;15 : F41 – F47 .
- 43 . OuCY, Tkebe Y, Wniger BG LuoCC KalishML Auwrit W etal. Independent introduction of two major HIV-1 genotypes into distinct high-risk populations in Thailand . Lancet 1993; 341 : 1171 1174 .
- 44 .McCutchan FE ,Hgerich PA , Brennan TP, Phanuphak P, Singharaj P,Jugsudee A et al . Geneticvariants of HIV-1 in Thailand . AIDSRes Hum Retroviruses 1992 8 : 1887 – 1895 .
- 45 . Dietrich U , Grez M , on Briesen H , Rinhans B , Geissendorfer M , Kihnel H et al . HIV1 strains from India are highly divergent from prototypic African and US/European strains, but are linked to a South African isolate . AIDS 1993 7 : 23 27.
- 46 . Noitsky VA , MontanoMA Esse M Molecularepidemiology of an HIV-1 subtype A subcluster among injection drug users in the Southern Ukraine . AIDS Res Hum Retro viruses 1998; 14 : 1079 1085 .
- 47. Nabato AA ,Kruchenko ON ,Julchuk MG ,Shcherbinskaya AM ,Lukasho VV Simultaneous introduction of HIV type 1 subtype A and B viruses into injecting drug users in

southern Ukraine at the beginning of the epidemic in the former Soviet Union. AIDS Res Hum Retroviruses 2002 $\,\sharp8\,$: 891 - 895 .

- 48 .Hemelaar J ,Gouws E ,Ghys PD ,Osmano S Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004 . AIDS 2006 20 : W13 W23 .
- 49 .Opde Coul and den Burg R AsjoB GoudsmitJ CupsaA Rescu R etal .Geneticevidence of multiple transmissions of HIV type 1 subtype F within Romania from adult blood donors to children . AIDSRes Hum Retroviruses 2000 16 : 327 - 336 .
- 50 .Zetterber V, UstinaV, LiitsolaK ZilmerK Kalikva N Sreastianova K etal .Two viral strains and a possible novel recombinant are responsible for the explosive injecting drug use-associated HIV type 1 epidemic in Estonia . AIDSRes Hum Retroviruses 2004 20 : 1148 – 1156 .
- 51 . Ouedraogo-Taore R Montaon C SanouT, Vdal N SangareL Sanu I etal .CRF06-cpxis the predominant HIV-1 variant in AIDS patients from Ouagadougou, the capital city of Burkina Faso. AIDS 2003 17 : 441 – 442.
- 52 .MarechalV, JauvinV, Selekin B LealJ PelembiP, Fikuma V etal .IncreasingHIV type 1 polymorphic diversity but no resistance to antiretro viral drugs in untreated patients from Central African Republic: a 2005 study. AIDSRes Hum Retroviruses 2006 22 : 1036 1044 .
- 53 .Arryo MA HoelscherM Sanders-BuellE HerbingerKH Samly E Maboko L etal .HIV type 1 subtypes among blood donors in the Mbe ya region of southwest Tanzania. AIDS Res Hum Retroviruses 2004 20 : 895 901 .
- 54. Mal N Niyongabo T, Nduwimana J Butel C Ndayiragije A Makana J et al .HIV type 1 diversity and antiretroviral drug resistance mutations in Burundi. AIDS Res Hum Retroviruses 2007 23 : 175 - 180.
- 55 . AbebeA PollakisG Entanet AL FissehaB Ægbaru B KliphuisA etal .Identification of a genetic subcluster of HIV type 1 subtype C (C') widespread in Ethiopia . AIDS Res Hum Retroviruses 2000 16 : 1909 1914 .
- 56 . ShankarappaR ChatterjeeR LearnGH NeogiD DingM Ry P etal .Humanimmunodeficiency virus type 1 en v sequences from Calcutta in eastern India: identif ication of features that distinguish subtype C sequences in India from other subtype C sequences . J Virol 2001; 75 : 10479 - 10487 .
- 57 .LoembaH BrennerB Priniak MA Ma'ayanS SpiraB MoisiD etal .Geneticdivergence of human immunodeficiency virus type 1 Ethiopian clade C re verse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of R T. Antimicrob Agents Chemother 2002 46 : 2087 2094 .
- 58. Vdal N MulangaC BazepeoSE Mwmba JK ,TshimpakaJW, KashiM etal .Distribution of HIV-1 variants in the Democratic Republic of Congo suggests increase of subtype C in Kinshasa between 1997 and 2002. JAcquir Immune Defic Syndr 2005 40: 456 – 462.
- 59 .Hierholzer M Graham RR El K.I Æsker S Darwish M Chapman GD et al .HIV type 1 strains from East and W est Africa are intermix ed in Sudan . AIDS Res Hum Retro viruses 2002 18 : 1163 – 1166 .
- 60 . Soares MA deOliveira T, Brindeiro RM Diaz RS Sabino EC Brigdo L et al . A specific subtype C of human immunodeficiency virus type 1 circulates in Brazil . AIDS 2003 ;17:11-21.
- 61 . SoaresEA Martinez AM SouzaTM SantosAF, DaH V, Siløira J etal .HIV1 subtype C dissemination in southern Brazil . AIDS 2005 ;19 Suppl4 : S81 S86 .
- 62. Takebe Y, Motomura K, Tatsumi M, Lwin HH, Zw M, Kasagawa S. High prevalence of diverse forms of HIV-1 intersubtype recombinants in Central Myanmar: geographical hot spot of extensive recombination. AIDS 2003 17: 2077 – 2087.
- 63 .SaadMD AJaufy A GrahanRR NadaiY, EarhartKC Sanchez/L etal .HIVtype l strains common in Europe, Africa, and Asia cocirculate in Y emen. AIDS Res Hum Retro viruses 2005 21 : 644 – 648 .
- 64 . SuL GrafM ZhangY, on Briesen H XingH Kestler Jet al .Characterizationof a virtually full-length human immunodeficiency virus type 1 genome of a pre valent intersubtype (C/B') recombinant strain in China . JVirol 2000 74 : 11367 11376 .
- 65 . PiyasirisilpS McCutchanFE CarrJK Sanders-BuellE LiuW, Gen Jet al A recent outbreak of human immunodeficiency virus type 1 infection in southern China w as initiated by two

highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant . JVirol 2000 74 : 11286 - 11295.

- 66 .ChenYM LanYC LaiSF, Yang JY, TsaiSF, Ko SH HIV1 CRF07_BC infections, injecting drug users, Taiwan. Emerg Infect Dis 2006 ;12 : 703 – 705.
- 67 .Dwling WE ,KimB ,MasonCJ ,Wasunna KM ,AlamU ElsonL et al .Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants . AIDS 2002 ;16 : 1809 1820 .
- 68 .HarrisME Serwadda D Swankambo N KimB KigoziG Kiwanuka N etal .Among46 near full length HIV type 1 genome sequences from Rakai District, Uganda, subtype D and AD recombinants predominate . AIDSRes Hum Retroviruses 2002 18 : 1281 1290 .
- 69 . Herbinger KH , Gerhardt M , Piyasirisilp S , Mloka D , Arroo MA , Hffmann O et al . Frequency of HIV type 1 dual infection and HIV di versity: analysis of lo w- and high-risk populations in Mbeya Region, Tanzania . AIDSRes Hum Retroviruses 2006 22 : 599 – 606 .
- 70 . Serxis J LambertC KaritaE Minhove D FischerA BaurithT etal .HIVtype 1 pol gene diversity and archived nevirapine resistance mutation in pre gnant women in Rwanda. AIDS Res Hum Retroviruses 2004 20 : 279 – 283 .
- 71 .Bobkv A Cheingsong-Popø R Selimøa L LadnayaN Kazennøa E Kravchenko A etal . An HIV type 1 epidemic among injecting drug users in the former So viet Union caused by a homogeneous subtype A strain . AIDSRes Hum Retroviruses 1997 13 : 1195 – 1201 .
- 72 . Meloni ST, KimB Sankale JL Hamel DJ Javanabutra S MbourS et al .Distinct human immunodeficiency virus type 1 subtype A virus circulating in West Africa: sub-subtype A3. JVirol 2004 78 : 12438 – 12445 .
- 73 . Meloni ST, Sankale JL, Hamel DJ, Eisen G, Guye-Ndiaye A, Mboup S et al. Molecular epidemiology of human immunodeficiency virus type 1 sub-subtype A3 in Senegal from 1988 to 2001. JVirol 2004 78 : 12455 12461.
- 74 . NiamaFR β ure-Kane C λ dal N ρ benguiP, BikandouB NdoundouNkodia MY etal .HIV1 subtypes and recombinants in the Republic of Congo . InfectGenet Evol 2006 6 : 337 343 .
- 75 . Sarrami-Brooshani R Das SR , Sabahi F, Adeli A Esmaeili R , Wahren B et al . Molecular analysis and phylogenetic characterization of HIV in Iran . JMed Virol 2006 78 : 853 863 .
- 76 . KhanS RaiMA KhananiMR KhanMN AliSH HIV1 subtype A infection in a community of intravenous drug users in Pakistan . BMCInfect Dis 2006 6 : 164 .
- 77 .CiccozziM GoriC BorosS Ruiz-Álarez MJ HarxhiA DervishiM etal .Moleculardiversity of HIV in Albania. JInfect Dis 2005 192 : 475 479 .
- 78. Praskevis D MagiorkinisE KatsoulidouA HatzitheodorouE AntoniadouA Papadopoulos A et al. Prevalence of resistance-associated mutations in ne wly diagnosed HIV-1 patients in Greece. Virus Res 2005 ;112 : 115 – 122.
- 79 . Thomson MM ,Casado G ,Posada D ,Sierra M ,Nájera R Identification of a no vel HIV-1 complex circulating recombinant form (CRF18_cpx) of Central African origin in Cuba AIDS 2005 19 : 1155 1163 .
- 80. PérezL ThomsonMM BledaMJ AragonésC GonzálezZ Pérezl etal .HIVType 1 molecular epidemiology in cuba: high genetic diversity, frequent mosaicism, and recent expansion of BG intersubtype recombinant forms. AIDSRes Hum Retroviruses 2006 22 : 724 – 733.
- 81 . SubbaraoS Minichseni S HuDJ KitayapornD Choopana K Rakham S etal .Geneticcharacterization of incident HIV type 1 subtype E and B strains from a prospective cohort of injecting drug users in Bangkok, Thailand . AIDSRes Hum Retroviruses 2000 16:699 – 707.
- 82 . Motomura K , Kasagawa S , Lwin HH , Thwe M , Kato K , Oishi K et al . Diferent subtype distributions in two cities in Myanmar: evidence for independent clusters of HIV-1 transmission . AIDS 2003 ;17 : 633 636 .
- 83. Ying R XiaX Jásagawa S ZhangC BenK Jakebe Y On-going generation of multiple forms of HIV-1 intersubtype recombinants in the Y unnan Province of China. AIDS 2002; 16: 1401 – 1407.
- 84 . Te KK LiXJ NohtomiK NgKP, Kamarulzaman A Akebe Y Identification of a no vel circulating recombinant form (CRF33_01B) disseminating widely among v arious risk populations in Kuala Lumpur, Malaysia . JAcquir Immune Defic Syndr 2006 43 : 523 – 529 .

- 85 .SuB LiuL Wang F, GuiX ZhaoM Jen P et al HIV-1 subtype B' dictates the AIDS epidemic among paid blood donors in the Henan and Hubei provinces of China. AIDS 2003; 17 : 2515 2520.
- 86 .KangMR ChoYK ChunJ KimYB LeeI LeeHJ etal. Phylogenetic analysis of the nef gene reveals a distinctive monophyletic clade in Korean HIV-1 cases. J Acquir Immune Defic Syndr Hum Retrovirol 1998 \$7 : 58 – 68.
- 87 .Bello G ,EyesSilva WA , Couto-Fernandez JC ,Guimaraes ML ,ChequesFernandez SL ,
 Tixeira SL etal .Demographichistory of HIV-1 subtypes B and F in Brazil . InfectGenet Evol 2007 7 : 263 270 .
- 88 .Mogado MG , Sabino EC , Shpaer EG , Bongertz V, Brigido L , Guimaæs MD et al .V3 region polymorphisms in HIV-1 from Brazil: prevalence of subtype B strains divergent from North American/European prototype and detection of subtype FAIDS Res Hum Retroviruses 1994 10 : 569 576 .
- 89 .Peeters M ,Esu-Williams E ,Vrgne L ,Montwon C ,Mulanga-Kabya C ,Harry T et al . Predominance of subtype A and G HIV type 1 in Nigeria, with geographical dif ferences in their distribution . AIDSRes Hum Retroviruses 2000 ;16 : 315 – 325 .
- 90 .Estæs A Arreira R , Arnenno T, Franco M Piedade J ,Germanod S et al .Molecular epidemiology of HIV type 1 infection in Portugal: high prevalence of non-B subtypes. AIDS Res Hum Retroviruses 2002 ;18 : 313 325 .
- 91 .Estæs A ærreira R Piedade J ærnenno T, Franco M Germano dS et al .Spreading of HIV-1 subtype G and envB/gagG recombinant strains among injecting drug users in Lisbon, Portugal . AIDSRes Hum Retroviruses 2003 $\ddagger9:511-517$.
- 92 .ThomsonMM DelgadoE ManjonN OcampoA Mahermosa ML Maino A etal .HIV1 genetic diversity in Galicia Spain: BG intersubtype recombinant viruses circulating among injecting drug users . AIDS 2001 15 : 509 516 .
- 93 .Delgado E ,Thomson MM ,Vlahermosa ML ,Sierra M ,Ocampo A ,Mialles C et al . Identification of a newly characterized HIV-1 BG intersubtype circulating recombinant form in Galicia, Spain, which exhibits a pseudotype-like virion structure. J Acquir Immune Defic Syndr 2002 29 : 536 – 543 .
- 94. Wal N, Kyalta D, Richard V, Lechiche C, Ndinaromtan T, Djimsngar A et al. High genetic diversity of HIV-1 strains in Chad, W est Central Africa. J Acquir Immune Def ic Syndr 2003 33 : 239 – 246.
- 95. M XF, ChenJ ShaoY, Berer C LiuB Wang Z etal. Emerging HIV infections with distinct subtypes of HIV-1 infection among injection drug users from geographically separate locations in Guangxi Province, China. JAcquir Immune Defic Syndr 1999 22: 180 – 188.
- 96 .ZhangY, LuL BaL LiuL Xng L JiaM etal Dominance of HIV-1 subtype CRF01_AE in sexually acquired cases leads to a new epidemic in Yunnan province of China. PLoS Med 2006 3 : e443.
- 97 .LiitsolaK RistolaM HolmstromP, SalminenM BrummerKorvenkontio H, SimolaS etal . An outbreak of the circulating recombinant form AECM240 HIV -1 in the Finnish injection drug user population . AIDS 2000 14 : 2613 – 2615 .
- 98 .Nyambi P, Hændrickx L, Wreecken K, Burda S, DeHouwer K, Coppns S et al. Predominance of infection with HIV -1 circulating recombinant form CRF02_A G in major Cameroonian cities and towns. AIDS 2002 16 : 295 – 296.
- 99 . OrtizM SánchezI GonzálezMP, LeónMI AbesoN AsumuE etal .Molecularepidemiology of HIV type 1 subtypes in Equatorial Guinea . AIDSRes Hum Retroviruses 2001 ;17 : 851 – 855 .
- 100 .Peeters M Joure-Kane C Nangasong JN Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials . AIDS 2003 17 : 2547 - 2560 .
- 101 .Rousseau CM ,Learn GH ,Bhattacharya T, Nickle DC ,Heckrman D Chetty S et al . Extensive intrasubtype recombination in South african human immunodeficiency virus type 1 subtype C infections . JVirol 2007 81 : 4492 – 4500 .
- 102 . Att ID ,Barlaw KL ,Chevley JP, GillON ,Arry JV Surveillance of HIV-1 subtypes among heterosexuals in England and W ales, 1997–2000. J Acquir Immune Def ic Syndr 2004; 36 : 1092 – 1099 .

- 103 .FleuryH Recordon-PinsonP, CaumontA Fure M RoquesP, Platier JC etal .HIVtype 1 diversity in France, 1999–2001: molecular characterization of non-B HIV type 1 subtypes and potential impact on susceptibility to antiretro viral drugs. AIDS Res Hum Retro viruses 2003 ;19 : 41 - 47 .
- 104 .SnoeckJ & Laethem K HermansP, & Wijngaerden E DerdelinckxI, SchrootenY et al. Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983–2001. J Acquir Immune Defic Syndr 2004 35 : 279 285.
- 105 .Montano MA Noitsky VA, Blackard JT, Cho NL Katzenstein DA, Esex M Divergent transcriptional regulation among expanding human immunodeficiency virus type 1 subtypes. JVirol 1997 71: 8657 – 8665.
- 106 .Montano MA ,Nixon CP, Esse M Dysregulation through the NF-kappaB enhancer and TATA box of the human immunodef iciency virus type 1 subtype E promoter . J Virol 1998; 72 : 8446 – 8452 .
- 107 .MontanoMA NixonCP, Ndung'uT, BussmannH Nøitsky VA, Dickman D etal .Elevated tumor necrosis factor-alpha activation of human immunodeficiency virus type 1 subtype C in Southern Africa is associated with an NF-kappaB enhancer gain-of-function. J Infect Dis 2000 181 : 76 - 81.
- 108 .Quiy V, AdamE ColletteY, DemonteD ChariotA Mnhulle C etal .Synegistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the de velopment of therapeutic strate gies. J Virol 2002 76 : 11091 – 11103 .
- 109 .LemieuxAM Rre ME AudetB Lgault E LefortS BoucheN etal .Tcell activation leads to poor activation of the HIV-1 clade E long terminal repeat and weak association of nuclear factor-kappaB and NFAT with its enhancer region .JBiol Chem 2004 279 : 52949 52960 .
- 110 .Jeeninga RE ,Hoogenkamp M ,Armand-Ugon M ,deBaar M ,Irhoef K Berkhout B Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G. JVirol 2000 74 : 3740 3751 .
- 111 .am Opijnen T, JeeningaRE BoerlijstMC PollakisGP, Zetterbeg V SalminenM etal. Human immunodeficiency virus type 1 subtypes ha ve a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner. J Virol 2004; 78 : 3675 - 3683.
- 112 . Wrhoef K Sanders W, Entaine V, KitajimaS BerkhoutB Evolution of the human immunodeficiency virus type 1 long terminal repeat promoter by con version of an NF-kappaB enhancer element into a GABP binding site . JVirol 1999 73 : 1331 – 1340 .
- 113 .RoofP, RicciM GeninP, MontanoMA Esse M Wainberg MA etal. Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the T at transactivator. Virology 2002 296 : 77 – 83 .
- 114 .MooreJP, KitchenSG PugachP, ZackA TheCCR5 and CXCR4 coreceptors—central to understanding the transmission and pathogenesis of human immunodef iciency virus type 1 infection . AIDSRes Hum Retroviruses 2004 20 : 111 126 .
- 115 . Tresmette M deGoede RE AlBJ While IN GrutersRA CuypersHT etal .Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodef iciency syndrome (AIDS) and AIDS-related complex . JVirol 1988 62 : 2026 2032 .
- 116 .ZhangL HuangY, HeT, CaoY, HoDD HIV1 subtype and second-receptor use . Nature 1996 383 : 768 .
- 117 .PeetersM Micent R PerretJL Lask M Petrel D Ligeois F etal .Evidencefor differences in MT2 cell tropism according to genetic subtypes of HIV -1: syncytium-inducing variants seem rare among subtype C HIV -1 viruses. J Acquir Immune Defic Syndr Hum Retro virol 1999 20 : 115 - 121 .
- 118 .TscherningC AlaeusA FredrikssonR BjorndalA DengH Littnan DR etal .Diferences in chemokine coreceptor usage between genetic subtypes of HIV-1. Vtrology 1998 ; 241 : 181 – 188 .

- 119 .AbebeA DemissieD GoudsmitJ BrouwerM Kiken CL PollakisG etal .HIV1 subtype C syncytium- and non-sync ytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS . AIDS 1999 \$3 : 1305 - 1311 .
- 120 .PingLH NelsonA , Hoffman IF, SchockJ LamersSL GoodmanM etal .Characterization of V3 sequence heterogeneity in subtype C human immunodef iciency virus type 1 isolates from Malawi: underrepresentation of X4 variants . JVirol 1999 73 : 6271 – 6281 .
- 121 .Cecilia D , Kulkarni SS , Tipathy SP, Gangakhedkar RR , Paranjape RS, Gadkari DA . Absence of coreceptor switch with disease progression in human immunodef iciency virus infections in India . Virology 2000 271 : 253 – 258 .
- 122 .JohnstonER ZijenahLS Mutetwa S KantorR Kittinumorakoon C KatzensteinDA High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients recei ving antiretroviral treatment. J Virol 2003; 77 : 7682 – 7688 .
- 123 .MonteiroJP, FerraroGA Olieira T, Goldani LZ KashimaS Alantara LC etal .Genetic and biologic characterization of HIV type 1 subtype C isolates from south Brazil. AIDS Res Hum Retroviruses 2007 23 : 135 – 143 .
- 124 .Pérez-Álærez L DelgadoE , Mlahermosa ML Cueas MT, GarcíaV, Vázquezde Parga et al. Biological characteristics of ne wly described HIV-1 BG recombinants in Spanish individuals . AIDS 2002 ;16 : 669 – 672 .
- 125 . W XF, Wing Z Bører C CelentanoDD KhamboonruangC AllenE etal .Phenotypicand genotypic characteristics of human immunodeficiency virus type 1 from patients with AIDS in northern Thailand . JVirol 1995 69 : 4649 4655 .
- 126 .KatoK SatoH Akebe Y Roleof naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism. JVirol 1999 73 : 5520 – 5526 .
- 127 .Holm-HansenC BaanE AsjoB Rscu FR GoudsmitJ Delong JJ Determinantsfor the syncytium-inducing phenotype of HIV-1 subtype F isolates are located in the V3 re gion. AIDSRes Hum Retroviruses 2000 16 : 867 - 870.
- 128 .JensenMA CoetzerM sm't Wout AB MorrisL MullinsJI Areliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol 2006 80 : 4698 – 4704 .
- 129 . CoetzerM CilliersT, PingLH Swinstrom R MorrisL Geneticcharacteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates . Virology 2006 356 : 95 – 105 .
- 130 . Puashvili MN Nookhatsky AS ,Shcherbalova TI Characteristics of HIV-1 env V3 loop sequences for subtype A1 variant spread in Eastern Europe . InfectGenet Evol 2005 5 : 45 53 .
- 131 .DesfossesY, SolisM SunQ Grandaux N In Lint C Burn A etal .Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins. J Virol 2005; 79 : 9180 - 9191 .
- 132 . Kirosu T, MukaiT, Kimoto S JbrahimMS LiYG Kayashi T etal .Humanimmunodeficiency virus type 1 subtype C e xhibits higher transactivation activity of Tat than subtypes B and E. MicrobioIImmunol 2002 46 : 787 - 799 .
- 133 . RanjbarS RajsbaumR GoldfeldAE Transactivator of transcription from HIV type 1 subtype E selectively inhibits TNF gene expression via interference with chromatin remodeling of the TNF locus. JImmunol 2006 ;176 : 4182 - 4190 .
- 134 .Buonaguro L ,Barillari G ,Chang HK ,Bohan CA ,Kao V, Mogan R et al .Effects of the human immunodeficiency virus type 1 T at protein on the expression of inflammatory cytokines. JVirol 1992 66 : 7159 – 7167 .
- 135 .Ranjbar S ,Tsytsykva AV , Lee SK ,Rajsbaum R ,Felvo JV, Liebernan J et al .NFAT5 Regulates HIV-1 in Primary Monocytes via a Highly Conserved Long Terminal Repeat Site. PLoSPathog 2006 2 : e130 .
- 136 .ConantK Garzino-DemoA NathA McArthurJC HallidayW, Pwer C etal .Induction of monocyte chemoattractant protein-1 in HIV -1 Tat-stimulated astrocytes and ele vation in AIDS dementia . ProcNatl Acad Sci U S A 1998 95 : 3117 – 3121 .

- 137 . Wriss JM , Nath A , Major EO , Berman JW , HIV1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes. JImmunol 1999 ;163 : 2953 – 2959 .
- 138 .Pu H , Jan J , Flora G , Lee YW, Nath A , Hennig B et al . HIV1 Tat protein upregulates inflammatory mediators and induces monoc yte invasion into the brain . Mol Cell Neurosci 2003 24 : 224 – 237 .
- 139 .RangaU ShankarappaR SiddappaNB RamakrishnaL NagendranR Mahalingam M et al. Tat protein of human immunodef iciency virus type 1 subtype C strains is a defective chemokine. JVirol 2004 78 : 2586 2590.
- 140 .CampbellGR Watkins JD SinghKK LoretEP, SpectorSA Thehuman immunodeficiency virus type 1 subtype C T at fails to induce intracellular calcium flux and induces reduced tumor necrosis factor production from monocytes. JVirol 2007 81 : 5919 – 5928.
- 141 .SatishchandraP, NaliniA Gourie-Dei M KhannaN Santosh V Ravi V etal .Profile of neurologic disorders associated with HIV/AIDS from Bangalore, south India (1989–96) .
 IndianJ Med Res 2000 111 : 14 23 .
- 142 . Walia RS Pujari SN Kathari S Udhar M Kalkarni S BhagatS et al . Neurological manifestations of HIV disease . JAssoc Physicians India 2001 49 : 343 348 .
- 143 .Deshpande AK , R MM Nonopportunistic neurologic manifestations of the human immunodeficiency virus: an Indian study . MedGenMed 2005 7 : 2 .
- 144. Yepthomi T, Rul R, Malabhaneni S, Kamarasamy N, Ate DF, Solmon S et al. Neurocognitive consequences of HIV in southern India: a preliminary study of clade C virus JInt Neuropsychol Soc 2006 ;12 : 424 - 430.
- 145 .RiedelD GhateM NeneM Pranjape R MehendaleS BollingerR et al .Screening for human immunodeficiency virus (HIV) dementia in an HIV clade C-infected population in India . JNeurovirol 2006 12 : 34 – 38 .
- 146 .ModiG HariK ModiM MochanA Thefrequency and profile of neurology in black South African HIV infected (clade C) patients – a hospital-based prospecti ve audit. J Neurol Sci 2007 254 : 60 – 64 .
- 147 .Ball SC ,Abraha A ,Collins KR ,Marozsan AJ ,Baird H ,Quiñones-Mateu ME et al . Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. JVirol 2003 77 : 1021 – 1038 .
- 148 .ArienKK AbrahaA Quiñones-MateuME Kestens L Maham G Art EJ Thereplicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates . JVirol 2005 79 : 8979 – 8990 .
- 149 . Vsan A RenjifoB HertzmarkE ChaplinB MsamangaG Esse M etal .Different rates of disease progression of HIV type 1 infection in T anzania based on infecting subtype . ClinInfect Dis 2006 42 : 843 – 852 .
- 150 .Glynn JR Sonnenber P, Nelson G Bester A Shearer S Murray J Survival from HIV-1 seroconversion in Southern Africa: a retrospective cohort study in nearly 2000 gold-miners over 10 years of follow-up. AIDS 2007 21: 625 – 632.
- 151 . Knings FA, BurdaST, UrbanskiMM ZhongP, NadasA NyambPN Humanimmunodeficiency virus type 1 (HIV-1) circulating recombinant form 02_A G (CRF02_AG) has a higher in vitro replicative capacity than its parental subtypes A and G . J Med Virol 2006 ; 78 : 523 - 534 .
- 152 . NjaiHF, GaliY, Ynham G Clyberth C JennesW, Ydal N etal .Thepredominance of Human Immunodeficiency Virus type 1 (HIV -1) circulating recombinant form 02 (CRF02_A G) in West Central Africa may be related to its replicative fitness . Retrovirology 2006 3 : 40 .
- 153 .Rink de Wit TF, Tsgaye A Wolday D HailuB AkliluM Sander E etal .PrimaryHIV-1 subtype C infection in Ethiopia . JAcquir Immune Defic Syndr 2002 30 : 463 – 470 .
- 154 . Gray CM , Wiliamson C , Bredell H , Puren A , Xia X , Filter R et al . Viral dynamics and CD4 + T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa . AIDSRes Hum Retroviruses 2005 21 : 285 291 .
- 155 . HuDJ ¥nichseni S MastroTD RakthamS ¥ung NL MockPA etal. Viral load differences in early infection with two HIV-1 subtypes . AIDS 2001 15 : 683 691 .

- 156 .Kiela PS KrolA SalminenMO GeskusRB SuniJI AnttilaVJ etal .Highplasma HIV load in the CRF01-AE outbreak among injecting drug users in Finland . Scand J Infect Dis 2005 37 : 276 – 283 .
- 157 .FischettiL Opare-SemO CandottiD LeeH AllainJP Higherviral load may explain the dominance of CRF02_AG in the molecular epidemiology of HIV in Ghana . AIDS 2004; 18 : 1208 - 1210 .
- 158 .SarrAD EisenG Guye-Ndiaye A MullinsC Taore I DiaMC etal .Vral dynamics of primary HIV-1 infection in Senegal, West Africa . JInfect Dis 2005 191 : 1460 – 1467 .
- 159 .Marlink R Kanki P, Thior I Tavers K Eisen G Siby T et al .Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994 265 : 1587 1590 .
- 160 .PopperSJ SarrAD Tavers KU Guge-Ndiaye A MboupS Esse ME etal .Lower human immunodeficiency virus (HIV) type 2 viral load reflects the dif ference in pathogenicity of HIV-1 and HIV-2. JInfect Dis 1999 ;180 : 1116 – 1121 .
- 161 .AnderssonS Norgren H daSilva Z BiagueA BambaS Kwk S etal .Plasmaviral load in HIV-1 and HIV-2 singly and dually infected indi viduals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV -2 infection than in HIV -1 infection. ArchIntern Med 2000 160 : 3286 - 3293 .
- 162 .AlaeusA LidmanK BjorkmanA Gieseck J AlbertJ Similarrate of disease progression among individuals infected with HIV-1 genetic subtypes A-D. AIDS 1999 13 : 901 – 907.
- 163 . DeAmo J Petruckvitch A PhillipsA JohnsonAM StephensonJ DesmondN etal .Disease progression and survival in HIV-1-infected Africans in London . AIDS 1998 ;12 : 1203 1209 .
- 164 .GalaiN Kalinkwich A BursteinR ,Vlaho D BentwichZ African HIV-1 subtype C and rate of progression among Ethiopian immigrants in Israel . Lancet 1997 349 : 180 181 .
- 165 .KankiPJ HamelDJ SankaleJL HsiehC ThiorI BarinF etal .Humanimmunodeficiency virus type 1 subtypes differ in disease progression . JInfect Dis 1999 179 : 68 73 .
- 166 .LaurentC Bougeois A Feye MA MougnutouR Sydi M Guye M etal .Nodifference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02_AG strain and patients not infected with CRF02_AG, in Western and West-Central Africa: a four-year prospective multicenter study. JInfect Dis 2002 186 : 486 - 492 .
- 167 .Kaleeb P, FrenchN MaheC Mrrell D Matera C Magoba F etal .Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a lage cohort of HIV-1-positive persons in Uganda . JInfect Dis 2002 185 : 1244 – 1250 .
- 168. Kiwanuka N, Laeyendecker O, Robb M, Kigozi G, Arro yo M, McCutchan F et al. Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV -1 infection. J Infect Dis 2008; 197:707–713.
- 169 .BaetenJM ChohanB Lareys L ChohanV, McClellandRS Certai L etal .HIV1 Subtype D Infection Is Associated with Faster Disease Progression than Subtype A in Spite of Similar Plasma HIV-1 Loads . JInfect Dis 2007 ;195 : 1177 – 1180 .
- 170. Kaleeb P, Nanka IL, Yrrell DL, Shafer LA, Kjosiimire-Lugemwa J, Lule DB et al. Relation between chemokine receptor use, disease stage, and HIV -1 Subtypes A and D: results from a rural Ugandan Cohort. JAcquir Immune Defic Syndr 2007 45 : 28 – 33.
- 171 .EshlemanSH GuayLA FlemingT, Mwtha A MracnaM Beckr-Pergola G etal .Survival of Ugandan infants with subtype A and D HIV-1 infection (HIVNET 012). J Acquir Immune Defic Syndr 2002 31 : 327 – 330 .
- 172 .Santoro-LopesG HarrisonLH Tavares MD Xxeo A DosSantos AC, SchechterM HIV disease progression and V3 serotypes in Brazil: is B dif ferent from B-Br? AIDS Res Hum Retroviruses 2000 16: 953 958.
- 173 .CassebJ Kamninakis S AbdallaL BrigidoLF, RodriguesR Arajo F etal .HIVdisease progression: is the Brazilian v ariant subtype B' (GWGR motif) less pathogenic than US/European subtype B (GPGR) . IntJ Infect Dis 2002 6 : 164 – 169 .
- 174 .dBrito A Kamninakis SC Nooa P, deOliveira RM Enseca LA Duarte AJ etal .Women infected with HIV type 1 Brazilian v ariant, subtype B (B'-GWGR motif) ha ve slower

progression to AIDS, compared with patients infected with subtype B (B-GPGR motif) . ClinInfect Dis 2006 43 : 1476 - 1481 .

- 175 .Kanki PJ , Tavers KU , Mboup S , Hsieh CC , Marlink RG , Guye-Ndiaye A et al .Slover heterosexual spread of HIV-2 than HIV-1 . Lancet 1994 343 : 943 946 .
- 176 .GilbertPB McKague IW, EisenG MullinsC Guge-Ndiaye A Mbup S etal .Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Stat Med 2003; 22 : 573 - 593 .
- 177 .Adjorlolo-JohnsonG DeCock KM EkpiniE Miter KM SibaillyT, Brattgaard K et al . Prospective comparison of mother -to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. AMA 1994 272 : 462 – 466 .
- 178. O'Donnan D AriyoshiK MilliganP, OtaM Yamuah L Sage-Njie R etal .Maternalplasma viral RNA levels determine marked differences in mother-to-child transmission rates of HIV-1 and HIV-2 in The Gambia. MRC/Gambia Go vernment/University College London Medical School working group on mother-child transmission of HIV. AIDS 2000 14 : 441 448.
- 179 .Mastro TD ,Satten GA ,Nopksorn T, Sangkharomya S ,Longini IM ,Jr .Probability of female-to-male transmission of HIV-1 in Thailand . Lancet 1994 343 : 204 207 .
- 180 .NelsonKE RungruengthanakitK Magolick J SuriyanonV, NiyomthaiS, deBoer MA et al. High rates of transmission of subtype E human immunodeficiency virus type 1 among heterosexual couples in Northern Thailand: role of sexually transmitted diseases and immune compromise. JInfect Dis 1999 180 : 337 343.
- 181 .MastroTD Mcenzi, I. deProbabilities f sexual HIV-1 transmission . AIDS 1996 10 Suppl A: S75 – S82 .
- 182 .Soto-RamírezLE Renjifo B McLane MF, Marlink R O'HaraC Suthent R et al .HIV1 Langerhans' cell tropism associated with heterose xual transmission of HIV. Science 1996; 271 : 1291 – 1293 .
- 183 .PopeM Frankl SS MascolaJR Tkola A IsdellF, BirxDL etal .Humanimmunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism. JVirol 1997 71 : 8001 – 8007.
- 184 .DittmarMT, Simmons G, Hibbitts S, O'Hare M, Louisirirotchanakul S, Beddws S et al . Langerhans cell tropism of human immunodef iciency virus type 1 subtype A through F isolates derived from different transmission groups. JVirol 1997 71: 8008 – 8013.
- 185 .GrayRH Waver MJ Brookmyer R Swankambo NK Serwadda D Wabwire-Mangen F et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1discordant couples in Rakai, Uganda . Lancet 2001 357 : 1149 – 1153 .
- 186 .John-Stevart GC NduatiRW, RousseauCM Mbori-NgachaDA, RichardsonBA, Rainweter S etal .SubtypeC Is associated with increased vaginal shedding of HIV-1. JInfect Dis 2005; 192: 492 - 496.
- 187 .HudgensMG LonginiIM Jr, Ynichseni S HuDJ KitayapornD MockPA etal .Subtypespecific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand . AmJ Epidemiol 2002 ;155 : 159 – 168 .
- 188 . Ying C LiM Novman RD ShiYP, Asisi J yn Eijk AMet al .Geneticdiversity of HIV-1 in western Kenya: subtype-specific differences in mother-to-child transmission . AIDS 2003 ; 17 : 1667 – 1674 .
- 189 .Murray MC ,Embree JE ,Ramdahin SG ,Anzala AO , Njenga S ,Plummer A .Efect of human immunodeficiency virus (HIV) type 1 viral genotype on mother-to-child transmission of HIV-1 . JInfect Dis 2000 ;181 : 746 – 749 .
- 190 .RenjifoB Fwzi W, Mwkagile D HunterD MsamangaG Spigelman D etal .Diferences in perinatal transmission among human immunodef iciency virus type 1 genotypes . J Hum Virol 2001 4 : 16 – 25 .
- 191 .BlackardJT, RenjifoB Jrwzi W, HertzmarkE MsamangaG Mwakagile D et al .HIV1 LTR subtype and perinatal transmission . Virology 2001 287 : 261 265 .
- 192 .Martinez AM ,Hora VP, Santos AL ,Mendoza-Sassi R , Im Groll A Soares EA et al . Determinants of HIV-1 mother-to-child transmission in Southern Brazil . An Acad Bras Cienc 2006 78 : 113 – 121 .

- 193 . Tapia N Francos Puig-BasagoitiF, MenendezC AlonsoPL MsInda H et al . Influence of human immunodeficiency virus type 1 subtype on mother-to-child transmission. JGen Virol 2003 84 : 607 - 613 .
- 194 .FischettiL DansoK DomprehA AddoV, HaaheimL AllainJP Vertical transmission of HIV in Ghanaian women diagnosed in cord blood and post-natal samples. J Med Virol 2005; 77 : 351 – 359 .
- 195 .Renjifo B ,Chung M ,Gilbert P, Mwkagile D ,Msamanga G ,Fwzi W et al .In-utero transmission of quasispecies among human immunodef iciency virus type 1 genotypes . Vrology 2003 307 : 278 – 282 .
- 196 . Kulinska IN Mamor E MsamangaG Fwzi W, BlackardJ Renifo B etal .Riskof HIV-1 transmission by breastfeeding among mothers infected with recombinant and non-recombinant HIV-1 genotypes . Vrus Res 2006 ;120 : 191 – 198 .
- 197 . Favers SA , Clevley JP, Glynn JR , Fine PE , Crampin AC , Sibande F et al . Timing and reconstruction of the most recent common ancestor of the subtype C clade of human immunodeficiency virus type 1. JVirol 2004 78 : 10501 10506 .
- 198 .Fiore JR Zhang YJ Bjorndal A Distefano M Angarano G Istore G et al .Biological correlates of HIV-1 heterosexual transmission . AIDS 1997 ;11 : 1089 1094 .
- 199 .SterlingTR Vlahø D AstemborskiJ Hover DR Magolick JB Quinn TC Initialplasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001 ; 344 : 720 - 725 .
- 200 .GeldmacherC CurrierJR GerhardtM HauleA Mabob L BirxD etal . Ina mixed subtype epidemic, the HIV-1 Gag-specific T-cell response is biased to wards the infecting subtype . AIDS 2007 21 : 135 – 143 .
- 201 .McKinnonLR BallTB KimaniJ Wichihi C MatuL LuoM etal .Cross-cladeCD8(+) T-cell responses with a preference for the predominant circulating clade . J Acquir Immune Defic Syndr 2005 40 : 245 – 249 .
- 202 .CoplanPM GuptaSB Duby SA PitisuttithumP, NikasA Mbwe B etal .Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV -1 clades in HIV-1-positive individuals from 4 continents . JInfect Dis 2005 191 : 1427 – 1434 .
- 203 . Binly JM WrinT, Korber B ZwickMB Wing M Chappy C etal .Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies . JVirol 2004 78 : 13232 – 13252 .

Opportunistic Infections in the Brain in Developing Countries

Marcus Tulius T. Silva and Beatriz Grinsztejn

Introduction

Since the early stages of AIDS epidemic in the de veloped world, it has been reported that the nerv ous system is af fected both directly and indirectly by HIV infection (1). Health professionals involved in HIV care recognize that at least one-third of patients with adv anced AIDS have some neurologic impairment, and almost 50% will present one or more neurologic complication during the course of HIV disease (2, 3). Several autopsy studies in HIV population show that more than 80% of patients have some nervous system disease (4).

Although less reported in the initial phase of the HIV epidemic, neurologic complications in AIDS patients from developing countries are also quite common. Globally, 40 million individuals are living with HIV in the w orld, 24.5 million of these in sub-Saharan Africa (www.who.int). From 1980 to June 2006, 433,000 AIDS patients were registered in the database of the Brazilian Ministry of Health (www.aids.gov.br). Unfortunately, the situation is not different in other developing countries, with an increasing number of HIV/AIDS cases each year . Considering that highly active antiretroviral therapy (HAART) access, diagnostic tools, and proper opportunistic infection treatment are not uniformlyavailable in poor countries, we can expect that neurologic diseases associated with HIV infection will ha ve a considerable social and economical impact in these areas.

It is clear that HIV disease is essentially the same in an y country, although the course of HIV-2 disease – seen in some places of Africa – appears to be associated with a slower disease progression and to be less severe than HIV-1 disease. However, regarding neurologic diseases associated with AIDS it is possible that some differences

M.T.T. Silva (🖂)

The Clinical Research Laboratory on Neuroinfection,

Evandro Chagas Clinical Research Institute, Oswaldo Cruz Foundation (FIOCRUZ), Avenida Brasil 4365, Rio de Janeiro, Brasil

marcustulius@ipec.fiocruz.br

between developed and developing countries exist. The prevalence and importance of some pathogens v ary considerably from the de veloping to the de veloped world, changing therefore the pattern of neurologic complications in these re gions. Neurotuberculosis, for example, is the most common neurologic complication associated with a focal brain lesion in some de veloping countries, while cerebral toxoplasmosis is the first one in the developed world. Chagas' diseases, malaria, and paracoccidioidomycosis are other e xamples of endemic diseases that could ha ve some impact upon neurologic manifestations of AIDS in specific places. These differences are of clinical importance, as people may migrate from poor endemic areas to developed countries, and also to proper management of brain lesions in patients from developing world. For example, it is belie ved that any focal brain lesion in patients with advanced AIDS is cerebral toxoplasmosis until proved otherwise. This could be true to the majority of countries from the de veloped and even from the developing world, but not to all (see below). If we strictly adhere to available guidelines from developed countries, a large number of patients from the developing world will be inappropriately managed. This chapter will discuss some infections in the brain and their management in AIDS patients from the developing world.

A Special Consideration in Limited-Resources Areas

Physicians from developing countries involved in HIV care frequently have difficulties to reach a confirmed diagnosis in patients presenting with neurologic syndromes. Unfortunately, an absolute lack of diagnostic tools is the rule in many countries. A recent medical management review done at a hospital in Uganda showed that physicians tended to perform lumbar puncture in patients with acute neurological dysfunction 2.5 days after admission (5). The main reasons for failure or for delayed lumbar puncture were the absolute lack of needles and bottles and limited working hours of the laboratory staff.

Clinical algorithms from developed countries include brain CT scan before lumbar puncture in all AIDS patients presenting with an acute neurological disease. If possible, it is a good practice to submit an y patient with probable focal brain lesion to a brain CT scan before lumbar puncture. However, a real difficulty in a normal workday of physicians from some limited-resources area is the lack of any brain imaging study. In some cases it may be difficult to differentiate a focal from a non-focal brain lesion caused by cerebral toxoplasmosis and tuberculous meningitis. F or instance, sometimes, cerebrospinal fluid (CSF) analysis is the only neurologic investigative tool available. The decision to not perform a lumbar puncture due to fear of complications in a patient with neurologic dysfunction associated with AIDS could result in delay of diagnosis and inadequate treatment. Even in the presence of a cerebral mass, uncal or tonsillar herniation leading to neurologic deterioration or death is quite uncommon. For example, in a series of 447 lumbar punctures performed on 401 patients with neoplasm, some complication was observed in only one (6). In a metanalysis including 418 patients with papilledema, complications due to lumbar puncture occurred in only

1.2% (7). When the presence of increased intracranial pressure is suspected, a bolus dose of mannitol (1 g/kg of body weight) can be given intravenously and lumbar puncture can be performed 20 min later (8). Performing a lumbar puncture without a previous CT scan in a resource limited setting could be more appropriable than treating patients empirically for two or more possible diseases.

Parasitic Infections

Toxoplasmosis

Toxoplasma gondii, the etiologic agent of toxoplasmosis, is an intracellular parasite for which the domestic cat, a fe w other mammals, and some ground-feeding birds are the primary hosts. Man, one of the alternative host, acquires infection most frequently by ingestion of both oocysts in contaminated food or water and bradyzoites in uncooked, contaminated meat. Primary infection is more often asymptomatic or results in a mononucleosis-lik e syndrome in immunocompetent indi viduals. Soon after primary infection, toxoplasmosis remains quiescent in any nucleated cell.

Antitoxoplasmic antibodies prevalence in both the general population and HIVinfected patients varies according to the re gion studied and reflects culinary and hygienic habits. It is estimated that in Latin America the seroprevalence approaches 70% in the general population (9). Seroepidemiological studies demonstrate prevalence of 80% in Iran (10), 19% in Turkey (11), 5.17% in China (12), and 0.79% among pregnant woman in Korean (13). Interestingly, 21% of children less than 5-years old in the Democratic Republic of Sao T ome and Principe were positi ve to anti-*T.gondii* (14). Regarding HIV-infected patients, the available studies show a prevalence of 71% in Brazil (15), 55% in Colombia (16), 54% in Uganda (17), 38% in Nigeria (18), 28% in Burkina Faso (19), and 10.2% in Taiwan (20).

Cerebral toxoplasmosis, one of the most common neurologic diseases in AIDS patients – even in some developing countries -, almost al ways result from recrudescence of latent infection acquired earlier in life. Its incidence is directly associated with the seroprevalence of anti-*T.gondii* in the general population. It is the most common cause of focal brain lesion in Brazil, being diagnosed in 25–68% of AIDS patients presenting some neurologic dysfunction (9, 21). Other papers from developing world about neurologic diseases among HIV-infected patients shows that cerebral toxoplasmosis is seen in 19% of cases in Republic of Cameron (22), 19% in Me xico (23), about 15% in the Western African (24), 12% in some parts of India (25), and in 4% of the children in Abidjan (26). It is expected that about one-third of HIV -infected people with past *T. gondii* infection develop cerebral toxoplasmosis. F or instance, 25% of HIV-infected patients in Brazil with positive anti-*T.gondii* antibodies developed cerebral toxoplasmosis during the course of HIV disease (15).

As in the developed world, headache, seizures, motor impairment, and deterioration of mental status e volving acute or subacutely are the main neurologic f indings.

Presumed diagnosis is based on a compatible clinical presentation, CD4+ count less than 100 cells/mm³, typical abnormalities on brain images, and presence of anti-*T. gondii* antibodies indicating past exposure.

The typical features on CT scan are hypodense, multiple ring-enhanced lesions with surrounding edema and mass effect (Fig. 1a). Ring-enhancement depends on the presence of reactive cells in the lesions. The lack of reactive cells and, consequently, of ring-enhancement is considered a marker of poor prognosis. Expansive lesions without contrast enhancement were seen in 16% of cerebral toxoplasmosis patients from Brazil, being associated with severe immunodepression and poor outcome (27). Unfortunately, MRI, which is more sensitive than CT scan, is not available in most developing countries as effortlessly as in developed countries.

Less than 6% of AIDS patients with cerebral toxoplasmosis had ne gative anti-*T.gondii* antibodies in a Brazilian series (27). However, in the developed world – where brain biopsy is a vailable more easily than in de veloping countries – 22% of patients with cerebral toxoplasmosis confirmed by biopsy had negative *T.gondii*-IgG antibodies (28). So, the absence of serum antibodies should not e xclude the




Fig. 1 (a) CT scan showing typical hypodense, ring-enhanced lesions of cerebral toxoplasmosis in right anterior limb of internal capsule and left thalamus; (b) CT scan showing cystic lesions of neurocysticercosis at cortical-subcortical junction with ring-enhancement. A nodular enhancement inside the cyst corresponding to the scolex is seen in two lesions (*arrows*); (c) axial gadoliniumenhanced T1-weighted MRI scan sho wing left parietal lesion with mild mass effect, perilesional edema, and ring-enhancement in AIDS patient with cerebral Chagas' disease (*Courtesy of Dr. Marcelo Corti, HIV/AIDS Division, Infectious Diseases F. J. Muñiz Hospital, Buenos Aires*); (d) gadolinium-enhanced T1-weighted MRI scan showing cryptococoma (*arrow*) and mild meningeal enhancement in a patient with cryptococcal meningitis; (e) axial gadolinium-enhanced T1-weighted MRI scan showing two contiguous lesions in right parietal lobe in a man with cerebral paracoccidioidomycosis; (f) CT scan showing gross meningeal enhancement in a patient with tuberculous meningitis; (g) coronal gadolinium-enhanced T1-weighted MRI scan showing a tuberculoma (*arrow*) and hydrocephalus in a AIDS patients with neurotuberculosis

diagnosis of cerebral toxoplasmosis in the conte xt of a typical clinical picture jointly with classical brain images. The lack of toxoplasmosis prophylaxis history is considered indicative of probable cerebral toxoplasmosis.

The main differential diagnosis of cerebral toxoplasmosis in some de veloping countries is neurotuberculosis, especially in endemic areas. In So weto, South Africa, neurotuberculosis was the final diagnosis in 69% of 32 consecuti ve HIV-infected patients with focal brain lesions (cerebral toxoplasmosis corresponded to only 3% of the cases) (29). Interesting, none of the patients were on prophylactic treatment for *Pneumocystis carinii* or toxoplasmosis. In Bangalore, India, 30% of patients with some neurologic disorder had neurotuberculosis, and only 4% of them had cerebral toxoplasmosis (30). The presence of basal meningeal enhancement on brain images, evidence of pulmonary tuberculosis on chest film, acid-fast bacilli on sputum microscopy, and typical CSF abnormalities (increased protein, decreased glucose, and pleocytosis) are indicative of neurotuberculosis. Other alternative differential diagnoses in an appropriated setting are Chagas' disease, neurocysticercosis, intracranial brain abscesses, and paracoccidioidomycosis.

Cerebral toxoplasmosis has considerable associated morbidity and mortality. In a recent series from Brazil, 13% of patients died in the sixth week of treatmen(27). Associated factors related to poor outcome were alteration of consciousness le vel, fever, multiple lesions on brain scan, CD4+ lymphoc ytes count less than 24%, Karnofsky scale less than 70, seizures, and atypical brain scan abnormalities.

Treatment should include p yrimethamine, sulfadiazine, and folinic acid. Pyrimethamine is administered orally in an initial loading dose of 200 mg followed by 50–75 mg/day, and sulfadiazine at 4–6 g/day divided in four doses. Folinic acid at 5–10 mg/day is needed to diminish bone marro w suppression. Some alterative drugs to sulfadiazine are clindamycin, azithromycin, and doxyc ycline. Secondary prophylaxis with trimethoprim–sulfamethoxazole must be maintained until CD4+ count rise up to 200 cells/mm³.

Cysticercosis

Neurocysticercosis is the most frequent helminthic infection of the central nervous system (CNS) and the commonest cause of acquired epilepsy in the w orld. It is caused by the enc ysted larva of the pork tape worm *Taenia solium*, which can remain latent for years in the brain parenchyma. Symptoms usually coincide with larval death and subsequent intense inflammatory reaction induced by larval antigens. Then, the cyst transforms into a granuloma that shrinks and e ventually calcifies or disappears completely.

Cysticercosis is endemic in de veloping countries of Latin America, Asia, and Africa. Cysticercosis occurs when humans act as intermediate hosts by accidental ingestion of *T. solium* eggs from food – mainly fruits and vegetables – contaminated with feces of human carriers of adult cestodes. The ingestion of c ysts present in uncooked, contaminated pork meat results in taeniasis, and not in c ysticercosis.

Although neurocysticercosis is not considered a classic neurologic opportunistic infection in AIDS patients, the increasing frequency of HIV infection in c vsticercosis endemic areas will render this coinfection to be more frequent. F or instance, neurocysticercosis has been associated with up to 27% of brain lesions in HIV infected individuals presenting with neurologic symptoms in South Africa (29).However. little is known about the influence of HIV infection on the frequency and clinical course of neurocysticercosis. It is unlikely that HIV infection increases the frequency of neurocysticercosis, but AIDS could potentially influence its clinical course. Theoretically, clearance of invasive larvae by immune response at an early stage of T. solium infection could be decreased in HIV-infected patients leading to a higher chance for cysticercosis development in HIV-positive compared with HIVnegative patients. Also, the symptoms of neuroc vsticercosis depend more on the host cell-mediated immune response than on the parasite itself (31). Hence, its clinical course could be dif ferent in an immunodepressed setting. It has been reported that giant cysts and racemose forms of neurocysticercosis are more frequent in HIV-infected patients than in HIV-negative patients (32–34). This could be due to an uncontrolled parasitic gro wth secondary to impaired cell-mediated immune response. Furthermore, cases of unusually se vere and disseminated c vsticercosis have been reported in patients with hematological malignancies (35). Together, these reports show that immunodepression alters the clinical course of neuroc ysticercosis. Another interesting and not yet studied issue is the influence of HAAR T on neurocysticercosis course. It cannot be excluded that neurocysticercosis can be paradoxically worsened during the immune reconstitution period (36).

Sometimes it is difficult to discriminate a focal brain lesion due to neurocysticercosis from cerebral toxoplasmosis or even neurotuberculosis, the main differential diagnosis (Fig. 1a, b). An additional practical challenge is that approximately one-third of patients with neurocysticercosis and HIV infection could present with at least one other neurologic infection at the same time (36). The clinical manifestations of neurocysticercosis depends not only on the number , size, and location of the brain lesions but also on the intensity of the host immune response(31). Typically, symptoms begin years after initial infection, when host inflammatory response de velops against T. solium antigens released after the death of the parasite. Seizures are by far the most common neurologic manifestation, but others symptoms such as headache, motor deficits, and ataxia may be present. Recently, a review showed that 27 cases of neurocysticercosis in HIV-infected patient were reported in the literature. The most frequent presentation was multiple parenchymal lesions (enhanced or nonenhanced cysts), seen in 61% of cases. Other presentations included single parenchymal lesions (17% of cases), atypical forms such as a giant brain cyst and spinal epidural lesion (9%), and mixed forms (parenchymal, subarachnoidal, and ventricular, corresponding to 13% of cases). In 30% of patients another concomitant cerebral infec tion was diagnosed (36).

Definitive diagnosis is made if (1) there is histopathologic e vidence of neurocysticercosis (brain biopsy is not al ways available in developing world), or (2) a scolex within a cystic lesion is visible on brain CT or MRI (the last one is more sensitive but almost never available in poor countries), or (3) a suggestive lesion of neurocysticercosis or a clinical response to treatment is added to serologic evidence of *T. solium* infection by CSF ELISA (37). In a series, more than one-half of patients had a positive cysticercal serology, which underscores its importance for the noninvasive diagnosis of the infection (36). However, 50% of patients with solitary parenchymal lesions are serone gative. This is especially problematic in India, where the majority of patients have single enhancing lesions (37), neurocysticercosis is endemic, and where neurotuberculosis is one of the most common neurologic manifestations in AIDS patients. Imaging and clinical features of cerebral tuberculoma are sometimes very similar to that of neuroc ysticercosis and it is quite dif ficult to differentiate one from the other. Moreover, because of the high prevalence of both conditions, the presence of these two disorders can occur in the same patient. Generally, neurocysticercosis lesions are usually round in shape, 20 mm or less in size, with ring-enhancement or visible scole x (Fig. 1b), and cerebral edema is severe enough to produce midline shift. Neurologic defcits are not seen in all cases. Cerebral tuberculoma is usually irre gular, solid and greater than 20 mm in size, often associated with severe perilesional edema and a focal neurologic deficit (38). Another important differential diagnosis is cerebral toxoplasmosis, which preferably involves subcortical structures as thalamus, basal ganglia, and cerebellum, while in neurocysticercosis the lesions are characteristically located at the cortical-subcortical interface.

Treatment of neurocysticercosis can be done with albendazole (15 mg/kg/day for 7–21 days) or praziquantel (50 mg/kg/day for 14 days). Steroids can be used in some cases to prevent neurologic complications produced by edema follo wing the antigens' exposure after the c ysticercus's death. The response rate to c ysticidal therapy in HIV patients is about 85%, similar to that reported in the literature for the general population (36).

Malaria

As with neurocysticercosis, malaria is not an opportunistic infection b ut will be briefly discussed here because there is e vidence that HIV infection has a negative impact on its natural history, which could predispose HIV-infected patients to cerebral malaria.

The intracellular protozoan *Plasmodium sp.* is the etiologic agent of malaria, being transmitted to mammalians by the female of *Anopheles* mosquito. Any of the *Plasmodium* species can cause malaria (*P. falciparum*, *P. ovale*, *P. vivax*, and *P. malariae*) but most severe cases, as cerebral malaria, are associated with *P. falciparum*.

The importance of HIV–malaria coinfection is ob vious since almost 90% of the annual 300 million infections tak e place in sub-Saharan Africa, where about 24 million people are living with HIV today (39). Other possible convergence zones for HIV and *Plasmodium sp* are located mainly in Haiti and Latin America, e ven though in this last one *P. vivax* is more common. Although seminal papers did not

find any association (40), recent reports ha ve demonstrated that the course of malaria can be altered by HIV infection and *vice-versa*. This is particularly true to pregnant women and patients with advanced AIDS. HIV-infected patients have 2.3 more chance for severe malaria, as cerebral malaria, and 7.5 more chance for f atal outcome than HIV-negative patient (41). Other reports have also demonstrated that clinical severity of malaria w orsens with advanced immunosuppression (42–44). On the opposite side, malaria appears to alter HIV viral load, which theoretically could have an impact on HIV disease. Plasma HIV levels were tested in coinfected patients at baseline, during malaria, and post-malaria: HIV -1-RNA concentration was twice between baseline and parasitemia, f alling to baseline levels two months later (45). Interestingly, patients who remained aparasitaemic sho wed no changes in HIV-1-RNA concentration.

Cerebral malaria is defined as impairment of consciousness v arying from somnolence to unarousable coma and hyperparasitemia (>4%; in hyper or holoendemic areas, 20% or more) (46). Diagnosis is not easy in some situations because malaria may mimic many infections of the CNS and the demonstration of the parasite in the blood is sometimes hard. Classically , patients present fe ver, severe headache, delirium, and progressi ve stupor. Occasionally, focal neurologic manifestations may occur. Systemic features that corroborate the diagnosis of cerebral malaria are splenomegaly, hepatomegaly, severe anemia, icterus, and surface-core temperature dissociation. Hypoglycemia may be encountered and can indicate a poor prognosis. Seizures can also be seen in some cases, especially in children. Mortality rates can reach up to 30% in some series (47).

The Brazilian Ministry of Health recommends as f irst line therapy intravenous artesunate (loading dose of 2.4 mg/kg followed by a dose of 1.2 mg/kg in 4 h, 24 h, and 48 h later) or intramuscular artemeter (3.2 mg/kg in the f irst day followed by 1.6 mg/kg each day for 4 days). After this, clindamycin (20 mg/kg for 5 days divided in two doses) or doxyc ycline (3.3 mg/kg/day divided in two doses for 5 days) are used. Alternative drugs to artesunato and artemeter are intravenous quinine with or without intravenous clindamycin (48).

American Trypanosomiais (Chagas' Disease)

Chagas' disease is an antropozoonosis caused by the flagellated protozoa *Trypanosoma cruzi*, which is transmitted to human and animals by a group of hematophagus triatominae insects. These bugs live in rural areas, doing their nests in precarious houses, which are generally made of w ood and clay. Besides the inoculation of *T. cruzi* by the bite of these b ugs, Chagas' disease can also be transmitted to humans by blood transfusion, transplacental route, or contaminated transplanted organ.

Chagas' disease occurs only in the American continent, af fecting almost 18 million people. It is estimated that chronic infection is present in 22% of the general population in Bolivia, 7.2% in Argentina, 10% in Chile, and 4.3% in Brazil (49).

The growing number of AIDS cases in Latin America and the spreading of HIV infection to rural areas will potentially result in an increasing number of HIV *-T. cruzi* coinfection cases. This is rele vant as the natural history of Chagas' disease can be modified by immunosuppression. The CNS, which is almost never damaged during the course of the disease except in very young children is the most affected organ in the reacti vation of chronic, asymptomatic *T. cruzi* infection when the immunodeficiency evolves (see below).

There are two distinct phases during the course of Chagas' disease. In the acute phase, which last for 1–2 months, the majority of patients are asymptomatic, although very young children may de velop myocarditis or meningoencephalitis, the latest being fatal in almost 50% of the cases (50). Parasitologic tests detect *T. cruzi* trypomastigota bloodforms by microscopic examination and are useful in the acute phase, as there are lar ge numbers of parasite circulating in the bloodstream. Importantly , these tests may also be employed in the CSF. In fact, since the seminal description of Chagas' disease by Carlos Chagas (a Brazilian researcher), in 1913, it has been reported that the detection of *T. cruzi* in the CSF is possible in the acute phase of the disease (*apud* (51)). In the chronic phase, *T. cruzi* infection may remain dormant for decades. About 15% of the patients will develop myocarditis or digestive tract alterations, but the CNS is never affected in immunocompetent patients. Since in this phase the parasites are not seen in the bloodstream, the main diagnostic tool for chronic Chagas' disease is the detection of parasite antigen by serologic testing such as ELISA, indirect immunofluorescence, and indirect hemagglutination.

Reactivation of chronic Chagas' disease is observed in immunodeficiency states, as in prolonged corticosteroids use, after or gan transplantation, and lymphoproliferative diseases (51). It is expected that the spreading of HIV in endemic areas will result in an increased number of reactivated diseases. Most often, Chagas' disease reactivates when CD4+ count is less than 200 cells/mm³ (28). Both acute myocarditis and cerebral involvement may be observed, the last one associated with high morbidity and mortality if not promptly recognized. Acute meningoencephalitis, tumor-like lesions, and granulomatous encephalitis ha ve been described (52). Neurologic symptoms depend on the number and location of the lesions, and include headache, fe ver, cognitive disturbances, seizures, and hemiparesis. Meningeal signs are rarely seen. Unlik e cerebral toxoplasmosis, which typically involves basal ganglia and thalamus, brain focal lesions of Chagas' disease are seen preferentially in the subcortical white matter of the cerebral hemispheres (53). The cerebellum and brain stem are less frequently af fected. In a clinical series of 23 HIV-infected patients with Chagas' disease, 87% had multifocal or dif fuse acute meningoencephalitis (54). CSF analysis disclosed pleocytosis with a predominance of lymphocytes, protein increase, and presence of protozoa in the majority of cases. Pseudotumoral lesions were seen in 15 out of 16 CT scans, and in 50% of patients only one lesion was observed. Typically, brain scans disclose ring-enhanced lesions similar to that of cerebral toxoplasmosis, but involving preferentially the white matter (Fig. 1c). Anatomopathological studies sho w that the brain of a HIV -infected patient with cerebral Chagas' disease has increased weight and v olume, with enlargement and flattening of the gyri and narrowing of the sulci (53). Microscopy

reveals meningoencephalitis with necrosis and hemorrhages, the presence of microglial nodules in the gray and white matter, and edema. Amastigote forms of *T. cruzi* may be encountered within the glial cells and macrophages b ut also in the periphery of microglial nodules. Neuronal parasitism is uncommon.

If not properly treated, cerebral Chagas' disease is f atal. Nifurtimox for 2–3 months and benznidazole for 1–2 months are the drugs used in all stages of *T. cruzi* infection, including cerebral Chagas' disease. Benznidazole, which is the recommended drug in Brazil, is used for 2 months at 8 mg/kg/day di vided in two doses. In HIV-infected patients, lifetime secondary prophylaxis with benznidazole is recommended (200 mg three times a week).

Strongyloides stercoralis

Although extra-intestinal strongyloidiasis is no more considered an opportunistic infection in AIDS, a brief consideration about this will be included in this chapter due to some reports about severe meningitis associated with *Strongyloides stercoralis* infection in HIV-infected patients.

S. stercoralis is an intestinal nematode endemic in man y developing countries, which may cause an asymptomatic, lifelong infection. This is explained because *S. stercoralis* larvae may directly pass to an infective larval form inside the host gut, resulting in autoinfection. The dissemination of *S. stercoralis* throughout the body (disseminate strongyloidiasis) is possible and f atal in the absence of therap y. Disseminated strongyloidiasis is almost al ways associated with host immunosuppression, and Human T L ymphotropic Virus type 1-infected patients appear to be more susceptible to both *S. stercoralis* infection and disseminated strongyloidiasis (55). Both hyperinfection and disseminated infection are uncommon in HIV – infected patients, but can occur in those with more se vere immunosuppression (CD4+ count less than 200 cells/mm³).

The occurrence of bacteremia in *S. stercoralis* infection is well documented. Enteric organisms may enter the bloodstream either by bo wel wall ulceration or carried by in vasive *S. stercoralis* larvae. There are reports of disseminated strongyloidiasis in HIV-*S. stercoralis* coinfected patients resulting in bacterial meningitis. In one of these reports, a HIV-infected woman developed bacterial meningitis (56) .During the investigation, *Streptococcus bovis* was cultured in the CSF and *S. stercoralis* was identified in specimens from the colon obtained by colonoscopy. Direct brain involvement by filariform larvae was documented in the past in tw o AIDS patients. The authors observed granulomatous ependymitis and identified the filariform larvae in the brain (57). In another report, a HIV -infected patient with Burkitts lymphoma de veloped lymphomatous leptomeningeal in volvement, and filariform larvae of S. *stercoralis* were seen in CSF cytology (58). *Escherichia coli* meningitis was diagnosed in a man who had recently started antiretro viral therapy (59). The authors speculated that disseminated strongyloidiasis occurred due to immune reconstitution syndrome and that *E. coli*, part of the gastrointestinal tract flora, was carried by *S. stercoralis* to the CNS. Although uncommon in HIV disease, physicians in developing countries with endemic *S. stercoralis* infection should consider that disseminated strongyloidiasis can be more diagnosed in AIDS patients receiving antiretroviral therapy. In some of these, the CNS can be af fected.

Ivermectin (200 mcg/kg/day) or thiabendazole (25 mg/kg twice a day) are the main drugs used to treat *S. stercoralis* infection and should be maintained for at least 7 days.

Leishmaniasis

Leishmania sp is a dimorphic, obligate intracellular protozoa mainly transmitted by the bite of a female sand fly. There are reports sho wing that *Leishmania sp*. can also be transmitted by needle sharing in intræenous drug users. Leishmaniasis is endemic in man y developing countries, affecting almost two million people each year (60). The majority of leishmaniasis cases are due to the *Leishmania donovani* group. Cutaneous, mucocutaneous, and visceral in volvement are seen in patients infected by some *Leishmania sp*, some of these affecting one or more of these organs.

Immunologic impairment seen in HIV disease alters the clinical manifestations of *Leishmania* and their response to treatment. HIV-*Leishmania* coinfection is associated with a higher risk for disseminated infection, atypical localization of the lesions, chronic and relapsing diseases, and poor response to therap y, especially in patients with CD4+ cell counts less than 50 cells/mm³ (61). Although rare, CNS involvement is possible and has been described as a result of a contiguous infection (62). In fact, multiple visceral localizations of *Leishmania* outside the reticuloendothelial system such as in the CNS are one of the features of leishmaniasis as an AIDS-defining disease. Most neurologic cases are due to cranial nerve or meningeal involvement throughout paranasal sinuses infection (63).

Diagnosis of leishmaniasis is dif ficult in HIV-infected patients since less than 50% of patients have typical features of visceral disease, as fever, splenomegaly, and hepatomegaly. Also, characteristic antibodies can be detected only in 50% of the cases (61). Definitive diagnosis is achieved mainly by direct identification of amastigote forms in biopsy tissue or in leuk ocytes on peripheral blood smears. Amastigotes have been detected in CSF in a boy with visceral leishmaniasis (64). Brain CT scans disclose bone invasion or sinus destruction in some cases, but there are no specific abnormalities associated with leishmaniasis.

Although the majority of coinfected patients initially respond well to both pentavalent antimonial and anphoptericin B, 25–80% relapse later (9). Worthy of note, HAART reduces the incidence of visceral leishmaniasis b ut even combined with secondary prophylaxis only a group of patients will be free of relapses in the future. Treatment is with intravenous or intramuscular *N*-glucantine antimoniate at 20 mg/ kg/day for up to 40 days. An alternative drug is amphotericin B at 0.6–1 mg/kg/day for 14 days.

Fungal Infections

Cryptococcosis

Worldwide, cryptococcal meningitis is one of the most common opportunistic infections in AIDS patients. Although probably underestimated, the incidence of cryptococcosis in Latin America is expected to be around 4.5-16.2% in Argentina, 10.2% in Peru, and 4.3% in Brazil (65). In Brazil, cryptococcosis was the AIDSdefining disease in 6% of the AIDS patients reported to the Brazilian Ministry of Health AIDS case surveillance system (www.aids.gov.br). Analysis of cryptococcosis cases in a Brazilian hospital revealed that from 1984 to 1996 its incidence was 3.5 times higher than that observed up to 1983 (66) .In Central Africa, the prevalence of cryptococcosis ranged from 8 to 36% (67). In a serological screening performed in HIV-infected patients from Zaire, cryptococcal antigens were detected in 44 out of 450 indi viduals. In 66% of these CSF analysis resulted in the detection of Cryptococcus neoformans by direct microscopy or culture (68). Seroepidemiological surveillance in a rural zone from Uganda disclosed that 5.8% of 377 HIV -infected patients had positive serological results. More death w as observed among these patients compared with those without cryptococcal antigenemia (the calculated risk of death was 6.6) (69).

Regardless of the country, more than 95% of cryptococcosis cases in AIDS patients are caused by *C. neoformans* variety *neoformans*. A few cases of disease caused by *C. neoformans* var. *gattii* have been described, mostly in Brazil (65). *C. neoformans* var. *neoformans* is a cosmopolitan fungus encountered mainly in soil and feces of several birds, especially pigeons. Infection occurs via the respiratory system. From the lung, the fungus disseminates to other organs, including the CNS, which is susceptible to infection due to the lack of complement and immunoglobulins in the CSF. Worthy of note, the immune reconstitution secondary to HAAR T may unmask latent infection and precipitate clinically apparent meningitis (70). Due to increased a vailability of HAART in the de veloping countries, health care providers in these places will increasingly face this situation.

Cryptococcal meningitis is one of the most common neurologic manifestations of AIDS in developing countries. In Brazil, several series shows that cryptococcal meningitis is the second most frequent neurologic disease, occurring in 13–33% of the neurologic patients (21). In a series of 177 consecuti ve autopsies in AIDS patients from Me xico, the CNS w as the fourth most af fected system (11% of patients) (23). Among these neurological cases, cryptococcal meningitis was diagnosed in 10%, the second most common after cerebral toxoplasmosis. In a clinical series of 500 HIV-infected patients with neurologic disease from India, cryptococcal meningitis was detected in 25% of them, preceded only by neurotuberculosis, diagnosed in 30% of patients (30). In sub-Saharan Africa, it is the third most common neurologic disease and AIDS-def ining disease for 90% of patients (71). In a prospective cohort about natural history of HIV disease in Uganda, cryptococcal meningitis was the cause of death in 13% of the patients, being preceded by wasting

syndrome (diagnosed in 31% cases), and chronic diarrhea, which w as the death cause in 22% (72). In Singapore, cryptococcosis w as the fourth most common cause of all deaths occurring in a cohort of 504 AIDS patients (73).

Normally, cryptococcal meningitis occurs in patients with CD4+ count less than 100 cells/mm³. The main clinical symptoms are headache and fe ver, present in more than 80% of cases. Neck stif fness is seen in less than one-third of patients (74). Typically, the symptoms develop over several weeks but some patients have a more acute course, which is associated with a worse outcome. Also, altered mental status, high CSF pressure, and a higher number of oganisms in the CSF are indicative of poor prognosis. Cryptococcal meningitis is an important contributor to mortality in developing countries. In sub-Saharan Africa, cryptococcosis cases have shown a tendency to be more acute and lethal compared with cases from the de veloped world (67). In Uganda, the median survival time after cryptococcal disease diagnosis is 22 days (43). In Zimbabwe, median survi val time from diagnosis w as only 14 days, with less than 25% surviving more than 30 days (75).

About 75% of patients with proven cryptococcal meningitis had mild mononuclear pleocytosis, elevated CSF protein, and raised opening pressure. Cryptococcal antigen is positive in almost all cases and the India ink test detects the or ganism in about 70% of them. Fungal culture is important to determine species and document sterilization of the CSF. Brain imaging can reveal meningeal enhancement, hydrocephalus, and even cryptococomas, the later seen in about 10% of cases (Fig. 1d).

The main drugs used to treat cryptococcal meningitis are fluconazole and amphotericin B. Although pre viously tested as primary therap y (76), fluconazole alone appears to be an unsatisf actory choice for the treatment of this disease (77). In a recent report from South Africa, patients treated with fluconazole as monotherapy had a higher chance to de velop symptomatic relapse of cryptococcal meningitis (78). Worthy of note are the multiple drug interactions, which can determine inadequate CNS levels of fluconazole. One special situation is the frequent concurrence of tuberculosis along with cryptococcal meningitis in patients with AIDS in developing countries. It is well kno wn that rif ampicin substantially increases the clearance of fluconazole, lo wering its serum le vels and CSF concentration. This way, amphotericin with or without fluc ytosine has been considered as a f irst line therapy. In resource limited settings, where adequate administration of amphotericin B is not possible, fluconazole in higher doses can be a reasonable alternati ve (79).

Paracoccidioidomycosis

Paracoccidioidomycosis is endemic in Latin America. In Brazil, it is the most common deep mycosis and is pre valent mainly in rural areas, with an estimated annual incidence of 1–3 cases in 100,000 inhabitants (80). Habitually, patients are infected inhaling the conidia of the dimorphic fungus *Paracoccidioides brasiliensis*, present mainly in the soil. Early infection results in a primary pulmonary infection. In most individuals, the innate or acquired immune defenses can eliminate the agent or

establish equilibrium between host and fungus. Only in a minority of the patients does the infection progress to o vert disease, evolving into one of the tw o major clinical forms, namely acute/subacute or juv enile type and chronic or adult type (81). In some patients, the fungus may remain viable in latent foci of infection. A disturbance on cellular immune response may result in overt paracoccidioidomy-cosis originating from the primary infection comple x or from the reacti vation of quiescent foci (82).

Most frequently affected organs are lymph nodes, skin, lungs, oropharyngeal mucosa, liver, and spleen. In HIV -negative individuals, CNS in volvement is detected in 9.9–27.3% of cases (83, 84). In autopsy series, CNS in volvement is around 27% (85, 86). Preferentially, the lesions are located in the cerebral hemispheres, but can also be observed in cerebellum, brain stem, and spinal cord. CT scans of patients with cerebral paracoccidioidomycosis sho ws hypodense, mass effect enhanced lesions, sometimes resembling cerebral toxoplasmosis (Fig. 1e). Even in a country as Brazil, endemic to paracoccidioidomycosis and where the HIV epidemic is spreading to rural areas, HIV -P. brasiliensis coinfection incidence appears to be less than e xpected. The prevalence of paracoccidioidomycosis in AIDS patients varies from 0.02 to 1.5% (65). The lower numbers of paracoccidioidomycosis in HIV-infected patients compared to other systemic mycoses could be explained by the widespread use of trimethoprim-sulf amethoxale as prophylaxis for *P. carinii* pneumonia, which is also v ery effective against *P. brasiliensis*. HIVparacoccidioidomycosis coinfection cases has been described both in Brazil and in other Latin American countries such as V enezuela and Colombia (87). In 74% of the patients, paracoccidioidomycosis w as the first life-threatening disease to be diagnosed. The clinical presentation resembled the acute/subacute form of classical paracoccidioidomycosis, usually with a short course of fe ver, weight loss, fatigue, and anorexia, associated with lymphadenopathy (81). Involvement of the CNS or bone was detected in two cases each.

Several treatment regimens are used and sometimes more than one drug is need. The main drugs used in paracoccidioidomycosis are amphotericin B, trimethoprim–sulfamethoxazole, itraconazole, and fluconazole.

Histoplasmosis

Histoplasmosis is a systemic mycosis produced by the dimorphic fung**M***sistoplasma capsulatum* variety *capsulatum*, which is acquired via the respiratory system. Histoplasmosis is endemic in man y countries of the Americas, Asia, and Africa, and its prevalence has been estimated by the histoplasmin skin test. In Brazil, for instance, the positive skin reaction pre valence ranges from 2.6 to 93.2% (*apud* (88)). Approximately, 5% of the AIDS patients had disseminated histoplasmosis in Buenos Aires, Argentina (65). With an incidence of 2.9/100 person-years among HIV-infected patients, disseminated histoplasmosis w as the second most frequent opportunistic infection and the first cause of death in a series from French Guiana (89). Skin testing showed that 29% of individuals in Guyana and 42% in Trinidad were reactive to histoplasmin (90). In a recent series of 74 patients with histoplasmosis from Rio de Janeiro, 49% occurred in HIV -infected patients who presented with disseminated disease. Histoplasmosis was the AIDS-defining disease in one-third of those (88).

Generally, the primary infection is asymptomatic, b ut more severe cases may be seen either when a great inoculum is aspirated or in a setting of immunosuppression (91). Reactivation of quiescent infection occurs during immunosuppression (92). The clinical manifestations of disseminated histoplasmosis are prolonged high fever, weight loss, asthenia, anorexia, diarrhea or vomiting, hepatosplenomegaly, multiple adenomegalies, and skin lesions. CNS in volvement may be a manifestation of widely disseminated disease or an isolated illness, and is clinically recognized in 5-10% of disseminated histoplasmosis cases (93). In a case series from Brazil, 39 out of 164 HIV-infected patients with disseminated histoplasmosis had some neurologic manifestation, which was independently associated with an increased risk of death (OR 5.8) (94). Neurologic syndromes include subacute or chronic meningitis, focal brain or spinal cord lesions, stroke syndromes, and encephalitis. Focal brain or spinal cord lesions, are also described.

Histoplasmosis is a challenge for clinicians because the clinical symptoms are not specific and no diagnostic test is at the same time specific and sensitive. So, multiple tests make the clinical investigation truly expensive for many countries. Also important is the possibility of false-positive results from nonculture-based tests, including the *Histoplasma* antigen assay. Although diagnosis may be simple for patients with disseminated disease, since organisms may be identified in multiple organs, difficulties occur to diagnose those with isolated CNS involvement. For such patients, positive results may only be found through CSF, meningeal, or brain tissue e valuation. At least 10 mL of CSF should be cultured to increase the sensiti vity for isolating small numbers of yeast or ganisms (95). Serologic tests for anti-Histoplasma antibodies in the CSF are also helpful, ha ving positive results in up to 80% of cases. However, the antibody response may be impaired in immunosuppressed individuals. For example, in patients with disseminated histoplasmosis, anti- Histoplasma antibodies were present in serum in samples from 67% of patients with AIDS, 80% of those with other immunosuppressive disorders, and 86% of those without underlying immunosuppression (96). Also, serologic tests may have false-positive results due to cross-reactions caused by infection with other fungi, including C. neoformans (97).

Optimal treatment for CNS histoplasmosis is presently unknown, but amphotericin B and fluconazole are the main options.

Sporotrichosis

Sporotrichosis is endemic worldwide. It is caused by *Sporothrix schenckii*, a dimorphic fungus that is mostly encountered in plants and soil. Therefore, agricultural workers are most at risk for infection. People can be infected mainly by direct inoculation

of spores after a traumatic skin lesion, b ut infection via respiratory system is also possible. The disease is generally restricted to skin and subcutaneous tissues, but it has been well recognized that AIDS patients can develop a severe and disseminated form of this fungal disease (98–100).

The CNS is rarely involved in sporothricosis, but some cases of meningitis due to *S. schenckii* have been described in HIV -infected patients with disseminated sporothricosis. In a Brazilian case description, a farm-worker developed meningitis after irregular therapy with itraconazole for cutaneous sporothricosis. CSF analysis disclosed a moderate lymphoc ytic pleocytosis and moderate increase in protein level. The CT scan showed small hypodense lesions in temporal and parietal lobes. Chronic granulomatous inflammation was seen in the meninges mainly in the basal skull, and yeast-like forms similar to *S. schenckii* were identified (101). Other similar reports from the de veloped world showed that brain MRI may disclose nonenhanced lesions in the brainstem, basal ganglia, thalamus, and centrum semiovale along with meningeal enhancement (99, 102). CSF antibodies specific to *S. schenckii* and fungal cultures are crucial to the diagnosis.

Cutaneous sporothricosis is treated mainly with itraconazole. Since itraconazole shows poor penetration into the CSF, amphotericin B is the best option to treat meningitis due to *S. schenckii*.

Bacterial Infections

Tuberculosis

The prevalence of tuberculosis is directly associated with po verty. More than 80% of cases worldwide are seen in de veloping countries. Of 8.8 million ne w cases of tuberculosis worldwide registered in 2005, 1.9 million occurred in India (www. who.int). A socio-economic surv ey in a rural population in South India disclosed that the prevalence of tuberculosis was 343/100,000 in areas with a low standard of living index, while in areas with a high index the prevalence was 92/100,000 inhabitants (103). Actually, in Brazil, 50 million people are infected by *Mycobacterium tuberculosis*, and 116,000 ne w diagnoses are made each year (pre valence of 68/100,000 inhabitants). In 2005, 4278 out of 1,006,827 deaths that occurred in Brazil were directly associated with tuberculosis (www.datasus.gov.br).

Overall, it is assumed that HIV-infected individuals are six times more likely to develop tuberculosis than individuals who are not HIV infected (104). HIV-infected patients are particularly susceptible to e xtrapulmonary tuberculosis. Furthermore, HIV infection is associated with increased mortality in patients with neurologic manifestations of tuberculosis, especially meningitis. HIV -infected patients with tuberculous meningitis had higher rates of multidrug-resistant tuberculosis and mortality than HIV-negative controls in V ietnam (105). High mortality rates are mainly associated with late diagnosis, which is common in poor countries due to lack of appropriate diagnostic tools.

It has been estimated that the CNS is affected in 5-10% of patients with pulmonary tuberculosis, corresponding either to quiescent infection reactivation or spreading of *M. tuberculosis* from other infected tissue in disseminated tuberculosis. By f ar tuberculous meningitis is the most common neurologic manifestation of *M. tuber*culosis infection, but tuberculoma and abscess can also be encountered. The highest rate of neurotuberculosis in AIDS patients from a developed country is 1.4% (half of patients were drug users) (106). In developing countries, the prevalence of neurotuberculosis is approximately 12% in unselected autopsies (tuberculoma and tuberculous abscesses were seen in 6% of the cases) (24, 107). In Latin America, neurotuberculosis is diagnosed in 4-14% of AIDS patients (9). Probably these figures are underestimates, as tuberculosis is highly pre valent in man y Latin American countries. This can be due to the difficulty in diagnosis. In a recent series from Brazil, tuberculous meningitis was the third most common neurological disease in AIDS patients, occurring in 10.8% of patients (108). In an autopsy study from Mexico, tuberculous meningitis was the third most common diagnosis, encountered in 7% of 160 patients who died of neurological complications during HIV disease (23). In South Africa, where the general prevalence of tuberculosis is 315/100,000 inhabitants, neurotuberculosis was the most common diagnosis in 32 consecutive patients with a focal brain lesion (69% of cases, while cerebral toxoplasmosis corresponded to only 3%) (29). Tuberculous meningitis was seen in 11% of adult AIDS patients in 294 autopsied patients from Côte d'Iv oire, West Africa (24). Among 500 cases of HIV/AIDS with neurologic manifestations from Bangalore, India, neurotuberculosis was the most prevalent one (25).

Tuberculous meningitis typically present as subacute meningitis evolving in several days or weeks, characterized by signs of meningeal irritation, headache, lo w and persistent fever, irritability, and altered mental status (109). Focal neurological signs such as cranial nerve paralysis along with seizures can appear later . In non-treated patients coma and high fever herald death, which occur 5–8 weeks after the b@inning of symptoms (110). CT scanning is abnormal in more than tw o-thirds of patients, and most of them sho w hydrocephalus or meningeal enhancement (Fig. 1f). Focal brain lesion can be observ ed and are characterized by iso- or hypodense rounded lesions with ring or nodular enhancement. MRI is more sensiti ve to disclose such lesions but is not available in many poor settings. Presence of meningeal enhancement is the most important characteristic to discriminate a focal brain lesion due to tuberculosis from cerebral toxoplasmosis or neurocysticercosis (29).

Clinical features of focal forms of neurotuberculosis, namely tuberculoma and tuberculous abscess, are similar to other e xpansive lesions in AIDS patients and include headache, fe ver, seizures, and focal def icits on neurologic e xamination, with or without meningeal signs. CT scans are nonspecific, but a relationship among histopathologic findings and radiological characteristics can be observed. Noncaseating granulomas are rounded, multiple hypodense lesions that sho w a nodular enhancement after contrast injection (Fig. 1g), while caseating granulomas are hypodense, ring-enhanced lesions (111). The so-called "target sign," a central nest either of calcification or of contrast enhancement surrounded by a hypodense, ring-enhanced lesion is unique but an infrequent finding of tuberculoma.

CSF analysis in neurotuberculosis typically discloses lymphoc ytic pleocytosis, increased protein levels, and decreased glucose levels. Sometimes, neutrophils can predominate, and this finding was associated with a higher chance for positi ve *M. tuberculosis* CSF culture in a Brazilian series (112). Direct smears of CSF are positive in minority of patients. In Brazil, none of proven tuberculous meningitis cases were positive on direct examination (112). However, a detailed microscopic examination and a greater v olume of the fluid could result in an increase in the sensitivity of this method. Although CSF culture is the gold-standard method for a correct diagnosis, it is not useful to make a rapid clinical decision because *M. tuberculosis* shows a slow growth in the Lowenstein-Jensen medium (30–60 days). PCR test has a reasonable sensitivity of the de veloping countries (113, 114). An elevated concentration of adenosine deaminase in the CSF may be useful as an auxiliary diagnostic tool, but lacks specificity since that is elevated also in many other neurologic disorders, such as bacterial or fungal meningitis and lymphoma (115).

Tuberculous meningitis treatment is with isoniazid (300 mg/day), rif ampin (600 mg/day), and pyrazinamide (1–2 g/day) plus ethambutol (800–1,600 mg/day) or streptomycin (1 g/day). A scheme of four doses should be used for 2 or 4 months, followed by a course of isoniazid plus rifampin for 7–9 months. Instead of tuberculous meningitis and tuberculoma, which are treated clinically , tuberculous abscess requires both surgical and pharmacological treatment.

Viruses

Only JC virus infection will be discussed here because the prevalence of the disease associated with this poliomavirus is different from developing to developed world.

JC Virus

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the CNS. It is the result of a productive infection of the oligodendrocytes by the ubiquitous JC virus. Since the beiginning of HIV epidemic, PML has been described as one of the most frequent opportunistic disease in AIDS patients in developed countries. The incidence of PML in AIDS patients in this setting has been estimated to be around 4% (116, 117). In Italy, PML was the third most common neurological disorder in a cohort of HIV patients (118). However, a few cases have been reported in developing world. Difficulty in rendering a diagnosis, which requires either molecular techniques or brain MRI, is probably the main but not the only reason that explains the few PML cases reported in limited-resource areas, especially in Africa and India.

In Brazil, in spite of a JC virus seropre valence of 92%, only a few PML cases have been described. Since 1998, only 10 cases of PML were seen in a lar ge

University Hospital in Rio de Janeiro (Chimelli, personal communication). In our cohort (unpublished data), only 17 cases were diagnosed since 1985, 16 of these in the post-HAAR T era. Ne vertheless, a 48.2% pre valence of JC virus in 56 Brazilian AIDS patients with focal brain lesions b ut without mass ef fect was recently reported (119). Maybe the scaling up of HAAR T use in Brazil and in other developing countries could result in an increasing number of PML cases since its incidence appears to ha ve increased compared with other opportunistic infections or tumors (120). On the other side, there are reports sho wing that both infection by HIV clade C and dif ferent JC virus types could justify the lo w incidence of PML in patients from Africa compared with patients from the W estern world (121–123). It has been reported that the majority of Caucasians from United States and Europe e xcrete JC virus types 1 or 2B (124), while different strains, namely African genotypes of JC virus types 3 and 6, were observed in individuals from West Africa (121).

There are no differences in the clinical presentation of PML patients either from the developed or developing world. The most common neurologic abnormalities are hemiparesis, ataxia, cognitive disturbance, and visual impairment. MRI is by far more sensitive than CT scan and sho ws hypodense, nonenhanced lesions without mass effect predominately localized in the white matter. CSF is usually normal and amplification of JC virus DNA by PCR from spinal fluid is a very useful diagnostic tool but not available in the majority of developing countries. So, spinal fluid analysis is important to exclude alternative diseases but not to diagnose a PML case in a limited-resource area that is not possible to perform molecular tests.

The best treatment to PML is HAART. In countries where HAART is not available, PML follows its lethal course in a couple of months.

Conclusion

Neurologic manifestations in AIDS patients from developing countries are as common and relevant as in the de veloped world. However, the majority of guidelines for management of these patients was elaborated in the developed world and includes expensive diagnostic methods such as molecular biology and stereotaxic cerebral biopsy. Also, very few papers have been published about neurologic disturbances in HIV-infected patients from de veloping countries, which result in dubiousness about the real pre valence of certain pathogens. This w ay, physicians working in poor countries frequently encounter limited information in the literature about neurologic diseases in their areas and have difficulty to ascertain the right diagnosis due to lack of complementary e xams. Another important aspect is that some neurologic diseases caused by certain pathogens endemic in de veloping countries may be encountered in the developed world due to immigration of people. So, physicians from developed world should consider alternative diagnosis in patients from poor countries presenting a neurologic disturbance, such as c ysticercosis and Chagas' diseases.

References

- 1 .PriceRW, Brav B SidtisJ RosenblumM ScheckAC, ClearyP The brain in AIDS: central
nervous system HIV -1 infection and AIDS dementia complex. Science
1988 ; 239 (4840) : 586 92 .
- 2 .Ley RM BredesenDE RosenblumML Neurologicalmanifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. J Neurosurg 1985 ; 62 (4) : 475 – 95 .
- 3. Snider WD ,Simpson DM ,Nielsen S ,Gold JW, Metroka CE ,PosnerJB .Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol 1983 ; 14 (4) : 403 18 .
- 4 .Gray F, Gherardi R ,Scamilli F .The neuropathology of the acquired immune deficiency syndrome (AIDS). A review. Brain 1988 ; 11(Pt2) : 245 66 .
- 5 .Fachtenberg JD Kambgu AD McKillar M SemitalaF, Mayanja-KizzaH SamoreMH, etal .Themedical management of central nervous system infections in Uganda and the potential impact of an algorithm-based approach to improve outcomes. Int J Infect Dis 2007; 11 (6): 524 30.
- 6 .Lubic LG ,Marotta JT .Brain tumor and lumbar puncture . AMA Arch Neurol Psychiatry 1954 ; 72 (5) : 568 72 .
- 7 . Earns RW Complications of lumbar puncture . NeurolClin 1998 ; 16 (1) : 83 105 .
- 8 . Roos
K Cerebrospinalfluid . In: Roos
K editor. Principles
of Neurologic Infectious Diseases . New York : McGraw-Hill ; 2005 p.
 $1\,-\,12\,$.
- 9. CahnP, BellosoWH MurilloJ Prada-Tujillo G AIDS in Latin America .Infect Dis Clin North Am 2000 ; 14 (1) : 185 – 209 .
- 10 SharifM ZiaeiH DaryaniA AjamiA Seroepidemiologicalstudy of toxoplasmosis in intellectual disability children in rehabilitation centers of northern Iran . Res Dev Disabil 2007 ; 28 (3) : 219 24 .
- 11 Azar S EserB Ay M Prevalence of anti-toxoplasma Gondii antibodies in Turkish blood donors . EthiopMed J 2006 ; 44 (3) : 257 61 .
- 12 Chen XG , Wi K ,Lun ZR Toxoplasmosis researches in China . Chin Med J (Engl) 2005 ; 118 (12) : 1015 21 .
- 13 SongKJ ShinJC ShinHJ NamHW Seroprevalence of toxoplasmosis in Korean pregnant women . Korean J Parasitol 2005 ; 43 (2) : 69 71 .
- 14 Fin CK HungCC SuKE SungFC ChiouHY, GilV,etal .Seroprevalence of *Toxoplasma gondii* infection among pre-schoolchildren aged 1–5 years in the Democratic Republic of Sao Tome and Principe, Western Africa . Trans R Soc Trop Med Hyg 2006 ; 100 (5) : 446 9 .
- 15. Echado A Ente L AlbertiE HadadP, Enseca L MachinR, etal .Usefulnessof the detection of *Toxoplasma gondii* antigens in AIDS patients . Rev Inst Med Trop Sao Paulo 1994 ; 36 (6) : 525 – 9 .
- 16 .Silar F, Torres A PradaG Encefalitis por toxoplasma y SIDA: Análisis de 27 episodios . Rev Panam Infectol 1997 ; 1 (1) : 4 9 .
- 17 LindstromI Kaddu-Mulindw DH KirondeF, LindhJ Prevalence of latent and reactivated *Toxoplasma gondii* parasites in HIV-patients from Uganda . ActaTrop 2006; 100 (3) : 218 22.
- 18 Unek CJ DuhlinskaDD NjokuMO NgwuBA Seroprevalence of acquired toxoplasmosis in HIV-infected and apparently healthy individuals in Jos, Nigeria . Parassitologia 2005 ; 47 (2) : 233 – 6 .
- 19 SimporeJ Stadogo A JlboudoD Nadambga MC EspositoM , Yra J et al *Toxoplasma gondii*, HCV, and HBV seropre valence and co-infection among HIV -positive and -negative pregnant women in Burkina Faso. JMed Virol 2006; 78 (6): 730 3.
- 20 HungCC ChenMY, HsiehSM HsiaoCF, ShengWH ChangSC Prevalence of *Toxoplasma gondii* infection and incidence of toxoplasma encephalitis in non-haemophiliac HIV -1-infected adults in Taiwan . IntJ STD AIDS 2005; 16 (4): 302 6.

- 21 Silæ MT, Araujo A Highlyactive antiretroviral therapy access and neurological complications of human immunodef iciency virus infection: impact v ersus resources in Brazil . J Neurovirol 2005 ; ISuppl3: 11 – 5.
- 22 Adesse T, Langford D Manji K Mehari E Patterns of neuroAIDS in Africa . JNeurovirol 2005 ; ISuppl1: 22 6 .
- 23 MoharA RomoJ SalidoF, JessurunJ Poncede Leon S Rese E et al . The spectrum of clinical and pathological manifestations of AIDS in a consecutive series of autopsied patients in Mexico . AIDS 1992 ; 6 (5) : 467 - 73 .
- 24 LucasSB HounnouA PeacockC BeaumelA DjomandG N'GbichiJM etal .Themortality and pathology of HIV infection in a west African city . AIDS 1993; 7 (12) : 1569 – 79 .
- 25 SatishchandraP, NaliniA, Gourie-Dei M, KhannaN, SantoshV, Ravi V, et al. Profle of neurologic disorders associated with HIV/AIDS from Bangalore, south India (1989–96). IndianJ Med Res 2000; 111: 14 – 23.
- 26 BellJE Lwrie S Kiffi K HondeM AndohJ DcCock KM etal .Theneuropathology of HIV-infected African children in Abidjan, Cote d'Iv oire. J Neuropathol Exp Neurol 1997 ; 56 (6) : 686 – 92 .
- 27 Mal JE Hernandez AV, deOliveira AC, Dauar RF, Barbosa SP, Jr, Focaccia R Cerebral toxoplasmosis in HIV-positive patients in Brazil: clinical features and predictors of treatment response in the HAART era. AIDSPatient Care STDS 2005; 19 (10): 626 34.
- 28 Walker M ,Zunt JR Parasitic central nervous system infections in immunocompromised hosts . ClinInfect Dis 2005 ; 40 (7) : 1005 15 .
- 29 ModiM MochanA ModiG Managementof HIV-associated focal brain lesions in developing countries . Qjm 2004 ; 97 (7) : 413 – 21 .
- 30 Shankar SK ,Mahadean A ,Satishchandra P, Kimar RU, Yasha TC ,Santosh V, et al . Neuropathology of HIV/AIDS with an o verview of the Indian scene . Indian J Med Res 2005 ; 121 (4) : 468 – 88 .
- 31 White AC Jr Neurocysticercosis: a major cause of neurological disease worldwide. Clin Infect Dis 1997; 24 (2): 104uiz11B4;5.
- 32 SoteloJ GuerreroV, RubioF Neurogysticercosis: a new classification based on active and inactive forms. A study of 753 cases . ArchIntern Med 1985 ; 145 (3) : 442 5 .
- 33 SotdHernandez JL Ostrosk Zeichner L Twera G GomezAvina A Neurogysticercosis and HIV infection: report of two cases and review. Sug Neurol 1996 ; 45 (1) : 57 61.
- 34 .ThorntonCA HoustonS LatifAS Neurogysticercosis and human immunodeficiency virus infection. A possible association . ArchNeurol 1992 ; 49 (9) : 963 5 .
- 35 Mauad T, Battlehner CN, Bedrikw CL, Capelozzi VL, Saldia PH Case report: massive cardiopulmonary cysticercosis in a leukemic patient. Bathol Res Pract 1997; 193 (7): 527 9.
- 36 SerpaA, MoranA GoodmanJC GiordanoTP, WhiteAC, Jr Neurocysticercosis in the HIV era: a case report and review of the literature. AmJ Trop Med Hyg 2007; 77 (1): 113 7.
- 37 Kmar GR Diagnostic criteria for neurocysticercosis: some modifications are needed for Indian patients. NeurolIndia 2004 ; 52 (2) : 171 77.
- 38 RajshekharV, ChandyMJ Validation of diagnostic criteria for solitary cerebral cysticercus granuloma in patients presenting with seizures. ActaNeurol Scand 1997; 96 (2): 76 81.
- 39 Harms G Feldmeier H The impact of HIV infection on tropical diseases . Infect Dis Clin North Am 2005 ; 19 (1) : 12ix - 35 ,
- 40 Simoya OO MwendapoleRM SiziyaS FlemingAF Relationbetween falciparum malaria and HIV seropositivity in Ndola, Zambia . BMJ 1988 ; 297 (6640) : 30 1 .
- 41 Grimwde K FrenchN MbathaDD ZunguDD DedicoatM GilksCF HIVinfection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa. AIDS 2004 ; 18 (3) : 547 - 54.
- 42 Francesconi P, Febiani M Dente MG Lukwiya M Okwye R Ouma J et al . HIV malaria parasites, and acute febrile episodes in Ugandan adults: a case-control study . AIDS 2001 ; 15 (18) : 2445 50 .

- 43 French N, Nakiyingi J, Lugada E, Watera C, Whitworth JA, Gilks CF Increasing rates of malarial fever with deteriorating immune status in HIV -1-infected Ugandan adults. AIDS 2001; 15 (7): 899 – 906.
- 44 .Whitworth J Mogan D Quigle M SmithA MayanjaB EotuH ,etal .Efect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study . Lancet 2000 ; 356 (9235) : 1051 6 .
- 45 Julie JG , Ranaik P, Jere CS , Miller WC , Hoffman IF, Chimbiya N et al . Effect of *Plasmodium falciparum* malaria on concentration of HIV -1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet 2005; 365 (9455): 233 40.
- Severe falciparum malaria. World Health Or ganization, Communicable Diseases Cluster . Trans R Soc Trop Med Hyg 2000;94 Suppl 1:S1–90.
- 47 SchmutzhardE Protozoalinfections .In: RooK editor. Principles Neurologic Infectious Diseases . New York : McGraw-Hill ; 2001 pp. 265 – 306 .
- 48 MalariaIn: BrasiMdSd editor. Guiade Vigilância Epidemiológica. Brasília Ministério da Saúde ; 2005 p. 521 40 .
- 49. Chagas' disease: frequency and geographical distribution. Wkly Epidemiol Rec 1990;65:257–64.
- 50 PrataA Chagas' disease . InfectDis Clin North Am 1994 ; 8 (1) : 61 76 .
- 51 . JardimE **A**kayanagui OM Chagasicmeningoencephalitis with detection of *Trypanossoma cruzi* in the cerebrospinal fluid of an immunodepressed patient . JTrop Med Hyg 1994 ; 97 : 367 70 .
- 52. Recommendations for diagnosis, treatment and follow-up of the Trypanosoma cruzi: HUMAN immunodeficiency virus co-infection. Rev Soc Bras Med Trop 2006;39(4):392–415.
 - 53 Lazo J Meneses AC, Rocha A Ferreira MS Marquez JO Chapadeir E et al Chagasic meningoencephalitis in the immunodeficient. ArqNeuropsiquiatr 1998 ; 56 (1) : 93 7.
 - 54 RochaA FerreiraMS NishiokaSA Silar AM Bugarelli MK Sila M etal .Trypanosoma cruzi meningoencephalitis and myocarditis in a patient with acquired immunodeficiency syndrome . Rev Inst Med Trop Sao Paulo 1993 ; 35 (2) : 205 8 .
 - 55 Wrdonck K ,GonzalezE ,Win Dooren S ,Windamme AM ,Winham G ,Gtuzzo E Human T-lymphotropic virus 1: recent kno wledge about an ancient infection . Lancet Infect Dis 2007 ; 7 (4) : 266 81 .
 - 56 deSilva T, RaychaudhuriM PoultonM HIVinfection associated with *Strongyloides sterc-oralis* colitis resulting in *Streptococcus bovis* bacteraemia and meningitis. S& Transm Infect 2005; 81: 276 277.
 - 57 Mogello S SoiferFM LinCS Wilfe DE Centralnervous system *Strongyloides stercoralis* in acquired immunodeficiency syndrome: a report of two cases and review of the literature. ActaNeuropathol (Berl) 1993; 86 (3): 285 – 8.
 - 58 .DutcherJP, MarcusSL Tanowitz HB Wittner M FuksJZ Wernik PH Disseminatedstrongyloidiasis with central nerv ous system in volvement diagnosed antemortem in a patient with acquired immunodeficiency syndrome and Burkitts lymphoma. Cancer 1990; 66 (11): 2417 – 20.
 - 59 Brown M CartledgeJD MillerRF Dissemination of *Strongyloides stercoralis* as an immune restoration phenomenon in an HIV-1-infected man on antiretroviral therapy. Int J STD AIDS 2006 ; 17 (8) : 560 1.
- 60. Leishmaniasis. Geneva: World Health Organization 2005.
- 61 Alar J ,Cannate C ,Gutierrez-Solar B ,Jimenez M ,Laguna F, Lpez-Velez R et al . *Leishmania* and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997 ; 10 (2) : 298 – 319 .
- 62 HashimA, AhmedAE eHassan M eMubarak MH Xgi H Ibrahin EN etal .Neurologic changes in visceral leishmaniasis . AmJ Trop Med Hyg 1995 ; 52 (2) : 149 54 .
- 63 Walker M Jublin JG ZuntJR Parasitic central nervous system infections in immunocompromised hosts: malaria, microsporidiosis, leishmaniasis, and African trypanosomiasis. Clin Infect Dis 2006; 42 (1): 115 – 25.
- 64 PrasadLS SenS Migration of *Leishmania donovani* amastigotes in the cerebrospinal fluid . AmJ Trop Med Hyg 1996 ; 55 (6) : 652 – 4 .

- 65 Marques SA, Robles AM, Jortorano AM, Jiculet MA, Ngroni R, Medes RP. Mycoses associated with AIDS in the Third World. MedMycol 2000; 3980ppl1: 269 79.
- 66 DarzeC LucenaR GomesI MeloA Theclinical laboratory characteristics of 104 cases of cryptococcal meningoencephalitis. Rev Soc Bras Med Trop 2000 ; 33 (1) : 21 6.
- 67 MolezJF Thehistorical question of acquired immunodeficiency syndrome in the 1960s in the Congo River basin area in relation to cryptococcal meningitis
 1998 (3): 273 6.
- 68 Desmet P, Kayembe KD DeVroey C The value of cryptococcal serum antigen screening among HIV-positive/AIDS patients in Kinshasa, Zaire . AIDS 1989; 3 (2): 77 – 8.
- 69 Liechty CA ,Solbeg P, Wre W, Ekwru JP, Ransom RL ,Wridle PJ et al .Asymptomatic serum cryptococcal antigenemia and early mortality during antiretro viral therapy in rural Uganda. Trop Med Int Health 2007 ; 12 (8) : 929 – 35.
- 70 Woods ML 2nd MacGinly R EisenDP, Allworth AM HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection. AIDS 1998; 12 (12): 1491 4.
- 71 Robertson K Kepnisky K Mielk J Appiah K Hall C PriceR et al. Assessment of neuroAIDS in Africa. JNeurovirol 2005; Suppl1: 7 16.
- 72 .Okngo M Mogan D MayanjaB RossA ,Whitworth J Causesof death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda . IntJ Epidemiol 1998; 27 (4): 698 – 702.
- 73 BellamyR SangeethaS Peton NI Causes of death among patients with HIV in Singapore from 1985 to 2001: results from the Singapore HIV Observ ational Cohort Study (SHOCS). HIVMed 2004 ; 5 (4) : 289 – 95 .
- 74 .Brev B Cryptococcal meningitis .In: Bree B editor. HIV Neurology . New York : Oxford University Press ; 2001 p. 91 95 .
- 75 Hyderman RS GangaidzoIT, HakimJG Mielk J Jiziwa A Musaire P,etal .Cryptococcal meningitis in human immunodef iciency virus-infected patients in Harare, Zimbabwe . Clin Infect Dis 1998 ; 26 (2) : 284 – 9 .
- 76 SaagMS Powderly WG CloudGA RobinsonP, GriecoMH Sharky PK etal .Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis The NIAID Mycoses Study Group and the AIDS Clinical T rials Group. N Engl J Med 1992 ; 326 (2) : 83 – 9 .
- 77 .LarsenRA LealMA ChanLS Fluconazolecompared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial . AnnIntern Med 1990 ; 113 (3) : 183 – 7 .
- 78 BicanicT, HarrisonT, NiepiekloA Dyakpu N MeintjesG Symptomatic relapse of HIVassociated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. ClinInfect Dis 2006 ; 43 (8) : 1069 – 73.
- 79 HamillR Freefluconazole for Cryptococcal Meningitis:too little of a good thing? ClinInfect Dis 2006 ; 43 : 1074 – 76 .
- 80 Winke B Londero A Epidemiology and paracoccidioidomycosis infection .In: FrancoM, Lacaz C ,Restrepo-Moreno A ,DelNegro G editors. Paracoccidiodomycosis . Boca Raton : CRCPress; 1994 p. 109 – 17 .
- 81 Iniago AM ,deFreitas AC , Aguiar ES ,Aguiar JI ,daCunha RV , @stro AR et al . Paracoccidioidomycosis in patients with human immunodeficiency virus: review of 12 cases observed in an endemic region in Brazil . JInfect 2005 ; 51 (3) : 248 - 52 .
- 82 SugarAM RestrepoA Steens DA Raracoccidioidomycosis in the immunosuppressed host: report of a case and review of the literature . AmRev Respir Dis 1984 ; 129 (2) : 340 - 2 .
- 83 PlaMP, Hartung C, Mendoza P, Stukanoff A, Moreno MJ Neuroparacoccidioidomycosis: case reports and review. Mycopathologia 1994 ; 127 (3) : 139 44.
- 84 Figundes-Pereyra WJ ,Caradho GT, deMiranda Goes A ,dasChagas Lima e Silva F de Sousa AA [Central nervous system paracoccidioidomycosis: analysis of 13 cases]. Arq Neuropsiquiatr 2006 ; 64 (2A) : 269 – 76.
- 85 . Duart Maia ADuarte J Furtado C Paracoccidioidomicose cerebral: relato de um caso e revisão da literatura. Res Pes Med 1997; 31: 37 – 41.

- 86. RaphaeA Localizaçãonervosa da blastomicose sul-americana. Vér Hosp Clin (São Paulo) 1966 ; 24 : 69 – 90 .
- 87. GoldanLZ "Sugar AM Paracoccidioidomycosis and AIDS: an overview. Clin Infect Dis 1995; 21 (5): 1275 – 81.
- 88 . Leiman PizziniC MunizM Albquerque P, MonteiroP, ReisR etal .Histoplasmosisin
 a Brazilian center: clinical forms and laboratory tests . Rev Iberoam Micol 2005 ; 22 : 141 46 .
- 89. Iwden C Sobesk M CabieA CouppieP, BoulardF, BissuelF Causesof death among HIV-infected adults in French Guyana and the French West Indies in the era of highly active antiretroviral therapy (HAART). MedMal Infect 2004 ; 34 : 286 – 92.
- 90. HaRJ WhiteHS FieldsPE QuaminaDB DanM JonesTR. Histoplasmosisin the eastern Caribbean: a preliminary survey of the incidence of the infection. J Trop Med Hyg 1981; 84 (1): 9 - 12.
- 91. Bulloc W Histoplasma capsulatum In: MandelG Douglas J Dolin R editors. Principles and Practice of Infectious Diseases . New York : ChurchillLivingstone ; 1995 pp. 2340 53 .
- 92. Wheat J Kauffman CA Histoplasmosis InfectDis Clin North Am 2003 ; 17 1(1) 19vij .
- 93. WheaLJ ,Batteiger BE ,Sathapatayaongs B *Histoplasma capsulatum* infections of the central nervous system. A clinical review. Medicine(Baltimore) 1990 ; 69 (4) : 244 60.
- 94. derancesco Daher E ,deSousa Barros FA , daSilva Junior GB ,akeda CF,Mota RM , FerreiraMT, etal .Riskfactors for death in acquired immunodeficiency syndrome-associated disseminated histoplasmosis . AmJ Trop Med Hyg 2006 ; 74 (4) : 600 – 3 .
- 95. CouppiP, AznarC CarmeB NacherM Americanhistoplasmosis in developing countries with a special focus on patients with HIV : diagnosis, treatment, and prognosis. Curr Opin Infect Dis 2006 ; 19 (5) : 443 – 9.
- 96 . LeimanBC ,Pizzini CV, Muniz MM ,Albquerque PC ,Monteiro PC Reis RS et al . Histoplasmosis in a Brazilian center: clinical forms and laboratory tests. Rev Iberoam Micol 2005 ; 22 (3) : 141 – 6 .
- 97. Crum≱, CorderJR Henshw NG RellerLB Development, implementation, and impact of acceptability criteria for serologic tests for infectious diseases . J Clin Microbiol 2004 ; 42 (2) : 881 – 3.
- 98. RochMM DassinT, LiraR LimaEL Seero LC Londero AT Sporotrichosisin patient with AIDS: report of a case and review. Rev Iberoam Micol 2001; 18 (3): 133 6.
- 99. Donabediahi Q'DonnellE Qlszwski C MacArthurRD BuddN Disseminated cutaneous and meningeal sporotrichosis in an AIDS patient. DiagnMicrobiol Infect Dis 1994 ; 18 (2) : 111 – 5.
- 100 . HelleHM ,Fuhrer J Disseminated sporotrichosis in patients with AIDS: case report and review of the literature . AIDS 1991 ; 5 (10) : 1243 6 .
- 101 . Sit-Vergara ML ,Maneira FR ,DeOliveira RM ,Santos CT , EtchebehereRM , Adad SJ Multifocal sporotrichosis with meningeal in volvement in a patient with AIDS . Med Mycol 2005 ; 43 (2) : 187 90 .
- 102 . Hardmaß Stephenson I Jenkins DR Weelka MJ Johnson EM Disseminated Sporothix schenckii in a patient with AIDS . JInfect 2005 ; 51 (3) : e73 - 7 .
- 103 . Muniyand M Ramachandran R GopiPG Chandrasekaran V, Subramani R Sadacharam K , et al. The prevalence of tuberculosis in different economic strata: a community survey from South India . IntJ Tuberc Lung Dis 2007 ; 11 (9) : 1042 5.
- 104 . CorbetEL Watt CJ Walker N MaherD Waliams BG Ruiglione MC etal .Thegrowing burden of tuberculosis: global trends and interactions with the HIV epidemic . Arch Intern Med 2003 ; 163 (9) : 1009 - 21 .
- 105 . Thinkes GE LanNT, DungNH QuyHT, OanhDT, ThoaNT, et al. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis . JInfect Dis 2005 ; 192 (1) : 79 88 .
- 106 . UKe K LlenaJF, Juman WD SoeiroR Wordenheim KM HiranoA etal .Humanimmunodeficiency virus-1 infection of the nervous system: an autopsy study of 268 adult, pediatric, and fetal brains . HumPathol 1991; 22 (7) : 700 – 10.
- 107 . Lanjær DN Jain PP, Shetty CR Profle of central nervous system pathology in patients with AIDS: an autopsy study from India . AIDS 1998 ; 12 (3) : 309 13 .

- 108 . Okira JF, GrecoDB Okieira GC ChristoPP, GuimaraesMD Øveira RC Neurological disease in HIV-infected patients in the era of highly acti ve antiretroviral treatment: a Brazilian experience. Rev Soc Bras Med Trop 2006 ; 39 (2) : 146 – 51.
- 109. Bare B Taberculous meningitis. In: Bare B editor. HIV Neurology. New York: Oxford University Press; 2001 pp. 97 – 99.
- 110 . Garcia-Monco CNSTuberculosis and Mycobacteriosis .In: Roos editor. Principles of Neurologic Infectious Diseases . New York : McGraw-Hill ; 2005 pp. 195 – 214 .
- 111 . Bernaert A Minhoenacker FM Parizel PM Min Goethem JW, Min Altena R, Laridon A et al. Tuberculosis of the central nervous system: overview of neuroradiological findings. Eur Radiol 2003 ; 13 (8) : 1876 90 .
- 112 . Puccioni-SohleM BrandaoCO Factors associated to the positive cerebrospinal fluid culture in the tuberculous meningitis . ArqNeuropsiquiatr 2007 ; 65 (1) : 48 53 .
- 113 . Thankes GE flan TH Tuberculous meningitis: many questions, too few answers . Lancet Neurol 2005 ; 4 (3) : 160 70 .
- 114 . MachadoLR , Isiramento A , Bydlwski SP, Bendit I ,Brao LM ,Sina-Franca A Polymerase chain reaction in the diagnosis of tuberculous meningitis. Preliminary report . ArqNeuropsiquiatr 1994 ; 52 (3) : 445 6 .
- 115 . MachadbD Liramento A, Spina-FrancaA [Adenosinedeaminase in the cerebrospinal fluid of patients with acquired immunodeficiency syndrome]. ArqNeuropsiquiatr 1995 ; 53 (4) : 755 – 9 .
- 116 . Beer JR Kaszwitz B PostMJ DickinsonG Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases . AnnIntern Med 1987 ; 107 (1) : 78 – 87 .
- 117 .on Giesen HJ Neuen-JacobE DorriesK Jablonwski H RoickH Arendt G Diagnostic criteria and clinical procedures in HIV -1 associated progressive multifocal leuk oencephalopathy. JNeurol Sci 1997; 147 (1): 63 – 72.
- 118 . Antinoral CingolaniA LorenziniP, GiancolaML Uccellal Bossolasco S et,al. Clinical epidemiology and survival of progressive multifocal leuk oencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). JNeurovirol 2003; Suppl1: 47 53.
- 119 . FinMC Penala de Oliveira AC , MilagresFA , Vdal JE Picerno-PouzaAF , DuarteNeto A, et al. JC virus DNA in cerebrospinal fluid samples from Brazilian AIDS patients with focal brain lesions without mass effect . JInfect 2006 ; 52 (1) : 30 6.
- 120. Beer JR Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions. JNeurovirol 2003; Suppl1: 38 – 41.
- 121 . AgostirHiT, Brubaker GR ShaoJ Lein A Ryschkwitsch CF, Bittner WA ,etal .BKvirus and a new type of JC virus excreted by HIV-1 positive patients in rural Tanzania. Arch Virol 1995 ; 140 (11) : 1919 – 34 .
- 122 . Shanka&K , SatishchandraP, Mahadean A , Msha TC , NagarajaD Taly AB et, al. Low prevalence of progressive multifocal leuk oencephalopathy in India and Africa: is there a biological explanation ? JNeurovirol 2003 ; Suppl1: 59 67.
- 123 . Chim&C AgostiniHT, Ryschkwitsch CF, LucasSB StonerGL Rogressive multifocal leukoencephalopathy and JC virus genotypes in West African patients with acquired immunodeficiency syndrome: a pathologic and DN A sequence analysis of 4 cases. Arch Pathol Lab Med 1999 ; 123 (5) : 395 – 403 .
- 124 . AgostinHT, Ynagihara R Duis V, Ryschkwitsch CF, StonerGL Asian genotypes of JC virus in Native Americans and in a Pacific Island population: markers of viral evolution and human migration. ProcNatl Acad Sci U S A 1997 ; 94 (26) : 14542 6.

Impact of Clade Diversity on Neuropsychological Outcomes

Robert Paul, Ned Sacktor, Lucette Cysique, Bruce Brew, and Victor Valcour

Introduction

Studies of clade diversity and cognitive function associated with HIV are effectively studies of cross-cultural neuropsychology, given the global geography of the different clades. This produces unique challenges in understanding the impact of HIV on the brain, since cross-cultural neuropsychology requires careful attention to the translation and modification of cognitive tests, as well as concerted ef forts to assure cultural relevancy. In some developing countries this may pose e ven further challenges, as few if any neuropsychological measures may e xist and research teams might be required to develop a battery from scratch. The effort, however, is important because our knowledge regarding HIV brain involvement is limited to the genetic strain of the virus present in North America, Europe and Australia, while little is known about the more prevalent genetic strains in the world. Yet, when considered globally, it is estimated that HIV is one of the most common causes of dementia among individuals under the age of 40 (1). As such, there is a signif icant need to understand the neuropathogenesis of cognitive impairment across the major clade subtypes.

As described by Thomson in Chap. 13, it is possible that the dif ferent clade subtypes exhibit unique biological characteristics that lead to dif ferential levels of vulnerability within the CNS. For example, differences may exist across clades in specific protein binding sites and binding characteristics, replicati ve capacity (2), and possibly in the development of treatment resistance (3, 4), though much more work is needed in this area. Evidence of faster disease progression among individuals in Africa infected with clade D virus of fers yet additional evidence that the viral clades may exert unique biological impact on body systems (5). Yet the nature and direction of these differences, particularly in terms of the brain, are not well described and in some cases the y have been inconsistently described. F or example, some authors have suggested that a defect in the Tat protein in clade C may result in less

R. Paul (🖂)

Department of Psychology, Behavioral Neuroscience, University of Missouri – St. Louis, One University Blvd, St, Louis ,MO 63121, USA paulro@umsl.edu

neurovirulence (6), whereas others have suggested that clade C may be associated with higher rates of dementia because this clade has a strong affinity for the CCR5 receptor, which is itself associated with macrophage infiltration into the CNS (7).

The purpose of this chapter is to describe the current state of knowledge regarding clade subtype and the expression of HAND. As noted earlier, such a review almost inherently becomes organized by geography, but we have elected to identify each clade as the primary principle of or ganization below. It should be noted that a fe w studies have actually confirmed the clade subtype in studies, and it is possible that recombinant forms render the outcomes less clear . With these caveats noted, the following chapter describes the impact of clade di versity on cognitive function. Subsequently we review recommendations for future neuropsychological studies based on international settings.

Clade C

Clade C accounts for more than half of all HIV cases w orldwide and early studies suggested that the brain was less vulnerable in clade C HIV (e.g., 8, 9). Based on clinical studies, the prevalence of HIV-associated dementia was reported to be less than 5%, roughly one-fourth the rate that w as often reported in association with clade B HIV in North America (10, 11). Interestingly, Ranga et al. (6) demonstrated an important natural variation in the dicysteine motif of the Tat protein (C31S) that was conserved only in clade C virus. Further , the authors demonstrated that the variation was functionally significant, as the mutation diminished monocyte chemokine migration properties. Since the Tat protein promotes viral replication directly and it reduces HIV-resistance in uninfected cells, a functional change in the T at protein could significantly impact the virulence of the virus. Indeed, studies have demonstrated that Tat is selectively involved in the migration of monoctyes into the brain via upregulation of inflammatory cytokines and adhesion molecules (12). Tat has also been shown to disrupt the tight-junction proteins that support the blood-brain barrier (13), and therefore a defect in the T at protein could offer some protection against CNS involvement. Another recent study suggests that the T at gene in subtype C is associated with increased cell survival in rat hippocampal neuron cultures compared with subtype B (Li, unpublished data, personal communication).

Consistent with the biological properties described earlier, Clifford et al. (14) did not find significant neurocognitive differences between nontreated HIV+ indi viduals and demographically matched HIV– counterparts in Ethiopia, a ragion that is presumed to be largely associated with clade C virus. In this study, a brief neuropsychological battery was administered to treatment-naïve patients and a group of well-matched control subjects. The battery included the International HIV Dementia Scale, finger tapping, timed gait, and the grooved pegboard test. Of these tests, the HIV patients exhibited significantly slower performances on the finger tapping test, but performances were similar between the groups on the other measures. The authors of number of possible e xplanations for the lack of group dif ferences, including the possibility that clade C is less neuro virulent, though the y also cautioned that the restricted cognitive battery may not have provided sufficient sensitivity to detect the presence of actual group differences.

In contrast to the results from Ethiopia, se veral studies have now identified significant cognitive impairment associated with clade C HIV in India. Riedel et al. (7) reported a prevalence of 35% of HAND using the international HIV dementia scale in a large, untreated urban cohort from Pune, India. Another study in SouthIndia provided a much higher rate using a more comprehensi ve assessment (15). This study was conducted by members of our group with funding from the NIH. In thisstudy, 30 HIV+ individuals infected with clade C virus in India were compared with 30 healthy controls from the surrounding community on measures of neuropsychological function. The healthy controls were matched to the HIV group according to se x, age, and education. All subjects were administered a battery of neuropsychological measures that had been adapted from traditional US-based tests. The tests were translated and back-translated and adapted for cultural rele vance. Comparisons of HIV+ patients and the serone gative controls demonstrated significant differences between the two groups for v erbal list learning total recall, v erbal list learning delayed recall, visual learning and memory, fine motor speed and de xterity, and cognitive flexibility. Performances did not dif fer between the groups on the response inhibition. Overall, the range of impairment was 4% (Stroop incongruent) to 40%, with the lar gest percentages evident on the test of visual learning and cognitive flexibility. Further, 46% of the HIV participants with advanced HIV met criterion for impairment on two tests.

Nearly identical results have been obtained in a study conducted by Gupta et al. (16) In this study 119 HIV+ untreated individuals with clade C HIV underwent neuropsychological testing, and performances were compared with 126 seronegative individuals similar in demographic characteristics. The neuropsychological battery consisted of tapping, animal fluency, phonemic fluency, verbal working memory, visual working memory, executive function (Tower of London), and verbal auditory memory. Results indicated that more than one half of the HIV sample e xhibited mild to moderate cognitive impairments in the domains of verbal fluency, working memory, verbal learning, and v erbal memory. Overall immune system status did not correlate with cognitive function, though patients with CD4 counts belo w 200 or viral loads greater than 1,000,000 copies demonstrated poorer performance on a test of visual w orking memory. The in vestigators examined the percentage of patients with deficits (defined as performance below the 16th percentile) on each test, and reported that as man y as 30% of patients were impaired on the 2-back verbal working memory test, and nearly 35% of patients were impaired on the test of verbal auditory learning

These results along with the results of our own study indicate that cognition can be impaired among patients with clade C infection. Of particular interest is that the pattern of cognitive deficits associated with clade C is highly consistent with the pattern evident in clade B, and suggests that the same subcortical regions of the brain (including white matter) are impacted in this viral clade. Given the empirical evidence that cognition is af fected in clade C, it is possible that the reported lo w prevalence of HAND associated with clade C may be due to the fact that most other studies did not employ standardized cognitive tests to determine the presence of impairment rates, and therefore the prevalence of significant impairment may be higher than that initially reported. It is also possible thatless severe, but still clinically meaningful, difficulties on cognitive tests are present among individuals with clade C virus. Clearly, more comprehensive studies are needed, given the disparate results from Ethopia using the smaller battery. Members of our group are now working with the University of Cape Town, University of Stellenbosch, and University of Western Cape to complete comprehensive cross-clade studies of HIV neuropathogenesis in South Africa. These studies include neuroimaging and we believe these studies will significantly advance our understanding of clade C HIV and the brain.

Clades A and D

Several recent studies have been completed that e xamined cognitive function in patients residing in Africa with clades A or D. Sacktoret al. (17) examined the utility of an international HIV dementia scale in Uganda, an area of Africa known to be predominately A and D. In this study, 81 HIV+ individuals in Uganda and 61 HIV+ individuals in the US completed the screening measure, which includes tests of psychomotor speed, tapping, and recall. Neuropsychological assessments were also completed in order to test the sensitivity and specificity of the screening measure. In this study, the screening measure demonstrated a sensitivity of 80% and specificity of 55% in the Ugandan sample and nearly identical psychometric properties in the US sample.

More recently, Robertson et al. (18) reported that the neuropsychological battery administered in the Sacktor et al. study identif ied significant differences in verbal learning and memory, speed of processing, attention, and e xecutive function, with HIV patients in Uganda performing significantly more poorly than seronegative controls from the same region of Africa. Further work from this group has demonstrated that cognitive function improves with HAART among individuals from Uganda, and to our knowledge this is the first evidence of cognitive benefit from HAART in the context of clade diversity. Additional follow-up studies have been conducted on this cohort from Uganda, with a recent report from Wong et al. (19) that the prevalence of HAD was 31% in an urban cohort attending an AIDS clinic. The authors also showed that age and current CD4 cell counts were the only factors associated with HAD. This prevalence estimate is likely to be an underestimate considering the selection of their study population, which was likely to be healthier than some of their HIV+ counter parts in the rural areas of the country. In another study from Uganda, subtyping was performed in 60 HIV+ individuals who received detailed neurocognitive assessments. Eight of nine (89%) HIV+ individuals with subtype D had HIV dementia, compared with 7 of 33 (24%) HIV+ indi viduals with subtype A (Sacktor et al., CROI abstract 2008) (43). These findings are the first results in well-characterized HIV+ individuals in sub-Saharan Africa to demonstrate that HIV subtype may have different biological properties with respect to its capacity to cause HAND.

The reported prevalence of dementia in sub-Saharan Africa noted above is greater than the prevalence reported in the pre-HAART WHO study, which noted a 7% dementia prevalence in Nairobi and Kinshasa (20). Despite being dif ferent countries, it is likely that the prevalence may have been higher, but this study did not include many patients with AIDS. As noted by Wong et al. (19), differences in study method, type of clinics, type of HIV population studies, adv ancement of the disease, and use of nonstandard criteria may signif icantly affect the pre valence rate. These results demonstrate the feasibility of translating traditional US-based neuropsychological tests into local non-English languages in de veloping countries. Further, the results of these studies provide additional evidence that cognition appears to be affected in the A and D subtypes of HIV in addition to the B subtype.

Clade E

Circulating recombinant form (CRF) 01_AE, commonly referred to as clade E virus is one of the predominant circulating subtypes in Thailand, an area where some neurocognitive data have been acquired. Bangkok was one of the original five sites evaluated in a cross-cultural effort conducted by Maj et al. in the early 1990s (21). Here, the authors identif ied significant differences in neuropsychological testing among seronegative controls, symptomatic HIV adults, and asymptomatic HIV adults using their newly compiled neuropsychological battery designed to minimize cross-cultural influences (21). Specifically, symptomatic HIV patients showed deficits in the color trails one test, the groo ved pegboard dominant hand, trail making A, and two tests of v erbal fluency. In contrast, asymptomatic HIV patients dif fered from controls only in the grooved pegboard dominant hand. This early study identified neuropsychological deficits in Thai nationals with HIV, although clade determination was not included in this study.

More recently, members of our team replicated this work among 15 individuals diagnosed by a Thai neurologist to have HAD and matched HIV individuals without cognitive complaints of similar age and CD4 counts(22). Thirty age-and education-matched controls were used for comparison. Performance on a global composite score differed by serostatus. As a group, HAD cases performed w orse than did HIV+ controls in verbal learning and recall, psychomotor speed, and in one test of visuospatial skill, a pattern that is relatively similar to that previously described in clade B virus. All HIV cases were naïv e to HAART and confirmed to be infected with the CRF AE_01 subtype. With near uniformity, cases exhibited a robust cognitive response to HAART (Valcour, personal communication).

To our knowledge, HAND prevalence estimates have not been determined for clade E virus. Meanwhile, focused studies have identified clade-specific alterations that may impact cognition. Ranjbar et al. evaluated Tat proteins in clade E compared with clade B and C viruses, identifying selective inhibition of TNF gene transcription and gene production in clade E associated with a tryptophan substitution at residue 32 of the clade E T at gene. Such do wn-regulation in clade E may be e xpected to

impact neurovirulence. More recently, investigators in our group failed to identify differences in cellular activation markers (CD14+/16+) and inflammatory protein profiles in HAD compared with non-HAD patients in this Thai cohort in stark contrast to that previously described in presumably clade B infected subjects from the US (23, 24) This study provides an added cellular basis for differences by clade. Interestingly, this w ork also identified higher rates of cellular activation in seronegative controls from Bangkok when compared with seronegative controls in the US, highlighting the challenges in distinguishing cultural, environmental, host, and HIV genetic factors when interpreting the prevalence of neurocognitive impairment across international sites (23).

Further International Studies

In Latin America where the dominant clade is B, studies specif ically dedicated to investigate the rate of HAND are lacking. An epidemiological study of HIV+ neurological complications (25) reported a prevalence of 4.6% for dementia in an infectious disease clinic, in Brazil. Trujillo et al. (26) conducted a study in the preHAART era comparing US and Mexican samples on the prevalence of neurological complications. They found that dementia was the most common neurological manifestation in both groups, while intracranial tuberculoma w as present only in the Me xican population. A recent panel of e xperts from the US and Brazil reported se veral strategies to start to carefully study HAND in Brazil (27). It is hoped that from these initiatives, a more accurate picture of HAND will emer ge in the near future for Latin America.

In China where clade B is predominant with some clade E in the South and other recombinants, two studies have provided preliminary results. Pilot results from a study, including subjects from Beijing and the Anhui pro vince, found that HIV+ individuals performed worse than did their HIV- counterparts, who were matched for age, education, and gender on all standard neuropsychological tests included in the battery. On a global neuropsychological summary score, the dif ference between HIV+ and HIV- yielded a medium effect size (d = 0.55). The HIV+ group included mainly individuals with AIDS (28). In addition, the authors also found that the magnitude and pattern of neuropsychological testing did not differ compared with a US cohort matched for age and disease severity. This pilot study was the first phase of a larger investigation in former plasma donors in the rural area of Anhui (China) for which detailed results are forthcoming (29). Briefly, the authors developed demographically corrected norms (T-score conversions) on a comprehensive battery of neuropsychological tests using uninfected indi viduals for both HIV and HCV Using a global summary score, neuropsychological impairment was found in 34.2% of the HIV mono-infected group as compared with 12% in the controls (p < 0.0001(30)). Finally, the Asia P acific NeuroAIDS Consortium (APN AC) conducted a multisite study in HIV-infected outpatient from a wide range of clinics in China, Malaysia, Thailand, Cambodia, India, and P apua New Guinea (31). Their brief

neuropsychological battery included the timed gait, finger tapping (nondominant), grooved pegboard (dominant hand), and semantic fluency (category animal). Their criterion for significant neuropsychological impairment was defined as minus 2 SD in two of the four tests detecting moderate to severe impairment levels (i.e., HAD). Using local norms, they found that 12% of their cohort met the criteria for neurocognitive impairment.

The Assessment of Cognitive Functions in Developing Countries

The assessment of cogniti ve functions in de veloping countries in HIV -infected individuals poses a number of challenges to the adaptation of the neuropsychological method that have initially been developed in Western countries. First, it is often that in limited resources settings brief neurological and neuropsychological assessment will provide the most efficient mode of evaluation. To this effect, Sacktor et al. (32) have developed the international HIV dementia scale (IHDS) and a brief timed gait scale, respectively, with normative standards. However, as in W estern countries, these instruments should be primarily used for screening pur pose and caution should be applied when deriving prevalence of HAND only from them. Ideally an assessment similar in length to the one recommended by Antinori et al. (33) is necessary for reliable diagnosis of HAND and effort to accomplish this kind of studies is underway.

Second, educational attainment in de veloping countries v aries much more widely than in Western countries and includes individuals with very low or no formal education. In addition, dif ferences in educational attainment may v ary in function of gender, and whether individuals reside in urban vs. rural areas. It is known that poor educational attainment and illiteracy render the interpretation of conventional neuropsychological tests difficult (34). Indeed, most neuropsychological tests are based on the use of symbols, letters and numbers, visuo-spatial skills, and conceptual rules that will f avor individuals with high educational achie vement. Reversely, these tests may compound poor performance in individuals who already exhibit cognitive deficits due to HIV and have very low educational achievement. In this extreme case, even normative data may not adequately translate the e xtent of cognitive impairment due to HIV, because the performance will reach the lowest level in many instances. The WHO studies (20) made recommendations for the use of tests that are less biased in that sense (e.g., Color Trails rather than Trail Making Test). In addition to the careful selection of test measures, adequate selection of control population matched not only for age, education and gender, but also residence area is certainly required in de veloping countries. In f act large-scale normative studies (inclusive of a wider range of educational le vels) are required, such as the ones originally conducted in Western countries (35). In these forthcoming studies, it would be hoped that the effects of age, education, and gender as well as extended demographics are thoroughly explored on the most commonly used neuropsychological tests in NeuroAIDS research.

Third, specific considerations for translation need to be implemented. This means that literal translation of tests is not appropriate. The adaptation will ideally require the involvement of bilingual neuropsychologists in order to have the assurance that the conceptual basis of the test is respected in the translation. Moreover, in the case of language based tests, frequency of use, and semantic adequacy of the translation will have to be determined. F or example, as noted earlier, the WHO battery (20) included a test of verbal memory that appears not to have been modified for cultural relevancy in that the verbal memory test was translated but not modified to ensure that the target words retained similar meaning in the local languages. This is an important point, because simple translation does not equate to cultural rele vancy and in many circumstances modifications will be needed. In our w ork (15), we replaced an entire semantic category from the Hopkins Verbal Learning Test-Revised, because the existing category did not provide the same meanings and task demands once translated into the local languages, T amil and Telugu. Similarly, we have modified the WHO battery for cultural relevancy in Thailand, because some words from the verbal memory test did not have equal meaning in Thai. Investigators are truly obligated to take any necessary steps to ensure optimum cultural rele vancy. This is a prerequisite to correctly interpret the nature and pre-valence of HAND in developing countries, and guidance from the International T est Commission Guidelines can provide a meaningful starting point for investigators beginning this work (wwwintestcom.org/).

Fourth, certain comorbid conditions, either pree xisting HIV infection (e.g., malnutrition as children) or sometimes concomitant to HIV infection (e.g., tuberculosis, malaria, and other endemic diseases), need to be carefully recorded in limitedresource settings. Ideally, their independent ef fects on neuropsychological performance would need to be evaluated. In addition, HIV-related brain opportunistic infection, almost eradicated in Western countries with the widespread use of HAAR T, could account for some of the clinical impairment identified. This may happen especially in limited-resource settings where e xclusion of opportunistic infections is often impossible to complete with certainty. Therefore, reports should make an effort to record as carefully as possible the pre valence of brain opportunistic infection in their study population. Major psychiatric illnesses should be e valuated, such as major depressive disorder or substance use disorders, as their prevalence may vary significantly between countries or geographic re gions within a same country . Ideally again, their potential confounding effect on neurocognitive outcome should be independently evaluated.

Finally, investigators should take advantage of the research strategy gained from testing minority populations in W estern countries such as in Hispanic-Americans (36, 37), African-Americans (38, 39), and in Aboriginal-Australians (40) as well as some guidelines to foster good ethics practice in the conte xt of cross-cultural neuropsychology (41). In this respect local collaborators are essential interlocutors for providing and assessing the relevant information to their countries, cities, or villages reinforcing the need for a collaborative cross-cultural scientific strategy. International studies are also likely to involve training of some local collaborators, ideally again the training strategy should be reported by investigators to forge standardized practices.

Discussion

Overall it appears that cognitive function is impaired across most clades. There remains some uncertainty regarding clade C, but the two most comprehensive studies suggest that impairment is evident. Collectively these results provide further support for the possibility that HIV may be the most common form of dementia globally among individuals under the age of 40. Much more ef fort is needed to determine whether the impairment evident across clades reflects a common neuropathogenic pathway, as it is possible that the outcomes are similar b ut the routes are dif ferent (Jernigan, personal communication). If true, and studies are able to delineate the pathw ays, then we will have learned critical information about ho w this virus, and perhaps other viruses, negatively impact brain structure and function.

Fortunately, there is strong interest to develop this area of research. In 2007, investigators at the University of California, San Die go, initiated the International Consortium of NeuroAIDS Scientists; a major focus of this group is to promote and facilitate cross-clade and international neuropsychological studies. It is certainly timely that the Western scientific community is allocating some resources to study HAND in the developing countries (42). It is hoped that this strategy will inform us about the characteristics of HAND in developing countries as well as assist the training of local clinicians to correctly diagnose and address the manifestations of cognitive disorders. Reciprocally, the local clinicians are v aluable and essential collaborators as well as interlocutors in order to better understand the characteristics of HAND in their countries.

References

- 1 . Sacktor N
 Nakasujja N Sklasky R etal. Antiretroviral therapy improves cognitive impairment
 in HIV+ individuals in sub-Saharan Africa . Neurology 2006
 67 : 311 - 314 $\,.$
- 2 .Centlire M SommerP, MichelM Fing R Gofflo S Maladeau J etal. HIV1 clade promoters strongly influence spatial and temporal dynamics of viral replication in vivo. Journal of Clini Invest 2005 ±115 (2) : 348 358.
- 3 . GrossmanZ Mrdinon N ChemtobD AlkanM BentwichZ Burk M etal. IsraelMulti-center study group. Genotypic v ariation of HIV-1 reverse transcriptase and protease: comparati ve analysis of clade C and clade B . AIDS 2001 15 (12) : 1453 1460 .
- 4 .KantorR ZijenahL ShaferR Mutetwe S JohnstonE Llød R ,etal. HIVsubtype C reverse transcriptase and protease genotypes in Zimbabwean patients f ailing antiretroviral therapy. AIDSRes Hum Retroviruses 2002 ;18 (18) : 1407 1413 .
- 5. Kiwanuka N Lagendecker O RobbM KigoziG Arroyo M McCutcha F, EllerLA EllerM, MakumbiF, BirxD Wabwire-Mangen F, Serwadda D Swankambo NK QuinfIC, Waver M, GrayR Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV -1 infection. J Infect Dis 2008; 197 (5) : 707 13.
- 6 .RangaU ShankarappaR SiddappaN RamakrishnaL NagendranR Mahalingam M etal. Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine . Virology 2004 78 (5) : 2586 – 2590 .

- 7 .Riedel D ,Ghate M ,Nene M et al. Screening for human immunodeficiency virus (HIV) dementia in an HIV clade C-infected population in India . JNeurovirol 2006 ;12 : 34 38 .
- Satishchandra P, Nalini A, Gourie-Dei M, Khanna N, Santosh V, Rvi V, et al. Profle of neurologic disorders associated with HIV/AIDS from Bangalore, South India (1989–96). Indian J Med Res 2000 111 : 14 – 23.
- 9. Widia R PujariS Kothari S UdharM Kulkarni S BhagatS, etal. Neurologicalmanifestations of HIV disease . JAssoc Physicians India 2001 49 : 343 348 .
- GrantI HeatonR & AtkinsonJ Neurocognitive disorders in HIV-1 infection. HNRC Group. HIV Neurobehavioral research center. CurrTopics Microbiol Immunol 1995 202 : 11 – 32.
- 11 .Simpson D Human immunodeficiency virus-associated dementia: review of pathogenesis, prophylaxis, and treatment studies of zidovudine therapy. ClinInfect Dis 1999 29 (1) : 19 34.
- 12. PuH Jan J FloraG LeeYW, NathA HennigB Joborek M HIV1 Tat protein upregulates inflammatory mediators and induces monoc yte invasion into the brain. Mol Cell Neurosci 2003 24 (1): 224 – 237.
- 13 . Andras IE , Pu H , Deli MA , Nath A , Hennig B , Joborek M HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells. J Neurosci Res 2003 74 (2): 255 - 65.
- 14 .Clifford DB ,Mitik MT, Meknnen Y, et al. Neurological evaluation of untreated human immunodeficiency virus infected adults in Ethiopia. JNeurovirol 2007 13:67 72.
- 15. Ypthomi T, Rul R Malabhaneni S etal. Neurocognitive consequences of HIV in southern India: a preliminary study of clade C virus. JInt Neuropsychol Soc 2006 ;12 : 424 – 430.
- 16 .GuptaJD SatishchandraP, GopukumarK Wikie F, Wildrop-Valverde D, EllisR OwnbyR, SubbakrishnaDK DesaiA KamatA Rui V, RaoBS SatishKS Kamar M Neuropsychological deficits in human immunodef iciency virus type 1 clade C-seropositi ve adults from South India. JNeurovirol 2007 ;13 (3): 195 – 202
- 17 .SacktorN NakasujjaN Skalsky R RobertsonK Wing M MusisiS RonaldA Katabira E. Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa. Neurology 2006 67 (2) : 311 4
- 18 . Robertson KR ,Nakasujja N ,Wing M et al. Pattern of neuropsychological performance among HIV positive patients in Uganda . BMCNeurol 2007 7:8.
- 19 . Wing MH RobertsonK NakasujjaN etal. Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology 2007 68 : 350 355 .
- 20 .MajM SatzP, JanssenR et al. WHOneuropsychiatric AIDS study, cross-sectional phase II . ArchGen Psychiatry 1994 51 : 51 – 61 .
- 21. Maj M Janssen R , Satz P, Zaudig M , Starace F, Boor D Sughondhabirom B ,Bing EG , Luabea MK NdeteiD etal. TheWorld Health Organization's cross-cultural study on neuropsychiatric aspects of infection with the human immunodef iciency virus 1 (HIV -1). Preparation and pilot phase. BrJ Psychiatry 1991 159 : 351 – 6
- 22. Mcour VG, Sithinamsuwm P, Nidhinandanas Thittichianlert S Ratto-KimS Apateerapong W, ShiramizuBT, DesouzaMS ChitpatimaST, Wtt G ChuenchitraT, Rbertson KR Rul RH McArthurJC KimJH ShikumaCM Neuropsychologicalabnormalities in patients with dementia in CRF 01_AE HIV-1 infection. Neurology 2007 68 (7): 525 7
- 23 . Ratto-Kim S ,Chuenchitra T, Pulliam L , Rris R ,Sukwit S ,Gongwon S ,Sithinamsuwan P, Nidhinandanas Thitrichianlert S ShiramizuBT, deSouza MS ChitpatimaST, SunB Rempel H NitayaphanS ,Miliams K KimJH ShikumaCM Mcour VG theSoutheast Asia Research Collaboration with the Uni versity of Ha waii (SEARCH) 001 protocol team. Expression of monocyte markers in HIV-1 infected individuals with or without HIV associated dementia and normal controls in Bangkok Thailand . JNeuroimmunol 2008 ;195 (1–2) : 100 107
- 24 .PulliamL GasconR StubblebineM McGuireD McGrathMS Unique monocyte subset in patients with AIDS dementia . Lancet 1997 349 (9053) : 692 5
- 25 . Okieira JF, GrecoDB Okieira GC ChristoPP, GuimaraesMD Okieira RC Neurological disease in HIV-infected patients in the era of highly active antiretroviral treatment: a Brazilian experience. Rev Soc Bras Med Trop 2006 39 : 146 – 151.

- 26 . Tujillo JR Garcia-RamosG Nøak IS Riera VM HuertaE Esse M Neurologicmanifestations of AIDS: a comparative study of two populations from Mexico and the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1995 8 : 23 – 29 .
- 27 .EllisRJ JosephJ deAlmeida SM NeuroAIDSin Brazil . JNeurovirol 2007 13 : 89 96 .
- 28 .CysiqueLA JinH FranklinDR et-al. Neurobehavioral effects of HIV-1 infection in China and the United States: A pilot study. JInt Neuropsychol Soc 2007 13 : 781 790.
- 29. Heaton RK. Neurobeha vioral effects of HIV infection in China. Personal communication at International Society of Neurovirology meeting, San Diego October 2007.
- 30. Cysique LA, Chuan S, Xin Y, Hong K, Wu Z, Franklin D, Ake C, Marcotte T, Letendre S, Jin H, Grant I, Heaton R.K. Neurobeha vioral Effects of HIV Infection among F ormer Plasma Donors in rural China. Abstract at the 36th Annual International Neuropsychological Society Meeting, Hawaii. Feb 2008.
- 31 .WrightE Brev BJ Araywichanont A etal. Neurological disorders are prevalent in HIV positive outpatients in the Asia-Pacific region neurology. Neurology 2008 71 : 50 56
- 32 . SacktorNC Wong M NakasujjaN etal. The international HIV dementia scale: a new rapid screening test for HIV dementia . AIDS 2005 19 : 1367 1374 .
- 33 .Antinori A Arendt G Beckr JT, Brw BJ Byrd DA, Cherner M, Clifford DB , Cinque P, Epstein LG , Goodkin K , Gisslen M , Grant I , Heaton RK , Joseph J Marder K , Marra CM , McArthur JC , Nunn M Price RW , Pulliam L Robertson KR , Sacktor N , Mcour V , Wijna VE Updated research nosology for HIV-associated neurocognitive disorders . Neurology 2007 69 (18) : 1789 – 99 .
- 34 .LezakM Hwieson D LoringD HannayJ FischerJ Neuropsychobgical Assessment , 4th ed . Oxford OxfordUniversity Press , 2004 .
- 35 . Heaton R Miller W, Taylor MJ Grant I Revised Comprehensive Norms for an Expended Halstead Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults Lutz, FL Psychological Assessment Resources, 2004.
- 36 . Cherner M ,Suárez P, Posada C , Frtuny LA ,Marcotte T, Grant ,Heaton R ,Group TH Equivalency of Spanish language versions of the trail making test part B including or excluding "CH". ClinNeuropsychol 2008 22 (4): 662 5.
- Judd T, Capetillo D, Carrión-Baralt J, et al . Neuropsychological Evaluation of Hispanics: Ethics and Guidelines Hispanic Neuropsychological Society' s Position P aper Committee. Arch Clin Neuropsychol Rev 2008;18(3):179–183.
- 38 . ManlyJJ BrickmanAM CaboR etal. Deconstructing race and ethnicity: implications for measurement of health outcomes . MedCare 2006 ±4 : S10 - 16 .
- 39 . ManlyJJ EchemendiaRJ Race-specifc norms: using the model of hypertension to understand issues of race, culture, and education in neuropsychology
 Arch Clin Neuropsychol 2007; 22 : 319 325 .
- 40 . Cairne S & Maruff P AboriginalCulture, Petrol Sniffing and the Brain: Between Sorcery and Neuroscience. In Cohen & S. B (Eds.), Fragments from the mind and brain: Pulling together the pieces of the physical and psychological representations of consciousness Marquette, MI : Northern Michigan University Press, 2005.
- 41 .Brickman AM ,Cabo R ,Manly JJ et al. Ethical issues in cross-cultural neuropsychology . ApplNeuropsychol 2006 13 : 91 - 100 .
- 42 .Brev BJ ,Gonzalez-Scarano F HIVassociated dementia: an inconvenient truth . Neurology 2007 68 : 324 325 .
- 43. Sacktor, N., Nakasujja, N., Rezapour, M., Skolasky, R., Musisi, S., Katabira, E., Robertson, K., Clifford, D., Laeyendecker, O., Quinn, T. HIV subtype D is associated with a higher risk for dementia than subtype A in sub-Saharan Africa. 15 th Conference on Retro viruses and Opportunistic Infections. February 2008.

The Effects of Aging on HIV Disease

Robert C. Kalayjian and Lena Al-Harthi

Characteristics of Older Persons Living with HIV

Because of marked improvements in survival as a result of combination antiretroviral therapy (cART), persons older than 50 years constitute a rapidly gro wing segment of the pre valent, HIV-1 infected population. This age cutof f, although arbitrary, has prognostic validity in identifying a subset of persons who experience a greater rate of HIV disease progression, who are at a greater risk for cardiovascular and renal disease, and who are more likely to experience neurocognitive impairment. This chapter re views the epidemiologic and the clinical characteristics of HIV disease in older adults, and summarizes the current understanding of the effects of aging on the immunopathogenesis of HIV disease.

Persons 50 years or older ha ve represented approximately 12% of the ne wly diagnosed AIDS cases in the US since 2005 (1). In an analysis of such cases between 1991 and 1995, older persons were more likely to present with encephalopathy and w asting syndrome, and were more likely to die within one month of presentation, (2). Although the largest HIV transmission cate gory in this analysis were men who have sex with men, several studies also have demonstrated lower rates of HIV serocon version and lower rates of unprotected anal intercourse among older men, however (3–5).

In a recent community-based surv ey of se xuality among older Americans, although the majority of respondents were sexually active with a partner (83.7% of men, and 61.6% of women), and reported at least one bothersome se xual problem, only a minority of these older persons (only 38% of men, and 28% of women) had disscussed sex with their physicians (6). Together, these observations suggest that

R.C. Kalayjian (🖂)

Director of Infectious Diseases, MetroHealth Medical Center, Case Western Reserve University School of Medicine, 2500 MetroHealth Dr, Cleveland, OH 44109USA

rkalayjian@metrohealth.org

older persons are tested for HIV-1 infection later during their HIV disease course, because of lower self-perceived risks for infection, or lo wer risks as perceived by their health care providers.

Older Age and Accelerated HIV Disease Progression

A strong, detrimental contribution of older age to the natural history of HIV disease was recognized early in the AIDS epidemic. Signif icantly lower survival rates were evident among older persons with AIDS (40 years or older) compared with younger ages, in one of the earliest lar ge cohorts involving 5,833 AIDS cases diagnosed in New York city before 1986 (7). Because this association may have been confounded by longer durations of infection among older persons, stronger evidence for the contributions of age to the natural history of HIV disease was derived from a cohort of hemophiliacs with AIDS that included 319 persons with known dates of HIV-1 seroconversion, in which significant reductions in survival were associated with older age at seroconversion; this age-effect was evident as early as the second decade of life (8). These observations were confirmed in an analysis from 38 studies, before the a vailability of cART, that included 13,030 persons with kno wn dates of serocon version, in which each 10-year increment in the age of serocon version was associated with a 1.47-fold increased risk of death (9). In this analysis, the median time to an AIDS diagnosis fell from 11 years to 8.6, and 4 years, for persons who seroconverted between the ages of 15-24, 35-44, and 65 or older, respectively.

The detrimental effects of age on the natural history of HIV persist despite cART. Older age at the time of cART initiation was associated with a higher probability of a new AIDS defining event or death in three lar ge cohort studies that included 3,015 participants in the French Hospital Database, 12,574 participants in the International Antiretroviral Therapy Cohort Collaboration, and 16,198 participants in a rapid scale-up project of cART application in Zambia (10–12). Despite adjusting for relevant baseline differences, analyses of these cohorts demonstrated more rapid HIV disease progression in persons who be gan cART at the age of 50 or older , in the studies from industrialized settings, and at the age of 41 or older , in the resources limited setting.

Additional, compelling evidence for the detrimental effects of age on HIV disease progression were deri ved from a population-based cohort of 3,990 HIV -1 infected Danish patients during the late cART-era (from 2000 to 2005) that included 379,872 persons from the general population (13). Although the relative mortality rates for HIV disease decreased in association with older age, because of agedependent increases in mortality within the general population, the e xcess HIVattributable mortality rates increased in association with older age; this rate did not exceed 12.3 per 1,000 person-years for persons younger than 50, b ut increased to 19.5, and 53.8 per 1,000 person-years for those aged 55–60, and 65–70, respectively. These studies confirm the strong effect of age on HIV disease progression, which in the absence of antiretroviral therapy, is evident at young ages, within the second decade of life. This effect is reduced, but is not eliminated by the application of cART, and is apparent in industrialized, and in resources limited-settings alik e.

Adherence, Tolerability, and Viral Suppression with cART

Despite concerns of reduced tolerability and increased medication-associated toxicities among older persons, adherence to antiretro viral medications appears to be at least as good, if not better in older patients compared with their younger counterparts (14–18)This was most evident in an analysis of self-reported adherence in the Anti Protease Cohort that included 970 patients with at least 12 months of follow-up, in which moderate and poor medication adherence w as independently associated with younger age; additional correlates included treatment side effects, more frequent dosing, and protease inhibitor-based regimens (18).

Consistent with these adherence dif ferences, several studies also have demonstrated that older persons were more likely to achieve sustained viral suppression in association with cART (19–21). For example, older age was the most significant baseline predictor of viral suppression over 144 weeks of cART, as demonstrated in an observational cohort study of 1,083 subjects in the AIDS Clinical T rials Group (ACTG) Longitudinal Linked Randomized Trial, in which subjects be gan their first cART regimen through one of se veral randomized clinical trials. Similarly, older age was associated with a longer time to the emergence of indinavir resistance, in a multi variable analysis to identify correlates of resistance among demographic, immunologic, virologic and pharmacokinetic factors from five randomized clinical trials (22).

The association between older age and cART-related toxicities are less clear. In a single-center, retrospective cohort of 222 subjects from Madrid, older age w as associated with an increased risk of hepatic toxicity in association with cART (23). No significant age-group differences in any medication-associated toxicities were observed in a prospecti ve, multicenter, age-differentiated cohort study (A CTG Protocol 5015) of 90 subjects; ho wever, who were e venly divided into older (median age 50, range 45–79) and younger (median age 26, range 18–30) agegroups, and who received 192 weeks of a uniform protease inhibitor cART regimen (24). Older persons were significantly less likely to modify or to change their initial cART regimen due to toxicity, in an analysis of 556 subjects of the Ro yal Free Hospital in London, and there were no dif ferences according to age in subsequent modifications of cART due to toxicity, in the multicenter ATHENA cohort of 2,470 subjects (25, 26).

Several studies have documented a signif icantly higher risk of lipoatrophy in older persons, in association with cART (27–30). Therefore, although older persons are at a greater risk of lipoatrophy and possibly hepatotoxicity, they often exhibit better adherence to cART, and they are more likely to achieve superior levels of viral suppression than younger persons.

Comorbidities and Adverse Clinical Events

Older persons have more comorbid conditions, and take more medications for these conditions (31, 32). In ACTG Protocol 5015, older persons were more likely to receive a new diagnosis of hypertension or cardio vascular disease during the 192 weeks of follow-up (24). In a retrospective cohort of 165 older patients (ages 55 years or older) from three outpatient clinics in New York city, 147 patients (89%) had a mean of 2.4 comorbid conditions (32). Although 133 patients (81%) received a mean of 2.7 medications for these conditions, the likelihood of viral suppression was not adversely associated with either the presence of comorbidities, or with the number of concurrent medications that were prescribed.

The risk of cardio vascular and kidney disease is strongly associated with older age among HIV -1 infected persons, as it is in the general population (33-37). In the large prospective data collection on adverse events of anti-HIV drugs study group of 23,468 HIV-1 infected patients who were followed between 1999 and 2001, each 5-year increment in age w as associated with a 38% increased risk of myocardial inf arction (34). Older age w as associated with higher hospitalization rates for cardiovascular or cerebrovascular disease among 36,766 HIV infected patients who recei ved care at v eterans affairs facilities (between 1993 and 2001),(33) and older age (greater than 45 years) was associated with a greater risk of v enous or pulmonary thrombosis, in the multicenter adult/adolescent spectrum of HIV disease project of 42,935 HIV-1 infected outpatients (38). HIV disease has been associated with an increased risk of cardiovascular disease in some, but not all studies (39, 40). In one study of more than three million California medicaid recipients, this increased cardio vascular risk was evident among younger (up to the ages of 34 in men, and 44 in women), but not in older persons (39).

HIV disease is associated with both primary and secondary causes of kidne y disease, and the risk of acute and chronic kidne y disease increases with age (35–37). Several studies have demonstrated increased mortality rates in association with acute, and chronic kidne y disease (defined by either proteinuria or reduced serum creatinine) among HIV-1 infected persons, which were independent of other relevant baseline factors (35, 36).

As the incidence of AIDS defining malignancies has fallen markedly in association with cART, accounting for 1.1 deaths/1,000 person-years in a recent analysis from the Data Collection on Adverse Events of Anti-HIV Drugs Study Group (D:A:D), the death rate from non-AIDS defining malignancies, including lung, gastrointestinal, hematologic and anal cancers ha ve increased, to 1.8 deaths/1,000 person-years (41). The risk of death for both AIDS defining, and non-AIDS defining malignancies in this study was associated with CD4⁺ cell depletion; older age, cigarette ab use and active hepatitis B infection were additional risk factors for death from non-AIDS defining cancers.

In an analysis of 319 lung cancer cases in persons with AIDS, HIV disease accounted for higher than e xpected rates of lung cancer, when adjusted for age, race, sex and smoking intensity (42). This excess risk was evident in men who were

Comparisons of older vs. younger persons with HIV-1 infection	Comment
Epidemiologic differences Accelerated HIV disease progres- sion (9– 12)	Evident during the second decade of life in the pre- cART era, and after the fourth decade of life in association with cART (9, 10–12)
Lower rates of HIV seroconversion and unprotected anal intercourse, among men who have sex with men (3–5)	
Clinical differences	
More advanced immunodeficiency at presentation, with more encephalopathy and wasting (2)	
Better adherence to cART (14– 18)	
Higher proportions of persons with sustained viral suppression (19-22)	
Greater risk of lipoatrophy in asso- ciation with cART (27- 30)	
Greater risk of cardiac, cerebrov- ascular and peripheral vascular events (33, 34, 38, 39)	HIV was associated with greater cardiovascular risk among younger, but not older persons, however (39)
Greater risk or renal disease (35–37) Greater number of co-morbidities (31, 32)	
Greater risk of death from non- AIDS defining malignancies (41, 42)	HIV was associated with higher than expected rates of lung cancer, among women, ages <50 years, and among men, ages <60 year (42)

 Table 1
 Significant epidemiologic and clinical differences in older HIV-infected persons, compared with younger HIV-infected persons

IDU injection drug use

younger than 60, and in women who were younger than 50, but it was not evident among older men or women. Therefore, the increased risk of lung cancer that is attributable to HIV may be the result of higher than expected cancer rates among younger persons, but lung cancer rates among older, HIV-1 infected persons may not exceed those of the general population.

Finally, older HIV-1 infected persons may have a higher risk of AIDS dementia complex, as was demonstrated in a cross-sectional analysis of the 202 HIV -1-infected subjects in the Hawaii Aging with HIV-1 Cohort (43). After adjusting for education, race, current substance dependence, depression, cART use, HIV-1 viral load and CD4⁺ cell counts, participants o ver 50 years old were 3.26 time more likely to meet criteria of HIV -associated dementia complex than were younger subjects in this cohort.

Aging and the Immunopathgenesis of HIV Disease

HIV disease and normal aging are both associated with enhanced susceptibility to infections by encapsulated organisms, increased risks of tuberculosis and varicella zoster reactivation, and higher rates of malignanc y (44, 45). Because many of the same immunologic changes that de velop during normal aging also arise as a consequence of HIV disease [Table 2], this has lead to the hypothesis that HIV disease induces an accelerated aging of the immune system, resulting in the premature exhaustion of immune resources (46). A better understanding of the mechanisms that underlie the association between aging and HIV disease progression may facilitate a better understanding of the immunopathogenesis of both processes.

Both normal aging and HIV disease are characterized by a shift from a predominance of naïve to memory T -cell phenotype (47, 48). Both conditions also are associated with: T-cell dysfunction and reduced proliferative responses to antigenic and to mitogenic stimulation;(49, 50) reduced IL-2 production in response to T-cell receptor (TCR)-mediated stimulation; (51–53) post TCR-mediated signal transduction abnormalities with impaired cell c ycle progression;(54, 55) lower expression of the costimulatory molecule, CD28 on CD8⁺ cells;(56, 57)B-cell dysfunction that

Immune differences	Aging	HIV	Comment
T-cells			
Thymic output	\downarrow	\downarrow	Thymic involution with aging, impaired intrathymic proliferation with HIV-1-infection (65–68)
Circulating naive T-cells	\downarrow	\downarrow	Involves CD4 ⁺ and CD8 ⁺ cells in both aging and HIV disease (47, 48)
T-cell proliferation	\downarrow	\downarrow	To both antigenic and mitogenic stimulation with both aging and HIV disease (49, 50)
Expression of the coactivation mol- ecule (CD28) on T-cells	\downarrow	\downarrow	Expansion of CD28 negative cells, and contraction of CD28 positive cells with both aging and HIV (56, 57)
TCR signal transduc- tion	\downarrow	\downarrow	Abnormalities in cell cycle progression following TCR stimulation (54, 55)
T-cell activation	Ţ	Ŷ	Heightened HLA-DR, Fas and FasL expression on CD4+and CD8+cells with both HIV and aging (60-62)
Replicatitve senes- cence	ſ	ſ	Telomere shortening involves CD4 ⁺ and CD8 ⁺ cells with aging, and CD8+cells with HIV disease (105-108)
sTNFR-II	-	\downarrow	sTNFR-II is elevated with HIV, particularly in older persons with HIV, but not with normal aging (68)
B-cell proliferation	\downarrow	\downarrow	B-cell proliferation defects with both aging and HIV disease (58, 59)

Table 2 A comparison of similar immunologic parameters that have been observed, both inassociation with normal aging, and in association with HIV disease

TCR T-cell receptor; FasL Fas ligand; sTNFR-II soluble tumor necrosis factor receptor II

impairs the generation of high affinity antibodies;(58, 59) and heightened immune activation with enhanced susceptibility to activation induced cell death (60–62).

CD4⁺ Cell Regeneration in Response to cART

Older age is associated with reduced CD4⁺ cell restoration in response to cART (63, 64). Among 1,956 patients who initiated a cAR T regimen in the prospective, multicenter EuroSIDA cohort, older age (greater than 40 years) at cART initiation was associated with a lo wer likelihood of achie ving circulating CD4 ⁺ cell count increases of 100 or 200 cells/µL above baseline, and with a longer time in achieving absolute CD4⁺ cell counts greater than 200/µL (63).

Similarly, greater CD4⁺ cell reco very was associated with younger age, in a multivariable analysis that was adjusted for sex, baseline HIV-1 viral load, baseline CD4⁺ cell counts, and included post-baseline contrib utions by viral suppression, from a multicenter, prospective, randomized ACTG trial of 980 subjects who began their first cART regimen (64). In this study, older age (greater than 40 years) w as associated with lo wer median CD4⁺ cell increases from baseline (by 40–50 cells/ μ L), over 144 weeks of observation.

Naïve T-Cell Depletion and Thymic Dysfunction

This reduced capacity to restore total CD4 $^+$ cells may result from a diminished capacity to generate naïve CD4⁺ cells, because of impaired thymic output from ageassociated thymic involution, or because of HIV-associated impairments in thymocyte proliferation (65–68).

Involution of the thymus follows a biphasic, exponential pattern of volume contraction that begins at puberty but may be accelerated be yond the third decade of life (69). Despite this process, however, several lines of evidence suggest that thymopoiesis and de no vo T-cell synthesis continues throughout adulthood (70–73). Specifically, this evidence includes the isolation of functional thymocytes from the thymic tissue of older adults, and the measurement of signal-joint or coding-joint TCR gene rearrangement excision circles (sjTREC or cjTREC) (70–73).

TRECs are DNA plasmids that are products of TCR gene rearrangement, encoding the δ locus of the α -TCR chain, which occurs in the thymus during the double positive stage of T-cell development (CD3⁺ CD4⁺ CD8⁺). TREC containing cells, therefore, identify recent thymic emigrants, and reductions in TREC concentrations within lymphocytes indicate reduced de no vo T-cell synthesis. When measured in this way, reduced thymic output has been demonstrated in association with both aging and HIV disease (70, 72). Lower TREC concentrations independently predicted accelerated HIV disease progression in the absence of antiretroviral therapy, when adjusted for the age at HIV -1 seroconversion(74), and increases in TREC concentrations were observed in association with cART application, suggesting that HIV-associated thymic dysfunction may be reversible (70, 75). Because TRECs do not replicate, ho wever, their concentrations within recent thymic emigrants may be diluted with each c ycle of cell division. Therefore, in an environment of accelerated cell di vision, reductions in TREC concentration may indicate a higher rate of cellular proliferation, from the dilution of TREC signal, rather than reductions in de no vo T-cell synthesis. These dilutional effects can be avoided by measuring β -chain TCR gene rearrangement products (β TREC), a process that occurs earlier in thymoc yte development, during the triple-ne gative stage of T-cell development (CD34⁺ CD1⁺ CD3⁻ CD4⁻ CD8⁻) (76). Intra-thymic proliferation can then be estimated by the ratio of β TREC: sjTREC, and this ratio is not susceptible to these diluting effects on TREC concentration. When measured in this way, impairments of intrathymic proliferation with reduced thymic output have similarly been demonstrated, both in association with HIV disease and with aging, and enhanced thymic output also w as demonstrated in HIV disease with cAR T application (76).

Thymic volume can be estimated by noncontrasted chest CT (77), and larger thymic volumes also have been correlated with higher circulating naïv e and total CD4⁺ cell counts, and with greater CD4 ⁺ cell increases in response to cAR T (78–82). These associations similarly support the importance of thymic contributions to CD4⁺ cell homeostasis in adults.

Thymic independent pathw ays of peripheral T -cell expansion in response to cART also have been demonstrated in adults with HIV disease; ho wever, and in other T-cell depleting conditions including bone marro w transplantation, and normal aging (83–86). A better understanding of the e xtent to which total and naïv e CD4⁺ cell restoration in response to cART is limited by thymic output, and the ability of these thymic independent pathways to compensate for reduced thymic output may be informative in devising strategies to enhance CD4⁺ cell recovery in HIV disease, and in other T-cell depleting conditions.

Heightened Immune Activation

Heightened immune activation is a cardinal manifestation of HIV disease, and to a lesser extent, is also associated with normal aging. Substantial ele vations in the expression of the activation markers HLA-DR, CD38, and F as (CD95) on CD4 ⁺ and CD8⁺ cells have been consistently demonstrated in HIV disease (61, 87), and elevations in HLA-DR expression on T-cells also has been observed in association with normal aging (60). In HIV disease, markers of immune activation were better correlates of CD4⁺ cell depletion than were plasma HIV-1 RNA concentrations, and more rapid disease progression was predicted by higher HLA-DR/CD38 expression on CD8⁺ T-cells in untreated patients, independent of baseline plasma HIV-1 RNA concentrations (88–90). Reductions in T-cell activation in response to cAR T also correlates with CD4 ⁺ cell increases when adjusting for suppression of HIV -1 plasma viremia (91–93). Although heightened T-cell activation may persist despite

several years of antiretroviral therapy, normalization of this activation marker was demonstrated in one cohort after 6 years of cART (64, 94, 95).

Fas is a member of the tumor necrosis factor (TNF) receptor superfamily, and is a major mediator of apoptosis. Fas binding by Fas ligand (FasL) initiates apoptosis by the activation of caspases, which activate cellular proteases and endonucleases that cleave host cell structural and regulatory proteins and nuclear DNA (96). The soluble TNF receptor type II (sTNFR-II) is deri ved from proteolytic cleavage of the cellsurface receptor, p75TNF-R, and modulates TNF- α activity through competitive binding with this cell-surface receptor (97). T-cells from HIV-1-infected donors and older, healthy donors (65–95 years), exhibit heightened susceptibility to apoptosis in association with increased Fas and FasL expression, and cART reduces apoptosis in association with reductions in Fas expression (62, 98) .Soluble TNFR-II was a strong, independent predictor of HIV disease progression in three cohorts of subjects who did not receive cART (99- 101)CD4+ cell increases during cART also were associated with polymorphisms in se veral TNF-related genes, including TNF- α , TNFR-I, TNFR-II, TNF-related apoptosis inducing ligand (TRAIL), and caspase-8, and higher sTNFR-II concentrations were associated with less naive CD4⁺ cell recovery in a casecontrolled study of immunologic nonresponders to cART (102, 103).

These studies support a gro wing consensus of a major role by heightened immune activation in AIDS pathogenesis. Among the many unanswered questions are included: what are the causes of immune activation in HIV disease, and to what extent does immune acti vation represent a cause, rather than a consequence of immune damage? (104).

Replicative Senescence

Telomeres are repeating DN A–protein structures located on the ends of chromosomes that shorten (by approximately 50–200 base pairs) with each cell division. In the absence of compensatory mechanisms to lengthen telomeres, by telomerase, cell death ensues when a critical telomeric length is achie ved (105). As such, telomeres may serve as a mitotic clock in predicting the replicative capacity of a cell.

Telomere shorting in peripheral blood mononuclear cells (PBMC) of HIV -1infected persons is accelerated compared with healthy adults (to 100–300 base pairs/year, compared with 30–50 base pairs/year). This shortening is consistently observed within CD8⁺, but not CD4⁺ cells; however, and is associated with reductions of CD28 cell-surf ace expression, the primary costimulatory molecule for naïv e T-cells (106–108)Circulating lymphocytes from HIV-1-infected persons, and from healthy older adults have increased frequencies of terminally differentiated, CD28^{-/} CD8⁺ cells. Telomere lengths within this terminally differentiated subset were comparable to those of PBMC from centenarians (109). This terminally differentiated subset is also characterized by the cell-surface expression of CD57, and the absence of CD27 expression. In HIV disease, this subset also was inversely correlated with circulating CD4⁺ cell counts (110). These observations suggest that ele vated and chronic immune activation in the context of HIV-1-infection may drive CD8⁺ cell differentiation towards a state of replicative senescence and may contribute to an exhaustion of immune capacity.

Age-Associated Immunologic Differences in Response to cART

In ACTG protocol 5,015, older HIV -1-infected subjects had signif icantly lower naïve CD4⁺ and CD8⁺ cells, lower total CD4⁺ cells, lower frequencies of CD8⁺ cells that expressed CD28, and higher F as (CD95) expression on T-cells at baseline (111). They also had lower thymic volumes as estimated by CT, and lower sjTREC concentrations within PBMCs and higher sTNFR-II plasma concentrations compared with their younger counterparts (68). Despite more durable HIV-1 suppression during 192 weeks of follow-up among older subjects, they exhibited lower naïve CD4 cell increase but demonstrated substantial B-cell expansion, to levels that were significantly higher than age-matched, healthy controls (24).

Greater rates of nai ve CD4⁺ and CD8⁺ cell increases were predicted by lo wer frequencies of CD8⁺ cells that expressed Fas, in longitudinal, multivariable models; larger thymic volumes and viral suppression to <400 copies of HIV1 RNA/mL also were associated with greater rates of naïv e CD4⁺ cell increase (112). These observations highlight the comple x, detrimental contributions by immune activation to cART- mediated CD4⁺ cell restoration, and implicate heightened TNF-activity and reduced thymic output as potential mediators of impaired naïve CD4⁺ cell recovery among older people in response to cART. A better understanding of these contributions may inform more effective strategies to restore immunity, in addition to that which is achieved with antiretroviral therapy alone.

Concluding Remarks

The challenges that are imposed by HIV disease include not only viral eradication but also the reconstitution of a battered immune system. Because of the strong effects of age on HIV disease progression, and the similarities between the immunopathogenesis of HIV disease and that of immunosenscence, a better understanding of aging in the conte xt of HIV disease may pro vide important insights into both processes. Correlates of age-associated dif ferences in HIV disease outcomes may help to identify underlying mechanisms that are responsible for this effect, and may lead to interventions that enhance thymic output, improve T-cell survival or selectively reduce immune activation, so as to augment the benef icial effects of HIV-1 viral suppression and improve immune restoration. A better understanding of the unique challenges that are associated with the care of older HIV -1-infected persons is essential for optimal care and impro ved outcomes in this rapidly growing segment of the population.

References

- Centers for Disease Control and Pre vention. HIV/AIDS Surveillance Report, 2005, Vol 17. Rev ed. Atlanta:available at:http//cdc.gov/hiv/topics/surveillance/resources/reports/. Accessed 4/26/08. 2003.
- AIDS among persons aged > or = 50 years–United States, 1991–1996. MMWR Morb Mortal Wkly Rep 1998; 47 (2): 21 – 7.
- 3 . Penkwer L Dev MA Kingsly L etal .Behavioral, health and psychosocial factors and risk for HIV infection among se xually active homosexual men: the Multicenter AIDS Cohort Study .Am J Public Health 1991; 81 (2): 194 – 6.
- 4. eKy A, Murphy DA, Roffman RA et al . Acquired immunodeficiency syndrome/human immunodeficiency virus risk behavior among gay men in small cities. Findings of a 16-city national sample *.Arch Intern Med* 1992; 152 (11): 2293 7.
- 5 . BuchbindeSP, Douglas JM ,Jr , McKirnan DJ ,Judson FN ,Katz MH MacQueen KM Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk beha vior, seroincidence, and willingness to participate . J Infect Dis 1996 ; 174 (5) : 954 61 .
- 6 . LindaßT, SchummLP, LaumannEO Læinson W, O'MuircheartaighCA Waite LJ Astudy of sexuality and health among older adults in the United States . N Engl J Med 2007 ; 357 (8) : 762 74 .
- 7 . Rothenbgr R Welfel M Stonebrner R Milbeg J Prker R Tuman B Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City. *N Engl J Med* 1987; 317 (21): 1297 302.
- 8 . GoederlJ Kessler CM AledortLM etal .Aprospective study of human immunodeficiency virus type 1 infection and the de velopment of AIDS in subjects with hemophilia . N Engl J Med 1989; 321 (17): 1141 8.
- Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-acti ve antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 2000;355(9210):1131–7.
- 10 .EggerM MayM CheneG etal .Prognosisof HIV-1-infected patients starting highly active antiretroviral therapy: a collaborati ve analysis of prospecti ve studies. *Lancet* 2002 ; 360 (9327) : 119 – 29 .
- 11 .GrabarS Kusignian I SobelA etal .Immunologicand clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV AIDS 2004; 18 (15): 2029 – 38.
- 12 .StringerJS ZuluI Ley J etal .Rapidscale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. *JAMA* 2006 ; 296 (7) : 782 93 .
- 13 .LohseN HansenAB PedersenG etal .Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med 2007; 146 (2): 87 – 95.
- 14 . Reterson DL , Swindells S , Mohr J et al . Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. *Ann Intern Med* 2000; 133 (1): 21 30.
- 15 .CarrieriP, CailletonV, LeMoing V, etal .Thedynamic of adherence to highly active antiretroviral therapy: results from the French National APR OCO cohort. J Acquir Immune Defic Syndr 2001; 28 (3): 232 – 9.
- 16 .Stone VE ,Hogan JW, Schuman P, et al . Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their re gimens: survey of women in the her study *J Acquir Immune Defic Syndr* 2001; 28 (2) : 124 31.
- 17 .Hinkin CH ,Hardy DJ ,Mason KI et al .Medication adherence in HIV-infected adults: effect of patient age, cogniti ve status, and substance ab use. *AIDS* 2004 ; 1**S**uppl 1 : S19 25 .
- 18 .CarrieriMP, LeportC ProtopopescuC etal .Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced

by missing data in the treatment maintenance phase $\ .\ J\ Acquir\ Immune\ Defic\ Syndr$ 2006 ; 41 (4) : 477 – 85 .

- MocroftA GillMJ Duidson W, PhillipsAN Predictors of a viral response and subsequent virological treatment f ailure in patients with HIV starting a protease inhibitor . *AIDS* 1998 ; 12 (16) : 2161 7 .
- 20 LeMoing V, CheneG CarrieriMP, etal. Predictorsof virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002; 16 (1): 21 – 9.
- 21 BoschRJ BennettK CollierAC, ZackinR BensonCA Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretro viral therapy. *J Acquir Immune Defic Syndr* 2007; 44 (3): 268 77.
- 22 DrusanoGL BilelloA, SteinDS et al. Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic v ariables. J Infect Dis 1998; 178 (2): 360 - 7.
- 23 Nunez M JLana R , Mendoza JL , Martin-Carbonero L , Soriano V .Rik factors for severe hepatic injury after introduction of highly active antiretroviral therapy. *J Acquir Immune Defic Syndr* 2001; 27 (5): 426 31.
- 24. Kalayjian R, Matining R, Tebas P, et al. Older persons have impaired restoration of naive CD4 cells in response to HAAR T. 13th Conf on Retro viruses and Oppor Infect, Den ver 2006; Abstract#444.
- 25 Dieleman JP, Jambroes M, Gyssens IC et al. Determinants of recurrent toxicity-driven switches of highly acti ve antiretroviral therapy. The A THENA cohort. AIDS 2002 ; 16 (5) : 737 - 45.
- 26 MocroftA Jule M MooreA etal .Reasonsfor modification and discontinuation of antiretrovirals: results from a single treatment centre. *AIDS* 2001 ; 15 (2) : 185 – 94 .
- 27 MallalSA JohnM MooreCB JamesIR McKinnonEJ Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous f at wasting in patients with HIV infection . AIDS 2000 ; 14 (10) : 1309 - 16 .
- 28 Heath KV, Hogg RS, Chan KJ et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database . AIDS 2001 ; 15 (2) : 231 – 9 .
- 29 Martinez E ,Mocroft A ,Garcia-Yejo MA et al .Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospecti ve cohort study . *Lancet* 2001 ; 357 (9256) : 592 8 .
- 30 LichtensteinKA Wird DJ MoormanAC ,etal .Clinicalassessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001; 15 (11): 1389 – 98.
- 31 SkiestDJ RubinstienE Carly N GioiellaL Lons R Theimportance of comorbidity in HIV-infected patients o ver 55: a retrospecti ve case-control study. Am J Med 1996; 101 (6): 605 - 11.
- 32 ShahSS McGwan JP, SmithC BlumS KleinRS Comorbid conditions, treatment, and health maintenance in older persons with human immunodef iciency virus infection in Ne w York City. *Clin Infect Dis* 2002 ; 35 (10) : 1238 43.
- 33 Bozzette SA Ak CF, Tim HK Chang SW, Louis TA Cardiovascular and cerebrovascular events in patients treated for human immunodef iciency virus infection. N Engl J Med 2003 ; 348 (8) : 702 - 10.
- 34 Friis-MollerN SabinCA Weber R etal .Combinationantiretroviral therapy and the risk of myocardial infarction .*N Engl J Med* 2003 ; 349 (21) : 1993 2003 .
- 35 SzczechLA Hover DR FeldmanJG etal .Associationbetween renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. *Clin Infect Dis* 2004 ; 39 (8) : 1199 – 206 .
- 36 .Watt CM AronsRR KlotmanPE KlotmanME Acuterenal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. *AIDS* 2006; 20 (4) : 561 5.
- 37 MocroftA KirkO GatellJ etal .Chronicrenal failure among HIV-1-infected patients *AIDS* 2007 ; 21 (9) : 1119 27 .

- 38 Sullian PS ,Dworkin MS ,Jones JL ,Hooper WC Epidemiology of thrombosis in HIV-infected individuals. The adult/adolescent spectrum of HIV disease project . AIDS 2000 ; 14 (3) : 321 4 .
- 39 Currier JS , Tylor A , Byd F, et al . Coronary heart disease in HIV-infected individuals . J Acquir Immune Defic Syndr 2003 ; 33 (4) : 506 – 12 .
- 40 .Goulet JL ,Fultz SL ,McGinnis KA ,Justice AC Relative prevalence of comorbidities and treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans. *AIDS* 2005 ; ISuppl3 : S99 – 105 .
- 41. d'Arminio Monforte A, Abrams D, Pradier D, et al. HIV-induced immunodeficiency and risk of fatal AIDS-defining malignancies: resuts from the D:A:D study. 14th Conf on Retroviruses and Oppor Infect, Los Angeles 2007:Abstract #84.
- 42 Chaturedi AK Pfeifer RM ChangL GoedertJJ BiggarRJ Engls EA Elevated risk of lung cancer among people with AIDS. *AIDS* 2007; 21 (2): 207 13.
- 43 Mcour V, Shikuma C, Shiramizu B et al . Higher frequency of dementia in older HIV-1 individuals: the Hawaii aging with HIV-1 Cohort. *Neurology* 2004; 63 (5) : 822 7.
- 4. Rajagopalan S Tuberculosis and aging: a global health problem. *Clin Infect Dis* 2001; 33 (7): 1034 9.
- 45 SchmaderK Herpeszoster in older adults . Clin Infect Dis 2001 ; 32 (10) : 1481 6 .
- 46 .Appay V, Rwland-Jones SL Premature ageing of the immune system: the cause of AIDS? Trends Immunol 2002; 23 (12): 580 – 5.
- 47 Fignoni FF, Viscovini R Reseri G etal .Shortageof circulating naive CD8(+) T cells provides new insights on immunodeficiency in aging. *Blood* 2000; 95 (9) : 2860 8.
- 48 RoedererM DubsJG AndersonMT, RajuPA, Herzenbeg LA Herzenberg LA CD8naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest 1995; 95 (5): 2061 6.
- 49 Hessen MT, Kaye D , Murask DM Heterogeneous effects of exogenous lymphokines on lymphoproliferation of elderly subjects. *Mech Ageing Dev* 1991; 58 (1): 61 73.
- 50 LedermanMM Ratnoff OD ScillianJJ JonesPK SchacterB Impaired cell-mediated immunity in patients with classic hemophilia. *N Engl J Med* 1983; 308 (2): 79 83.
- 51 NagelJE ChopraRK ChrestFJ etal .Decreased proliferation, interleukin 2 synthesis, and interleukin 2 receptor expression are accompanied by decreased mRNA expression in phytohemagglutinin-stimulated cells from elderly donors. *J Clin Invest* 1988; 81 (4): 1096 102.
- 52 Clerici M Stocks NI Zajac RA et al .Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodef iciency virus-seropositive patients. Independence of CD4 + cell numbers and clinical staging. J Clin Invest 1989; 84 (6): 1892 – 9.
- 53 Ilton JC Luskin MR Johnson AJ et al . Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4 + T cells are a consequence of antigen load. *J Virol* 2007 ; 81 (6) : 2713 25 .
- 54 .Sig SF, HardingCV, LedermanMM HIV1 infection impairs cell cycle progression of CD4(+) T cells without affecting early activation responses. *J Clin Invest* 2001 ; 108 (5) : 757 64 .
- 55 Arbogast A ,Boutet S ,Phelouzat MA ,Plastre O ,Quadri R ,Proust JJ Failure of T lymphocytes from elderly humans to enter the cell cycle is associated with low Cdk6 activity and impaired phosphorylation of Rb protein. *Cell Immunol* 1999 ; 197 (1) : 46 54 .
- 56 Jegnoni FF, Vscovini R MazzolaM etal .Expansionof cytotoxic CD8 + CD28- T cells in healthy ageing people, including centenarians. *Immunology* 1996 ; 88 (4) : 501 – 7.
- 57 .Ostrwski SR GerstoftJ PedersenBK UllumH Alow level of CD4 + CD28 + T cells is an independent predictor of high mortality in human immunodef iciency virus type 1-infected patients .J Infect Dis 2003 ; 187 (11) : 1726 34 .
- 58 Lane HC ,Masur H ,Edgar LC ,Whalen G ,Rook AH ,Fuci AS Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodef iciency syndrome. *N Engl J Med* 1983 ; 309 (8) : 453 - 8.
- 59 Worksler ME ,Szabo P .The effect of age on the B-cell repertoire. J Clin Immunol 2000 ; 20 (4) : 240 9 .
- 60 SansoniP, CossarizzaA BriantiV, etal .lymphocyte subsets and natural killer cell activity in healthy old people and centenarians. *Blood* 1993; 82 (9) : 2767 73.

- 61 Boudet F, Lecoeur H Gougeon ML Apoptosis associated with ex vivo down-regulation of Bcl-2 and up-regulation of Fas in potential cytotoxic CD8 + T lymphocytes during HIV infection *J Immunol* 1996 ; 156 (6) : 2282 – 93 .
- 62 Aggarwal S GuptaS Increased apoptosis of T cell subsets in aging humans: altered expression of Fas (CD95), Fas ligand, Bcl-2, and Bax. J Immunol 1998 ; 160 (4) : 1627 37.
- 63 Xard JP, MocroftA ChiesiA etal .Influenceof age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis 2001; 183 (8): 1290 – 4.
- 64 .Gandhi RT, Spritzler J, Chan E et al .Efect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretro viral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr 2006; 42 (4): 426 34.
- 65 FryTJ MackallCL What limits immune reconstitution in HIV infection? Divergent tools converge on thymic function. *AIDS* 2001 ; 15 (14) : 1881 2.
- 66 LedermanMM McKinnisR kelleher D etal .Cellularrestoration in HIV infected persons treated with abacavir and a protease inhibitor: age in versely predicts naive CD4 cell count increase .*AIDS* 2000 ; 14 (17) : 2635 42 .
- 67 .CoherStuart J HamannD Borlefs J etal .Reconstitution of naive T cells during antiretroviral treatment of HIV-infected adults is dependent on age. *AIDS* 2002; 16 (17): 2263 – 6.
- KalayjianRC SpritzlerJ PuM etal .Distinct mechanisms of T cell reconstitution can be identified by estimating thymic v olume in adult HIV -1 disease. J Infect Dis 2005; 192 (9): 1577 87.
- 69 Tsi P, Kraft R LuziP, et al. Involution patterns of the human thymus. I Size of the cortical area as a function of age. *Clin Exp Immunol* 1982 ; 47 (2) : 497 504 .
- 70 .DouekDC McFrland RD Keiser PH etal .Changes in thymic function with age and during the treatment of HIV infection. *Nature* 1998 ; 396 (6712) : 690 5.
- 71 JamiesonBD DouekDC KillianS etal .Generationof functional thymocytes in the human adult .*Immunity* 1999 ; 10 (5) : 569 75 .
- 72 . ZhangL Lavin SR Markwitz M etal . Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J Exp Med 1999; 190 (5): 725 – 32.
- 73 Steffens CM Al-HarthiL ShottS Mogev R LandayA Evaluation of thymopoiesis using T cell receptor excision circles (TRECs): dif ferential correlation between adult and pediatric TRECs and naive phenotypes. *Clin Immunol* 2000 ; 97 (2) : 95 101 .
- 74 .HatzakisA Juloumi G KaranicolasR etal .Efect of recent thymic emigrants on progression of HIV-1 disease. Lancet 2000; 355 (9204): 599 604.
- 75 Steffens CM SmithKY, LandayA etal .Tcell receptor excision circle (TREC) content following maximum HIV suppression is equi valent in HIV-infected and HIV-uninfected individuals .AIDS 2001 ; 15 (14) : 1757 – 64 .
- 76 DionML PoulinJF, BordiR etal .HIVinfection rapidly induces and maintains a substantial suppression of thymocyte proliferation. *Immunity* 2004 ; 21 (6) : 757 68 .
- 77 McCuneJM Loftus R SchmidtDK et al .Highprevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. J Clin Invest 1998; 101 (11): 2301 8.
- 78 SmithKY, Mdez H LandayA etal .Thymicsize and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zido vudine, lamivudine, and ritonavir therapy .J Infect Dis 2000 ; 181 (1) : 141 - 7 .
- 79 Æixeira L , Mdez H McCune JM et al . Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. *Aids* 2001 ; 15 (14) : 1749 56 .
- 80 FrancoJM RubioA Martinez-Mya M etal .Tcell repopulation and thymic volume in HIV-1-infected adult patients after highly acti ve antiretroviral therapy. *Blood* 2002 ; 99 (10) : 3702 - 6 .
- 81 Kilte L Drees AM ErsbollAK et al .Association between larger thymic size and higher thymic output in human immunodef iciency virus-infected patients recei ving highly active antiretroviral therapy. J Infect Dis 2002; 185 (11): 1578 – 85.

- 82 Ruiz-MateosE RubioA Melejo A etal .Thymicvolume is associated independently with the magnitude of short- and long-term repopulation of CD4 + T cells in HIV -infected adults after highly active antiretroviral therapy (HAART). *Clin Exp Immunol* 2004; 136 (3): 501 6.
- 83 Heitger A ,Neu N ,Kern H et al . Essential role of the thymus to reconstitute naive (CD45RA+) T-helper cells after human allogeneic bone marro w transplantation. *Blood* 1997 ; 90 (2) : 850 - 7 .
- 84 Walker RE CarterCS MuulL etal .Peripheralexpansion of pre-existing mature T cells is an important means of CD4 + T -cell regeneration HIV-infected adults. *Nat Med* 1998 ; 4 (7) : 852 6.
- 85 HaynesBF, HaleLP, Winhold KJ et al .Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection. *J Clin Invest* 1999 ; 103 (6) : 921 .
- KimmigS PrzybylskiGK SchmidtCA etal . Two subsets of naive T helper cells with distinct T cell receptor e xcision circle content in human adult peripheral blood . J Exp Med 2002 ; 195 (6) : 789 94 .
- 87 SousaAE CarneiroJ MeierSchellersheim M GrossmanZ Victorino RM CD4T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. *J Immunol* 2002 ; 169 (6) : 3400 – 6.
- 88 BouscaratF, Leacher-Clergeot M DazzaMC etal .Correlation of CD8 lymphocyte activation with cellular viremia and plasma HIV RN A levels in asymptomatic patients infected by human immunodeficiency virus type 1. *AIDS Res Hum Retroviruses* 1996; 12 (1): 17 – 24.
- 89 Leng Q Borkw G Wisman Z Stein M Kalinkvich A Bentwich Z Immune activation correlates better than HIV plasma viral load with CD4 T -cell decline during HIV infection. J Acquir Immune Defic Syndr 2001 ; 27 (4) : 389 – 97.
- 90 .Giogi JV, Jeles RH MatudJL et al .Predictive value of immunologic and virologic markers after long or short duration of HIV -1 infection. *J Acquir Immune Defic Syndr* 2002; 29 (4): 346 55.
- 91 Anthon KB Moder C MetcalfA, etal .IncompleteCD4 T cell recovery in HIV-1 infection after 12 months of highly acti ve antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. *J Acquir Immune Defic Syndr* 2003 ; 33 (2) : 125 33.
- 92 BenitoJM LopezM LozanoS et al .Diferential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4 + T cells under successful highly active antiretroviral therapy *J Acquir Immune Defic Syndr* 2005 ; 38 (4) : 373 81 .
- 93 HuntPW, MartinJN SinclairE etal .Tcell activation is associated with lower CD4 + T cell gains in human immunodef iciency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003 ; 187 (10) : 1534 43.
- 94. Kalayjian R, Matining R, Tebas P, et al. Older persons have imparied restoration of naive CD4 cells in response to HAAR T. 13th Conf on Retro viruses and Oppor Infect, Den ver 2006:Abstract #444.
- 95 LandayA daSilva BA, KingMS etal .Evidenceof ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. *Clin Infect Dis* 2007; 44 (5): 749 54.
- 96 Badly AD PilonAA LandayA Lynch DH Mechanisms of HIV-associated lymphocyte apoptosis .*Blood* 2000 ; 96 (9) : 2951 64 .
- 97 . Carpentier CoornaertB Byaert R Functionand regulation of tumor necrosis factor type 2. *Curr Med Chem* 2004 ; 11 (16) : 2205 – 12 .
- 98 . Grel**B** CampagnaS LichtnerM etal .Spontaneousand anti-Fas-induced apoptosis in lymphocytes from HIV-infected patients undergoing highly active anti-retroviral therapy. *AIDS* 2000; 14 (8): 939 49.
- 99 . Erikstrup Kallestrup P, Zinama-Gutsire RB et al .Reduced mortality and CD4 cell loss among carriers of the interleukin-10 -1082G allele in a Zimbabwean cohort of HIV1-infected adults .*AIDS* 2007 ; 21 (17) : 2283 − 91 .

- 100 . GodfrieMH an der Poll T, Werling GJ etal .Solublereceptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodef iciency virus type 1 infection .J Infect Dis 1994 ; 169 (4) : 739 45.
- 101. SteiDS Les RH GrahamNM etal .Predictingclinical progression or death in subjects with early-stage human immunodeficiency virus (HIV) infection: a comparative analysis of quantification of HIV RNA, soluble tumor necrosis f actor type II receptors, neopterin, and beta2-microglobulin. Multicenter AIDS Cohort Study. J Infect Dis 1997; 176 (5): 1161 7.
- 102. Beeniste O FlahaultA RollotF, etal .Mechanismsinvolved in the low-level regeneration of CD4 + cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. *J Infect Dis* 2005; 191 (10): 1670 9.
- 103 . HaaSW , GeraghtyDE AndersenJ etal .Immunogeneticsof CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical T rials Group study . J Infect Dis 2006 ; 194 (8) : 1098 – 107 .
- 104 Sodora DL Siløstri G Immuneactivation and AIDS pathogenesis AIDS 2008 ; 22 (4) : 439 46 .
- 105 Hodes RJ HathcockKS Wing NP Elomeres in T and B cells *Nat Rev Immunol* 2002 ; 2 (9) : 699 706.
- 106 .Wolthers KC BeaG .Woman A etal .Tcell telomere length in HIV-1 infection: no evidence for increased CD4 + T cell turno ver. *Science* 1996 ; 274 (5292) : 1543 7 .
- 107 Palmer LD Wing N Luine BL JuneCH LaneHC HodesRJ. Elomere length, telomerase activity, and replicative potential in HIV infection: analysis of CD4 + and CD8 + T cells from HIV-discordant monozygotic twins. J Exp Med 1997; 185 (7): 1381 6.
- 108 Kaushal S Landay AL Lederman MM et al .Increases in T cell telomere length in HIV infection after antiretro viral combination therapy for HIV-1 infection implicate distinct population dynamics in CD4 + and CD8 + T cells . *Clin Immunol* 1999 ; 92 (1) : 14 24 .
- 109 Effros RB AllsoppR ChiuCP,etal .Shortenedtelomeres in the expanded CD28-CD8 + cell subset in HIV disease implicate replicati ve senescence in HIV pathogenesis . *AIDS* 1996 ; 10 (8) : F17 22 .
- 110 Papagno L SpinaCA MarchantA etal .Immuneactivation and CD8 + T-cell differentiation towards senescence in HIV-1 infection. *PLoS Biol* 2004 ; 2 (2) : E20 .
- 111 Kalayjian RC LandayA PollardRB etal .Age-relatedimmune dysfunction in health and in human immunodeficiency virus (HIV) disease: association of age and HIV infection with naive CD8 + cell depletion, reduced expression of CD28 on CD8 + cells, and reduced thymic volumes *J Infect Dis* 2003 ; 187 (12) : 1924 – 33.
- 112. Kalayjian R, Spritzler J, Matining R, et al. Dif ferences in the activation of tumor necrosis factor superfamily pathways may contribute age-associated differences in naive CD4 cell recovery and to functional immune responses to HAAR T. 15th Conf on Retro viruses and Oppor Infect, Boston 2008; Abstract#437.

Neuropsychology of Healthy Aging

Molly E. Zimmerman and Adam M. Brickman

Introduction

As the population of adults with HIV continues to gro wolder, clinicians and researchers are becoming increasingly interested in the unique health care needs of older adults with HIV. Cognitive abilities are one aspect of general well-being and health that are compromised in older individuals with HIV. However, it is also well-established that cognitive abilities decline among healthy older adults without HIV or other frank neurological conditions. Therefore, an emer ging scientific challenge is the systematic exploration of the syner gistic impact of both HIV and age on the cognitive abilities of older adults. To facilitate an understanding of this complex relationship, the cognitive changes that accompany healthy aging have to be characterized, and this is the purpose of this chapter . Subsequent chapters will address specific relationships between advanced age and cognitive impairment in individuals with HIV.

The number of adults o ver the age of 65 is projected to represent a relatively greater proportion of the general world population in the coming years (1). As the number of older adults continues to increase, so does the critical importance of an expanded characterization of biological and behavioral manifestations of aging. Cognitive (from the Latin *cognoscere*, "to know") processes are a fundamental aspect of the human experience, mediating individuals' understanding of both themselves and their relation to a broader environmental and social context. Accordingly, fear of cognitive decline is a ubiquitous effects on the psychological well-being of affected individuals and their caregivers (3). In addition, substantial health care costs associated with cognitive dysfunction are likely to increase as the proportion of older adults in the general population rises.

M.E. Zimmerman()

Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461, USA mzimmerm@aecom.yu.edu

There is an important distinction between cognitive change due to pathological processes and cognitive change due to normal aging. As an individual grows older, they may experience cognitive decline as a result of a degenerative condition (e.g., Alzheimer's disease, Parkinson's disease), infection with HIV, vascular disease, or other pathological conditions. The degree of cognitive change can range from mild to severe and is likely to have a detrimental effect on activities of daily living. Healthy older adults may also experience cognitive decline, albeit to a lesser degree, that is associated with normal biological aging processes of the brain. The e xtant literature suggests that advancing age in healthy adults is associated with heterogeneous cognitive decline across a variety of cognitive domains, including memory, language, and higher-order executive processes (4–6). In addition, cogniti ve abilities are highly variable in healthy older adults, with substantial evidence of both intra- and inter-individual variability in test performance compared with younger adults (5). An enhanced understanding of normal age-related cogniti ve decline.

This chapter seeks to provide a broad overview of the cognitive changes that occur in healthy older adults; that is, older adults that are free of known disease. We will use a neuropsychological assessment framework to summarize recent research findings, focusing on the cognitive domains of attention, executive function, memory, language, visuospatial abilities, and speed/information processing.

Attention

Consideration and manipulation of attention as a cognitive process has long been of interest to researchers and clinicians. The term "attention" broadly refers to complex, multifaceted cognitive processes that serve to orient an individual toward a stimulus (7, 8). Assessment of v arious forms of attention is an important aspect o f the neuropsychological evaluation because attentional processes frequently sup port performance on many other tests of cognitive function, such as memory and executive function (9). Although not exhaustive, the primary components of attention that will be discussed herein include selective attention, sustained attention, and divided attention.

Selective Attention

One of the more thoroughly e xplored aspects of attention, selecti ve attention is characterized as the filtering of stimuli in order to process relevant information and ignore or inhibit a response to irrele vant information. A commonly used selecti ve attention paradigm is "visual search," in which an individual is directed to identify the location or presence of a tar get in a visual display. In general, older adults exhibit poorer performance on selecti ve attention tasks compared with younger adults (10, 11) particularly when executing a demanding task that requires selection of a complex target (10, 12). Researchers have suggested, however, that this age-associated performance decrement may be largely a function of the older adult's

difficulty inhibiting an inappropriate response (13) or to an overloading of attentional capacity demands (14). Importantly, age-related impairments may be attenuated if an older individual is given specific cues to direct their focus (15) or if the individual has previous experience with the target (16, 17). Presentation of easily discernable targets (e.g., using contrasting colors or easily distinguishable forms) has also been shown to facilitate selective attention abilities in older adults (18–20).

Divided Attention

Divided attention refers an indi vidual's ability to allocate resources in order to simultaneously perform two or more tasks. Research paradigms that utilize relatively simple task designs, such as perceptual identification, suggest that older and younger adults demonstrate comparable performance (21). As task complexity increases, however, older adults are more likely to exhibit impairments in performance (22, 23). For instance, McDowd and Craik (22) conducted a study in which younger and older adults were asked to monitor a list of words while simultaneously discriminating between visually presented letter and number characters. Older adults demonstrated marked difficulties performing this dual-task compared with younger adults, providing support for age-related declines in divided attention processing. Hartle y and colleagues have also shown that older adults e xhibit declines in performance on dual-tasks when both tasks require a manual response (24, 25). Similar to selective attention abilities, however, the amount of practice or pre vious experience with a stimulus has been shown to facilitate performance in healthy elderly (26, 27). Attentional switching is another type of di vided attention in which an indi vidual alternately monitors two or more stimuli. Research pro vides support for age-associated declines in attentional switching for auditory information but not visual information in older adults (28). Although both younger and older adults demonstrate task switch costs, or task switch declines in efficiency (29), older adults demonstrate relatively poorer efficiency compared with younger adults (29, 30).

Sustained Attention

Sustained attention is conceptualized as an indi vidual's ability to maintain mental performance over time. This aspect of attentional processes is most commonly measured as performance on a vigilance task in which an indi vidual is asked to direct his or her attention to a display in order to identify tagets presented at infrequent intervals over an extended period of time (see (31) for a re view). In general, researchers have reported that younger and older adults demonstrate comparable rates of decline in performance on vigilance tasks, although age-related def icits have been demonstrated on tasks that require distinctions between tar gets and nontargets that are not readily discernable (32). These results suggest that the older adult's difficulty with vigilance tasks may be secondary to impairments in otheraspects of cognition that are tapped by general task demands, such as tar get detection (33).

Executive Functions

Executive functioning refers to a set of cognitive processes involved in complex goal-directed behavior, planning, cognitive flexibility, and allocation of attentional resources (34). Although the construct is some what heterogeneous, there is some consensus in the neuropsychological literature for its standardized assessment (35). Executive functioning is thought to be mediated by the frontal lobes (36) and frontal-subcortical circuitry (37, 38). Because reports from the neuropsychological, cognitive neuroscience, and neurobiological literatures indicate that there are relatively greater rates of age-associated decline in executive abilities than other cogniti ve domains, it is often thought of as the cognitive ve domain most sensitive to normal aging (39, 40), although this view has not gone unchallenged (41, 42). In this section, we briefly discuss the construct of executive function and review recent evidence of changes in executive functioning that accompany normal aging.

Defining Executive Function

As noted previously, the construct of executive functioning captures a number of related cognitive abilities. In neuropsychology, authors sometimes def ine the concept as performance on a specific test or use the term to mean "frontal lobe functioning" specifically. Lezak (43) discusses executive functioning in general terms, describing it as "those capabilities that enable a person to engage successfully in independent, purposive, self-serving behavior (p. 42)," comprising four components that include goal formation, planning, goal execution, and effective performance. However, a range of other concepts have been assigned to the category of executive functioning (reviewed in (44)), such as cognitive flexibility or concept formation (45); strategy control (46); goal setting (47); planning, impulse control, concept formation, fle xibility (48); reasoning (49); problem solving, generation of strategies, sequencing complex behaviors (36); and coordinated or ganization of behavior (50). Although some of these ideas appear conceptually unrelated, what unif ies them is their "e xecutive" nature. That is, much like a business executive, they all view executive functioning as having some "supervisory authority" over more basic cognitive processes.

Executive Functioning and Aging

When considering the role of e xecutive functioning in aging, it is important to establish whether executive functioning represents a unique construct, whether executive functioning mediates age-associated decline in other cognitive domains, and whether there is decline in executive function per se even in the absence of its secondary impact on other cognitive domains. Salthouse and colleagues (e.g., (42, 51))

have conducted among the most elegant work to address these issues. They showed that performance on tasks ostensibly measuring executive functioning showed relatively good convergent validity, but the shared variance among tests of executive function was highly related to other constructs, most notably fluid intelligence (51). This overlap between variance attributed to executive function and variance attributed to fluid intelligence was interpreted as lack of evidence for discriminant validity of the former. In a follow up study (42), two large, independent data sets were used to show that performance on tests hypothesized to reflect executive functioning were highly related to perceptual speed and reasoning abilities. Further , few of the tests o f executive functioning were related to age after the association between age and performance on the other cognitive tests was taken into account statistically. The researchers interpreted the findings as evidencing weak support for an independent construct of executive functioning. However, these findings may also be interpreted to suggest that reasoning ability might be a central feature across various tasks of executive functioning.

A number of studies from the neuropsychological literature ha ve supported the idea of pronounced and consistent decline in executive abilities with normal aging. In our own work (52), we used a cluster analysis approach applied to performance across a range of neuropsychological tests to cate gorize the cognitive profiles of older, neurologically healthy adults compared with younger controls. We identified three groups of older adults: those with selective impairment in executive functioning (defined as performance one standard deviation below the mean of the young control group on a computerized set shifting test), those with def icits in three domains (i.e., attention, executive function, and motor speed), and those with global cognitive deficits across all domains. The f indings highlight the heterogeneity in patterns of cognitive aging among healthy adults. More importantly , they demonstrate that executive dysfunction was a characteristic of all three of the cogniti ve aging.

Among the most popular measures of e xecutive functioning is the W isconsin Card Sorting Test (WCST; (53, 54). The test in volves sorting cards using rules based on one of three characteristics of the card stimuli (i.e., color , shape, and number), which systematically change throughout the test trial. The number of correct categories and number of perse verative errors are the most common performance measures. A recent meta-analysis sho wed that, across studies, both measurements decline markedly with age (55).

Tests of executive functioning can also be divided grossly into subdomains, including attentional control, planning, set shifting, and verbal fluency (44). Attentional control includes abilities such as inhibiting irrele vant information and is often evaluated with tests such as the Continuous Performance Test and Stroop Test (56, 57). There are a number of examples of significant age-associated performance decrement on these tests (58–60), even after control of processing speed ((61) reviewed in (44)). The Tower of Hanoi Test (62), in which subjects are required to rearrange different sized and colored rings across three pegs, is commonly used to assess planning ability. Several studies have shown age-associated decreases in performance on this task, which may bgin as early as age 60(63). Age-associated performance differences on the Tower of Hanoi Test are characterized by a greater

number of moves required to reach criteria and increased number of rule violations (64). As noted above, there are consistent findings in the literature of age-related decline in performance on set shifting tasks, as measured by the T railmaking Test or WCST. Although Salthouse et al. (65) found little evidence for aging effects on performance on a test similar to the Trailmaking Test after accounting for age-associated differences in perceptual speed, others have found that aging effects persist even after control of motor and perceptual speed (66). Tests of verbal fluency may also be considered executive abilities, although they can clearly be considered primary tests of language as well. In typical tasks of fluency, the subject is asked to generate as many words as possible within an allotted time period. In a large, cross-sectional aging analysis, we found that both letter v erbal fluency and semantic v erbal fluency showed a linear age-associated effect, but the degree of age-associated decline was greater for the latter (67). A recent meta-analysis is consistent with these f indings in showing a significant age effect on verbal fluency performance (68).

Though not without contro versy, there is e vidence in the neuropsychological literature of a relatively pronounced age-associated decline in e xecutive abilities. Age-associated changes in e xecutive function have been link ed to concomitant declines in instrumental activities of daily living (69) and linked to age-associated reductions in frontal lobe grey and white matter volume (70, 71).

Memory

Memory refers to the ability to e xplicitly or implicitly recall information that has been encoded in the recent or distant past. Current conceptualization of this cognitive domain usually divides the construct into hierarchical taxonomic modules based on the type of information that is being retrie ved and the duration of the retention interval. For the purpose of the current discussion, we frame our discussion of memory in the structure put forth by Squire and colleagues(72, 73), in which long-term memory is divided into declarative and nondeclarative subcomponents. Declarative, or explicit, long-term memory is the ability to recall facts (semantic memory), events (episodic memory), or perceptual information (perceptual memory). Nondeclarative memory refers to the implicit recall of information and is often divided into procedural, priming, or simple conditioning.

Short-term memory is distinct from long-term memory and refers to the retention of information on a time scale on the order of seconds or minutes. Working memory is a type of short-term memory in which certain mental operations are performed during the retention period. Because working memory involves the manipulation of stored information during short-term memory, it is often included as a type of executive functioning, which is discussed in greater detail earlier in the chapter.

Memory functions are of particular interest in the study of older adults, as most diagnostic schemes for neurodegenerative disorders, such as dementia, incorporate significant memory loss as central to the diagnostic criteria. Cross-sectional and longitudinal studies of healthy aging demonstrate that dif ferent subcomponents of memory show a differential vulnerability to the effects of age.

Long-Term Memory

Declarative Memory

SemanticMemory

Despite the common anecdotal report of dif ficulty recalling the names of objects, names, or other well-learned information among older adults, semantic memory is among the more stable memory systems across the adult lifespan. Semantic memory is often evaluated by asking an indi vidual to define words or provide answers to factual questions, such as on the Vocabulary and Information subtests of the Wechsler Adult Intelligence Scales (74). Longitudinal data from the Canberra Study (75), which followed neurologically healthy adults o ver age 70, sho wed performance stability on semantic-based tasks o ver an 8-year period (5). Other reports ha ve demonstrated a gradual improvement in semantic memory (e.g., w ord knowledge) in later adulthood (76), suggesting that semantic knowledge accumulates across the lifespan with little or no age-associated decline. Perceived difficulty with semantic memory among older adults may be attributable to a tip-of-the-tongue phenomenon, in which older individuals have the feeling that the y know a piece of information, yet have difficulty recalling it e xplicitly (77, 78). This common e xperience is discussed in greater detail in the Language section of this chapter.

EpisodicMemory

The distinction between episodic and semantic memorywas introduced by Tulving in the 1970s (79). Episodic memory is the "what," "where," and "when" of information storage (80) and interacts with semantic memory. The observation that episodic memory declines mark edly with normal aging has e xisted in the literature for decades (81) and has been well-documented. Neuropsychologists typically evaluate episodic memory by asking subjects to learn information e xplicitly (e.g., a list or story) and recall it after a delay period. This paradigm permits the e valuation of three aspects of episodic memory – encoding, storage, and retrie val – that show differential aging effects. Older adults e vidence a more shallo w depth of encoding than younger adults. After a delay period, the y recall less information than their younger counterparts, b ut the degree of retrie val differences between younger and older adults is some what attenuated when the amount of for getting (i.e., the amount of information lost during a delay relati ve to the amount of information encoded) is considered (82, 83). Furthermore, older adults tend to endorse more distracter stimuli, or foils, in during recognition paradigms (84). Salthouse (85) recently proposed three important observ ations regarding episodic memory decline and aging. First, patterns of age-associated differences in performance on tasks of episodic memory are similar across modalities (e.g., story recall, paired associated learning, etc.). Second, cross-sectional e vidence suggests that episodic memory begins to decline as early as age 20 and continues linearly until

about age 60, at which time there is a more precipitous age-associated decline. Third, in well-screened samples of healthy older adults, there does not appear to be increased variability in performance on tasks of episodic memory compared with younger adults, although some in vestigators have noted increased variability with age (e.g., (86)).

Source memory, a component of episodic memory, refers to the context in which information is learned. Even with successful episodic recall, older adults may have exaggerated difficulty recalling the source from which the information was acquired (87–89). For example, older adults often ha ve the experience of recalling a ne ws item, but have difficulty recalling whether the information w as acquired from television, the radio, or newspaper.

Nondeclarative Memory

Nondeclarative memory, sometimes referred to as implicit memory, describes the occurrence of learning and recall outside of conscious a wareness. The construct is generally divided into procedural memory and priming. Nondeclarative systems are relatively spared across the adult lifespan.

ProceduralMemory

Nondeclarative memory encompasses procedural or skill learning. Procedural memory involves the nonconscious acquisition and retention of motoric sequences. Among the most common examples is the process of learning how to ride a bicycle. A novice cyclist needs to recollect consciously ho w to maneuver the bicycle, yet with practice, the skill enters procedural memory and control becomes automatic. Very little w ork has e xamined age-associated changes in procedural memory . Although there is clearl motoric slo wing with age, results of studies e xamining procedural memory with age have been somewhat equivocal (90, 91). Studies that examine aging experts, such as typists or pianists, report a trend for slo wing but maintenance of performance with age (92, 93). Further, while older adults may learn motoric sequences at a slo wer rate than their younger counterparts, the y are able to retain procedural kno wledge similarly (94). Problems with studying procedural memory among older adults include the potential confounding effects of motoric speed, other cogniti ve abilities (e.g., w orking memory), and distinction between learning and memory.

Priming

Repetition priming is special type of implicit memory that describes the phenomenon of enhanced recall of a stimulus based on prior e xposure. For example, a subject would be more likely to complete the word stem "STR____" with "EET" (to form the

word "STREET") than with "ONG" (to form the w ord "STRONG") if the word "STREET" had been previously exposed. Although priming is not typically evaluated clinically, the topic has a long history of research in the cognitive aging literature. Earlier reports in the 1980s suggested minimal aging effects across a number of priming modalities, including picture naming (95), word identification (96), and word stem completion (reviewed in (97)). More recent in vestigations have shown small, but statistically reliable, decrements in priming with age (98).

Short-term Memory

In contrast to long-term memory in which information is stored on the order of minutes to years, short-term memory is def ined by memory storage in conscious awareness for seconds. Short-term memory is a qualitati vely distinct memory system that interacts with long-term memory; for information to enter long-term memory, it must first enter short-term memory. The "modal model" of information transfer (99) remains a popular conceptual frame work for short-term memory. Briefly, information from the environment enters primary sensory stores and then a short-term store, which can include rehearsal, coding, or decision. From there, it is either forgotten, leads to some form of behavioral response, or enters long-term storage, which is relatively permanent. When information is dra wn from long-term memory, it exists in short-term memory while in conscious a wareness. For many years, psychologists believed that the average capacity of short-term memory was seven plus or minus two items or chunks (100). However, more contemporary theorists believe that short-term memory span is closer to four items (101) or dependent on individual differences in processing speed (102).

The term "short-term memory" makes reference to the passive storage of information. There is little evidence for significant change in short-term memory per se with normal aging. However, it is difficult to discuss the effects of age on short-term memory without consideration of the process by which information is retained in storage. Working memory is the cogniti ve manipulation of information that is contained within short-term memory. Indeed, there is ample evidence of significant age-associated decline in w orking memory abilities (103). In a typical w orking memory paradigm, a subject is ask ed to perform mental operations on items held in conscious awareness (i.e., short-term memory), such as reordering numbers or solving simple arithmetic problems while remembering a digit from each problem (104). Efficacy of inhibition (13, 105) and shortened span (104) are two components of working memory that decline most rapidly with normal aging. Age-related decline across working memory task modalities, such as letter rotation, reading span, computation span, and line span, appears to decline with age at a similar magnitude as age-associated decline in episodic memory or speed of processing (76). There is also some e vidence that age-related decline in w orking memory mediates age-associated loss in other cognitive domains (104).

Course

Several studies suggest that normal age-associated memory decline may be gin as early as the early- or mid-twenties and decline linearly (106, 107). Longitudinal studies highlight more precipitous decline with memory after about age 60 (108).

Language

Human language processing and production is a rich arena of cogniti ve study. Our understanding of language function encompasses a wide range of complex abilities that include spontaneous speech, repetition, speech comprehension, naming, reading, and writing (35). The effect of age on each of these functions is heterogeneous, with preserved and even improved abilities in some areas and decrements in other areas as an individual grows older (109, 110). In general, older adults have a more extensive vocabulary range than younger adults, yet they experience more difficulty with the production of words in both spontaneous speech and controlled laboratory settings (111, 112). In this section we will focus on two broad categorizations of language function: expressive and receptive language.

Expressive Language

One of the more common objective research findings and subjective complaints of older adults is the tip-of-the-tongue phenomenon, in which an individual is temporarily unable to orally express a word that they feel they know (113). Typically, lexical retrieval is most difficult for proper names compared to other words (78, 114). This difficulty is ameliorated; ho wever, when older adults are ask ed to pronounce phonologically similar words (115), particularly words sharing an initial syllable with the target word (116).

Slips of the tongue, or the misproduction of a sound in an intended w ord or sentence (e.g., saying "bobbin" instead of "robin") are also quite common in elderly adults. Studies have shown that older adults are more lik ely to omit sounds when required to produce words to a task demand, while younger adults are more lik ely to substitute different sounds (117).

Older adults are also slower and less accurate when performing confrontational naming of pictures of common and uncommon objects, such as the Boston Naming Test (118). Zec et al. (119) reported data from a longitudinal study of 541 healthy older adults who demonstrated relatively preserved lexical retrieval until the age of 70, at which point only v ery minor declines in performance were observ ed. Findings from a more recent cross-sectional study (120), however, indicate more severe naming deficits in a healthy elderly group compared with younger adults.

A similar pattern of findings was reported by Connor et al. (121), with cross-sectional analyses indicating relatively greater performance declines in the naming abilities of older adults than longitudinal analyses. Other researchers (122) have found no differences between object and action naming in older adults, although there w as an age-associated decline in overall naming abilities. A study (123) examining both confrontational naming and spontaneous discourse found that older adults exhibited significantly more word-retrieval errors, but had a higher overall naming accuracy than older adults. The authors speculated that this unexpected latter finding may be related to generational familiarity with some of the items.

Finally, healthy older adults frequently demonstrate difficulty expressing complex ideas in written autobiographies (124) and spoken responses (125). Similarly, elderly adults also display relatively increased off-topic verbosity when compared with younger adults, which may be due to an inability to inhibit inappropriate responses (126).

Receptive Language

Consistent findings have emerged that are supportive of the relative preservation of general word, sentence, and discourse kno wledge in old age (111, 127). Older adults have a larger vocabulary than younger adults (125) and perform better than younger adults when pronouncing irre gularly spelled words (e.g., the National Adult Reading Test; Nelson, 1985) even after controlling for education(128). Some studies have reported that vocabulary may even continue to improve in old age (5, 129). However, longitudinal studies have shown that healthy older adults may be gin to exhibit a relative decline in vocabulary comprehension following the age of 90 (130).

Beyond single w ord knowledge, sentence comprehension declines in healthy older adults, including the ability to characterize details and generate inferences (131, 132). Comprehension of grammatical rules, or syntax, has also been sho wn to decline with age (133). Compared with younger adults, older adults also e xhibit relatively increased difficulty accurately identifying language that is presented at an increased rate of speech (134). Provision of a meaningful context may be a useful comprehension aid for the elderly (135). For instance, older adults' comprehension of "real world" information presented in a television newscast was found to be relatively well-preserved compared with younger adults (136).

It is important to consider the effect of age-related memory declines on receptive language processes, as older adults have been shown to exhibit declines in comprehension measures that rely on working memory processes (125, 133). Also important are the effects of hearing loss on language abilities. Both clinically significant (137) and nonclinically significant (138) age-associated hearing loss has been shown to exert negative effects on auditory processing abilities (see (127) for further discussion). Finally, age-associated inhibitory control difficulties may also have a deleterious effect on language abilities, where irrele vant thoughts and associations intrude on cognitive processes necessary for efficient language function (139, 140).

Visuospatial, Visuoconstructional, and Visuoperceptual Abilities

Visuospatial, visuoconstructional, and visuoperceptual abilities are utilized for the processing, manipulation, or reproduction of visual information. Visuospatial abilities refer to an appreciation of spatial aspects of the visual en vironment, including localization of points in space, judgment of direction and distance, and topographical orientation (e.g., route descriptions) (141). Visuoconstruction refers to the motoric action of assembling parts to form a unified whole, exemplified by the performance demands on the Block Design subtest from the W AIS-III (142). Visuoperceptual abilities comprise fine visual discriminations, separations of f igures from ground, or synthesis of disparate components into a meaningful unit or object (141). Although the general literature on this topic is broad, herein we highlight selective research findings as they relate to the healthy aging process.

Older adults perform more poorly than younger adults across a variety of spatial, constructional, and perceptual information processing tasks (143). Healthy elderly exhibit lower total scores and poorer quality of responses on the visual reproduction subtest of the Wechsler Memory Scale (144-146). Shay and Roth (147) examined cognitive performance in 105 men across the age spectrum and found decrements in an older adult group aged 60-73 onvisuospatial and visuoperceptual tasks that included visual reproduction from the WMS (144), the Digit Symbol subtest from the WAIS-R (148), Hooper Visual Organization test (149), and the Re y-Osterrieth Complex Figure Test (150, 151). Within the older adult group, performance differences on these tasks were noted between individuals divided into low and high aerobic fitness groups. This finding suggests that older adults who participate in physically stimulating exercise may demonstrate relatively better visuospatial and visuoperceptual performance than their nonexercising age-matched peers. A large community-based study of 219 healthy older adults aged 75-96 reported age-associated impairments on tests of both visuospatial abilities and spatial orientation (152). In a recent study of spatial abilities, Driscoll et al. (153) reported age-associated declines in performance on a virtual spatial learning task and a mental rotation test. Finally , using a comparative neuropsychology approach in which tasks originally de veloped to examine cognition in animals are adapted for use in humans, Boutet and associates (154) reported that older adults performed more poorly than younger adults on a spatial discrimination task.

Speed and Information Processing

Speed, accuracy, and motor control are important aspects of task performance under laboratory conditions and in everyday life. It is well known that as an individual grows older, motor behaviors executed in response to a stimulus are disproportionately slowed (155, 156). Performance on a commonly used neuropsychological measure, finger tapping, has been sho wn to decline with age (157, 158). Age-associated declines in the time tak en to complete a letter cancellation task ha ve also been

reported (159). A recent e xamination of perceptual and cogniti ve speeded tasks requiring a verbal response revealed age-associated declines in performance (160). In addition, statistical control of generalized slowing has been reported to minimize age-related changes in performance on tasks of other cogniti ve functions. Both cross-sectional and longitudinal studies have reported that many age group differences observed in cognitive performance may be better accounted for by age-relatedchanges in processing speed and psychomotor speed (161–163). For instance, Pietrzak et al. (164) report an age group difference on a task of spatial learning efficiency that was attenuated when measures of processing speed were considered. Age-related psychomotor slowing in w ord production speed has also been sho wn to be an important predictor of performance on a v erbal fluency task (165). An enhanced understanding of speeded processing measures provides an important context in which to interpret both healthy age-associated and pathological changes in cognition.

One of the most common indices of speed of information processing is reaction time (RT), a measure of the amount of time utilized to detect a stimulus and ecute a response. There are several types of RT, including simple reaction time and choice reaction time, in which an indi vidual is required to select a correct response from several possible responses. Longitudinal studies ha ve shown that simple R T increases with age at a rate of approximately 0.5 ms/year (166). Researchers have also reported that total R T measures are at least 25% longer in older adults compared with younger adults (167–169). Interestingly, an increase in preparation time prior to task performance actually results in an increase in R T differences between younger and older adults, indicating that older adults do not benef it from extended preparation times (167, 170). Older adults ask ed to perform choice R T tasks are approximately 30–60% slower than younger adults (171, 172). Choice RT rates have been shown to increase at a rate of 1.6 ms/year in longitudinal studies (166). Performance is further impaired in older adults when stimuli become more difficult to discriminate (173) and as the number of choices increases (166, 169). Age differences in choice RT have also been noted for non verbal information, but not verbal information. These differences are somewhat attenuated when opportunities for practice are provided, but they are not entirely eliminated (174). Importantly, studies have revealed that level of physical fitness may have a beneficial effect on RT in older adults (175).

Conclusions

Clinical and research reports have generated a wealth of information on the cognitive aging process of the healthy older adult. A review of the findings suggests that age-related changes in cognitive processing are heterogeneous, with both declines and preservation evident across cognitive domains. Performance on selective and divided attention tasks generally declines with age, although older adults may benefit from previous experience or practice with attentional stimuli. Executive function abilities, such as problem solving and concept formation, are frequently

compromised as an individual ages, and may be the abilities most sensiti ve to the biological sequelae of healthy aging. Older adults commonly report decline in memory abilities, particularly in the areas of episodic memory. However, semantic memory abilities are relatively preserved across the lifetime. Older adults also exhibit difficulties with expressive language, such as confrontational naming and the tip-of-the-tongue phenomenon, while receptive language abilities remain generally intact. Spatially-mediated tasks e vidence age-associated decline, particularly visuospatial and visuoconstructional tasks. Finally, generalized slowing is a common feature of the cognitive aging process, with declines noted on tasks of motor control and speed of information processing. This brief re view of the recent literature on the neuropsychology of healthy aging may be used to better understand the behavioral and cognitive manifestations of cognitive aging in older adults with HIV and other pathological processes.

References

- 1 . Win H , Sengupta M , Makoff VA , DeBarros KA 65+ in the United States . In: US census bureau current population reports . Washington, D.C. : U.S. Government Printing Office ; 2005 : 23 209 .
- 2 . MartinGM Defeatingdementia . Nature 2004 ; 431 : 247 8 .
- 3 . MelzerD McWiliams B BrayneC JohnsonT, BondJ Profile of disability in elderly people: estimates from a longitudinal population study. BMJ 1999 ; 318 : 1108 11 .
- 4 . Anstę KJ Lov LF Normalcognitive changes in aging . AustFam Physician 2004 ; :3783 7 .
- 5 . Christensen H Whatcognitive changes can be expected with normal ageing ? Aust N Z J Psychiatry 2001 ; 35 : 768 - 75 .
- 6 . Keefover RW Agingand cognition . NeurolClin 1998 ; 16 : 635 48 .
- 7 .KramerAF, MaddenDJ Attention In: CrailFIM SalthouseTA eds. The handbook of aging and cognition . 3rded . New York : PsychologyPress ; 2007 : 189 249 .
- 8 .RogersWA, FiskAD Understandingthe role of attention in cogntive aging research .In: BirrenJE, Schaie KW eds. Handbook of the psychology of aging. 5th ed. New York : AcademicPress; 2001 : 267 - 87.
- 9 .Craik FIM ,McDwd JM Age differences in recall and recognition . J Exp Psychol Learn Mem Cogn 1987 ; 13 : 474 9 .
- 10 .PludeDJ Doussard-Rooseelt A Aging, selective attention, and feature integration . Psychol Aging 1989 ; 4 : 98 105 .
- PludeDJ EnnsJT, BrodeurD Thedevelopment of selective attention: a life-span overview. ActaPsychol (Amst) 1994 ; 86 : 227 - 72 .
- 12 .Madden DJ Aging, attention, and the use of meaning during visual search . Cogn Dev $1987\ ;\ 2\ :\ 201\ -\ 16\ .$
- HasherL ZacksRT Working memory, comprehension, and aging: A review and a new view.
 In: Boer GK ed. Thepsychology of learning and motivation. SanDiego: AcademicPress;
 1988: 193 225.
- 14 . MaylorEA Luie N Theinfluence of perceptual load on age differences in selective attention. PsycholAging 1998 ; 13 : 563 73.
- 15 .Madden DJ Adult age differences in the time course of visual attention .J Gerontol 1990 ; 45 : P9 16 .
- 16 .Clany SM ,Hyer WJ Age and skill in visual search. Developmental Psychology 1994 ; 30 : 545 52 .

- 17 . Hyper WJ IngolfsdottirD Age,skill, and contextual cuing in target detection . PsycholAging 2003 ; 18 : 210 8 .
- 18 . Humphry DG , KramerAF Age differences in visual search for feature, conjunction, and triple-conjunction targets . Psychol Aging 1997 ; 12 : 704 - 17 .
- 19 .MaddenDJ PierceTW, AllenPA Adultage differences in the use of distractor homogeneity during visual search . PsycholAging 1996 ; 11 : 454 74 .
- 20 .PludeDJ Hyper WJ Age and the selectivity of visual information processing .PsycholAging 1986 ; 1 : 4 – 10 .
- 21 . Sombeg BL Salthouse TA Divided attention abilities in young and old adults. J Exp Psychol Hum Percept Perform 1982 ; 8 : 651 63 .
- 22 .McDwd JM CraikFI Effects of aging and task difficulty on divided attention performance . JExp Psychol Hum Percept Perform 1988; 14: 267 – 80.
- 23 . Salthouse A , Rogan JD Prill KA Division of attention: age differences on a visually presented memory task . MemCognit 1984 ; 12 : 613 20 .
- 24 . Hartly AA Age differences in dual-task interference are localized to response-generation processes . PsycholAging 2001 ; 16 : 47 54 .
- 25 .Hartly AA LittleDM Age-related differences and similarities in dual-task interference . JExp Psychol Gen 1999 ; 128 : 416 – 49 .
- 26 . Rogers WA, Bertus EL, Gilbert DK, Dual-task assessment of age differences in automatic process development. Psychol Aging 1994; 9: 398 413.
- 27 .BaronA MattilaWR Responseslowing of older adults: effects of time-limit contingencies on single- and dual-task performances . PsycholAging 1989 ; 4 : 66 72 .
- 28 .McDwd JM ,Birren JE Aging and attentional processes .In: Birren JE ,Schaie KW eds. Handbook of the Psychology of Aging . New York : Academic Press ; 1990 : 222 – 33 .
- 29 .KrayJ LiKZ Lindenberger U Age-related changes in task-switching components: the role of task uncertainty. BrainCogn 2002 ; 49 : 363 81 .
- 30 . MayrU Agedifferences in the selection of mental sets: the role of inhibition, stimulus ambiguity, and response-set overlap . PsycholAging 2001 ; 16 : 96 109 .
- 31 . Parasuraman R Daies DR Varieties of attention . SanDiego : AcademicPress ; 1984
- 32. Prasuraman R ,GiambraL Skilldevelopment in vigilance: effects of event rate and age. PsycholAging 1991; 6: 155 – 69.
- 33 .Giambra LM . Sustained attention and aging: Overcoming the decrement? Exp Aging Res 1995 ; 23 : 145 61 .
- 34 . LoringDW INSDictionary of Neuropsychology. New York : OxfordUniversity Press ; 1999 .
- 35 .LezakMD Hwieson DB LoringDW NeuropsychologicalAssessment . 4thed . New York : OxfordUniversity Press ; 2004 .
- 36 .ElliottR Executive functions and their disorders . BrMed Bull 2003 ; 65 : 49 59 .
- 37 .Alæander GE ,Crutcher MD Functional architecture of basal ganglia circuits: neural substrates of parallel processing . Trends Neurosci 1990 ; 13 : 266 – 71 .
- 38 .Lichter DG ,Cummings JL Erontal-subcortical circuits in psychiatric and neurological disorders . New York : GuilfordPress ; 2001 .
- 39 . Moscwitch M , Whocur G Frontal lobes, memory, and aging . Ann N Y Acad Sci 1995 ; 769 : 119 50 .
- 40 . West RL Anapplication of prefrontal cortex function theory to cognitive aging . PsycholBull 1996 ; 120 : 272 92 .
- 44 . Greenwood PM The frontal aging hypothesis evaluated . J Int Neuropsychol Soc 2000 ; 6 : 705 26 .
- 42 .Salthouse $\mathbb A$ Relations between cognitive abilities and measures of executive functioning . Neuropsychology 2005 ; 19 : 532 45 .
- 43 . LezakMD NeuropsychologicalAssessment . 3rded . New York : OxfordUniversity Press ; 1995
- 44 . Jurado MB Rosselli M The elusive nature of executive functions: a review of our current understanding . Neuropsychol Rev 2007 ; 17 : 213 – 33 .
- 45 . LaflecheG AlbertM Executive function deficits in mild Alzheimer's disease . Neuropsychology 1995 ; 9 : 313 20 .

- 46 . Borkwsky JG Burk JE Theories, models and measurements of executive functioning: An information processing perspective .In: Jon GR Krasngor NA eds. Attention, memory, and executive function. Baltimore Rul H. Brookes; 1996.
- 47 . Anderson W, Anderson P, Northam E, Jacobs R, Catroppa C, Development of executive functions through late childhood and adolescence in an Australian sample. Dev Neuropsychol 2001; 20: 385 406.
- 48 .Delis D ,Kaplan E ,Kramer N Delis-Kaplan executive function system. Odessa, FL: PsychologicalAssessment Resources; 2001.
- 49 .PiguetO GraysonDA, BroeGA et al .Normalaging and executive functions in "old-old" community dwellers: poor performance is not an ine vitable outcome. Int Psychogeriatr 2002; 14: 139 59.
- 50 . BanichMT Cognitive neuroscience and neuropsychology . Boston HoughtonMifflin ; 2004 .
- 51 . Salthouse TA, Atkinson TM, Berish DE Executive functioning as a potential mediator of age-related cognitive decline in normal adults. JExp Psychol Gen 2003; 132: 566 94.
- 52 . GunstadJ Rul RH BrickmanAM etal . Patterns of cognitive performance in middle-aged and older adults: A cluster analytic examination . JGeriatr Psychiatry Neurol 2006 ; 19 : 59 64 .
- 53 .Grant DA, Beg EA A behavioral analysis of reinforcement and ease of shifting new responses in a Weigel-type card-sorting problem . JExp Psychol 1948; 38 : 404 11 .
- 54 .HeatonRK CheluneGJ Talley JL KayG CurtissG Wisconsin Card Sorting Test manual: Revised and expanded . Odessa,FL : PsychologicalAssessment Resources ; 1993 .
- 55 .RhodesMG Age-related differences in performance on the Wisconsin card sorting test: a meta-analytic review . Psychol Aging 2004 ; 19 : 482 94 .
- 56 . StroopJR Studies of interference in serial verbal reaction . JExp Psychol 1935 ; 18 ÷ 6623 .
- 57 .GoldenCJ Stroopcolor and word test: A manual for clinical and experimental uses . Chicago, IL : Stoelting ;1978 .
- 58 .Belleille S RouleauN ¼n der Linden M Useof the Hayling task to measure inhibition of prepotent responses in normal aging and Alzheimer's disease .BrainCogn 2006 ; 62 : 113 – 9 .
- 59 . HaarmannHJ AshlingGE Duelaar EJ UsherM Age-relateddeclines in context maintenance and semantic short-term memory. QJ Exp Psychol A 2005 ; 58 : 34 – 53 .
- 60 . RushBK BarchDM Braer TS Accounting for cognitive aging: context processing, inhibition or processing speed? NeuropsycholDev Cogn B Aging Neuropsychol Cogn 2006; 13: 588 610.
- 61 . an der Linden MW, an der Slik AR ZanelliE etal .Sixmicrosatellite markers on the short arm of chromosome 6 in relation to HLA-DR3 and TNF-308A in systemic lupus erythematosus . GenesImmun 2001; 2: 373 – 80.
- ${\bf @}$. Simon HA The functional equivalence of problem solving skills . Cognit Psychol 1975 ; 7 : 268 88 .
- 63 .ZookN Wash MC EwingV Performance of healthy, older adults on the Tower of London Revised: Associations with verbal and nonverbal abilities. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 2006 ; 13 : 1 – 19 .
- 64 . Ronnlund M Løden M Nilsson LG Adultage differences in Tower of Hanoi performance: Influence from deographic and cognitive variables . Aging, Neuropsychol Cogn 2001; 8: 269 – 83.
- 65 . Salthouse A, Joth J Daniels K et al . Effects of aging on efficiency of task switching in a variant of the trail making test . Neuropsychology 2000 ; 14 : 102 11 .
- 66 . Wecker NS KramerJH HallamBJ DelisDC Mental flexibility: age effects on switching. Neuropsychology 2005; 19: 345 – 52.
- 67 .BrickmanAM Rul RH CohenRA etal .Category and letter verbal fluency across the adult lifespan: relationship to EEG theta power. ArchClin Neuropsychol 2005; 20: 561 73.
- 68 .Rodriguez-ArandaC MartinussenM Age-related differences in performance of phonemic verbal fluency measured by Controlled Oral Word Association Task (COWAT): a meta-analytic study. Dev Neuropsychol 2006 ; 30 : 697 – 717 .
- 69 . Ryall DR Plmer R ChiodoLK PolkMJ Normalrates of cognitive change in successful aging: the freedom house study. JInt Neuropsychol Soc 2005 ; 11 : 899 909 .
- 70 . BrickmanAM ZimmermanME Rul RH etal .Regional white matter and neuropsychological functioning across the adult lifespan . BiolPsychiatry 2006 ; 60 : 444 53 .

- 71 .ZimmermanME BrickmanAM Pul RH etal .Therelationship between frontal gray matter volume and cognition v aries across the healthy adult lifespan . Am J Geriatr Psychiatry 2006 ; 14 : 823 33 .
- 72 . SquireLR Memory systems of the brain: a brief history and current perspective . Neurobiol Learn Mem 2004 ; 82 : 171 7 .
- 73 . SquireLR Kwlton BJ The medial temporal lobe, the hippcomapus, and the memory systems of the brain .In: GazzanigaMS ed. TheNew Cognitive Neurosciences . Cambridge TheMIT Press; 1999 .
- 74 . Wechsler D Wechsler Adult Intelligence Scale III . San Antonio, TX : Psychological Coorporation ; 1997 .
- 75 . Kerten AE HendersonAS ChristensenH etal .Aprospective study of cognitive function in the elderly. PsycholMed 1997 ; 27 : 919 30 .
- 76 . Rrk DC LautenschlagerG HeddenT, Duidson NS SmithAD Smith PK Modelsof visuospatial and verbal memory across the adult life span . PsycholAging 2002 ; 17 : 299 – 320 .
- 77 . Sunderland A , Watts K , Baddely AD , Harris JE Subjective memory assessment and test performance in elderly adults . JGerontol 1986 ; 41 : 376 84 .
- 78 .JamesLE Specifc effects of aging on proper name retrieval: now you see them, now you don't .JGerontol 2006 ; 61 : P180 3 .
- 79 . Triving E Episodicand semantic memory .In: úTving E DonaldsonWeds. Oganization of Memory . New York : AcademicPress; 1972.
- 80 . Talving E Episodic memory: from mind to brain . AnnuRev Psychol 2002; 53 : 1 25.
- 81 . KralVA Neuro-psychiatricobservation in an old peoples' home. Studies of memory dysfunction in senescence. JGerontol 1958; 13: 169 – 76.
- 82 . Dunlos J Salthouse A Adeomposition of age-related differences in mult-trial free recall. Aging Neuropsychol Cogn 1996; 3 : 2 – 14.
- 83 .SmallSA PereraGM DeLaRz R MayeuxR SternY Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease. Ann Neurol 1999 ; 45 : 466 – 72 .
- 84 . ZacksRT, HasherL LiKZH HumanMemory.In: CraikFIM SalthouseTA eds. TheHandbook of Aging and Cognition . 2ndEdition ed. Mahwah : Lawrence Erlbaum Associates ; 2000 .
- 85 . Salthouse TA Memoryaging from 18 to 80 . Alzheimer Dis Assoc Disord 2003 ; 17 : 162 7
- 86 . RappPR AmaralDG Individual differences in the cognitive and neurobiological consequences of normal aging . Trends Neurosci 1992 ; 15 : 340 – 5 .
- 87. Wegesin DJ, Friedman D, Wrughese N, Stern Y. Age-related changes in source memory retrieval: an ERP replication and extension. BrainRes Cogn Brain Res 2002; 13: 323 38.
- 88 . Wegesin DJ Jacobs DM Zubin NR , Writura PR , Stern Y .Source memory and encoding strategy in normal aging . JClin Exp Neuropsychol 2000 ; 22 : 455 64 .
- 89 .ZelinskiEM LightLL Young and older adults' use of context in spatial memory. Psychol Aging 1988; 3: 99 - 101.
- 90 .WrightBM Ryne RB Effects of aging on sex differences in psychomotor reminiscence and tracking proficiency. JGerontol 1985 ; 40 : 179 84 .
- 91 .SchugensMM DaumI SpindlerM BirbaumerN Differential effects of aging on explicit and implicit memory. AgingNeuropsychol Cogn 1997; 4: 33 44.
- 92 . Salthouse A Efects of age and skill in typing . JExp Psychol Gen 1984 ; 113 : 345 71 93 . Krampe R , Ericsson KA Maintaining excellence: deliberate practice and elite performance
- in young and older pianists. JExp Psychol Gen 1996; 125: 331 59.
- 94 . SmithCD Walton A Loreland AD Umberer GH KryscioRJ GashDM Memoriesthat last in old age: motor skill learning and memory preservation. NeurobiolAging 2005; 26: 883 – 90.
- 95 . MitchellDB How many memory systems? Evidence from aging . JExp Psychol Learn Mem Cogn 1989 ; 15 : 31 49 .
- 96 .LightLL SinghA Implicitand explicit memory in young and older adults . JExp Psychol Learn Mem Cogn 1987 ; 13 : 531 41 .
- 97 .FleischmanDA , GabrieliJD Repetitionpriming in normal aging and Alzheimer's disease: a review of findings and theories . PsycholAging 1998 ; 13 : 88 119 .

- 98 .LaVoie D LightLL Adultage differences in repetition priming: a meta-analysis . Psychd Aging 1994 ; 9 : 539 53 .
- AtkinsonRC Shiffin RM Humanmemory: A proposed system and its control processes.
 In: SpenceKW, Spence JT eds. The Psychology of Learning and Motivation. London : AcademicPress; 1968.
- 100 .MillerG Themagical number seven, plus or minus two: Some limits on our capcacity for processing information . PsycholRev 1956 ; 63 : 81 – 97 .
- 101 . Covan N Themagical number 4 in short-term memory: a reconsideration of mental storage capacity. Behav Brain Sci 2001; 24: 87 discutsion-85.
- 102 .LehrS FischerB Abasic information psychological parameter (BIP) for the reconstruction of concepts of intelligence . EurJ Pers 1990 ; 4 : 259 86 .
- 103 .Grady CL ,Craik FI Changes in memory processing with age . Curr Opin Neurobiol 2000 ; 10 : 224 31 .
- 104 . Salthouse TA, Mitchell DR, Skyronek E, Babcock RL Effects of adult age and working memory on reasoning and spatial abilities. JExp Psychol Learn Mem Cogn 1989; 15: 507 – 16.
- 105 .Grant JD ,Dagenbach D Further considerations regarding inhibitory processes, working memory, and cognitive aging . AmJ Psychol 2000; 113: 69 – 94.
- 106 .CraikFIM Memorychanges in normal aging . CurrDir Psychol Sci 1994 ; 3 : 155 8 .
- 107 . Rrk DC SmithAD LautenschlagerG etal . Mediators
of long-term memory performance across the life span . Psychol
Aging 1996 ; 11 : 621 – 37 .
- 108 .Schaie KW .Intellectual development in adulthood: The Seattle Longitudinal Study. Cambridge CambridgeUniversity Press; 1996 .
- 109 . Burk DM ShaftoMA Languageand Aging .In: CraikFIM SalthouseTA eds. The handbook of aging and cognition . 3rded. New York : PsychologyPress ; 2000 : 373 443 .
- 110. Kemper S MitznerTL Language production and comprehension. In: BirrenJE Schaie KW, eds. Handbookof the psychology of aging . 5thed. New York : AcademicPress; 2001 : 378 98.
- 111 Burk DM MacKayDG JamesLE Theoreticalapproaches to language and aging .In: PerfectT, MaylorEA eds. Models of cognitive aging . Oxford Oxford University Press; 2000 : 204 - 37 .
- 112 . Kemper S Language in adulthood . In: Bialystok E , Craik FIM eds. Lifespan cognition: Mechanisms of change . Oxford OxfordUniversity Press; 2006 : 223 – 38 .
- 113 .RyanC Measures of cognitive function .In: Bradje C ed. Handbook of psychology and diabetes: A guide to psyolgical measurement in diabetes research and practice . New York: PsychologyPress; 1994 : 191 – 219 .
- 114 .Burk DM Locantore JK Austin AA ,Chae B Cherry pit primes Brad Pitt: Homophone priming effects on young and older adults' production of proper names
 . Psychol Sci 2004 ; 15 : 164 70 .
- 115 .JamesLE Burk DM Phonological priming effects on word retrieval and tip-of-the-tongue experiences in young and older adults .JExp Psychol Learn Mem Cogn 2000 ; 26 : 1378 91 .
- 116. White KK, Abrams L. Does priming specific syllables during tip-of-the-tongue states facilitate word retrieval in older adults? Psychol Aging 2002; 17: 226 35.
- 117 .MacKayDG JamesLE Sequencing, speech production, and selective effects of aging on phonological and morphological speech errors . PsycholAging 2004 ; 19 : 93 107 .
- 118 .KaplanE GoodglassH Wintraub S TheBoston naming test . Philadelphia Iea & Febiger; 1983 .
- 119 .ZecRF, MarkwellSJ Burktt NR LarsenDL Alongitudinal study of confrontation naming in the "normal" elderly. JInt Neuropsychol Soc 2005; 11: 716 – 26.
- 120. ZecRF, Burktt NR MarkwellSJ LarsenDL Across-sectional study of the effects of age, education, and gender on the Boston Naming Test. TheClinical neuropsychologist 2007; 21: 587 – 616.
- 121 .ConnorIT, Spiro A 3rd, OblerLK Albert ML Change in object naming ability during adulthood. JGerontol 2004; 59: P203 – 9.
- 122 .MackayAI ConnorIT, AlbertML OblerLK Nounand verb retrieval in healthy aging . JInt Neuropsychol Soc 2002; 8: 764 – 70.

- 123 .SchmittetEdgecombe M Jøsneski M JonesDW Agingand word-finding: a comparison of spontaneous and constrained naming tests . ArchClin Neuropsychol 2000 ; 15 : 479 − 93 .
- 124 . Kemper S GreinerLH MarquisJG Prenoost K MitznerTL Language decline across the life span: findings from the Nun Study. PsycholAging 2001 ; 16 : 227 39 .
- 125 . Kemper S Summer A Thestructure of verbal abilities in young and older adults . Psychol Aging 2001 ; 16 : 312 22 .
- 126 . Arbckle TY, Nohara-LeClairM PushkarD Effect of off-target verbosity on communication efficiency in a referential communication task. PsycholAging 2000; 15:65 77.
- 127 . Whgfield A Stine-Morrow EAL Languageand speech .In: CrailFIM SalthouseTA eds. Thehandbook of aging and cognition . 2nded . Mahwah, NJ : Lawrence Erlbaum Associates ; 2000 : 359 - 416 .
- 128 .UttlB NorthAmerican adult reading test: age norms, reliability, and validity. JClin Exp Neuropsychol 2002 ; 24 : 1123 37 .
- 129 .Schaie KW .Developmental influences on adult intelligence . Oxford :Oxford University Press ; 2005 .
- 130 .SingerT, Vrhaeghen P, GhislettaP, Lindenbeger U BaltesPB The fate of cognition in very old age: six-year longitudinal f indings in the Berlin Aging Study (B ASE). Psychol Aging 2003 ; 18 : 318 - 31 .
- 131 .JohnsonRE Agingand the remembering of text . Dev Rev 2003 ; 23 : 261 346 .
- $132\,$. Macknzie C Therelevance of education and age in the assessment of discourse comprehension . ClinLinguist Phon 2000 ; 14 : 151 61 .
- 133 .CaplanD Waters GS Verbal working memory and sentence comprehension. Behav Brain Sci 1999 ; 22 : 77disc@ussion5-126.
- 134 . Gordon-SalanS FitzgibbonsPJ Sourcesof age-related recognition difficulty for timecompressed speech . JSpeech Lang Hear Res 2001 ; 44 : 709 – 19 .
- 135 .ManentiR RepettoC Bentroato S MarconeA BatesE CappaSF Theeffects of ageing and Alzheimer's disease on semantic and gender priming . Brain 2004 ; 127 : 2299 306 .
- 136 .StineEA Wingfield A MyersSD Agedifferences in processing information from television news: the effects of bisensory augmentation. JGerontol 1990; 45 : P1 – 8.
- 137 .MorrellCH Gordon-SalantS PearsonJD BrantLJ For JL Age- and gender-specific reference ranges for hearing le vel and longitudinal changes in hearing le vel. J Acoust Soc Am 1996 ; 100 : 1949 – 67 .
- 138 .SchneiderBA , Pichora-FullerMK Kwalchuk D LambM Gapdetection and the precedence effect in young and old adults . JAcoust Soc Am 1994 ; 95 : 980 – 91 .
- 139 .ConnellySL HasherL ZacksR Ageand reading: the impact of distraction . Psychol Aging 1991; 6: 533 – 41.
- 140 .HasherL ZacksR , MayCP Inhibitory control, circadian arousal, and age .In: GopherD , Kriat A eds. Attention and performance XVII: Cognitive regulation of performance: Interaction of theory and application . Cambridge,MA : MITPress; 1999 .
- 141 .Benton A , Fanel D Vsuoperceptual, Visuospatial, and Visuocontructive Disorders .In: HeilmarKM Menstein E, eds. ClinicalNeuropsychology . 3rded. Oxford OxfordUniversity Press; 1993 : 165 – 214 .
- 142 .Wechsler D Wechsler Adult Intelligence Scale Third Edition . San Antonio, TX : The Psychological Corporation ; 1997 .
- 143 . GolombJ dd_eon MJ KlugerA Geoge AE Trshish C FerrisSH Hippocampalatrophy in normal aging. An association with recent memory impairment. ArchNeurol 1993; 50: 967 – 73.
- 144 . Wechsler D Wechsler memory scale Revised . San Antonio, TX : The Psychological Corporation ; 1987 .
- 145 .KaplanE Aprocess approach to neuropsychological assessment .In: BolITJ BryanBK , eds. Clinical neuropsychology and brain function: Research, measurement, and practice . Washington, D.C. : AmericanPsychological Association ; 1988 : 129 – 67 .
- 146 .McCarthy SM ,Sigler IC ,Logue PE Cross-sectional and longitudinal patterns of three Wechsler Memory Scale Subtests . JGerontol 1982 ; 37 : 169 – 75 .

- 147 .ShayKA RothDL Association between aerobic fitness and visuospatial performance in healthy older adults . PsycholAging 1992 ; 7:15 24 .
- 148 .Wechsler D Wechsler Adult Intelligence Scale Revised. San Antonio, TX : The Psychological Corporation ; 1981 .
- 149 .Hooper HE The hooper visual organization test: Manual . Boverly Hills, CA : Western Psychological Services ; 1958 .
- 150 .Ry A L'examen psychologique dans les cas d'encephalopathie traumatique . Archives de Psychologie 1941 ; 28 : 286 – 340 .
- 151 .OsterriethPA Letest de copie d'une figure complex: Contribution a l'etude de la perception et de la memoire . Archives de Psychologie 1944 ; 30 : 286 356 .
- 152 . While TB BackmanL Within A Winblad B Visuospatial functioning and spatial orientation in a community-based sample of healthy v ery old persons. Arch Gerontol Geriatr 1993 ; 17 : 165 – 77 .
- 153 . DriscollI HamiltonDA, Yo RA BrooksWM SutherlandRJ Virtual navigation in humans: the impact of age, sex, and hormones on place learning. HormBehav 2005; 47: 326 – 35.
- 154 .BoutetI MilgramNW, FreedmanM Cognitive decline and human (Homo sapiens) aging: an investigation using a comparati ve neuropsychological approach. J Comp Psychol 2007; 121: 270 – 81.
- 155 .Madden DJ Speed and timing of behavioral processes . In: BirrenJE ,Schaie KW eds. Handbookof the psychology of aging . 5thed. New York : AcademicPress ; 2001 : 288 - 312 .
- 156 . Ketcham CJ StelmachGE Age-relateddeclines in motor control .In: BirrenJE Schaie KW, eds. Handbook of the psychology of aging. 5th ed. New York: Academic Press; 2001 : 313 48.
- 157 .Ruff RM Jarker SB Gender and age-specific changes in motor speed and eye-hand coordination in adults: normative values for the finger tapping and grooved pegboard tests. PerceptMot Skills 1993 ; 76 : 1219 30 .
- 158 .Shimwama I Ninchoji T, Uemura K The finger-tapping test. A quantitative analysis. ArchNeurol 1990 ; 47 : 681 – 4 .
- 159 .UttlB Pilknton-Taylor C Letter cancellation performance across the adult life span . TheClin Neuropsychol 2001 ; 15 : 521 – 30 .
- 160 .Wig EH NielsenNP, JacobsonJM AQuick test of cognitive speed: patterns of age groups 15 to 95 years . PerceptMot Skills 2007 ; 104 : 1067 - 75 .
- 161 .Salthouse TA Therole of representations in age differences in analogical reasoning .Psychol Aging 1987 ; 2 : 357 62 .
- 162 .Salthouse TA , MitchellDRD Effects of age and naturally occurring experience on spatial visualization performance . Dev Psychol 1990 ; 26 : 845 54 .
- 163 .SchaieKW Perceptualspeed in adulthood: cross-sectional and longitudinal studies . Psychol Aging 1989 ; 4 : 443 53 .
- 164 .PietrzakRH CohenH Spider PJ Spatiallearning efficiency and error monitoring in normal aging: an investigation using a no vel hidden maze learning test . Arch Clin Neuropsychol 2007 ; 22 : 235 – 45 .
- 165 .Rodriguez-ArandaC Waterloo K SparrS SundetK Age-related psychomotor slowing as an important component of v erbal fluency: evidence from healthy individuals and Alzheimer's patients . JNeurol 2006 ; 253 : 1414 – 27 .
- 166 . For JL , Vercryssen M , Reprolds SL , Hancock PA , Quilter RE Age differences and changes in reaction time: the Baltimore longitudinal study of aging . J Gerontol 1994 ; 49 : P179 – 89 .
- 167 . AmrheinPC StelmachGE GogginNL Agedifferences in the maintenance and restructuring of movement preparation . PsycholAging 1991 ; 6 : 451 66 .
- 168 .StelmachGE GogginNL AmrheinPC Agingand the restructuring of precued movements . PsycholAging 1988; 3 : 151 – 7 .
- 169 . Walker N Philbin DA , Fisk AD Age-related differences in movement control: adjusting submovement structure to optimize performance . JournalsGerontol 1997 ; 52 : P40 52 .

- 170 .Smith GA $\,$,Brover $\,N\,$ Slowness and age: speed-accuracy mechanisms . Psychol Aging $\,1995\,$; $\,10\,$: $\,238\,$ $\,47\,$.
- 171 .SeidlerRD StelmachGE Motorcontrol. Engclopedia Gerontol 1996 ; 2 : 8577 -
- 172 . Welford AT Betweenbodily changes and performance: some possible reasons for slowing with age . ExpAging Res 1984 ; 10 : 73 88 .
- 173 .SimonJR PouraghabagherAR Theeffect of aging on the stages of processing in a choice reaction time task . JGerontol 1978 ; 33 : 553 61 .
- 174 .SpirdusoWW, MacRaePG Motorperformance and aging .In: BirrenJE SchaieKW eds. Handbookof the Psychology of Aging . New York : AcademicPress ; 1990 : 183 – 200 .
- 175 .Dustman RE ,Ruhling RO , Russell EM et al .Aerobic exercise training and improved neuropsychological function of older individuals . NeurobiolAging 1984 ; 5 : 35 42 .
- 176. Nelson HE, Willison J. The National Adult Reading T est (NART): Test Manual (2nd ed.) Windsor, UK: NFER Nelson.

Interactions Between Advanced Age and HIV Cognitive Impairment

Victor Valcour and Aaron M. McMurtray

Epidemiology of Aging with HIV

Age-Related Demographic Changes in HIV Infection

Important changes are occurring in the frequency of HIV in older adults, driven in large part by extended survival due to effective antiretroviral treatment (1, 2). With no effective cure in sight, HIV infection has entered the realm of chronic diseases that require long-term management. Moreover, it is often accompanied by a multitude of comorbidities, both medical and psychiatric. This is common in geriatric medicine and typically requires a multidisciplinary approach. Most older HIV patients acquired infection at a younger age and aged with HIV ; however, older individuals also acquire infection in their sixth or older decade of life and remain an often hidden population. Not surprisingly, the frequency of becoming infected in older age may also be rising (3). Epidemiological trends indicate greater risk beha viors in this population with insufficient public health emphasis for safer se xual practices (3). New infections occurring in older adults are disproportionately occurring in women and the majority of these older female cases occur in minority populations (4).

It is currently estimated that there are 0 ver 114,000 adults over 50 years living with HIV in the United States (Fig. 1) (5–8). In 2005, 15% of ne w infections occurred in individuals over 50 years of age (6); while in some states, the rate approached 30% (9). While coming into greater attention more recently , these changes were suggested even in the early 1990s, prior to HAAR T, where the rates for developing AIDS rose twice as fast in persons 50 plus years than it did in persons younger than 50 (22% compared with 9%, respectively) (6, 10). A recent statement by a member of the US Senate Committee on Aging estimated that up to 50% of

A.M. McMurtray (🖂)

Division of Neurology, Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96816, Hawaii aaronmnm@hawaii.edu




Fig. 1 Changing demographic distribution of prevalent HIV cases as reported to the Centers for Disease Control and Prevention (CDC) between 2001 (*black bars*) and 2005 (*open bars*)

US prevalent HIV cases will be over 50-years old by 2015 (11). There is little doubt that this is a burgeoning population.

Clinical Factors Associated with Aging in HIV Infection

The demographic and clinical features of these older HIV indi viduals may differ from that of younger populations in a manner that could be e xpected to impact cognition (Table 1). Older adults tend to have a longer overall duration of infection and possibly a longer duration of exposure to antiretroviral medications (12, 13). In the Hawaii Aging with HIV Cohort (HAHC), patients o ver 50 years reported 11.8 years of HIV infection, on a verage, compared with only 7.2 years in their counterparts who were younger than forty (14). Based on this range of duration, many older individuals would be expected to have survived a period of time when HAART was not yet conceived, thus opening up the possibility that survivorship tendencies exist in this population, whereby unrecognized host or viral f actors are associated with long-term survival in the absence of effective treatment. Older patients may be more likely to have been exposed to more toxic antiretroviral medications, such as dideoxy-nucleoside re verse transcriptase inhibitors (NR TI), which are currently less commonly used in the de veloped world, but were very commonly employed in the early HAART era. Limited magnetic resonance spectroscopy (MRS) data suggest that such treatment could impact brain health (15). The extended duration of illness also implies the possibility that man y of these individuals were treated with mono or dual therapy, increasing the likelihood of periods of incomplete viral suppression and therefore, possibly increased resistance. Central nervous system compartmentalization of resistance patterns has been described and demonstrated to correlate with neurocognitive deficits (16). Perhaps least studied, but of potential great importance is the role of chronic lo w-level immune activation that likely

Longer duration of infection and chronic immune activation
Longer duration of ARV exposure
Greater risk for previous exposure to more toxic ARVs
Greater risk for incomplete viral suppression with past mono or dual therap y, possibly increas-
ing ARV resistance patterns
Delayed diagnosis with greater duration of immunosuppression
Possible survivorship tendencies

 Table 1
 Clinical factors potentially associated with HIV at older ages

occurs in patients with controlled infection that is below the level of detection (17). This might be represented as so called "viral blips" of intermittent plasma HIV RNA detectability, which may be larger with chronic disease (18). Continued infection of the monocyte cellular subset (reservoir) of peripheral mononuclear cells is well described in successfully treated HIV patients with kno wn implications on HIV disease progression (19), monocyte activation (20), and cogni tion (21). Whether these relationships are due to immune activation is an area of ongoing study.

Individuals who become infected in older life may have unique cognitive risk factors. Several groups have identified delayed diagnosis to occur more commonly in older adults (22–25). This has lead some to speculate that the pre-AIDS phase in older adults may be less symptomatic (24, 26). HIV and other lentiviruses are known to have neurotropic qualities (27) and HIV is known to enter the brain early in infection (28). The cognitive implications of early compared with late initiation of HAART are incompletely studied. However, the delayed diagnosis translates to longer periods of time with untreated HIV, continued HIV viremia and likely with a prolonged period of immunosuppression, which is a known risk factor for HIV dementia (29). A diagnosis of dementia concurrent with first identification of HIV infection occurs more frequently with advanced age (30).

The relationship between age and HIV clinical outcomes including progression, immunological response to HAAR T, and mortality is the subject of numerous publications. Advancing age was recognized early in the epidemic as a risk f actor for more rapid progression of disease (31, 32); a finding that remains present in the era of HAART (33, 34); although argued by some to possibly reflect access to care(2). Most authors also identify a blunted immunological response to HAAR T in older individuals despite comparable virological responses (35–37) with some dis crepant reports (26). Despite increases in complications (38, 39), older patients tend to have greater rates of adherence to medications (40), possibly making up for limitations in HAART response. We refer the reader to these excellent reviews of clinical outcomes in aging HIV patients, a topic that is be yond the scope of this chapter.

Evidence That Age Impacts Cognitive Performance in HIV

Several groups have investigated the effects of aging on development of cognitive dysfunction in HIV, yielded conflicting results possibly associated with methodological challenges. The majority of these studies, but not all, suggest that age detrimentally impacts cognitive performance with advancing age, increasing the risk for clinically

relevant cognitive dysfunction. These findings are more robust for clinical outcomes than they are for neuropsychological findings, where most published studies have been limited in power or methodological approaches. More consistent findings in clinical or epidemiological outcomes compared to neuropsychological outcomes may also reflect the importance of motor and behavioral symptoms in HIV dementia, items captured less well in neuropsychological testing. W e will first present the epidemiological data, which relies upon physician reporting of illness, and one report that utilized clinical endpoints diagnosed with structured neuropsychological and neurological evaluations. We will then re view available studies of age ef fect on neuropsychological performance.

Epidemiological and Clinical Diagnostic Outcomes

The introduction of HAART changed the epidemiological and clinical characteristics of cognitive disorders in de veloped countries (41–43). Data reported from the pre-HAART era provides a glimpse at HIV -specific effects on age-related brain function, since during this period, control of HIV replication w as sub-optimal and the confounds of antiretro viral medication effects were generally absent. During this period, several epidemiological studies identified age as a robust risk factor for HIV-associated cognitive disease (30, 44). The AIDS in Europe study, which evaluated the AIDS cases reported between 1979 and 1989, identif ied a 14% increased risk for AIDS Dementia Comple x (ADC) at the time of AIDS diagnosis per 5-year increase in age (44). This was accompanied by a 19% increased risk of developing ADC during follow-up. In the United States, in vestigators from the Multicenter AIDS Cohort Study (MACS) reported a relative hazard ratio for dementia of 1.60 per decade of life at AIDS onset (29). Using data from 1987 to 1991, Janssen et al. reported an age-related risk for HIV encephalopathy based on US Centers for Disease Control and Prevention (CDC) reports (30). They identified that 19% of reported AIDS cases over 75 years had HIV encephalopathy compared with only 6% among patients between 15- and 34-years old.

This increased risk appears to carry forw ard in the era of HAAR T. Age was one of the few risk factors that emerged from the Concentrated Action on Serocon version to AIDS and Death in Europe (CASCADE) in the era of HAAR T with a relative risk of 3.24 per 10-year increase (45). Age was also associated with an increased risk for transition from a non-dementia status to dementia in the Northeast AIDS Dementia cohort (46). A similar increase in cognitive diagnoses has been reported using structured clinical assessments in the HAHC. Using a consensus conference and American Academy of Neurology 1991 criteria (12, 47), this work identified that patients over 50 years have greater than twice the risk of meeting HIV -associated dementia (HAD) criteria. At the time of publication, this cohort was comprised of 202 HIV patients living in Hawaii, 96 with ages younger than 40 years and 106 with age \geq 50. Outcomes were adjusted for education, race, substance dependence, antiretro viral medication status, plasma HIV RNA (viral load), CD4 lymphoc yte count, and depression scores (Fig. 2). Although




Fig. 2 Cognitive diagnostic outcomes in the Hawaii Aging with HIV Cohort

these data are compelling that age impacts cognitive outcomes in HIV, the etiology of the impairment remains less clear. Most cases in this cohort were cate gorized as "possible" rather than "probable" dementia, a qualiferent that indicates the likelihood that comorbid illness impacted cognitive performance. This finding highlights the heterogeneous etiology of cognitive deficits in HIV.

Neuropsychological Performance Outcomes

Despite a number of reports addressing the effect of aging on neuropsychological performance in HIV infection, the relationship remains incompletely understood (Table 2). Both aging and HIV infection are associated with declines in neuropsychological performance, a factor highly suggestive that at least additive effects may be found (reviewed in (48)). Some authors describe domain-specific overlap of performance deficits with both age and HIV differentially affecting psychomotor speed and cognitive flexibility (49, 50). However, conflicting findings are noted in other studies, and, if present, the age at which these f indings would translate into clinically relevant outcomes remains to be defined.

In the pre-HAART era, van Gorp et al. reported an e valuation of age effects on cognitive performance in two studies, one using the MACS cohort (study one) and a second using a clinical cohort (study two) (51). The first study compared neuropsychological performance among 1,066 HIV+ and 1,004 HIV- MACS enrollees, of whom only five HIV cases were over the age of 55. They identified age effects; but interestingly, failed to identify HIV or HIV -age interaction effects. The second study investigated relationships within a clinical cohort that included 76 HIV+ individuals, 29 of whom were o ver the age of 55. Both age and HIV effects were noted on most measures with interaction effects limited to the groo ved pegboard test, a test of psychomotor speed and manual de xterity. They did not report the

Table 2 Select	Table 2 Scienced reports of figuropsychological outcouries associated with aging in FITA fillectuoli	ssociated with aging III HI V IIIIC	cuoli	
Author and reference	Patient population	Outcome measure	Major findings	Limitations
Becker et al., AIDS (53)	22 HIV+ age 50+ vs. 100 age<50	Dementia and cognitive impairment not dementia (CIND) defined by neu- ropsychological measures	22% of older compared with 9% of younger patients with "dementia" at baseline; 14% of older compared with 22% of younger with CIND; 1-year incidence of dementia at 7% older vs. 4% younger	Limited age matching to controls; NP abnormal- ity requirements for mild impairment were mild (0 to -1 SD abnor- mality); 40% classified as "dementia" denied symptoms
Cherner et al. AIDS (13)	67 HIV+ age 50+ vs. 52 < 35 years	Cognitive impairment rating scales based on neuropsy- chological performance	Trends for age-associated differences were noted on most ability domains. Age-CSF HIV RNA interaction effects identified	Preliminary report, unclear if sample size was adequate
Hardy et al. (49)	257 HIV+ b/w 1989 and 1995. Divided into 2 groups (older/younger) at the median of 36 years	Neuropsychological testing battery	Age effects were seen on most neuro- cognitive measures in HIV+ patients	No seronegative control group to determine HIV × age effects
Kissel et al. (59)	66 HIV- (10 over 45 years old) compared with 188 HIV+ (25 over 45 years)	Neuropsychological testing battery	Both age and HIV effects noted on summary deficit score; interaction effects not identified	Limited HIV – individuals over 45 years of age
Van Gorp 1994	<i>Study 1</i> : 1,066 HIV+ (<1% over 55-years old) and 1,004 HIV-; <i>Study</i> 2: 76 HIV+ (age 29–55, 41 of whom had symptomatic HIV disease) and 47 age-matched HIV- controls	Neuropsychological testing battery	Study 1: age (but not serostatus) was associated with poorer performance on most tests; age × serostatus effects not detected. Study 2: age × serostatus interaction effects seen only in grooved pegboard test on nondominant hand	Patients in study one were relatively young (5 greater than 55-years old)
Wilkie et al. (50)	Younger groups (age 19–39): HIV– ($n = 30$), HIV+ ($n = 56$); Older groups (age 50+): HIV– ($n = 29$), HIV+ ($n = 36$)	Neuropsychological testing scores	Age x HIV effects were not identified	Preliminary report, not clear if sufficient power existed

 Table 2
 Selected reports of neuropsychological outcomes associated with aging in HIV infection

presence or absence of neuropathy symptoms, an aspect of the clinical examination that may have impacted performance on this test and is known to be more frequent with aging (52).

Several important points can be drawn from these two studies that may provide insight into the challenges of studying age ef fects in HIV and that may have influenced other studies attempting to identify HIV -aging interaction effects. The MACS reports an educational cohort ef fect whereby older enrollees ha ve higher educational attainment. This has been conf irmed in other studies (12, 49). Since lower educational attainment is an independent risk for cogniti ve impairment in HIV (53, 54) and other neurodegenerative disorders (55), such a finding will impair our ability to identify age-specific HIV effects in cohorts with insufficient sample sizes to properly adjust for this covariate. Educational attainment, age, and depression scores were included as covariates in both the MACS and HAHC reports. In addition, the second study re vealed a greater representation of indi viduals with advanced disease (AIDS) when compared with the MACS study. Advanced HIV disease is a well-accepted risk factor for cognitive impairment (29) and likely represents a sub-population most vulnerable to the effects of age. It is not surprising that interaction effects are more readily identifiable in this population, and less identified in other studies largely composed of asymptomatic subjects. Interaction effects between age and advanced disease (AIDS) are noted in other studie649). Neuropsychological performance in asymptomatic HIV patients is a past topic of great controversy and is beyond the scope of this chapter; but is likely associated only with modest group effects, requiring large sample sizes and detailed batteries to conf idently identify (48). Thus, population-based studies of predominantly asymptomatic or minimally symptomatic patients may be less likely to identify relationships with age.

This study also highlights a potential methodological challenge in the interpretation of neuropsychological data in HIV. As described by Wilkie et al. (50) and recommended in a National Institutes of Mental Health workgroup (56), comparison of group mean scores may not be sensitive in identifying HIV effects, since it is suspected that only a proportion of these individuals will ultimately develop cognitive dysfunction and relevant findings may be obscured due to inclusion of individuals with less overall risk. Even in the pre-HAART era, when HIV infection was largely untreated, only a portion of individuals developed clinically important cognitive dysfunction, suggesting that host or viral factors are critical (29). These authors recommended approaches that utilize cut-points to evaluate proportions of individuals in each group who may be exhibiting neuropsychological compromise, rather than comparing group means. Should age impact cogniti ve performance, one w ould expect to identify a higher proportion of individuals meeting impairment criteria in older ages. Other studies have employed this technique resulting in more suggesti ve associations.

For example, a recent study conducted by Cherner et al. evaluated patients from the HIV Neurobehavioral Research Center (HNRC) using the recommended cut-point approach to identify rates of impaired performance by age group. They compared 67 HIV individuals over 50-years old with 52 individuals aged 35 or less. The younger group was chosen to best match the demographics of the older group; b ut reported shorter HIV duration (8 years compared with 12 years). Over half of both older and younger patients were categorized as having stage C disease. They identified a tendency for greater impairment in older subjects compared with younger subjects in most ability domains. Statistically signif icant differences were not identified, perhaps owing to the relatively small sample size and limited power in what the authors define as a preliminary report.

Importantly, these investigators identified an interaction between age and CSF HIV RNA levels whereby older individuals with detectable CSF HIV RN A had twice the rate of impairment than did their older counterparts who had undetectable CSF HIV RNA. In contrast, they detected no relationship to detectability of CSF HIV RNA among younger individuals. The authors speculate that CSF virus in younger individuals may be more representative of "transient" seeding (transfer across the blood–brain barrier); whereas, in older patients it may represent more permanent autonomous virus (derived from independent replication in the nerv ous system), which could be considered to be more deleterious. An alternative interpretation is that older individuals exhibit a greater degree of CNS vulnerability and cannot withstand higher levels of CNS HIV viremia. This vulnerability factor may be suggested by their finding that 76% of older patients notreceiving HAART compared with 57% of older patients on HAART met impairment criteria while the rates in younger patients were unchanged by HAART status (54% vs. 52%); although, this interaction did not meet statistical significance.

Similarly, data from the HAHC identified an age-associated cognitive vulnerability associated with having at least one apolipoprotein epsilon 4 allele. In this population, the presence of an epsilon E4 allele did not appear to impact cognitive outcomes in younger adults; ho wever, a significant risk was identified in older adults (57). Arendt et al. identified age-associated changes in cognitive information processing in HIV using cognitive event-related potentials, similarly identifying age-associated vulnerability in HIV (58).

Other groups have attempted to identify age-associated differences on neuropsychological performance in HIV with mix ed results. Beck er et al. reported rates of neuropsychological testing abnormalities among older compared with younger participants in the Allegheny County Neuropsychological Survey, which included 290 HIV+ and 114 seronegative individuals. They identified 37% of older (n = 22, >50 years) compared with 31% of younger indi viduals (<50-years old) tested in an impaired range, with most of the older patients ha ving greater degrees of impairment (23% defined as "dementia" compared with 9% in the younger group). In this w ork, a dementia designation was based on neuropsychological performance rather than clinical diagnostic characterization. Consequently, they report that 40% of such subjects were clinically asymptomatic. Other methodological challenges were identified, including use of normative data that were not well-matched for age and the potential to rate indi viduals as impaired with only minimal standard deviation abnormality on individual tests.

Hardy et al. identified differences by age in performance among HIV patients; however, they were unable to e valuate HIV-age interaction as the y did not ha ve a comparative seronegative group (49). They identified age-effects on most neuropsy-chological tests. Kessel et al. compared the performance of 25 individuals over 45 years with 155 HIV individuals who were less than 35 years. They identified HIV effects

and age effects but failed to identify age-HIV interaction effects (59). Their sample included only 6 HIV– individuals over 45 years. Goodkin et al. identified higher rates of minor cognitive motor disorder (MCMD) symptom reporting among older patients (41). This finding should be interpreted with caution given that symptom reporting is often more reflective of affective state rather than objective cognitive functioning (51, 60, 61) although, this report carefully adjusted for such factors in the analyses.

The age at which individuals are considered "old" varies in these studies and does not appear to be based on clear physiological criteria. Pre viously, it was suggested that 50 years w as appropriate. This age represented an approximately 2 standard deviation cut-point from the mean for age of HIV patients in the mid 1990s (62): however, this distinction has v ery little pathological or physiological signif icance and has likely been altered with the changing demographics of HIV/AIDS in developed countries. Early epidemiological data hinted at an age threshold effect, whereby risk increased to a greater degree above 65 years (30) (reviewed in (51)). This cut-point needs to be considered cautiously as this study relied on physician reporting of diagnoses, a factor that may be influenced by the patient's age. In many studies, the chosen age cut-point appears to be based on practical issues of sample a vailability. There are no reported studies in HIV with suf ficient enrollees to consider the neuropsychological interaction effect in populations o ver 60. Another approach is to consider age as a continuous variable in regression analyses, but this approach risks obscuring thresholds where brain vulnerability may sharply increase.

We conclude that the interaction effects between age and cognitive function are most robust for epidemiological studies and clinical diagnostic studies. The effects identified in neuropsychological performance are less clear owing to methodological limitations in available studies. The lik elihood that age impacts cognitive performance in HIV is supported by the recognition that CSF HIV RNA levels, apolipoprotein E4 status, and cognitive information processing by cognitive event-related potentials may have an age-associated impact in HIV and the recognition that such an age effect is common in other dementias such as Alzheimer's (63) (reviewed in (51)). Proper longitudinal evaluations with adequate samples of older age subsets are needed.

Age-Specific Risk Factors for Cognitive Impairment in HIV

To our knowledge, no other group besides the HAHC has e valuated age-specific risk factors of cognitive impairment in HIV. This evaluation is not only limited by the small number of aging cohorts with cogniti ve characterization, but also by the changing characteristics of cognitive diseases in the era of HAAR T, resulting in a need to re-analyze the applicability of most pre-HAAR T risk f actors in all age groups (42, 64). One might anticipate that duration of infection would impact either frequency or severity of impairment; ho wever, self-reported duration of infection has not emerged as an important risk f actor in the HAHC (12). In both young and old patients, nadir CD4 lymphoc yte count appears to be an important predictor of neurological and cognitive outcomes in HIV (52, 65, 66). This factor may be more

applicable to older patients who would be expected to have had a greater risk of low CD4 counts prior to initiation of AR V therapy due to longer duration of illness or delayed diagnosis. Metabolic dysfunction in the HAHC, including diabetes (67) and insulin resistance (68), as well as apolipoprotein epsilon 4 status (57) appear to have increased applicability to middle aged and older adults. This topic is discussed further in a later portion of this chapter . Due to the lack of data in this f ield, neuropathogenic models are necessarily speculative.

Age-Related Comorbidities That May Influence Cognition in HIV Infection

A Model for the Role of Comorbidity in HIV Cognitive Outcomes – Brain Reserve

As presented above, epidemiological and neurocognitive clinical outcome studies suggest the possible role of aging in augmenting the risk for cognitive outcomes in HIV; although it is not clear that the etiology of the increased risk is directly attributable to HIV itself. A finding that diabetes and insulin resistance contribute to cognitive impairment in older patients suggest a need to consider heterogeneous etiologies that include ARV side effects (short and long-term), chronic inflammation, and concurrent neurodegeneration.

The concept of brain reserve is a useful model to compile these factors (Fig 3.). This construct has been considered in the context of other dementias (69, 70) and suggests that the symptoms of dementia will be more prominent and/or present earlier in individuals with a decreased reserve of brain function. In other dementias, postulated reasons for a decreased reserv e include factors such as low education. head trauma, developmental factors, and genetic factors (70–73). Among patients with HIV infection, we must consider the possibility of concurrent neuropathology relating to age-associated neurode generative processes including Alzheimer's disease and cerebro vascular disease (resulting from hypertension, diabetes, hypercholesterolemia, or cardiac disease). Immunological f actors and the longterm effects of ARV therapy may contribute as well. The effects of these factors may be counter-balanced, at least partially, by increased adherence rates with older age (40). Although mild cognitive impairment is known to negatively impact adherence and may minimize the impact in this older population (74). It is possible that complicated interaction effects exist among comorbid illness, chronic antiretroviral treatment and age-related brain changes, such as cerebro vascular disease (75)

Vascular Complications

Cerebrovascular disease either alone or in combination with other neurodgenerative disorders is a common cause of cogniti ve impairment in the general population




Fig. 3 A model for the multifactoral etiology of cognitive/behavioral/motor disorders in older adults

(76). The types of cerebrovascular damage that can cause or contribute to cognitive impairment vary greatly and include large cortical strokes, small lacunar infarcts in strategic locations, small vessel vascular disease, and hemorrhage. Although not all patients with such lesions develop dementia, several studies report a high frequency of cognitive impairment among patients admitted for stroke, with up to 32% developing impairment sufficient to meet clinical diagnostic criteria for dementia (77, 78). Since stroke is relatively common among older individuals, with a lifetime risk for ischemic stroke alone approaching 20% (79), the potential contribution of vascular damage to cognitive dysfunction in aging HIV patients can not be o verlooked.

In HIV, cerebrovascular disease can be caused by both HIV and non-HIV related factors (75). Specific to HIV, reports suggest a potential relationship to HIV-related cardiac disease (80), arterial thromboembolism of cardiac source (81), hematological disorders affecting clotting ability such as antiphospholipid antibody syndrome or protein S deficiency (82), and vasculitis secondary to opportunistic infections or substance abuse. Treatment with certain antiretroviral medications are also associated with changes in blood lipid levels that may contribute to arterial clot or plaque formation, such as decreased HDL cholesterol, increased LDL cholesterol, and ele vated triglycerides (41, 83–86). Protease inhibitors have been particularly linked to increased risk of myocardial infarction (87) and may be related to v asomotor CO_2 reactivity by transcranial Doppler, particularly among patients who develop lipoatrophy (88). The presence of chronic inflammation and activated monocytes, even at low levels, may be expected to contribute to accelerated atherosclerosis as well (89).

Risk factors for cerebro vascular disease that are not directly related to HIV infection will likely play an increasing role in HIV patients as they age, since many of the risks increase with age. Such factors include hypertension, diabetes mellitus, cardiac disease, and dyslipidemia. Smoking is a rob ust risk for cerebro vascular disease and may be of particular interest for older HIV patients where this behavior is more frequent, reported to be as high as 54% among individuals living with HIV in San Francisco and 55% and among 881 HIVseropositive veterans in the Veterans Aging Cohort Three-Site Study (VACS 3) (90, 91). In a study of 3,221 HIV+ men and women enrolled in the Terry Beirn Community Programs for Clinical Research on AIDS, current smokers were more likely than individuals who never smoked to develop AIDS dementia comple x after adjustment for CD4 count, prior disease progression, and use of antiretro viral therapy (92). These f indings suggest that cerebrovascular disease prevention and control will be important for the cogniti ve health of aging HIV patients.

To date, there is very little published work on small vessel cerebrovascular injury in HIV. The large D:A:D (data collection on adv erse events of anti-HIV drugs) study identified an increased risk of cardio- and cerebrovascular events in HIV associated with antiretroviral medication use (93). Described in the literature infrequently (94), lacunar strokes do not appear to be a major component of MRI abnormalities seen in HIV infected patients. Series that ha ve described an increase relationship are often confounded by opportunistic infections or illicit drug use and are commonly compiled from younger populations, where traditional risk f actors may have less barring (95–99). Patients with HIV infection are reported to have an increased rate of cerebral infarction at autopsy compared with the general popula tion, with the prevalence ranging from 4 to 29% (99, 100). In these series, vasculitis does not appear to be a major determinant. The relationship with hypercoagulable states remains controversial, but does not appear to be a major determinant (82, 101, 102). Although classically associated with dementia in younger HIV patients and thought to possibly represent gliosis, the periventricular white-matter changes identified in older HIV patients may be more closely related to cerebrovascular risk factors than to HIV parameters in the era of HAAR T (103). This circumstantial evidence may suggest that considering a cerebrovascular ischemic etiology may be of increasing importance when interpreting such MRI data in older HIV adults. These findings support increased concern for cerebrovascular contributions to cognitive impairment in older HIV patients (104).

Neurodegenerative Disorders

It is theorized that HIV infection may synergistically or additively impact neurodegenerative disorders, possibly altering disease characteristics such as age of presentation, rate of cognitive decline and mortality. To date, this topic has not been thoroughly investigated or defined; although, some groups ha ve started to in vestigate the relationship between classic Alzheimer's disease (AD) risk factors and cognition in HIV patients, including apolipoprotein epsilon 4 genotype, the presence of brain amyloid, and AD-like plaque formation.

Apolipoprotein E is an essential element in the metabolism and transport of serum lipids and is involved in cholesterol metabolism within the brain where it is produced primarily by astroc ytes (105). Polymorphisms in the gene that encodes for Apo E are associated with a number of detrimental neurological processes including increased amyloid beta deposition in cerebral v essels [cerebral amyloid angiopathy (CAA)] (106), both the accelerated loss of synaptic connections and the development of plaques in Alzheimer' s disease (AD) (107), and poor outcome following head trauma (108). Carrying an E4 allele nearly doubles the lifetime risk of AD (109). Although independent of classic cerebro vascular risk factors such as hypertension and hyperglycemia (110, 111), the risk associated with Apo E4 may be partially mediated through vascular mechanism (112).

Among patients infected with HIV, there are mixed reports regarding the influence of having an apolipoprotein E4 isoform and neurological disease. In one series, dementia was twice as prevalent among E4 carriers and was further associated with neuropathy (113); while in another study, no statistically significant relationship was identified (114). Data from the HAHC suggest the role of APO E4 may be more important in older HIV patients compared with younger HIV patients (57). In this cohort, older patients were 50 or more years, and the v ast majority of dementia cases were recognized to ha ve had potential contributions from non-HIV f actors, including the possibility of concurrent neurode generative disease or v ascular complications; although no patients had o vert AD. It is ne vertheless possible that such confounding underlies this finding.

Both intracellular and extracellular amyloid is a common f inding in the brains of HIV infected patients, particularly in the frontal cortex, and may be more frequent among patients with an apolipoprotein epsilon 4 allele (115). In the era prior to HAART, argyrophilic amyloid plaques were identified in AIDS patients with an age-related increased frequency (116). In the era of HAAR T, the pattern of CSF amyloid and tau levels in HIV dementia patients is similar to that described in AD; although a clear age-association has not been described (117).

There is a limited but growing cadre or reports exploring the biochemical basis for an interaction between HIV infection and neurode generative disorder such as AD. Increased expression of beta-amyloid precursor protein (β -APP), a protein implicated in the early cascade leading to amyloid plaques in humans with AD, has been described in the brains of asymptomatic HIV patients (118) and may be related to the presence of inflammatory mediators, such as interleukin-1 (119). The presence of gp41 correlates to the degree of β -APP staining in the corpus callosum of HIV patients (120). Furthermore, inflammatory markers, such as tumor necrosis factor (TNF)- α and interferon- γ increase the de gradation of APP to amyloid beta by stimulating gamma secretase-related clea vage (121). More recently, the HIV protein tat has been associated with inhibition of the amyloid beta dgradation enzyme, neprolysin (122). These findings provide a theoretical frame work for an increased amyloid burden in HIV patients. Kno wledge that insulin de gredation enzyme (IDE) may modulate intracellular amyloid processing (123) has lead to speculation that aging and prolonged HAART may be accompanied by e ven larger risks for amyloid deposition in such patients (115).

From a clinical perspective, the investigation of interaction effects between HIV dementia and non-HIV neurode generation may present substantial challenges (53). Accepted definitions for probable Alzheimer's disease, exclude individuals where another medical condition that could potentially account for the cognitive symptoms is present (124). Similarly, consensus diagnostic criteria for HIV cognitive disorders exclude patients from a diagnosis of clinically probable HIV -associated dementia when another condition exists that may cause cognitive decline (47). The paucity of substantial markers for either disorder further complicate the dilemma(42). The more general descriptions suggested in a revised consensus report for HIV cognitive disorders in the era of HAART may provide greater flexibility (125); however, prospective observational trials that include excellent neuropsychological and neurological characterization, the best available biomarkers, and, critically, neuropathological correlation, will be needed to fully address these important questions.

Physiological Changes in the Aging Brain That May Impact HIV Cognitive Disorders

There is a rob ust relationship between f ailure of the immune system and the development of clinically significant cognitive disorders among individuals without access to HAART and likely among those failing HAART (29, 45). It is therefore reasonable to consider age-related changes in immune function to potentially impact cognition in older patients. Older age is associated with more rapid immunologic decline and poorer survi val (32, 126). Advanced age is associated with a lo wer magnitude of rise of naïv e CD4 cells specifically (127), possibly due to thymic involution with age and f ailure of thymic producti vity (128). Many aspects of HIV-related immune dysfunction mirror that of aging, including a shift from a naïve to a memory T-cell phenotype, reduction in T-cell proliferative ability (associated with reduced telomere length and increase in CD8 cell population that are CD28-), and decreased production of IL-2 and IL-2 receptors (129-132). The expansion of CD8+ CD28- cells that have been described in typical aging (133) may be considered to augment the pathogenic tendencies of HIV in older adults. Enhanced IFN- γ and TNF- α production by the CD8+ CD28- subset has been described in both HIV+ individuals and aged blood donors (134). An age-associated increased expression of other proinflammatory c ytokines in the brain, including IL-1a, IL-6 has been described (135, 136). By virtue of their inflammatory roles, such c ytokines may play an important role in cognition among aged HIV patients.

A second potential immunological mechanism relates to the increase in activated monocytes/macrophages (CD14+/CD69+) seen in the context of HIV dementia and Alzheimer disease (137, 138). Activation of peripheral monoc ytes may enhance transmigration of these cells into the brain consequently allo wing the initiation of

inflammatory processes leading to HAD (139, 140). It is possible that common shared inflammatory pathways of both HIV infection and aging may synegistically effect cognitive function in older HIV -seropositive adults (141). Age related changes in brain glial cells may impact brain vulnerability in older adults. Glial cells are critical to brain neuroplasticity (142). Based on human and rodent models, aging is associated with detrimental effects of brain repair processes, such as attenuated neurotrophic responses (143), weakened astrocytic responses (144), and a reduced capacity for neuronal sprouting (143).

HIV infection is associated with both structural and functional changes in brain microvascular endothelial cells causing alterations of the blood-brain barrier, which may contribute to cognitive dysfunction. Structural changes observed in HIV infection includes: increased diameter of cortical vessels, disruption of tight junctions, apoptosis of brain microvascular endothelial cells, thinning of the basal lamina, and loss of membrane glycoproteins (145–147). Disruption of tight junction proteins, such as occludin and zona occludens-1, is thought to be the most important and characteristic feature of blood-brain barrier disruption in HIV infection(148). Chemokines secreted by infected CD4+ T-lymphocytes and monocytes, such as monocyte chemotactic protein-1 (MCP-1), contribute to upregulation of adhesion molecules, chemotaxis, which result in increased transmigration of infected and non-infected monoc ytes, lymphocytes, and granulocytes (149–153). The aging brain may be more vulnerable to blood-brain barrier disruption through the effects of the inflammatory response and HIV infection (154, 155). The increased microglial production of proinflammatory cytokines (135, 136, 156) contribute to blood-brain barrier dysfunction and, potentially, to increased transmigration of infected microglial cells into the CNS (140).

Successful Cognitive Aging in HIV

The over-arching aim for successful cognitive aging in patients living with HIV is to minimize the frequency and severity of CNS complications and to maximize the quality and duration of life. Successful strate gies are not currently tested in this population and must be lar gely drawn from our knowledge of risk reduction for other cognitive disorders and our knowledge of high quality HIV care. Some broad recommendations can be made.

The basic principles of excellent HIV care may be the most important recommendation. Adherence to medications is of highest priority as immune suppression is known to increase the risk for dementia. At present, there are no strong data to recommend specific antiretroviral regimens in a population basis. Ho wever, the importance of CNS penetrating ARV regimens is an active area of research and new recommendations may be forthcoming. Among indi viduals who exhibit cognitive decline on HAART, this issue is clearer and recommendations are currently published (64). In the cognitively impaired population, extant data suggest that higher penetrating regimens are likely associated with improved outcomes (157–159). It is premature to consider that older indi viduals are at suf ficient increased risk to support use of more penetrating re gimens as first line therapy; however, this is an area of research that might be particularly valuable. Early diagnosis of HIV is mandatory and among older indi viduals likely represents an area where there is room for improvement.

Given the emerging evidence that cerebrovascular risk factors are more prevalent in aging HIV patients and, in preliminary studies, may impact cognition, this is another area where vigilance may be valuable. HIV infection, itself, by virtue of its inflammatory characteristics, may increase cardio vascular and cerebro vascular risk. Therefore, it may be reasonable to consider HIV infections as a cardiovascular risk equivalent when choosing lipid goals for treatment (160). Regular evaluations for diabetes with timely initiation of appropriate interv entions are recommended. Physical exercise and maintenance of proper weight not only assists in minimizing cerebrovascular risk factors, such as diabetes, hyperlipidemia and hypertension, but may also have a direct positi ve impact on cognition (161). Smoking cessation should be strongly encouraged as should absence from illicit drug use. Finally , close attention should be paid to proper psychiatric care including careful observation for depression to allow early intervention. These strategies provide hope that healthy aging can be realized, regardless of HIV status.

References

- Pelella, FJ., Jr etal. Decliningmorbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study In vestigators. N Engl J Med 338, 853 - 60998).
- 2 .Manfredi, R. HIV infection and advanced age emerging epidemiological, clinical, and management issues . Ageing Res Rev 3 31 -5 ± 004) .
- 3 .Zablotsk, D.& Kennedy, M. Riskfactors and HIV transmission to midlife and older women: knowledge, options, and the initiation of safer sexual practices. J Acquir Immune Defic Syndr 33 Suppl2, S122 - 3(2003).
- 4 . Wysdorf , S.L. The aging of the AIDS epidemic: emerging legal and public health issues for elderly persons living with HIV/AIDS . ElderLaw J 10 47 - 82002) .
- 5 .Stoff, D.M. , Khalsa J.H. , Monjan A.& Portgies , P Introduction:HIV/AIDS and aging. AIDS 18 Suppl1 , S1 (2004) .
- 6. CDC. *HIV/AIDS Surveillance Report, 2005* (Atlanta: US Department of Health and Human Services, Center for Disease Control and Prevention, 2007).
- 7 .Mack K.A. & Ory M.G. AIDS and older Americans at the end of the twentieth century . JAcquir Immune Defic Syndr 33 Suppl2 , S68 – 72003) .
- 8 .Luther V P. & Wikin , A.M. HIV infection in older adults . ClinGeriatr Med 23 567 83 , vii (2007) .
- 9. Hawaii Department of Health, HIV/AIDS surveillance semi-annual report, June 2003.
- 10. CDC.16 (1998).
- 11. Statement of Senator Gordon H. Smith. Aging Hearing. HIV o ver fifty: exploring the new threat, *Senate Committee on Aging*, Washington, DC 2005 (http://aging.senate.go v/public/_ files/hr141gs.pdf).
- 12 . Mcour , V etal. Higherfrequency of dementia in older HIV-1 individuals: the Hawaii aging with HIV-1 Cohort . Neurology 63 822 (2004) .
- 13. Cherner , M. et al .Efects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings . AIDS 18 Suppl1 , S27 – 34004) .

- 14 . Mcour, V & Rul, R. HIVinfection and dementia in older adults. ClinInfect Dis 42 1449 54 (2006).
- 15 . Schweinsbrg, B.C. etal .Brainmitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirol 11, 356 – (2005).
- Pillai Ş.K. et al. Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain 129 1872 - 82006).
- 17 . Almeida M. Cordero M. Almeida J,& Orfo, A. Abnormalcytokine production by circulating monocytes and dendritic cells of myeloid origin in AR T-treated HIV-1+ patients relates to CD4+ T-cell recovery and HCV co-infection. CurrHIV Res 5 325 – 3(2007).
- 18 .DiMascio, M. et al .Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection. JVirol 78 10566 – 7(2004).
- 19 .Goujard Ç. etal. CD4cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients
 Clin Infect Dis 42, 709 ((2006)).
- 20. Shiramizu, B., Shikuma, C., Ratto-Kim, S. & V alcour, V. 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles, California, 2007).
- 21 . Shiramizu B. etal. Circulating proviral HIV DNA and HIV-associated dementia . AIDS 19 , 45 – $5\!\!2005)$.
- 22 .Castilla J. et al .Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence . AIDS 16 1945 5(2002) .
- 23 .Nogueras M. etal .Epidemiologicaland clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more . BMCInfect Dis 6 159 (2006) .
- 24 .Ferro S.& Salit I,E. HIVinfection in patients over 55 years of age . JAcquir Immune Defic Syndr 5 348 5(3992) .
- 25 .Muguero , M.J. , Castellano C. Edelman D.& Hicks C. Latediagnosis of HIV infection: the role of age and sex . AmJ Med 120 370 (2007) .
- 26 . Timbarello, M. et al . Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy. BMCInfect Dis 4 46 (2004) .
- Clements J,E. & Zink M.C. Molecularbiology and pathogenesis of animal lentivirus infections. ClinMicrobiol Rev 9 ,100 – 1(1996).
- 28 . An S.F., Gross, M. Gray F & Scarailli, F Earlyentry and widespread cellular involvement of HIV-1 DNA in brains of HIV -1 positive asymptomatic individuals. J Neuropathol Exp Neurol 58 ,1156 – 6(2999).
- 29 .McArthur, J.C. et al .Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 43 2245 5(2993).
- 30 .Janssen R.S., Nwnyanwu, O.C., Selik R.M. & StehtGreen, J.K. Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology 42 ,1472 – (6992).
- 31 .Carre N. etal .Effect of age and exposure group on the onset of AIDS in heterosexual and homosexual HIV-infected patients. SEROCO Study Group . AIDS 8 797 80(2994) .
- 32 .Phillips A.N. etal .Morerapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts . JAcquir Immune Defic Syndr 4 970 (1991) .
- 33 .Egger M. et al .Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies . Lancet $360\,\,119\,-\,22002)$.
- 34 .Butt A.A. etal. Humanimmunodeficiency virus infection in elderly patients . SouthMed J 94 397 -400001) .
- 35 . Grabar S. etal. Immunologicand clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS 18 2029 -3 2004).
- 36 .Goetz M.B., Boscardin W J., Wey, D.& Alkasspooles S. Decreased recovery of CD4 lymphocytes in older HIV -infected patients be ginning highly active antiretroviral therapy. AIDS 15 .1576 – (2001).
- 37 . Vard, J.P. etal. Influenceof age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. JInfect Dis 183 J290 – (2001) .

- 38 . Manfredi R HIV disease and advanced age: an increasing the rapeutic challenge . Drugs Aging 19 $\,647$ – 62002) .
- 39 .Justman J.E. etal. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. JAcquir Immune Defic Syndr 32 298 – 30(2003).
- 40 . Murphy D.A., Marelich W D., Hoffman, D.& Steers W N. Predictors of antiretroviral adherence . AIDSCare 16 471 8(2004) .
- 41 .Goodkin K. etal .Aging and neuro-AIDS conditions and the changing spectrum of HIV-1associated morbidity and mortality. JClin Epidemiol 54 Suppl1, S35 – 4(2001).
- 42 . McArthur, J.C. et al. Humanimmunodeficiency virus-associated dementia: an evolving disease . JNeurovirol 9 205 – 22003).
- 43 .Sacktor, N. et al. HIVassociated neurologic disease incidence changes: multicenter AIDS Cohort Study, 1990–1998. Neurology 56 257 – 6(2001).
- 44 .Chiesi A. etal .Epidemiologyof AIDS dementia complex in Europe. AIDS in Europe Study Group . JAcquir Immune Defic Syndr Hum Retrovirol 11 39 – 44996) .
- 45 .Bhatnagar J. etal. Detection West Nile virus in formalin-fixed, paraffin-embedded human tissues by RT-PCR: a useful adjunct to conventional tissue-based diagnostic methods. J Clin Virol 38 106 (2007) .
- 46. Baldassari, L., Sacktor, N., Marder, K., Schifitto, G., Adams, D., Skolasky, R. et al. Predictors of progression from HIV-Associated minor cognitive motor disorder to HIV dementia. Paper presented at the International Society of Neurovirology, San Diego (2007).
- 47. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. *Neurology* 41, 778–85 (1991).
- 48 . White D.A., Heaton R.K. & Monsch A.U. Neuropsychological studies of asymptomatic human immunodeficiency virus-type-1 infected indi viduals. The HNRC Group. HIV Neurobehavioral Research Center. JInt Neuropsychol Soc 1 304 – (5995).
- 49 .Hardy J. etal. Agedifferences and neurocognitive performance in HIV-infected adults . NZ J Psychol 28 94 - 10(1999) .
- 50 . Wikie, F.L. etal .Cognitive functioning in younger and older HIV-1-infected adults . JAcquir Immune Defic Syndr 33 Suppl 2 S93 10(2003) .
- 51 . an Gorp, WG. etal. Therelationship between age and cognitive impairment in HIV-1 infection: findings from the Multicenter AIDS Cohort Study and a clinical cohort Neurology 44, 929 3(1994).
- 52. Writers, M. R. et al. Symptomatic distal sensory polyneuropathy in HIV after age 50. Neurology 62 1378 – 82004).
- 53 .Beckr, J.T., Lopez Q.L., Dw, M.A. & Aizenstein H.J. Prevalence of cognitive disorders differs as a function of age in HIV virus infection. AIDS 18 Suppl1, S11 (2004).
- 54 . Satz P etal. Low education as a possible risk factor for cognitive abnormalities in HIV-1: findings from the multicenter AIDS Cohort Study (MACS). J Acquir Immune Defic Syndr 6, 503 1(1993).
- 55 .Letenneur L. etal. Educationand the risk for Alzheimer's disease: sex makes a difference. EURODEM pooled analyses. EURODEM Incidence Research Group . AmJ Epidemiol 151 , 1064 – 7(2000) .
- 56 .Butters N. et al .Assessment of AIDS-related cognitive changes: recommendations of the NIMH Workshop on Neuropsychological Assessment Approaches. J Clin Exp Neuropsychol 12 963 – 78990) .
- 57 . Mocour, V etal. Age, apolipoprotein E4, and the risk of HIV dementia: the Hawaii Aging with HIV Cohort . JNeuroimmunol 157 ,197 20(2004) .
- 58 . Arendt G. Hefter H. Nelles H.W., Hilperath F & Strohmyer, G. Age-dependentdecline in cognitive information processing of HIV -positive individuals detected by e vent-related potential recordings. JNeurol Sci 115 223 – (9993).
- 59 .Kissel E.C., Pukay-Martin N.D. & Bornstein R.A. The relationship between age and cognitive function in HIV-infected men. JNeuropsychiatry Clin Neurosci 17 180 (\$2005).

- 60 . an Gorp, W.G. etal .Metacognitionin HIV-1 seropositive asymptomatic individuals: self-ratings versus objective neuropsychological performance. Multicenter AIDS Cohort Study (MACS). JClin Exp Neuropsychol 13 812 (9991).
- 61 . Wikins , J.W. etal .Implications of self-reported cognitive and motor dysfunction in HIV-positive patients . AmJ Psychiatry 148 641 (3991) .
- 62 .Linsk N.L. HIV among older adults: age-specific issues in prevention and treatment . AIDS Read 10 430 – 40000) .
- 63 .Jorm A.F. & Jolly, D. Theincidence of dementia: a meta-analysis. Neurology 51 728 33 (1998).
- 64 .McArthur, J.C., Brøv, B.J. & Nath A. Neurological complications of HIV infection. Lancet Neurol 4 543 – 5(2005).
- 65 . Mcour, V etal .Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodef iciency virus type 1 infection–The Hawaii Aging with HIV Cohort. JNeurovirol 12 387 9(2006).
- 66 .Lichtenstein K.A. etal. Modifcation of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 40 148 5(2005).
- 67 . Moour, VG. etal. Diabetes, insulin resistance, and dementia among HIV-1-infected patients . JAcquir Immune Defic Syndr 38 31 3(2005).
- 68 . Valcour, VG. etal .Insulinresistance is associated with cognition among HIV-1-infected patients: The Hawaii Aging With HIV Cohort . JAcquir Immune Defic Syndr 43 405 – 41(2006) .
- 69 . Mortimer, J.A. Brainreserve and the clinical expression of Alzheimer's disease . Geriatrics 52 Suppl2, S50 – (3997).
- 70 . Abbott B.D. etal .Heightas a marker of childhood development and late-life cognitive function: the Honolulu-Asia Aging Study. Pediatrics 102 602 (9998) .
- 71 . Snwdon, D.A. etal .Linguisticability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study . AMA 275 528 32996).
- 72 . Graes, A. B. et al. The association between head trauma and Alzheimer's disease. Am J Epidemiol 131 491 50(1990) .
- 73 .Cdfey, C.E., Saxton J.A., Ratcliff, G. Bryan R.N. & Luck, J.F. Relation of education to brain size in normal aging: implications for the reserv e hypothesis. Neurology 53, 189 9(6999).
- 74 . Hinkin C.H. et al. Medicationadherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology 59 \downarrow 944 -50002).
- 75. Mcour, V.G., Shikuma C.M., Watters, M.R. & Sacktor N.C. Cognitive impairment in older HIV-1-seropositive individuals: prevalence and potential mechanisms. AIDS 18 Suppl 1 S79 8(2004).
- 76 . McMurtray A. Clark D.G., Christine D.& Mendez M.F. Early-onsetdementia: frequency and causes compared to late-onset dementia. DementGeriatr Cogn Disord 21 59 – 6(2006).
- 77 .Desmond D.W. etal Frequency and clinical determinants of dementia after ischemic stroke . Neurology 54 1124 – 3(2000) .
- 78 . Pohjaswara, T etal. Clinical determinants of poststroke dementia. Strole 29 75 1 8(1998) .
- 79 . Seshadri S. etal. Thelifetime risk of stroke: estimates from the Framingham Study . Stroke 37 345 50006).
- 80 . Cardoso J.S. etal. Leftventricular dysfunction in human immunodeficiency virus (HIV)-infected patients . IntJ Cardiol 63 37 43998) .
- Roldan E.O., Moskwitz, L.& Hensly, G.T. Pathology of the heart in acquired immunodeficiency syndrome. ArchPathol Lab Med 111 943 – (6987).
- 82 . Qureshi A.I. etal. Humanimmunodeficiency virus infection and stroke in young patients . ArchNeurol 54 ,1150 – (3997) .
- 83 .Grunfeld C. etal. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 74 1045 – 5(2992) .

- 84. Constans J, etal .Plasmalipids in HIV-infected patients: a prospective study in 95 patients . Eur J Clin Invest 24 416 – 20994) .
- 85. Zangerle R. etal .Decreasedplasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune acti vation. J Acquir Immune Def ic Syndr 7, 1149 – 5(6994).
- Khwidhunkit, W., Memon R.A., Feingold K.R. & Grunfeld C. Infectionand inflammationinduced proatherogenic changes of lipoproteins. JInfect Dis 181 Suppl 3 \$462 – 7(2000).
- 87 .Friis-Moller N. et al .Classof antiretroviral drugs and the risk of myocardial infarction . N Engl J Med 356 1723 – 32007).
- 88 .Concha M. etal .Riskof cerebrovascular disease in HIV-1-infected subjects with lipodystrophy syndrome and long-term exposure to protease inhibitors . Stroke 34 295 (2003) .
- 89 . Tesch , G.H. Roleof macrophages in complications of type 2 diabetes . ClinExp Pharmacol Physiol 34 ,1016 (2007) .
- 90 .Smola S. etal .Veterans aging cohort three-site study (VACS 3): overview and description . JClin Epidemiol 54 Suppl 1 S61 7(2001) .
- 91 .Mamary E.M., Bahrs D.& Martinez S. Cigarettesmoking and the desire to quit among individuals living with HIV. AIDSPatient Care STDS 16 39 4(2002).
- 92 .Burns D.N. etal .Cigarettesmoking, bacterial pneumonia, and other clinical outcomes in HIV-1 infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 13 374 – 83996).
- 93 .d'Arminio A. et al .Cardio-and cerebrovascular events in HIV-infected persons . AIDS 18 , 1811 - (2004) .
- 94 . Mizuswa, H. Hirano A. Llena J.F. & Shintaku M. Cerebrovascular lesions in acquired immune deficiency syndrome (AIDS). ActaNeuropathol (Berl) 76 451 (1988).
- 95 .Cole J.W. etal. Acquired immunodeficiency syndrome and the risk of stroke . Stroke 35 , 51 (2004) .
- 96 .Beger, J.R., Harris J.O., Gregorios, J.& Norenber, M. Cerebrovascular disease in AIDS: a case-control study. AIDS 4 239 44990).
- 97 .Hoffmann, M. Beger, J.R., Nath A.& Rayens M. Cerebrovascular disease in young, HIVinfected, black Africans in the Kw aZulu Natal province of South Africa. J Neurovirol 6, 229 – 3(2000).
- 98 . Evers , S. et al . Ischaemiccerebrovascular events in HIV infection: a cohort study . Cerebrovasc Dis 15 , 199 202003) .
- 99 .Rabinstein A.A. Strole in HIV-infected patients: a clinical perspective . Cerebrovasc Dis 15 37 42003).
- 100 .Connor, M. D. et al .Cerebral infarction in adult AIDS patients: observations from the Edinburgh HIV Autopsy Cohort . Stroke 31 2117 – 2(2000) .
- 101 .Ortiz G. Kich, S. Romano J.G., Brteza, A.M. & Rabinstein A.A. Mechanisms of ischemic stroke in HIV-infected patients. Neurology 68 1257 – (2007).
- 102 .Mochan A. Modi M.& Modi G. ProteinS deficiency in HIV associated ischaemic stroke: an epiphenomenon of HIV infection . JNeurol Neurosurg Psychiatry 76 1455 – (2005) .
- 103 .McMurtray A. Nakamoto B. Shikuma C.& Mcour, V Small-vessel vascular disease in human immunodeficiency virus infection: The Ha waii aging with HIV Cohort Study . Cerebrovasc Dis 24 236 – 24(2007) .
- 104 .Beger, J.R. AIDS and stroke risk . LancetNeurol 3 206 (2004) .
- 105 .Lws, S.M., Hone E. Gandy S.& Martins R.N. Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. JNeurochem 84 ,1215 – 3(2003).
- 106 . Pfeifer L.A., White L.R., Ross G.W., Petrwitch, H.& Launer L J. Cerebralamyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology 58, 1629 – 3(2002).
- 107 .Polvikski, T et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein . NEngl J Med 333 1242 – (1995) .
- 108 .Samatøicz, R.A. Genetics and brain injury: apolipoprotein E .JHead Trauma Rehabil 15 , 869 – 742000) .

- 109 .Mayeux R. etal .Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's disease centers consortium on apolipoprotein E and Alzheimer's disease. NEngl J Med 338 506 1(1998) .
- 110 .Carmelli D. etal. Midlifecardiovascular risk factors, ApoE, and cognitive decline in elderly male twins . Neurology 50 1580 - (\$1998) .
- 111 .Prince M. etal. The association between APOE and dementia does not seem to be mediated by vascular factors . Neurology 54 397 – 402000).
- 112 .Deane R. etal. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain . NatMed 9 907 1(2003) .
- 113 .Corder E.H. etal. HIVinfected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy. NatMed 4 ,1182 (4998) .
- 114 . Dunlop Q. etal .HIVdementia and apolipoprotein E . ActaNeurol Scand 95 315 (8997) .
- 115 .Green D.A. etal .Braindeposition of beta-amyloid is a common pathologic feature in HIV positive patients . AIDS 19 $\,407 1(2005)$.
- 116 . Esiri M.M., Biddolph S.C. & Morris C.S. Prevalence of Alzheimer plaques in AIDS . JNeurol Neurosurg Psychiatry 65 29 – 3(3998) .
- 117 .Brw, B.J., Pemberton L. Blennw, K. Mallin, A.& Hagber, L.CSF amyloid beta42 and tau levels correlate with AIDS dementia complex . Neurology 65 ,1490 (2005) .
- 118 .Nebloni, M. etal .Betaamyloid precursor protein and patterns of HIV p24 immunohistochemistry in different brain areas of AIDS patients . AIDS 15 571 – (2001) .
- 119 . Frloni, G. Demicheli F, Giogi, S. Bendotti C.& Angeretti N. Expression of amyloid precursor protein mRN As in endothelial, neuronal and glial cells: modulation by inter leukin-1. BrainRes Mol Brain Res 16 J28 – 3(4992).
- 120 .Mankwski, J.L., Queen S.E., Tarwater, P.M., Fx, K.J. & PerryV. H. Accumulation of beta-amyloid precursor protein in axons correlates with CNS expression of SIV gp41. JNeuropathol Exp Neurol 61 85 – 9(2002).
- 121 .Liao YF., Wing, B.J., Cheng H.T., Koo, L.H. & Wolfe, M.S. Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated clea vage of amyloid precursor protein through a JNK-dependent MAPK pathway. J Biol Chem 279, 49523 3(2004).
- 122 .Rempel H.C. & Pulliam L. HIV1 Tat inhibits neprilysin and elevates amyloid beta . AIDS 19 127 32005).
- 123 . Sudoh S. Frosch M.P. & Wilf, B.A. Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between deter gent-soluble and -insoluble pools in CHO-695 cells. Biochemistry 41 1091 (2002).
- 124. APA. *Diagnostic and Statistical Manual of Mental Disorders* (American Psychiatric Association, Washington, DC, 2000).
- 125 . Antinori A. etal. Updatedresearch nosology for HIV-associated neurocognitive disorders . Neurology 69 1789 – 92007) .
- 126 .Gardner L. I., Jr et al. Predictors of HIV-1 disease progression in early- and late-stage patients: the U.S. Army Natural History Cohort. Military medical consortium for applied retrovirology. JAcquir Immune Defic Syndr 5 782 – 9(3992).
- 127 . Lederman M. M. et al. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS 14 ,2635 – 42 (2000).
- 128 .Smith K.Y. etal .Thymicsize and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zido vudine, lamivudine, and ritonavir therapy. J Infect Dis 181 ,141 – (2000) .
- 129 . Egnoni, F.F. etal. Shortageof circulating naive CD8(+) T cells provides new insights on immunodeficiency in aging . Blood 95 2860 (2000) .
- 130 .Ngoro, S. etal. Age-related changes of the function of T cell subsets: predominant defect of the proliferative response in CD8 positive T cell subset in aged persons Mech Ageing Dev 39 263 - 7(9987).

- 131 .Bestily, L.J., Gill M.J., Mody C.H. & Riabwol, K.T. Acceleratedreplicative senescence of the peripheral immune system induced by HIV infection. AIDS 14 771 – 802000).
- 132 . Mdez, H. etal. Limitedimmune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 16 ,1859 (@002) .
- 133 . Egnoni, F.F. etal. Expansion of cytotoxic CD8+ CD28- T cells in healthy ageing people, including centenarians. Immunology 88 501 – (1996).
- 134 . Eylar E.H. etal. HIVinfection and aging: enhanced Interferon- and Tumor Necrosis Factor-alpha production by the CD8+ CD28- T subset . BMCImmunol 2 ,10 (2001) .
- 135 . ¥, S.M. & Johnson R.W. Increased interleukin-6 expression by microglia from brain of aged mice. JNeuroimmunol 93 139 – 48999).
- 136 .Sheng J.G., Mrak R.E. & Griffin, W.S. Enlaged and phagocytic, but not primed, interleukin-1 alpha-immunoreactive microglia increase with age in normal human brain . Acta Neuropathol (Berl) 95 229 – 3(4998) .
- 137 .Pulliam L. Gascon R. Stubblebine M. McGuire D.& McGrath M.S. Uniquemonocyte subset in patients with AIDS dementia . Lancet 349 692 – (\$1997) .
- 138 . Kisdra, L. Rempel H. Mffe, K.& Pulliam L. Elevation of CD69+ monocyte/macrophages in patients with Alzheimer's disease. Immunobiology 202 26 – 3(2000).
- 139 . Gonzalez-Scarano F & Baltuch G. Microgliaas mediators of inflammatory and degenerative diseases . AnnuRev Neurosci 22 219 – 40999) .
- 140 .Gonzalez-Scarano F & Martin-Garcia J. The neuropathogenesis of AIDS . Nat Rev Immunol 5 69 – 8(2005) .
- 141 .Minagar A. etal .Therole of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis . JNeurol Sci 202 ,13 – 2(2002) .
- 142 .Hatten M.E., Liem R.K., Shelanski M.L. & Mason C.A. Astrogliain CNS injury. Glia 4 233 – 43991).
- 143 . Woods, A.G., Guthrie K.M., Kirlawalla, M.A. & Gall C.M. Deaferentation-induced increases in hippocampal insulin-lik e growth factor-1 messenger RN A expression are severely attenuated in middle aged and aged rats. Neuroscience 83 663 – (8998).
- 144 .Dziwulska, D. Age-dependent changes in astroglial reactivity in human ischemic stroke. Immunohistochemical study. Folia Neuropathol 35 99 – 10(6997).
- 145 .Kim T A. etal .HIV1 Tat-mediated apoptosis in human brain microvascular endothelial cells . JImmunol 170 2629 – 3(2003) .
- 146 . Wris, S. Haug H. & Budka H. Vascular changes in the cerebral cortex in HIV-1 infection:
 I. A morphometric in vestigation by light and electron microscop y. Clin Neuropathol 15, 361 (6996).
- 147 . Buttner A. Mehraein P.& Wris, S Vascular changes in the cerebral cortex in HIV-1 infection.
 II. An immunohistochemical and lectinhistochemical investigation. Acta Neuropathol (Berl)
 92 35 4(1996) .
- 148 .Dallasta L. M. et al .Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis . AmJ Pathol 155 ,1915 2(1999) .
- 149 . Cinque P et al .Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication . AIDS 12 1327 – 32998) .
- 150. Kelder, W, McArthur J.C., Nance-Sproson T, McClernon D.& Griffin, D.E. Betachemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. AnnNeurol 44 831 – (1998).
- 151 .Mukaida N. Harada A.& Matsushima K. Interleukin-8(IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. CytokineGrowth Factor Rev 9 9 – 2(3998).
- 152 . Jiang Y, Beller D.I., Frendl G.& Graes, D.T. Monogte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol 148, 2423 – (8992).
- 153 . Wiss, J.M., Nath A. Major E.O. & Berman J.W. HIV1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain

barrier and up-regulates CCR5 expression on human monocytes . J Immunol 163 ,2953 – 9 (1999) .

- 154 . Garton M.J., Kir, G. Lakshmi M.V. & Thompson E.J. Age-related changes in cerebrospinal fluid protein concentrations . JNeurol Sci 104 74 80991) .
- 155 .Kleine T.O., Hackler R.& Zofel P. Age-relatedalterations of the blood-brain-barrier (bbb) permeability to protein molecules of different size. ZGerontol 26 256 (9993).
- 156 .Perry V H., Matyszak M.K. & Fearn S. Altered antigen expression of microglia in the aged rodent CNS . Glia 7 60 – (7993) .
- 157 Letendre \$.L. et al .Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders . AnnNeurol 56 416 22004).
- 158 .Cysique L.A., Maruff, P & Brev, B.J. Antiretroviral therapy in HIV infection: are neurologically active drugs important? ArchNeurol 61 1699 70(2004).
- 159 .Antinori A. et al. Eficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. ClinInfect Dis 41 ,1787 – 9(2005).
- 160. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285, 2486–97 (2001).
- 161 .Hillman C.H., Erickson K.I. & Kramer A.F. Besmart, exercise your heart: exercise effects on brain and cognition. NatRev Neurosci 9 58 62008).

Index

A

Acquired immunodeficiency syndrome (AIDS) Africa, 10-11 Asia. 11–12 CD4 T-cell count (CD4) and plasma HIV-RNA level, 3-4 combination therapy, 3 Eastern Europe and Central Asia, 13 enfurvitide and raltegravir, 6 global epidemiology, 10 hepatitis C co-infection, 14-15 highly active antiretroviral therapy (HAART), 5-6 HIV strains, 9-10 HIV-1 identification, 2 Latin America and Caribbean, 13-14 maraviroc, 6 neurocognitive changes, 7-8 North America and Western Europe, 14 Pneumocystis pneumonia (PCP), 1 protease inhibitors, 4 zidovudine, 2-3 Adjunctive therapy, cognitive impairment asymptomatic neurocognitive impairment (ANI), 249 autopsy, 249 comorbid psychiatric disorders Beck Depression Inventory (BDI), 256 depression, 255-258 fatigue, 258 HAART, 256 modafinil, 258 HIV-1-associated neurocognitive disorders (HAND), 249 HIV-associated dementia (HAD) antioxidants, 252-253 calcium channel blockers, 254 HAART, 250

lexipafant, 253 lithium, 255 memantine, 254 minocycline, 254-255 psychostimulants, 250-251 selegiline, 251-252 valproic acid (VPA), 253 mild neurocognitive disorder (MND), 249 Advanced age and HIV cognitive impairment brain aging, physiological changes glial cells, 383 peripheral monocytes activation, 382-383 proinflammatory cytokines, 382 brain reserve model, 378, 379 clinical factors cognitive risk factors, 371 Hawaii Aging with HIV Cohort (HAHC), 370 viral blips, 371 demographic changes Centers for Disease Control and Prevention (CDC), 369, 370 distribution, 369, 370 diabetes and smoking cessation, 384 epidemiological and clinical diagnostic outcomes HAART introduction, 372 Hawaii aging, 372, 373 medications process, 383-384 neurodegenerative disorders Apolipoprotein E, 381 beta-amyloid precursor protein (B-APP), 381 neuropsychological performance outcomes CSF HIV RNA, 376 HIV Neurobehavioral Research Center (HNRC), 375-376

Advanced age and HIV cognitive impairment (cont.) MACS cohort and clinical cohort, 373.375 minor cognitive motor disorder (MCMD) symptom, 377 risk factors metabolic dysfunction, 378 nadir CD4 lymphocyte count, 377 vascular complications cerebrovascular disease, 378-380 risk factors, 380 Terry Beirn Community Programs, 380 Aging effects cART antiretroviral medications, 333 CD4+ cell regeneration, 337 immunologic difference, 340 thymic volume, 338 CD4 + cell restoration, 337 comorbid conditions and clinical events ACTG Protocol 5015, 334 cardiovascular and kidney disease, 334 epidemiologic and clinical differences, 335 immune activation activation markers, 338 Fas ligand (FasL), 339 immunologic parameters, 336-337 naïve T-cell depletion and thymic dysfunction β-chain TCR gene rearrangement products, 338 TCR gene rearrangement excision circles, 337 older person characteristics combination antiretroviral therapy (cART), 331 lower survival rates, 332 relative mortality rates, 332-333 telomere shorting, replicative senescence, 339 AIDS dementia complex (ADC), 7, 111 AIDS neuropathology, pre-HAART era β amyloid precursor protein (β APP), 34 common opportunistic CNS conditions, 31 Cryptococcus, 32 HIVE, 33, 34 primary central nervous system lymphoma (PCNSL), 32, 33 Toxoplasma gondii, 32 American Academy of Neurology, 111 Antioxidants, 252-253

Antiretroviral treatment, cognitive function gestation, early stages, 193 HAART, 192–193 zidovudine, 193 Apolipoprotein E, neurodegenerative disorders, 381 Astrocytes, 55

B

Biomarkers astrocytes, 55 biomarker repair B12 deficiency and hypothyroidism, 64 confirmatory value and sphingomyelin, 63-64 CSF leukocyte count, 65 clinical assessment, 51-52 disease activity, 50 endothelial cells/blood-brain barrier albumin and immunoglobulin G, 62 intercellular adhesion molecule, 62 - 63matrix metalloproteinases, 63 serum VEGF, 62 host toxins arachidonic acid metabolites/ prostaglandins, 60 nitric oxide and PAF, 60-61 lymphocytes β-2-microglobulin, 53 CD4 cell count, 52 microglia, 54-55 modulators chemokines, 58 IFNs and IP-10, 57 interleukins, 55-56 TGF-B and uPAR, 58-59 TNF superfamily proteins, 56-57 monocytes CD14+/CD69+, 53 neopterin and quinolinic acid, 54 soluble CD14 (sCD14), 53-54 neurons neurofilament-light (NFL), 61 Tau, neuronal proteins, 61-62 neurophysiology, 63 objective and diagnostic marker, 49-50 pre-HAART era, 51 types, 50-51 viral toxins HIV RNA and DNA, 59-60 HIV-encoded proteins, 60

Index

Brain infections American trypanosomiais causible agent, 299 neurologic symptoms, 301 phases in, 301 treatments, 303 cryptococcosis clinical symptoms and treatments, 305 in Latin America, 304 cysticercosis CSF ELISA, 299 helminthic infection, 297 symptoms and diagnosis, 300-301 treatment, 299 histoplasmosis histoplasma antigen assay, 307 primary infection, 307 systemic mycosis, 306 HIV epidemic lumbar puncture, 294-295 nervous system disease, 293-294 IC virus HAART treatment, 311 Progressive multifocal leukoencephalopathy (PML), 310-311 leishmaniasis, 303 malaria etiologic agent, 299 plasma HIV levels, 300 treatments, 299 neurotuberculosis, 294 paracoccidioidomycosis affected organs and treatments, 306 parasities, 305 sporotrichosis causable agent, 307 itraconazole treatment, 308 Strongyloides stercoralis filariform larvae, 302 intestinal nematode endemic, 302 treatments, 303 toxopalsmosis CT scan, 296-297 diagnosis and treatment, 297 in AIDS, 295 intracellular parasite, 295 tuberculosis CSF analysis and treatment, 310 socio-economic survey, 308 subacute meningitis, 309 target sign, 309 Brain-derived neurotropic factor (BDNF), 155-156

С

Calcium channel blockers, 254 cART antiretroviral medications, 333 CD4 + cell regeneration, 337 immunologic difference, 340 thymic volume, 338 Chagas' disease distinct phases, 301 neurologic symptoms, 301-302 See also American Trypanosomiais, 300-302 treatment, 302 Chemokines, 58 Children and adolescents, epidemiological data prevention of mother-to-child transmission (PMTCT), 187-188 transmission, other routes, 188 Clade A and D virus CD4 cell counts, 322 cognitive function, 322 in sub-Saharan Africa, 323 Clade C virus international HIV dementia scale, 320 neuropsychological battery, 320-321 Tat protein (C31S), 320 Clade diversity Asia Pacific NeuroAIDS Consortium (APNAC), 324 clade A and D virus CD4 cell counts, 322 cognitive function, 322 in sub-Saharan Africa, 323 clade C virus international HIV dementia scale, 321 neuropsychological battery, 320-321 Tat protein (C31S), 320 clade E virus Circulating recombinant form (CRF) 01 AE, 323 HAND prevalence estimates, 323-324 cognitive functions, developing countries international HIV dementia scale (IHDS), 325 translation process and comorbid conditions, 326 international studies, 324-325 unique biological characteristics, 319 Clade E virus Circulating recombinant form (CRF)01_AE, 323 HAND prevalence estimates, 323-324 Cognitive-motor disorder (CMD), 140

Computerized Adaptive Placement Assessment and Support System (COMPASS), 243 Cryptococcosis clinical symptoms, 305 in Latin America, 304 main drugs, 305 *Cryptococcus*, 32 Cysticercosis CSF ELISA, 299 diagnosis, 298–299 helminthic infection, 297 symptoms, 298 treatment, 299

D

Delirium, 155 Diffusion magnetic resonance imaging, 87–91 Diffusion tensor imaging (DTI), 87–91

Е

Encephalopathy, HIV clinical presentation, 190–191 patterns, 191–192 prevalence, 189–190 Endothelial cells/blood–brain barrier albumin and immunoglobulin G, 62 intercellular adhesion molecule, 62–63 matrix metalloproteinases, 63 serum VEGF, 62 Epstein-Barr virus (EBV), 32

F

Fractional anisotropy (FA), 87 Functional MRI (fMRI), 91–93

G

Glial fibrillary acid protein (GFAP), 55

H

HAD. See HIV-related dementia HAD complex, 111 Halstead-Reitan battery, 112 Hawaii Aging with HIV Cohort (HAHC), 370 Hepatitis C co-infection, 14–15 Hepatitis C virus (HCV) characteristics, 147–148 neural mechanisms, interactions

Trojan horse mechanism, 221 tumor necrosis factor- α (TNF- α), 222 neuroimaging, 222 neuropsychological effects, 222-223 Highly active antiretroviral therapy (HAART), 5-6, 76, 80, 189, 233, 250 AIDS neuropathology, pre-HAART era β amyloid precursor protein (βAPP), 34 common opportunistic CNS conditions, 31 Cryptococcus, 32 HIVE, 33, 34 primary central nervous system lymphoma (PCNSL), 32, 33 Toxoplasma gondii, 32 cognitive functions assessment appropriate norms, importance of, 114-115 defining change, 118-120 long-term follow-up, importance of, 115-117 neuropsychological assessment, 111-114 practice effect and regression towards the mean, 117-118 drug abuse effects, brain, 35 HIV-infected subjects, 30 post-HAART era hyperphosphorylated Tau accumulation, 39-41 immune reconstitution syndrome (IRIS), 37 neurodegenerative proteins accumulation, 41 paired helical filament (PHF), 38 phosphorylation state, 38 Tau de-regulation and dysfunction, 41, 42 Tau protein biology, 38, 39 toxoplasmosis, 36 untreated pre-symptomatic HIV-infected individuals, 30-31 Histoplasmosis Histoplasma antigen assay, 307 primary infection, 307 systemic mycosis, 306 HIV Neurobehavioral Research Center (HNRC), 375-376 HIV, HCV, and SUD common co-occurrence injection drug use, 214 neurobehavioral deficits, 215 transmission, mechanisms, 214 comorbid consequences, 215-216

Index

regression model, 224 treatment-related issues, 224-225 HIV-1 genetic diversity circulating recombinant forms (CRF), 267 classification CRF. 267 Democratic Republic of Congo (DRC), 271 phylogenetic groups, 268 coreceptor usage, 273 disease progression, 276 geographic distribution subtype viruses, 270-272 subtypes, 270 unique recombinant forms (URF), 272 mechanisms, 268 pandemic strains, 267 plasma viral loads, 276 replicative capacity, 273 tat function, 273 transmission heterosexual, 278 mother to child transmission (MTCT), 278 - 279needle sharing, IDU, 278 viral promoter activity, 273 HIV-1 Minor Cognitive Motor Disorder (MCMD). 111 HIV-1-associated dementia β-fibroblast growth factor (FGF), 259-260 brain-derived neurotrophic factor (BDNF), 260 cytokine erythropoietin (EPO), 259 estradiol. 261 lithium, 260 nerve growth factor (NGF) and neomycin B hexa-arginine, 259 neurons, mitochondria, 260 opioid agents, 261 tolbutamide, 260 viral replication suppression, 261 HIV-1-associated mild neurocognitive disorder (MND), 111 HIV-associated brain dysfunction aging brain, 159 apathy, 154-155 asymptomatic patients, 148-149 brain-derived neurotropic factor (BDNF), 155-156 chemokines and inflammatory response, 149 chronic infection, aging, 161-162 factors affecting, 162-163 HAART era and cognitive function, 156-157

Hepatitis C virus (HCV), 147-148 language functions, 142-143 major depressive disorder (MDD), 153 mechanisms directly and indirect infection, 137 leukoencephalopathy, 138 viral and nonviral infections. 137 - 138viral replication, 136-137 neurocognitive dysfunction attention and executive impairments, 140 - 141CD4 cell. 144-145 cognitive-motor disorder (CMD), 140 dementia, 139-140 functional protection, 150 immune system suppression, 145 learning and memory, 142 nosology, 158-159 preserved function, 143-144 prevalence, 138-139 proviral DNA, 147 psychomotor functioning, 141-142 reaction time and information processing speed, 140 viral load, 146-147 neurocognitive symptoms, 160-161 neuropsychiatric symptoms, 153-154 psychiatric comorbidity, 150-151 psychosis and delirium, 155 substance abuse problems, 151-152 symptomatic patients, 148 transformation, 136 visual functions, 143 HIV-associated neurocognitive decline driving ability assessment attention/working memory, 242, 243 visual attention, 242 employment COMPASS, 243 loss, 244, 245 vocational status, 243 highly active antiretroviral therapy (HAART), 233 medication adherence actual adherence rates, 236 aging and neuropsychological impairment, 238-239 drug use/abuse, 239-240 neuropsychological dysfunction and regimen complexity, 237-238 neuropsychological functioning, 237 self-report, 234 unannounced pill counts, 236

HIV-associated neurocognitive disorders (HAND) assessment, 109 appropriate norms, importance of, 114-115 cognitive functions assessment IADL scale, 113 medication adherence, 113 neuropsychological battery, 112 complexities, 110 defining change, 118-120 long-term follow-up, importance of. 115-117 neurocognitive profile, changing aging, as HAND changing patterns, 121 - 123female gender, influence, 123-124 HCV and HIV, potential additive effect, 123 sex hormones, influence, 123-124 practice effect and regression towards the mean, 117-118 risk factors HIV duration, 125 immune reconstitution inflammatory syndrome (IRIS), 125-126 nadir CD4, 124-125 neuro HAART, importance of, 125 HIV-related CNS disease, children AIDS dementia complex, 190 clinical presentation encephalopathy, 190-191 utero transmission, 190 zidovudine, 191 highly active antiretroviral therapy (HAART), 189-190 key features, 189 main patterns encephalopathy, 191-192 mild neurocognitive disorder (MND), 192 HIV-related dementia (HAD), 29, 30

I

Immune reconstitution inflammatory syndrome (IRIS), 20–22, 37, 125–126 Inducible nitric oxide synthase (iNOS), 18–19 Instrumental Activities of Daily Living (IADL) Scale, 113 Intracerebral calcifications, 194

L

Leishmaniasis, 303 Leukoencephalopathy, 138 Lexipafant, 253 Lithium, 255

M

Magnetic resonance spectroscopy (MRS), 82-86 Magnetization transfer imaging (MTI), 95-96 Major depressive disorder (MDD), 153 Malaria, 299-300 Matrix matalloproteinases (MMP), 18 Mean diffusivity (MD), 87 Medication adherence actual adherence rates, 236 aging and neuropsychological impairment, 238-239 drug use/abuse, 239-240 neuropsychological dysfunction and regimen complexity, 237-238 neuropsychological functioning, 237 self-report, 234 unannounced pill counts, 236 Medication Event Monitoring System (MEMS), 236 Memantine, 254 Mild neurocognitive disorder (MND), 30 Minocycline, 254-255 Modafinil, 258 Modulators chemokines, 58 IFNs and IP-10, 57 interleukins, 55-56 TGF-B and uPAR, 58-59 TNF superfamily proteins, 56-57

Ν

N-acetyl aspartate (NAA) signal, 194 NAA/Cr (creatine) ratio, 194 National Institute of Mental Health (NIMH) battery, 112 Neopterin, 54 Neurocognitive dysfunction, HIV attention and executive impairments, 140-141 CD4 cell, 144-145 cognitive-motor disorder (CMD), 140 dementia, 139-140 functional protection, 150 immune system suppression, 145 learning and memory, 142 nosology, 158-159 preserved function, 143-144 prevalence, 138-139

proviral DNA, 147 psychomotor functioning, 141-142 reaction time and information processing speed, 140 viral load, 146-147 Neurodevelopmental function, children assessment, 201-202 attention deficit/hyperactivity disorder (ADHD), 199 cognitive function full scale IQ distributions, 195–196 seroreverters, 195 emotional and behavioral difficulties, 199 executive function, assessment, 197-198 family and adaptive functioning, 199 gross motor function, 198 language deficits, 196-197 memory, 198 outcomes, 200-201 psychiatric illness, 199 Neurofilament-light (NFL), 61 Neuroimaging, HIV-infected patients diffusion magnetic resonance imaging, 87 - 91functional MRI (fMRI), 91-93 future directions for research, 97–100 HIV-associated CNS injury, reason for examining, 75-76 magnetic resonance spectroscopy (MRS), 82-86 magnetization transfer imaging (MTI), 95-96 perfusion MRI (pMRI), 95 positron emission tomography (PET), 93-94 qualitative and quantitative structural neuroimaging, 77-82 single positron emissions computed tomography (SPECT), 93-94 Neuropathogenesis HIV reservoirs regulation, 22-23 host genetic factors, 24 immune reconstitution syndrome CD4+ cells, 21 central nervous system, 21-22 innate immune responses inducible nitric oxide synthase (iNOS), 18 - 19matrix matalloproteinases (MMP), 18 modulation, 22 nonspecific antiviral effects, 19 viral strains and clades role, 23-24 Neuropathology, 188 Nonnucleoside reverse transcriptase inhibitor (NNRTI), 5

P

Pan troglogdytes troglodytes, 268 Paracoccidioidomycosis affected organs and treatment, 306 dimorphic fungus, 305 Perfusion MRI (pMRI), 95 Pneumocystis pneumonia (PCP), 1 Positron emission tomography (PET), 93-94 Postcontrast enhancement imaging, 95, 96 Primary central nervous system lymphoma (PCNSL), 32, 33 Progressive multifocal leucoencephalopathy (PML), 32 Proton magnetic resonance spectrometry, 82-86 Proton magnetic resonance spectroscopy (¹HMRS), 194 Psychosis, 155 Psychostimulants, 250-251

R

Regression-based change score (RCS), 119 Reliable change index (RCI) method, 119, 121

S

Selegiline, 251–252 Single positron emissions computed tomography (SPECT), 93-94 Sporotrichosis causable organism, 307 treatment, 308 Strongyloides stercoralis intestinal nematode endemic, 302 main drugs, 303 Substance use disorders (SUD) neural mechanisms, interactions cocaine, 216, 217 immune function suppression, 216 methamphetamine, 216, 217 neuropathology and neuroimaging alcoholism, 218 HIV encephalitis, 217, 218 magnetic resonance spectroscopy (MRS), 218 neuropsychological function cocaine, 220 marijuana, 219

Т

Tensor-based morphometry (TBM) approach, 80 Tolbutamide, 260 Toxins host toxins arachidonic acid metabolites/ prostaglandins, 60 nitric oxide and PAF, 60-61 viral toxins HIV RNA and DNA, 59-60 HIV-encoded proteins, 60 Toxoplasma gondii, 32 Toxoplasmosis CT scan, 296-297 diagnosis and treatment, 297 in AIDS, 295 intracellular parasite, 295 Transforming Growth Factor (TGF)- B, 58-59 Transmission heterosexual, 278 mother to child transmission (MTCT), 278-279 needle sharing, IDU, 278 Trojan horse mechanism, 221 Tuberculosis CSF analysis and treatment, 310 socio-economic survey, 308 subacute meningitis, 309 target sign, 309 Tumor necrosis factor- α (TNF- α), 222

U

Urokinase plasminogen activator receptor (suPAR), 59

V

Valproic acid (VPA), 253 Viruses HAART, 311 JC virus, 310–311 progressive multifocal leukoencephalopathy, 310

W

Wechsler adult intelligence scale (WAIS-III), 114 Wechsler memory scale (WMS-III), 114 White-matter signal abnormalities (WMSA), 81, 82

Z

Zidovudine (ZDV), 191, 193